PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	OMalley, M				OMalley, M			Clinical evaluation of pesticide exposure and poisonings	LANCET			English	Article							ORGANOPHOSPHATE INSECTICIDE; BLOOD DYSCRASIAS; BREAST-CANCER; RISK; CHLORDANE; PARAQUAT; WORKERS; HEPTACHLOR; MORTALITY; LYMPHOMA	Pesticide exposures cause disorders varying from straightforward topical irritant reactions, such as those to synthetic pyrethroid insecticides, to complex systemic illness, such as that resulting from cholinesterase inhibition by organophosphate pesticides. The acute illness syndromes associated with pesticides most commonly encountered by clinicians are illustrated here by cases reported to the California Pesticide Illness Surveillance Program. The issues raised include asthma associated with exposure to contaminants in organophosphate insecticides, systemic toxicity of ingested pyrethroids (in children), and illnesses associated with spills or misuse of fumigants.			OMalley, M (corresponding author), UNIV CALIF DAVIS,EMPLOYEE HLTH SERV,501 OAK AVE DAVIS,DAVIS,CA 95616, USA.							ALAVANJA MCR, 1987, J TOXICOL ENV HEALTH, V22, P247, DOI 10.1080/15287398709531068; AMES RG, 1991, ARCH ENVIRON HEALTH, V46, P213, DOI 10.1080/00039896.1991.9937451; Ames RG, 1995, ARCH ENVIRON HEALTH, V50, P440, DOI 10.1080/00039896.1995.9935980; BARBOSA A, 1994, OCCUP ENVIRON MED, V51, P700, DOI 10.1136/oem.51.10.700; BRADFORD JC, 1990, CLIN MANAGEMENT POIS, P1241; BROWN DP, 1992, SCAND J WORK ENV HEA, V18, P155, DOI 10.5271/sjweh.1593; *CA DEP FOOD AGR, 1980, EX SUMM DEF BUT MERC; DESCHAMPS D, 1994, LANCET, V344, P1712, DOI 10.1016/S0140-6736(94)90498-7; EKINS BR, 1994, WESTERN J MED, V161, P68; EPSTEIN SS, 1987, TERATOGEN CARCIN MUT, V7, P527, DOI 10.1002/tcm.1770070604; FORGET G, 1993, P S OTT CAN SEP 17 2; GARRY VF, 1993, J LAB CLIN MED, V122, P739; GARRY VF, 1992, CANCER EPIDEM BIOMAR, V1, P287; Hayes WJ, 1990, HDB PESTICIDE TOXICO; HE FS, 1989, ARCH TOXICOL, V63, P54, DOI 10.1007/BF00334635; HOAR SK, 1986, JAMA-J AM MED ASSOC, V256, P1141, DOI 10.1001/jama.256.9.1141; HUGHES JT, 1988, NEUROTOXICOLOGY, V9, P243; INFANTE PF, 1978, SCAND J WORK ENV HEA, V4, P137, DOI 10.5271/sjweh.2718; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; JEYARATNAM J, 1985, SCAND J WORK ENV HEA, V11, P229, DOI 10.5271/sjweh.2230; Jones A. T., 1964, AM IND HYG ASSOC J, V25, P375; KILBURN KH, 1995, ENV HLTH PERSPECT, V103, P691; KOLLER WC, 1986, NEUROLOGY, V36, P1147, DOI 10.1212/WNL.36.8.1147-b; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LIBERSA CC, 1988, CLIN CARDIOL, V11, P454, DOI 10.1002/clc.4960110704; LINDQUIST NG, 1988, NEUROSCI LETT, V93, P1, DOI 10.1016/0304-3940(88)90002-X; MAIZLISH N, 1987, AM J IND MED, V12, P153, DOI 10.1002/ajim.4700120205; MALLEY LA, 1985, TOXICOL LETT, V9, P51; Metcalf D R, 1969, Ann N Y Acad Sci, V160, P357, DOI 10.1111/j.1749-6632.1969.tb15857.x; MIDTLING JE, 1985, WESTERN J MED, V142, P514; MILKER T, 1988, KLIN WOCHENSCHR, V66, P1138; OMALLEY MA, 1990, WESTERN J MED, V153, P619; ROSENSTOCK L, 1990, AM J IND MED, V18, P321, DOI 10.1002/ajim.4700180313; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; ROWLEY DL, 1987, PEDIATRICS, V79, P928; SAVAGE E, 1990, ARCH ENVIRON HEALTH, V43, P38; SENANAYAKE N, 1987, NEW ENGL J MED, V316, P761, DOI 10.1056/NEJM198703263161301; SENANAYAKE N, 1982, NEW ENGL J MED, V306, P155, DOI 10.1056/NEJM198201213060306; SHEETS LP, 1994, TOXICOL APPL PHARM, V126, P186, DOI 10.1006/taap.1994.1106; SHINDELL S, 1986, J OCCUP ENVIRON MED, V28, P497, DOI 10.1097/00043764-198607000-00009; Song JH, 1995, J PHARMACOL EXP THER, V275, P1402; STEENLAND K, 1994, AM J PUBLIC HEALTH, V84, P731, DOI 10.2105/AJPH.84.5.731; STEPHENS R, 1995, LANCET, V345, P1135, DOI 10.1016/S0140-6736(95)90976-1; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; TABERSHAW IR, 1966, JOM-J OCCUP MED, V8, P5; TIPPE A, 1993, ZBL HYG UMWELTMED, V194, P342; *US EPA, 1994 MEM LIST CHEM E; WOHLFAHRT DJ, 1982, MED J AUSTRALIA, V1, P512, DOI 10.5694/j.1326-5377.1982.tb124157.x; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; XUE SZ, 1987, AM J IND MED, P269	51	149	157	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1161	1166		10.1016/S0140-6736(96)07222-4	http://dx.doi.org/10.1016/S0140-6736(96)07222-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113024				2022-12-28	WOS:A1997WU54400041
J	Kaisho, T; Schwenk, F; Rajewsky, K				Kaisho, T; Schwenk, F; Rajewsky, K			The roles of gamma 1 heavy chain membrane expression and cytoplasmic tail in IgG1 responses	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; B-CELLS; MONOCLONAL-ANTIBODIES; SWITCH RECOMBINATION; AFFINITY MATURATION; DEFICIENT MICE; MEMORY; LYMPHOCYTES; REPERTOIRE; ALPHA	In antibody responses, B cells switch from the expression of immunoglobulin (Ig) mu and delta heavy (H) chains to that of other Ig classes (alpha, gamma, or epsilon), each with a distinct effector function. Membrane-bound forms of alpha, gamma, and epsilon, but not mu and delta, have highly conserved cytoplasmic tails. Mutant mice unable to express membrane gamma 1 H chains or producing tailless gamma 1 H chains failed to generate efficient IgG1 responses and IgG1 memory. H chain membrane expression after class switching is thus required for these functions, and class switching equips the B cell antigen receptor with a regulatory cytoplasmic tail that naive B cells lack.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Cologne			Kaisho, Tsuneyasu/B-4130-2012	Rajewsky, Klaus/0000-0002-6633-6370				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; Ferradini L, 1996, SCIENCE, V271, P1416, DOI 10.1126/science.271.5254.1416; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GRUTZMAN R, 1981, THESIS U COLOGNE GER; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HONJO T, 1979, CELL, V18, P559, DOI 10.1016/0092-8674(79)90072-2; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KAISHO T, UNPUB; KIM KJ, 1979, J IMMUNOL, V122, P549; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OKUMURA K, 1976, EUR J IMMUNOL, V6, P467, DOI 10.1002/eji.1830060704; PULENDRAN B, 1995, J IMMUNOL, V155, P1141; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROES J, 1995, J IMMUNOL METHODS, V183, P231, DOI 10.1016/0022-1759(95)00059-J; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SHAN H, 1990, J EXP MED, V172, P531, DOI 10.1084/jem.172.2.531; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEISER P, 1994, EUR J IMMUNOL, V24, P665, DOI 10.1002/eji.1830240327; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	29	117	121	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					412	415		10.1126/science.276.5311.412	http://dx.doi.org/10.1126/science.276.5311.412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103199				2022-12-28	WOS:A1997WU47700039
J	Olivetti, G; Abbi, R; Quaini, F; Kajstura, J; Cheng, W; Nitahara, JA; Quaini, E; DiLoreto, C; Beltrami, CA; Krajewski, S; Reed, JC; Anversa, P				Olivetti, G; Abbi, R; Quaini, F; Kajstura, J; Cheng, W; Nitahara, JA; Quaini, E; DiLoreto, C; Beltrami, CA; Krajewski, S; Reed, JC; Anversa, P			Apoptosis in the failing human heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL BLOOD-FLOW; GROWTH-FACTOR-I; CELL-DEATH; DILATED CARDIOMYOPATHY; PRESSURE-OVERLOAD; BCL-2; FAILURE; DISEASE; DNA; CARDIOMYOCYTES	Background Loss of myocytes is an important mechanism in the development of cardiac failure of either ischemic or nonischemic origin. However, whether programmed cell death (apoptosis) is implicated in the terminal stages of heart failure is not known. We therefore studied the magnitude of myocyte apoptosis in patients with intractable congestive heart failure. Methods Myocardial samples were obtained from the hearts of 36 patients who underwent cardiac transplantation and from the hearts of 3 patients who died soon after myocardial infarction. Samples from 11 normal hearts were used as controls. Apoptosis was evaluated histochemically, biochemically, and by a combination of histochemical analysis and confocal microscopy. The expression of two proto-oncogenes that influence apoptosis, BCL2 and BAX, was also determined. Results Heart failure was characterized morphologically by a 232-fold increase in myocyte apoptosis and biochemically by DNA laddering (an indicator of apoptosis). The histochemical demonstration of DNA-strand breaks in myocyte nuclei was coupled with the documentation of chromatin condensation and fragmentation by confocal microscopy. Ail these findings reflect apoptosis of myocytes. The percentage of myocytes labeled with BCL2 (which protects cells against apoptosis) was 1.8 times as high in the hearts of patients with cardiac failure as in the normal hearts, whereas labeling with BAX (which promotes apoptosis) remained constant. The near doubling of the expression of BCL2 in the cardiac tissue of patients with heart failure was confirmed by Western blotting. Conclusions Programmed death of myocytes occurs in the decompensated human heart in spite of the enhanced expression of BCL2 this phenomenon may contribute to the progression of cardiac dysfunction. (C) 1997, Massachusetts Medical Society.	NEW YORK MED COLL,DEPT MED,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT PATHOL,VALHALLA,NY 10595; UNIV PARMA,DEPT PATHOL,I-43100 PARMA,ITALY; UNIV UDINE,DEPT PATHOL,I-33100 UDINE,ITALY; DE GASPERIS DIV CARDIAC SURG,MILAN,ITALY; BURNHAM INST,LA JOLLA,CA 92037	New York Medical College; New York Medical College; University of Parma; University Hospital of Parma; University of Udine; Sanford Burnham Prebys Medical Discovery Institute			beltrami, carlo a/A-8026-2008; Di Loreto, Carla/A-7529-2010	Quaini, Federico/0000-0003-2377-4810	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040561, R01HL039902, R01HL038132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40561, HL-39902, HL-38132] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANVERSA P, 1993, CARDIOVASC RES, V27, P145, DOI 10.1093/cvr/27.2.145; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BELTRAMI CA, 1994, CIRCULATION, V89, P151, DOI 10.1161/01.CIR.89.1.151; BELTRAMI CA, 1995, J MOL CELL CARDIOL, V27, P291, DOI 10.1016/S0022-2828(08)80028-4; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CANNON PJ, 1977, PROG CARDIOVASC DIS, V20, P95, DOI 10.1016/0033-0620(77)90002-0; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Colucci WS, 1996, NEW ENGL J MED, V335, P1224, DOI 10.1056/NEJM199610173351610; GENG YJ, 1995, AM J PATHOL, V147, P251; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH G, 1995, AM J PATHOL, V146, P1325; James TN, 1996, CIRCULATION, V93, P1424, DOI 10.1161/01.CIR.93.7.1424; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kajstura J, 1996, LAB INVEST, V74, P86; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Liu Y, 1995, LAB INVEST, V73, P771; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; OLIVETTI G, 1995, J AM COLL CARDIOL, V26, P1068, DOI 10.1016/0735-1097(95)00282-8; OLIVETTI G, 1994, CARDIOVASC RES, V28, P1199, DOI 10.1093/cvr/28.8.1199; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PARODI O, 1993, CIRCULATION, V88, P509, DOI 10.1161/01.CIR.88.2.509; RAKUSAN K, 1992, CIRCULATION, V86, P38, DOI 10.1161/01.CIR.86.1.38; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RESNICOFF M, 1995, CANCER RES, V55, P2463; Sharov VG, 1996, AM J PATHOL, V148, P141; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	39	1337	1402	1	48	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1131	1141		10.1056/NEJM199704173361603	http://dx.doi.org/10.1056/NEJM199704173361603			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099657				2022-12-28	WOS:A1997WU00300003
J	Moloney, DM; Wall, SA; Ashworth, GJ; Oldridge, M; Glass, IA; Francomano, CA; Muenke, M; Wilkie, AOM				Moloney, DM; Wall, SA; Ashworth, GJ; Oldridge, M; Glass, IA; Francomano, CA; Muenke, M; Wilkie, AOM			Prevalence of Pro250Arg mutation of fibroblast growth factor receptor 3 in coronal craniosynostosis	LANCET			English	Article							AUTOSOMAL-DOMINANT CRANIOSYNOSTOSIS; CROUZON-SYNDROME; PFEIFFER-SYNDROME; GENE CAUSE; FGFR2; FAMILY	Background The C749G (Pro250Arg) mutation in the gene for fibroblast growth factor receptor 3 (FGFR3) has been found in patients with various types of craniosynostosis. We aimed to find out the proportion of cases of apparently nonsyndromic coronal craniosynostosis attributable to this mutation. Methods We studied 26 patients with coronal craniosynostosis but no syndromic diagnosis, who were referred to a supra-regional specialist centre. Genomic DNA was analysed by PCR and restriction-enzyme digestion to identify the C749G mutation in FGFR3, Family members of patients found to have the mutation were also tested. Findings Eight (31%) of the 26 probands were heterozygous for the C749G mutation. In two cases, the mutation showed autosomal dominant transmission with evidence of variable expressivity; the remaining six cases were sporadic. We demonstrated in six families that the mutation had arisen de novo from clinically unaffected parents. Interpretation The C749G mutation in FGFR3 is a frequent cause of apparently non-syndromic coronal craniosynostosis. Our finding will aid genetic counselling and prenatal diagnosis. The mutation rate at this nucleotide is one of the highest described in the human genome.	JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DS,ENGLAND; RADCLIFFE INFIRM,OXFORD CRANIOFACIAL UNIT,OXFORD OX2 6HE,ENGLAND; MT SINAI SCH MED,DEPT HUMAN GENET,NEW YORK,NY; NIH,MED GENET BRANCH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET & MOL BIOL,PHILADELPHIA,PA 19104	University of Oxford; Radcliffe Infirmary; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Pennsylvania; Childrens Hospital of Philadelphia			Wilkie, Andrew/AAC-3820-2020	Wilkie, Andrew/0000-0002-2972-5481; Muenke, Maximilian/0000-0002-7719-6545	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLUS GA, 1995, AM J HUM GENET, V56, P368; Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096-174; CARTER CO, 1982, J MED GENET, V19, P280, DOI 10.1136/jmg.19.4.280; ElGhouzzi V, 1997, NAT GENET, V15, P42; Glass I A, 1994, Clin Dysmorphol, V3, P215; GOLLA A, IN PRESS J MED GENET; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOLLWAY GE, 1995, HUM MOL GENET, V4, P681, DOI 10.1093/hmg/4.4.681; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; HUNTER AGW, 1977, TERATOLOGY, V15, P301, DOI 10.1002/tera.1420150312; HUNTER AGW, 1976, TERATOLOGY, V14, P185, DOI 10.1002/tera.1420140209; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Lajeunie E, 1996, AM J MED GENET, V62, P282, DOI 10.1002/(SICI)1096-8628(19960329)62:3<282::AID-AJMG15>3.0.CO;2-G; LAJEUNIE E, 1995, NAT GENET, V9, P108, DOI 10.1038/ng0295-108; LAJEUNIE E, 1995, AM J MED GENET, V55, P500, DOI 10.1002/ajmg.1320550422; MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295-462; Moloney DM, 1996, NAT GENET, V13, P48, DOI 10.1038/ng0596-48; Muenke M, 1997, AM J HUM GENET, V60, P555; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; REARDON W, 1994, J MED GENET, V31, P393, DOI 10.1136/jmg.31.5.393; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SOMMER SS, 1995, TRENDS GENET, V11, P141, DOI 10.1016/S0168-9525(00)89028-9; vonGernet S, 1996, AM J MED GENET, V63, P177; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Winter RM, 1996, LONDON DYSMORPHOLOGY	27	108	109	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1059	1062		10.1016/S0140-6736(96)09082-4	http://dx.doi.org/10.1016/S0140-6736(96)09082-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107244				2022-12-28	WOS:A1997WU00200010
J	Zetterstrom, RH; Solomin, L; Jansson, L; Hoffer, BJ; Olson, L; Perlmann, T				Zetterstrom, RH; Solomin, L; Jansson, L; Hoffer, BJ; Olson, L; Perlmann, T			Dopamine neuron agenesis in Nurr1-deficient mice	SCIENCE			English	Article							NEUROTROPHIC FACTOR; BRAIN; DEHYDROGENASE; NURR1; BDNF	Dopamine neurons of the substantia nigra and ventral tegmental area regulate movement and affective behavior and degenerate in Parkinson's disease. The orphan nuclear receptor Nurr1 was shown to be expressed in developing dopamine neurons before the appearance of known phenotypic markers for these cells. Mice lacking Nurr1 failed to generate midbrain dopaminergic neurons, were hypoactive, and died soon after birth, Nurr1 expression continued into adulthood, and brains of heterozygous animals, otherwise apparently healthy, contained reduced dopamine levels. These results suggest that putative Nurr1 ligands may be useful for treatment of Parkinson's disease and other disorders of midbrain dopamine circuitry.	LUDWIG INST CANC RES,STOCKHOLM BRANCH,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN; NIDA,INTRAMURAL RES PROGRAM,NIH,BALTIMORE,MD 21224	Ludwig Institute for Cancer Research; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)				Zetterstrom, Rolf/0000-0002-3016-0019				ANDERSSON H, 1995, NEUROTOXICOLOGY, V16, P201; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Fallon James H., 1995, P215; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FOSTER GA, 1988, INT J DEV NEUROSCI, V6, P367, DOI 10.1016/0736-5748(88)90020-2; HOKFELT T, 1973, HISTOCHEMISTRY, V33, P231; Hokfelt T., 1984, CLASSICAL NEUROTRANS, V2, P277; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; HYNES M, 1995, NEURON, V15, P33; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Joyner AL, 1993, GENE TARGETING PRACT; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LIU FC, 1992, J NEUROSCI, V12, P4281; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; OLSON L, 1972, BRAIN RES, V44, P283, DOI 10.1016/0006-8993(72)90385-X; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANCHEZ MP, 1996, NATURE, V382, P73; SNYDERKELLER AM, 1991, J NEUROSCI, V11, P810; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0	34	871	919	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					248	250		10.1126/science.276.5310.248	http://dx.doi.org/10.1126/science.276.5310.248			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092472				2022-12-28	WOS:A1997WT92500043
J	Angle, N; Bergan, JJ				Angle, N; Bergan, JJ			Chronic venous ulcer	BRITISH MEDICAL JOURNAL			English	Review							LEG ULCER; INSUFFICIENCY; EXTENT; REFLUX; STASIS		UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103	University of California System; University of California San Diego								Arnoldi C C, 1965, Acta Chir Scand, V130, P570; ARNOLDI CC, 1966, ACTA CHIR SCAND, V132, P427; Bauersachs J, 1996, PHLEBOLOGY, V11, P16, DOI 10.1177/026835559601100105; Bergan JJ, 1996, ANN VASC SURG, V10, P211, DOI 10.1007/BF02001884; BERGAN JJ, 1993, J CARDIOVASC SURG, V1, P624; CALLAM MJ, 1987, BRIT MED J, V294, P929, DOI 10.1136/bmj.294.6577.929; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; DAVIES DM, 1985, BRIT MED J, V290, P910, DOI 10.1136/bmj.290.6472.910; DUNN RM, 1994, J VASC SURG, V19, P525, DOI 10.1016/S0741-5214(94)70081-8; GILCHRIST B, 1989, BRIT J DERMATOL, V121, P337, DOI 10.1111/j.1365-2133.1989.tb01427.x; GLOVICZKI P, IN PRESS J VASC SURG; GOLDMAN MP, 1995, AMBULATORY TREATMENT, P13; GUYTON AC, 1965, CIRC RES, V16, P452, DOI 10.1161/01.RES.16.5.452; HANRAHAN LM, 1991, J VASC SURG, V13, P805; JOBST C, 1985, SURG VEINS, P529; JOHNSON G, 1985, SURGERY VEINS, P541; LABROPOULOS N, 1994, J VASC SURG, V20, P953, DOI 10.1016/0741-5214(94)90233-X; LEES TA, 1993, BRIT J SURG, V80, P725, DOI 10.1002/bjs.1800800617; LINEAWEAVER W, 1985, ARCH SURG-CHICAGO, V120, P267; Linton RR, 1938, ANN SURG, V107, P582, DOI 10.1097/00000658-193804000-00013; MAYBERRY JC, 1989, VENOUS DISORDERS, P383; MOYSES C, 1987, INT J MICROCIRC, V5, P311; NELZEN O, 1991, J VASC SURG, V14, P557, DOI 10.1016/0741-5214(91)90251-O; Partsch H, 1988, Acta Chir Scand Suppl, V544, P25; Payne SPK, 1996, EUR J VASC ENDOVASC, V11, P195, DOI 10.1016/S1078-5884(96)80051-7; RAJU S, 1991, J VASC SURG, V14, P305, DOI 10.1016/0741-5214(91)90081-5; Sarin Sanjeev, 1993, Journal of Vascular Surgery, V17, P444; THOMAS PR, 1988, BRIT MED J, V290, P1693; Travers JP, 1996, EUR J VASC ENDOVASC, V11, P230, DOI 10.1016/S1078-5884(96)80058-X; Walsh JC, 1996, VASCULAR SURG, V30, P89, DOI 10.1177/153857449603000202; Whiston Richard J., 1993, Journal of Vascular Surgery, V17, P445; Widmer L. K., 1978, BASEL STUDY, VIII, P43; WOOD MK, 1995, ANN ROY COLL SURG, V77, P222; 1996, NEW ENGL J MED, V334, P1642	34	38	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1019	1023		10.1136/bmj.314.7086.1019	http://dx.doi.org/10.1136/bmj.314.7086.1019			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112848	Green Published			2022-12-28	WOS:A1997WT15200027
J	Agrawal, A; Schatz, DG				Agrawal, A; Schatz, DG			RAG1 and RAG2 form a stable postcleavage synaptic complex with DNA containing signal ends in V(D)J recombination	CELL			English	Article							STRAND-BREAK REPAIR; PROTEINS; REARRANGEMENT; ANTIBODIES; MECHANISM; SEQUENCES; BINDING; MUTANTS; SITE; GENE	During V(D)J recombination, RAG1 and RAG2 cleave DNA adjacent to highly conserved recombination signals, but nothing is known about the protein-DNA complexes that exist after cleavage. Using a properly regulated in vitro V(D)J cleavage system, together with nuclease sensitivity, mobility shift, and immunoprecipitation experiments, we provide evidence that a stable complex is formed postcleavage between synapsed recombination signals. This complex includes the proteins RAG1, RAG2, HMG-1 or the closely related HMG-2 protein, and the components of the DNA-dependent protein kinase. The existence of such a stable complex explains a number of in vivo observations and suggests that remodeling of postcleavage synaptic complexes is an important step in the resolution of signal ends in V(D)J recombination.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University	Agrawal, A (corresponding author), YALE UNIV, SCH MED, IMMUNOBIOL SECT, 310 CEDAR ST, NEW HAVEN, CT 06520 USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032524] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07019, AI-32524] Funding Source: Medline; NIGMS NIH HHS [GM-07324] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chaconas G, 1996, CURR BIOL, V6, P817, DOI 10.1016/S0960-9822(02)00603-6; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HLOM K, 1997, CELL, V88, P65; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Livak F, 1996, MOL CELL BIOL, V16, P609; Livak F, 1997, J MOL BIOL, V267, P1, DOI 10.1006/jmbi.1996.0834; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1997, IN PRESS SEMIN IMMUN, V9; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	46	244	249	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					43	53		10.1016/S0092-8674(00)80181-6	http://dx.doi.org/10.1016/S0092-8674(00)80181-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094713	hybrid			2022-12-28	WOS:A1997WR68500008
J	Rawls, A; Olson, EN				Rawls, A; Olson, EN			MyoD meets its maker	CELL			English	Review							MUSCLE; CELLS; EXPRESSION; MIGRATION; ELEMENTS; PAX-3; GENE				Rawls, A (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,6000 HARRY HINES BLVD,DALLAS,TX 75225, USA.							ASAKURA A, 1995, DEV BIOL, V171, P386, DOI 10.1006/dbio.1995.1290; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; Braun T, 1996, EMBO J, V15, P310, DOI 10.1002/j.1460-2075.1996.tb00361.x; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Daston G, 1996, DEVELOPMENT, V122, P1017; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; JOSTES B, 1991, MECH DEVELOP, V33, P27; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Yang XM, 1996, DEVELOPMENT, V122, P2163; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	15	103	105	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					5	8		10.1016/S0092-8674(00)80175-0	http://dx.doi.org/10.1016/S0092-8674(00)80175-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094707	Bronze			2022-12-28	WOS:A1997WR68500002
J	Jain, N; Catania, KC; Kaas, JH				Jain, N; Catania, KC; Kaas, JH			Deactivation and reactivation of somatosensory cortex after dorsal spinal cord injury	NATURE			English	Article							MACACA-MULATTA; MONKEYS; LESIONS; DEAFFERENTATION; REPRESENTATION; REORGANIZATION; ORGANIZATION; PLASTICITY; HAND	Sensory stimuli to the body are conveyed by the spinal cord to the primary somatosensory cortex It has long been thought that dorsal column afferents of the spinal cord represent the main pathway for these signals(1-3), but the physiological and behavioural consequences of cutting the dorsal column have been reported to range from mild and transitory(4-8) to markedg(9-13). We have re-examined this issue by sectioning the dorsal columns in the cervical region and recording the responses to hand stimulation in the contralateral primary somatosensory cortex (area 3b), Following a complete section of the dorsal columns, neurons in area 3b become immediately and perhaps permanently unresponsive to hand stimulation, Following a partial section, the remaining dorsal column afferents continue to activate neurons within their normal cortical target territories, but after five or more weeks the area of activation is greatly expanded, After prolonged recovery periods of six months or more, the deprived hand territory becomes responsive to inputs from the face (which are unaffected by spinal cord section), Thus, area 3b of somatosensory cortex is highly dependent on dorsal spinal column inputs, and other spinal pathways do not substitute for the dorsal columns even after injury.	VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240	Vanderbilt University			Jain, Neeraj/B-2882-2010	Jain, Neeraj/0000-0002-3672-5850				ANDERSSON SA, 1975, ACTA PHYSIOL SCAND, V93, P119, DOI 10.1111/j.1748-1716.1975.tb05797.x; Beck C H, 1976, Can J Neurol Sci, V3, P1; Darian-Smith, 1984, HDB PHYSL 2 1, V3, P789; DAVIS RW, 1993, ARCH PHYS MED REHAB, V74, P79; DREYER DA, 1974, J NEUROPHYSIOL, V37, P119, DOI 10.1152/jn.1974.37.1.119; EIDELBERG E, 1975, EXP NEUROL, V47, P419, DOI 10.1016/0014-4886(75)90074-6; FLORENCE SL, 1989, J COMP NEUROL, V286, P48, DOI 10.1002/cne.902860104; Florence SL, 1995, J NEUROSCI, V15, P8083; FLORENCE SL, 1991, J COMP NEUROL, V311, P563, DOI 10.1002/cne.903110410; Gallyas F, 1979, Neurol Res, V1, P203; GIBSON AR, 1984, BRAIN RES, V298, P235, DOI 10.1016/0006-8993(84)91423-9; GLENDINNING DS, 1993, EXP BRAIN RES, V93, P104; GLENDINNING DS, 1993, NEUROLOGY, V43, P363, DOI 10.1212/WNL.43.2.363; GLENDINNING DS, 1991, SOMATOSENS MOTOR RES, V9, P61; JAIN N, 1995, J NEUROPHYSIOL, V73, P1537, DOI 10.1152/jn.1995.73.4.1537; Jain N., 1996, Society for Neuroscience Abstracts, V22, P1054; KAAS JH, 1983, PHYSIOL REV, V63, P206, DOI 10.1152/physrev.1983.63.1.206; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; MERZENICH MM, 1978, J COMP NEUROL, V181, P41, DOI 10.1002/cne.901810104; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; SCHNEIDER RJ, 1990, EXP BRAIN RES, V83, P105; SWEET WH, 1975, NEUROCHIRURGIA, V18, P139; Tommerdahl M, 1996, CEREB CORTEX, V6, P131, DOI 10.1093/cercor/6.2.131; VIERCK CJ, 1973, BRAIN RES, V58, P69, DOI 10.1016/0006-8993(73)90824-X; VIERCK CJ, 1985, SOMATOSENS RES, V3, P45, DOI 10.3109/07367228509144576; WALL PD, 1970, BRAIN, V93, P505, DOI 10.1093/brain/93.3.505; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	28	153	154	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					495	498		10.1038/386495a0	http://dx.doi.org/10.1038/386495a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087408				2022-12-28	WOS:A1997WR25600052
J	Jackson, S; Smith, P				Jackson, S; Smith, P			Fortnightly review - Diagnosing and managing genitourinary prolapse	BRITISH MEDICAL JOURNAL			English	Review							VAGINAL VAULT PROLAPSE; PELVIC FLOOR; URINARY-INCONTINENCE; SURGICAL-MANAGEMENT; SACRAL COLPOPEXY; WOMEN; HYSTERECTOMY; CHILDBIRTH				Jackson, S (corresponding author), SOUTHMEAD GEN HOSP,DEPT OBSTET & GYNAECOL,BRISTOL BS10 5NB,AVON,ENGLAND.							ALCALAY M, 1995, BRIT J OBSTET GYNAEC, V102, P740, DOI 10.1111/j.1471-0528.1995.tb11434.x; ALLEN RE, 1990, BRIT J OBSTET GYNAEC, V97, P770, DOI 10.1111/j.1471-0528.1990.tb02570.x; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0; CREIGHTON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1150, DOI 10.1111/j.1471-0528.1991.tb15368.x; DELANCEY JO, 1993, AM J OBSTET GYNECOL, V166, P717; FELDING C, 1992, MATURITAS, V15, P241, DOI 10.1016/0378-5122(92)90208-L; FRANCIS WJA, 1961, J OBSTET GYN BR COMM, V68, P1; GOLDMAN J, 1981, EUR J OBSTET GYN R B, V12, P31, DOI 10.1016/0028-2243(81)90063-0; HAHN I, 1993, BRIT J UROL, V72, P421, DOI 10.1111/j.1464-410X.1993.tb16170.x; IOSIF CS, 1993, ACTA OBSTET GYN SCAN, V72, P214; Jackson S., 1996, Neurourology and Urodynamics, V15, P327; Jackson SR, 1996, LANCET, V347, P1658, DOI 10.1016/S0140-6736(96)91489-0; MORLEY GW, 1988, AM J OBSTET GYNECOL, V158, P872, DOI 10.1016/0002-9378(88)90088-9; NEZHAT CH, 1994, OBSTET GYNECOL, V84, P885; NICHOLS DH, 1996, VAGINAL SURG, P245; NORTON PA, 1995, OBSTET GYNECOL, V85, P225, DOI 10.1016/0029-7844(94)00386-R; PORGES RF, 1994, AM J OBSTET GYNECOL, V171, P1518, DOI 10.1016/0002-9378(94)90395-6; RICHARDSON AC, 1976, AM J OBSTET GYNECOL, V126, P568, DOI 10.1016/0002-9378(76)90751-1; SHUMAKER SA, 1994, QUAL LIFE RES, V3, P291, DOI 10.1007/BF00451721; SMITH ARB, 1989, BRIT J OBSTET GYNAEC, V96, P24, DOI 10.1111/j.1471-0528.1989.tb01571.x; SNOOKS SJ, 1984, LANCET, V2, P546; STANTON SL, 1982, BRIT J OBSTET GYNAEC, V89, P459, DOI 10.1111/j.1471-0528.1982.tb03637.x; STANTON SL, 1992, GYNAECOLOGY, P437; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; THOMAS AG, 1995, J REPROD MED, V40, P299; VALAITIS SR, 1994, BRIT J OBSTET GYNAEC, V101, P518, DOI 10.1111/j.1471-0528.1994.tb13154.x; VERDEJA AM, 1995, AM J OBSTET GYNECOL, V173, P1468, DOI 10.1016/0002-9378(95)90634-7; Wilson PD, 1996, BRIT J OBSTET GYNAEC, V103, P154, DOI 10.1111/j.1471-0528.1996.tb09668.x; YATES MJ, 1975, BRIT J OBSTET GYNAEC, V82, P817, DOI 10.1111/j.1471-0528.1975.tb00579.x; ZACHARIN RF, 1980, OBSTET GYNECOL, V55, P141	31	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					875	880						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093101				2022-12-28	WOS:A1997WQ02800032
J	Lewis, J				Lewis, J			Primary care - Opportunities and threats - The changing meaning of the GP contract	BRITISH MEDICAL JOURNAL			English	Article								The meaning of the GP contract has changed since the last major upheaval in the mid-1960s. The government has always dealt with general practitioners as independent contractors, but the way in which it treated them in 1990 was entirely different from the way in which they were treated in 1966. In 1966, the profession's independent contractor status effectively served to protect professional autonomy. Ln 1990, with the change in the form of government towards a ''contract state,'' general practitioners were treated as independent contractors more in the sense of business entrepreneurs. The article finishes by raising the issue of how general practitioners can gain control over the medicopolitical agenda in the future.			Lewis, J (corresponding author), UNIV OXFORD ALL SOULS COLL,OXFORD OX1 4AL,ENGLAND.							BOGLE I, 1992, GEN PRACTICE WHICH W; *DEP HLTH WELSH OF, 1996, CHOIC OPP PRIM CAR F; *FRAS WORK PART, 1964, POL 1964 5 MIN MEM S; *GEN MED SERV COMM, 1986, REP SPEC C REPR LMCS; *GEN MED SERV COUN, 1991, BUILD YOUR OWN FUT A; GLENNERSTER H, 1989, WSP399 STICERD LOND; GLENNERSTER H, 1996, WSP123 STICERD LOND; *GMSC, 1996, DEF CAR SERV GEN PRA; HARDNE I, 1993, CONTRACTING STATE; JEFFERYS M, 1981, RETHINKING GENERAL P; KLEIN R, 1990, INT C S SERIES, V171, P127; KRASNIK A, 1990, BRIT MED J, V300, P168; Le Grand J., 1993, QUASIMARKETS SOCIAL; PETCHEY R, 1996, SOCIAL POLICY REV, V8; ROSEN B, 1989, SOC SCI MED, V29, P455, DOI 10.1016/0277-9536(89)90294-3; *ROYAL COLL GEN PR, 1995, NAT GEN MED PRACT; *ROYAL COLL GEN PR, 1985, WHAT SORT DOCT; SCOTT T, 1991, 82 U YORK CTR HLTH E; SHIELDS PJ, 1965, BRIT MED J, V1, P52; TOON P, 1994, 65 ROYAL COLL GEN PR; 1965, BMJ S, V1, P63	21	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					895	898						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093110				2022-12-28	WOS:A1997WQ02800042
J	Hofman, A; Ott, A; Breteler, MMB; Bots, ML; Slooter, AJC; vanHarskamp, F; vanDuijn, CN; Van Broeckhoven, C; Grobbee, DE				Hofman, A; Ott, A; Breteler, MMB; Bots, ML; Slooter, AJC; vanHarskamp, F; vanDuijn, CN; Van Broeckhoven, C; Grobbee, DE			Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study	LANCET			English	Article							INTIMA-MEDIA THICKNESS; COMMON CAROTID-ARTERY; WALL THICKNESS; MENTAL STATE; POPULATION; DETERMINANTS; ALLELE; DIAGNOSIS	Background Vascular disorders have been implicated in dementia, but whether atherosclerosis is related to the most frequent type of dementia, Alzheimer's disease, is not known. The apolipoprotein-E genotype has been associated with Alzheimer's disease, and we postulate that it plays a part, together with atherosclerosis, in the aetiology of Alzheimer's disease. We investigated the frequency of dementia and its subtypes in relation to atherosclerosis and apolipoprotein E. Methods We did a population-based study of 284 patients with dementia, 207 of whom had Alzheimer's disease, and 1698 individuals who were not demented. Indicators of atherosclerosis included vessel wall thickness and plaques of the carotid arteries, assessed by ultrasonography, and the ratio of ankle-to-brachial systolic blood pressure as a measure of generalised atherosclerosis. Based on these indicators participants were scored from 0 (no atherosclerosis) to 3 (severe atherosclerosis) for degree of atherosclerosis. Apolipoprotein-E polymorphisms were assessed in 246 patients and in 928 controls. Findings All indicators of atherosclerosis were associated with dementia (odds ratios ranging from 1.3 to 1.9) and its major subtypes Alzheimer's disease (odds ratios 1.3-1.8) and vascular dementia (odds ratios 1.9-3.2). The frequencies of all dementia, Alzheimer's disease, and vascular dementia increased with the degree of atherosclerosis. The odds ratio for Alzheimer's disease in those with severe atherosclerosis compared with those without atherosclerosis was 3.0 (95% CI 1.5-6.0; p=0.001). In participants with the apolipoprotein-E epsilon 4 genotype and an atherosclerosis score of 2 or 3 the odds ratio for all dementia was 4.5 (2.0-10.1; p<0.001), for Alzheimer's disease was 3.9 (1.6-9.6; p=0.002), and for vascular dementia was 19.8 (4.1-95.0; p<0.001). Interpretation These findings suggest that dementia and its two major subtypes Alzheimer's disease and vascular dementia are associated with atherosclerosis and that there is an interaction between apolipoprotein E and atherosclerosis in the aetiology of Alzheimer's disease.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT NEUROL, NL-3000 DR ROTTERDAM, NETHERLANDS; UNIV INSTELLING ANTWERP, BORN BUNGE FDN, NEUROGENET LAB, B-2610 WILRIJK, BELGIUM	Erasmus University Rotterdam; University of Antwerp	Hofman, A (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS.		Van Broeckhoven, Christine/G-8362-2017; Grobbee, Diederick/C-7651-2014; Breteler, Monique M.B./J-5058-2014; Van Broeckhoven, Christine/M-7853-2019	Van Broeckhoven, Christine/0000-0003-0183-7665; Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305; Van Broeckhoven, Christine/0000-0003-0183-7665				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; BOTS ML, 1994, ARTERIOSCLER THROMB, V14, P1885, DOI 10.1161/01.ATV.14.12.1885; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DEWEY ME, 1990, 1 I HUM AG; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; Hachinski V, 1983, Neurol Clin, V1, P27; HACHINSKI V, 1992, LANCET, V340, P645; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P736, DOI 10.1093/ije/20.3.736; JARRIK GP, 1995, NEUROLOGY, V45, P1092; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; WENDELHAG I, 1992, ARTERIOSCLER THROMB, V12, P70, DOI 10.1161/01.ATV.12.1.70; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	29	1108	1139	0	55	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1997	349	9046					151	154		10.1016/S0140-6736(96)09328-2	http://dx.doi.org/10.1016/S0140-6736(96)09328-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111537				2022-12-28	WOS:A1997WC86100007
J	Wright, MC; Joyce, GF				Wright, MC; Joyce, GF			Continuous in vitro evolution of catalytic function	SCIENCE			English	Article							RNA; RIBOZYMES; SEQUENCES	A population of RNA molecules that catalyze the template-directed ligation of RNA substrates was made to evolve in a continuous manner in the test tube. A simple serial transfer procedure was used to achieve approximately 300 successive rounds of catalysis and selective amplification in 52 hours. During this time, the population size was maintained against an overall dilution of 3 x 10(298). Both the catalytic rate and amplification rate of the RNAs improved substantially as a consequence of mutations that accumulated during the evolution process. Continuous in vitro evolution makes it possible to maintain laboratory ''cultures'' of catalytic molecules that can be perpetuated indefinitely.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute								BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Breaker RR, 1996, CURR OPIN BIOTECH, V7, P442, DOI 10.1016/S0958-1669(96)80122-4; BREAKER RR, 1994, P NATL ACAD SCI USA, V91, P6093, DOI 10.1073/pnas.91.13.6093; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; Hager AJ, 1996, CHEM BIOL, V3, P717, DOI 10.1016/S1074-5521(96)90246-X; KUMAR PKR, 1995, FASEB J, V9, P1183, DOI 10.1096/fasebj.9.12.7672511; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; TSANG J, 1994, BIOCHEMISTRY-US, V33, P5966, DOI 10.1021/bi00185a038; Tsang J, 1996, J MOL BIOL, V262, P31, DOI 10.1006/jmbi.1996.0496; TSANG J, 1996, METHOD ENZYMOL, V267, P411	14	143	159	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					614	617		10.1126/science.276.5312.614	http://dx.doi.org/10.1126/science.276.5312.614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110984				2022-12-28	WOS:A1997WV72100051
J	Harden, PN; MacLeod, MJ; Rodger, RSC; Baxter, GM; Connell, JMC; Dominiczak, AF; Junor, BJR; Briggs, JD; Moss, JG				Harden, PN; MacLeod, MJ; Rodger, RSC; Baxter, GM; Connell, JMC; Dominiczak, AF; Junor, BJR; Briggs, JD; Moss, JG			Effect of renal-artery stenting on progression of renovascular renal failure	LANCET			English	Article							WALLSTENT ENDOPROSTHESIS; DISEASE; STENOSIS; ANGIOPLASTY; PLACEMENT	Background Placement of renal-artery stents has a high technical success rate in atherosclerotic renovascular disease, but little is known about the clinical benefits of the procedure. We monitored renal function serially before and after stent insertion in patients with renovascular renal failure. Methods Renal function was assessed before and after stent placement by means of serial serum creatinine Values in 32 patients with atherosclerotic renal-artery stenosis. The effect on the progression of renal failure was analysed in 23 patients by comparison of the reciprocal slopes of serum creatinine versus time plots before and after stent placement. Findings 33 transluminal stents were placed in 32 patients with atherosclerotic renovascular disease. Immediate patency was achieved in all cases; the angiographic restenosis rate at 6 months was 12% (n=24). One patient died after a procedure-related haemorrhage. Median diastolic blood pressure was significantly lower after stenting than before (95 [IQR 86-103] vs 87 [81-90] mm Hg; p>0.01) but the requirement for antihypertensive drugs was unchanged. Renal function improved or stabilised in 22 (69%) of the 32 patients. Progression of renal failure was significantly slowed after the procedure; the mean (SE) of the slopes of reciprocal serum creatinine values was -4.34 (0.85) L mu mol(-1) day(-1) before stent placement, and -0.55 (1.0) L mu mol(-1) day(-1) after stent placement (p<0.01, two-sample t test). Interpretation Renal-stent placement in selected patients slows the progression of renovascular renal failure and may delay the need for renal replacement therapy.	UNIV GLASGOW,WESTERN INFIRM,RENAL UNIT,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT MED & RADIOL,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow; University of Glasgow			Dominiczak, Anna F/D-2262-2009; Dominiczak, Anna F/P-9390-2017	Dominiczak, Anna F/0000-0003-4913-3608; Macleod, Mary Joan/0000-0003-2115-8184				HENNEQUIN LM, 1994, RADIOLOGY, V191, P713, DOI 10.1148/radiology.191.3.8184051; Henry M, 1996, J VASC INTERV RADIOL, V7, P343, DOI 10.1016/S1051-0443(96)72864-6; JOFFRE F, 1992, CARDIOVASC INTER RAD, V15, P313, DOI 10.1007/BF02733956; KUHN FP, 1991, RADIOLOGY, V180, P367, DOI 10.1148/radiology.180.2.1829842; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; PATTISON JM, 1992, Q J MED, V85, P883; PATTYNAMA PMT, 1994, CARDIOVASC INTER RAD, V17, P143; REES CR, 1991, RADIOLOGY, V181, P507, DOI 10.1148/radiology.181.2.1924796; ROWE PA, 1989, AM J NEPHROL, V9, P38, DOI 10.1159/000167932; SCOBLE JE, 1993, POSTGRAD MED J, V69, P461, DOI 10.1136/pgmj.69.812.461; SCOBLE JE, 1989, CLIN NEPHROL, V31, P119; VANDEVEN PJG, 1995, LANCET, V346, P672, DOI 10.1016/S0140-6736(95)92283-0; WILMS GE, 1991, RADIOLOGY, V179, P457, DOI 10.1148/radiology.179.2.2014292; WOLLENWEBER J, 1968, AM J CARDIOL, V21, P60, DOI 10.1016/0002-9149(68)90014-3; ZIERLER RE, 1994, J VASC SURG, V19, P250, DOI 10.1016/S0741-5214(94)70100-8	15	340	350	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1133	1136		10.1016/S0140-6736(96)10093-3	http://dx.doi.org/10.1016/S0140-6736(96)10093-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113012				2022-12-28	WOS:A1997WU54400010
J	Nance, J; Abbott, K; Morris, L; Couper, R				Nance, J; Abbott, K; Morris, L; Couper, R			An unfortunate consequence of being tickled	LANCET			English	Article							ARTERY		UNIV ADELAIDE,WOMENS & CHILDRENS HOSP,DEPT PAEDIAT,ADELAIDE,SA 5006,AUSTRALIA; UNIV ADELAIDE,WOMENS & CHILDRENS HOSP,GEN PAEDIAT DIV,ADELAIDE,SA 5006,AUSTRALIA; UNIV ADELAIDE,WOMENS & CHILDRENS HOSP,PAEDIAT NEUROL DIV,ADELAIDE,SA 5006,AUSTRALIA; UNIV ADELAIDE,WOMENS & CHILDRENS HOSP,PAEDIAT RADIOL DIV,ADELAIDE,SA 5006,AUSTRALIA	University of Adelaide; Womens & Childrens Hospital Australia; University of Adelaide; Womens & Childrens Hospital Australia; University of Adelaide; Womens & Childrens Hospital Australia; University of Adelaide; Womens & Childrens Hospital Australia								Hart R G, 1983, Neurol Clin, V1, P155; LEVY C, 1994, RADIOLOGY, V190, P97, DOI 10.1148/radiology.190.1.8259436; STURZENEGGER M, 1995, NEUROLOGY, V45, P691, DOI 10.1212/WNL.45.4.691	3	4	4	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1142	1142		10.1016/S0140-6736(97)02414-8	http://dx.doi.org/10.1016/S0140-6736(97)02414-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113014				2022-12-28	WOS:A1997WU54400012
J	Haber, JE				Haber, JE			A super new twist on the initiation of meiotic recombination	CELL			English	Review							YEAST; MEIOSIS; RAD50; PROTEINS; REPAIR; MRE11; SITE		BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University	Haber, JE (corresponding author), BRANDEIS UNIV,ROSENSTIEL CTR,WALTHAM,MA 02254, USA.			Haber, James/0000-0002-1878-0610				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; GILBERTSON LA, 1994, P NATL ACAD SCI USA, V91, P11934, DOI 10.1073/pnas.91.25.11934; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; JOHZUKA K, 1995, GENETICS, V139, P1521; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KLAPHOLZ S, 1985, GENETICS, V110, P187; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; Malkova A, 1996, GENETICS, V143, P741; MaoDraayer Y, 1996, GENETICS, V144, P71; MCKEE AHZ, 1997, IN PRESS GENETICS; PRINZ S, 1997, IN PRESS GENETICS; Risseeuw E, 1996, MOL CELL BIOL, V16, P5924; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9	20	32	32	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					163	166		10.1016/S0092-8674(00)80194-4	http://dx.doi.org/10.1016/S0092-8674(00)80194-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108470	Bronze			2022-12-28	WOS:A1997WU88800002
J	Zheng, LB; Cornel, AJ; Wang, R; Erfle, H; Voss, H; Ansorge, W; Kafatos, FC; Collins, FH				Zheng, LB; Cornel, AJ; Wang, R; Erfle, H; Voss, H; Ansorge, W; Kafatos, FC; Collins, FH			Quantitative trait loci for refractoriness of Anopheles gambiae to Plasmodium cynomolgi B	SCIENCE			English	Article							MALARIA VECTOR; AEDES-AEGYPTI; SUSCEPTIBILITY; ASSOCIATION; GALLINACEUM; MOSQUITO; MAP	The severity of the malaria pandemic in the tropics is aggravated by the ongoing spread of parasite resistance to antimalarial drugs and mosquito resistance to insecticides. A strain of Anopheles gambiae, normally a major vector for human malaria in Africa, can encapsulate and kill the malaria parasites within a melanin-rich capsule in the mosquito midgut. Genetic mapping revealed one major and two minor quantitative trait loci (QTLs) for this encapsulation reaction. Understanding such antiparasite mechanisms in mosquitoes may lead to new strategies for malaria control.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; CTR DIS CONTROL & PREVENT,CHAMBLEE,GA 30341	European Molecular Biology Laboratory (EMBL); Centers for Disease Control & Prevention - USA			Wang-Sattler, Rui/B-5354-2014; Ansorge, Wilhelm/AAN-8780-2020	Wang-Sattler, Rui/0000-0002-8794-8229; 				ALMASHHADANI HM, 1980, T ROY SOC TROP MED H, V74, P585, DOI 10.1016/0035-9203(80)90146-7; BEARD CB, 1995, J HERED, V86, P375, DOI 10.1093/oxfordjournals.jhered.a111606; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; COLLINS FS, UNPUB; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; CREWSOYEN AE, 1993, AM J TROP MED HYG, V49, P341, DOI 10.4269/ajtmh.1993.49.341; Dimopoulos G, 1996, GENETICS, V143, P953; Gorman MJ, 1996, EXP PARASITOL, V84, P380, DOI 10.1006/expr.1996.0126; GORMAN MJ, IN PRESS GENETICS; GRAVES PM, 1982, ANN TROP MED PARASIT, V76, P633, DOI 10.1080/00034983.1982.11687594; KILAMA WL, 1969, ANN TROP MED PARASIT, V63, P419, DOI 10.1080/00034983.1969.11686645; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; Lee W., UNPUB; MACDONALD WW, 1965, ANN TROP MED PARASIT, V59, P64, DOI 10.1080/00034983.1965.11686284; MANSFIELD DC, 1994, GENOMICS, V24, P225, DOI 10.1006/geno.1994.1610; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; Severson David W., 1994, Insect Molecular Biology, V3, P67, DOI 10.1111/j.1365-2583.1994.tb00153.x; SEVERSON DW, 1995, GENETICS, V139, P1711; Shahabuddin M, 1995, EXP PARASITOL, V81, P386, DOI 10.1006/expr.1995.1129; STAM P, 1993, PLANT J, V3, P739, DOI 10.1111/j.1365-313X.1993.00739.x; VERNICK KD, 1989, AM J TROP MED HYG, V40, P593, DOI 10.4269/ajtmh.1989.40.593; VERNICK KD, 1995, EXP PARASITOL, V80, P583, DOI 10.1006/expr.1995.1074; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; ZHENG LB, 1993, SCIENCE, V261, P605, DOI 10.1126/science.8342025; Zheng LB, 1996, GENETICS, V143, P941	25	160	169	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					425	428		10.1126/science.276.5311.425	http://dx.doi.org/10.1126/science.276.5311.425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103203				2022-12-28	WOS:A1997WU47700043
J	Davis, GJ				Davis, GJ			A winter's tale	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1198	1198		10.1001/jama.277.15.1198	http://dx.doi.org/10.1001/jama.277.15.1198			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103336				2022-12-28	WOS:A1997WT40300017
J	Troy, CJ; Peeling, RW; Ellis, AG; Hockin, JC; Bennett, DA; Murphy, MR; Spika, JS				Troy, CJ; Peeling, RW; Ellis, AG; Hockin, JC; Bennett, DA; Murphy, MR; Spika, JS			Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRAIN-TWAR; FAMILY; TRANSMISSION; EPIDEMIC; PSITTACI	Objective.-To determine the extent and severity of illness and mode of transmission of Chlamydia pneumoniae infection in 3 nursing home outbreaks. Design and Setting.-Retrospective cohort study in 3 nursing homes in Ontario from September to November 1994. Subjects.-A total of 549 residents and 65 staff members. Main Outcome Measures.-Morbidity and mortality were determined by a review of disease surveillance forms, residents' charts, and a self-administered questionnaire to staff. Single and paired serum samples for C pneumoniae serological testing and nasopharyngeal swabs for C pneumoniae culture were collected, and direct fluorescent antibody assays were performed to confirm C pneumoniae infection. Results.-The attack rates for confirmed and suspected cases combined were 68%, 46%, and 44% among residents in nursing homes A, B, and C, respectively, and 34% among nursing home C staff. A total of 16 cases of pneumonia confirmed by chest x-ray and 6 deaths were identified. The spectrum of illness among nursing home C residents included a new cough in 58 (100%), fever in 37 (64%), sore throat in 14 (24%), and hoarseness in 8 (14%). Staff members at nursing home C were more likely to report hoarseness (P<.001) and sore throat (P<.001). Residents who smoked had onset of illness earlier than nonsmokers (P=.007), which perhaps is related to airborne transmission in a designated smoking room. Conclusions.-Chlamydia pneumoniae caused serious morbidity and mortality among residents and morbidity among staff; C pneumoniae is an important cause of respiratory disease outbreaks in nursing homes, and diagnostic tests must be readily available for early recognition of C pneumoniae infections.	HLTH CANADA,LAB CTR DIS CONTROL,FIELD EPIDEMIOL TRAINING PROGRAM,OTTAWA,ON K1A 0L2,CANADA; ONTARIO MINIST HLTH,TORONTO,ON M5W 1R5,CANADA; WINDSOR ESSEX CTY HLTH UNIT,WINDSOR,ON,CANADA; WINDSOR REG PUBL HLTH LAB,WINDSOR,ON,CANADA; HLTH CANADA,LAB CTR DIS CONTROL,BUR INFECT DIS,OTTAWA,ON K1A 0L2,CANADA; HLTH CANADA,LAB CTR DIS CONTROL,BUR MICROBIOL,OTTAWA,ON K1A 0L2,CANADA	Health Canada; Health Canada; Health Canada								BANNATYNE RM, 1979, CUMITECH 10 LAB DIAG; BLASI F, 1994, EUR RESPIR J, V7, P102, DOI 10.1183/09031936.94.07010102; CASEY HL, 1965, PHS PUBLICATION, V1228; DAVIS C, 1989, CHEST S, V95, P206; EKMAN MR, 1993, CLIN INFECT DIS, V17, P420, DOI 10.1093/clinids/17.3.420; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; FALSEY AR, 1993, J INFECT DIS, V168, P493, DOI 10.1093/infdis/168.2.493; GHOSH K, 1992, J INFECTION, V25, P99, DOI 10.1016/0163-4453(92)92223-6; GRAYSTON JT, 1989, EUR J CLIN MICROBIOL, V8, P191, DOI 10.1007/BF01965260; GRAYSTON JT, 1993, J INFECT DIS, V168, P1231, DOI 10.1093/infdis/168.5.1231; GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HYMAN CL, 1991, J CLIN MICROBIOL, V29, P2082, DOI 10.1128/JCM.29.9.2082-2083.1991; KISHIMOTO T, 1994, CHLAMYDIAL INFECT, P465; KLEEMOLA M, 1988, J INFECT DIS, V157, P230, DOI 10.1093/infdis/157.2.230; KUO CC, 1988, ANTIMICROB AGENTS CH, V32, P257, DOI 10.1128/AAC.32.2.257; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; MCKINNEY RM, 1979, J CLIN MICROBIOL, V9, P103; MORDHORST CH, 1992, EUR J CLIN MICROBIOL, V11, P617, DOI 10.1007/BF01961668; MORDHORST CH, 1994, CHLAMYDIAL INFECTION, P488; Nicolle LE, 1996, CLIN MICROBIOL REV, V9, P1; PETHER JVS, 1989, EPIDEMIOL INFECT, V103, P395, DOI 10.1017/S0950268800030752; ROBLIN PM, 1992, J CLIN MICROBIOL, V30, P1968, DOI 10.1128/JCM.30.8.1968-1971.1992; SAIKKU P, 1985, J INFECT DIS, V151, P832, DOI 10.1093/infdis/151.5.832; Schmidt NJ, 1989, DIAGNOSTIC PROCEDURE; TANG PW, 1986, J CLIN MICROBIOL, V24, P556, DOI 10.1128/JCM.24.4.556-558.1986; THEUNISSEN HJH, 1993, APPL ENVIRON MICROB, V59, P2589, DOI 10.1128/AEM.59.8.2589-2593.1993; WANG SP, 1997, NONGONOCOCCAL URETHR, P237; YAMAZAKI T, 1990, J INFECT DIS, V162, P1390, DOI 10.1093/infdis/162.6.1390	30	74	74	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1214	1218		10.1001/jama.277.15.1214	http://dx.doi.org/10.1001/jama.277.15.1214			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103345				2022-12-28	WOS:A1997WT40300032
J	Gazzard, BG; Moyle, GJ; Weber, J; Johnson, M; Bingham, JS; Brettle, R; Churchill, D; Fisher, M; Griffin, G; Jefferies, D; King, E; Gormer, R; Lee, C; Pozniak, A; Smith, JR; TudorWilliams, G; Williams, I				Gazzard, BG; Moyle, GJ; Weber, J; Johnson, M; Bingham, JS; Brettle, R; Churchill, D; Fisher, M; Griffin, G; Jefferies, D; King, E; Gormer, R; Lee, C; Pozniak, A; Smith, JR; TudorWilliams, G; Williams, I			British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; IN-VIVO; ZIDOVUDINE; COMBINATION; THERAPY	Only incomplete data are available to guide decisions on anti-HIV treatment. A British HIV Association consensus is that guidance must draw on other evidence besides the randomised trial. Marker studies, work on disease pathogenesis and viral dynamics, and expanding knowledge of resistance patterns mean that the approach to therapy is constantly evolving. There is a need for well-informed dialogue between HIV-infected patient and physician to achieve rational, Individualised treatment. However, the following broad principles have a wide consensus amongst HIV-treating physicians in the UH: (1) treatment should be offered before substantial immunodeficiency ensues; (2) initial treatment should include combinations of at least two drugs; (3) switches in therapy should involve substitution or addition of at least two new agents; (4) viral load and CD4 measurements are essential; (5) reduction in viral load to below the detection level of a sensitive assay represents the optimal treatment response and failure to achieve or sustain this control should prompt consideration of therapy modification. This response seems to be achieved most reliably with combinations of two nucleoside analogues plus a third agent (a protease inhibitor, a nonnucleoside reverse-transcriptase inhibitor, or a third nucleoside analogue) or of two protease inhibitors.			Gazzard, BG (corresponding author), CHELSEA & WESTMINSTER HOSP,LONDON SW10 9TH,ENGLAND.		Churchill, Duncan/AAT-5441-2020	Smith, Jane/0000-0003-1844-3910				CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Fauci AS, 1996, ANN INTERN MED, V124, P654, DOI 10.7326/0003-4819-124-7-199604010-00006; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUGHES MD, 1995, J ACQ IMMUN DEF SYND, V10, pS1; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; KATLAMA C, 1996, 3 INT C DRUG THER HI; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KAVLICK MF, 1995, ANTIVIR RES, V28, P133, DOI 10.1016/0166-3542(95)00044-M; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; LALEZARI J, 1996, 11 INT C AIDS VANC J; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Moyle G, 1996, DRUGS, V51, P701, DOI 10.2165/00003495-199651050-00001; MOYLE G, 1996, EXPERT OPIN INV DRUG, V5, P155; Moyle GJ, 1996, DRUGS, V52, P168, DOI 10.2165/00003495-199652020-00002; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PORTEGIES P, 1995, LANCET, V346, P124; RICHMAN DD, 1994, J ACQ IMMUN DEF SYND, V7, P135; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354; SHAPIRO JM, 1996, ANN INTERN MED, V124, P1039; SHARLAND M, IN PRESS ARCH DIS CH; TUDORWILLIAMS G, ABC AIDS; Vella S, 1995, AIDS, V9, pS21; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1993, LANCET, V341, P109; 1996, LANCET, V348, P283	40	190	193	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1086	1092		10.1016/S0140-6736(96)12073-0	http://dx.doi.org/10.1016/S0140-6736(96)12073-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107259				2022-12-28	WOS:A1997WU00200040
J	Greenwood, R				Greenwood, R			Value of recording duration of posttraumatic amnesia	LANCET			English	Editorial Material							HEAD-INJURY				Greenwood, R (corresponding author), HOMERTON HOSP,REG NEUROL REHABIL UNIT,LONDON E9 6SR,ENGLAND.							BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Russell W.R., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198; 1961, LANCET, V2, P1445	9	16	17	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1041	1042		10.1016/S0140-6736(05)62288-X	http://dx.doi.org/10.1016/S0140-6736(05)62288-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107239				2022-12-28	WOS:A1997WU00200005
J	Young, LA; Yelle, RV; Young, R; Seiff, A; Kirk, DB				Young, LA; Yelle, RV; Young, R; Seiff, A; Kirk, DB			Gravity waves in Jupiter's thermosphere	SCIENCE			English	Article							JOVIAN UPPER-ATMOSPHERE; UPPER-STRATOSPHERE; OCCULTATIONS; VOYAGER-2; EMISSIONS; NEPTUNE; URANUS	The Atmosphere Structure Instrument on the Galileo probe detected wavelike temperature fluctuations superimposed on a 700-kelvin temperature increase in Jupiter's thermosphere. These fluctuations are consistent with gravity waves that are viscously damped in the thermosphere. Moreover, heating by these waves can explain the temperature increase measured by the probe, This heating mechanism should be applicable to the thermospheres of the other giant planets and may help solve the long-standing question of the source of their high thermospheric temperatures.	NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035; SAN JOSE STATE UNIV FDN,DEPT METEOROL,SAN JOSE,CA 95192; UNIV OREGON,EUGENE,OR 97403	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California State University System; San Jose State University; University of Oregon	Young, LA (corresponding author), BOSTON UNIV,CTR SPACE PHYS,BOSTON,MA 02215, USA.							ATREYA SK, 1979, GEOPHYS RES LETT, V6, P795, DOI 10.1029/GL006i010p00795; BROADFOOT AL, 1989, SCIENCE, V246, P1459, DOI 10.1126/science.246.4936.1459; CLARKE JT, 1987, J GEOPHYS RES, V92, P15139, DOI 10.1029/JA092iA13p15139; FRENCH RG, 1974, J ATMOS SCI, V31, P1707, DOI 10.1175/1520-0469(1974)031<1707:WITJUA>2.0.CO;2; GILL, 1982, ATMOSPHERE OCEAN DYN, P294; HERBERT F, 1987, J GEOPHYS RES, V92, P15093, DOI 10.1029/JA092iA13p15093; HOLTON, 1993, J ATMOS SCI, V41, P2653; HUNTEN DM, 1977, PLANET SPACE SCI, V25, P817, DOI 10.1016/0032-0633(77)90035-6; MARTEN A, 1994, PLANET SPACE SCI, V42, P391, DOI 10.1016/0032-0633(94)90128-7; NISHIDA, 1991, J GEOPHYS RES, V86, P9945; ROQUES F, 1994, ASTRON ASTROPHYS, V288, P985; SCARGLE JD, 1982, ASTROPHYS J, V263, P835, DOI 10.1086/160554; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SEIFF A, 1997, SCIENCE, V276, P402; SMITH GR, 1983, J GEOPHYS RES-SPACE, V88, P8667, DOI 10.1029/JA088iA11p08667; VEVERKA J, 1974, ASTRON J, V79, P73, DOI 10.1086/111534; Waite JH, 1997, SCIENCE, V276, P104, DOI 10.1126/science.276.5309.104; WHITEWAY JA, 1995, J GEOPHYS RES-ATMOS, V100, P14113, DOI 10.1029/95JD00511; Yelle RV, 1996, J GEOPHYS RES-PLANET, V101, P2149, DOI 10.1029/95JE03384	19	89	89	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					108	111		10.1126/science.276.5309.108	http://dx.doi.org/10.1126/science.276.5309.108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082979				2022-12-28	WOS:A1997WR38600057
J	Low, PA; Gilden, JL; Freeman, R; Sheng, KN; McElligott, MA				Low, PA; Gilden, JL; Freeman, R; Sheng, KN; McElligott, MA			Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension - A randomized, double-blind multicenter study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTONOMIC FAILURE	Objective.-To evaluate the efficacy of a 10-mg dose of midodrine 3 times per day in improving blood pressure (BP) and ameliorating symptoms of orthostatic hypotension in patients with neurogenic orthostatic hypotension. Midodrine hydrochloride, an alpha-agonist, could improve orthostatic BP by increasing vasomotor and venomotor tone. Design/Methods.-A total of 171 patients with orthostatic hypotension participated in a multicenter, randomized, placebo-controlled study. They were randomized to a 10-mg dose of midodrine or placebo 3 times per day in a 6-week study, comprising single-blind run-in (at week 1) and washout at weeks 5 and 6, with an intervening double-blind period (weeks 2 to 4). Setting.-Twenty-five centers, with most patients evaluated in referral centers. Main Outcome Measures.-The primary end points were improvement in standing systolic BP, symptoms of lightheadedness, and a global symptom relief score (by the investigator and patient separately). Results.-Nine patients were not evaluable because of noncompliance or taking concomitant vasoactive medications (3 in the midodrine group, 6 in the placebo group). In the evaluable patients, midodrine resulted in improvements in standing systolic BP at all time points (P<.001 at visits 2, 3, 4, and 5), in reported symptoms by the end of the second week of treatment (P=.001), and in the global symptom relief score rated by both the patient (P=.03) and the investigator (P<.001). There was no effect by center, severity of orthostatic hypotension, use of fludrocortisone or compression garments, or diagnosis. The main adverse effects were those of pilomotor reactions, urinary retention, and supine hypertension. Conclusions.-Midodrine is efficacious and safe in the treatment of neurogenic orthostatic hypotension.	FINCH UNIV HLTH SCI CHICAGO MED SCH,N CHICAGO,IL 60064; BETH ISRAEL DEACONESS MED CTR,BOSTON,MA; ROBERTS PHARMACEUT CORP,EATONTOWN,NJ	Chicago Medical School; Harvard University; Beth Israel Deaconess Medical Center	Low, PA (corresponding author), MAYO CLIN & MAYO FDN,DEPT NEUROL,AUTON REFLEX LAB,811 GUGGENHEIM BLDG,ROCHESTER,MN 55905, USA.							BANNISTER R, 1993, CLIN AUTONOMIC DISOR, P517; COHEN J, 1987, ANN NEUROL, V22, P692, DOI 10.1002/ana.410220604; DOBKIN BH, 1989, NEUROLOGY, V39, P30, DOI 10.1212/WNL.39.1.30; FEALEY RD, 1993, CLIN AUTONOMIC DISOR, P731; GROBECKER H, 1987, ARZNEIMITTEL-FORSCH, V37-1, P447; JANKOVIC J, 1993, AM J MED, V95, P38, DOI 10.1016/0002-9343(93)90230-M; LOW PA, 1995, NEUROLOGY, V45, pS19; Low PA, 1993, CLIN AUTONOMIC DISOR, P395; MCTAVISH D, 1989, DRUGS, V38, P757, DOI 10.2165/00003495-198938050-00004; ROBERTSON D, 1995, NEUROLOGY, V45, pS26; Sandroni P, 1991, Clin Auton Res, V1, P147, DOI 10.1007/BF01826212; THOMAS DJ, 1980, J NEUROL SCI, V44, P205, DOI 10.1016/0022-510X(80)90127-6; THOMAS JE, 1970, ARCH NEUROL-CHICAGO, V22, P289, DOI 10.1001/archneur.1970.00480220003001; THULESIUS O, 1979, EUR J CLIN PHARMACOL, V16, P423, DOI 10.1007/BF00568204; WRIGHT A, 1995, NEUROLOGY, V45, pA396; ZACHARIAH PK, 1986, CLIN PHARMACOL THER, V39, P586, DOI 10.1038/clpt.1986.101	16	358	365	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1046	1051		10.1001/jama.277.13.1046	http://dx.doi.org/10.1001/jama.277.13.1046			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091692				2022-12-28	WOS:A1997WQ08900029
J	Singer, CRJ				Singer, CRJ			ABC of clinical haematology - Multiple myeloma and related conditions	BRITISH MEDICAL JOURNAL			English	Article											Singer, CRJ (corresponding author), ROYAL UNITED HOSP,BATH BA1 3NG,AVON,ENGLAND.							Bergsagel DE, 1995, BAILLIERE CLIN HAEM, V8, P783, DOI 10.1016/S0950-3536(05)80259-8; KYLE RA, 1992, HEMATOL ONCOL CLIN N, V6, P347, DOI 10.1016/S0889-8588(18)30348-4; Kyle RA, 1995, BAILLIERE CLIN HAEM, V8, P761, DOI 10.1016/S0950-3536(05)80258-6	3	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					960	963		10.1136/bmj.314.7085.960	http://dx.doi.org/10.1136/bmj.314.7085.960			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099124	Green Published			2022-12-28	WOS:A1997WQ16900033
J	Horton, R				Horton, R			nvCJD: After the hype, some real data	LANCET			English	Editorial Material																		Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; CRAIG O, 1997, SUNDAY TIMES    0316, P13; Fleminger S, 1997, BRIT J PSYCHIAT, V170, P103, DOI 10.1192/bjp.170.2.103; Gore SM, 1996, BRIT MED J, V312, P791, DOI 10.1136/bmj.312.7034.791	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					820	820		10.1016/S0140-6736(05)61748-5	http://dx.doi.org/10.1016/S0140-6736(05)61748-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121254				2022-12-28	WOS:A1997WP40300007
J	McLean, GR				McLean, GR			A case for goodwill	BRITISH MEDICAL JOURNAL			English	Article											McLean, GR (corresponding author), UNIV WITWATERSRAND,DEPT PHILOSOPHY,JOHANNESBURG,SOUTH AFRICA.			McLean, Graeme/0000-0003-3632-0906					0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					890	890						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093107				2022-12-28	WOS:A1997WQ02800040
J	More, RS; Chauhan, A				More, RS; Chauhan, A			Antiplatelet rather than anticoagulant therapy with coronary stenting	LANCET			English	Editorial Material							ANGIOPLASTY		PAPWORTH HOSP,DEPT CARDIAC,CAMBRIDGE,ENGLAND	Papworth Hospital	More, RS (corresponding author), ST MARYS HOSP,ACAD CARDIAC DEPT,PRAED ST,LONDON W2 1NY,ENGLAND.							BRUNEL P, 1995, CIRCULATION S1, V92, P87; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Hall P, 1996, CIRCULATION, V93, P215, DOI 10.1161/01.CIR.93.2.215; Inoue T, 1996, CIRCULATION, V94, P1523; JORDAN C, 1994, CIRCULATION, V90, P125; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201	9	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					146	147		10.1016/S0140-6736(97)22003-9	http://dx.doi.org/10.1016/S0140-6736(97)22003-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111532				2022-12-28	WOS:A1997WC86100002
J	Raghuraman, MK; Brewer, BJ; Fangman, WL				Raghuraman, MK; Brewer, BJ; Fangman, WL			Cell cycle-dependent establishment of a late replication program	SCIENCE			English	Article							FRAGILE-X SYNDROME; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; YEAST PLASMID; S-CEREVISIAE; ORIGIN; TELOMERES; LOCALIZATION; INHERITANCE; EXPRESSION	DNA replication origins in chromosomes of eukaryotes are activated according to a temporal program. In the yeast Saccharomyces cerevisiae, activation of origins in early S phase appears to be a default state. However, cis-acting elements such as telomeres can delay origin activation until late S phase, Site-specific recombination was used to separate origin from telomere in vivo, thereby demonstrating that the signal for late activation is established between mitosis and START in the subsequent G(1) phase. Once set, the signal can persist through the next S phase in the absence of the telomere, Establishment of the temporal program and of initiation competence of origins may be coincident events.			Raghuraman, MK (corresponding author), UNIV WASHINGTON, DEPT GENET, BOX 35-7360, SEATTLE, WA 98195 USA.				PHS HHS [18926] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARAKI H, 1992, J MOL BIOL, V225, P25, DOI 10.1016/0022-2836(92)91023-I; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 1995, J CELL SCI, P67; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; GNIRKE A, 1994, GENOMICS, V24, P199, DOI 10.1006/geno.1994.1607; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; LAIRD CD, 1987, GENETICS, V117, P587; LI JJ, 1995, CURR BIOL, V5, P472, DOI 10.1016/S0960-9822(95)00094-7; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RAGHURAMAN MK, 1994, GENE DEV, V8, P554, DOI 10.1101/gad.8.5.554; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Rivier DH, 1992, CURR OPIN GENET DEV, V2, P286, DOI 10.1016/S0959-437X(05)80286-2; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	33	135	136	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					806	809		10.1126/science.276.5313.806	http://dx.doi.org/10.1126/science.276.5313.806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115207				2022-12-28	WOS:A1997WW90000061
J	Kaplan, MR; MeyerFranke, A; Lamber, S; Bennett, V; Duncan, ID; Levinson, SR; Barres, BA				Kaplan, MR; MeyerFranke, A; Lamber, S; Bennett, V; Duncan, ID; Levinson, SR; Barres, BA			Induction of sodium channel clustering by oligodendrocytes	NATURE			English	Article							RETINAL GANGLION-CELLS; MYELIN-DEFICIENT RAT; OPTIC-NERVE; SURVIVAL; DIFFERENTIATION; EXPRESSION; RANVIER; MUTANT; BRAIN; GENE	As oligodendrocytes wrap axons of the central nervous system (CNS) with insulating myelin sheaths, sodium channels that are initially continuously distributed along axons become segregated into regularly spaced gaps in the myelin called nodes of Ranvier(1). It is not known whether the regular spacing of nodes results from regularly spaced glial contacts or is instead intrinsically specified by the axonal cytoskeleton. Contact with Schwann cells induces clustering of sodium channels along the axons of peripheral neurons in vitro and in vivo(2-4). Similarly, it has been suggested that astrocyte contact induces clustering of sodium channels along CNS axons(5,6). Here we show that oligodendrocytes are necessary for clustering of sodium channels in vitro and in vivo. The induction, but not the maintenance, of sodium-channel clustering along the axons of highly purified rat retinal ganglion cells in culture depends on a protein secreted by oligodendrocytes. Surprisingly, the oligodendrocyte-induced clusters are regularly spaced at the predicted interval in the absence of glial-axonal contact. Mutant rats that are deficient in oligodendrocytes develop few axonal sodium channel clusters in vivo. These results demonstrate a crucial role for oligodendrocytes in inducing clustering of sodium channels.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; WORCHESTER FDN,SHREWSBURY,MA 01545; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV WISCONSIN,SCH VET MED,DEPT MED SCI,MADISON,WI 53706; UNIV COLORADO,HLTH SCI CTR,SCH MED,DEPT PHYSIOL,DENVER,CO 80262	Stanford University; Duke University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bhat RV, 1996, GLIA, V17, P169; Black Joel A., 1995, P116; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CSIZA CK, 1979, AM J PATHOL, V95, P215; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DUGANDZIJA NS, 1995, J NEUROSCI, V1, P492; ELLISMAN M, 1979, J NEUROCYTOL, V8, P6719; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HESS A, 1949, NATURE, V164; HILDEBRAND C, 1984, J COMP NEUROL, V224, P25, DOI 10.1002/cne.902240103; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUXLEY AF, 1949, J PHYSIOL-LONDON, V108, P315, DOI 10.1113/jphysiol.1949.sp004335; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUMAR S, 1988, J NEUROSCI RES, V21, P268, DOI 10.1002/jnr.490210219; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; NADON NL, 1995, J NEUROSCI RES, V41, P96, DOI 10.1002/jnr.490410111; Peters A., 1991, FINE STRUCTURE NERVO; ROSENBLUTH J, 1990, ANN NY ACAD SCI, V605, P194; Sanchez I, 1996, J NEUROSCI, V16, P5095; SKOFF RP, 1976, J COMP NEUROL, V169, P313, DOI 10.1002/cne.901690304; SMITH K, 1983, J NEUROL SCI, V54, P13; UTZSCHNEIDER DA, 1993, P ROY SOC B-BIOL SCI, V254, P245, DOI 10.1098/rspb.1993.0153; Vabnick I, 1996, J NEUROSCI, V16, P4914; Waxman Stephen G., 1995, P587	30	251	257	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					724	728		10.1038/386724a0	http://dx.doi.org/10.1038/386724a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109490				2022-12-28	WOS:A1997WU38700058
J	Keene, WE; Sazie, E; Kok, J; Rice, DH; Hancock, DD; Balan, VK; Zhao, T; Doyle, MP				Keene, WE; Sazie, E; Kok, J; Rice, DH; Hancock, DD; Balan, VK; Zhao, T; Doyle, MP			An outbreak of Escherichia coli O157:H7 infections traced to jerky made from deer meat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC-UREMIC SYNDROME; FOOD	Objective.-To investigate a 1995 outbreak of Escherichia coli O157:H7 infections and to assess the safety of meat dehydration methods. Design.-Survey subsequent to routine surveillance report, environmental investigations, and laboratory experimentation. Setting.-Oregon community. Participants.-Members of an extended household and their social contacts with confirmed or presumptive E coli O157:H7 infections. Results.-A total of 6 confirmed and 5 presumptive cases were identified. Homemade venison jerky was implicated as the source of transmission. E coli O157:H7 with the same distinctive, pulsed-field gel electrophoresis pattern seen in the case isolates was recovered from leftover jerky, uncooked meat from the same deer, a saw used to dismember the carcass, and fragments of the deer hide. In a subsequent survey, E coli O157:H7 was recovered from 3 (9%) of 32 deer fecal pellets collected in nearby forest land. In the laboratory, inoculated venison was dried at several time and temperature combinations, ranging up to 10 hours at 62.8 degrees C. Viable organisms were recovered under all conditions tested. Conclusions.-Deer can be colonized by E coli O157,H7 and can be a source of human infections, Conditions necessary to ensure the safety of dried meat deserve further review. Game should be handled with the same caution indicated for commercially slaughtered meat.	OREGON HLTH DIV, ACUTE & COMMUNICABLE DIS PROGRAM, PORTLAND, OR 97232 USA; BENTON CTY HLTH DEPT, CORVALLIS, OR USA; WASHINGTON STATE UNIV, FIELD DIS INVEST UNIT, PULLMAN, WA 99164 USA; UNIV GEORGIA, CTR FOOD SAFETY & QUAL ENHANCEMENT, GRIFFIN, GA USA	Oregon Health & Science University; Washington State University; University System of Georgia; University of Georgia	Keene, WE (corresponding author), OREGON HLTH DIV, OREGAON STATE PUBL HLTH LAB, 800 NE OREGON ST, SUITE 772, PORTLAND, OR 97232 USA.							Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; GLASS KA, 1992, APPL ENVIRON MICROB, V58, P2513, DOI 10.1128/AEM.58.8.2513-2516.1992; Gray Larry D., 1995, P450; Harrison JA, 1996, J FOOD PROTECT, V59, P1336, DOI 10.4315/0362-028X-59.12.1336; Kudva IT, 1996, J CLIN MICROBIOL, V34, P431, DOI 10.1128/JCM.34.2.431-433.1996; MCGOWAN KL, 1989, LANCET, V1, P967; MILLEY DG, 1993, APPL ENVIRON MICROB, V59, P4223, DOI 10.1128/AEM.59.12.4223-4229.1993; PADHYE NV, 1991, APPL ENVIRON MICROB, V57, P2693, DOI 10.1128/AEM.57.9.2693-2698.1991; PAI CH, 1984, ANN INTERN MED, V101, P738, DOI 10.7326/0003-4819-101-6-738; Paton AW, 1996, J CLIN MICROBIOL, V34, P1622, DOI 10.1128/JCM.34.7.1622-1627.1996; PIERARD D, 1994, INT CONGR SER, V1072, P77; PIERARD D, 1995, 95 AM SOC MICR GEN M, P383; RICE DH, 1995, VET REC, V137, P524, DOI 10.1136/vr.137.20.524; ROWE PC, 1994, J PEDIATR-US, V124, P21, DOI 10.1016/S0022-3476(94)70249-7; SANDERSON MW, 1995, J CLIN MICROBIOL, V33, P2616, DOI 10.1128/JCM.33.10.2616-2619.1995; Shukla R, 1995, Commun Dis Rep CDR Rev, V5, pR86; SUMNER JL, 1977, J SCI FOOD AGR, V28, P829, DOI 10.1002/jsfa.2740280909; Trevena WB, 1996, VET REC, V138, P400; *US BUR CENS, 1993, 1991 NAT SURV FISH H; *US FDA, 1992, BACT AN MAN	23	219	222	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1229	1231		10.1001/jama.277.15.1229	http://dx.doi.org/10.1001/jama.277.15.1229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103348				2022-12-28	WOS:A1997WT40300035
J	Frank, SM; Fleisher, LA; Breslow, MJ; Higgins, MS; Olson, KF; Kelly, S; Beattie, C				Frank, SM; Fleisher, LA; Breslow, MJ; Higgins, MS; Olson, KF; Kelly, S; Beattie, C			Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTOPERATIVE MYOCARDIAL-ISCHEMIA; OPERATING-ROOM TEMPERATURE; HALOTHANE ANESTHESIA; GENERAL-ANESTHESIA; NONCARDIAC SURGERY; OXYGEN-CONSUMPTION; SPINAL-ANESTHESIA; COLD ENVIRONMENT; PURKINJE-FIBERS; HEART-DISEASE	Objective.-To assess the relationship between body temperature and cardiac morbidity during the perioperative period. Design.-Randomized controlled trial comparing routine thermal care (hypothermic group) to additional supplemental warming care (normothermic group). Setting.-Operating rooms and surgical intensive care unit at an academic medical center. Subjects.-Three hundred patients undergoing abdominal, thoracic, or vascular surgical procedures who either had documented coronary artery disease or were at high risk for coronary disease. Outcome Measure. The relative risk of a morbid cardiac event (unstable angina/ischemia, cardiac arrest, or myocardial infarction) according to thermal treatment. Cardiac outcomes were assessed in a double-blind fashion. Results.-Mean core temperature after surgery was lower in the hypothermic group (35.4+/-0.1 degrees C) than in the normothermic group (36.7+/-0.1 degrees C) (P<.001) and remained lower during the early postoperative period, Perioperative morbid cardiac events occurred less frequently in the normothermic group than in the hypothermic group (1.4% vs 6.3%; P=.02). Hypothermia was an independent predictor of morbid cardiac events by multivariate analysis (relative risk, 2.2; 95% confidence interval, 1.1-4.7; P=.04), indicating a 55% reduction in risk when normothermia was maintained. Postoperative ventricular tachycardia also occurred less frequently in the normothermic group than in the hypothermic group (2.4% vs 7.9%; P=.04). Conclusion.-In patients with cardiac risk factors who are undergoing noncardiac surgery, the perioperative maintenance of normothermia is associated with a reduced incidence of morbid cardiac events and ventricular tachycardia.	JOHNS HOPKINS MED INST,DEPT ANESTHESIOL & CRIT CARE MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT SURG,BALTIMORE,MD 21205; VANDERBILT UNIV,MED CTR,DEPT ANESTHESIOL,NASHVILLE,TN	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Vanderbilt University			Lee A, Fleisher/Q-9894-2019		NIGMS NIH HHS [GM38117] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINTON D, 1977, BRIT J PREV SOC MED, V31, P49; BAY J, 1968, BRIT J ANAESTH, V40, P398, DOI 10.1093/bja/40.6.398; BRESLOW MJ, 1993, ANESTHESIOLOGY, V79, P1202, DOI 10.1097/00000542-199312000-00010; CHENG C, 1995, ANESTHESIOLOGY, V82, P1160, DOI 10.1097/00000542-199505000-00011; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; EPSTEIN SE, 1969, NEW ENGL J MED, V280, P7, DOI 10.1056/NEJM196901022800102; FEDIDA D, 1989, AM J PHYSIOL, V256, pH1500, DOI 10.1152/ajpheart.1989.256.5.H1500; FLEISHER LA, 1995, ANESTHESIOLOGY, V83, P906, DOI 10.1097/00000542-199511000-00003; FLEISHER LA, 1991, AM HEART J, V122, P980, DOI 10.1016/0002-8703(91)90461-P; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; FRANK SM, 1992, ANESTHESIOLOGY, V77, P252, DOI 10.1097/00000542-199208000-00005; FRANK SM, 1995, ANESTHESIOLOGY, V83, P241, DOI 10.1097/00000542-199508000-00002; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; FRANK SM, 1994, THERMAL BALANCE HLTH, P325; FRANK SM, 1967, AM J PHYSIOL, V272, pR557; HAMRA M, 1988, CIRCULATION, V78, P1495, DOI 10.1161/01.CIR.78.6.1495; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; HOSMER DW, 1989, APPL LOGISTIC REGRES, P109; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; Jalife, 1990, CARDIAC ELECTROPHYSI, P312; JUNEAU M, 1989, CIRCULATION, V79, P1015, DOI 10.1161/01.CIR.79.5.1015; KIMURA S, 1984, CIRCULATION, V70, P1074, DOI 10.1161/01.CIR.70.6.1074; Krenzischek D A, 1995, J Post Anesth Nurs, V10, P69; KURZ A, 1993, ANESTHESIOLOGY, V79, P465, DOI 10.1097/00000542-199309000-00008; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; KURZ A, 1993, ANESTH ANALG, V77, P721; LASSVIK CT, 1979, BRIT HEART J, V42, P396; LENNON RL, 1990, ANESTH ANALG, V70, P424; LIEBERMAN RW, 1983, ANESTHESIOLOGY, V59, P36, DOI 10.1097/00000542-198307000-00007; LOPEZ M, 1994, ANESTHESIOLOGY, V80, P780, DOI 10.1097/00000542-199404000-00009; MACINTYRE PE, 1987, ANESTH ANALG, V66, P751; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MEINERT CL, 1986, CLIN TRIALS DESIGN C, P212; MORRIS RH, 1971, ARCH SURG-CHICAGO, V102, P95; MUDGE GH, 1976, NEW ENGL J MED, V295, P1333, DOI 10.1056/NEJM197612092952401; NELSON AH, 1993, CRIT CARE MED, V21, P860, DOI 10.1097/00003246-199306000-00013; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OZAKI M, 1994, ANESTHESIOLOGY, V81, P282, DOI 10.1097/00000542-199408000-00004; RAMANATHAN NL, 1964, J APPL PHYSIOL, V19, P531, DOI 10.1152/jappl.1964.19.3.531; ROSE G, 1966, BRIT J PREV SOC MED, V20, P97; RUBINSTEIN EH, 1990, ANESTHESIOLOGY, V73, P541, DOI 10.1097/00000542-199009000-00027; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P594, DOI 10.1097/00000542-199110000-00009; SESSLER DI, 1993, FASEB J, V7, P638, DOI 10.1096/fasebj.7.8.8500688; SESSLER DI, 1988, ANESTHESIOLOGY, V68, P836, DOI 10.1097/00000542-198806000-00002; SHERIDAN DJ, 1980, J CLIN INVEST, V65, P161, DOI 10.1172/JCI109647; SLOGOFF S, 1988, ANESTHESIOLOGY, V68, P676, DOI 10.1097/00000542-198805000-00004; SMITH RC, 1992, AM HEART J, V123, P73, DOI 10.1016/0002-8703(92)90749-L; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; VAUGHAN MS, 1981, ANESTH ANALG, V60, P746	51	794	856	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1127	1134		10.1001/jama.277.14.1127	http://dx.doi.org/10.1001/jama.277.14.1127			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087467				2022-12-28	WOS:A1997WR34200031
J	Blaser, MJ				Blaser, MJ			Not all Helicobacter pylori strains are created equal: Should all be eliminated?	LANCET			English	Editorial Material							GASTRIC INFECTION; PEPTIC-ULCERATION; BACTERIA; STOMACH; ACID		DEPT VET AFFAIRS MED CTR,MED SERV,NASHVILLE,TN 37212	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Blaser, MJ (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,DIV INFECT DIS,A-3310 MED CTR N,NASHVILLE,TN 37232, USA.							APELMELK BJ, 1996, INFECT IMMUN, V64, P2031; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Blaser MJ, 1996, ALIMENT PHARM THER, V10, P73, DOI 10.1046/j.1365-2036.1996.22164008.x; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; Blaser MJ, 1996, HELICOBACTER PYLORI, P33; DUBOIS A, 1995, J CLIN MICROBIOL, V33, P1492, DOI 10.1128/JCM.33.6.1492-1495.1995; DUBOIS A, 1994, GASTROENTEROLOGY, V106, P1405, DOI 10.1016/0016-5085(94)90392-1; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; Fairchok MP, 1996, CLIN INFECT DIS, V22, P966, DOI 10.1093/clinids/22.6.966; FUJIMOTO S, 1994, J CLIN MICROBIOL, V32, P331, DOI 10.1128/JCM.32.2.331-334.1994; Go MF, 1996, J BACTERIOL, V178, P3934, DOI 10.1128/jb.178.13.3934-3938.1996; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; KIRSCHNER DE, 1995, J THEOR BIOL, V176, P281, DOI 10.1006/jtbi.1995.0198; KOELZ HR, 1992, SCAND J GASTROENTERO, V27, P2, DOI 10.3109/00365529209095998; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; MARSHALL BJ, 1984, LANCET, V1, P1311; PASTER BJ, 1991, INT J SYST BACTERIOL, V41, P31, DOI 10.1099/00207713-41-1-31; POUNDER RE, 1995, ALIMENT PHARM THERAP, V9, pS33; SUSSER M, 1962, LANCET, V1, P115; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; TAYLOR NS, 1995, J CLIN MICROBIOL, V33, P918, DOI 10.1128/JCM.33.4.918-923.1995	22	161	167	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					1020	1022		10.1016/S0140-6736(96)09133-7	http://dx.doi.org/10.1016/S0140-6736(96)09133-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100641				2022-12-28	WOS:A1997WR62100044
J	Farrell, AM				Farrell, AM			Acquired perforating dermatosis in renal and diabetic patients	LANCET			English	Editorial Material							COLLAGENOSIS; MELLITUS; PATHOGENESIS; ELIMINATION; FAILURE				Farrell, AM (corresponding author), CHURCHILL HOSP,DEPT DERMATOL,OXFORD OX3 7LJ,ENGLAND.							BAYOUMI AHM, 1978, BRIT J DERMATOL, V99, P611, DOI 10.1111/j.1365-2133.1978.tb07054.x; COCHRAN RJ, 1983, CUTIS, V31, P55; FAVER IR, 1994, J AM ACAD DERMATOL, V30, P575, DOI 10.1016/S0190-9622(94)70065-6; HAFTEK M, 1993, J CUTAN PATHOL, V20, P350, DOI 10.1111/j.1600-0560.1993.tb01274.x; Morton CA, 1996, BRIT J DERMATOL, V135, P671; PATTERSON JW, 1992, INT J DERMATOL, V31, P201, DOI 10.1111/j.1365-4362.1992.tb03937.x; POLIAK SC, 1982, NEW ENGL J MED, V306, P81, DOI 10.1056/NEJM198201143060206; ZELGER B, 1991, ARCH DERMATOL, V127, P695, DOI 10.1001/archderm.127.5.695	8	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					895	896		10.1016/S0140-6736(05)62693-1	http://dx.doi.org/10.1016/S0140-6736(05)62693-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093247				2022-12-28	WOS:A1997WR25400005
J	Knauth, M; Ries, S; Pohimann, S; Kerby, T; Forsting, M; Daffertshofer, R; Hennerici, M; Sartor, K				Knauth, M; Ries, S; Pohimann, S; Kerby, T; Forsting, M; Daffertshofer, R; Hennerici, M; Sartor, K			Cohort study of multiple brain lesions in sport divers: Role of a patent foramen ovale	BRITISH MEDICAL JOURNAL			English	Article							CENTRAL-NERVOUS-SYSTEM; DECOMPRESSION-SICKNESS; PULSE SEQUENCE; MR; PREVALENCE; STROKE; SPACES	Objective: To investigate the role of a patent foramen ovale in the pathogenesis of multiple brain lesions acquired by sport divers in the absence of reported decompression symptoms. Design: Prospective double blind cohort study. Setting: Diving clubs around Heidelberg and departments of neuroradiology and neurology. Subjects: 87 sport divers with a minimum of 160 scuba dives (dives with self contained underwater breathing apparatus). Main outcome measures: Presence of multiple brain lesions visualised by cranial magnetic resonance imaging and presence and size of patent foramen ovale as documented by echocontrast transcranial Doppler ultrasonography. Results: 25 subjects were found to have a right-to-left shunt, 13 with a patent foramen ovale of high haemodynamic relevance. A total of 41 brain lesions were detected in 11 divers. There were seven brain lesions in seven divers without a right-to-left shunt and 34 lesions in four divers with a right-to-left shunt, Multiple brain lesions occurred exclusively in three divers with a large patent foramen ovale (P=0.004). Conclusions: Multiple brain lesions in sport divers were associated with presence of a large patent foramen ovale, This association suggests paradoxical gas embolism as the pathological mechanism. A patent foramen ovale of high haemodynamic relevance seems to be an important risk factor for developing multiple brain lesions in sport divers.	UNIV HEIDELBERG,KLINIKUM MANNHEIM,DEPT NEUROL,D-6900 HEIDELBERG,GERMANY; UNIV FRANKFURT KLINIKUM,DEPT BIOL,D-6000 FRANKFURT,GERMANY	Ruprecht Karls University Heidelberg; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Knauth, M (corresponding author), UNIV HEIDELBERG,KLINIKUM HEIDELBERG,DEPT NEURORADIOL,NEUENHEIMER FELD 400,D-69120 HEIDELBERG,GERMANY.		Forsting, Michael/C-6925-2013					BUTLER BD, 1979, J APPL PHYSIOL, V47, P537, DOI 10.1152/jappl.1979.47.3.537; *CIB GEIG AG, 1980, WISS TAB GEIG TEILB; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; DITULLIO M, 1993, STROKE, V24, P1020, DOI 10.1161/01.STR.24.7.1020; ECKENHOFF RG, 1990, J APPL PHYSIOL, V69, P914, DOI 10.1152/jappl.1990.69.3.914; FUEREDI GA, 1991, AM J NEURORADIOL, V12, P67; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HASHEMI RH, 1995, RADIOLOGY, V196, P505, DOI 10.1148/radiology.196.2.7617868; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; HOVENS MMC, 1995, LANCET, V346, P384; JUNGREIS CA, 1988, RADIOLOGY, V169, P101, DOI 10.1148/radiology.169.1.3420242; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MOON RE, 1989, LANCET, V1, P513; REUL J, 1995, LANCET, V345, P1403, DOI 10.1016/S0140-6736(95)92598-8; RINCK PA, 1991, JMRI-J MAGN RESON IM, V1, P293, DOI 10.1002/jmri.1880010306; RYDBERG JN, 1994, RADIOLOGY, V193, P173, DOI 10.1148/radiology.193.1.8090888; SCHMINKE U, 1995, CEREBROVASC DIS, V5, P133, DOI 10.1159/000107838; SCHMINKE U, 1996, CEREBROVASC DIS S2, V6, P164; SWEENEY LJ, 1979, AM HEART J, V98, P194, DOI 10.1016/0002-8703(79)90221-7; TEAGUE SM, 1991, STROKE, V22, P740, DOI 10.1161/01.STR.22.6.740; TODNEM K, 1991, ELECTROEN CLIN NEURO, V79, P322, DOI 10.1016/0013-4694(91)90127-P; WARREN LP, 1988, AM J ROENTGENOL, V151, P1003, DOI 10.2214/ajr.151.5.1003; WILMSHURST P, 1995, LANCET, V346, P384, DOI 10.1016/S0140-6736(95)92268-7; WILMSHURST PT, 1989, LANCET, V2, P1302	25	172	177	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					701	705		10.1136/bmj.314.7082.701	http://dx.doi.org/10.1136/bmj.314.7082.701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116544	Green Published			2022-12-28	WOS:A1997WM77600019
J	Kennedy, S				Kennedy, S			Primary dysmenorrhoea	LANCET			English	Editorial Material							YOUNG-WOMEN				Kennedy, S (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Kennedy, Stephen/B-8950-2009					ANDERSCH B, 1982, AM J OBSTET GYNECOL, V144, P655, DOI 10.1016/0002-9378(82)90433-1; Hadfield R, 1996, HUM REPROD, V11, P878; Harlow SD, 1996, BRIT J OBSTET GYNAEC, V103, P1134, DOI 10.1111/j.1471-0528.1996.tb09597.x; JAMIESON DJ, 1996, OBSTET GYNECOL, V1, P55; KLEIN JR, 1981, PEDIATRICS, V68, P661; SUNDELL G, 1990, BRIT J OBSTET GYNAEC, V97, P588, DOI 10.1111/j.1471-0528.1990.tb02545.x; SVANBERG L, 1981, ARCH GYNECOL, V230, P173, DOI 10.1007/BF02111800	7	48	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1116	1116		10.1016/S0140-6736(05)63018-8	http://dx.doi.org/10.1016/S0140-6736(05)63018-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113008				2022-12-28	WOS:A1997WU54400006
J	Achatz, G; Nitschke, L; Lamers, MC				Achatz, G; Nitschke, L; Lamers, MC			Effect of transmembrane and cytoplasmic domains of IgE on the IgE response	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; GERMINAL-CENTERS; STEM-CELLS; RECOMBINATION; DISRUPTION	B cells use immunoglobulin M (IgM) and IgD as antigen receptors, but after contact with antigen they can switch and use IgG, IgA, or IgE. In mice lacking the transmembrane and cytoplasmic domains of IgE, serum IgE is reduced by more than 95 percent and, after immunization, specific responses are negligible. In mice lacking most of the cytoplasmic tail of IgE, serum IgE levels are reduced by 50 percent and specific responses are reduced by 40 to 80 percent, without a clear secondary response. Thus, membrane expression is indispensable for IgE secretion in vivo, and the cytoplasmic tail influences the degree and quality of the response.	MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY	Max Planck Society			Achatz, Gernot/E-5073-2011					Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Kaisho T, 1997, SCIENCE, V276, P412, DOI 10.1126/science.276.5311.412; KELSOE G, 1995, IMMUNOL TODAY, V16, P324, DOI 10.1016/0167-5699(95)80146-4; KOHLER G, 1996, TRANSGENIC RES, V5, P487; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Lamers MC, 1995, IMMUNOL REV, V148, P71, DOI 10.1111/j.1600-065X.1995.tb00094.x; LEBRUN P, 1987, J IMMUNOL, V139, P1459; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; NITSCHKE L, 1997, IMMUNOLOGY METHODS M, P218; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SEDGWICK JD, 1983, J EXP MED, V157, P2178, DOI 10.1084/jem.157.6.2178; STREET NE, 1990, J IMMUNOL, V144, P1629; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	26	102	103	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					409	411		10.1126/science.276.5311.409	http://dx.doi.org/10.1126/science.276.5311.409			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103198				2022-12-28	WOS:A1997WU47700038
J	Gebo, DL; MacLatchy, L; Kityo, R; Deino, A; Kingston, J; Pilbeam, D				Gebo, DL; MacLatchy, L; Kityo, R; Deino, A; Kingston, J; Pilbeam, D			A hominoid genus from the early Miocene of Uganda	SCIENCE			English	Article							PROCONSUL-NYANZAE; BODY-WEIGHT; KENYA; MORPHOLOGY; ALLOMETRY; VARIABLES; PRIMATES; MACACA; ISLAND; TIBIA	Fossils from a large-bodied hominoid from early Miocene sediments of Uganda, along with material recovered in the 1960s, show features of the shoulder and vertebral column that are significantly similar to those of living apes and humans. The large-bodied hominoid from Uganda dates to at least 20.6 million years ago and thus represents the oldest known hominoid sharing these derived characters with living apes and humans.	SUNY STONY BROOK, DEPT ANAT SCI, STONY BROOK, NY 11794 USA; MAKERERE UNIV, DEPT ZOOL, KAMPALA, UGANDA; BERKELEY GEOCHRONOL CTR, BERKELEY, CA 94709 USA; YALE UNIV, DEPT GEOL & GEOPHYS, NEW HAVEN, CT 06520 USA; HARVARD UNIV, DEPT ANTHROPOL, CAMBRIDGE, MA 02138 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Makerere University; Berkeley Geochronolgy Center; Yale University; Harvard University	Gebo, DL (corresponding author), NO ILLINOIS UNIV, DEPT ANTHROPOL, DE KALB, IL 60115 USA.		Klein, Richard G/B-5910-2009					AIELLO LC, 1994, AM J PHYS ANTHROPOL, V95, P409, DOI 10.1002/ajpa.1330950405; ALLBROOK D, 1963, NATURE, V197, P1187, DOI 10.1038/1971187a0; ANDREWS P, 1991, PHILOS T R SOC B, V334, P199, DOI 10.1098/rstb.1991.0109; ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; Andrews P.J., 1978, Bulletin of the British Museum (Natural History) Geology, V30, P85; AZZAROLI A, 1986, J HUM EVOL, V15, P533, DOI 10.1016/S0047-2484(86)80072-0; BEARD KC, 1986, FOLIA PRIMATOL, V47, P97; BENEFIT BR, 1995, ANNU REV ANTHROPOL, V24, P237; BISHOP WW, 1969, AM J SCI, V267, P669, DOI 10.2475/ajs.267.6.669; Cebula G.T., 1986, TERRA COGNITA, V6, P139; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; CONROY GC, 1994, J HUM EVOL, V27, P373, DOI 10.1006/jhev.1994.1051; CORRUCCINI R S, 1978, Primates, V19, P35, DOI 10.1007/BF02373225; DAGOSTO M, 1992, INT J PRIMATOL, V13, P307, DOI 10.1007/BF02547818; DEAN D, 1992, NATURE, V359, P676, DOI 10.1038/359676a0; ELLIOT DG, 1912, REV PRIMATES, V3, P225; FILLER AG, 1981, AM J PHYS ANTHROPOL, V54, P218; GINGERICH PD, 1977, AM J PHYS ANTHROPOL, V47, P395, DOI 10.1002/ajpa.1330470308; Groves CP, 1972, GIBBON SIAMANG, V1, P1; HARRISON T, 1996, NATURE, V379, P541; Leakey L.S.B., 1962, ANN MAG NAT HIST, V13, P689, DOI DOI 10.1080/00222936108651194; LEAKEY RE, 1988, AM J PHYS ANTHROPOL, V76, P289, DOI 10.1002/ajpa.1330760303; MacLatchy LM, 1996, J HUM EVOL, V31, P425, DOI 10.1006/jhev.1996.0070; MCHENRY HM, 1980, FOLIA PRIMATOL, V33, P241, DOI 10.1159/000155939; MoyaSola S, 1996, NATURE, V379, P156, DOI 10.1038/379156a0; PICKFORD M, 1981, J HUM EVOL, V10, P73, DOI 10.1016/S0047-2484(81)80026-7; PICKFORD M, 1986, C R ACAD SCI PARIS 2, V9, P681; PILBEAM D, 1986, AM ANTHROPOL, V88, P295, DOI 10.1525/aa.1986.88.2.02a00010; Pilbeam D, 1996, MOL PHYLOGENET EVOL, V5, P155, DOI 10.1006/mpev.1996.0010; Pilbeam D. R., 1969, Bulletin of the Peabody Museum of Natural History, V31, P1; RAFFERTY KL, 1995, AM J PHYS ANTHROPOL, V97, P391, DOI 10.1002/ajpa.1330970406; Roberts D., 1974, P171; Rose M.D., 1983, P405; ROSE MD, 1992, J HUM EVOL, V22, P171, DOI 10.1016/S0047-2484(05)80006-5; Rose Michael D., 1993, P252; RUFF C, 1988, J HUM EVOL, V17, P687, DOI 10.1016/0047-2484(88)90025-5; RUFF C, 1987, FOLIA PRIMATOL, V48, P9, DOI 10.1159/000156283; RUFF CB, 1992, ANNU REV ANTHROPOL, V21, P407; RUFF CB, 1993, AM J PHYS ANTHROPOL, V91, P21, DOI 10.1002/ajpa.1330910103; RUNESTAD JA, 1994, THESIS J HOPKINS U B; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; SANDERS WJ, 1994, J HUM EVOL, V26, P203, DOI 10.1006/jhev.1994.1012; SARMIENTO EE, 1987, AM MUS NOVIT, P1; Tyler DE, 1993, EVOLVING LANDSCAPES, P228; WALKER A, 1968, NATURE, V217, P980, DOI 10.1038/217980a0; Walker A.C., 1983, P325; WARD CV, 1993, AM J PHYS ANTHROPOL, V90, P77, DOI 10.1002/ajpa.1330900106; WARD CV, 1993, AM J PHYS ANTHROPOL, V92, P291, DOI 10.1002/ajpa.1330920306; WARD CV, 1991, J HUM EVOL, V21, P215, DOI 10.1016/0047-2484(91)90062-Z; WARD SC, 1983, AM J PHYS ANTHROPOL, V61, P157, DOI 10.1002/ajpa.1330610204; WARD SC, COMMUNICATION	51	115	120	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					401	404		10.1126/science.276.5311.401	http://dx.doi.org/10.1126/science.276.5311.401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WU477	9103195				2022-12-28	WOS:A1997WU47700035
J	Soderlund, M; vonEssen, R; Haapasaari, J; Kiistala, U; Kiviluoto, O; Hedman, K				Soderlund, M; vonEssen, R; Haapasaari, J; Kiistala, U; Kiviluoto, O; Hedman, K			Persistence of parvoviris B19 DNA in synovial membranes of young patients with and without chronic arthropathy	LANCET			English	Article							RHEUMATOID-ARTHRITIS; PROTEINS VP1; BONE-MARROW; INFECTION; VIRUS; FLUID	Background Human parvovirus B19 replicates in erythroid precursors of the bone marrow, and several diseases have been attributed to this virus including some cases of juvenile chronic arthropathy. Methods Tissue samples from children with juvenile arthritis and from healthy young adults with recent joint trauma were examined for B19 DNA by PCR. We also studied the timing of the parvovirus infection serologically. Findings All samples of synovial fluid, bone marrow, and blood were negative for B19 DNA. Eight (28%) of the 29 children with chronic arthritis had B19 DNA in synovial tissue. However, an even higher proportion of the non-arthropathy controls were positive for B19 DNA in synovial membranes (13 [48%] of 27). All the individuals with B19 DNA in synovial membrane had serum IgG antibodies to B19. Interpretation Genomic B19 DNA can persist in the synovial membranes not only in patients with chronic arthropathy but also in healthy immunocompetent individuals. The diagnostic criteria for parvovirus arthropathy must be reevaluated.	UNIV HELSINKI,HAARTMAN INST,DEPT VIROL,FIN-00014 HELSINKI,FINLAND; RHEUMATISM FDN HOSP,SF-18120 HEINOLA,FINLAND; CENT MIL HOSP,HELSINKI,FINLAND	University of Helsinki; Rheumatism Foundation Hospital			Hedman, Klaus/D-5379-2009; Söderlund-Venermo, Maria/AAX-2112-2020					ANDERSON MJ, 1982, J CLIN PATHOL, V35, P744, DOI 10.1136/jcp.35.7.744; BROWN CS, 1990, VIRUS RES, V15, P197, DOI 10.1016/0168-1702(90)90028-A; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; DIJKMANS BAC, 1988, ARTHRITIS RHEUM, V31, P279, DOI 10.1002/art.1780310218; EDWARDS JCW, 1994, J ANAT, V184, P493; FOTO F, 1993, J INFECT DIS, V167, P744, DOI 10.1093/infdis/167.3.744; Franssila R, 1996, CLIN DIAGN VIROL, V6, P41, DOI 10.1016/0928-0197(96)00156-0; Hedman K., 1993, REV MED MICROBIOL, V4, P123, DOI DOI 10.1097/00013542-199307000-00001; KERR JR, 1995, BRIT J RHEUMATOL, V34, P809; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LINDE A, 1988, MONOGR ALLERGY, V23, P27; MIKI NPH, 1992, J GEN VIROL, V73, P1559, DOI 10.1099/0022-1317-73-6-1559; NAIDES SJ, 1993, RHEUM DIS CLIN N AM, V19, P457; NIKKARI S, 1995, ANN RHEUM DIS, V54, P597, DOI 10.1136/ard.54.7.597; REID DM, 1985, LANCET, V1, P422; SAAL JG, 1992, RHEUMATOL INT, V12, P147, DOI 10.1007/BF00274934; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; Soderlund M, 1997, SCAND J INFECT DIS, V29, P129, DOI 10.3109/00365549709035872; SODERLUND M, 1995, J INFECT DIS, V171, P710, DOI 10.1093/infdis/171.3.710; SODERLUND M, 1995, J INFECT DIS, V172, P1431, DOI 10.1093/infdis/172.6.1431; TAYLOR HG, 1992, CLIN RHEUMATOL, V11, P548, DOI 10.1007/BF02283117; VONPOBLOTZKI A, 1995, J INFECT DIS, V172, P1356, DOI 10.1093/infdis/172.5.1356; WHITE DG, 1985, LANCET, V1, P419; WOOLF AD, 1995, ANN RHEUM DIS, V54, P535, DOI 10.1136/ard.54.7.535	24	198	204	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1063	1065		10.1016/S0140-6736(96)09110-6	http://dx.doi.org/10.1016/S0140-6736(96)09110-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107245				2022-12-28	WOS:A1997WU00200011
J	Shupliakov, O; Low, P; Grabs, D; Gad, H; Chen, H; David, C; Takei, K; DeCamilli, P; Brodin, L				Shupliakov, O; Low, P; Grabs, D; Gad, H; Chen, H; David, C; Takei, K; DeCamilli, P; Brodin, L			Synaptic vesicle endocytosis impaired by disruption of dynamin-SH3 domain interactions	SCIENCE			English	Article							NEUROTRANSMITTER RELEASE; SH3 DOMAINS; MEMBRANE; PROTEINS; AMPHIPHYSIN; DISTINCT; SHIBIRE; BINDING; GTPASE; GAMMA	The proline-rich COOH-terminal region of dynamin binds various Src homology 3 (SH3) domain-containing proteins, but the physiological role of these interactions is unknown. In living nerve terminals, the function of the interaction with SH3 domains was examined. Amphiphysin contains an SH3 domain and is a major dynamin binding partner at the synapse. Microinjection of amphiphysin's SH3 domain or of a dynamin peptide containing the SH3 binding site inhibited synaptic vesicle endocytosis at the stage of invaginated clathrin-coated pits, which resulted in an activity-dependent distortion of the synaptic architecture and a depression of transmitter release. These findings demonstrate that SH3-mediated interactions are required for dynamin function and support an essential role of clathrin-mediated endocytosis in synaptic vesicle recycling.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN	Yale University; Howard Hughes Medical Institute; Yale University; Karolinska Institutet			Gad, Helge/J-2238-2014; Shupliakov, Oleg/R-9148-2016	Shupliakov, Oleg/0000-0001-5352-6848; Gad, Helge/0000-0001-6530-1443; Takei, Kohji/0000-0002-6555-9425	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRODIN L, 1994, J NEUROPHYSIOL, V75, P592; BUCHANAN JT, 1992, BIOL CYBERN, V67, P123, DOI 10.1007/BF00201019; Chen H. M., UNPUB; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Estes PS, 1996, J NEUROSCI, V16, P5443; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRABS D, IN PRESS J BIOL CHEM; GUNDERSEN V, 1995, J NEUROSCI, V15, P4417; Henkel AW, 1995, J NEUROSCI, V15, P8246; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LINIAL M, 1994, NEUROREPORT, V5, P2009, DOI 10.1097/00001756-199410270-00005; LOW PJ, UNPUB; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SHUPLIAKOV O, 1995, EUR J NEUROSCI, V7, P1111, DOI 10.1111/j.1460-9568.1995.tb01099.x; SHUPLIAKOV O, UNPUB; SHUPLIAKOV O, 1992, J NEUROSCI, V7, P1111; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935	33	382	388	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					259	263		10.1126/science.276.5310.259	http://dx.doi.org/10.1126/science.276.5310.259			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092476				2022-12-28	WOS:A1997WT92500047
J	Inskip, H				Inskip, H			Childhood leukaemia near nuclear sites re-examined	LANCET			English	Editorial Material							LEUKEMIA; ENGLAND; WALES				Inskip, H (corresponding author), UNIV SOUTHAMPTON,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				BARON JA, 1984, BRIT J CANCER, V50, P815, DOI 10.1038/bjc.1984.261; BITHELL JF, 1994, BRIT MED J, V309, P501, DOI 10.1136/bmj.309.6953.501; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P355; KINLEN L, 1988, LANCET, V2, P1323; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; Sharp L, 1996, OCCUP ENVIRON MED, V53, P823, DOI 10.1136/oem.53.12.823	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					969	970		10.1016/S0140-6736(05)62890-5	http://dx.doi.org/10.1016/S0140-6736(05)62890-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100621				2022-12-28	WOS:A1997WR62100006
J	Olesen, AB; Ellingsen, AR; Olesen, H; Juul, S; ThestrupPedersen, K				Olesen, AB; Ellingsen, AR; Olesen, H; Juul, S; ThestrupPedersen, K			Atopic dermatitis and birth factors: Historical follow up by record linkage	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ECZEMA; PREVALENCE; POPULATION	Objective: To study if factors at birth are associated with later development of atopic dermatitis. Design: Historical follow up by record linkage from Danish medical birth register. Children were followed up for 5.5 to 8.5 years. Second historical follow up study comprising questionnaire to mothers of singleborn children 6.5 to 9.5 years after birth. Setting: Private dermatology clinics and dermatology and paediatric departments in the municipality of Aarhus, Denmark, Subjects: 7862 singletons born in hospital between 1 January 1984 and 31 December 1986 to mothers living in the municipality of Aarhus. Questionnaires sent to 985 mothers. Main outcome measures: Gestational age, birth weight, parity, and age of mother at the time of birth. Atopy in children diagnosed by specialists in dermatology and physicians. Family size; diagnosis of atopic dermatitis, allergic rhinitis, and asthma; family predisposition; and mothers' smoking habits during pregnancy determined from questionnaires. Results: Of 7862 children, 403 were diagnosed as having atopic dermatitis by a specialist; the cumulative incidence at age 7 was 5.6%. High gestational age and low parity were associated with an increased risk of atopic dermatitis, Among 985 children atopic dermatitis had been diagnosed by any physician in 184; the cumulative incidence at age 7 was 18.7%. High birth weight high gestational age, and family history of atopy were associated with increased risk of atopic dermatitis. Conclusion: In both studies the incidence of atopic dermatitis was associated with high gestational age and in one with high birth weight also. The causes for these associations are at present unknown but may indicate that even during gestation factors associated with atopic dermatitis influence maturation.	AARHUS UNIV,INST EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS C,DENMARK	Aarhus University	Olesen, AB (corresponding author), AARHUS UNIV HOSP,DEPT DERMATOL,DK-8000 AARHUS C,DENMARK.			Ellingsen, Anne Ringer/0000-0001-9173-9617				ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BRYAN EM, 1983, MATERNAL CHILD H MAY, P201; CARR RD, 1964, ARCH DERMATOL, V89, P27, DOI 10.1001/archderm.1964.01590250033006; *DAN NAT HLTH BOAR, 1993, MED BIRTH STAT 1991; DAVID TJ, 1988, ARCH DIS CHILD, V63, P435, DOI 10.1136/adc.63.4.435; FREIDRICH L, 1983, TWINS HDB; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P171; HANIFIN JM, 1987, MONOGR ALLERGY, V21, P116; KALTOFT K, 1994, ARCH DERMATOL RES, V287, P42, DOI 10.1007/BF00370717; Kaltoft K, 1995, CANCER GENET CYTOGEN, V85, P68, DOI 10.1016/0165-4608(95)00118-2; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; KENDALL MD, 1991, J ANAT, V177, P1; Kristensen J, 1996, J CLIN EPIDEMIOL, V49, P893, DOI 10.1016/0895-4356(96)00018-2; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LARSEN FS, 1992, ACTA DERM-VENEREOL, V176, P7; LARSEN FS, 1985, THESIS U ODENSE ODEN; LINNEY J, 1983, MULTIPLE BIRTHS; MacGillivray I, 1988, TWINNING TWINS; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Peters T J, 1987, Paediatr Perinat Epidemiol, V1, P80, DOI 10.1111/j.1365-3016.1987.tb00092.x; RAJKA G, 1986, INT J DERMATOL, V25, P301, DOI 10.1111/j.1365-4362.1986.tb02249.x; RAJKA G, 1989, ESSENTIAL ASPECTS AT; SANDBANK AC, 1988, ACTA GENET MED GEMEL, V37, P161, DOI 10.1017/S0001566000004086; SPSS, 1995, STAT PACK SOC SCI VE; Storm K, 1986, Ugeskr Laeger, V148, P3295; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; ThestrupPedersen K, 1997, ACTA DERM-VENEREOL, V77, P20; VICKERS CFH, 1980, ACTA DERM-VENEREOL, V92, P113; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132	33	121	122	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1003	1008		10.1136/bmj.314.7086.1003	http://dx.doi.org/10.1136/bmj.314.7086.1003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112844	Green Published			2022-12-28	WOS:A1997WT15200021
J	Perrimon, N; Perkins, LA				Perrimon, N; Perkins, LA			There must be 50 ways to rule the signal: The case of the Drosophila EGF receptor	CELL			English	Review							PROTEIN; TRIGGERS; PATHWAY		MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	Perrimon, N (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				Allard JD, 1996, DEVELOPMENT, V122, P1137; Cleghon V, 1996, GENE DEV, V10, P566, DOI 10.1101/gad.10.5.566; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Gabay L, 1996, DEVELOPMENT, V122, P3355; Golembo M, 1996, DEVELOPMENT, V122, P223; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hsu T, 1996, GENE DEV, V10, P1411, DOI 10.1101/gad.10.11.1411; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SCHNEPP B, 1996, GENE DEV, V10, P2303; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8	17	125	127	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					13	16		10.1016/S0092-8674(00)80177-4	http://dx.doi.org/10.1016/S0092-8674(00)80177-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094709	Bronze			2022-12-28	WOS:A1997WR68500004
J	Nightingale, SL				Nightingale, SL			Gradual phaseout of CFC metered dose inhalers planned	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1997, FED REG         0306, V62, P10242	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-28	WOS:A1997WQ08900005
J	Slutsker, L; Ries, AA; Greene, KD; Wells, JG; Hutwagner, L; Griffin, PM				Slutsker, L; Ries, AA; Greene, KD; Wells, JG; Hutwagner, L; Griffin, PM			Escherichia coli O157:H7 diarrhea in the United States: Clinical and epidemiologic features	ANNALS OF INTERNAL MEDICINE			English	Article							HEMOLYTIC-UREMIC-SYNDROME; HEMORRHAGIC COLITIS; WASHINGTON-STATE; 0157-H7 INFECTIONS; BLOODY DIARRHEA; NURSING-HOME; OUTBREAK; MINNESOTA; CULTURES	Background: Escherichia coli O157:H7 is increasingly recognized as a cause of bacterial diarrhea in the United States, but the frequency of its isolation and the clinical and epidemiologic features of E. coli O157:H7 infection in a large, geographically diverse population of patients have not been well described. Objective: To determine the frequency of isolation of E. coli O157:H7 relative to that of other bacterial enteric pathogens in a nationwide sample of patients and to identify the clinical and epidemiologic features of E. coli O157:H7 infection. Design: Population prevalence study from October 1990 to October 1992. Setting: 10 U.S. hospitals. Patients: Both inpatients and outpatients who had stool samples submitted to 1 of 10 laboratories for routine pathogen identification. Measurements: Clinical, epidemiologic, and laboratory information was collected for infected and uninfected patients. Isolates of E. coli O157:H7 were tested for production of Shiga toxin. Patient charts were then reviewed. Results: Escherichia coli O157:H7 was isolated from 118 (0.39%) of the 30 463 fecal specimens tested. The proportion of fecal specimens with isolates was higher at northern sites (0.57%) than at southern sites (0.13%) (P < 0.001). Escherichia coli O157:H7 was more likely to be isolated from visibly bloody stool specimens than from specimens without visible blood (odds ratio [OR], 59.2 [95% CI, 36.6 to 96.01]) and was the pathogen most commonly isolated from visibly bloody stool specimens that yielded a bacterial enteric pathogen (39% of such specimens). The highest age-specific isolation proportions from fecal specimens for E. coli O157:H7 were in patients 5 to 9 years of age (0.90%) and 50 to 59 years of age (0.89%). Clinical features independently associated with E. coli O157:H7 infection com pared with the other enteric pathogens included a history of bloody diarrhea (OR, 18.6 [CI, 7.4 to 48.6]), visibly bloody stool specimens (OR, 8.1 [CI, 3.6 to 18.3]), no reported fever (OR, 8.3 [CI, 1.6 to 50.0]), leukocyte count greater than 10 x 10(9)/L(OR, 4.0 [CI, 1.7 to 9.5]), and abdominal tenderness on physical examination (OR, 2.9 [CI, 1.2 to 7.2]). Conclusions: In some geographic areas and some age groups, isolation proportions from fecal specimens for E. coli O157:H7 surpassed those of other common enteric pathogens. One third of isolates of this organism came from nonbloody specimens. Because person-to-person transmission of E. coli O157:H7 is not uncommon and infection with this organism may cause severe disease, stool specimens from all patients with a history of acute bloody diarrhea should be cultured for E. coli O157:H7.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, BIOSTAT & INFORMAT MANAGEMENT BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	Slutsker, L (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, FOODBORNE & DIARRHEAL DIS BRANCH, MAILSTOP A-38, ATLANTA, GA 30333 USA.							BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BLASER MJ, 1983, ANN INTERN MED, V98, P360, DOI 10.7326/0003-4819-98-3-360; BOYCE TG, 1995, J CLIN MICROBIOL, V33, P3275, DOI 10.1128/JCM.33.12.3275-3277.1995; BOYCE TG, 1995, NEW ENGL J MED, V333, P364, DOI 10.1056/NEJM199508103330608; BROTMAN M, 1995, GASTROENTEROLOGY, V108, P1923, DOI 10.1016/0016-5085(95)90159-0; Calderwood SB, 1996, ASM NEWS, V62, P118; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; Ewing WH, 1986, IDENTIFICATION ENTER; FARMER JJ, 1985, J CLIN MICROBIOL, V22, P620, DOI 10.1128/JCM.22.4.620-625.1985; GRANSDEN WR, 1986, J INFECT DIS, V154, P522, DOI 10.1093/infdis/154.3.522; Griffin Patricia M., 1995, P739; GRIFFIN PM, 1990, GASTROENTEROLOGY, V99, P142, DOI 10.1016/0016-5085(90)91241-W; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HANCOCK DD, 1994, EPIDEMIOL INFECT, V113, P199, DOI 10.1017/S0950268800051633; HARRIS AA, 1985, J INFECT DIS, V152, P775, DOI 10.1093/infdis/152.4.775; JONES RN, 1993, PERFORMANCE STANDARD; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MARSHALL WF, 1990, MAYO CLIN PROC, V65, P787, DOI 10.1016/S0025-6196(12)62567-1; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; Morris AJ, 1996, J CLIN MICROBIOL, V34, P355, DOI 10.1128/JCM.34.2.355-357.1996; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; PAI CH, 1988, J INFECT DIS, V157, P1054, DOI 10.1093/infdis/157.5.1054; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SIEGLER RL, 1994, PEDIATRICS, V94, P35; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; STROCKBINE NA, 1992, MOL CELL PROBE, V6, P93, DOI 10.1016/0890-8508(92)90052-Y; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; 1995, MMWR-MORBID MORTAL W, V44, P557; 1995, MMWR-MORBID MORTAL W, V44, P550; 1990, NNIS NEWS, V8, P4; 1995, MMWR-MORBID MORTAL W, V44, P417; 1995, MMWR-MORBID MORTAL W, V44, P501; 1994, MMWR MORTAL WKLY REP, V43, P81	44	200	212	0	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					505	+		10.7326/0003-4819-126-7-199704010-00002	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092315				2022-12-28	WOS:A1997WQ19500011
J	Yassi, A				Yassi, A			Repetitive strain injuries	LANCET			English	Article							CARPAL-TUNNEL SYNDROME; CUMULATIVE TRAUMA DISORDERS; MUSCULOSKELETAL DISORDERS; UPPER-EXTREMITY; WORKERS; PREVALENCE; INDUSTRY	Repetitive strain injuries (RSI) present an increasingly common challenge to clinicians. They consist of a variety of musculoskeletal disorders, generally related to tendons, muscles, or joints, as well as some common peripheral-nerve-entrapment and vascular syndromes. These disorders generally affect the back, neck, and upper limbs, although lower limbs may also be involved. Although RSI may occur as a result of sports and recreational activities, occupational RSIs, affecting the patient's livelihood, are particularly important. These injuries result from repetitive and forceful motions, awkward postures, and other work-related conditions and ergonomic hazards. Occupationally induced RSIs are generally costly, creating a strong incentive for physicians to become familiar with the symptoms, signs, and risk factors so that they can be diagnosed early and appropriate interventions facilitated.			Yassi, A (corresponding author), UNIV MANITOBA,OCCUPAT & ENVIRONM HLTH UNIT,S112-750 BANNATYNE AVE,WINNIPEG,MB R3E 0W3,CANADA.							ASHBURY FD, 1995, J OCCUP ENVIRON MED, V37, P479, DOI 10.1097/00043764-199504000-00021; BARNHART S, 1991, SCAND J WORK ENV HEA, V17, P46, DOI 10.5271/sjweh.1735; BELL DS, 1989, MED J AUSTRALIA, V151, P280, DOI 10.5694/j.1326-5377.1989.tb101196.x; BLACK P, 1987, MED J AUSTRALIA, V147, P257; Brogmus GE, 1996, J OCCUP ENVIRON MED, V38, P401, DOI 10.1097/00043764-199604000-00019; Buchbinder R, 1996, AM J IND MED, V29, P171, DOI 10.1002/(SICI)1097-0274(199602)29:2<171::AID-AJIM7>3.0.CO;2-V; *BUR LAB STAT, 1993, US DEP LAB B, V2424; *BUR LAB STAT, 1994, USDL94600 BUR LAB ST; CHATTERJEE DS, 1987, J SOC OCCUP MED, V37, P100; CHIANG HC, 1993, SCAND J WORK ENV HEA, V19, P126, DOI 10.5271/sjweh.1496; CLELAND LG, 1987, MED J AUSTRALIA, V147, P236, DOI 10.5694/j.1326-5377.1987.tb133417.x; DELGROSSO I, 1991, INT ARCH OCC ENV HEA, V63, P267, DOI 10.1007/BF00386376; GELLMAN H, 1989, J HAND SURG-AM, V14A, P863, DOI 10.1016/S0363-5023(89)80091-7; GERR F, 1991, ANNU REV PUBL HEALTH, V12, P543; GUIDOTTI TL, 1992, AM FAM PHYSICIAN, V45, P585; KILBOM A, 1988, ERGONOMICS, V31, P735, DOI 10.1080/00140138808966717; LEE K, 1992, APPL ERGON, V23, P387, DOI 10.1016/0003-6870(92)90370-B; *NAT I OCC SAF HLT, 1995, CUM TRAUM DIS WORKPL; NILSSON T, 1994, SCAND J WORK ENV HEA, V20, P189, DOI 10.5271/sjweh.1409; OSORIO AM, 1994, AM J IND MED, V25, P229, DOI 10.1002/ajim.4700250209; PUTZANDERSON V, 1988, TRENDS ERGONOMICS HU, V5, P601; REMPEL DM, 1992, JAMA-J AM MED ASSOC, V267, P838, DOI 10.1001/jama.267.6.838; SCHOTTLAND JR, 1991, J OCCUP ENVIRON MED, V33, P627; SILVERSTEIN BA, 1988, J OCCUP ENVIRON MED, V30, P922, DOI 10.1097/00043764-198812000-00008; SILVERSTEIN BA, 1986, BRIT J IND MED, V43, P779; SILVERSTEIN BA, 1987, AM J IND MED, V11, P343, DOI 10.1002/ajim.4700110310; STOCK SR, 1991, AM J IND MED, V19, P87, DOI 10.1002/ajim.4700190111; TANAKA S, 1995, AM J IND MED, V27, P451, DOI 10.1002/ajim.4700270402; YASSI A, IN PRESS AM J IND ME	29	124	129	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					943	947		10.1016/S0140-6736(96)07221-2	http://dx.doi.org/10.1016/S0140-6736(96)07221-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093264				2022-12-28	WOS:A1997WR25400046
J	McArthur, JH; Moore, FD				McArthur, JH; Moore, FD			The two cultures and the health care revolution - Commerce and professionalism in medical care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROMOTE QUALITY; INSURANCE; ECONOMY; 1990S; PLAN	The current trend toward the invasion of commerce into medical care, an arena formerly under the exclusive purview of physicians, is seen by the authors as an epic clash of cultures between commercial and professional traditions in the United States. Both have contributed to US society for centuries; both have much to offer in strengthening medical care and reducing costs. At the same time, this invasion by commercialism of an arena formerly governed by professionalism poses severe hazards to the care of the sick and the welfare of communities: the health of the public and the public health. Some of these hazards are briefly listed and reviewed, together with a brief outline of standards that mig ht be established nationally to abate these hazards. A national agency in the private sector is proposed, the National Council on Medical Care, to set standards and provide an approval mechanism that would then be the basis for state enforcement through licensing. Two models for such an initiative are outlined, one based on the National Academy of Sciences as the initiating force, and the other on an initiative provided by a consortium of national charitable foundations interested in health policy. In both cases, wide support from the national foundations would be essential. In the case of the academy model, some government funds might also be available without loss of the freedom of a private-sector initiative. Some operational options for such a national council, its membership, and the conduct of its affairs are briefly outlined as a basis for further discussion.	PARTNERS HEALTHCARE INC,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH BUSINESS,BOSTON,MA 02115	Partners Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University								ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; Gradison W, 1995, B NEW YORK ACAD MED, V72, P586; Snow Charles Percy, 1959, 2 CULTURES SCI REVOL	4	68	68	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					985	989		10.1001/jama.277.12.985	http://dx.doi.org/10.1001/jama.277.12.985			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091672				2022-12-28	WOS:A1997WN99200034
J	The, I; Hannigan, GE; Cowley, GS; Reginald, S; Zhong, Y; Gusella, JF; Hariharan, IK; Bernards, A				The, I; Hannigan, GE; Cowley, GS; Reginald, S; Zhong, Y; Gusella, JF; Hariharan, IK; Bernards, A			Rescue of a Drosophila NF1 mutant phenotype by protein kinase A	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; RECEPTOR TYROSINE KINASE; NEUROFIBROMATOSIS TYPE-1; SEVENLESS PROTEIN; DEVELOPMENTAL ABNORMALITIES; GENE ENCODES; EGF RECEPTOR; CELL FATE; RAS; EXPRESSION	The neurofibromatosis type 1 (NF1) tumor suppressor protein is thought to restrict cell proliferation by functioning as a Ras-specific guanosine triphosphatase-activating protein. However, Drosophila homozygous for null mutations of an NF1 homolog showed no obvious signs of perturbed Ras1-mediated signaling, Loss of NF1 resulted in a reduction in size of larvae, pupae, and adults. This size defect was not modified by manipulating Ras1 signaling but was restored by expression of activated adenosine 3',5'-monophosphate-dependent protein kinase (PKA). Thus, NF1 and PKA appear to interact in a pathway that controls the overall growth of Drosophila.	MASSACHUSETTS GEN HOSP, CTR CANC, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, CHARLESTOWN, MA 02129 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Cold Spring Harbor Laboratory			Hannigan, Greg/A-5092-2009; The, Inge/B-8884-2011	Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034779, R01NS036084] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22229, NS34779, NS36084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brill S, 1996, MOL CELL BIOL, V16, P4869; DALBY B, 1995, GENETICS, V139, P757; DANGLOT G, 1995, HUM MOL GENET, V4, P915, DOI 10.1093/hmg/4.5.915; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Dob[r]zhansky T., 1929, Archiv fuer Entwicklungsmechanik Berlin, V115, P363, DOI 10.1007/BF02078996; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; ENGELS WR, 1986, FOCUS, V8, P6; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Glantz SA., 1997, PRIMER BIOSTATISTICS; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; GUTMANN DH, 1993, HUM MOL GENET, V2, P989; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KIM HA, 1995, ONCOGENE, V11, P325; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LI Y, 1995, GENOMICS, V25, P9, DOI 10.1016/0888-7543(95)80104-T; LINDSLEY DL, 1992, GENETICS BIOL DROSOP; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MONTE P, 1989, BEHAV GENET, V19, P267, DOI 10.1007/BF01065910; NISHI T, 1991, ONCOGENE, V6, P1555; Patel N. H, 1994, DROSOPHILA MELANOGAS; Richards S, 1996, GENETICS, V142, P1215; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; WEHNER R, 1972, J INSECT PHYSIOL, V18, P1531, DOI 10.1016/0022-1910(72)90232-6; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	45	187	194	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					791	794		10.1126/science.276.5313.791	http://dx.doi.org/10.1126/science.276.5313.791			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115203				2022-12-28	WOS:A1997WW90000057
J	Newman, LS; Rose, CS; Maier, LA				Newman, LS; Rose, CS; Maier, LA			Medical progress - Sarcoidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BRONCHOALVEOLAR LAVAGE FLUID; LOW-DOSE METHOTREXATE; ACTIVE PULMONARY SARCOIDOSIS; TRANSBRONCHIAL LUNG-BIOPSY; NECROSIS-FACTOR-ALPHA; ISLE-OF-MAN; BERYLLIUM DISEASE; LYMPHOCYTES-T; CUTANEOUS SARCOIDOSIS; ALVEOLAR MACROPHAGE		NATL JEWISH MED & RES CTR, OCCUPAT ENVIRONM MED SECT, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV PULM SCI & CRIT CARE MED, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Newman, LS (corresponding author), NATL JEWISH MED & RES CTR, DEPT MED, DIV PULM, 1400 JACKSON ST, RM G-010, DENVER, CO 80206 USA.		Maier, Lisa/AAA-4378-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006538, R29ES006538] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00051] Funding Source: Medline; NHLBI NIH HHS [HL27353] Funding Source: Medline; NIEHS NIH HHS [ES06538] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JS, 1989, ANN INTERN MED, V111, P437, DOI 10.7326/0003-4819-111-5-437; AGOSTINI C, 1993, AM J MED, V95, P466, DOI 10.1016/0002-9343(93)90328-M; ALBERTS C, 1995, EUR RESPIR J, V8, P682; Almenoff PL, 1996, THORAX, V51, P530, DOI 10.1136/thx.51.5.530; Arbustini E, 1996, AM J RESP CRIT CARE, V153, P851, DOI 10.1164/ajrccm.153.2.8564143; BADRINAS F, 1989, LANCET, V2, P455; BALL JB, 1991, THORAX, V46, P933, DOI 10.1136/thx.46.12.933; BARNES PF, 1996, TUBERCULOSIS, P291; BASILE JN, 1993, J CLIN INVEST, V91, P1396, DOI 10.1172/JCI116342; Baumer I, 1997, AM J RESP CELL MOL, V16, P171; BELLOCQ A, 1994, AM J RESP CRIT CARE, V149, P646, DOI 10.1164/ajrccm.149.3.7906994; BERTRAN G, 1992, CHEST, V101, P996, DOI 10.1378/chest.101.4.996; BJERMER L, 1991, EUR RESPIR J, V4, P965; BJERMER L, 1991, RESP MED, V85, P229, DOI 10.1016/S0954-6111(06)80085-5; BOST TW, 1994, AM J RESP CELL MOL, V10, P506, DOI 10.1165/ajrcmb.10.5.8179912; BRENNAN NJ, 1984, THORAX, V39, P14, DOI 10.1136/thx.39.1.14; BRESNITZ EA, 1983, EPIDEMIOL REV, V5, P124, DOI 10.1093/oxfordjournals.epirev.a036255; BRESNITZ EA, 1986, ANN NY ACAD SCI, V465, P632, DOI 10.1111/j.1749-6632.1986.tb18540.x; BURKE WMJ, 1990, LANCET, V336, P1579, DOI 10.1016/0140-6736(90)93354-R; CARLESIMO M, 1995, J AM ACAD DERMATOL, V32, P866, DOI 10.1016/0190-9622(95)91549-4; CASAVILLA FA, 1993, ANN INTERN MED, V118, P865, DOI 10.7326/0003-4819-118-11-199306010-00007; CASELLA FJ, 1993, J AM SOC NEPHROL, V3, P1555; COSTABEL U, 1994, EUR RESPIR J, V7, P624; CULLEN MR, 1987, AM REV RESPIR DIS, V135, P201; CZAJA MJ, 1987, J BIOL CHEM, V262, P13348; DEREMEE RA, 1995, MAYO CLIN PROC, V70, P177, DOI 10.4065/70.2.177; DEVUYST P, 1987, AM REV RESPIR DIS, V135, P493; DOHI M, 1994, J IMMUNOL, V152, P1983; DUBOIS RM, 1992, AM REV RESPIR DIS, V145, P1205, DOI 10.1164/ajrccm/145.5.1205; DUBOIS RM, 1991, CLIN EXP ALLERGY, V21, P9; DUBOIS RM, 1994, EUR RESPIR J, V7, P1203, DOI 10.1183/09031936.94.07071203; DUNCAN MR, 1985, J EXP MED, V162, P516, DOI 10.1084/jem.162.2.516; EDMONDSTONE WM, 1985, BRIT J DIS CHEST, V79, P27, DOI 10.1016/0007-0971(85)90004-X; EDMONDSTONE WM, 1988, THORAX, V43, P342, DOI 10.1136/thx.43.4.342; EISENBERG H, 1978, TISSUE ANTIGENS, V11, P484, DOI 10.1111/j.1399-0039.1978.tb01289.x; EKLUND A, 1986, LUNG, V164, P325, DOI 10.1007/BF02713657; EKLUND AG, 1992, AM REV RESPIR DIS, V145, P646, DOI 10.1164/ajrccm/145.3.646; EPPS RE, 1995, J AM ACAD DERMATOL, V33, P528, DOI 10.1016/0190-9622(95)91407-2; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FORMAN JD, 1994, J CLIN INVEST, V94, P1533, DOI 10.1172/JCI117494; FORRESTER JM, 1994, J IMMUNOL, V153, P4291; FORST LS, 1993, BRIT J IND MED, V50, P497; FOURY BW, 1994, CHEST, V106, P677; FUSS M, 1992, CLIN RHEUMATOL, V11, P28, DOI 10.1007/BF02207080; GARDNER J, 1984, THORAX, V39, P19, DOI 10.1136/thx.39.1.19; Gibson GJ, 1996, THORAX, V51, P238, DOI 10.1136/thx.51.3.238; GILMAN MJ, 1980, AM REV RESPIR DIS, V122, P721, DOI 10.1164/arrd.1980.122.5.721; GIRGIS RE, 1995, AM J RESP CRIT CARE, V152, P71, DOI 10.1164/ajrccm.152.1.7599865; GRUNEWALD J, 1994, P NATL ACAD SCI USA, V91, P4965, DOI 10.1073/pnas.91.11.4965; GRUNEWALD J, 1992, EUR J IMMUNOL, V22, P129, DOI 10.1002/eji.1830220120; HAMBLIN AS, 1994, CLIN EXP IMMUNOL, V96, P335; HARRINGTON DW, 1994, SARCOIDOSIS, V11, P240; HARRISON BDW, 1991, RESP MED, V85, P59, DOI 10.1016/S0954-6111(06)80211-8; HENDERSON CA, 1994, J ROY SOC MED, V87, P632; HENKE CE, 1986, AM J EPIDEMIOL, V123, P840, DOI 10.1093/oxfordjournals.aje.a114313; HEYLL A, 1994, BONE MARROW TRANSPL, V14, P161; HILLERDAL G, 1984, AM REV RESPIR DIS, V130, P29; HILLS SE, 1987, THORAX, V42, P427, DOI 10.1136/thx.42.6.427; Hiraga Y, 1994, Nihon Rinsho, V52, P1438; HIROSE Y, 1994, CLIN NUCL MED, V19, P522, DOI 10.1097/00003072-199406000-00012; HOLTER JF, 1992, AM REV RESPIR DIS, V145, P864, DOI 10.1164/ajrccm/145.4_Pt_1.864; HUNNINGHAKE CW, 1994, AM J RESP CRIT CARE, V149, P893, DOI 10.1164/ajrccm.149.4.8143052; HUNNINGHAKE GW, 1980, NEW ENGL J MED, V302, P594, DOI 10.1056/NEJM198003133021102; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; INA Y, 1989, CHEST, V95, P1257, DOI 10.1378/chest.95.6.1257; Inoue Y, 1996, AM J PATHOL, V149, P2037; JAMES DG, 1992, LUPUS, V1, P129, DOI 10.1177/096120339200100302; JAMES DG, 1993, INTERSTITIAL LUNG DI, P159; JAWAD ASM, 1989, BRIT J RHEUMATOL, V28, P178; JOHNSON BA, 1993, AM REV RESPIR DIS, V148, P1373, DOI 10.1164/ajrccm/148.5.1373; Kaplan MM, 1996, NEW ENGL J MED, V335, P1570, DOI 10.1056/NEJM199611213352107; KAYE O, 1995, BRIT J RHEUMATOL, V34, P642; KAZEROONI EA, 1994, RADIOLOGY, V192, P461, DOI 10.1148/radiology.192.2.8029415; KELLER AZ, 1971, AM J EPIDEMIOL, V94, P222, DOI 10.1093/oxfordjournals.aje.a121316; KERN DG, 1993, AM REV RESPIR DIS, V148, P974, DOI 10.1164/ajrccm/148.4_Pt_1.974; KLEIN JT, 1995, J IMMUNOL, V154, P1450; LAVIOLETTE M, 1991, CHEST, V100, P380, DOI 10.1378/chest.100.2.380; LECOSSIER D, 1991, AM REV RESPIR DIS, V144, P861, DOI 10.1164/ajrccm/144.4.861; LENHART K, 1990, DIS MARKERS, V8, P23; LIMPER AH, 1994, AM J RESP CRIT CARE, V149, P197, DOI 10.1164/ajrccm.149.1.8111583; LOWER EE, 1990, AM J MED SCI, V299, P153, DOI 10.1097/00000441-199003000-00002; LOWER EE, 1995, ARCH INTERN MED, V155, P846, DOI 10.1001/archinte.155.8.846; LUKE RA, 1987, NEUROLOGY, V37, P461, DOI 10.1212/WNL.37.3.461; MANA J, 1994, RESPIRATION, V61, P219; MARCILLE R, 1992, CHEST, V102, P1444, DOI 10.1378/chest.102.5.1444; MARIGIAPAN G, 1995, SARCOIDOSIS, V12, P20; MARTINEZ FJ, 1994, CHEST, V106, P1597, DOI 10.1378/chest.106.5.1597; MAYOCK RL, 1963, AM J MED, V35, P67, DOI 10.1016/0002-9343(63)90165-7; MCNICOL MW, 1985, J ROY COLL PHYS LOND, V19, P179; MILLER A, 1995, CHEST, V107, P323, DOI 10.1378/chest.107.2.323; MILMAN N, 1994, J INTERN MED, V236, P285, DOI 10.1111/j.1365-2796.1994.tb00798.x; MITCHELL DN, 1974, AM REV RESPIR DIS, V110, P774; MROZ MM, 1991, J ALLERGY CLIN IMMUN, V88, P54, DOI 10.1016/0091-6749(91)90300-D; MULLERQUERNHEIM J, 1992, AM REV RESPIR DIS, V145, P187; MUNRO CS, 1987, THORAX, V42, P321, DOI 10.1136/thx.42.5.321; MUNRO CS, 1986, J CLIN PATHOL, V39, P176, DOI 10.1136/jcp.39.2.176; MURDOCH J, 1992, AM J ROENTGENOL, V159, P473, DOI 10.2214/ajr.159.3.1503008; NEWMAN LS, 1993, SCIENCE, V262, P197, DOI 10.1126/science.8105535; NEWMAN LS, 1995, SARCOIDOSIS, V12, P7; NEWMAN LS, 1995, NEW ENGL J MED, V333, P1128, DOI 10.1056/NEJM199510263331707; OHARA K, 1993, ARCH OPHTHALMOL-CHIC, V111, P642, DOI 10.1001/archopht.1993.01090050076033; OKAYAMA K, 1995, CHEST, V107, P330, DOI 10.1378/chest.107.2.330; ONI AA, 1992, J HEART LUNG TRANSPL, V11, P367; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420; PARKES SA, 1985, THORAX, V40, P284, DOI 10.1136/thx.40.4.284; PASTURENZI L, 1993, CHEST, V104, P1170, DOI 10.1378/chest.104.4.1170; PAZ HL, 1994, CHEST, V106, P1603, DOI 10.1378/chest.106.5.1603; PERRY A, 1995, ARCH PATHOL LAB MED, V119, P167; PESCI A, 1993, CHEST, V103, P989, DOI 10.1378/chest.103.4.989; PRIOR C, 1991, AM REV RESPIR DIS, V143, P53, DOI 10.1164/ajrccm/143.1.53; PUERINGER RJ, 1993, CHEST, V103, P832, DOI 10.1378/chest.103.3.832; REDLINE S, 1986, BRIT J IND MED, V43, P652; REISNER D, 1967, AM REV RESPIR DIS, V96, P361; RICHELDI L, 1993, SCIENCE, V262, P242, DOI 10.1126/science.8105536; ROMAN J, 1995, AM J MED SCI, V309, P124, DOI 10.1097/00000441-199503000-00002; ROSE CS, 1993, INTERSTITIAL LUNG DI, P231; ROSE CS, IN PRESS AM J PUBLIC; Russo Glenn, 1994, Comprehensive Therapy, V20, P418; Rybicki BA, 1997, AM J EPIDEMIOL, V145, P234, DOI 10.1093/oxfordjournals.aje.a009096; Rybicki BA, 1996, GENET EPIDEMIOL, V13, P23; SALTINI C, 1990, J EXP MED, V171, P1123, DOI 10.1084/jem.171.4.1123; SCOTT TF, 1993, NEUROLOGY, V43, P8, DOI 10.1212/WNL.43.1_Part_1.8; SELROOS O, 1994, SARCOIDOSIS, V11, P80; SEMENZATO G, 1991, EUR RESPIR J, V4, P94; SHAMMAS RL, 1993, CLIN CARDIOL, V16, P462, DOI 10.1002/clc.4960160603; SHARMA OP, 1993, AM REV RESPIR DIS, V147, P1598, DOI 10.1164/ajrccm/147.6_Pt_1.1598; SHARMA OP, 1991, ARCH INTERN MED, V151, P1317, DOI 10.1001/archinte.151.7.1317; SILTZBACH LE, 1974, AM J MED, V57, P847, DOI 10.1016/0002-9343(74)90160-0; Silver M R, 1994, J Am Optom Assoc, V65, P321; SKELTON HG, 1993, J AM ACAD DERMATOL, V28, P874, DOI 10.1016/0190-9622(93)70122-A; SMITH MJ, 1981, THORAX, V36, P296, DOI 10.1136/thx.36.4.296; SOUTHERN JF, 1989, JAMA-J AM MED ASSOC, V261, P1467, DOI 10.1001/jama.261.10.1467; SPITERI MA, 1990, GUT, V31, P208, DOI 10.1136/gut.31.2.208; STANDIFORD TJ, 1993, J IMMUNOL, V151, P2852; STEFFEN M, 1993, J ALLERGY CLIN IMMUN, V91, P939, DOI 10.1016/0091-6749(93)90352-G; STERN BJ, 1992, ARCH NEUROL-CHICAGO, V49, P1065, DOI 10.1001/archneur.1992.00530340089023; STJERNBERG N, 1984, ACTA MED SCAND, V215, P121; SWIDER C, 1995, CLIN EXP IMMUNOL, V100, P401; TAKADA K, 1993, J CLIN EPIDEMIOL, V46, P359, DOI 10.1016/0895-4356(93)90150-Y; THOMAS PD, 1987, AM REV RESPIR DIS, V135, P747; Tinkle SS, 1997, J IMMUNOL, V158, P518; TIWARI JL, 1995, HLA DISEASE ASS; Tsuda T, 1994, Nihon Rinsho, V52, P1456; TURNERWARWICK M, 1986, THORAX, V41, P903, DOI 10.1136/thx.41.12.903; VALANTINE H A, 1987, Journal of Heart Transplantation, V6, P244; VANETTA LL, 1983, REV INFECT DIS, V5, P1012; VOLDEN G, 1992, ACTA DERM-VENEREOL, V72, P69; WALLAERT B, 1986, ANN NY ACAD SCI, V465, P201, DOI 10.1111/j.1749-6632.1986.tb18496.x; WEBSTER GF, 1991, J AM ACAD DERMATOL, V24, P451, DOI 10.1016/0190-9622(91)70071-9; WHEAT LJ, 1989, ARCH INTERN MED, V149, P2421, DOI 10.1001/archinte.149.11.2421; WHITSETT CF, 1983, TISSUE ANTIGENS, V21, P348; WILLIAMS WR, 1986, BRIT J EXP PATHOL, V67, P167; WINTERBAUER RH, 1993, CHEST, V104, P352, DOI 10.1378/chest.104.2.352; WYNN TA, 1993, J IMMUNOL, V151, P1430; Yamada Haruyoshi, 1995, Journal of Dermatology (Tokyo), V22, P149; YAMAMOTO M, 1992, SARCOID SUP, V9, P33; ZIC JA, 1991, ARCH DERMATOL, V127, P1034, DOI 10.1001/archderm.127.7.1034; ZYCH D, 1993, SARCOIDOSIS, V10, P56; 1990, NEW ENGL J MED, V322, P116	159	1135	1175	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1224	1234		10.1056/NEJM199704243361706	http://dx.doi.org/10.1056/NEJM199704243361706			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110911				2022-12-28	WOS:A1997WV33200006
J	Zhang, ZY; Lagally, MG				Zhang, ZY; Lagally, MG			Atomistic processes in the early stages of thin-film growth	SCIENCE			English	Review							SCANNING-TUNNELING-MICROSCOPY; MOLECULAR-BEAM EPITAXY; BY-LAYER GROWTH; DIFFUSION-LIMITED AGGREGATION; ENERGY-ELECTRON DIFFRACTION; SURFACE SELF-DIFFUSION; METAL-SURFACES; HOMOEPITAXIAL GROWTH; ISLAND MORPHOLOGY; CLUSTER MOBILITY	Growth of thin films from atoms deposited from the gas phase is intrinsically a non-equilibrium phenomenon governed by a competition between kinetics and thermodynamics. Precise control of the growth and thus of the properties of deposited films becomes possible only after an understanding of this competition is achieved. Here, the atomic nature of the most important kinetic mechanisms of film growth is explored. These mechanisms include adatom diffusion on terraces, along steps, and around island corners; nucleation and dynamics of the stable nucleus; atom attachment to and detachment from terraces and islands; and interlayer mass transport. Ways to manipulate the growth kinetics in order to select a desired growth mode are briefly addressed.	UNIV WISCONSIN,DEPT MAT SCI & ENGN,MADISON,WI 53706; UNIV WISCONSIN,DEPT PHYS,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Zhang, ZY (corresponding author), OAK RIDGE NATL LAB,DIV SOLID STATE,POB 2008,OAK RIDGE,TN 37831, USA.							AMAR JG, 1995, PHYS REV LETT, V74, P2066, DOI 10.1103/PhysRevLett.74.2066; Andersohn L, 1996, J VAC SCI TECHNOL A, V14, P312, DOI 10.1116/1.579894; BALES GS, 1994, PHYS REV B, V50, P6057, DOI 10.1103/PhysRevB.50.6057; BALES GS, 1995, PHYS REV LETT, V74, P4879, DOI 10.1103/PhysRevLett.74.4879; BARTELT MC, 1993, PHYS REV B, V47, P13891, DOI 10.1103/PhysRevB.47.13891; BEDROSSIAN PJ, 1995, PHYS REV LETT, V74, P3648, DOI 10.1103/PhysRevLett.74.3648; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; Bott M, 1996, PHYS REV LETT, V76, P1304, DOI 10.1103/PhysRevLett.76.1304; Brocks G, 1996, PHYS REV LETT, V76, P2362, DOI 10.1103/PhysRevLett.76.2362; BROCKS G, 1992, SURF SCI, V269, P860, DOI 10.1016/0039-6028(92)91362-F; BROMANN K, 1995, PHYS REV LETT, V75, P677, DOI 10.1103/PhysRevLett.75.677; BRUNE H, 1994, PHYS REV LETT, V73, P1955, DOI 10.1103/PhysRevLett.73.1955; Brune H, 1996, SURF SCI, V349, pL115, DOI 10.1016/0039-6028(95)01347-4; BURTON WK, 1951, PHILOS T R SOC S-A, V243, P299, DOI 10.1098/rsta.1951.0006; CHEN CL, 1990, PHYS REV LETT, V64, P3147, DOI 10.1103/PhysRevLett.64.3147; COPEL M, 1989, PHYS REV LETT, V63, P632, DOI 10.1103/PhysRevLett.63.632; DIJKKAMP D, 1992, ORDERING SURFACES IN, P85; DURR H, 1995, SURF SCI, V328, pL527, DOI 10.1016/0039-6028(95)00087-9; EHRLICH G, 1966, J CHEM PHYS, V44, P1039, DOI 10.1063/1.1726787; ERNST HJ, 1994, PHYS REV LETT, V72, P112, DOI 10.1103/PhysRevLett.72.112; ESCH S, 1994, PHYS REV LETT, V72, P518, DOI 10.1103/PhysRevLett.72.518; FAHRENBACHER M, 1996, J VAC SCI TECHNOL A, V14, P1499; FEIBELMAN PJ, 1990, PHYS REV LETT, V65, P729, DOI 10.1103/PhysRevLett.65.729; Fu TY, 1996, PHYS REV B, V54, P5932, DOI 10.1103/PhysRevB.54.5932; HAMERS RJ, 1989, ULTRAMICROSCOPY, V31, P10, DOI 10.1016/0304-3991(89)90029-6; HAMILTON JC, 1995, PHYS REV LETT, V74, P2760, DOI 10.1103/PhysRevLett.74.2760; Harris S, 1995, PHYS REV B, V52, P16793, DOI 10.1103/PhysRevB.52.16793; HELLER EJ, 1992, APPL PHYS LETT, V60, P2675, DOI 10.1063/1.106892; Hohage M, 1996, PHYS REV LETT, V76, P2366, DOI 10.1103/PhysRevLett.76.2366; HWANG RQ, 1991, PHYS REV LETT, V67, P3279, DOI 10.1103/PhysRevLett.67.3279; JACOBSEN J, 1995, PHYS REV LETT, V74, P2295, DOI 10.1103/PhysRevLett.74.2295; Jacobsen J, 1996, SURF SCI, V359, P37, DOI 10.1016/0039-6028(96)00365-2; JOHNSON MD, 1994, PHYS REV LETT, V72, P116, DOI 10.1103/PhysRevLett.72.116; KANDEL D, 1995, PHYS REV LETT, V75, P2742, DOI 10.1103/PhysRevLett.75.2742; KELLOGG GL, 1990, PHYS REV LETT, V64, P3143, DOI 10.1103/PhysRevLett.64.3143; KELLOGG GL, 1994, SURF SCI REP, V21, P1, DOI 10.1016/0167-5729(94)90007-8; KELLOGG GL, 1994, PHYS REV LETT, V73, P1833, DOI 10.1103/PhysRevLett.73.1833; KHARE SV, 1995, PHYS REV LETT, V75, P2148, DOI 10.1103/PhysRevLett.75.2148; KITAMURA N, 1993, PHYS REV LETT, V71, P2082, DOI 10.1103/PhysRevLett.71.2082; KITAMURA N, 1993, PHYS REV LETT, V71, P2923; KUNKEL R, 1990, PHYS REV LETT, V65, P733, DOI 10.1103/PhysRevLett.65.733; LEWIS B, 1967, J VAC SCI TECHNOL, V4, P209, DOI 10.1116/1.1492548; Liu F, 1996, PHYS REV LETT, V76, P3156, DOI 10.1103/PhysRevLett.76.3156; LIU SD, 1993, PHYS REV LETT, V71, P2967, DOI 10.1103/PhysRevLett.71.2967; LIU SD, 1995, PHYS REV B, V52, P2907, DOI 10.1103/PhysRevB.52.2907; MARKOV I, 1994, PHYS REV B, V50, P11271, DOI 10.1103/PhysRevB.50.11271; MARKOV VA, 1991, SURF SCI, V250, P229, DOI 10.1016/0039-6028(91)90725-8; MEAKIN P, 1983, PHYS REV A, V27, P1495, DOI 10.1103/PhysRevA.27.1495; METIU H, 1992, SCIENCE, V255, P1088, DOI 10.1126/science.255.5048.1088; MEYER JA, 1995, PHYS REV B, V51, P14790, DOI 10.1103/PhysRevB.51.14790; MICHELY T, 1993, PHYS REV LETT, V70, P3943, DOI 10.1103/PhysRevLett.70.3943; MO YW, 1992, SURF SCI, V268, P275, DOI 10.1016/0039-6028(92)90968-C; MO YW, 1991, PHYS REV LETT, V66, P1998, DOI 10.1103/PhysRevLett.66.1998; MO YW, 1989, PHYS REV LETT, V63, P2393, DOI 10.1103/PhysRevLett.63.2393; MO YW, 1990, J VAC SCI TECHNOL A, V8, P201, DOI 10.1116/1.577066; MORGENSTERN K, 1995, PHYS REV LETT, V74, P2058, DOI 10.1103/PhysRevLett.74.2058; OPPO S, 1993, PHYS REV LETT, V71, P2437, DOI 10.1103/PhysRevLett.71.2437; Ostwald W, 1900, Z PHYS CHEM-STOCH VE, V34, P495; Pearson C, 1996, PHYS REV LETT, V76, P2306, DOI 10.1103/PhysRevLett.76.2306; PIMPINELLI A, 1992, PHYS REV LETT, V69, P985, DOI 10.1103/PhysRevLett.69.985; POHL DW, 1988, REV SCI INSTRUM, V59, P840, DOI 10.1063/1.1139790; Quesenberry PE, 1996, PHYS REV B, V54, P8218, DOI 10.1103/PhysRevB.54.8218; RATSCH C, 1994, PHYS REV LETT, V72, P3194, DOI 10.1103/PhysRevLett.72.3194; RATSCH C, 1996, IN PRESS P NATO ASI; RODER H, 1995, PHYS REV LETT, V74, P3217, DOI 10.1103/PhysRevLett.74.3217; RODER H, 1993, NATURE, V366, P141, DOI 10.1038/366141a0; ROSENFELD G, 1993, PHYS REV LETT, V71, P895, DOI 10.1103/PhysRevLett.71.895; ROUSSET S, 1992, PHYS REV LETT, V69, P3200, DOI 10.1103/PhysRevLett.69.3200; SCHWOEBEL RL, 1966, J APPL PHYS, V37, P3682, DOI 10.1063/1.1707904; Shi ZP, 1996, PHYS REV LETT, V76, P4927, DOI 10.1103/PhysRevLett.76.4927; SMMITH AP, 1996, PHHYS REV LETT, V77, P1326; STEIGERWALD DA, 1988, SURF SCI, V202, P472, DOI 10.1016/0039-6028(88)90048-9; Stranski I. N., 1938, SITZUNGSBER AK 2B MN, V146, P797; STROSCIO JA, 1994, PHYS REV B, V49, P8522, DOI 10.1103/PhysRevB.49.8522; STROSCIO JA, 1995, PHYS REV LETT, V75, P4246, DOI 10.1103/PhysRevLett.75.4246; STROSCIO JA, 1993, PHYS REV LETT, V70, P3615, DOI 10.1103/PhysRevLett.70.3615; Sutter P, 1995, J CRYST GROWTH, V157, P172, DOI 10.1016/0022-0248(95)00384-3; SUTTER P, 1994, APPL PHYS LETT, V65, P2220, DOI 10.1063/1.112766; Swartzentruber BS, 1996, PHYS REV LETT, V77, P2518, DOI 10.1103/PhysRevLett.77.2518; SWARTZENTRUBER BS, 1990, PHYS REV LETT, V65, P1913, DOI 10.1103/PhysRevLett.65.1913; Swartzentruber BS, 1996, PHYS REV LETT, V76, P459, DOI 10.1103/PhysRevLett.76.459; Tersoff J, 1996, PHYS REV LETT, V76, P1675, DOI 10.1103/PhysRevLett.76.1675; TERSOFF J, 1994, PHYS REV LETT, V72, P266, DOI 10.1103/PhysRevLett.72.266; TERSOFF J, 1995, PHYS REV LETT, V75, P2730, DOI 10.1103/PhysRevLett.75.2730; THEIS W, 1996, PHYS REV LETT, V76, P2773; TROMP RM, 1985, PHYS REV LETT, V55, P1303, DOI 10.1103/PhysRevLett.55.1303; TSONG TT, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881389; VANNOSTRAND JE, 1995, PHYS REV LETT, V74, P1127, DOI 10.1103/PhysRevLett.74.1127; VASEK JE, 1995, PHYS REV B, V51, P17207, DOI 10.1103/PhysRevB.51.17207; VENABLES JA, 1973, PHILOS MAG, V27, P697, DOI 10.1080/14786437308219242; VILLAIN J, 1992, J PHYS I, V2, P2107, DOI 10.1051/jp1:1992271; VILLAIN J, 1991, J PHYS I, V1, P19, DOI 10.1051/jp1:1991114; Volmer M, 1926, Z PHYS CHEM-STOCH VE, V119, P277; VOTER AF, 1986, PHYS REV B, V34, P6819, DOI 10.1103/PhysRevB.34.6819; VRIJMOETH J, 1994, PHYS REV LETT, V72, P3843, DOI 10.1103/PhysRevLett.72.3843; WANG SC, 1990, SURF SCI, V239, P301, DOI 10.1016/0039-6028(90)90232-W; WANG XS, 1990, PHYS REV LETT, V65, P2430, DOI 10.1103/PhysRevLett.65.2430; WEN JM, 1994, PHYS REV LETT, V73, P2591, DOI 10.1103/PhysRevLett.73.2591; WITTEN TA, 1981, PHYS REV LETT, V47, P1400, DOI 10.1103/PhysRevLett.47.1400; WOLKOW RA, 1995, PHYS REV LETT, V74, P4448, DOI 10.1103/PhysRevLett.74.4448; WU F, 1995, THESIS U WISCONSINMA; Yamasaki T, 1996, PHYS REV LETT, V76, P2949, DOI 10.1103/PhysRevLett.76.2949; Zhang Z., UNPUB; ZHANG ZY, 1991, SURF SCI, V248, pL250; ZHANG ZY, 1995, PHYS REV LETT, V74, P3644, DOI 10.1103/PhysRevLett.74.3644; ZHANG ZY, 1991, SURF SCI, V255, pL543, DOI 10.1016/0167-2584(91)90180-Y; ZHANG ZY, 1994, PHYS REV LETT, V73, P1829, DOI 10.1103/PhysRevLett.73.1829; ZHANG ZY, 1994, PHYS REV LETT, V72, P693, DOI 10.1103/PhysRevLett.72.693; Zhang ZY, 1996, SURF REV LETT, V3, P1449, DOI 10.1142/S0218625X96002461; ZHANG ZY, 1993, PHYS REV B, V48, P4952; ZUO JK, 1994, PHYS REV LETT, V72, P3064, DOI 10.1103/PhysRevLett.72.3064	111	829	864	10	441	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					377	383		10.1126/science.276.5311.377	http://dx.doi.org/10.1126/science.276.5311.377			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103189				2022-12-28	WOS:A1997WU47700029
J	Fletcher, SW				Fletcher, SW			Whither scientific deliberation in health policy recommendations? Alice in the Wonderland of breast-cancer screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Fletcher, SW (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; *G C MERR, 1980, WEBST NEW COLL DICT; KOLATA G, 1997, NY TIMES        0224, pA1; Kolata G., 1997, NY TIMES        0128, pC1; Mathews Jessica, 1997, Washington Post, pA19; *NIH CONS STAT, 1997, BREAST CANC SCREEN W	6	104	104	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1180	1183		10.1056/NEJM199704173361612	http://dx.doi.org/10.1056/NEJM199704173361612			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099666				2022-12-28	WOS:A1997WU00300012
J	Paydarfar, D; delaMonte, SM; Buchbinder, BR; Colin, RB				Paydarfar, D; delaMonte, SM; Buchbinder, BR; Colin, RB			A 50-year-old woman with multiple sclerosis and an enlarging frontal-lobe mass - Oligodendroglioma, focally anaplastic, mixed with low-grade astrocytoma. Multiple sclerosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR; MATURE OLIGODENDROCYTES; BRAIN METASTASIS; NERVOUS-SYSTEM; LESIONS; COINCIDENCE; HEMISPHERE; EXPERIENCE; DIAGNOSIS; DISEASES		TUFTS UNIV,SCH MED,MEDFORD,MA 02155	Tufts University	Paydarfar, D (corresponding author), ST ELIZABETHS MED CTR,BOSTON,MA 02135, USA.		de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306				AARLI JA, 1989, EUR NEUROL, V29, P312, DOI 10.1159/000116437; ADAMS RD, 1952, AM J MED, V12, P510, DOI 10.1016/0002-9343(52)90234-9; ANDERSON M, 1980, BRAIN, V103, P603, DOI 10.1093/brain/103.3.603; ARENELLA LS, 1984, ARCH NEUROL-CHICAGO, V41, P1162, DOI 10.1001/archneur.1984.04050220060015; ARMINGTON WG, 1985, RADIOLOGY, V157, P367, DOI 10.1148/radiology.157.2.4048443; Bailey P, 1929, J PATHOL BACTERIOL, V32, P735, DOI 10.1002/path.1700320403; BALKO MG, 1992, HUM PATHOL, V23, P706; BARNARD RO, 1987, CANCER, V60, P1519, DOI 10.1002/1097-0142(19871001)60:7<1519::AID-CNCR2820600719>3.0.CO;2-1; BARNARD RO, 1967, J NEUROL SCI, V5, P441, DOI 10.1016/0022-510X(67)90084-6; BJORNSSON J, 1985, J NEUROPATH EXP NEUR, V44, P32, DOI 10.1097/00005072-198501000-00003; CHIAPPA KH, 1983, EVOKED POTENTIALS CL; Courville CB, 1930, ARCH NEURO PSYCHIATR, V24, P439, DOI 10.1001/archneurpsyc.1930.02220150002001; DAUMASDUPORT C, 1988, NEUROSURGERY, V23, P545, DOI 10.1227/00006123-198811000-00002; DECASTRO CC, 1991, NEUROIMAG CLIN N AM, V1, P119; FORSYTH PA, 1993, NEUROLOGY, V43, P1678, DOI 10.1212/WNL.43.9.1678; Gainotti G, 1972, Cortex, V8, P41; GOLDBERG G, 1981, ARCH NEUROL-CHICAGO, V38, P683, DOI 10.1001/archneur.1981.00510110043004; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; HADDAD SF, 1992, NEUROSURGERY, V31, P171, DOI 10.1227/00006123-199208000-00001; HO KL, 1981, CANCER-AM CANCER SOC, V47, P2913, DOI 10.1002/1097-0142(19810615)47:12<2913::AID-CNCR2820471229>3.0.CO;2-1; HWANG TL, 1993, NEUROSURGERY, V32, P451, DOI 10.1227/00006123-199303000-00018; JELLINGER K, 1973, ACTA NEUROPATHOL, V25, P291, DOI 10.1007/BF00691757; KEPES JJ, 1993, ANN NEUROL, V33, P18, DOI 10.1002/ana.410330105; KISHI K, 1982, ARCH PATHOL LAB MED, V106, P133; LAHL R, 1980, EUR NEUROL, V19, P192, DOI 10.1159/000115146; LEE YY, 1989, AM J NEURORADIOL, V10, P119; LOUIS DN, 1995, BRAIN PATHOL, V5, P145, DOI 10.1111/j.1750-3639.1995.tb00588.x; LUDWIN SK, 1984, NATURE, V308, P274, DOI 10.1038/308274a0; MALMGREN RM, 1984, CLIN NEUROPATHOL, V3, P1; MATHEWS T, 1972, ARCH NEUROL-CHICAGO, V27, P263, DOI 10.1001/archneur.1972.00490150071010; NAHSER HC, 1986, SURG NEUROL, V26, P45, DOI 10.1016/0090-3019(86)90062-5; NAKAMURA Y, 1985, CANCER, V55, P103, DOI 10.1002/1097-0142(19850101)55:1<103::AID-CNCR2820550117>3.0.CO;2-K; OSBORNE AG, 1994, DIAGNOSTIC RADIOLOGY; PALMA L, 1993, NEUROSURGERY, V32, P169, DOI 10.1227/00006123-199302000-00003; PALO J, 1977, J NEUROL, V216, P217, DOI 10.1007/BF00313623; PEREZDIAZ C, 1985, SURG NEUROL, V24, P581, DOI 10.1016/0090-3019(85)90278-2; PHILIPPON JH, 1993, NEUROSURGERY, V32, P554; PIEPMEIER JM, 1987, J NEUROSURG, V67, P177, DOI 10.3171/jns.1987.67.2.0177; PRAYSON RA, 1992, AM J CLIN PATHOL, V97, P398, DOI 10.1093/ajcp/97.3.398; RAYMOND AA, 1994, BRAIN, V117, P461, DOI 10.1093/brain/117.3.461; ROSS ED, 1981, ARCH NEUROL-CHICAGO, V38, P561, DOI 10.1001/archneur.1981.00510090055006; Russell D., 1989, PATHOLOGY TUMORS NER; Scherer H., 1938, J BELG NEUROL PSYCHI, V38, P1; SHANKAR SK, 1989, NEUROSURGERY, V25, P982, DOI 10.1227/00006123-198912000-00024; SHAW EG, 1992, J NEUROSURG, V76, P428, DOI 10.3171/jns.1992.76.3.0428; SMALLEY SR, 1992, J NEUROSURG, V77, P531, DOI 10.3171/jns.1992.77.4.0531; SMITH AS, 1991, AM J NEURORADIOL, V12, P175; SPAAR FW, 1978, J NEUROL, V218, P23, DOI 10.1007/BF00314715; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; SUWANWELA N, 1994, HEADACHE, V34, P435, DOI 10.1111/j.1526-4610.1994.hed3407435.x; VAKILI ST, 1983, J NEUROSURG, V59, P332, DOI 10.3171/jns.1983.59.2.0332; VIEREGGE P, 1984, CLIN NEUROPATHOL, V3, P10; Yamashita K, 1989, No To Shinkei, V41, P199; ZAGZAG D, 1993, AM J SURG PATHOL, V17, P537, DOI 10.1097/00000478-199306000-00001	54	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1163	1171		10.1056/NEJM199704173361608	http://dx.doi.org/10.1056/NEJM199704173361608			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099662				2022-12-28	WOS:A1997WU00300008
J	Dracup, K; Alonzo, AA; Atkins, JM; Bennett, NM; Braslow, A; Clark, LT; Eisenberg, M; Ferdinand, KC; Frye, R; Green, L; Hill, MN; Kennedy, JW; KlineRogers, E; Moser, DK; Ornato, JP; Pitt, B; Scott, JD; Selker, HP; Silva, SJ; Thies, W; Weaver, WD; Wenger, NK; White, SK				Dracup, K; Alonzo, AA; Atkins, JM; Bennett, NM; Braslow, A; Clark, LT; Eisenberg, M; Ferdinand, KC; Frye, R; Green, L; Hill, MN; Kennedy, JW; KlineRogers, E; Moser, DK; Ornato, JP; Pitt, B; Scott, JD; Selker, HP; Silva, SJ; Thies, W; Weaver, WD; Wenger, NK; White, SK			The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: Recommendations from the National Heart Attack Alert Program	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE CHEST PAIN; PRE-HOSPITAL PHASE; THROMBOLYTIC THERAPY; CORONARY ANGIOPLASTY; DISEASE; EMERGENCY; SYMPTOMS; ARRIVAL; TIME; INTERVENTION	Physicians and other health care professionals play an important role in reducing the delay to treatment in patients who have an evolving acute myocardial infarction. A multidisciplinary working group has been convened by the National Heart Attack Alert Program (which is coordinated by the National Heart, Lung, and Blood Institute of the National Institutes of Health) to address this concern. The working group's recommendations target specific groups of patients: those who are known to have coronary heart disease, atherosclerotic disease of the aorta or peripheral arteries, or cerebrovascular disease. The risk for acute myocardial infarction or death in such patients is five to seven times greater than that in the general population. The working group recommends that these high-risk patients be clearly informed about symptoms that they mig ht have during a coronary occlusion, steps that they should take, the importance of contacting emergency medical services, the need to report to an appropriate facility quickly, treatment options that are available if they present early, and rewards of early treatment in terms of improved quality of life. These instructions should be reviewed frequently and reinforced with appropriate written material, and patients should be encouraged to have a plan and to rehearse it periodically. Because of the important role of the bystander in increasing or decreasing delay to treatment, family members and significant others should be included in all instruction. Finally, physicians' offices and clinics should devise systems to quickly assess patients who telephone or present with symptoms of a possible acute myocardial infarction.	NHLBI, NATL HEART ATTACK ALERT PROGRAM, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								Adams P F, 1995, Vital Health Stat 10, P1; ALONZO AA, 1986, SOC SCI MED, V22, P1297, DOI 10.1016/0277-9536(86)90093-6; [Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1994, Ann Emerg Med, V23, P311; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BANDURA A, 1965, J PERS SOC PSYCHOL, V1, P589, DOI 10.1037/h0022070; Bandura A., 1971, SOCIAL LEARNING THEO; BERGER PB, 1994, AM J CARDIOL, V73, P231, DOI 10.1016/0002-9149(94)90225-9; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; CANNON CP, 1995, J AM COLL CARDIOL, pA231; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; CLARK LT, 1992, J NATL MED ASSOC, V84, P931; CRAWFORD SL, 1994, AM J PUBLIC HEALTH, V84, P957, DOI 10.2105/AJPH.84.6.957; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DRACUP K, 1995, SOC SCI MED, V40, P379, DOI 10.1016/0277-9536(94)00278-2; DRACUP K, 1991, HEART LUNG, V20, P570; DRACUP K, IN PRESS MED J AUST; FETRO JV, 1992, PERSONAL SOCIAL SKIL; GHALI JK, 1993, J NATL MED ASSOC, V85, P180; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; HACKETT TP, 1969, AM J CARDIOL, V24, P651, DOI 10.1016/0002-9149(69)90452-4; HERLITZ J, 1993, CARDIOLOGY, V82, P347, DOI 10.1159/000175885; HO MT, 1988, CIRCULATION, V78, P187; HOFGREN K, 1988, HEART LUNG, V17, P274; Johnson J A, 1995, Am J Crit Care, V4, P29; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; KATHLEEN E, 1994, AM J PUBLIC HEALTH, V84, P965, DOI 10.2105/AJPH.84.6.965; KULLER L, 1975, CIRCULATION, V52, P1; LEE TH, 1992, AM J CARDIOL, V69, P145, DOI 10.1016/0002-9149(92)91294-E; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEITCH JW, 1989, MED J AUSTRALIA, V150, P6, DOI 10.5694/j.1326-5377.1989.tb136310.x; MARGOLIS JR, 1973, AM J CARDIOL, V32, P1, DOI 10.1016/S0002-9149(73)80079-7; MAYNARD C, 1989, AM J CARDIOL, V63, P1296, DOI 10.1016/0002-9149(89)91038-2; McKendall G.R, 1991, CIRCULATION S2, V84, pII; MEISCHKE H, 1993, ANN EMERG MED, V22, P1597, DOI 10.1016/S0196-0644(05)81267-3; MOSS AJ, 1969, AM J CARDIOL, V24, P659, DOI 10.1016/0002-9149(69)90453-6; MOSS AJ, 1970, CIRCULATION, V41, P737, DOI 10.1161/01.CIR.41.5.737; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RACZYNSKI JM, 1994, AM J PUBLIC HEALTH, V84, P951, DOI 10.2105/AJPH.84.6.951; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; Reilly A, 1994, Am J Crit Care, V3, P300; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; SIMON AB, 1972, AM J CARDIOL, V30, P476, DOI 10.1016/0002-9149(72)90037-9; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TURI ZG, 1986, AM J CARDIOL, V58, P203, DOI 10.1016/0002-9149(86)90047-0; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEAVER WD, 1992, THROMBOSIS CARDIOVAS, P275; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4; 1988, J AM COLL CARDIOL  S, V12, pA3	61	135	136	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					645	651		10.7326/0003-4819-126-8-199704150-00010	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WT580	9103133				2022-12-28	WOS:A1997WT58000012
J	Waterworth, DM; Bennett, ST; Gharani, N; McCarthy, MI; Hague, S; Batty, S; Conway, GS; White, D; Todd, JA; Franks, S; Williamson, R				Waterworth, DM; Bennett, ST; Gharani, N; McCarthy, MI; Hague, S; Batty, S; Conway, GS; White, D; Todd, JA; Franks, S; Williamson, R			Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome	LANCET			English	Article							GROWTH FACTOR-I; OBESE WOMEN; LOCUS; HYPERANDROGENISM; SUSCEPTIBILITY; MINISATELLITE; ENDOCRINE; DISEASE; PATTERN; DEFECTS	Background Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 10% of women of reproductive age. Women with anovulatory PCOS have hyperinsulinaemia, insulin resistance, and dyslipidaemia, and the syndrome is associated with greatly increased risks of non-insulin-dependent diabetes mellitus and cardiovascular disease and it often clusters in families. The VNTR (variable number of tandem repeats) locus upstream of the insulin gene (INS) regulates insulin expression. We have studied INS VNTR as a candidate genetic locus for susceptibility to PCOS. Methods We evaluated linkage of PCOS to the INS VNTR locus on chromosome 11p15.5 in 17 families with several cases, and looked for an association between VNTR and PCOS in two additional clinic populations. VNTR genotypes were designated I/I, I/III, and III/III and linkage disequilibrium mapping was used to test the primary role of the VNTR. Findings In a group of PCOS/male pattern baldness families, we obtained positive evidence for linkage to 11p15.5 (p = 0.002). The INS VNTR III/III genotype was associated with an increased risk of PCOS in two independent case-control studies (odds ratios 8.20 [p = 0.005] and 5.70 [p = 0.043]). Multilocus linkage disequilibrium mapping suggests that VNTR itself is the predisposing locus. Interpretation Mapping of susceptibility to PCOS to the INS VNTR implies that PCOS is due, in part, to an inherited alteration in insulin production, The data suggest a mechanistic link between type 2 diabetes and PCOS, which is a risk factor for diabetes later in life.	ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT BIOCHEM & MOL GENET, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT OBSTET & GYNAECOL, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, METAB MED UNIT, LONDON W2 1PG, ENGLAND; UNIV OXFORD, NUFFIELD DEPT SURG, WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 7BN, ENGLAND; ROYAL CHILDRENS HOSP, MURDOCH INST, MELBOURNE, VIC, AUSTRALIA; MIDDLESEX HOSP, DEPT ENDOCRINOL, LONDON, ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of Oxford; Wellcome Centre for Human Genetics; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of London; University College London			Todd, John A/A-3542-2010; McCarthy, Mark/M-3763-2015	Todd, John A/0000-0003-2740-8148; McCarthy, Mark/0000-0002-4393-0510	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; BAIRD DT, 1977, J CLIN ENDOCR METAB, V45, P798, DOI 10.1210/jcem-45-4-798; Bennett ST, 1996, J AUTOIMMUN, V9, P415, DOI 10.1006/jaut.1996.0057; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; CAREY AH, 1993, CLIN ENDOCRINOL, V38, P653, DOI 10.1111/j.1365-2265.1993.tb02150.x; CONWAY GS, 1990, CLIN ENDOCRINOL, V33, P593; CONWAY GS, 1992, CLIN ENDOCRINOL, V37, P119, DOI 10.1111/j.1365-2265.1992.tb02295.x; DAHLGREN E, 1992, ACTA OBSTET GYN SCAN, V71, P599, DOI 10.3109/00016349209006227; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; DUNAIF A, 1992, DIABETES, V41, P1257, DOI 10.2337/diabetes.41.10.1257; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HOLTE J, 1995, J CLIN ENDOCR METAB, V80, P2586, DOI 10.1210/jc.80.9.2586; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KIDDY DS, 1992, CLIN ENDOCRINOL, V36, P105, DOI 10.1111/j.1365-2265.1992.tb02909.x; KIDDY DS, 1990, CLIN ENDOCRINOL, V32, P213, DOI 10.1111/j.1365-2265.1990.tb00857.x; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; OMEARA NM, 1993, J CLIN ENDOCR METAB, V76, P1241, DOI 10.1210/jc.76.5.1241; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; Poretsky L, 1994, ENDOCR REV, V2, P125; ROBINSON S, 1993, CLIN ENDOCRINOL, V39, P351, DOI 10.1111/j.1365-2265.1993.tb02376.x; SHARP PS, 1991, CLIN ENDOCRINOL, V35, P253, DOI 10.1111/j.1365-2265.1991.tb03531.x; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; THOMSON G, 1995, AM J HUM GENET, V57, P487; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; WEAVER JU, 1992, EUR J CLIN INVEST, V22, P265, DOI 10.1111/j.1365-2362.1992.tb01461.x; Willis D, 1996, J CLIN ENDOCR METAB, V81, P302, DOI 10.1210/jc.81.1.302	32	242	258	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	1997	349	9057					986	990		10.1016/S0140-6736(96)08368-7	http://dx.doi.org/10.1016/S0140-6736(96)08368-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100625				2022-12-28	WOS:A1997WR62100011
J	Thome, M; Schneider, P; Hofmann, K; Fickenscher, H; Meinl, E; Neipel, F; Mattmann, C; Burns, K; Bodmer, JL; Schroter, M; Scaffidi, C; Krammer, PH; Peter, ME; Tschopp, J				Thome, M; Schneider, P; Hofmann, K; Fickenscher, H; Meinl, E; Neipel, F; Mattmann, C; Burns, K; Bodmer, JL; Schroter, M; Scaffidi, C; Krammer, PH; Peter, ME; Tschopp, J			Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors	NATURE			English	Article							INTERACTS; DOMAIN	Viruses have evolved many distinct strategies to avoid the host's apoptotic response(1,2). Here we describe a new family of viral inhibitors (v-FLIPs) which interfere with apoptosis signalled through death receptors(3) and which are present in several gamma-herpesviruses (including Kaposi's-sarcoma-associated human herpesvirus-8), as well as in the tumorigenic human molluscipoxvirus(4). v-FLIPs contain two death-effector domains which interact with the adaptor protein FADD(5,6) and this inhibits the recruitment and activation of the protease FLICE(7,8) by the CD95 death receptor(3). Cells expressing v-FLIPs are protected against apoptosis induced by CD95 or by the related death receptors TRAMP(9-12) and TRAIL-R. The herpesvirus saimiri FLIP is detected late during the lytic viral replication cycle, at a time when host cells are partially protected from CD95-ligand-mediated apoptosis, protection of virus-infected cells against death-receptor-induced apoptosis may lead to higher virus production and contribute to the persistence and oncogenicity(13) of several FLIP-encoding viruses.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; SWISS INST EXPT CANC RES,BIL BIOMED RES CTR,CH-1066 EPALINGES,SWITZERLAND; UNIV ERLANGEN NURNBERG,INST CLIN & MOL VIROL,D-91054 ERLANGEN,GERMANY; GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,DIV IMMUNOGENET,D-69120 HEIDELBERG,GERMANY	University of Lausanne; Swiss Institute Experimental Cancer Research; University of Erlangen Nuremberg; Helmholtz Association; German Cancer Research Center (DKFZ)			Thome, Margot/F-8167-2011; Watzl, Carsten/B-4911-2013; Hofmann, Kay/D-6714-2011; Fickenscher, Helmut/J-9655-2019; Fickenscher, Helmut/A-3004-2010	Thome, Margot/0000-0002-5656-2139; Watzl, Carsten/0000-0001-5195-0995; Hofmann, Kay/0000-0002-2289-9083; Fickenscher, Helmut/0000-0003-0043-1153; Peter, Marcus Ernst/0000-0003-3216-036X; Schneider, Pascal/0000-0003-0677-9409; Meinl, Edgar/0000-0002-2570-6785				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fickenscher H, 1996, J VIROL, V70, P6012, DOI 10.1128/JVI.70.9.6012-6019.1996; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; MEDEMA J, IN PRESS EMBO J; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Tschopp J, 1996, TRENDS MICROBIOL, V4, P91, DOI 10.1016/0966-842X(96)81522-8; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YU GL, 1996, SCIENCE, V274, P990	30	902	947	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					517	521		10.1038/386517a0	http://dx.doi.org/10.1038/386517a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087414	Green Submitted			2022-12-28	WOS:A1997WR25600058
J	Gardner, M				Gardner, M			Information retrieval for patient care	BRITISH MEDICAL JOURNAL			English	Article								Doctors need clinical information during most consultations with patients, and much of this need could be satisfied by material from online sources. Advances in data communication technologies mean that multimedia information can be transported rapidly to various clinical care locations. However, selecting the few items of information likely to be useful in a particular clinical situation from the mass of information available is a major problem. Current information retrieval systems are designed primarily for use in research rather than clinical care. The design, implementation, and critical evaluation of ne iv information retrieval systems for clinical care should be guided by knowledgeable clinical users.			Gardner, M (corresponding author), UNIV GLASGOW,DEPT COMP SCI,INFORMAT RETRIEVAL RES GRP,GLASGOW G12 8QQ,LANARK,SCOTLAND.							Smith R, 1996, BRIT MED J, V313, P1062	1	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					950	953		10.1136/bmj.314.7085.950	http://dx.doi.org/10.1136/bmj.314.7085.950			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099122	Green Published			2022-12-28	WOS:A1997WQ16900030
J	Schnider, P; Binder, M; Kittler, H; Steinhoff, N; Auff, E				Schnider, P; Binder, M; Kittler, H; Steinhoff, N; Auff, E			Uses of botulinum toxin	LANCET			English	Letter									UNIV VIENNA,DERMATOL CLIN,DEPT GEN DERMATOL,VIENNA,AUSTRIA	University of Vienna	Schnider, P (corresponding author), UNIV VIENNA,NEUROL CLIN,DEPT NEUROREHABIL,A-1090 VIENNA,AUSTRIA.		Kittler, Harald/AAK-1502-2020; Kittler, Harald/K-7574-2013	KITTLER, HARALD/0000-0002-0051-8016				Bushara KO, 1996, CLIN EXP DERMATOL, V21, P276, DOI 10.1111/j.1365-2230.1996.tb00093.x; DROBIK C, 1995, ACTA OTO-LARYNGOL, V115, P459, DOI 10.3109/00016489509139348; NAUMANN, 1997, LANCET, V349, P252; Schnider P, 1996, BRIT J DERMATOL, V134, P1160, DOI 10.1111/j.1365-2133.1996.tb07974.x; SCHNIDER P, IN PRESS BR J DERMAT	5	8	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					953	953		10.1016/S0140-6736(05)62729-8	http://dx.doi.org/10.1016/S0140-6736(05)62729-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093270				2022-12-28	WOS:A1997WR25400053
J	Kumararatne, M				Kumararatne, M			Why publish?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		SELLAHEWA KH, 1994, AM J TROP MED HYG, V51, P823, DOI 10.4269/ajtmh.1994.51.823	1	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					957	957		10.1001/jama.277.12.957	http://dx.doi.org/10.1001/jama.277.12.957			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091659				2022-12-28	WOS:A1997WN99200014
J	Crofts, TJ; Griffiths, JMT; Sharma, S; Wygrala, J; Aitken, RJ				Crofts, TJ; Griffiths, JMT; Sharma, S; Wygrala, J; Aitken, RJ			Surgical training: An objective assessment of recent changes for a single health board	BRITISH MEDICAL JOURNAL			English	Article								The reduction in doctors' hours and the introduction of specialist training have reduced general surgical training by 60%. This study assessed the implications for a single health board. A questionnaire listing 13 representative operations was sent to 44 trainees and 52 trainers to determine the number of operations a trainee should perform. The total number of operations required for training was compared against the total actually performed across the health board, Operating times for five representative operations were audited prospectively. Trainers and trainees recommended a similar and conservative number of operations. The total number of operations available for training (4913) was 38% less than the number recommended (7946). Trainees required 50-75% more operating time than consultants. To increase the proportion of operations undertaken by trainees from the current 30% to 70% would require an extra 270 theatre days (or pound 1.3m) yearly. The minimum number of operations required for training must be defined and the proportion of supervised operations undertaken by trainees substantially increased. Service and financial implications will have to be addressed. Action is needed urgently, as the first trainees will become consultants in less than five years.			Crofts, TJ (corresponding author), EASTERN GEN HOSP,EDINBURGH EH6 7LN,MIDLOTHIAN,SCOTLAND.			Sharma, Sanjeev Kumar/0000-0002-3273-0708				BOTTOMLEY V, 1992, NATL HLTH SERVICE AR; Buck N, 1987, REPORT CONFIDENTIAL; Bulstrode C, 1996, BRIT MED J, V312, P326; *DEP HLTH, 1996, GUID SPEC REG TRAIN; GRUER R, 1986, LANCET, V1, P23; Milne A A, 1996, Ann R Coll Surg Engl, V78, P177; *NEW CHURCH CO W S, 1996, CAT CHANG; *NHS MAN EX, 1991, JUN DOCT NEW DEAL WO; OPIT LJ, 1991, ANN ROY COLL SURG, V73, P389; *PARL OFF SCI TECH, 1995, MIN ACC SURG; Potter M A, 1996, Ann R Coll Surg Engl, V78, P11; POTTER MA, 1995, ANN R COLL SURG EN S, V4, P191; *UK HLTH DEP JOINT, 1987, HOSP MED STAFF ACH B; *WORK GROUP SPEC M, 1993, HOSP DOCT TRAIN FUT	14	61	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					891	895						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093109				2022-12-28	WOS:A1997WQ02800041
J	Moon, RT; Brown, JD; YangSnyder, JA; Miller, JR				Moon, RT; Brown, JD; YangSnyder, JA; Miller, JR			Structurally related receptors and antagonists compete for secreted Wnt ligands	CELL			English	Review									UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,PROGRAM MOL & CELLULAR BIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Moon, RT (corresponding author), UNIV WASHINGTON,SCH MED,HOWARD HUGHES MED INST,SEATTLE,WA 98195, USA.		Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; LARABELL CA, 1997, IN PRESS J CELL BIOL; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Spemann H., 1938, EMBRYONIC DEV INDUCT; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	14	100	105	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					725	728		10.1016/S0092-8674(00)81915-7	http://dx.doi.org/10.1016/S0092-8674(00)81915-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118212	Bronze			2022-12-28	WOS:A1997WQ10000001
J	vandeWetering, M; Cavallo, R; Dooijes, D; vanBeest, M; vanEs, J; Loureiro, J; Ypma, A; Hursh, D; Jones, T; Bejsovec, A; Peifer, M; Mortin, M; Clevers, H				vandeWetering, M; Cavallo, R; Dooijes, D; vanBeest, M; vanEs, J; Loureiro, J; Ypma, A; Hursh, D; Jones, T; Bejsovec, A; Peifer, M; Mortin, M; Clevers, H			Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF	CELL			English	Article							HMG BOX PROTEIN; CELL-ADHESION; MELANOGASTER; EXPRESSION; WINGLESS; MUTATIONS; PATTERN; EMBRYOGENESIS; CONNECTION; DOMINANT	The vertebrate transcription factors TCF (T cell factor) and LEF (lymphocyte enhancer binding factor) interact with beta-catenin and are hypothesized to mediate Wingless/Wnt signaling. We have cloned a maternally expressed Drosophila TCF family member, dTCF. dTCF binds a canonical TCF DNA motif and interacts with the beta-catenin homolog Armadillo. Previous studies have identified two regions in Armadillo required for Wingless signaling. One of these interacts with dTCF, while the other constitutes a transactivation domain. Mutations in dTCF and expression of a dominant-negative dTCF transgene cause a segment polarity phenotype and affect expression of the Wingless target genes engrailed and Ultrabithorax. Epistasis analysis positions dTCF downstream of armadillo. The Armadillo-dTCF complex mediates Wingless signaling as a bipartite transcription factor.	NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA; AMERICAN UNIV, DEPT BIOL, WASHINGTON, DC 20016 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; UNIV N CAROLINA, DEPT BIOL & CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American University; Northwestern University; University of North Carolina; University of North Carolina Chapel Hill	vandeWetering, M (corresponding author), UNIV UTRECHT HOSP, DEPT IMMUNOL, NL-3508 GA CHAPEL HILL, NETHERLANDS.		Peifer, Mark/A-1152-2010; van+Es, Johan/ABD-5411-2021; Mortin, Mark A/B-4251-2008	Hursh, Deborah/0000-0002-5614-7111; Peifer, Mark/0000-0003-1412-3987; Bejsovec, Amy/0000-0002-8019-5789	NIGMS NIH HHS [GM07092] Funding Source: Medline; PHS HHS [47857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Florence B, 1997, DEVELOPMENT, V124, P839; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; HOCHMAN B, 1971, GENETICS, V67, P235; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HURSH DA, 1993, DEVELOPMENT, V117, P1211; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; KORINEK V, 1997, IN PRESS SCIENCE; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORIN PJ, 1997, IN PRESS SCIENCE; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RAY RP, 1991, DEVELOPMENT, V113, P35; ROBERTSON HM, 1988, GENETICS, V118, P461; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUBINFELD B, 1997, IN PRESS SCIENCE; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SLUSARSKI DC, 1995, GENETICS, V139, P229; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yu X, 1996, DEVELOPMENT, V122, P849	53	1052	1065	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	1997	88	6					789	799		10.1016/S0092-8674(00)81925-X	http://dx.doi.org/10.1016/S0092-8674(00)81925-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118222	Bronze, Green Submitted			2022-12-28	WOS:A1997WQ10000011
J	Strauss, EJ; Falkow, S				Strauss, EJ; Falkow, S			Microbial pathogenesis: Genomics and beyond	SCIENCE			English	Article							BACTERIAL VIRULENCE GENES; ESCHERICHIA-COLI STRAINS; SELECTION	The growing number of complete microbial genome sequences provides a powerful tool for studying the biology of microorganisms. In combination with assays for function, genomic-based approaches can facilitate efficient and directed research strategies to elucidate mechanisms of bacterial pathogenicity. As genomic information accrues, the challenge remains to construct a picture of the biology that accurately reflects how individual genes collaborate to create the complex world of microbial specialization.			Strauss, EJ (corresponding author), STANFORD UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,STANFORD,CA 94305, USA.				NIAID NIH HHS [AI 26195] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bajaj V, 1996, MOL MICROBIOL, V22, P703, DOI 10.1046/j.1365-2958.1996.d01-1718.x; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; FINLAY BB, IN PRESS MICROBIOL R; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HERMANT D, 1995, MOL MICROBIOL, V17, P781, DOI 10.1111/j.1365-2958.1995.mmi_17040781.x; Hood DW, 1996, P NATL ACAD SCI USA, V93, P11121, DOI 10.1073/pnas.93.20.11121; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MAHAN MJ, 1996, ESCHERICHIA COLI SAL; Marshall E, 1997, SCIENCE, V275, P777, DOI 10.1126/science.275.5301.777; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; RELMAN DA, 1995, PRINCIPLES PRACTICE; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; SJOGREN R, 1994, GASTROENTEROLOGY, V106, P306, DOI 10.1016/0016-5085(94)90587-8; Theriot JA, 1995, ANNU REV CELL DEV BI, V11, P213, DOI 10.1146/annurev.cb.11.110195.001241; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; WHITTAM TS, 1993, INFECT IMMUN, V61, P1619, DOI 10.1128/IAI.61.5.1619-1629.1993	30	134	140	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					707	712		10.1126/science.276.5313.707	http://dx.doi.org/10.1126/science.276.5313.707			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115190				2022-12-28	WOS:A1997WW90000036
J	Poser, CM				Poser, CM			Intravenous immunoglobulin for multiple sclerosis	LANCET			English	Letter											Poser, CM (corresponding author), BETH ISRAEL HOSP, DEPT NEUROL, BOSTON, MA 02215 USA.			Ellis, Simon/0000-0002-9131-6427				Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4	1	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	1997	349	9059					1177	1178		10.1016/S0140-6736(05)63059-0	http://dx.doi.org/10.1016/S0140-6736(05)63059-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113039				2022-12-28	WOS:A1997WU54400058
J	Harrison, CJ; HayerHartl, M; DiLiberto, M; Hartl, FU; Kuriyan, J				Harrison, CJ; HayerHartl, M; DiLiberto, M; Hartl, FU; Kuriyan, J			Crystal structure of the nucleotide exchange factor GrpE bound to the ATPase domain of the molecular chaperone DnaK	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; REACTION CYCLE; HSP70; GROEL; TRANSLOCATION; DISSOCIATION; HYDROLYSIS; KINETICS; BINDING	The crystal structure of the adenine nucleotide exchange factor GrpE in complex with the adenosine triphosphatase (ATPase) domain of Escherichia coli DnaK [heat shock protein 70 (Hsp70)] was determined at 2.8 angstrom resolution. A dimer of GrpE binds asymmetrically to a single molecule of DnaK. The structure of the nucleotide-free ATPase domain in complex with GrpE resembles closely that of the nucleotide-bound mammalian Hsp70 homolog, except for an outward rotation of one of the subdomains of the protein. This conformational change is not consistent with tight nucleotide binding. Two long alpha helices extend away from the GrpE dimer and suggest a role for GrpE in peptide release from DnaK.	ROCKEFELLER UNIV, LAB MOL BIOPHYS, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; HOWARD HUGHES MED INST, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute			Hayer-Hartl, Manajit/V-8078-2017; Hartl, F. Ulrich/Y-8206-2019	Hayer-Hartl, Manajit/0000-0001-8213-6742; 				BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HOHFELD J, 1995, CELL, V83, P589; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; LALORAYA S, 1995, MOL CELL BIOL, V15, P7098; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MINOR W, UNPUB; Naylor DJ, 1996, FEBS LETT, V396, P181, DOI 10.1016/0014-5793(96)01100-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Turk D., UNPUB; VANDUYNE GD, UNPUB; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; WU B, 1994, J BACTERIOL, V176, P6965, DOI 10.1128/JB.176.22.6965-6973.1994; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	35	397	410	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					431	435		10.1126/science.276.5311.431	http://dx.doi.org/10.1126/science.276.5311.431			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103205				2022-12-28	WOS:A1997WU47700045
J	Liu, XS; Zou, H; Slaughter, C; Wang, XD				Liu, XS; Zou, H; Slaughter, C; Wang, XD			DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis	CELL			English	Article							POLY(ADP-RIBOSE) POLYMERASE; RAT THYMOCYTES; LEUCINE-ZIPPER; CELL-DEATH; IDENTIFICATION; PURIFICATION; CLEAVES; ENZYME; CED-3; GENE	We have identified and purified from HeLa cytosol a protein that induces DNA fragmentation in coincubated nuclei after it is activated by caspase-3. This protein, designated DNA Fragmentation Factor (DFF), is a heterodimer of 40 kDa and 45 kDa subunits. The amino acid sequence of the 45 kDa subunit, determined from its cDNA sequence, reveals it to be a novel protein. Caspase-3 cleaves the 45 kDa subunit at two sites to generate an active factor that produces DNA fragmentation without further requirement for caspase-3 or other cytosolic proteins. In cells undergoing apoptosis, the 45 kDa subunit is cleaved in the same pattern as it is cleaved by caspase-3 in vitro. These data delineate a direct signal transduction pathway during apoptosis: caspase-3 to DFF to DNA fragmentation.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; EMORY UNIV,SCH MED,GRAD DIV BIOL & BIOMED SCI,ATLANTA,GA 30322; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Wang, Xiaodong/0000-0001-9885-356X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boulakia CA, 1996, ONCOGENE, V12, P529; CACIOLAROSEN L, 1996, J EXP MED, V183, P1957; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GERNANDESALNEMR.G, 1994, J BIOL CHEM, V269, P30761; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hasegawa J, 1996, CANCER RES, V56, P1713; Ibrado AM, 1996, CANCER RES, V56, P4743; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McConkey DJ, 1996, J BIOL CHEM, V271, P22398, DOI 10.1074/jbc.271.37.22398; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIKONOVA LV, 1993, EUR J BIOCHEM, V215, P893, DOI 10.1111/j.1432-1033.1993.tb18107.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Sambrook J., 2002, MOL CLONING LAB MANU; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1996, J EXP MED, V183, P1523	51	1589	1667	2	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					175	184		10.1016/S0092-8674(00)80197-X	http://dx.doi.org/10.1016/S0092-8674(00)80197-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108473	Bronze			2022-12-28	WOS:A1997WU88800005
J	Reddi, AH				Reddi, AH			Bone morphogenesis and modeling: Soluble signals sculpt osteosomes in the solid state	CELL			English	Review							BIOLOGY		UNIV CALIF DAVIS,DEPT ORTHOPAED SURG,SACRAMENTO,CA 95817	University of California System; University of California Davis	Reddi, AH (corresponding author), UNIV CALIF DAVIS,CTR TISSUE REGENERAT & REPAIR,SACRAMENTO,CA 95817, USA.							Aderka Dan, 1996, Cytokine and Growth Factor Reviews, V7, P231, DOI 10.1016/S1359-6101(96)00026-3; BARON R, 1993, PHYSL PHARM BONE, P111; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; FLEISCH HA, 1997, BISPHOSPHONATES BONE; HYMAN AR, 1996, DEVELOPMENT, V122, P3151; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; Piez K.A., 1984, EXTRACELLULAR MATRIX; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; REDDI AH, 1981, COLLAGEN REL RES, V1, P209; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; VUKICEVIC S, 1990, CELL, V63, P437, DOI 10.1016/0092-8674(90)90176-F	13	47	59	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					159	161		10.1016/S0092-8674(00)80193-2	http://dx.doi.org/10.1016/S0092-8674(00)80193-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108469	Bronze			2022-12-28	WOS:A1997WU88800001
J	Lehmann, LS; Brancati, FL; Chen, MC; Roter, D; Dobs, AS				Lehmann, LS; Brancati, FL; Chen, MC; Roter, D; Dobs, AS			The effect of bedside case presentations on patients' perceptions of their medical care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Concern that case presentations at the bedside may make patients uncomfortable has led many residency programs to move presentations to the conference room. We performed a randomized, controlled trial of the effect of these two approaches on patients' perceptions of their care. Methods The study patients were adults admitted to the general medical service of a teaching hospital. Four house-staff ''firms'' (each comprising teams of physicians) were randomly assigned to make their case presentations during morning rounds either at the patient's bedside or in a conference room for one week, to switch to the alternate site for a second week, and to return to the initial site for a third week. To as sess patients' perceptions, a questionnaire was administered within 24 hours of admission. Results During the three weeks of the study, 95 patients had bedside presentations and 87 patients had conference-room presentations. When the former were compared with the latter, the patients with bedside presentations reported that their doctors spent more time with them on morning rounds (10 vs. 6 minutes, P<0.001). The patients with bedside presentations were also somewhat more likely to report favorable perceptions of their inpatient care (range of adjusted odds ratios, 1.12 to 2.17), although none of the associations were statistically significant. Better-educated patients were less likely to report that physicians used confusing terminology and explained tests and medications inadequately than were patients who had not completed high school. Conclusions These data suggest that from the patient's perspective, bedside case presentations are at least as good as conference-room presentations, and perhaps preferable. When physicians make presentations at the bedside of less well educated patients, they should be especially careful to avoid medical jargon and to explain fully their plans for inpatient care. (C) 1997, Massachusetts Medical Society.	JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT BIOSTAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Roter, Debra L/N-8830-2014					BANISKY S, 1994, BALTIMORE SUN   0511, pA1; BELKIN BM, 1992, ANN INTERN MED, V116, P863, DOI 10.7326/0003-4819-116-10-863; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COLLINS GF, 1978, J MED EDUC, V53, P429; KAUFMAN MR, 1956, J MT SINAI HOSP, V23, P782; LINFORS EW, 1980, NEW ENGL J MED, V303, P1230, DOI 10.1056/NEJM198011203032110; Osler W., 1903, MED NEWS NEW YORK, V82, P49; REICHSMAN F, 1964, J Med Educ, V39, P147; Romano J., 1941, JAMA CHICAGO ILL, V117, P664; *SAS I, 1996, STAT AN SYST; SHANKEL SW, 1986, JAMA-J AM MED ASSOC, V256, P725, DOI 10.1001/jama.256.6.725; SIMONS RJ, 1989, NEW ENGL J MED, V321, P1273, DOI 10.1056/NEJM198911023211821; WANGCHENG RM, 1989, J GEN INTERN MED, V4, P284, DOI 10.1007/BF02597397; 1989, LANCEDT, V2, P1309; 1986, HOPKINS MED NEWS, V10, P10; 1995, MONTHL CENS REP 0718	16	162	168	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1150	1155		10.1056/NEJM199704173361606	http://dx.doi.org/10.1056/NEJM199704173361606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099660				2022-12-28	WOS:A1997WU00300006
J	Stratton, JF; Gayther, SA; Russell, P; Dearden, J; Gore, M; Blake, P; Easton, D; Ponder, BAJ				Stratton, JF; Gayther, SA; Russell, P; Dearden, J; Gore, M; Blake, P; Easton, D; Ponder, BAJ			Contribution of BRCA1 mutations to ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERMLINE MUTATIONS; BREAST; GENE; FAMILIES; HETERODUPLEX	Background Inherited mutations in the BRCA1 gene confer a high risk of breast and ovarian cancer in some families. To determine the contribution of BRCA1 mutations to ovarian cancer in the general population, we analyzed DNA samples from a consecutive series of women with ovarian cancer seen at one center. Methods We studied 374 women who received a diagnosis of epithelial ovarian cancer before the age of 70 years and were treated at the Royal Marsden Hospital between July 1993 and September 1995. Genomic DNA was analyzed by multiplex heteroduplex analysis. Variants were further identified by sequencing. Results Probable germ-line BRCA1 mutations were identified in 13 of the 374 women (3 percent; 95 percent confidence interval, 2 to 6 percent). Six of the variants have not been described previously. Of the 13 mutations, 12 are predicted to result in a truncated protein product. An additional variant results in an in-frame deletion just outside the putative zinc-finger domain. Nine of the 12 women with truncating mutations had family histories of breast or ovarian cancer or both. Conclusions Assuming that our method has a sensitivity of 70 percent, mutations in BRCA1 occur in approximately 5 percent (95 percent confidence interval, 3 to 8 percent) of women in whom ovarian cancer is diagnosed before the age of 70 years. (C) 1997, Massachusetts Medical Society.	CANC RES CAMPAIGN, HUMAN CANC GENET RES GRP, CAMBRIDGE, ENGLAND; ROYAL MARSDEN HOSP, DEPT CLIN ONCOL, LONDON SW3 6JJ, ENGLAND; INST PUBL HLTH, CANC RES CAMPAIGN, GENET EPIDEMIOL UNIT, CAMBRIDGE, ENGLAND	CRUK Cambridge Institute; Royal Marsden NHS Foundation Trust; CRUK Cambridge Institute; University of Cambridge	Stratton, JF (corresponding author), ADDENBROOKES HOSP, WELLBEING OVARIAN CANC RES CTR, BOX 238, CAMBRIDGE CB2 2QQ, ENGLAND.							ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; EASTON DF, 1995, AM J HUM GENET, V56, P265; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1457; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gayther SA, 1996, AM J HUM GENET, V58, P451; GLAVAC D, 1995, HUM MUTAT, V6, P281, DOI 10.1002/humu.1380060402; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Mathew CG, 1996, NEW ENGL J MED, V334, P1198; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1994, BRIT MED BULL, V50, P656, DOI 10.1093/oxfordjournals.bmb.a072915; ROSSETTI S, 1995, MOL CELL PROBE, V9, P195, DOI 10.1006/mcpr.1994.0028; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; TAKAHASHI H, 1995, CANCER RES, V55, P2998	20	196	199	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1125	1130		10.1056/NEJM199704173361602	http://dx.doi.org/10.1056/NEJM199704173361602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099656				2022-12-28	WOS:A1997WU00300002
J	Lumley, J				Lumley, J			How important is social class a factor in preterm birth?	LANCET			English	Editorial Material											Lumley, J (corresponding author), LA TROBE UNIV,CTR STUDY MOTHERS & CHILDRENS HLTH,CARLTON,VIC 3053,AUSTRALIA.							FEDRICK J, 1976, BRIT J OBSTET GYNAEC, V83, P342, DOI 10.1111/j.1471-0528.1976.tb00840.x; Logan S, 1996, BRIT MED J, V313, P1332; LUMLEY J, 1993, BAILLIERE CLIN OB GY, V7, P477, DOI 10.1016/S0950-3552(05)80445-6; MACFARLANE A, 1988, BRIT MED BULL, V44, P861, DOI 10.1093/oxfordjournals.bmb.a072298; Wildschut HIJ, 1997, BRIT J OBSTET GYNAEC, V104, P57, DOI 10.1111/j.1471-0528.1997.tb10650.x	5	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1040	1041		10.1016/S0140-6736(05)62287-8	http://dx.doi.org/10.1016/S0140-6736(05)62287-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107238				2022-12-28	WOS:A1997WU00200004
J	Soutter, WP; Lopes, AD; Fletcher, A; Monaghan, JM; Duncan, ID; Paraskevaidis, E; Kitchener, HC				Soutter, WP; Lopes, AD; Fletcher, A; Monaghan, JM; Duncan, ID; Paraskevaidis, E; Kitchener, HC			Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia	LANCET			English	Article							SEMM COLD COAGULATOR; CARCINOMA-INSITU; HYSTERECTOMY; DESTRUCTION; EXPERIENCE; LASER	Background Conservative outpatient therapy for cervical intraepithelial neoplasia (CIN) by ablative or excisional techniques is widely used. The main objective of this treatment is the prevention of invasive cervical cancer. We assessed the rate of invasive disease and the duration of the risk of developing invasive cervical cancer after such treatment. Methods Four UK centres have used life-table methods to analyse the long-term results of conservative treatment of GIN. We combined and updated data from these studies to investigate the rate of invasive disease after treatment and the duration of that risk. Findings The data comprised 44 699 woman-years of follow-up, with 2116 women under observation 8 years after treatment. 33 women developed invasive cancer, 14 of whom had microinvasion. The cumulative rate of invasion 8 years after treatment was 5.8 per 1000 women and the rate of invasive cancer during this period was 85 (95% CI 60-119) per 100 000 woman-years. The risk of developing cancer did not change throughout the 8 years of follow-up. Interpretation These data show that conservative outpatient therapy in women with CIN reduces the risk of invasive cancer of the cervix by 95% during the first 8 years after treatment. However, even with careful, long-term follow-up, the risk of invasive cervical cancer among these women is about five times greater than that among the general population of women throughout that period. Careful follow-up is essential for at least 10 years after conservative treatment of CIN.	QUEEN ELIZABETH HOSP, GATESHEAD HOSP NHS TRUST, GATESHEAD, TYNE & WEAR, ENGLAND; LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT STUDIES, LONDON, ENGLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DUNDEE DD1 9SY, SCOTLAND; ABERDEEN ROYAL INFIRM, DEPT OBSTET & GYNAECOL, ABERDEEN, SCOTLAND	University of London; London School of Hygiene & Tropical Medicine; University of Dundee; University of Aberdeen	Soutter, WP (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, INST OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND.		de Barros Lopes, Alberto/B-2116-2018; Paraskevaidis, Evangelos/ABH-4990-2020	de Barros Lopes, Alberto/0000-0002-8796-3891; 				Armitage P., 1971, STAT METHODS MED RES, V1; BOYES D A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P769; BURGHARDT E, 1980, OBSTET GYNECOL, V55, P539; DRAEBYKRISTIANSEN J, 1991, AM J OBSTET GYNECOL, V165, P43, DOI 10.1016/0002-9378(91)90220-L; FAWDRY RDS, 1984, BRIT J OBSTET GYNAEC, V91, P67, DOI 10.1111/j.1471-0528.1984.tb05281.x; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GEMMELL J, 1990, BRIT J OBSTET GYNAEC, V97, P58, DOI 10.1111/j.1471-0528.1990.tb01717.x; GORDON HK, 1991, BRIT J OBSTET GYNAEC, V98, P14, DOI 10.1111/j.1471-0528.1991.tb10304.x; KOLSTAD P, 1976, OBSTET GYNECOL, V48, P125; LOOBUYCK HA, 1993, BRIT J OBSTET GYNAEC, V100, P465, DOI 10.1111/j.1471-0528.1993.tb15273.x; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PARASKEVAIDIS E, 1991, OBSTET GYNECOL, V78, P80; PEARSON SE, 1989, BRIT J OBSTET GYNAEC, V96, P486, DOI 10.1111/j.1471-0528.1989.tb02429.x; SOUTTER P, 1993, PRACTICAL GUIDE COLP, P98; SOUTTER WP, 1986, COLP GYNECOL LAS SUR, V2, P35	15	197	216	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	1997	349	9057					978	980		10.1016/S0140-6736(96)08295-5	http://dx.doi.org/10.1016/S0140-6736(96)08295-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100623				2022-12-28	WOS:A1997WR62100009
J	Barnes, D; Hughes, RAC; Morris, RW; WadeJones, O; Brown, P; Britton, T; Francis, DA; Perkin, GD; Rudge, P; Swash, M; Katifi, H; Farmer, S; Frankel, J				Barnes, D; Hughes, RAC; Morris, RW; WadeJones, O; Brown, P; Britton, T; Francis, DA; Perkin, GD; Rudge, P; Swash, M; Katifi, H; Farmer, S; Frankel, J			Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis	LANCET			English	Article							ACUTE OPTIC NEURITIS; CORTICOSTEROIDS; THERAPY; MS	Background An intravenous rather than oral course of methylprednisolone is often prescribed for treating acute relapses in multiple sclerosis (MS) despite the lack of evidence to support this route of administration. Our double-blind placebo-controlled randomised trial was designed to compare the efficacy of commonly used intravenous and oral steroid regimens in promoting recovery from acute relapses in MS. Methods 42 patients with clinically definite relapse in MS received oral, and 38 intravenous, methylprednisolone, Clinical measurements at entry and at 1 week, 4 weeks, 12 weeks, and 24 weeks included Kurtzke's expanded disability status scale (EDSS), Hauser's Ambulatory Index, and an arm-function index. The primary outcome criterion was a difference between the two treatment groups of one or more EDSS grades at 4 weeks. Findings There were no significant differences between the two groups at any stage of the study in any measurement taken: the mean difference in EDSS at 4 weeks (adjusted for baseline level) was 0.07 grades more in those taking oral steroids (95% CI -0.46 to 0.60). The most optimistic outcome for intravenous therapy is an average benefit of less than half a grade improvement on EDSS over oral treatment. Interpretation Since our study did not show any clear advantage of the intravenous regime we conclude that it is preferable to prescribe oral rather than intravenous steroids for acute relapses in MS for reasons of patient convenience, safety, and cost.	UMDS, GUYS HOSP, LONDON, ENGLAND; ROYAL FREE HOSP, SCH MED, LONDON, ENGLAND; UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND; QUEEN ELIZABETH HOSP, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; CHARING CROSS HOSP, LONDON, ENGLAND; ROYAL LONDON HOSP, LONDON E1 1BB, ENGLAND; WESSEX NEUROL CTR, SOUTHAMPTON, HANTS, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Birmingham; Imperial College London; Barts Health NHS Trust; Royal London Hospital	Barnes, D (corresponding author), ATKINSON MORLEYS HOSP, DEPT NEUROL, LONDON SW20 0NE, ENGLAND.		Farmer, Simon F/D-1969-2012; Macedo, Ana/L-9912-2018; Brown, Peter/J-4307-2016	Farmer, Simon F/0000-0001-5193-8195; Macedo, Ana/0000-0002-6978-8989; Brown, Peter/0000-0002-5201-3044; Morris, Richard/0000-0001-7240-4563; Swash, Michael/0000-0002-8717-8914				ALAM SM, 1993, J NEUROL NEUROSUR PS, V56, P1219, DOI 10.1136/jnnp.56.11.1219; BARKHOF F, 1991, NEUROLOGY, V41, P1219, DOI 10.1212/WNL.41.8.1219; BARNES MP, 1985, J NEUROL NEUROSUR PS, V48, P157, DOI 10.1136/jnnp.48.2.157; BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BECK RW, 1995, ARCH OPHTHALMOL-CHIC, V113, P136, DOI 10.1001/archopht.1995.01100020014004; DEFER DL, 1995, EUR NEUROL, V35, P143, DOI 10.1159/000117110; KUPERSMITH MJ, 1994, NEUROLOGY, V44, P1; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LAMANTIA L, 1994, EUR NEUROL, V34, P199, DOI 10.1159/000117038; LYONS PR, 1988, J NEUROL NEUROSUR PS, V51, P285, DOI 10.1136/jnnp.51.2.285; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MILLER DH, 1992, J NEUROL NEUROSUR PS, V55, P450, DOI 10.1136/jnnp.55.6.450; MILLER H, 1961, LANCET, V2, P1120; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; ROSE AS, 1970, NEUROLOGY, V5, P1; THOMPSON AJ, 1989, NEUROLOGY, V39, P969, DOI 10.1212/WNL.39.7.969	17	158	165	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					902	906		10.1016/S0140-6736(96)06453-7	http://dx.doi.org/10.1016/S0140-6736(96)06453-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093250				2022-12-28	WOS:A1997WR25400009
J	Barry, MJ; Roberts, RG				Barry, MJ; Roberts, RG			Indications for PSA testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PROSTATE-SPECIFIC ANTIGEN; CANCER; MEN		UNIV WISCONSIN, SCH MED, DEPT FAMILY MED, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Madison	Barry, MJ (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA.							Barry M. J., 1996, JGIM, V11, P62; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Collins M. F. Mcnaughton, 1996, JGIM, V11, P81; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; Fowler Floyd J., 1996, Journal of Urology, V155, p681A; MANDELSON MT, 1995, ANNU REV PUBL HEALTH, V16, P283; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; SERSHON PD, 1994, EUR UROL, V25, P281; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107	10	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					955	956		10.1001/jama.277.12.955	http://dx.doi.org/10.1001/jama.277.12.955			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091657				2022-12-28	WOS:A1997WN99200012
J	Williams, AE; Thomson, RA; Schreiber, GB; Watanabe, K; Bethel, J; Lo, A; Kleinman, SH; Hollingsworth, CG; Nemo, GJ				Williams, AE; Thomson, RA; Schreiber, GB; Watanabe, K; Bethel, J; Lo, A; Kleinman, SH; Hollingsworth, CG; Nemo, GJ			Estimates of infectious disease risk factors in US blood donors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CONFIDENTIAL UNIT EXCLUSION; HIV-INFECTION; STATES; PREVALENCE; QUESTIONS; DONATION; BEHAVIOR; IMPACT	Objective.-Individuals who do not respond accurately to questions about infectious disease risk factors at the time of blood donation represent a potential threat to the safety of the blood supply. This study was designed to estimate the prevalence of undetected behavioral and other risks in current blood donors. Design.-Anonymous mail surveys to collect demographic, medical, and behavioral information were administered to individuals who had donated blood within the previous 2 months. Sampling weights were used in the analysis to adjust for differential sampling and response rates among demographic groups to provide prevalence estimates for the donor population. Setting.-Five geographically and demographically diverse US blood centers. Participants.-A stratified probability sample of 50 162 allogeneic blood donors. Main Outcome Measures.-Estimated prevalence rates for risk behaviors that would have been a basis for deferral if reported at the time of the donor screening interview (deferrable risk). Results.-Completed questionnaires were received for 34 726 donors (69.2% of the sample). A total of 186 per 10 000 respondents (1.9%) reported a deferrable risk that was present at the time of their past donation, while 39 per 10 000 (0.4%) reported this behavior within the 3 months prior to donation. Rates (with 95% confidence intervals [CIs]) of deferrable risk behaviors were 1.4 (95% CI, 1.2-1.6) times higher for men than women, 1.6 (95% CI, 1.3-2.0) times higher for first-time vs repeat donors, 2.7 (95% CI, 2.0-3.6) times higher for donors with reactive screening tests, and 7.6 (95% CI, 3.6-15.8) times higher for donors who used the confidential unit exclusion option. Conclusions.-Despite the high degree of transfusion safety in the United States today, a measurable percentage of active blood donors when assessed by anonymous survey report risks for human immunodeficiency virus and other infections not reported at the time of screening, suggesting the need for further refinements in the blood donor qualification process.	GREATER CHESAPEAKE & POTOMAC REG,BALTIMORE,MD; WESTAT CORP,ROCKVILLE,MD; AMER RED CROSS,BLOOD SERV,LOS ANGELES,CA 90006; NHLBI,NIH,BETHESDA,MD 20892	Westat; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Williams, AE (corresponding author), AMER RED CROSS,JEROME H HOLLAND LAB,BLOOD SERV,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.				NHLBI NIH HHS [N01-HB-97077, N01-HB-97078, N01-HB-47114] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097077, N01HB097078, N01HB047114] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILER SM, 1993, ADV DATA, V225; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; *CTR BIOL ENV RES, 1992, REC PREV HUM IMM VIR; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; JAFFE HW, 1983, J INFECT DIS, V148, P339, DOI 10.1093/infdis/148.2.339; JOHNSON ES, 1994, TRANSFUSION, V34, P769, DOI 10.1046/j.1537-2995.1994.34994378277.x; KAPLAN EH, 1990, EVALUATION REV, V14, P686, DOI 10.1177/0193841X9001400609; Kish L, 1965, SURVEY SAMPLING; KLEINMAN SH, 1995, 48 ANN M AM ASS BLOO; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LAUMANN EO, 1994, SOCIAL ORG SEXUALITY, P294; LEIGH BC, 1993, AM J PUBLIC HEALTH, V83, P1400, DOI 10.2105/AJPH.83.10.1400; LEITMAN SF, 1989, NEW ENGL J MED, V321, P17; LOIACONO BR, 1989, TRANSFUSION, V29, P823, DOI 10.1046/j.1537-2995.1989.29990070189.x; MAYO DJ, 1991, TRANSFUSION, V31, P466, DOI 10.1046/j.1537-2995.1991.31591263204.x; MCQUILLAN GM, 1994, AM J PUBLIC HEALTH, V84, P747, DOI 10.2105/AJPH.84.5.747; MILLER HG, 1990, AIDS 2ND DECADE, P289; MILLER RG, 1974, BIOMETRIKA, V61, P1; MOHADJER L, 1986, P AM STAT ASS, P258; *OFF BIOL RES REV, 1983, MAM ALL EST COLL HUM; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SCREIBER GB, IN PRESS J ACQUIR IM; SILVERGLEID AJ, 1989, TRANSFUSION, V29, P362, DOI 10.1046/j.1537-2995.1989.29489242806.x; *US DEP HHS, 1986, ADD REC RED FURTH NU	29	145	147	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					967	972		10.1001/jama.277.12.967	http://dx.doi.org/10.1001/jama.277.12.967			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN992	9091668				2022-12-28	WOS:A1997WN99200030
J	Brankin, E; Gallagher, A; Soukop, M				Brankin, E; Gallagher, A; Soukop, M			Hypoglycaemia associated with formestane treatment	BRITISH MEDICAL JOURNAL			English	Letter											Brankin, E (corresponding author), GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,LANARK,SCOTLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					869	869						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093099				2022-12-28	WOS:A1997WQ02800028
J	Oscier, DG				Oscier, DG			ABC of clinical haematology - The myelodysplastic syndromes	BRITISH MEDICAL JOURNAL			English	Article											Oscier, DG (corresponding author), ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,BOURNEMOUTH,DORSET,ENGLAND.							KOEFFLER HP, 1996, SEMINARS HEMATOL 1 2; MUFTI GJ, 1992, MYELODYSPLASIA SYNDR	2	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					883	886						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093103				2022-12-28	WOS:A1997WQ02800034
J	Williams, A				Williams, A			The rationing debate - Rationing health care by age - The case for	BRITISH MEDICAL JOURNAL			English	Article											Williams, A (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.								0	89	90	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					820	822		10.1136/bmj.314.7083.820	http://dx.doi.org/10.1136/bmj.314.7083.820			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN646	9081009	Green Published			2022-12-28	WOS:A1997WN64600040
J	Guo, HF; The, I; Hannan, F; Bernards, A; Zhong, Y				Guo, HF; The, I; Hannan, F; Bernards, A; Zhong, Y			Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides	SCIENCE			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; PROTEIN TYROSINE KINASE; PACAP-LIKE NEUROPEPTIDE; POTASSIUM CURRENTS; RAS GTPASE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; RUTABAGA; RECEPTOR; ENCODES	The human neurofibromatosis type 1 (NF1) tumor suppressor protein functions as a Ras-specific guanosine triphosphatase-activating protein, but the identity of Ras-mediated pathways modulated by NF1 remains unknown. A study of Drosophila NF1 mutants revealed that NF1 is essential for the cellular response to the neuropeptide PACAP38 (pituitary adenylyl cyclase-activating polypeptide) at the neuromuscular junction, The peptide induced a 100-fold enhancement of potassium currents by activating the Ras-Raf and adenylyl cyclase-adenosine 3',5'-monophosphate (cAMP) pathways, This response was eliminated in NF1 mutants, NF1 appears to regulate the rutabaga-encoded adenylyl cyclase rather than the Ras-Raf pathway, Moreover, the NF1 defect was rescued by the exposure of cells to pharmacological treatment that increased concentrations of cAMP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			The, Inge/B-8884-2011	Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034779, R01NS031747] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS31747, R01-NS34779] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUDAI Y, 1985, J NEUROGENET, V2, P365, DOI 10.3109/01677068509101423; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; NORTH K, 1994, NEUROLOGY, V44, P878, DOI 10.1212/WNL.44.5.878; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0; ZHONG Y, 1993, J NEUROGENET, V9, P15, DOI 10.3109/01677069309167273; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7	34	158	161	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					795	798		10.1126/science.276.5313.795	http://dx.doi.org/10.1126/science.276.5313.795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115204				2022-12-28	WOS:A1997WW90000058
J	Jolly, D; Haxeltine, A				Jolly, D; Haxeltine, A			Effect of low glacial atmospheric CO2 on tropical African montane vegetation	SCIENCE			English	Article							EQUATORIAL AFRICA; ICE; RECORD; CLIMATE; BP; BURUNDI	Estimates of glacial-interglacial climate change in tropical Africa have varied widely. Results from a process-based vegetation model show how montane vegetation in East Africa shifts with changes in both carbon dioxide concentration and climate. For the last glacial maximum, the change in atmospheric carbon dioxide concentration alone could explain the observed replacement of tropical montane forest by a scrub biome. This result implies that estimates of the last glacial maximum tropical cooling based on treeline shifts must be revised.			Jolly, D (corresponding author), LUND UNIV,DEPT ECOL,ECOL BLDG,S-22362 LUND,SWEDEN.							ANDERSON DM, 1994, NATURE, V367, P23, DOI 10.1038/367023a0; AUCOUR AM, 1994, QUATERNARY RES, V41, P225, DOI 10.1006/qres.1994.1024; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; BONNEFILLE R, 1990, NATURE, V346, P347, DOI 10.1038/346347a0; BONNEFILLE R, 1988, QUATERNARY RES, V30, P19, DOI 10.1016/0033-5894(88)90085-3; Bonnefille R, 1992, CLIM DYNAM, V6, P251, DOI 10.1007/BF00193538; BROCCOLI AJ, 1987, CLIM DYNAM, V1, P87; CLIMAP project members, 1981, GEOL SOC AM MAP CHAR; Coetzee JA., 1967, PALAEOECOL AFRICA, V3, P1; Colinvaux PA, 1996, SCIENCE, V274, P85, DOI 10.1126/science.274.5284.85; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; GRIFFITHS JF, 1972, CLIMATE AFRICA; Hamilton A.C., 1972, PALAEOECOL AFRICA, V7, P149; Hamilton A.C., 1982, ENV HIST E AFRICA ST; Haxeltine A, 1996, J VEG SCI, V7, P651, DOI 10.2307/3236377; Haxeltine A, 1996, FUNCT ECOL, V10, P551, DOI 10.2307/2390165; Haxeltine A, 1996, GLOBAL BIOGEOCHEM CY, V10, P693, DOI 10.1029/96GB02344; Hedberg O., 1951, SVENSK BOT TIDSKRIFT, V45, P141; JOLLY D, IN PRESS QUAT SCI RE; Leemans R., 1991, IIASA CLIMATE DATABA; Lewalle J., 1972, Bulletin du Jardin Botanique National de Belgique, V42, P1, DOI 10.2307/3667406; LIVINGSTONE DA, 1967, ECOL MONOGR, V37, P25, DOI 10.2307/1948481; LLOYD J, 1994, OECOLOGIA, V99, P201, DOI 10.1007/BF00627732; NEFTEL A, 1988, NATURE, V331, P609, DOI 10.1038/331609a0; PEARMAN GI, 1986, NATURE, V320, P248, DOI 10.1038/320248a0; PETERSON GM, 1979, QUATERNARY RES, V12, P47, DOI 10.1016/0033-5894(79)90091-7; PRENTICE IC, 1992, J BIOGEOGR, V19, P117, DOI 10.2307/2845499; RIND D, 1990, NATURE, V346, P317, DOI 10.1038/346317a0; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; STREETPERROTT FA, 1994, AMBIO, V23, P37; TAYLOR DM, 1990, PALAEOGEOGR PALAEOCL, V80, P283, DOI 10.1016/0031-0182(90)90138-W; TERASHIMA I, 1995, ECOLOGY, V76, P2663, DOI 10.2307/2265838; Van Zinderen Bakker E. M., 1982, PALAEOECOL AFR, V15, P77; VINCENS A, 1993, QUATERNARY RES, V40, P343, DOI 10.1006/qres.1993.1087; Walter H., 1979, VEGETATION EARTH ECO; Webb Thompson III, 1993, P514; 1988, SCIENCE, V241, P1043	38	181	190	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					786	788		10.1126/science.276.5313.786	http://dx.doi.org/10.1126/science.276.5313.786			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115201				2022-12-28	WOS:A1997WW90000055
J	Pazin, MJ; Bhargava, P; Geiduschek, EP; Kadonaga, JT				Pazin, MJ; Bhargava, P; Geiduschek, EP; Kadonaga, JT			Nucleosome mobility and the maintenance of nucleosome positioning	SCIENCE			English	Article							YEAST ALPHA-2 REPRESSOR; CHROMATIN STRUCTURE; TRANSCRIPTIONAL ACTIVATION; REMODELING FACTOR; DNA-REPLICATION; LAC REPRESSOR; PROMOTER; DISRUPTION; OPERATOR; BINDING	To study nucleosome mobility and positioning, the R3 lac repressor was used with an adenosine triphosphate (ATP)-dependent chromatin assembly system to establish the positioning of five nucleosomes, with one nucleosome located between two R3 lac operators, When R3 protein was dissociated from DNA with isopropyl beta-D-thiogalactopyranoside, the R3-induced nucleosome positions remained unchanged for at least 60 minutes in the absence of ATP but rearranged within 15 minutes in the presence of ATP. These results suggest that nucleosomes are dynamic and mobile rather than static and that a DNA binding factor is continuously required for the maintenance of nucleosome positioning.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA; CTR CELLULAR & MOL BIOL, HYDERABAD 500007, ANDHRA PRADESH, INDIA	University of California System; University of California San Diego; University of California System; University of California San Diego; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Pazin, Michael/0000-0002-7561-3640				ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Bulger M., 1994, METH MOL G, V5, P241; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN J, 1994, J BIOL CHEM, V269, P12482; ELGIN SCR, 1995, CHROMATIN STRUCTURE; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GRUNSTEIN M, 1992, SCI AM, V267, P68, DOI 10.1038/scientificamerican1092-68; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; SVAREN J, 1993, CURR OPIN GENET DEV, V3, P219, DOI 10.1016/0959-437X(93)90026-L; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; van Holde KE., 1989, SPRINGER SERIES MOL; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wolffe A., 1995, CHROMATIN STRUCTURE; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	43	88	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					809	812		10.1126/science.276.5313.809	http://dx.doi.org/10.1126/science.276.5313.809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115208				2022-12-28	WOS:A1997WW90000062
J	Calvert, GA; Bullmore, ET; Brammer, MJ; Campbell, R; Williams, SCR; McGuire, PK; Woodruff, PWR; Iverson, SD; David, AS				Calvert, GA; Bullmore, ET; Brammer, MJ; Campbell, R; Williams, SCR; McGuire, PK; Woodruff, PWR; Iverson, SD; David, AS			Activation of auditory cortex during silent lipreading	SCIENCE			English	Article							PERCEPTION	Watching a speaker's lips during face-to-face conversation (lipreading) markedly improves speech perception, particularly in noisy conditions. With functional magnetic resonance imaging it was found that these linguistic visual cues are sufficient to activate auditory cortex in normal hearing individuals in the absence of auditory speech sounds. Two further experiments suggest that these auditory cortical areas are not engaged when an individual is viewing nonlinguistic facial movements but appear to be activated by silent meaningless speechlike movements (pseudospeech). This supports psycholinguistic evidence that seen speech influences the perception of heard speech at a prelexical stage.	UNIV OXFORD, WARNEFORD HOSP, DEPT EXPT PSYCHOL, OXFORD OX3 7JX, ENGLAND; INST PSYCHIAT, LONDON SE5 8AF, ENGLAND; UCL, DEPT HUMAN COMMUN SCI, LONDON WC1 1PG, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON SE5 8AZ, ENGLAND	University of Oxford; University of London; King's College London; University of London; University College London; University of London; King's College London	Calvert, GA (corresponding author), UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND.		Brammer, Michael J/B-7128-2012; Campbell, Ruth/Y-4570-2019; Bullmore, Ed/C-1706-2012; Woodruff, Peter WR/B-5998-2009; David, Anthony S/C-1315-2011; Williams, Steve C/D-6979-2011; Campbell, Ruth/K-5934-2012; David, Anthony/O-1750-2019	Brammer, Michael J/0000-0001-9800-2052; Bullmore, Ed/0000-0002-8955-8283; David, Anthony S/0000-0003-0967-774X; Williams, Steve C/0000-0003-4299-1941; Campbell, Ruth/0000-0001-7324-1313; David, Anthony/0000-0003-0967-774X; opoku, anita/0000-0001-7243-8157; Calvert, Gemma/0000-0002-5487-8076; McGuire, Philip/0000-0003-4381-0532	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; Blumstein Sheila E., 1995, P915; Bonda E, 1996, J NEUROSCI, V16, P3737; BRAMMER MJ, 1996, NEUROIMAGE, V3, P52; BULIMORE ET, 1996, NEUROIMAGE, V4, P16; Bullmore E, 1996, MAGN RESON MED, V35, P261, DOI 10.1002/mrm.1910350219; David AS, 1996, NEUROREPORT, V7, P932, DOI 10.1097/00001756-199603220-00021; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Ekman Paul, 1973, DARWIN FACIAL EXPRES; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; GREEN KP, 1991, J EXP PSYCHOL HUMAN, V17, P278, DOI 10.1037/0096-1523.17.1.278; HABIB M, 1995, NEUROPSYCHOLOGIA, V33, P327, DOI 10.1016/0028-3932(94)00108-2; HECAEN H, 1979, STUDIES NEUROLINGUIS, V2, P269; Howard RJ, 1996, CURR BIOL, V6, P1015, DOI 10.1016/S0960-9822(02)00646-2; KUHL PK, 1982, SCIENCE, V218, P1138, DOI 10.1126/science.7146899; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; MASSARO DW, 1988, SPEECH PERCEPTION EA; McGuire PK, 1996, PSYCHOL MED, V26, P29, DOI 10.1017/S0033291700033699; MCGURK H, 1976, NATURE, V263, P747; Mellers JDC, 1995, NEUROREPORT, V7, P109, DOI 10.1097/00001756-199512000-00026; Papousek M., 1992, NONVERBAL VOCAL COMM; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; Reisberg D., 1987, HEARING EYE PSYCHOL, P97; SUMBY WH, 1954, J ACOUST SOC AM, V26, P212, DOI 10.1121/1.1907309; SUMMERFIELD Q, 1984, Q J EXP PSYCHOL-A, V36, P51, DOI 10.1080/14640748408401503; Talairach I., 1988, COPLANAR STEREOTACTI; WATSON JD, 1994, CEREB CORTEX, V3, P79	28	695	709	5	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					593	596		10.1126/science.276.5312.593	http://dx.doi.org/10.1126/science.276.5312.593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110978				2022-12-28	WOS:A1997WV72100045
J	Sandrock, AW; Dryer, SE; Rosen, KM; Gozani, SN; Kramer, R; Theill, LE; Fischbach, GD				Sandrock, AW; Dryer, SE; Rosen, KM; Gozani, SN; Kramer, R; Theill, LE; Fischbach, GD			Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo	SCIENCE			English	Article							BUNGAROTOXIN-TREATED RATS; ORIGINAL SYNAPTIC SITES; EPSILON-SUBUNIT GENE; ADULT MUSCLE-FIBERS; DIFFERENTIAL EXPRESSION; REGENERATING MUSCLE; CARDIAC DEVELOPMENT; MYASTHENIA-GRAVIS; CHICK MYOTUBES; MESSENGER-RNA	ARIA (for acetylcholine receptor-inducing activity), a protein purified on the basis of its ability to stimulate acetylcholine receptor (AChR) synthesis in cultured myotubes, is a member of the neuregulin family and is present at motor endplates. This suggests an important role for neuregulins in mediating the nerve-dependent accumulation of AChRs in the postsynaptic membrane. Nerve-muscle synapses have now been analyzed in neuregulin-deficient animals. Mice that are heterozygous for the deletion of neuregulin isoforms containing an immunoglobulin-like domain are myasthenic. Postsynaptic AChR density is significantly reduced, as judged by the decrease in the mean amplitude of spontaneous miniature endplate potentials and bungarotoxin binding. On the other hand, the mean amplitude of evoked end plate potentials was not decreased, due to an increase in the number of quanta released per impulse, a compensation that has been observed in other myasthenic states. Thus, the density of AChRs in the postsynaptic membrane depends on immunoglobulin-containing neuregulin isoforms throughout the life of the animal.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; AMGEN INC,THOUSAND OAKS,CA 91320	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Amgen					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001580, R01NS018458] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS18458, K08-NS01580] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; BRENNER HR, 1978, NATURE, V271, P366, DOI 10.1038/271366a0; BRENNER HR, 1992, DEVELOPMENT, V116, P41; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; BRENNER HR, 1983, J PHYSIOL-LONDON, V337, P159, DOI 10.1113/jphysiol.1983.sp014617; BUCCARON MH, 1983, DEV BIOL, V95, P378, DOI 10.1016/0012-1606(83)90039-8; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; CULLCANDY SG, 1980, J PHYSIOL-LONDON, V299, P621, DOI 10.1113/jphysiol.1980.sp013145; DENNIS MJ, 1981, DEV BIOL, V81, P266, DOI 10.1016/0012-1606(81)90290-6; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FISCHBACH GD, IN PRESS ANN REV NEU; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; KUO Y, 1994, SOC NEUR ABSTR, V20, P45218; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PLOMP JJ, 1994, J PHYSIOL-LONDON, V478, P125, DOI 10.1113/jphysiol.1994.sp020236; PLOMP JJ, 1992, J PHYSIOL-LONDON, V458, P487, DOI 10.1113/jphysiol.1992.sp019429; PLOMP JJ, 1995, ANN NEUROL, V37, P627, DOI 10.1002/ana.410370513; ROLE LW, 1985, J NEUROSCI, V5, P2197; ROSEN KM, IN PRESS COLD SPRING; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; SANES JR, 1991, DEVELOPMENT, V113, P1181; SIMON AM, 1992, DEVELOPMENT, V114, P545; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	49	239	242	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					599	603		10.1126/science.276.5312.599	http://dx.doi.org/10.1126/science.276.5312.599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110980				2022-12-28	WOS:A1997WV72100047
J	DiCarli, MF; Tobes, MC; Mangner, T; Levine, AB; Muzik, O; Chakroborty, P; Levine, TB				DiCarli, MF; Tobes, MC; Mangner, T; Levine, AB; Muzik, O; Chakroborty, P; Levine, TB			Effects of cardiac sympathetic innervation on coronary blood flow	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; ENDOTHELIUM-DEPENDENT RELAXATION; MYOCARDIAL-INFARCTION; NERVOUS-SYSTEM; HUMAN HEART; TRANSPLANTATION; DENERVATION; ARTERIES; ANGINA; METAIODOBENZYLGUANIDINE	Background The role of cardiac sympathetic nerves in regulating coronary blood flow is controversial. We sought to determine the degree to which cardiac efferent sympathetic signals modulate coronary blood flow. The heterogeneous sympathetic reinnervation in transplanted hearts provides a model for studying the vasomotor responses to adrenergic stimulation in reinnervated and denervated coronary territories of the same heart. Methods We studied 14 cardiac-transplant recipients who had normal coronary arteries and no evidence of rejection and 8 normal subjects. We used positron-emission tomography with [C-11]hydroxyephedrine, an analogue of norepinephrine, to delineate sympathetic innervation. Using [N-13]ammonia, we measured myocardial blood flow at rest, during adenosine-induced hyperemia, and in response to sympathetic stimulation induced by cold presser testing. Results In the transplant recipients, the uptake of [C-11]hydroxyephedrine was greater in the territory served by the left anterior descending artery (mean +/-SE, 0.15+/-0.01) than in those served by the right coronary artery (0.07+/-0.01, P<0.001) or the circumflex artery (0.09+/-0.01, P<0.001). The basal flow was similar in all three regions, as was the percent increase in flow during hyperemia. However, the increase in flow in response to cold presser testing was higher in the territory of the left anterior descending artery (46+/-10 percent) than in those of the right coronary artery (16+/-5 percent, P=0.01) or the circumflex artery (23+/-6 percent, P=0.06), although the changes in hemodynamics and levels of circulating catecholamines were similar, No such regional differences were observed in the normal subjects. Conclusions Increases in coronary blood flow in response to sympathetic stimulation correlated with the regional norepinephrine content in the cardiac sympathetic-nerve terminals. These findings suggest that cardiac adrenergic signals play an important part in regulating myocardial blood flow. (C) 1997, Massachusetts Medical Society.	WAYNE STATE UNIV, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT RADIOL, DETROIT, MI 48201 USA; HENRY FORD HEART & VASC INST, DETROIT, MI USA	Wayne State University; Wayne State University; Henry Ford Health System								Allman KC, 1993, J AM COLL CARDIOL, V22, P368, DOI 10.1016/0735-1097(93)90039-4; ANDERSON TJ, 1993, CIRCULATION, V88, P1093, DOI 10.1161/01.CIR.88.3.1093; BERKENBOOM G, 1991, J CARDIOVASC PHARM, V17, pS127, DOI 10.1097/00005344-199117003-00024; BERNE RM, 1964, PHYSIOL REV, V44, P1, DOI 10.1152/physrev.1964.44.1.1; BOGATY P, 1994, CIRCULATION, V90, P5, DOI 10.1161/01.CIR.90.1.5; CHILIAN WM, 1981, CIRC RES, V49, P866, DOI 10.1161/01.RES.49.4.866; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; DAE MW, 1991, J AM COLL CARDIOL, V17, P1416, DOI 10.1016/S0735-1097(10)80156-1; FAERMAN I, 1977, DIABETES, V26, P1147, DOI 10.2337/diabetes.26.12.1147; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GOLDSTEIN DS, 1981, LIFE SCI, V28, P467, DOI 10.1016/0024-3205(81)90139-9; GRAVES J, 1993, BRIT J PHARMACOL, V108, P631, DOI 10.1111/j.1476-5381.1993.tb12853.x; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HODGSON JM, 1989, CIRCULATION, V79, P797, DOI 10.1161/01.CIR.79.4.797; HUTCHINS GD, 1992, J NUCL MED, V33, P1243; INOUE H, 1988, CIRC RES, V62, P1111, DOI 10.1161/01.RES.62.6.1111; JONES CJH, 1993, CIRCULATION, V87, P1264, DOI 10.1161/01.CIR.87.4.1264; KAHN JK, 1986, J AM COLL CARDIOL, V7, P1303, DOI 10.1016/S0735-1097(86)80150-4; Kichuk MR, 1996, CIRCULATION, V94, P44, DOI 10.1161/01.CIR.94.1.44; LANGER A, 1995, J AM COLL CARDIOL, V25, P610, DOI 10.1016/0735-1097(94)00459-4; MUGGE A, 1993, J AM COLL CARDIOL, V21, P163; MUZIK O, 1993, J NUCL MED, V34, P83; NORVELL JE, 1973, TRANSPLANTATION, V15, P337, DOI 10.1097/00007890-197303000-00015; SAWADA S, 1995, J NUCL CARDIOL, V2, P413, DOI 10.1016/S1071-3581(05)80029-7; SCHOEN FJ, 1991, TRENDS CARDIOVAS MED, V1, P216, DOI 10.1016/1050-1738(91)90041-C; SCHWAIGER M, 1990, J NUCL MED, V31, P1352; SCHWAIGER M, 1990, CIRCULATION, V82, P457, DOI 10.1161/01.CIR.82.2.457; SCHWAIGER M, 1991, J CLIN INVEST, V87, P1681, DOI 10.1172/JCI115185; STANTON MS, 1989, J AM COLL CARDIOL, V14, P1519, DOI 10.1016/0735-1097(89)90391-4; Vanhoutte PM, 1988, VASODILATATION VASCU; VENTURA HO, 1995, AM HEART J, V129, P791, DOI 10.1016/0002-8703(95)90331-3; WILSON RF, 1993, CIRCULATION, V88, P165, DOI 10.1161/01.CIR.88.1.165; WILSON RF, 1991, CIRCULATION, V83, P1210, DOI 10.1161/01.CIR.83.4.1210; YASUE H, 1974, CIRCULATION, V50, P534, DOI 10.1161/01.CIR.50.3.534; YASUE H, 1979, AM J CARDIOL, V43, P647, DOI 10.1016/0002-9149(79)90026-2; YOUNG MA, 1987, PROG CARDIOVASC DIS, V30, P211, DOI 10.1016/0033-0620(87)90013-2; YOUNG MA, 1986, AM J PHYSIOL, V250, pH892, DOI 10.1152/ajpheart.1986.250.5.H892; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZEIHER AM, 1989, J AM COLL CARDIOL, V14, P1181, DOI 10.1016/0735-1097(89)90414-2	39	179	180	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1208	1215		10.1056/NEJM199704243361703	http://dx.doi.org/10.1056/NEJM199704243361703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110908				2022-12-28	WOS:A1997WV33200003
J	Schrott, HG; Bittner, V; Vittinghoff, E; Herrington, DM; Hulley, S				Schrott, HG; Bittner, V; Vittinghoff, E; Herrington, DM; Hulley, S			Adherence to national cholesterol education program treatment goals in postmenopausal women with heart disease - The heart and estrogen/progestin replacement study (HERS)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; COLESTIPOL-NIACIN; FOLLOW-UP; MORTALITY; ATHEROSCLEROSIS; MEN; REDUCTION; PREDICTOR	Objectives.-To determine the proportion of volunteer women with established heart disease who have low-density lipoprotein cholesterol (LDL-C) levels at or below the National Cholesterol Education Program Adult Treatment Panel goals and to determine what factors are associated with levels above goal or not receiving lipid-lowering medication when indicated. Design.-Cross-sectional measurement of lipids and lipoproteins, blood pressure, height, weight, and other demographic and cardiovascular risk factors in 2763 postmenopausal women with heart disease. Setting.-At 18 centers throughout the United States, participants were recruited by means of lists of women with coronary heart disease from coronary units and catheterization laboratories, direct mail to age-eligible women, and advertisements. Patients.-Mean age of the cohort was 66.7 years (range, 44-79 years) and the distribution by race/ethnicity was 88.7% white, 7.9% African American, 2.0% Hispanic/Latina, 0.8% Asian/Pacific Islander, and 0.7% other. Intervention.-We report cross-sectional analysis of the cohort at baseline. Outcome Measures.-We measured the frequency of achieving 1988 and 1993 Adult Treatment Panel treatment goals, and of being on a regimen of lipid-lowering medication. Results.-Although 47% of participants were taking a lipid-lowering medication, 63% did not meet the 1988 treatment goal of LDL-C level less than 3.4 mmol/L (130 mg/dL) and 91% did not meet the 1993 goal of LDL-C level less than 2.6 mmol/L (100 mg/dL). Factors independently associated with achieving the earlier goal were use of lipid-lowering medication, marital status, education, body mass index, exercise, hypertension, diabetes, gallbladder disease, and first diagnosis of coronary heart disease after 1990. Failure to use lipid-lowering medication was associated with age, being African American, marital status, body mass index, lack of exercise, alcohol consumption, current smoking, and first diagnosis of coronary heart disease before 1985. Conclusion.-The majority of women enrolled in the trial had LDL-C levels that significantly exceeded the treatment goals set by the 1988 and 1993 Adult Treatment Panel guidelines. Better implementation of these guidelines among women with coronary disease would be highly desirable.	UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV CALIF SAN FRANCISCO, HERS COORDINATING CTR, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CARDIOL SECT, WINSTON SALEM, NC USA	University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Francisco; Wake Forest University; Wake Forest Baptist Medical Center	Schrott, HG (corresponding author), UNIV IOWA, COLL MED, DEPT PREVENT MED, WESTLAWN S-231, IOWA CITY, IA 52242 USA.							BABIRAK SP, 1996, CIRCULATION S, V94, P50; BACHORIK PS, 1984, CLIN CHEM, V30, P839; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; Eaker E D, 1989, Cardiovasc Clin, V19, P129; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; *EXP PAN, 1993, JAMA-J AM MED ASSOC, V289, P3015; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Garber Alan J., 1996, Clinical Diabetes, V14, P9; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HALL WD, 1991, CARDIVOASCULAR DIS B, P157; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HOSMER DW, 1989, APPL LOGISTIC REGRES; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; Lewis SJ, 1996, CIRCULATION, V94, P69; MANOLIO TA, 1992, AM J MED, V92, P1, DOI 10.1016/0002-9343(92)90007-X; Marcelino JJ, 1996, AM J MED, V100, P605, DOI 10.1016/S0002-9343(96)00011-3; Miettinen TA, 1996, CIRCULATION, V94, P68; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; NAWROCKI JW, 1995, ARTERIOSCL THROM VAS, V15, P678, DOI 10.1161/01.ATV.15.5.678; PEDERSEN TR, 1994, LANCET, V344, P1383; RICH MW, 1992, AM J MED, V92, P7, DOI 10.1016/0002-9343(92)90008-Y; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SAS I INC, 1995, STAT AN SYST VERS 6; SCHROTT HG, 1995, AM J CARDIOL, V75, P34, DOI 10.1016/S0002-9149(99)80523-2; SCHROTT HG, 1994, J WOMENS HEALTH, V3, P155; WERBEL BL, 1994, J CARDIAC REHABIL, V14, P320; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676	35	207	210	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1281	1286		10.1001/jama.277.16.1281	http://dx.doi.org/10.1001/jama.277.16.1281			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109465				2022-12-28	WOS:A1997WU13500027
J	Hennig, A; Evans, JR; Pradhan, D; Johnson, GJ; Pokhrel, RP; Gregson, RMC; Hayes, R; Wormald, RL; Foster, A				Hennig, A; Evans, JR; Pradhan, D; Johnson, GJ; Pokhrel, RP; Gregson, RMC; Hayes, R; Wormald, RL; Foster, A			Randomised controlled trial of anterior-chamber intraocular lenses	LANCET			English	Article							IMPLANTATION; NEPAL	Background There are an estimated 16 million people blind in both eyes with cataracts. Most live in rural areas of developing countries where surgical resources are scarce. There is no consensus on the most appropriate type of intraocular lens in situations where high-volume low-cost surgery is required, This study was undertaken to evaluate the safety of multiflex open-loop anterior-chamber lenses (ACIOLs). Methods 2000 people attending Lahan Eye Hospital, southern Nepal, with bilateral cataracts reducing vision to 6/36 or less were randomly allocated to receive standard surgery-intracapsular extraction (ICCE) with aphakic correction-or ICCE with an ACIOL in their first operated eye. The primary outcome was a visual acuity of less than 6/60 in the operated eye at 1 year follow-up. Visual acuity was measured for 91% of the cohort at 1 year, The sample size was estimated to detect a doubling in poor visual outcome from an estimated rate of 4% in the standard surgery (control) group. Findings The median (range) time taken to do the surgery was 6.0 (3.0-17.2) min for the ACIOL group and 4.1 (2.4-10.3) min for the control group. 1 year after surgery, 5.0% of the ACIOL group and 5.4% of controls had functional Vision less than 6/60 (OR 0.93 [0.60-1.43], p=0.71). The causes of poor vision in the ACIOL and control groups were: correctable refractive error (22 and 29), uveitis/secondary glaucoma (13 and two), endophthalmitis (four and seven), pre-existing eye disease (four and five), retinal detachment (none and four), cystoid macular oedema (two and none), corneal ulcer (one and one), and corneal decompensation (none and one). Interpretation This study provides evidence that, in rural areas of developing countries, multiflex open-loop ACIOLs can be implanted safely by experienced ophthalmologists after routine ICCE, avoiding the disadvantages of aphakic spectacle correction. Further follow-up is planned.	MOORFIELDS EYE HOSP, INST OPHTHALMOL, DEPT OPHTHALM EPIDEMIOL, LONDON EC1V 2PD, ENGLAND; LAHAN EYE HOSP, LAHAN, NEPAL; INST OPHTHALMOL, DEPT PREVENT OPHTHALMOL, LONDON, ENGLAND; NEPAL NETRA JYOTI SINGH, Kathmandu, NEPAL; UNIV NOTTINGHAM HOSP, QUEENS MED CTR, NOTTINGHAM NG7 2UH, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London; University of Nottingham; University of London; London School of Hygiene & Tropical Medicine			Evans, Jennifer/F-4672-2012; Wang, Jessie/A-8840-2011	Evans, Jennifer/0000-0002-6137-2030; Foster, Allen/0000-0003-2368-4436; Hayes, Richard/0000-0002-1729-9892				ANMARKRUD N, 1993, ACTA OPHTHALMOL, V71, P796; APPLE DJ, 1987, J CATARACT REFR SURG, V13, P175, DOI 10.1016/S0886-3350(87)80132-3; APPLE DJ, 1987, J CATARACT REFR SURG, V13, P157, DOI 10.1016/S0886-3350(87)80131-1; AUFFARTH GU, 1994, OPHTHALMOLOGY, V101, P1913; BRESLOW NE, 1980, IARC SCI PUBL, V32, P133; BUCHER PJM, 1988, BRIT J OPHTHALMOL, V72, P721, DOI 10.1136/bjo.72.10.721; ERIKSEN JS, 1985, ACTA OPHTHALMOL, V63, P74; HENNIG A, 1993, LANCET, V341, P375, DOI 10.1016/0140-6736(93)90180-O; HOGEWEG M, 1992, ACTA OPHTHALMOL, V70, P407; NIKICA G, 1992, DOC OPHTHALMOL, V81, P309, DOI 10.1007/BF00161769; Rattigan SM, 1996, J CATARACT REFR SURG, V22, P243, DOI 10.1016/S0886-3350(96)80226-4; SNELLINGEN T, 1995, BRIT J OPHTHALMOL, V79, P1029; THYLEFORS B, WHOPBL9440	13	47	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	1997	349	9059					1129	1133		10.1016/S0140-6736(96)11043-6	http://dx.doi.org/10.1016/S0140-6736(96)11043-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113011				2022-12-28	WOS:A1997WU54400009
J	Arrigo, KR; Worthen, DL; Lizotte, MP; Dixon, P; Dieckmann, G				Arrigo, KR; Worthen, DL; Lizotte, MP; Dixon, P; Dieckmann, G			Primary production in Antarctic sea ice	SCIENCE			English	Article							DENSE MICROALGAL BLOOM; HIGH-RESOLUTION; MCMURDO SOUND; ECOSYSTEM; OCEAN	A numerical model shows that in Antarctic sea ice, increased flooding in regions with thick snow cover enhances primary production in the infiltration (surface) layer. Productivity in the freeboard (sea level) layer is also determined by sea ice porosity, which varies with temperature, Spatial and temporal variation in snow thickness and the proportion of first-year ice thus determine regional differences in sea ice primary production. Model results show that of the 40 teragrams of carbon produced annually in the Antarctic ice pack, 75 percent was associated with first-year ice and nearly 50 percent was produced in the Weddell Sea.	SCI SYST & APPLICAT INC,LANHAM,MD 20706; UNIV WISCONSIN,DEPT BIOL & MICROBIOL,OSHKOSH,WI 54901; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093; ALFRED WEGENER INST POLAR & MARINE RES,D-27570 BREMERHAVEN,GERMANY	Science Systems and Applications Inc; University of Wisconsin System; University of California System; University of California San Diego; Scripps Institution of Oceanography; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Arrigo, KR (corresponding author), NASA,GODDARD SPACE FLIGHT CTR,OCEANS & ICE BRANCH,CODE 9710,GREENBELT,MD 20771, USA.		Dieckmann, Gerhard S/B-4307-2010; Dixon, Philip Michael/I-4843-2019	Dixon, Philip Michael/0000-0002-1778-0686; Arrigo, Kevin/0000-0002-7364-876X				Arrigo K. R., 1996, 104640 NASA, V104640; ARRIGO KR, 1995, MAR ECOL PROG SER, V127, P255, DOI 10.3354/meps127255; ARRIGO KR, 1993, MAR ECOL PROG SER, V98, P173, DOI 10.3354/meps098173; ARRIGO KR, 1993, J GEOPHYS RES-OCEANS, V98, P6929, DOI 10.1029/93JC00141; ARRIGO KR, 1994, LIMNOL OCEANOGR, V39, P609, DOI 10.4319/lo.1994.39.3.0609; CONKRIGHT ME, 1994, WORLD ATLAS 1994, V1; da Silva A.M., 1994, ATLAS SURFACE MARINE, V6; Frazer Thomas K., 1997, P107; JACOBS SS, 1993, GEOPHYS RES LETT, V20, P1171, DOI 10.1029/93GL01200; LEGENDRE L, 1992, POLAR BIOL, V12, P429; Levitus S., 1994, WORLD OCEAN ATLAS 19, V3; MATHOT S, 1996, EOS, V76, pOS143; SMITH WO, 1986, BIOSCIENCE, V36, P251, DOI 10.2307/1310215; STRETCH JJ, 1988, MAR ECOL PROG SER, V44, P131, DOI 10.3354/meps044131; WADHAMS P, 1987, J GEOPHYS RES-OCEANS, V92, P14535, DOI 10.1029/JC092iC13p14535; Zwally H.J., 1983, NASA	16	184	191	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					394	397		10.1126/science.276.5311.394	http://dx.doi.org/10.1126/science.276.5311.394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103193				2022-12-28	WOS:A1997WU47700033
J	Chan, DC; Fass, D; Berger, JM; Kim, PS				Chan, DC; Fass, D; Berger, JM; Kim, PS			Core structure of gp41 from the HIV envelope glycoprotein	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; SOLUBLE RECEPTOR-BINDING; GCN4 LEUCINE-ZIPPER; TRANSMEMBRANE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; TYPE-1 GP41; HEPTAD REPEAT; COILED COILS; FUSION	The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) consists of a complex of gp120 and gp41. gp120 determines viral tropism by binding to target-cell receptors, while gp41 mediates fusion between viral and cellular membranes. Previous studies identified an cu-helical domain within gp41 composed of a trimer of two interacting peptides. The crystal structure of this complex, composed of the peptides N36 and C34, is a six-helical bundle. Three N36 helices form an interior, parallel coiled-coil trimer, while three C34 helices pack in an oblique, antiparallel manner into highly conserved, hydrophobic grooves on the surface of this trimer. This structure shows striking similarity to the low-pH-induced conformation of influenza hemagglutinin and likely represents the core of fusion-active gp41. Avenues for the design/discovery of small-molecule inhibitors of HIV infection are directly suggested by this structure.	MIT, HOWARD HUGHES MED INST, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Chan, DC (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Chan, Doris/O-1227-2014	Chan, Doris/0000-0002-4990-986X				ALLAN JS, 1990, SCIENCE, V247, P1084, DOI 10.1126/science.2309120; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; CHEN SSL, 1994, J VIROL, V68, P2002, DOI 10.1128/JVI.68.3.2002-2010.1994; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Cohen J, 1996, SCIENCE, V274, P502, DOI 10.1126/science.274.5287.502; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JONES TA, 1992, O MANUAL; KALYANARAMAN VS, 1990, AIDS RES HUM RETROV, V6, P371, DOI 10.1089/aid.1990.6.371; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Lipsky JJ, 1996, LANCET, V348, P800, DOI 10.1016/S0140-6736(95)12333-4; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Luciw PA, 1996, FIELD VIROLOGY, P1881; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; NARA PL, 1988, J VIROL, V62, P2622, DOI 10.1128/JVI.62.8.2622-2628.1988; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; STAMATATOS L, 1995, J VIROL, V69, P6191, DOI 10.1128/JVI.69.10.6191-6198.1995; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; Wilkinson D, 1996, CURR BIOL, V6, P1051, DOI 10.1016/S0960-9822(02)70661-1; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	76	1764	1883	0	162	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					263	273		10.1016/S0092-8674(00)80205-6	http://dx.doi.org/10.1016/S0092-8674(00)80205-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108481	Bronze			2022-12-28	WOS:A1997WU88800013
J	Simonet, WS; Lacey, DL; Dunstan, CR; Kelley, M; Chang, MS; Luthy, R; Nguyen, HQ; Wooden, S; Bennett, L; Boone, T; Shimamoto, G; DeRose, M; Elliott, R; Colombero, A; Tan, HL; Trail, G; Sullivan, J; Davy, E; Bucay, N; RenshawGegg, L; Hughes, TM; Hill, D; Pattison, W; Campbell, P; Sander, S; Van, G; Tarpley, J; Derby, P; Lee, R; Boyle, WJ				Simonet, WS; Lacey, DL; Dunstan, CR; Kelley, M; Chang, MS; Luthy, R; Nguyen, HQ; Wooden, S; Bennett, L; Boone, T; Shimamoto, G; DeRose, M; Elliott, R; Colombero, A; Tan, HL; Trail, G; Sullivan, J; Davy, E; Bucay, N; RenshawGegg, L; Hughes, TM; Hill, D; Pattison, W; Campbell, P; Sander, S; Van, G; Tarpley, J; Derby, P; Lee, R; Boyle, WJ			Osteoprotegerin: A novel secreted protein involved in the regulation of bone density	CELL			English	Article							TUMOR NECROSIS FACTORS; C-FOS; V-FPS; MICE; GENE; DIFFERENTIATION; MACROPHAGE; RESORPTION; ACTIVATION; CELLS	A novel secreted glycoprotein that regulates bone resorption has been identified. The protein, termed Osteoprotegerin (OPG), is a novel member of the TNF receptor superfamily. In vivo, hepatic expression of OPG in transgenic mice results in a profound yet nonlethal osteopetrosis, coincident with a decrease in later stages of osteoclast differentiation. These same effects are observed upon administration of recombinant OPG into normal mice. In vitro, osteoclast differentiation from precursor cells is blocked in a dose-dependent manner by recombinant OPG. Furthermore, OPG blocks ovariectomy-associated bone loss in rats. These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.	AMGEN INC, DEPT CELL BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PROT CHEM, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT COMPUTAT BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT MAMMALIAN CELL MOL BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT IMMUNOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PATHOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT BACTERIAL EXPRESS, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PROT STRUCT, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PROC SCI, THOUSAND OAKS, CA 91320 USA	Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen	Simonet, WS (corresponding author), AMGEN INC, DEPT MOL GENET, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.		Dunstan, Colin/G-6214-2013	Dunstan, Colin/0000-0001-7586-4071; Sullivan, John/0000-0001-9840-852X; De Rose, Margaret/0000-0001-9481-7334				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HUGHES DPM, 1995, J EXP MED, V182, P1395, DOI 10.1084/jem.182.5.1395; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KALU DN, 1989, ENDOCRINOLOGY, V124, P7, DOI 10.1210/endo-124-1-7; KAMPS MP, 1988, ONCOGENE, V2, P305; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; LUTHY R, 1994, PROTEIN SCI, V3, P139; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; MUNDY GR, 1992, INT J CELL CLONING, V10, P215, DOI 10.1002/stem.5530100404; MUNDY GR, 1993, GROWTH REGULAT, V3, P124; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; Schreiber M, 1996, J BIOL CHEM, V271, P13333, DOI 10.1074/jbc.271.23.13333; SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389; SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TABAS JA, 1991, GENOMICS, V9, P283, DOI 10.1016/0888-7543(91)90254-C; THOMSON BM, 1987, J IMMUNOL, V138, P775; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WRONSKI TJ, 1989, ENDOCRINOLOGY, V125, P810, DOI 10.1210/endo-125-2-810; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	38	3960	4381	10	237	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					309	319		10.1016/S0092-8674(00)80209-3	http://dx.doi.org/10.1016/S0092-8674(00)80209-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108485	Bronze			2022-12-28	WOS:A1997WU88800017
J	Appel, LJ; Moore, TJ; Obarzanek, E; Vollmer, WM; Svetkey, LP; Sacks, FM; Bray, GA; Vogt, TM; Cutler, JA; Windhauser, MM; Lin, PH; Karanja, N				Appel, LJ; Moore, TJ; Obarzanek, E; Vollmer, WM; Svetkey, LP; Sacks, FM; Bray, GA; Vogt, TM; Cutler, JA; Windhauser, MM; Lin, PH; Karanja, N			A clinical trial of the effects of dietary patterns on blood pressure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	69th Scientific-Session of the American-Heart-Assoc iation	NOV   13, 1996	NEW ORLEANS, LA	Amer Heart Assoc			NUTRITION EXAMINATION SURVEY; MILD HYPERTENSION; NATIONAL-HEALTH; VEGETARIAN DIET; POPULATION	Background It is known that obesity, sodium intake, and alcohol consumption influence blood pressure. In this clinical trial, Dietary Approaches to Stop Hypertension, we assessed the effects of dietary patterns on blood pressure. Methods We enrolled 459 adults with systolic blood pressures of less than 160 mm Hg and diastolic blood pressures of 80 to 95 mm Hg. For three weeks, the subjects were fed a control diet that was low in fruits, vegetables, and dairy products, with a fat content typical of the average diet in the United States. They were then randomly assigned to receive for eight weeks the control diet, a diet rich in fruits and vegetables, or a ''combination'' diet rich in fruits, vegetables, and low-fat dairy products and with reduced saturated and total fat. Sodium intake and body weight were maintained at constant levels. Results At base line, the mean (+/-SD) systolic and diastolic blood pressures were 131.3+/-10.8 mm Hg and 84.+/-4.7 mm Hg, respectively. The combination diet reduced systolic and diastolic blood pressure by 5.5 and 3.0 mm Hg more, respectively, than the control diet (P<0.001 for each); the fruits-and-vegetables diet reduced systolic blood pressure by 2.8 mm Hg more (P<0.001) and diastolic blood pressure by 1.1 mm Hg more (P=0.07) than the control diet. Among the 133 subjects with hypertension (systolic pressure, greater than or equal to 140 mm Hg; diastolic pressure, greater than or equal to 90 mm Hg; or both), the combination diet reduced systolic and diastolic blood pressure by 11.4 and 5.5 mm Hg more, respectively, than the control diet (P<0.001 for each); among the 326 subjects without hypertension, the corresponding reductions were 3.5 mm Hg (P<0.001) and 2.1 mm Hg (P=0.003). Conclusions A diet rich in fruits, vegetables, and low-fat dairy foods and with reduced saturated and total fat can substantially lower blood pressure. This diet offers an additional nutritional approach to preventing and treating hypertension. (C) 1997, Massachusetts Medical Society.	KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR 97227; JOHNS HOPKINS UNIV,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; MERCK & CO INC,WESTWOOD,MA; NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,BETHESDA,MD 20892; DUKE UNIV,MED CTR,DUKE HYPERTENS CTR,DURHAM,NC; DUKE UNIV,MED CTR,SARAH W STEDMAN CTR NUTR STUDIES,DURHAM,NC; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; PENNINGTON BIOMED RES CTR,BATON ROUGE,LA 70808	Kaiser Permanente; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Duke University; Duke University; Harvard University; Harvard T.H. Chan School of Public Health; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center			Appel, Larry/GLT-2608-2022	Moore, Thomas/0000-0002-5289-2018	NHLBI NIH HHS [HL50968, HL50981, HL50972] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL050981, U01HL050968, U01HL050972] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allender PS, 1996, ANN INTERN MED, V124, P825, DOI 10.7326/0003-4819-124-9-199605010-00007; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163; BRUSSAARD JH, 1981, AM J CLIN NUTR, V34, P2023, DOI 10.1093/ajcn/34.10.2023; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CLEVELAND L, 1996, DATA TABLES RESULTS; CUTLER JA, 1995, HYPERTENSION PATHOPH, V1, P253; *DEP AGR, 1995, NUTR YOUR HLTH DIET, V232; ELIASSON K, 1992, J HYPERTENS, V10, P195, DOI 10.1097/00004872-199202000-00014; HARLAN WR, 1984, AM J EPIDEMIOL, V120, P17, DOI 10.1093/oxfordjournals.aje.a113870; *JOINT NAT COMM DE, 1993, ARCH INTERN MED, V153, P154; KrebsSmith SM, 1995, AM J PUBLIC HEALTH, V85, P1623, DOI 10.2105/AJPH.85.12.1623; MARGETTS BM, 1986, BRIT MED J, V293, P1468, DOI 10.1136/bmj.293.6560.1468; Morris M. C., 1994, TXB HYPERTENSION, P605; *NAT CTR HLTH STAT, 1983, VIT HLTH STAT, V11; *NAT RES COUNC, 1989, DIET HLTH IMPL RED C, P301; Obarzanek E, 1996, JAMA-J AM MED ASSOC, V275, P1598, DOI 10.1001/jama.275.20.1598; ROUSE IL, 1983, LANCET, V1, P5; SACKS FM, 1974, AM J EPIDEMIOL, V100, P390, DOI 10.1093/oxfordjournals.aje.a112050; Sacks Frank M., 1995, Annals of Epidemiology, V5, P108, DOI 10.1016/1047-2797(94)00055-X; Stamler J, 1996, CIRCULATION, V94, P1629, DOI 10.1161/01.CIR.94.7.1629; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Stamler J, 1996, CIRCULATION, V94, P2417, DOI 10.1161/01.CIR.94.10.2417; *TREATM MILD HYP R, 1991, ARCH INTERN MED, V151, P1413; *TRIALS HYP PREV C, 1992, JAMA-J AM MED ASSOC, V267, P1213; *TRIALS HYP PREV C, 1992, JAMA-J AM MED ASSOC, V267, P2330; WHELTON PK, 1989, AM J CARDIOL, V63, pG26, DOI 10.1016/0002-9149(89)90215-4; WHELTON PK, 1993, HYPERTENSION PRIMER; *WORK GROUP PRIM P, 1993, ARCH INTERN MED, V153, P186	30	3661	3771	16	409	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1117	1124		10.1056/NEJM199704173361601	http://dx.doi.org/10.1056/NEJM199704173361601			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099655	Green Published			2022-12-28	WOS:A1997WU00300001
J	Blumenthal, D; Campbell, EG; Anderson, MS; Causino, N; Louis, KS				Blumenthal, D; Campbell, EG; Anderson, MS; Causino, N; Louis, KS			Withholding research results in academic life science - Evidence from a national survey of faculty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To identify the prevalence and determinants of data-withholding behaviors among academic life scientists. Design.-Mailed survey of 3394 life science faculty in the 50 universities that received the most funding from the National Institutes of Health in 1993. Participants.-A total of 2167 faculty responded to the survey, a 64% response rate. Outcome Measures.-Whether respondents delayed publication of their research results for more than 6 months and whether respondents refused to share research results with other university scientists in the last 3 years. Results.-A total of 410 respondents (19.8%) reported that publication of their research results had been delayed by more than 6 months at least once in the last 3 years to allow for patent application, to protect their scientific lead, to slow the dissemination of undesired results, to allow time to negotiate a patent, or to resolve disputes over the ownership of intellectual property. Also, 181 respondents (8.9%) reported refusing to share research results with other university scientists in the last 3 years, in multivariate analysis, participation in an academic-industry research relationship and engagement in the commercialization of university research were significantly associated with delays in publication. Odds ratios (ORs) and 95% confidence intervals (Cls) were 1.34 (1.07-1.59) and 3.15 (2.88-3.41), respectively. Variables associated with refusing to share results were conducting research similar to the Human Genome Project (OR, 2.09; 95% CI, 1.75-2.42), publication rate (OR, 1.02; 95% CI, 1.01-1.03), and engagement in commercialization of research (OR, 2.45; 95% CI, 2.08-2.82). Conclusions.-Withholding of research results is not a widespread phenomenon among life-science researchers, However, withholding is more common among the most productive and entrepreneurial faculty, These results also suggest that data withholding has affected a significant number of life-science faculty and further study on data-withholding practices is suggested.	PARTNERS HEALTHCARE SYST,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA; UNIV MINNESOTA,COLL EDUC & HUMAN DEV,MINNEAPOLIS,MN 55455	Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities	Blumenthal, D (corresponding author), MASSACHUSETTS GEN HOSP,DIV GEN INTERNAL MED,HLTH POLICY RES & DEV UNIT,50 STANIFORD ST,BOSTON,MA 02114, USA.			Seashore, Karen/0000-0003-1070-0273	NHGRI NIH HHS [HG00724-01] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R55HG000724, R01HG000724] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Blumenthal D, 1996, NEW ENGL J MED, V334, P368, DOI 10.1056/NEJM199602083340606; Blumenthal D, 1996, NEW ENGL J MED, V335, P1734, DOI 10.1056/NEJM199612053352305; BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; COHEN J, 1995, SCIENCE, V268, P1715, DOI 10.1126/science.7792594; KING RT, 1996, WALL STREET J   0425, pA1; LOUIS KS, 1989, ADMIN SCI QUART, V34, P110, DOI 10.2307/2392988; Merton R.K., 1979, SOCIOLOGY SCI; ROSENBERG SA, 1996, NEW ENGL J MED, V334, P292; WEINBERG RA, 1993, RESPONSIBLE SCI ENSU, V2, P66; 1994, FED REGISTER, V59, P55674; 1994, PETERSONS GUIDE GRAD	11	392	400	2	70	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1224	1228		10.1001/jama.277.15.1224	http://dx.doi.org/10.1001/jama.277.15.1224			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WT403	9103347				2022-12-28	WOS:A1997WT40300034
J	Kronzon, I; Tunick, PA				Kronzon, I; Tunick, PA			Atheromatous disease of the thoracic aorta: Pathologic and clinical implications	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHIC DETECTION; SYSTEMIC EMBOLIZATION; PROTRUDING ATHEROMAS; ELDERLY PATIENTS; ARCH THROMBUS; STROKE; BYPASS; EXPERIENCE; EMBOLISM; PLAQUE	Purpose: To review recent developments in the diagnosis, clinical epidemiology, pathology, and management of atherosclerosis of the thoracic aorta, especially atherosclerosis of the thoracic aorta as a source of embolization. Data Sources: MEDLINE searches, bibliographies of published papers, and consultation with experts in the field. Study Selection: English-language publications on atherosclerosis of the thoracic aorta were selected. Data Synthesis: During the last 6 years, the increasing use of transesophageal echocardiography has shown that atherosclerotic plaque in the thoracic aorta is a source of otherwise unexplained embolic events, including stroke, transient ischemic attack, and peripheral emboli. Retrospective studies have documented a strong independent association between larger lesions (4 mm to 5 mm) and previous embolic disease, and prospective studies have shown that patients with these lesions have a high risk for future events (in one study, the risk for stroke was 12%; in another, the risk for cerebral or peripheral events was 33% in a follow-up period of just 14 months). These lesions also pose a serious risk for embolization caused by manipulation of the aorta during catheterization, intra-aortic balloon-pump placement, and cannulation of the aorta for heart surgery. Pathologic examination has shown atherosclerotic plaque, often with superimposed thrombi that account for the mobile components seen on transesophageal echocardiography. The management of patients who have atherosclerotic lesions in the thoracic aorta has not been determined prospectively. However, anticoagulation may help prevent emboli, as it does for patients who have thrombi in other locations, such as the left atrium and the left ventricle. Conclusions: Protruding atherosclerotic lesions in the thoracic aorta, often with superimposed mobile thrombi, are an important cause of embolic disease. Transesophageal echocardiography should be considered in the work-up of patients who have unexplained embolic events.	NYU, MED CTR, NONIVAS CARDIOL LAB, NEW YORK, NY 10016 USA	New York University								AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; Amarenco P, 1996, NEW ENGL J MED, V334, P1216; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; Bansal R C, 1993, J Am Soc Echocardiogr, V6, P319; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; COY KM, 1992, AM HEART J, V123, P1684, DOI 10.1016/0002-8703(92)90823-E; CRAIG WR, 1996, J AM SOC ECHOCARDIOG, V9, P364; Culliford Alfred T., 1993, Journal of the American College of Cardiology, V21, p342A; DAHLBERG PJ, 1989, SURGERY, V105, P737; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DEMOPOULOS LA, 1995, AM HEART J, V129, P40, DOI 10.1016/0002-8703(95)90040-3; Estol CJ, 1996, STROKE, V27, P559, DOI 10.1161/01.STR.27.3.559; FARO RS, 1983, J THORAC CARDIOV SUR, V86, P616; FISHER M, 1951, AMA ARCH NEUROL PSY, V65, P346, DOI 10.1001/archneurpsyc.1951.02320030083009; FLORY CM, 1945, AM J PATHOL, V21, P549; FREEDBERG RS, 1993, AM HEART J, V125, P1445, DOI 10.1016/0002-8703(93)91026-B; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; HAUSMANN D, 1992, NEW ENGL J MED, V327, P500; HOROWITZ DR, 1992, NEUROLOGY, V42, P1602, DOI 10.1212/WNL.42.8.1602; HYMAN BT, 1987, AM J MED, V82, P1233, DOI 10.1016/0002-9343(87)90231-2; IMPARATO AM, 1979, PRINCIPLES SURG, P952; KARALIS D G, 1992, Journal of the American College of Cardiology, V19, p280A; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; KATZ ES, 1992, AM J CARDIOL, V69, P1635, DOI 10.1016/0002-9149(92)90716-C; Khatibzadeh M, 1996, J AM COLL CARDIOL, V27, P664, DOI 10.1016/0735-1097(95)00526-9; KOPPANG JR, 1992, ECHOCARDIOGR-J CARD, V9, P379, DOI 10.1111/j.1540-8175.1992.tb00481.x; KRONZON I, 1993, PROG CARDIOVASC DIS, V36, P39, DOI 10.1016/0033-0620(93)90021-5; Montgomery DH, 1996, J AM COLL CARDIOL, V27, P95, DOI 10.1016/0735-1097(95)00431-9; NIHOYANNOPOULOS P, 1993, AM J CARDIOL, V71, P1208, DOI 10.1016/0002-9149(93)90647-U; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; SALOMON NW, 1991, J THORAC CARDIOV SUR, V101, P209; SIMONS AJ, 1992, AM HEART J, V123, P224, DOI 10.1016/0002-8703(92)90772-N; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1991, ANN INTERN MED, V114, P391, DOI 10.7326/0003-4819-114-5-391; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; TUNICK PA, 1994, J AM COLL CARDIOL, V23, P1085, DOI 10.1016/0735-1097(94)90595-9; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TUNICK PA, 1992, AM HEART J, V124, P239; WAREING TH, 1992, J THORAC CARDIOV SUR, V103, P453	41	60	60	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					629	637		10.7326/0003-4819-126-8-199704150-00008	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103131				2022-12-28	WOS:A1997WT58000010
J	Ekpini, ER; Wiktor, SZ; Satten, GA; AdjorloloJohnson, GT; Sibailly, TS; Ou, CY; Karon, JM; Brattegaard, K; Whitaker, JP; Gnaore, E; DeCock, KM; Greenberg, AE				Ekpini, ER; Wiktor, SZ; Satten, GA; AdjorloloJohnson, GT; Sibailly, TS; Ou, CY; Karon, JM; Brattegaard, K; Whitaker, JP; Gnaore, E; DeCock, KM; Greenberg, AE			Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BREAST-MILK; TYPE-1; INFANT; INFECTION; RISK	Background HIV-1 can be transmitted from an infected mother to her infant through breastfeeding, although the precise risk of transmission by this route is unknown. A long-term follow-up of children born to HIV-infected women in Abidjan, Gate d'lvoire, has enabled us to estimate this risk. Methods Children born to 138 HIV-1-seropositive women, 132 HIV-2-seropositive women, 69 women seroreactive to both HIV-1 and HIV-2, and 274 HIV-seronegative women were enrolled at birth and followed up for as long as 48 months. All chidren were breastfed (median duration 20 months). Blood samples for either or both HIV PCR and HIV serology were obtained at 1, 2, and 3 months of age, and every 3 months thereafter. Early HIV infection was defined as a positive HIV-1 PCR result obtained in the first 6 months of life. Late postnatal transmission was diagnosed when a child had a negative PCR at 3 or 6 months of age, followed by either or both a positive HIV-1 PCR at 9 months or older, or persistently positive HIV-1 serology at 15 months or older. Findings 82 children born to HIV-1-seropositive mothers and 57 children born to mothers seropositive for both HIV-1 and HIV-2 had PCR results for samples taken within the first 6 months. By 6 months of age, 23 (28%; 95% CI 19-39) of the 82 children born to HIV-l-seropositive mothers and ten (18%; 95% CI 9-30) of the 57 children born to dually seropositive mothers were HIV-1 infected, Among children whose PCR results were negative at or before age 6 months, and who were followed up beyond 6 months, an additional four (9%) of the 45 children born to HIV-1-seropositive mothers and two (5%) of the 39 children born to dually seropositive mothers became HIV infected. The estimated rates of late postnatal transmission, with account taken of loss to follow-up and the observed pattern of weaning, were 12% (95% CI 3-23) and 6% (0-14), respectively. One of the five children whose mothers seroconverted from HIV-negative to HIV-1, and one of seven children whose mothers seroconverted from HIV-2 to dual reactivity, became HIV-1 positive. No case of late postnatal transmission occurred in children born to HIV-2-positive or persistently HIV-negative mothers. Interpretation Breastfed children born to mothers seropositive for HIV-1 alone or seropositive for HIV-1 and HIV-2 in Abidjan are at substantial risk of late postnatal transmission. Early cessation of breastfeeding at 6 months of age should be assessed as a possible intervention to reduce postnatal transmission of HIV.	PROJET RETRO CI,ABIDJAN 01,COTE IVOIRE; NATL AIDS CONTROL PROGRAM,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,ATLANTA,GA; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	Centers for Disease Control & Prevention - USA; University of London; London School of Hygiene & Tropical Medicine				Satten, Glen/0000-0001-7275-5371				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COHEN J, 1995, SCIENCE, V269, P624, DOI 10.1126/science.7624786; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DOUGLAS GC, 1992, CLIN INFECT DIS, V15, P678, DOI 10.1093/clind/15.4.678; DUNN DT, 1995, AIDS, V9, pF7, DOI 10.1097/00002030-199509000-00001; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; NEWELL ML, 1992, LANCET, V339, P1007; PALASANTHIRAN P, 1993, J INFECT DIS, V167, P441, DOI 10.1093/infdis/167.2.441; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; THIRY L, 1985, LANCET, V2, P891; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; VANDEPERRE P, 1992, CLIN INFECT DIS, V15, P502, DOI 10.1093/clind/15.3.502; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; ZIEGLER JB, 1985, LANCET, V1, P896; [No title captured]; [No title captured]	21	123	126	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1054	1059		10.1016/S0140-6736(96)06444-6	http://dx.doi.org/10.1016/S0140-6736(96)06444-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107243				2022-12-28	WOS:A1997WU00200009
J	Huber, C; Wachtershauser, G				Huber, C; Wachtershauser, G			Activated acetic acid by carbon fixation on (Fe,Ni)S under primordial conditions	SCIENCE			English	Article							CO DEHYDROGENASE; PYRITE FORMATION; NICKEL; BACTERIA; IRON; BIOCHEMISTRY; EVOLUTION; MONOXIDE; COENZYME; SULFIDE	In experiments modeling the reactions of the reductive acetyl-coenzyme A pathway at hydrothermal temperatures, it was found that an aqueous slurry of coprecipitated NiS and FeS converted CO and CH3SH into the activated thioester CH3-CO-SCH3, which hydrolyzed to acetic acid. In the presence of aniline, acetanilide was formed. When NiS-FeS was modified with catalytic amounts of selenium, acetic acid and CH3SH were formed from CO and H2S alone. The reaction can be considered as the primordial initiation reaction for a chemoautotrophic origin of life.	TECH UNIV MUNICH,DEPT ORGAN CHEM & BIOCHEM,D-85747 GARCHING,GERMANY	Technical University of Munich								BLOCHL E, 1992, P NATL ACAD SCI USA, V89, P8117, DOI 10.1073/pnas.89.17.8117; BRAY CJ, 1991, J GEOCHEM EXPLOR, V42, P167, DOI 10.1016/0375-6742(91)90066-4; COLLIN J, 1988, B SOC CHIM FR, P976; CRABTREE RH, 1994, ORGANOMETALLIC CHEM, P313; de Duve, 1991, BLUEPRINT CELL; DROBNER E, 1990, NATURE, V346, P742, DOI 10.1038/346742a0; FERRY JG, 1995, ANNU REV MICROBIOL, V49, P305, DOI 10.1146/annurev.mi.49.100195.001513; FUCHS G, 1985, EVOLUTION PROKARYOTE, P235; HAFENBRADL D, 1995, TETRAHEDRON LETT, V36, P5179; HALCROW MA, 1994, CHEM REV, V94, P2421, DOI 10.1021/cr00032a008; Heinen W, 1996, ORIGINS LIFE EVOL B, V26, P131, DOI 10.1007/BF01809852; Holland HD., 1984, CHEM EVOLUTION ATMOS; HOLLEMAN AF, 1985, LEHRBUCH ANORGANISCH, P1126; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; KASTING JF, 1990, ORIGINS LIFE EVOL B, V20, P199, DOI 10.1007/BF01808105; KELLER M, 1994, NATURE, V368, P836, DOI 10.1038/368836a0; KUMAR M, 1995, SCIENCE, V270, P628, DOI 10.1126/science.270.5236.628; LU Z, 1995, J AM CHEM SOC, V117, P3994, DOI 10.1021/ja00119a014; MATSUNAGA PT, 1994, ANGEW CHEM, V17, P1841; MATTIOLI GS, 1986, NATURE, V322, P626, DOI 10.1038/322626a0; Menon S, 1996, BIOCHEMISTRY-US, V35, P12119, DOI 10.1021/bi961014d; MERLIVAT L, 1987, EARTH PLANET SC LETT, V84, P100, DOI 10.1016/0012-821X(87)90180-4; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; NI SS, 1993, BIOGEOCHEMISTRY OF GLOBAL CHANGE, P796; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; QIU D, 1994, SCIENCE, V264, P817, DOI 10.1126/science.8171334; RAGSDALE SW, 1994, ACETOGENESIS, P88; Shim S. C., 1995, J ORG CHEM, V50, P149; SIGVALDASON GE, 1974, PHYSICAL VOLCANOLOGY, V6, P214; TANIMOTO Y, 1994, APPL ENVIRON MICROB, V60, P2450, DOI 10.1128/AEM.60.7.2450-2455.1994; THAUER RK, 1980, TRENDS BIOCHEM SCI, V5, P304, DOI 10.1016/0968-0004(80)90166-8; TUCCI GC, 1995, J AM CHEM SOC, V117, P6489, DOI 10.1021/ja00129a011; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Walker, 1977, EVOLUTION ATMOSPHERE, V32, P71; ZENKEVICH VA, 1991, VULKANOL SEISMOL, V3, P19; 1929, GMELINS HDB ANORGANI, P62	39	487	499	9	214	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					245	247		10.1126/science.276.5310.245	http://dx.doi.org/10.1126/science.276.5310.245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092471				2022-12-28	WOS:A1997WT92500042
J	Kawamoto, T; Holloway, JR				Kawamoto, T; Holloway, JR			Melting temperature and partial melt chemistry of H2O-saturated mantle peridotite to 11 gigapascals	SCIENCE			English	Article							TRANSITION ZONE; MODIFIED SPINEL; HIGH-PRESSURES; WATER; GPA; MAGMAS; SYSTEM; STABILITY; PETROLOGY; GENESIS	The H2O-saturated solidus of a model mantle composition (Kilborne Hole peridotite nodule, KLB-1) was determined to be just above 1000 degrees C from 5 to 11 gigapascals. Given reasonable H2O abundances in Earth's mantle, an H2O-rich fluid could exist only in a region defined by the wet solidus and thermal stability limits of hydrous minerals, at depths between 90 and 330 kilometers. The experimental partial melts monotonously became more mafic with increasing pressure from andesitic composition at 1 gigapascal to more mafic than the starting peridotite at 10 gigapascals. Because the chemistry of the experimental partial melts is similar to that of kimberlites, it is suggested that kimberlites may be derived by low-temperature melting of an H2O-rich mantle at depths of 150 to 300 kilometers.	ARIZONA STATE UNIV, DEPT GEOL, TEMPE, AZ 85287 USA; ARIZONA STATE UNIV, DEPT CHEM, TEMPE, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe			Kawamoto, Tatsuhiko/H-6088-2011	Kawamoto, Tatsuhiko/0000-0002-6989-874X				AGEE CB, 1988, J GEOPHYS RES-SOLID, V93, P3437, DOI 10.1029/JB093iB04p03437; Bose K, 1995, EARTH PLANET SC LETT, V136, P109, DOI 10.1016/0012-821X(95)00188-I; BOYD FR, 1985, NATURE, V315, P387, DOI 10.1038/315387a0; Domanik KJ, 1996, GEOCHIM COSMOCHIM AC, V60, P4133, DOI 10.1016/S0016-7037(96)00241-4; EGGLER DH, 1978, AM J SCI, V278, P305, DOI 10.2475/ajs.278.3.305; EGGLER DH, 1989, GEOLOGICAL SOC AUSTR, V14, P489; GASPARIK T, 1993, J GEOPHYS RES-SOL EA, V98, P4287, DOI 10.1029/92JB02530; GEE LL, 1988, J PETROL, V29, P1233, DOI 10.1093/petrology/29.6.1233; GREEN DH, 1973, EARTH PLANET SC LETT, V19, P37, DOI 10.1016/0012-821X(73)90176-3; Herzberg C, 1996, J GEOPHYS RES-SOL EA, V101, P8271, DOI 10.1029/96JB00170; HIROSE K, 1995, EARTH PLANET SC LETT, V133, P463, DOI 10.1016/0012-821X(95)00096-U; HIROSE K, 1995, EOS, V76, pF696; INOUE T, 1994, PHYS EARTH PLANET IN, V85, P237, DOI 10.1016/0031-9201(94)90116-3; INOUE T, 1995, GEOPHYS RES LETT, V22, P117, DOI 10.1029/94GL02965; INOUE T, 1993, HIGH PRESSURE RES AP, P323; KAMENETSKY VS, 1995, J PETROL, V36, P637, DOI 10.1093/petrology/36.3.637; KANZAKI M, 1991, PHYS EARTH PLANET IN, V66, P307, DOI 10.1016/0031-9201(91)90085-V; KATSURA T, 1989, J GEOPHYS RES-SOLID, V94, P15663, DOI 10.1029/JB094iB11p15663; Kawamoto T, 1996, EARTH PLANET SC LETT, V142, P587, DOI 10.1016/0012-821X(96)00113-6; Kawamoto T, 1996, EARTH PLANET SC LETT, V144, P577, DOI 10.1016/S0012-821X(96)00182-3; KAWAMOTO T, 1995, AIP CONF PROC, P229, DOI 10.1063/1.48731; KUSHIRO I, 1972, J PETROL, V13, P311, DOI 10.1093/petrology/13.2.311; KUSHIRO I, 1968, J GEOPHYS RES, V73, P6023, DOI 10.1029/JB073i018p06023; MCDONOUGH WF, 1995, EOS T AM GEOPHYS UN, V76, P266; Mitchell R. H., 1995, KIMBERLITES ORANGEIT; NISBET EG, 1993, LITHOS, V30, P291, DOI 10.1016/0024-4937(93)90042-B; OHTANI E, 1995, GEOPHYS RES LETT, V22, P2553, DOI 10.1029/95GL02338; PACALO REG, 1992, AM MINERAL, V77, P681; RINGWOOD AE, 1979, ORIGIN EARTH MOON; TAKAHASHI E, 1986, J GEOPHYS RES-SOLID, V91, P9367, DOI 10.1029/JB091iB09p09367; TATSUMI Y, 1989, J GEOPHYS RES-SOLID, V94, P4697, DOI 10.1029/JB094iB04p04697; WOOD BJ, 1995, SCIENCE, V268, P74, DOI 10.1126/science.268.5207.74; WYLLIE PJ, 1980, J GEOPHYS RES, V85, P6902, DOI 10.1029/JB085iB12p06902; ZHANG JZ, 1994, J GEOPHYS RES-SOL EA, V99, P17729, DOI 10.1029/94JB01406	34	186	195	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					240	243		10.1126/science.276.5310.240	http://dx.doi.org/10.1126/science.276.5310.240			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092469				2022-12-28	WOS:A1997WT92500040
J	Matricardi, PM; Rosmini, F; Ferrigno, L; Nisini, R; Rapicetta, M; Chionne, P; Stroffolini, T; Pasquini, P; DAmelio, R				Matricardi, PM; Rosmini, F; Ferrigno, L; Nisini, R; Rapicetta, M; Chionne, P; Stroffolini, T; Pasquini, P; DAmelio, R			Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus	BRITISH MEDICAL JOURNAL			English	Article							SERUM IMMUNOGLOBULIN-E; SKIN-TEST REACTIVITY; HAY-FEVER; POPULATION; CHILDHOOD; DISEASE; ASTHMA	Objective: To investigate the working hypothesis that common infections occurring early in life prevent atopy. Design: Cross sectional, retrospective study of young Italian men with results for hepatitis A serology and atopy. Setting: Air force school for military students in Caserta Italy. Subjects: 1659 male students aged 17-24, most of whom (90%) were from central and southern Italy. Main outcome measures: Skin sensitisation and specific IgE antibodies to locally relevant airborne allergens; diagnosis of respiratory allergy (asthma or rhinitis, or both); hepatitis A seropositivity. Results: 443 of the 1659 subjects (26.7%) were positive for hepatitis A virus antibody. Atopy was less common among seropositive than seronegative subjects according to skin sensitization (weal reaction greater than or equal to 3 mm) to one or more allergens (21.9% (97/443) v 30.2% (367/1216), P<0.001); polysensitisation (sensitive to three or more allergens) (2.7% (12/443) v 6.4% (78/1216), P<0.01); high specific IgE concentration (9.7% (43/443) v 18.4% (224/1216), P<0.00005); and lifetime prevalence of allergic rhinitis or asthma, or both (8.4% (37/443) v 16.7% (203/1216), P<0.001). Hepatitis A seropositivity remained inversely associated with atopy after adjusting for father's education, the number of older siblings, and the area of residence (based on the number of inhabitants). The prevalence of atopy was constantly low among seropositive subjects, whatever the number of older siblings; by contrast, it increased with a decreasing number of older siblings among seronegative subjects. Conclusion: Indirect but important evidence is added to the working hypothesis as common infections acquired early in life because of the presence of many older siblings (among seronegative subjects) or because of unhygienic living conditions (among seropositive subjects) may have reduced the risk of developing atopy.	IST SUPER SANITA,EPIDEMIOL & BIOSTAT LAB,I-00161 ROME,ITALY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY; WHO,DIV EMERGING & OTHER COMMUNICABLE DIS SURVEILLANC,CH-1211 GENEVA 27,SWITZERLAND	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); World Health Organization	Matricardi, PM (corresponding author), DIV AEREA STUDI RIC & SPERIMENTAZ,LAB IMMUNOL & ALLERGOL,A PRAT DI MARE,I-00040 POMEZIA,ROMA,ITALY.		Nisini, Roberto/M-4363-2015; CHIONNE, PAOLA/M-2959-2015	Nisini, Roberto/0000-0003-1077-423X; 				BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BURNEY PGJ, 1993, CLIN EXP ALLERGY, V23, P484; ENGELMAN L, 1990, BMDP STATISTICAL SOF, V2, P1013; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; MATRICARDI PM, 1994, INFECTION, V22, P51, DOI 10.1007/BF01780768; PAPAEVANGELOU G, 1992, VACCINE S1, V10, P63; PASQUINI P, 1984, INT J EPIDEMIOL, V13, P83, DOI 10.1093/ije/13.1.83; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; STRACHAN DP, 1994, CLIN EXP ALLERGY, V24, P603, DOI 10.1111/j.1365-2222.1994.tb00961.x; STRACHAN DP, 1994, THORAX, V49, pP1053; SZMUNESS W, 1977, AM J EPIDEMIOL, V106, P392, DOI 10.1093/oxfordjournals.aje.a112481; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132; Woolcock AJ, 1995, PROG ALLER CLIN IMM, V3, P167	20	403	421	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					999	1003		10.1136/bmj.314.7086.999	http://dx.doi.org/10.1136/bmj.314.7086.999			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112843	Green Published			2022-12-28	WOS:A1997WT15200020
J	Hay, JC; Chao, DS; Kuo, CS; Scheller, RH				Hay, JC; Chao, DS; Kuo, CS; Scheller, RH			Protein interactions regulating vesicle transport between the endoplasmic reticulum and Golgi apparatus in mammalian cells	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; YEAST; COMPLEX; DOCKING; FUSION; ACTIVATION; SECRETION; RECEPTORS; ENCODES	The proposed cis-Golgi vesicle receptor syntaxin 5 was found in a complex with Golgi-associated SNARE of 28 kDa (GOS-28), rbet1, rsly1, and two novel proteins characterized herein: rat sec22b and membrin, both cytoplasmically oriented integral membrane proteins. The complex appears to recapitulate vesicle docking interactions of proteins originating from distinct compartments, since syntaxin 5, rbet1, and GOS-28 localize to Golgi membranes, whereas mouse sec22b and membrin accumulate in the endoplasmic reticulum. Protein interactions in the complex are dramatically rearranged by N-ethylmaleimide-sensitive factor. The complex consists of two or more subcomplexes with some members (rat sec22b and syntaxin 5) in common and others (rbet1 and GOS-28) mutually exclusively associated. We propose that these protein interactions determine vesicle docking/fusion fidelity between the endoplasmic reticulum and Golgi.			Hay, JC (corresponding author), STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,DEPT CELLULAR & MOL PHYSIOL,STANFORD,CA 94305, USA.			Chao, Daniel/0000-0002-3544-5283				Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; Peterson MR, 1996, GENE, V169, P293, DOI 10.1016/0378-1119(95)00819-5; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613	26	168	176	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					149	158		10.1016/S0092-8674(00)80191-9	http://dx.doi.org/10.1016/S0092-8674(00)80191-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094723	Bronze			2022-12-28	WOS:A1997WR68500018
J	Laumann, EO; Masi, CM; Zuckerman, EW				Laumann, EO; Masi, CM; Zuckerman, EW			Circumcision in the United States - Prevalence, prophylactic effects, and sexual practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTIONS	Objective.-To assess the prevalence of circumcision across various social groups and examine the health and sexual outcomes of circumcision. Design.-An analysis of data from the National Health and Social Life Survey. Participants.-A national probability sample of 1410 American men aged 18 to 59 years at the time of the survey. In addition, an oversample of black and Hispanic minority groups is included in comparative analyses. Main Outcome Measures.-The contraction of sexually transmitted diseases, the experience of sexual dysfunction, and experience with a series of sexual practices. Results.-We find no significant differences between circumcised and uncircumcised men in their likelihood of contracting sexually transmitted diseases. However, uncircumcised men appear slightly more likely to experience sexual dysfunctions, especially later in life. Finally, we find that circumcised men engage in a more elaborated set of sexual practices. This pattern differs across ethnic groups, suggesting the influence of social factors. Conclusions.-The National Health and Social Life Survey evidence indicates a slight benefit of circumcision but a negligible association with most outcomes. These findings inform existing debates on the utility of circumcision. The considerable impact of circumcision status on sexual practice represents a new finding that should further enrich such discussion. Our results support the view that physicians and parents be informed of the potential benefits and risks before circumcising newborns.	UNIV CHICAGO,SCH SOCIAL SERV ADM,CHICAGO,IL 60637	University of Chicago	Laumann, EO (corresponding author), UNIV CHICAGO,DEPT SOCIOL,5848 S UNIV AVE,CHICAGO,IL 60637, USA.				NICHD NIH HHS [5 R01 HD28356] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028356] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BROWN MS, 1987, PEDIATRICS, V80, P215; BURGER R, 1974, PEDIATRICS, V54, P362; CLEARY TG, 1979, PEDIATRICS, V64, P301; *COMM FET NEWB, 1975, PEDIATRICS, V56, P610; GOODWIN WE, 1990, J UROLOGY, V144, P1203, DOI 10.1016/S0022-5347(17)39693-3; GRAVES EJ, 1995, VITAL HLTH STAT, V13, P128; HERZOG LW, 1989, AM J DIS CHILD, V143, P348, DOI 10.1001/archpedi.1989.02150150106026; LAUMANN EO, 1994, SOCIAL ORG SEXUALITY, pCH2; LILIENFELD AM, 1958, J NATL CANCER I, V21, P713; MASI CM, 1995, CIRCUMCISION MED ISS; Masters WH., 1966, HUMAN SEXUAL RESPONS; Morgan W K, 1967, Med J Aust, V1, P1102; PARKER SW, 1983, MED J AUSTRALIA, V2, P288, DOI 10.5694/j.1326-5377.1983.tb122467.x; PRESTON EN, 1970, J AMER MED ASSOC, V213, P1853, DOI 10.1001/jama.213.11.1853; SCHLOSSBERGER NM, 1991, J ADOLESCENT HEALTH, V12, P293; *STAT CORP, 1994, STATA VERS 4 0; *TASK FORC CIRC, 1989, PEDIATRICS, V84, P388; WISWELL TE, 1985, PEDIATRICS, V75, P901	18	238	244	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1052	1057		10.1001/jama.277.13.1052	http://dx.doi.org/10.1001/jama.277.13.1052			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091693				2022-12-28	WOS:A1997WQ08900030
J	LuYao, GL; Yao, SL				LuYao, GL; Yao, SL			Population-based study of long-term survival in patients with clinically localised prostate cancer	LANCET			English	Article							RADICAL PROSTATECTOMY; DECISION-ANALYSIS; MANAGEMENT; ANTIGEN	Background Choice of treatment in localised prostate cancer has been hampered by a lack of unbiased, representative data on outcome. Most existing data have come from small cohorts at specialised academic centres; precise overall and cancer-grade-specifc data are not available, and the data are subject to differential staging bias. Randomised clinical trials have been undertaken, but the results will not be available for another decade. We have carried out a large population-based study to ascertain overall and prostate-cancer-specific survival in men treated by prostatectomy, radiotherapy, or conservative management. Methods Data for 59 876 cancer-registry patients aged 50-79 were analysed. We examined the effect of differential staging of prostate cancer by analysing the data both by intention to treat and by treatment received. Estimated survival was calculated by the Kaplan-Meier method. Findings By the intention-to-treat approach, 10-year prostate-cancer-specific survival for grade 1 cancer was 94% (95% CI 91-95) after prostatectomy, 90% (87-92) after radiotherapy, and 93% (91-94) after conservative management. The corresponding survival figures in grade 2 cancers were 87% (85-89), 76% (72-79), and 77% (74-80); those in grade 3 cancer were 67% (62-71), 53% (47-58), and 45% (40-51). Although the intention-to-treat and treatment-received analyses yielded similar results for radiotherapy and conservative management, the 10-year disease-specific survival after prostatectomy differed substantially (83% [81-84] by intention to treat vs 89% [87-91] by treatment received). Interpretation The overall and cancer-grade-specific survival found in this study differ substantially from those in previous studies. Previous studies that used a treatment-received approach have generally overestimated the benefits of radical prostatectomy. We found that grade 3 tumours are highly aggressive irrespective of stage.	HLTH CARE FINANCING ADM, OFF RES & DEMONSTRAT, DIV HLTH INFORMAT & OUTCOMES, BALTIMORE, MD 21244 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD USA	Johns Hopkins University; Johns Hopkins Medicine				Lu-Yao, Grace/0000-0002-6017-9175	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008397] Funding Source: NIH RePORTER; AHRQ HHS [HS 08397] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Albertsen PC, 1996, J UROLOGY, V156, P127, DOI 10.1016/S0022-5347(01)65964-0; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; American Joint Committee on Cancer, 1992, MAN STAG CANC; AUSTENFELD MS, 1994, J UROLOGY, V152, P1866, DOI 10.1016/S0022-5347(17)32403-5; BAGSHAW MA, 1994, J UROLOGY, V152, P1781, DOI 10.1016/S0022-5347(17)32385-6; BARRY MJ, 1995, UROLOGY, V46, P2, DOI 10.1016/S0090-4295(99)80151-4; BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BECK JR, 1994, J UROLOGY, V152, P1677, DOI 10.1016/S0022-5347(17)32357-1; Bell Felicitie C., 1992, LIFE TABLES US SOCIA; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HORM JW, 1984, SURVEILLANCE EPIDMEI; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; MIDDLETON RG, 1995, J UROLOGY, V154, P2144, DOI 10.1016/S0022-5347(01)66718-1; Middleton RG, 1996, CA-CANCER J CLIN, V46, P249, DOI 10.3322/canjclin.46.4.249; NARAYAN P, 1995, UROLOGY, V46, P205, DOI 10.1016/S0090-4295(99)80195-2; *NAT CANC I, 1995, SURV EP END RES PROG; Norlen B J, 1994, Can J Oncol, V4 Suppl 1, P38; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; POTOSKY AL, 1993, MED CARE, V31, P732; SHAMBAUGH EM, 1986, SUMMARY STAGING GUID; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WILT TJ, 1994, J UROLOGY, V152, P1910, DOI 10.1016/S0022-5347(17)32413-8; ZIETMAN AL, 1995, INT J RADIAT ONCOL, V32, P287, DOI 10.1016/0360-3016(95)00123-G; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6; ZINCKE H, 1994, J CLIN ONCOL, V12, P2254, DOI 10.1200/JCO.1994.12.11.2254	30	285	289	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	1997	349	9056					906	910		10.1016/S0140-6736(96)09380-4	http://dx.doi.org/10.1016/S0140-6736(96)09380-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093251				2022-12-28	WOS:A1997WR25400010
J	Doorey, AJ				Doorey, AJ			Normal ECG in patients with severe coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ACUTE MYOCARDIAL-INFARCTION		THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, CARDIOL SECT, PHILADELPHIA, PA 19107 USA	Jefferson University	Doorey, AJ (corresponding author), MED CTR DELAWARE, NEWARK, DE USA.							Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; CHRISTIAN TF, 1994, ANN INTERN MED, V121, P825, DOI 10.7326/0003-4819-121-11-199412010-00001; DEWINTER RJ, 1995, CIRCULATION, V92, P3401, DOI 10.1161/01.CIR.92.12.3401; FISCH C, 1992, HEART DIS TXB CARDIO, P138; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; RUTHERFORD JD, 1992, HEART DIS TXB CARDIO, P1335; TOPAZ O, 1991, AM HEART J, V121, P450, DOI 10.1016/0002-8703(91)90711-P	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					956	956		10.1001/jama.277.12.956	http://dx.doi.org/10.1001/jama.277.12.956			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091658				2022-12-28	WOS:A1997WN99200013
J	Allery, LA; Owen, PA; Robling, MR				Allery, LA; Owen, PA; Robling, MR			Why general practitioners and consultants change their clinical practice: A critical incident	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTINUING MEDICAL-EDUCATION; PERFORMANCE; RESIDENTS	Objective: To describe the complete range of factors which doctors recognise as changing their clinical practice and provide a measure of how often education is involved in change. Design: Interviews using the critical incident technique. Setting: Primary and secondary care. Subjects: Random sample of 50 general practitioners and 50 consultants. Main outcome measures: Categories of reasons for change in clinical practice. Results: Doctors described 361 changes in clinical practice, with an average of 3.0 reasons per change. The three most frequently mentioned reasons were organisational factors, education, and contact with professionals, together accounting for 47.9% of the total number of reasons for change. Education accounted for one sixth (16.9%) of the reasons for change and was involved in one third (37.1%) of the changes. Education was seldom mentioned as a reason for change in referral practice but was more often mentioned in management and prescribing changes. Consultants were influenced by medical journals and scientific conferences, while general practitioners were more influenced by medical newspapers and postgraduate meetings. Conclusions: Education is involved in about a third of changes in clinical practice. The wide range of other factors affecting changes in practice need to be taken into account in providing and evaluating education. The role of education in the numerous changes in clinical practice that currently have no educational component should also be considered.	LLANEDEYRN HLTH CTR, CARDIFF CF3 7PN, S GLAM, WALES		Allery, LA (corresponding author), UNIV WALES COLL MED, SCH POSTGRAD MED & DENT EDUC, CARDIFF CF4 4XN, S GLAM, WALES.		Robling, Michael/B-5516-2009	Robling, Michael/0000-0002-1004-036X; Allery, Lynne/0000-0002-0890-4202				ALTMAIER EM, 1990, PEDIATRICS, V85, P139; Altman D.G., 1991, PRACTICAL STAT MED R; Armstrong D, 1996, BRIT MED J, V312, P949; Beaudry JS, 1989, J CONTIN EDUC HEALTH, V9, P285, DOI DOI 10.1002/CHP.4750090414; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; CALMAN KC, 1991, MED EDUC, V25, P51, DOI 10.1111/j.1365-2923.1991.tb00026.x; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DRAGE M, 1994, ED GEN PRACT, V5, P48; ESCOVITZ GH, 1990, ACAD MED, V65, P545, DOI 10.1097/00001888-199009000-00001; Fitzpatrick R, 1994, Qual Health Care, V3, P107; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Fox RD., 1989, CHANGING LEARNING LI; Graham I, 1996, LANCET, V347, P4, DOI 10.1016/S0140-6736(96)91550-0; HAYES DM, 1979, MED EDUC, V13, P175, DOI 10.1111/j.1365-2923.1979.tb01437.x; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; HUBBARD JP, 1965, NEW ENGL J MED, V272, P1321, DOI 10.1056/NEJM196506242722505; KERR DNS, 1993, BRIT MED J, V306, P1398, DOI 10.1136/bmj.306.6889.1398; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MCLAUGHLIN PJ, 1991, J CONTIN EDUC HEALTH, V11, P65; METCALFE DH, 1995, MED EDUC, V29, P193, DOI 10.1111/j.1365-2923.1995.tb02829.x; Miles M, 1994, QUALITATIVE DATA ANA, Vsecond; Patton M.Q., 1987, USE QUALITATIVE METH; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Robson C., 1993, REAL WORLD RES RESOU; SMITH WL, 1992, AM J ROENTGENOL, V159, P885, DOI 10.2214/ajr.159.4.1529859; STEIN LS, 1981, J MED EDUC, V56, P103; Wergin J. F., 1988, J CONTIN EDUC HEALTH, V8, P147	28	113	118	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	1997	314	7084					870	874						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093100				2022-12-28	WOS:A1997WQ02800030
J	Hawkey, PM				Hawkey, PM			Quinolones in sweat and quinolone resistance	LANCET			English	Editorial Material							COAGULASE-NEGATIVE STAPHYLOCOCCI; AUREUS; MUTATIONS; MUTANTS; GYRA				Hawkey, PM (corresponding author), UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							FERRERO L, 1995, ANTIMICROB AGENTS CH, V39, P1554, DOI 10.1128/AAC.39.7.1554; JAEHDE U, 1995, ANTIMICROB AGENTS CH, V39, P2092, DOI 10.1128/AAC.39.9.2092; KAATZ GW, 1993, ANTIMICROB AGENTS CH, V37, P1086, DOI 10.1128/AAC.37.5.1086; KOTILAINEN P, 1995, CLIN INFECT DIS, V21, P685, DOI 10.1093/clinids/21.3.685; Miller YW, 1996, J ANTIMICROB CHEMOTH, V38, P829; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; Piddock L J, 1995, Drugs, V49 Suppl 2, P29; SREEDHARAN S, 1991, ANTIMICROB AGENTS CH, V35, P2151, DOI 10.1128/AAC.35.10.2151; TAKENOUCHI T, 1995, ANTIMICROB AGENTS CH, V39, P1414, DOI 10.1128/AAC.39.7.1414; Tankovic J, 1996, ANTIMICROB AGENTS CH, V40, P2505, DOI 10.1128/AAC.40.11.2505; WILCOX MH, 1991, J ANTIMICROB CHEMOTH, V27, P685, DOI 10.1093/jac/27.5.685	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					148	149		10.1016/S0140-6736(05)60973-7	http://dx.doi.org/10.1016/S0140-6736(05)60973-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111534				2022-12-28	WOS:A1997WC86100004
J	Sawyers, CL				Sawyers, CL			Molecular genetics of acute leukaemia	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; FUSION TRANSCRIPT; MYELOGENOUS LEUKEMIA; AML1 GENE; PROTEIN; TEL; ABL; TRANSLOCATIONS	The outlook for patients with acute promyelocytic leukaemia has improved vastly with the use of all-trans retinoic acid. The development of this therapeutic agent stemmed from the finding that an abnormality of the retinoic acid receptor is involved in this disease. In the search for other molecular abnormalities in the acute leukaemias that might serve as therapeutic targets, the chromosomal translocations associated with this group of disorders have been helpful in indicating where to look for potential cancer genes. Some common signal-transduction pathways through which different such genes act have been identified, and compounds that interfere with these pathways are already being screened for.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Sawyers, CL (corresponding author), UNIV CALIF LOS ANGELES,DIV HEMATOL ONCOL,DEPT MED,11-934 FACTOR BLDG,10833 LE CONTE AVE,LOS ANGELES,CA 90095, USA.		Sawyers, Charles/G-5327-2016					Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CHEN SJ, 1995, STEM CELLS, V13, P22, DOI 10.1002/stem.5530130104; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOLUB TR, 1996, MOL CELL BIOL, V16, pH107; Hajra A, 1996, CURR TOP MICROBIOL, V211, P289; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; IHIE JN, 1995, TRENDS GENET, V11, P69; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; KUROKAWA M, 1995, ONCOGENE, V11, P833; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PRENDERGAST AM, 1993, CELL, V75, P175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABNITZ JE, 1991, LEUKEMIA, V10, P78; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shuai K, 1996, ONCOGENE, V13, P247; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; ZELEZNIKLE NJ, 1995, SEMIN HEMATOL, V32, P201; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044	40	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					196	200		10.1016/S0140-6736(96)07535-6	http://dx.doi.org/10.1016/S0140-6736(96)07535-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111557				2022-12-28	WOS:A1997WC86100046
J	deRege, PJF; Gladysz, JA; Horvath, IT				deRege, PJF; Gladysz, JA; Horvath, IT			Spectroscopic observation of the formyl cation in a condensed phase	SCIENCE			English	Article							ELECTROPHILIC REACTIONS; AROMATIC-SUBSTITUTION; SUPERACID MEDIA; CARBON-MONOXIDE; PRESSURE; ALKANES; NMR; CARBOCATIONS; ACID; HCO+	The formyl cation, HCO+, has long been believed to be an important intermediate in the chemistry of carbon monoxide (CO) in acidic environments, but its spectroscopic observation in solution has been elusive. This species was generated by the reaction of CO with the liquid superacid hydrofluoric acid-antimony pentafluoride (HF-SbF5) under pressure and was observed by nuclear magnetic resonance and infrared spectroscopy. Equilibria between CO in the gas phase, CO dissolved in HF-SbF5, the SbF5 adduct of formyl fluoride, and HCO+ associated with several equilibrating anions of the type [SbxF5x+1](-) are proposed to describe the system.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112; EXXON RES & ENGN CO,CORP RES LABS,ANNANDALE,NJ 08801	Utah System of Higher Education; University of Utah; Exxon Mobil Corporation			Horvath, Istvan T/M-8428-2013; Horvath, Istvan T/A-6825-2010; Gladysz, John A/B-4347-2015	Horvath, Istvan T/0000-0002-6324-186X; Gladysz, John A/0000-0002-7012-4872				AMANO T, 1983, J CHEM PHYS, V79, P3595, DOI 10.1063/1.446216; BETHELL D, 1979, COMPREHENSIVE ORGANI, V1, P411; Breitmaier E., 1987, CARBON 13 NMR SPECTR; BUHL D, 1970, NATURE, V228, P267, DOI 10.1038/228267a0; Crounse N. N., 1949, ORG REACTIONS, V5, P290; FABRE PL, 1982, CHEM REV, V82, P591, DOI 10.1021/cr00052a003; FAROOQ O, 1988, J AM CHEM SOC, V110, P864, DOI 10.1021/ja00211a027; GATES BC, 1992, CATALYTIC CHEM, pCH3; GILLESPI.RJ, 1966, J CHEM SOC A, P1170, DOI 10.1039/j19660001170; GILLESPIE RJ, 1968, ACCOUNTS CHEM RES, V1, P202, DOI 10.1021/ar50007a002; HARTZ N, 1993, J AM CHEM SOC, V115, P1277, DOI 10.1021/ja00057a009; HEANY H, 1979, COMPREHENSIVE ORGANI, V1, P241; HORVATH IT, 1991, REV SCI INSTRUM, V62, P1104, DOI 10.1063/1.1142016; HORVATH IT, 1991, CHEM REV, V91, P1339, DOI 10.1021/cr00007a003; ILLIES AJ, 1982, J CHEM PHYS, V77, P5847, DOI 10.1063/1.443745; JOST R, 1988, REV CHEM INTERMED, V9, P171, DOI 10.1007/BF03155683; KLEMPERER W, 1970, NATURE, V227, P1230, DOI 10.1038/2271230a0; MACIEL GE, 1970, J AM CHEM SOC, V92, P11, DOI 10.1021/ja00704a002; MACIEL GE, 1990, J AM CHEM SOC, V92, P1; March J., 1992, ADV ORG CHEM, V4th; MULLER N, 1962, J CHEM PHYS, V36, P359, DOI 10.1063/1.1732509; MULLER N, 1963, J PHYS CHEM-US, V67, P112, DOI 10.1021/j100795a026; ODONNEL TA, 1993, SUPERACIDS ACIDIC ME; OLAH G, COMMUNICATION; OLAH GA, 1960, J AM CHEM SOC, V82, P2380, DOI 10.1021/ja01494a065; OLAH GA, 1973, ANGEW CHEM INT EDIT, V12, P173, DOI 10.1002/anie.197301731; OLAH GA, 1973, J AM CHEM SOC, V95, P4960, DOI 10.1021/ja00796a031; OLAH GA, 1963, J AM CHEM SOC, V85, P1328, DOI 10.1021/ja00892a025; OLAH GA, 1968, J AM CHEM SOC, V90, P2726, DOI 10.1021/ja01012a066; OLAH GA, 1976, J AM CHEM SOC, V98, P296, DOI 10.1021/ja00417a080; OLAH GA, 1972, J AM CHEM SOC, V94, P4200, DOI 10.1021/ja00767a027; OLAH GA, 1985, J ORG CHEM, V50, P1483, DOI 10.1021/jo00209a025; OLAH GA, 1987, ACCOUNTS CHEM RES, V20, P422, DOI 10.1021/ar00143a006; OLAH GA, 1987, CHEM REV, V87, P671, DOI 10.1021/cr00080a001; OLAH GA, 1968, J AM CHEM SOC, V90, P933, DOI 10.1021/ja01006a600; OLAH GA, 1993, ANGEW CHEM INT EDIT, V32, P767, DOI 10.1002/anie.199307673; OLAH GA, 1962, J AM CHEM SOC, V84, P1328; OLAH GA, 1985, SUPERACIDS; OLAH GA, 1964, FRIEDEL CRAFTS RELAT, V3, P1153; PRICE NC, 1982, FUNDAMENTALS ENZYMOL, P157; PRITCHARD H, 1968, J CHEM PHYS, V48, P2827, DOI 10.1063/1.1669529; RIMMELIN P, 1981, ORG MAGN RESONANCE, V16, P160, DOI 10.1002/mrc.1270160220; SCHATTE G, 1989, J PHYS CHEM-US, V93, P6025, DOI 10.1021/j100353a019; SOMMER J, 1993, ACCOUNTS CHEM RES, V26, P370, DOI 10.1021/ar00031a003; TANAKA M, 1993, J ORG CHEM, V58, P3213, DOI 10.1021/jo00063a057; TANAKA M, 1995, J ORG CHEM, V60, P3846, DOI 10.1021/jo00117a041; TANAKA M, 1992, J ORG CHEM, V57, P2677, DOI 10.1021/jo00035a024; THAUER RK, 1995, ANGEW CHEM INT EDIT, V34, P2247; WILLNER H, 1992, J AM CHEM SOC, V114, P8972, DOI 10.1021/ja00049a030; WILLNER H, 1990, INORG CHEM, V29, P2195, DOI 10.1021/ic00337a004; WITCOFF HA, 1980, IND CHEM PERSPECTI 1, P226; WOODS RC, 1975, PHYS REV LETT, V35, P1269, DOI 10.1103/PhysRevLett.35.1269; Zhang DL, 1996, INORG CHEM, V35, P6113, DOI 10.1021/ic960525l; [No title captured]	54	41	41	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					776	779		10.1126/science.276.5313.776	http://dx.doi.org/10.1126/science.276.5313.776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115198				2022-12-28	WOS:A1997WW90000052
J	Edwards, RL; Cheng, H; Murrell, MT; Goldstein, SJ				Edwards, RL; Cheng, H; Murrell, MT; Goldstein, SJ			Protactinium-231 dating of carbonates by thermal ionization mass spectrometry: Implications for quaternary climate change	SCIENCE			English	Article							LAST INTERGLACIAL PERIOD; HOLE CALCITE VEIN; U-TH AGES; DEVILS-HOLE; TH-230 AGES; SEA LEVELS; C-14 AGES; CORALS; BARBADOS; SYSTEMATICS	Measurement of protactinium-231 (Pa-231) in carbonates by thermal ionization mass spectroscopy yields Pa-231 ages that are more than 10 times more precise than those determined by decay counting. Carbonates between 10 and 250,000 years old can now be dated with Pa-231 methods. Barbados corals that have identical Pa-231 and thorium-230 (Th-230) ages indicate that the timing of sea level change over parts of the last glacial cycle is consistent with the predictions of the Astronomical Theory. Two Devils Hole calcite subsamples record identical Pa-231 and Th-230 ages, suggesting that the chronology of this climate record is accurate.	LOS ALAMOS NATL LAB, CHEM SCI & TECHNOL DIV, LOS ALAMOS, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Edwards, RL (corresponding author), UNIV MINNESOTA, DEPT GEOL & GEOPHYS, MINNESOTA ISOTOPE LAB, MINNEAPOLIS, MN 55455 USA.		Goldstein, Steven/AAB-8870-2019; CHENG, HAI/H-3413-2017; Edwards, R. Lawrence/I-3124-2014	CHENG, HAI/0000-0002-5305-9458; Edwards, R. Lawrence/0000-0002-7027-5881				ALLEGRE C, 1964, CR HEBD ACAD SCI, V259, P4086; AMIEL AJ, 1973, SEDIMENTOLOGY, V20, P523, DOI 10.1111/j.1365-3091.1973.tb01629.x; ASMEROM Y, 1990, GEOL SOC AM BULL, V102, P961, DOI 10.1130/0016-7606(1990)102<0961:ZUTPAW>2.3.CO;2; BANNER JL, 1991, EARTH PLANET SC LETT, V107, P129, DOI 10.1016/0012-821X(91)90049-N; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; BARD E, 1991, GEOCHIM COSMOCHIM AC, V55, P2385, DOI 10.1016/0016-7037(91)90115-L; BARD E, 1990, NUCL INSTRUM METH B, V52, P461, DOI 10.1016/0168-583X(90)90458-7; BARD E, 1990, NATURE, V346, P456, DOI 10.1038/346456a0; BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; BERGER AL, 1978, QUATERNARY RES, V9, P139, DOI 10.1016/0033-5894(78)90064-9; CHAPPELL J, 1972, Quaternary Research (Orlando), V2, P244, DOI 10.1016/0033-5894(72)90042-7; CHEN JH, 1986, EARTH PLANET SC LETT, V80, P241, DOI 10.1016/0012-821X(86)90108-1; CHEN JH, 1991, GEOL SOC AM BULL, V103, P82, DOI 10.1130/0016-7606(1991)103<0082:PCOTLI>2.3.CO;2; CHENG HY, UNPUB, P5019; CROWLEY TJ, 1994, SCIENCE, V265, P1566, DOI 10.1126/science.265.5178.1566; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; EDWARDS RL, 1988, EARTH PLANET SC LETT, V90, P371, DOI 10.1016/0012-821X(88)90136-7; EDWARDS RL, 1993, SCIENCE, V259, P1626, DOI 10.1126/science.259.5101.1626; EDWARDS RL, 1987, SCIENCE, V236, P1547, DOI 10.1126/science.236.4808.1547; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; GOLDSTEIN SJ, 1989, EARTH PLANET SC LETT, V96, P134, DOI 10.1016/0012-821X(89)90128-3; HAMELIN B, 1991, EARTH PLANET SC LETT, V106, P169, DOI 10.1016/0012-821X(91)90070-X; HENDERSON GM, 1993, EARTH PLANET SC LETT, V115, P65, DOI 10.1016/0012-821X(93)90213-S; IMBRIE J, 1993, NATURE, V363, P531, DOI 10.1038/363531a0; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; KU TL, 1968, J GEOPHYS RES, V73, P2271, DOI 10.1029/JB073i006p02271; LI WX, 1989, NATURE, V339, P534, DOI 10.1038/339534a0; LUDWIG KF, COMMUNICATION; LUDWIG KR, 1993, SCIENCE, V259, P1626, DOI 10.1126/science.259.5101.1626-a; LUDWIG KR, 1992, SCIENCE, V258, P284, DOI 10.1126/science.258.5080.284; PELTIER WR, 1986, J ATMOS SCI, V44, P1351; PICKETT DA, 1994, ANAL CHEM, V66, P1044, DOI 10.1021/ac00079a020; RICHARDS DA, 1994, NATURE, V367, P357, DOI 10.1038/367357a0; RICHARDS DA, 1992, EOS, V73, P172; ROBERT J, 1969, RADIOCHIM ACTA, V11, P104; SACKETT WM, 1958, THESIS WASHINGTON U; Schmorak M. R., 1977, Nuclear Data Sheets, V21, P91, DOI 10.1016/S0090-3752(77)80092-6; SHACKLETON NJ, 1993, NATURE, V362, P596, DOI 10.1038/362596a0; Slowey NC, 1996, NATURE, V383, P242, DOI 10.1038/383242a0; STEIN M, 1993, GEOCHIM COSMOCHIM AC, V57, P2541, DOI 10.1016/0016-7037(93)90416-T; STIRLING CH, 1995, EARTH PLANET SC LETT, V135, P115, DOI 10.1016/0012-821X(95)00152-3; TILTON GR, 1960, J GEOPHYS RES, V65, P2933, DOI 10.1029/JZ065i009p02933; WAINWRIGHT SA, 1963, Q J MICROSC SCI, V104, P169; WASSERBURG GJ, 1963, J GEOPHYS RES, V68, P4823, DOI 10.1029/JZ068i016p04823; WETHERHILL G.W., 1956, EOS T AM GEOPHYS UN, V37, P320, DOI DOI 10.1029/TR037I003P00320; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255	47	152	155	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					782	786		10.1126/science.276.5313.782	http://dx.doi.org/10.1126/science.276.5313.782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115200				2022-12-28	WOS:A1997WW90000054
J	Burke, AP; Farb, A; Malcom, GT; Liang, YH; Smialek, J; Virmani, R				Burke, AP; Farb, A; Malcom, GT; Liang, YH; Smialek, J; Virmani, R			Coronary risk factors and plaque morphology in men with coronary disease who died suddenly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CLINICAL EVENTS; ARTERY DISEASE; ATHEROSCLEROSIS; REDUCTION; DEATH; PRAVASTATIN; ANGINA; DISRUPTION; THERAPY	Background Cigarette smoking and abnormal serum cholesterol concentrations are risk factors for acute coronary syndromes, but the underlying mechanisms are poorly understood. We studied whether cigarette smoking and abnormal cholesterol values may precipitate acute coronary thrombosis and sudden death resulting from either rupture of vulnerable coronary plaques or erosion of plaques. Methods We examined the hearts of 113 men with coronary disease who had died suddenly and also analyzed their coronary risk factors. We found an acute coronary thrombus in each of 59 men, and severe narrowing of the coronary artery by an atherosclerotic plaque without acute thrombosis (stable plaque) in 54. Cases of acute thrombosis were divided into two groups: 41 resulting from rupture of a vulnerable plaque (a thin fibrous cap overlying a lipid-rich core), and 18 resulting from the erosion of a fibrous plaque rich in smooth-muscle cells and proteoglycans. Vulnerable plaques that had not ruptured were counted in each heart. Results Cigarette smoking was a risk factor in 44 (75 percent) of the men with acute thrombosis, as compared with 22 (41 percent) of the men with stable plaques (P<0.001). The mean (+/-SD) ratio of serum total cholesterol to high-density lipoprotein (HDL) cholesterol was markedly elevated in the men who died of acute thrombosis with plaque rupture (8.5+/-4.0) but only mildly elevated in the men without acute thrombosis (5.5+/-2.4, P<0.001) and in the men with thrombi overlying eroded plaques (5.0+/-1.8, P<0.001). Multivariate analysis showed an association between an elevated ratio of serum total cholesterol to HDL cholesterol and the presence of vulnerable plaques (P<0.001). Conclusions Among men with coronary disease who die suddenly, abnormal serum cholesterol concentrations - particularly elevated ratios of total cholesterol to HDL cholesterol - predispose patients to rupture of vulnerable plaques, whereas cigarette smoking predisposes patients to acute thrombosis. (C) 1997, Massachusetts Medical Society.	ARMED FORCES INST PATHOL, DEPT CARDIOVASC PATHOL, WASHINGTON, DC 20306 USA; LOUISIANA STATE UNIV, NEW ORLEANS, LA USA; UNIV MARYLAND, BALTIMORE, MD 21201 USA	United States Department of Defense; Louisiana State University System; University System of Maryland; University of Maryland Baltimore								BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; Burke AP, 1996, CIRCULATION, V94, P3138, DOI 10.1161/01.CIR.94.12.3138; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; CHEN LJ, 1995, CHEST, V108, P364, DOI 10.1378/chest.108.2.364; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; Feld S, 1996, J AM COLL CARDIOL, V28, P97, DOI 10.1016/0735-1097(96)00102-7; FURBERG CD, 1995, AM J CARDIOL, V76, pC60, DOI 10.1016/S0002-9149(99)80472-X; FUSTER V, 1995, AM J CARDIOL, V76, pC24, DOI 10.1016/S0002-9149(99)80467-6; HUNG J, 1995, CIRCULATION, V92, P2432, DOI 10.1161/01.CIR.92.9.2432; KANNEL WB, 1988, AM HEART J, V115, P869, DOI 10.1016/0002-8703(88)90891-5; KITZMAN DW, 1988, MAYO CLIN PROC, V63, P137, DOI 10.1016/S0025-6196(12)64946-5; KJEKSHUS J, 1995, AM J CARDIOL, V76, pC64, DOI 10.1016/S0002-9149(99)80473-1; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; LOREE HM, 1994, ARTERIOSCLER THROMB, V14, P230, DOI 10.1161/01.ATV.14.2.230; MACISAAC AI, 1993, J AM COLL CARDIOL, V22, P1228, DOI 10.1016/0735-1097(93)90442-4; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P431, DOI 10.1161/01.ATV.15.4.431; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; Njolstad I, 1996, CIRCULATION, V93, P450; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Rapaport Elliot, 1996, American Journal of Medicine, V101, p61S, DOI 10.1016/S0002-9343(96)00322-1; RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236; SEGREST JP, 1994, CURR OPIN CARDIOL, V9, P404; SILVA JA, 1995, CIRCULATION, V92, P1731, DOI 10.1161/01.CIR.92.7.1731; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; VAARALA O, 1995, CIRCULATION, V91, P23, DOI 10.1161/01.CIR.91.1.23; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291	34	1231	1298	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1276	1282		10.1056/NEJM199705013361802	http://dx.doi.org/10.1056/NEJM199705013361802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113930				2022-12-28	WOS:A1997WW26000002
J	Horton, R				Horton, R			Conflicts of interest in clinical research: Opprobrium or obsession?	LANCET			English	Editorial Material							OF-INTEREST											Angeli M, 1996, NEW ENGL J MED, V335, P1055, DOI 10.1056/NEJM199610033351410; ANGELL M, 1996, SCI TRIAL CLASH MAT; [Anonymous], 1997, JAMA, V277, P927; HORTON R, 1995, BRIT MED J, V310, P985, DOI 10.1136/bmj.310.6985.985; HUTH E, 1996, CONFLICTS INTEREST C, P389; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; Manson JE, 1996, NEW ENGL J MED, V335, P1064, DOI 10.1056/NEJM199610033351414; Manson JE, 1997, EPIDEMIOLOGY, V8, P324; PITKIN RM, 1995, OBSTET GYNECOL, V86, P293; Rothman KJ, 1997, EPIDEMIOLOGY, V8, P223; SMITH R, 1994, BRIT MED J, V308, P4, DOI 10.1136/bmj.308.6920.4; Tenenbaum SA, 1997, LANCET, V349, P449, DOI 10.1016/S0140-6736(96)07131-0; Willerson JT, 1996, CIRCULATION, V93, P1943; 1996, LANCET, V348, P627	14	53	53	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1112	1113		10.1016/S0140-6736(97)22016-7	http://dx.doi.org/10.1016/S0140-6736(97)22016-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113004				2022-12-28	WOS:A1997WU54400002
J	Leyden, JJ				Leyden, JJ			Therapy for acne vulgaris	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROPIONIBACTERIUM-ACNES; COMPLEMENT ACTIVATION; 13-CIS-RETINOIC ACID; ORAL TETRACYCLINE; TOPICAL TREATMENT; CONGLOBATE ACNE; DOSE-RESPONSE; ISOTRETINOIN; HIRSUTISM; MULTICENTER		HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Leyden, JJ (corresponding author), UNIV PENN, SCH MED, DEPT DERMATOL, 3400 SPRUCE ST, 226 RHOADS PAVIL, PHILADELPHIA, PA 19104 USA.							BLADON PT, 1986, BRIT J DERMATOL, V114, P493, DOI 10.1111/j.1365-2133.1986.tb02856.x; BURKE BM, 1985, BRIT J DERMATOL, V112, P124, DOI 10.1111/j.1365-2133.1985.tb02305.x; CHALKER DK, 1987, J AM ACAD DERMATOL, V17, P251, DOI 10.1016/S0190-9622(87)70200-X; DALZIEL K, 1987, BRIT J DERMATOL, V117, P317, DOI 10.1111/j.1365-2133.1987.tb04138.x; DOWNING DT, 1986, J AM ACAD DERMATOL, V14, P221, DOI 10.1016/S0190-9622(86)70025-X; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; EADY EA, 1988, BRIT J DERMATOL, V118, P415, DOI 10.1111/j.1365-2133.1988.tb02437.x; ESTERLY NB, 1984, ARCH DERMATOL, V120, P1308, DOI 10.1001/archderm.120.10.1308; GOLDSCHMIDT H, 1977, ARCH DERMATOL, V113, P444, DOI 10.1001/archderm.113.4.444; GOODFELLOW A, 1984, BRIT J DERMATOL, V111, P209, DOI 10.1111/j.1365-2133.1984.tb04045.x; HAMMERSTEIN J, 1975, J STEROID BIOCHEM, V6, P827, DOI 10.1016/0022-4731(75)90311-8; HAMMERSTEIN J, 1983, J STEROID BIOCHEM, V19, P591, DOI 10.1016/0022-4731(83)90223-6; HARMS M, 1986, DERMATOLOGICA, V172, P148, DOI 10.1159/000249320; HARRIS HH, 1983, J AM ACAD DERMATOL, V8, P200, DOI 10.1016/S0190-9622(83)70023-X; JONES DH, 1983, BRIT J DERMATOL, V108, P333, DOI 10.1111/j.1365-2133.1983.tb03973.x; KELLY AP, 1971, ARCH DERMATOL, V104, P182, DOI 10.1001/archderm.104.2.182; KLIGMAN AM, 1969, ARCH DERMATOL, V99, P469, DOI 10.1001/archderm.99.4.469; KLIGMAN AM, 1968, ARCH DERMATOL, V98, P53, DOI 10.1001/archderm.98.1.53; KLIGMAN AM, 1975, ACTA DERM-VENEREOL, V55, P111; KNUTSON DD, 1974, J INVEST DERMATOL, V62, P288, DOI 10.1111/1523-1747.ep12676804; KOO JYM, 1991, PEDIATR DERMATOL, V8, P185, DOI 10.1111/j.1525-1470.1991.tb00856.x; KRANING KK, 1979, J INVEST DERMATOL, V73, P395; LANE JM, 1976, J BONE JOINT SURG AM, V58, P673, DOI 10.2106/00004623-197658050-00017; LAVKER RM, 1979, J ULTRA MOL STRUCT R, V69, P362, DOI 10.1016/S0022-5320(79)80053-2; LAYTON AM, 1993, J DERMATOL TREAT S2, V4, pS2; LEHUCHERCEYRAC D, 1981, ANN DERMATOL VENER, V108, P861; LEYDEN JJ, 1975, J INVEST DERMATOL, V65, P382, DOI 10.1111/1523-1747.ep12607634; LEYDEN JJ, 1985, J AM ACAD DERMATOL, V12, P308, DOI 10.1016/S0190-9622(85)80041-4; LEYDEN JJ, 1974, SOUTH MED J, V67, P20, DOI 10.1097/00007611-197401000-00007; LEYDEN JJ, 1983, J AM ACAD DERMATOL, V8, P41, DOI 10.1016/S0190-9622(83)70005-8; Leyden JJ, 1992, CUTIS, V49, P8; MARPLES RR, 1974, J INVEST DERMATOL, V62, P37, DOI 10.1111/1523-1747.ep12676718; MARPLES RR, 1971, ARCH DERMATOL, V103, P148, DOI 10.1001/archderm.103.2.148; MASSA MC, 1982, J AM ACAD DERMATOL, V6, P84, DOI 10.1016/S0190-9622(82)70008-8; MILLER JA, 1986, BRIT J DERMATOL, V114, P705, DOI 10.1111/j.1365-2133.1986.tb04880.x; NAULT P, 1985, ARCH DERMATOL, V121, P662, DOI 10.1001/archderm.121.5.662; O'Leary PA, 1940, ARCH DERMATOL SYPH, V41, P451, DOI 10.1001/archderm.1940.01490090003001; PECK GL, 1979, NEW ENGL J MED, V300, P329, DOI 10.1056/NEJM197902153000701; PLEWIG G, 1975, ACNE MORPHOGENESIS T, P274; PUHVEL SM, 1978, J INVEST DERMATOL, V71, P324, DOI 10.1111/1523-1747.ep12529815; PUHVEL SM, 1966, ARCH DERMATOL, V93, P364, DOI 10.1001/archderm.93.3.364; PYE RJ, 1977, BRIT MED J, V2, P1581, DOI 10.1136/bmj.2.6102.1581; STRAUSS JS, 1974, J INVEST DERMATOL, V62, P321, DOI 10.1111/1523-1747.ep12724280; STRAUSS JS, 1984, J AM ACAD DERMATOL, V10, P490, DOI 10.1016/S0190-9622(84)80100-0; STRAUSS JS, 1964, JAMA-J AM MED ASSOC, V190, P815; STRAUSS JS, 1960, ARCH DERMATOL, V82, P779, DOI 10.1001/archderm.1960.01580050121019; VERSCHOORE M, 1991, BRIT J DERMATOL, V124, P368, DOI 10.1111/j.1365-2133.1991.tb00600.x; VERSCHOORE M, 1993, J INVEST DERMATOL, V100, P221; VOWELS BR, 1995, INFECT IMMUN, V63, P3158, DOI 10.1128/IAI.63.8.3158-3165.1995; WEBSTER GF, 1982, ANTIMICROB AGENTS CH, V21, P770, DOI 10.1128/AAC.21.5.770; WEBSTER GF, 1979, INFECT IMMUN, V26, P183, DOI 10.1128/IAI.26.1.183-186.1979; WEBSTER GF, 1978, INFECT IMMUN, V22, P523, DOI 10.1128/IAI.22.2.523-529.1978; WEBSTER GF, 1980, INFLAMMATION, V4, P261, DOI 10.1007/BF00915027	53	172	187	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1156	1162		10.1056/NEJM199704173361607	http://dx.doi.org/10.1056/NEJM199704173361607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099661				2022-12-28	WOS:A1997WU00300007
J	Weliky, M; Katz, LC				Weliky, M; Katz, LC			Disruption of orientation tuning in visual cortex by artificially correlated neuronal activity	NATURE			English	Article							BASIC NETWORK PRINCIPLES; NEURAL ARCHITECTURE; COLUMNS; CELLS; CONNECTIONS; RECEPTORS; EMERGENCE; MECHANISM; INPUTS; MODEL	In the primary visual cortex, the development of orientation selectivity is influenced by patterns of neural activity. The introduction of artificially correlated activity into the visual pathway (through synchronous activation of retinal ganglion cell axons in the optic nerve) substantially weakens the orientation selectivity of neurons In superficial and deep cortical layers. This is consistent with activity having an instructive role sin shaping cortical neuron receptive field tuning properties.	DUKE UNIV,SCH MED,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University	Weliky, M (corresponding author), DUKE UNIV,SCH MED,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; [Anonymous], [No title captured]; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; Chapman B, 1996, J NEUROSCI, V16, P6443; CHAPMAN B, 1993, J NEUROSCI, V13, P5254; DUBIN MW, 1986, J NEUROSCI, V6, P1021; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; FREGNAC Y, 1981, EXP BRAIN RES, V42, P453; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8779, DOI 10.1073/pnas.83.22.8779; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8390, DOI 10.1073/pnas.83.21.8390; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P303, DOI 10.1152/jn.1983.49.2.303; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1994, J NEUROSCI, V14, P409; MIYASHITA M, 1992, NEUROREPORT, V3, P69, DOI 10.1097/00001756-199201000-00018; NAPLES GG, 1988, IEEE T BIO-MED ENG, V35, P905, DOI 10.1109/10.8670; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; WIESEL TN, 1974, J COMP NEUROL, V158, P308; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; WORGOTTER F, 1991, EXP BRAIN RES, V83, P665	29	152	155	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					680	685		10.1038/386680a0	http://dx.doi.org/10.1038/386680a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109486				2022-12-28	WOS:A1997WU38700046
J	Nesbitt, SA; Horton, MA				Nesbitt, SA; Horton, MA			Trafficking of matrix collagens through bone-resorbing osteoclasts	SCIENCE			English	Article							TRANSFORMING GROWTH-FACTOR-BETA-2; DEGRADATION; RESORPTION	An intracellular pathway for proteins liberated from mineralized matrix during resorption was identified in osteoclasts. Analysis by confocal microscopy of sites of active bone resorption showed that released matrix proteins, including degraded type I collagen, were endocytosed along the ruffled border within the resorption compartment and transcytosed through the osteoclast to the base lateral membrane. Intracellular trafficking of degraded collagen, as typified by the resorbing osteoclast, may provide the cell with a regulatory mechanism for the control of tissue degradation.			Nesbitt, SA (corresponding author), UCL, SCH MED, DEPT MED, BONE & MINERAL CTR, MORTIMER ST, LONDON W1N 8AA, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BILEZIKIAN JP, 1996, PRINCIPLES BONE BIOL; BLAIR HC, 1993, BIOCHEM J, V290, P873, DOI 10.1042/bj2900873; BONDE M, 1994, CLIN CHEM, V40, P2022; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CRITCHLOW MA, 1995, HISTOCHEM J, V27, P505; CRITCHLOW MA, 1994, J CELL SCI, V107, P499; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Foged NT, 1996, J BONE MINER RES, V11, P226; Guerrero R, 1996, OSTEOPOROSIS INT, V6, P297, DOI 10.1007/BF01623388; HELFRICH MH, 1993, J CELL SCI, V104, P663; HOLTROP ME, 1977, CLIN ORTHOP RELAT R, P177; HORTON MA, 1984, J PATHOL, V144, P282; MOSTOV KE, 1995, COLD SPRING HARB SYM, V40, P775; NESBITT SA, UNPUB; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salo J, 1996, J CELL SCI, V109, P301; SIMMONS K, 1985, ANN REV CELL BIOL, V1, P243; VAANANEN HK, 1995, J CELL SCI, V108, P2729; ZHOU H, 1993, CELL MATER, V3, P141	22	305	313	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					266	269		10.1126/science.276.5310.266	http://dx.doi.org/10.1126/science.276.5310.266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092478				2022-12-28	WOS:A1997WT92500049
J	Dearnaley, DP; Melia, J				Dearnaley, DP; Melia, J			Early prostate cancer - To treat or not to treat?	LANCET			English	Editorial Material									INST CANC RES, CANC SCREENING EVALUAT UNIT, SUTTON SM2 5NG, SURREY, ENGLAND	University of London; Institute of Cancer Research - UK	Dearnaley, DP (corresponding author), INST CANC RES, ROYAL MARSDEN NHS TRUST, SUTTON SM2 5NG, SURREY, ENGLAND.		Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806				Adib RS, 1997, BRIT J UROL, V79, P235; Bolla M, 1996, RADIOTHER ONCOL, V40, P233, DOI 10.1016/0167-8140(96)01790-2; CHAMBERLAIN J, 1997, HLTH TECHNOL ASS, V1; Dearnaley D P, 1995, Clin Oncol (R Coll Radiol), V7, P147, DOI 10.1016/S0936-6555(05)80505-9; Schroder FH, 1997, BRIT J UROL, V79, P68, DOI 10.1111/j.1464-410X.1997.tb00804.x; Selley S, 1997, HLTH TECHNOL ASSESS, V1; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8	7	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	1997	349	9056					892	893		10.1016/S0140-6736(97)22013-1	http://dx.doi.org/10.1016/S0140-6736(97)22013-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093244				2022-12-28	WOS:A1997WR25400002
J	Poulsen, AG; Aaby, P; Larsen, O; Jensen, H; Naucler, A; Lisse, IM; Christiansen, CB; Dias, F; Melbye, M				Poulsen, AG; Aaby, P; Larsen, O; Jensen, H; Naucler, A; Lisse, IM; Christiansen, CB; Dias, F; Melbye, M			9-year HIV-2-associated mortality in an urban community in Bissau, west Africa	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; HIV-2 INFECTION; GUINEA-BISSAU; HIV-1-ASSOCIATED MORTALITY; POPULATION; AIDS; TRANSMISSION; PREVALENCE; DISEASE; COHORT	Background Community studies with 1-3 years of follow-up have reported four to five;times higher mortality in HIV-2-infected than in uninfected adults. In a cohort study of HIV-1, an increasing difference in mortality rates of HIV-1-infected and uninfected individuals is expected over lime, because of rising mortality with advancing HIV-1 infection. We therefore investigated long-term survival of HIV-2-infected adults. Methods Adults enrolled in 1987 in a community study of HIV-2 infection in Guinea-Bissau were followed up with serological surveys in 1989 and 1992. Survival was assessed in 1995, 9 years after enrolment. Findings The annual incidence of HIV-2 was 0.7% for adults and tended to be higher for older individuals than for participants aged 15-44 years (relative risk 3.21 [95% CI 0.91-11.37]). With control for age, HIV-2-infected adults had twice as high mortality as uninfected individuals (mortality ratio 2.32 [1.18-4.57]); the mortality ratio was highest in the first year of the study (4.50 [1.31-15.43]). The difference between infected and uninfected individuals was stronger for adults under 45 years of age (mortality ratio 4.72 [1.86-11.97]) than for older people (1.35 [0.51-3.56]). HIV-2-infected individuals living with an infected spouse had significantly higher mortality than HIV-2-infected individuals living with an uninfected spouse (p=0.027). Interpretation HIV-2-associated mortality is not increasing with length of follow-up. Mortality in HIV-2-infected adults is only twice as high as that in uninfected individuals. In the majority of adults, HIV-2 has no effect on survival.	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN S,DENMARK; STATENS SERUM INST,DEPT VIROL,DK-2300 COPENHAGEN S,DENMARK; MINSAP,LAB NACL SAUDE PUBL,BISSAU,GUINEA BISSAU	Aarhus University; Statens Serum Institut; Statens Serum Institut				melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389; Poulsen, Anja/0000-0002-9656-1552				Aaby P, 1996, AIDS, V10, P1585, DOI 10.1097/00002030-199611000-00019; Ariyoshi K, 1996, J INFECT DIS, V173, P245, DOI 10.1093/infdis/173.1.245; BARIN F, 1985, LANCET, V2, P1387; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; Cox D. R., 1984, ANAL SURVIVAL DATA; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; Lisse IM, 1996, J ACQ IMMUN DEF SYND, V13, P355, DOI 10.1097/00042560-199612010-00009; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; MOLBAK K, 1986, LANCET, V2, P1214; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NAUCLER A, 1989, J ACQ IMMUN DEF SYND, V2, P88; NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015	22	117	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					911	914		10.1016/S0140-6736(96)04402-9	http://dx.doi.org/10.1016/S0140-6736(96)04402-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093252				2022-12-28	WOS:A1997WR25400011
J	Wilkinson, D; Sach, ME; Karim, SSA				Wilkinson, D; Sach, ME; Karim, SSA			Examination of attendance patterns before and after introduction of South Africa's policy of free health care for children aged under 6 years and pregnant women	BRITISH MEDICAL JOURNAL			English	Article									HLABISA HOSP,HLABISA,SOUTH AFRICA		Wilkinson, D (corresponding author), MRC,CTR EPIDEMIOL RES SO AFRICA,POB 658,ZA-3937 HLABISA,SOUTH AFRICA.		Karim, Salim Abdool/P-3117-2019; Karim, Salim Abdool/AAE-7118-2019; Wilkinson, David/A-6207-2008; Karim, Salim Safurdeen Abdool/N-5947-2013	Karim, Salim Abdool/0000-0002-4986-2133; Wilkinson, David/0000-0002-7265-9846; Karim, Salim Safurdeen Abdool/0000-0002-4986-2133				GILSON L, 1993, LANCET, V342, P800, DOI 10.1016/0140-6736(93)91560-9; WILKINSON D, IN PRESS S AFR MED	2	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					940	941		10.1136/bmj.314.7085.940	http://dx.doi.org/10.1136/bmj.314.7085.940			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099118	Green Published			2022-12-28	WOS:A1997WQ16900026
J	Tansey, WP; Herr, W				Tansey, WP; Herr, W			TAFs: Guilt by association?	CELL			English	Review							TRANSCRIPTIONAL ACTIVATORS; TBP				Tansey, WP (corresponding author), COLD SPRING HARBOR LAB, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298	20	70	70	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	1997	88	6					729	732		10.1016/S0092-8674(00)81916-9	http://dx.doi.org/10.1016/S0092-8674(00)81916-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118213	Bronze			2022-12-28	WOS:A1997WQ10000002
J	Wang, SW; Krinks, M; Lin, KM; Luyten, FP; Moos, M				Wang, SW; Krinks, M; Lin, KM; Luyten, FP; Moos, M			Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8	CELL			English	Article							XENOPUS-EMBRYOS; EARLY EMBRYOGENESIS; VENTRAL MESODERM; GENE; LAEVIS; LIMB; INDUCTION; XWNT-8; POLARITY; PATTERN	We isolated a Xenopus homolog of Frzb, a newly described protein containing an amino-terminal Frizzled motif. It dorsalized Xenopus embryos and was expressed in the Spemann organizer during early gastrulation. Unlike Frizzled proteins, endogenous Frzb was soluble. Frzb was secretable and could act across cell boundaries. In several functional assays, Frzb antagonized Xwnt-8, a proposed ventralizing factor with an expression pattern complementary to that of Frzb. Furthermore, Frzb blocked induction of MyoD, an action reported recently for a dominant-negative Xwnt-8. Frzb coimmunoprecipitated with Wnt proteins, providing direct biochemical evidence for Frzb-Wnt interactions. These observations implicate Frzb in axial patterning and support the concept that Frzb binds and inactivates Xwnt-8 during gastrulation, preventing inappropriate ventral signaling in developing dorsal tissues.	NIDR,CRANIOFACIAL & SKELETAL DIS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wang, SW (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DEV BIOL LAB,BETHESDA,MD 20892, USA.		Luyten, Frank/GPS-7793-2022; Moos, Malcolm C/F-3673-2011	Moos, Malcolm C/0000-0002-9575-9938; Wang, Shouwen/0000-0001-8484-1795				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DAWID IB, 1994, GROWTH FACTORS SIGNA, P199; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; EVANS JP, 1991, METHOD CELL BIOL, V36, P117; GONT LK, 1993, DEVELOPMENT, V119, P991; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; Gurdon JB, 1967, METHODS DEV BIOL; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Harlow E., 1988, ANTIBODIES LAB MANUA; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KAY BL, 1991, METHOD CELL BIOL, V36, P657; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; MOON RT, 1993, DEVELOPMENT, P85; Moos M, 1995, DEVELOPMENT, V121, P4293; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Sambrook J., 2002, MOL CLONING LAB MANU; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1991, DEVELOPMENT, V112, P747; Saunders Jr J.W., 1968, ECTODERMAL MESODERMA; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Wadsworth WG, 1996, BIOESSAYS, V18, P355, DOI 10.1002/bies.950180505; WANG SW, 1995, BIOTECHNIQUES, V18, P130; Wang YS, 1996, J BIOL CHEM, V271, P4468; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	67	428	466	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					757	766		10.1016/S0092-8674(00)81922-4	http://dx.doi.org/10.1016/S0092-8674(00)81922-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118219	Bronze			2022-12-28	WOS:A1997WQ10000008
J	deKlerk, GJ; Nieuwenhuis, G; Beutler, JJ				deKlerk, GJ; Nieuwenhuis, G; Beutler, JJ			Lesson of the week - Hypokalaemia and hypertension associated with use of liquorice flavoured chewing pum	BRITISH MEDICAL JOURNAL			English	Article							LICORICE	Prolonged ingestion of substances containing glycyrrhizinic acid such as liquorice, is a well known cause of exogenously induced hypermineralocorticoidism. This is characterised by sodium retention, hypokalaemia, hypertension, metabolic alkalosis, and suppression of the renin-aldosterone system.(1) We describe two cases showing that hypokalaemia induced by glycyrrhizinic acid should be considered in patients with hypertension or oedema even if they have not eaten sweets that obviously contain liquorice.	UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,NL-3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center			de Klerk, Geert-Jan/AAL-4416-2021					BERNARDI M, 1994, LIFE SCI, V55, P863, DOI 10.1016/0024-3205(94)90042-6; BIJISMA JA, 1995, 348801005 U HOSP UTR; BLANCHLEY JD, 1980, NEW ENGL J MED, V302, P784; CLYBURN EB, 1995, SEMIN NEPHROL, V15, P72; FARESE RV, 1991, NEW ENGL J MED, V325, P1223, DOI 10.1056/NEJM199110243251706; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; HERMESSE B, 1986, Archives Belges de Medecine Sociale Hygiene Medecine du Travail et Medecine Legale, V44, P60; MICHAUX L, 1993, REV MED INTERNE, V14, P121, DOI 10.1016/S0248-8663(05)81264-0; MOLHUYSEN JA, 1950, LANCET, V2, P381; ROSSEEL M, 1993, LANCET, V341, P175, DOI 10.1016/0140-6736(93)90036-G; SPINKS EA, 1990, FOOD ADDIT CONTAM A, V7, P769, DOI 10.1080/02652039009373939; STEWART PM, 1987, LANCET, V2, P821	12	67	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					731	732		10.1136/bmj.314.7082.731	http://dx.doi.org/10.1136/bmj.314.7082.731			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116553	Green Published			2022-12-28	WOS:A1997WM77600030
J	Wild, S; McKeigue, P				Wild, S; McKeigue, P			Cross sectional analysis of mortality by country of birth in England and Wales, 1970-92	BRITISH MEDICAL JOURNAL			English	Article								Objective: To compare mortalities for selected groups of immigrants with the national average. Design: Analysis of mortality for adults aged 20-69 in 1970-2 and 1989-92 using population data from 1971 and 1991 censuses. Mortality of Scottish and Irish immigrants aged 25-74 was also compared with mortality in Scotland and Ireland for 1991. Setting: England and Wales. Main outcome measures: Standardised mortality ratios for deaths from all causes, ischaemic heart disease, cerebrovascular disease, lung cancer, and breast cancer. Results: In 1989-92 mortality from all causes was higher than the national average for Scottish immigrants, by 32% for men and 36% for women; for Irish immigrants it was higher by 39% for men and 20% for women; and for Caribbean born men it was lower by 23%. Ischaemic heart disease and lung cancer accounted for 30-40% of the excess mortality in Scottish and Irish immigrants. For south Asians, excess mortality from circulatory disease was balanced by lower mortality fr om cancer. Standardised mortality ratios for cerebrovascular disease in 1989-92 were highest for west African immigrants (271 for men and 181 for women). Conclusions: Widening differences in mortality ratios for migrants compared with the general population were not simply due to socioeconomic inequalities. The low mortality from all causes for Caribbean immigrants could largely be attributed to low mortality from ischaemic heart disease, which is unexplained. The excess mortality from cerebrovascular and hypertensive diseases in migrants from both west Africa and the Caribbean suggests that genetic factors underlie the susceptibility to hypertension in people of black African descent.			Wild, S (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELSTEIN AM, 1986, IRISH MED J, V79, P185; BALARAJAN R, 1990, OPCS SERIES DS, V9, P103; Breslow N. E., 1987, STAT METHODS CANC RE, VII, P65; Harding S, 1996, BRIT MED J, V312, P1389, DOI 10.1136/bmj.312.7043.1389; MARMOT MG, 1984, OPCS STUDIES MED POP, V47; *OFF POP CENS SURV, 1993, CENS ETHN GROUP COUN; *OFF POP CENS SURV, 1994, UND GB; PEDOE HT, 1975, LANCET, V1, P833; *POP STAT DIV COLL, 1993, POPULATION TRENDS, V71, P22; RAFTERY J, 1990, SOC SCI MED, V31, P577, DOI 10.1016/0277-9536(90)90093-8; *REG GEN, 1993, NO IR ANN REP 1991; SIMPSON SN, 1994, J ROY STAT SOC A STA, V157, P313; *UN, 1994, 1992 DEM YB; *WHO, 1978, INT CLASS DIS; *WHO, 1992, WORLD HLTH STAT ANN, V1; *WHO, 1974, WORLD HLTH STAT ANN, V1; *WHO, 1994, WORLD HLTH STAT ANN, V1; Wild Sarah H., 1995, Annals of Epidemiology, V5, P432, DOI 10.1016/1047-2797(95)00058-5; World Health Organization, 1967, INT CLASS DIS; 1993, 1991 CENS REP SCOT 1, V1	20	309	311	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					705	710		10.1136/bmj.314.7082.705	http://dx.doi.org/10.1136/bmj.314.7082.705			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116545	Green Published			2022-12-28	WOS:A1997WM77600020
J	Sojka, P; Andersen, PM; Forsgren, L				Sojka, P; Andersen, PM; Forsgren, L			Effects of riluzole on symptom progression in amyotrophic lateral sclerosis	LANCET			English	Article									UMEA UNIV, UNIV HOSP NO SWEDEN, DEPT CLIN PHYSIOL, S-90185 UMEA, SWEDEN	Umea University	Sojka, P (corresponding author), UMEA UNIV, UNIV HOSP NO SWEDEN, NEUROCTR, S-90185 UMEA, SWEDEN.							ANDERSEN PM, 1995, NAT GENET, V10, P61, DOI 10.1038/ng0595-61; ANDRES PL, 1988, NEUROLOGY, V38, P405, DOI 10.1212/WNL.38.3.405; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; PRADAS J, 1993, NEUROLOGY, V43, P751, DOI 10.1212/WNL.43.4.751	4	10	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1997	349	9046					176	177		10.1016/S0140-6736(05)60977-4	http://dx.doi.org/10.1016/S0140-6736(05)60977-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111546				2022-12-28	WOS:A1997WC86100016
J	Ersfeld, K; Gull, K				Ersfeld, K; Gull, K			Partitioning of large and minichromosomes in Trypanosoma brucei	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; DNA; ORGANIZATION; GENES; CYCLE	The Trypanosoma brucei nuclear genome contains about 100 minichromosomes of between 50 to 150 kilobases and about 20 chromosomes of 0.2 to 6 megabase pairs. Minichromosomes contain nontranscribed copies of variant surface glycoprotein (VSG) genes and are thought to expand the VSG gene pool. Varying VSG expression allows the parasite to avoid elimination by the host immune system. The mechanism of inheritance of T. brucei chromosomes was investigated by in situ hybridization in combination with immunofluorescence. The minichromosome population segregated with precision, by association with the central intranuclear mitotic spindle. However, their positional dynamics differed from that of the large chromosomes, which were partitioned by kinetochore microtubules.			Ersfeld, K (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,2 205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.							ALLEVA I, UNPUB; BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; BURRI M, 1995, BIOL CELL, V83, P23, DOI 10.1016/0248-4900(96)89928-X; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; CORDINGLEY JS, 1985, MOL BIOCHEM PARASIT, V17, P321, DOI 10.1016/0166-6851(85)90006-4; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; GOTTESDIENER K, 1990, MOL CELL BIOL, V10, P6079, DOI 10.1128/MCB.10.11.6079; HASAN G, 1984, GENE, V27, P75, DOI 10.1016/0378-1119(84)90240-3; MELVILLE S, COMMUNICATION; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; SASSE R, 1988, J CELL SCI, V90, P577; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; SLOOF P, 1983, J MOL BIOL, V167, P1, DOI 10.1016/S0022-2836(83)80031-X; SOGIN L, 1991, CURR OPIN GENE DEV, V1, P453; SOLARI AJ, 1995, BIOCELL, V19, P65; VANDERPLOEG LHT, 1984, EMBO J, V3, P3109, DOI 10.1002/j.1460-2075.1984.tb02266.x; VANDERPLOEG LHT, 1984, CELL, V37, P77, DOI 10.1016/0092-8674(84)90302-7; VICKERMAN K, 1970, J CELL SCI, V6, P365; VICKERMAN K, 1994, INT J PARASITOL, V24, P1317, DOI 10.1016/0020-7519(94)90198-8; WEIDEN M, 1991, MOL CELL BIOL, V11, P3823, DOI 10.1128/MCB.11.8.3823; WILLIAMS RO, 1982, NATURE, V299, P417, DOI 10.1038/299417a0; ZOMERDIJK JCBM, 1992, NUCLEIC ACIDS RES, V20, P2725, DOI 10.1093/nar/20.11.2725	22	79	82	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					611	614		10.1126/science.276.5312.611	http://dx.doi.org/10.1126/science.276.5312.611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110983				2022-12-28	WOS:A1997WV72100050
J	Feldkamp, M; Jones, KL; Ornoy, A; Pastuszak, A; Rosenwasser, TS; Schick, B; Bar, J				Feldkamp, M; Jones, KL; Ornoy, A; Pastuszak, A; Rosenwasser, TS; Schick, B; Bar, J			Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995 (Reprinted from MMWR, vol 46, pg 240-242, 1997)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									CALIF TERATOGEN INFORMAT SERV,SAN DIEGO,CA; ISRAEL TERATOL INFORMAT SERV,JERUSALEM,ISRAEL; MOTHERISK PROGRAM,TORONTO,ON,CANADA; MASSACHUSETTS TERATOGEN INFORMAT SERV,BOSTON,MA; PREGNANCY HEALTHLINE,PHILADELPHIA,PA; BEILINSON TERATOL INFORMAT SERV,PETAH TIQWA,ISRAEL; CDC,BIRTH DEFECTS & GENET DIS BR,DIV BERTH DEFECTS & DEV DISABIL,NATL CTR ENVIRONM HLTH,ATLANTA,GA 30333	Rabin Medical Center; Centers for Disease Control & Prevention - USA	Feldkamp, M (corresponding author), PREGNANCY RISKLINE,SALT LAKE CITY,UT, USA.		ornoy, asher/J-8038-2018	ornoy, asher/0000-0002-7268-3512				BAKRIS GL, 1993, ANN INTERN MED, V118, P643, DOI 10.7326/0003-4819-118-8-199304150-00013; BARR M, 1994, TERATOLOGY, V50, P399, DOI 10.1002/tera.1420500606; Erickson J D, 1991, Int J Risk Saf Med, V2, P239, DOI 10.3233/JRS-1991-2502; Feldkamp ML, 1997, MMWR-MORBID MORTAL W, V46, P240; KALLEN B, 1991, CONTRACEPTION, V44, P173, DOI 10.1016/0010-7824(91)90117-X; Robert E, 1994, Int J Risk Saf Med, V6, P75, DOI 10.3233/JRS-1994-6201; SHOTAN A, 1994, AM J MED, V96, P451, DOI 10.1016/0002-9343(94)90172-4; VENTURA SJ, 1995, MONTHLY VITAL STAT S, V43	8	27	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1193	1194						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103332				2022-12-28	WOS:A1997WT40300011
J	Cronin, CC; Shanahan, F				Cronin, CC; Shanahan, F			Insulin-dependent diabetes mellitus and coeliac disease	LANCET			English	Editorial Material							CELIAC-DISEASE; PREVALENCE; CHILDREN; ANTIBODIES; ADOLESCENTS; POPULATION		NATL UNIV IRELAND UNIV COLL CORK,CORK,IRELAND	University College Cork	Cronin, CC (corresponding author), CORK UNIV HOSP,DEPT MED,CORK,IRELAND.			Shanahan, Fergus/0000-0003-0467-0936				BARDELLA MT, 1994, ARCH DIS CHILD, V70, P211, DOI 10.1136/adc.70.3.211; BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; CACCIARI E, 1987, ACTA PAEDIATR SCAND, V76, P671, DOI 10.1111/j.1651-2227.1987.tb10542.x; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; COLLIN P, 1989, SCAND J GASTROENTERO, V24, P81, DOI 10.3109/00365528909092243; COOPER BT, 1987, Q J MED, V63, P269; CRONIN CC, 1996, IR J MED SCI S4, V165, P2; DEVITIS I, 1996, GASTROENTEROLOGY S, V110, pA13; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; GADD S, 1992, AUST NZ J MED, V22, P256, DOI 10.1111/j.1445-5994.1992.tb02121.x; GOBBI G, 1992, LANCET, V340, P439; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; KOLETZKO S, 1988, EUR J PEDIATR, V148, P113, DOI 10.1007/BF00445915; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; MAKI M, 1984, ARCH DIS CHILD, V59, P739, DOI 10.1136/adc.59.8.739; MAKI M, 1995, GUT, V36, P239, DOI 10.1136/gut.36.2.239; PAGE SR, 1994, Q J MED, V87, P631; Rensch MJ, 1996, ANN INTERN MED, V124, P564, DOI 10.7326/0003-4819-124-6-199603150-00004; ROSSI TM, 1993, J PEDIATR-US, V123, P262, DOI 10.1016/S0022-3476(05)81699-3; SATEGNAGUIDETTI C, 1994, DIGEST DIS SCI, V39, P1633, DOI 10.1007/BF02087768; Saukkonen T, 1996, DIABETIC MED, V13, P464, DOI 10.1002/(SICI)1096-9136(199605)13:5<464::AID-DIA101>3.0.CO;2-R; SAVILAHTI E, 1986, J PEDIATR-US, V108, P690, DOI 10.1016/S0022-3476(86)81042-3; SHANAHAN F, 1982, Q J MED, V51, P329; SHER KS, 1994, DIGEST DIS, V12, P186, DOI 10.1159/000171452; SIGURS N, 1993, ACTA PAEDIATR, V82, P748, DOI 10.1111/j.1651-2227.1993.tb12551.x; Valdimarsson T, 1996, GUT, V38, P322, DOI 10.1136/gut.38.3.322; VERGE CF, 1994, DIABETOLOGIA, V37, P1113, DOI 10.1007/BF00418375; WALSH CH, 1978, Q J MED, V47, P89	29	181	188	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1096	1097		10.1016/S0140-6736(96)09153-2	http://dx.doi.org/10.1016/S0140-6736(96)09153-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107261				2022-12-28	WOS:A1997WU00200042
J	Poland, GA; Jacobson, RM; Thampy, AM; Colbourne, SA; Wollan, PC; Lipsky, JJ; Jacobsen, SJ				Poland, GA; Jacobson, RM; Thampy, AM; Colbourne, SA; Wollan, PC; Lipsky, JJ; Jacobsen, SJ			Measles reimmunization in children seronegative after initial immunization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	34th Interscience Conference on Antimicrobial Agents and Chemotherapy	OCT 03-07, 1994	ORLANDO, FL				LINKED IMMUNOSORBENT-ASSAY; VACCINE; ANTIBODY; SUSCEPTIBILITY; IMMUNITY; AGE	Objective.-To evaluate the success of measles reimmunization in children without measles antibody after the initial dose of measles vaccine. Design and Setting.-A prospective clinical trial in Olmsted County, Minnesota, and Northern Newfoundland and Labrador in Canada. Subjects.-A total of 130 healthy white, Innu, and Inuit schoolchildren. All subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier. Methods.-Children previously identified as measles antibody seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmunized. Measles antibody was measured a minimum of 6 weeks later using a whole-virus IgG measles-specific enzyme-linked immunoassay (EIA). Results.-Of the 130 children reimmunized, 106 (81.5%) became measles antibody seropositive, but 24 children (18.5%) remained seronegative. Younger age at initial immunization (<13 months vs greater than or equal to 13 months) was significantly associated with lack of seropositive antibody levels following reimmunization (odds ratio, 3.9; 95% confidence interval, 1.5-9.7). In addition, antibody levels after reimmunization were significantly reduced with increasing time since initial immunization (P=.001). Conclusions.-After 2 doses of measles vaccine, 98.2% of all subjects in this study were seropositive for measles antibody, despite the fact that almost 20% of children did not have measurable antibodies 4 to 11 years following a first dose, These findings suggest that the current public health policy recommending a 2-dose measles immunization strategy, with the second dose given at school entry, will provide high levels of immunity in the community.	MAYO CLIN & MAYO FDN,MAYO VACCINE RES GRP,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PEDIAT & ADOLESCENT MED,ROCHESTER,MN 55905; GRENFELL REG HLTH SERV,ST ANTHONY,NF,CANADA; DEPT INTERNAL MED,ST ANTHONY,NF,CANADA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Poland, GA (corresponding author), MAYO CLIN & MAYO FDN,CLIN PHARMACOL UNIT,601B GUGGENHEIM BLDG,200 1ST ST SW,ROCHESTER,MN 55905, USA.			Jacobsen, Steven/0000-0002-8174-8533; Jacobson, Robert/0000-0002-6355-8752	NIAID NIH HHS [AI33144] Funding Source: Medline; NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM AC PED, 1991, REP COMM INF DIS, P1; ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; BARKIN RM, 1975, AM J EPIDEMIOL, V102, P341, DOI 10.1093/oxfordjournals.aje.a112170; BOTELER WL, 1983, J CLIN MICROBIOL, V17, P814, DOI 10.1128/JCM.17.5.814-818.1983; BRUNELL PA, 1988, PEDIATRICS, V81, P722; BRUNELL PA, 1990, PEDIATRICS, V86, P474; BRUNELL PA, 1990, MEASLES CONTROL 1990, P1; *CDC, 1990, MMWR-MORBID MORTAL W, V39, P353; *CDC, 1978, MMWR-MORBID MORTAL W, V27, P391; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P369; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; COLBOURNE SA, 1992, P 26 NATL IMM C, P200; DESEDATOUS J, 1978, AM J DIS CHILD, V132, P287, DOI 10.1001/archpedi.1978.02120280071015; *DIV MICR INF DIS, 1995, JORD REP ACC DEV VAC, P1; JACOBSON RM, 1991, CLIN RES, V39, pA637; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; LINNEMANN CC, 1982, PEDIATRICS, V69, P332; MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MATHIAS RG, 1989, AM J PUBLIC HEALTH, V79, P475, DOI 10.2105/AJPH.79.4.475; MCGRAW TT, 1986, PEDIATRICS, V77, P45; MURPHY MD, 1984, PEDIATRICS, V74, P90; POLAND GA, 1991, CLIN RES, V39, pA639; RATNAM S, 1994, MEASLES UPDATE, V3, P4; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; SMOAK BL, 1994, J INFECT DIS, V170, P216, DOI 10.1093/infdis/170.1.216; STETLER HC, 1986, PEDIATRICS, V77, P471; WEIGLE KA, 1984, J CLIN MICROBIOL, V19, P376, DOI 10.1128/JCM.19.3.376-379.1984; WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6	30	52	55	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1156	1158		10.1001/jama.277.14.1156	http://dx.doi.org/10.1001/jama.277.14.1156			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087472				2022-12-28	WOS:A1997WR34200036
J	Hampton, KK; Preston, FE				Hampton, KK; Preston, FE			ABC of clinical haematology - Bleeding disorders, thrombosis, and anticoagulation	BRITISH MEDICAL JOURNAL			English	Article											Hampton, KK (corresponding author), ROYAL HALLAMSHIRE HOSP,DEPT HAEMATOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1026	1029		10.1136/bmj.314.7086.1026	http://dx.doi.org/10.1136/bmj.314.7086.1026			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112850	Green Published			2022-12-28	WOS:A1997WT15200029
J	Evangelista, M; Blundell, K; Longtine, MS; Chow, CJ; Adames, N; Pringle, JR; Peter, M; Boone, C				Evangelista, M; Blundell, K; Longtine, MS; Chow, CJ; Adames, N; Pringle, JR; Peter, M; Boone, C			Bni1p, a yeast formin linking Cdc42p and the actin cytoskeleton during polarized morphogenesis	SCIENCE			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE GENE; MAP KINASE CASCADE; BUD-SITE SELECTION; CELL POLARITY; MUTATIONAL ANALYSIS; PHEROMONE-RESPONSE; ACTIVATING PROTEIN; BUDDING YEAST; IDENTIFICATION	The Saccharomyces cerevisiae BNI1 gene product (Bni1p) is a member of the formin family of proteins, which participate in cell polarization, cytokinesis, and vertebrate limb formation. During mating pheromone response, bni1 mutants showed defects both in polarized morphogenesis and in reorganization of the underlying actin cytoskeleton, In two-hybrid experiments, Bni1p formed complexes, with the activated form of the Rho-related guanosine triphosphatase Cdc42p, with actin, and with two actin-associated proteins, profilin and Bud6p (Aip3p). Both Bni1p and Bud6p (like Cdc42p and actin) localized to the tips of mating projections. Bni1p may function as a Cdc42p target that links the pheromone response pathway to the actin cytoskeleton.	SIMON FRASER UNIV, INST MOL BIOL & BIOCHEM, BURNABY, BC V5A 1S6, CANADA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	Simon Fraser University; University of North Carolina; University of North Carolina Chapel Hill; Swiss Institute Experimental Cancer Research			Adames, Neil/C-8863-2012; Adames, Neil/AAO-7913-2020; Adames, Neil/S-1460-2017	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031006, R37GM031006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; AMBERG DC, IN PRESS MOL BIOL CE; BOONE C, 1992, NUCLEIC ACIDS RES, V20, P4661, DOI 10.1093/nar/20.17.4661; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHANG F, IN PRESS J CELL BIOL; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1994, GENETICS, V136, P1287; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EVANGELISTA M, UNPUB; FARES H, UNPUB; GEITZ RD, 1988, GENE, V74, P527; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HARRIS SD, IN PRESS EMBO J; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Imai J, 1996, GENETICS, V142, P359; James P, 1996, GENETICS, V144, P1425; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kaiser DA, 1996, J MOL BIOL, V256, P89, DOI 10.1006/jmbi.1996.0070; Kirchhausen T, 1996, CURR BIOL, V6, P676, DOI 10.1016/S0960-9822(09)00447-3; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; LIU HP, 1992, GENETICS, V132, P665; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Manseau L, 1996, DEVELOPMENT, V122, P2109; MARHOUL JF, 1995, GENETICS, V139, P537; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PETERSEN J, 1995, MOL CELL BIOL, V15, P3697; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WERTMAN KF, 1992, GENETICS, V132, P337; Yang S, 1997, J CELL BIOL, V136, P111, DOI 10.1083/jcb.136.1.111; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	72	527	530	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					118	122		10.1126/science.276.5309.118	http://dx.doi.org/10.1126/science.276.5309.118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082982				2022-12-28	WOS:A1997WR38600060
J	Zadina, JE; Hackler, L; Ge, LJ; Kastin, AJ				Zadina, JE; Hackler, L; Ge, LJ; Kastin, AJ			A potent and selective endogenous agonist for the mu-opiate receptor	NATURE			English	Article							TYR-W-MIF-1; ANALOGS; TYR-PRO-TRP-GLY-NH2; HEMOGLOBIN; TYR-MIF-1; ANALGESIA; ASSAY	Peptides have been identified in mammalian brain that are considered to be endogenous agonists for the delta (enkephalins) and kappa (dynorphins) opiate receptors, but none has been found to have any preference for the mu receptor(1-3). Because morphine and other compounds that are clinically useful and open to abuse act primarily at the mu receptor(4), it could be important to identify endogenous peptides specific for this site. Here we report the discovery and isolation from brain of such a peptide, endomorphin-1 (Tyr-Pro-Trp-Phe-NH2), which has a high affinity (K-i = 360 pM) and selectivity (4,000- and 15,000-fold preference over the delta and kappa receptors) for the mu, receptor. This peptide is more effective than the mu-selective analogue DAMGO in vitro and it produces potent and prolonged analgesia in mice. A second peptide, endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), which differs by one amino acid, was also isolated. The new peptides have the highest specificity and affinity for the mu receptor of any endogenous substance so far described and they maybe natural ligands fbr this receptor.	TULANE UNIV, SCH MED, NEW ORLEANS, LA 70146 USA	Tulane University	Zadina, JE (corresponding author), VET AFFAIRS MED CTR, NEW ORLEANS, LA 70146 USA.		Ge, Li/T-3955-2018	Ge, Li/0000-0002-1824-8034				AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; BRANTL V, 1984, EUR J PHARMACOL, V106, P213, DOI 10.1016/0014-2999(84)90702-7; BRANTL V, 1986, EUR J PHARMACOL, V125, P309, DOI 10.1016/0014-2999(86)90044-0; BUSCHER HH, 1976, NATURE, V261, P423, DOI 10.1038/261423a0; Corbett A.D., 1993, OPIOIDS, P645, DOI [10.1007/978-3-642-77460-7_26, DOI 10.1007/978-3-642-77460-7_26]; ELDE R, 1995, DIVERSITY INTERACTIN, P390; ERCHEGYI J, 1992, INT J PEPT PROT RES, V39, P477; ERCHEGYI J, 1993, PEPTIDE RES, V6, P31; ERCHEGYI J, 1992, PEPTIDES, V13, P623, DOI 10.1016/0196-9781(92)90165-Y; EVANS CJ, 1988, OPIATE RECEPTORS, P23; Gergen KA, 1996, EUR J PHARMACOL, V298, P235, DOI 10.1016/0014-2999(95)00823-3; Gergen KA, 1996, EUR J PHARMACOL, V316, P33, DOI 10.1016/S0014-2999(96)00656-5; GLAMSTA EL, 1991, REGUL PEPTIDES, V34, P169, DOI 10.1016/0167-0115(91)90176-H; HACKLER L, 1993, NEUROPEPTIDES, V24, P159, DOI 10.1016/0143-4179(93)90080-T; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; HAMEL E, 1984, NATURE, V312, P155, DOI 10.1038/312155a0; HERKENHAM M, 1991, ADV NEUROSC, V1, P63; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lenz G. R., 1986, OPIATES; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; SCHILLER PW, 1978, J MED CHEM, V21, P1110, DOI 10.1021/jm00209a004; WANG JX, 1993, INT J PEPT PROT RES, V42, P384; YAMAZAKI T, 1993, J MED CHEM, V36, P708, DOI 10.1021/jm00058a007; YOBURN BC, 1985, BRAIN RES, V331, P327, DOI 10.1016/0006-8993(85)91558-6; Zadina JE, 1996, NEUROSCI LETT, V215, P65, DOI 10.1016/S0304-3940(96)12928-1; ZADINA JE, 1992, LIFE SCI, V51, P869, DOI 10.1016/0024-3205(92)90615-V; ZADINA JE, 1993, NEUROSCI LETT, V155, P220, DOI 10.1016/0304-3940(93)90712-T; ZADINA JE, 1994, LIFE SCI, V55, P461	30	1160	1245	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	1997	386	6624					499	502		10.1038/386499a0	http://dx.doi.org/10.1038/386499a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087409				2022-12-28	WOS:A1997WR25600053
J	Dong, ZY; Kumar, R; Yang, XL; Fidler, IJ				Dong, ZY; Kumar, R; Yang, XL; Fidler, IJ			Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma	CELL			English	Article							HUMAN ALVEOLAR MACROPHAGES; 2ND TUMOR CHALLENGE; CANCER METASTASIS; MOUSE MACROPHAGE; STIMULATING FACTOR; GENE-EXPRESSION; IV COLLAGENASE; MURINE TUMORS; CELLS; ELASTASE	To determine the mechanism responsible for the in vivo production of angiostatin that inhibits growth and metastasis in Lewis lung carcinoma (3LL), we implanted 3LL variant cells into the subcutis of syngeneic C57BL/6 mice. The tumors were infiltrated by macrophages and expressed high levels of steady-state mRNA for metalloelastase (MME). Successive passages (more than three) of cultures established from the tumors resulted in complete depletion of macrophages; steady-state MME mRNA, elastinolytic activity, and production of angiostatin (in the presence of plasminogen) were correspondingly reduced. Coculture of macrophages with either 3LL cells or their conditioned media containing granulocyte-macrophage colony-stimulating factor resulted in secretion of MME and production of angiostatin by the macrophages, suggesting that angiostatin is produced by tumor-infiltrating macrophages whose MME expression is stimulated by tumor cell-derived granulocyte-macrophage colony-stimulating factor.			Dong, ZY (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA 16672, R35-CA42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKERMAN SL, 1986, JNCI-J NATL CANCER I, V77, P915; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BANDA MJ, 1983, J EXP MED, V157, P1184, DOI 10.1084/jem.157.4.1184; BANDA MJ, 1980, J EXP MED, V152, P1563, DOI 10.1084/jem.152.6.1563; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BUCANA CD, 1992, AM J PATHOL, V141, P1225; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; DONG Z, 1993, J EXP MED, V173, P1071; DONG ZY, 1994, JNCI-J NATL CANCER I, V86, P913, DOI 10.1093/jnci/86.12.913; Dong ZY, 1995, J LEUKOCYTE BIOL, V58, P725, DOI 10.1002/jlb.58.6.725; Fidler I J, 1994, Adv Pharmacol, V30, P271, DOI 10.1016/S1054-3589(08)60177-5; FIDLER IJ, 1985, CANCER RES, V45, P4714; FIDLER IJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P151, DOI 10.1016/0304-419X(88)90009-1; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FISHER B, 1989, CANCER RES, V49, P1996; Gately S, 1996, CANCER RES, V56, P4887; GORELIK E, 1978, INT J CANCER, V21, P617, DOI 10.1002/ijc.2910210512; GORELIK E, 1981, INT J CANCER, V27, P847, DOI 10.1002/ijc.2910270618; GORELIK E, 1983, CANCER RES, V43, P138; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GORELLK E, 1980, J NATL CANCER I, V65, P1257; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; JONES PDE, 1977, BRIT J CANCER, V35, P519, DOI 10.1038/bjc.1977.85; KATSUDA S, 1994, AM J PATHOL, V145, P1208; KELLER R, 1982, ADV EXP MED BIOL, V155, P289; Kumar R, 1996, J IMMUNOL, V157, P5104; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LEVY AT, 1991, CANCER RES, V51, P439; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MANTOVANI A, 1980, INT J CANCER, V25, P617, DOI 10.1002/ijc.2910250511; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NORMANN SJ, 1985, CANCER METAST REV, V4, P277, DOI 10.1007/BF00048093; OHLSSON K, 1974, SCAND J CLIN LAB INV, V34, P349, DOI 10.3109/00365517409049891; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; POLVERINI PJ, 1989, MACROPHAGE DERIVED C, P54; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PREHN RT, 1993, CANCER RES, V53, P3266; PREHN RT, 1991, CANCER RES, V51, P2; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; Shipley JM, 1996, J BIOL CHEM, V271, P4335; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SHOTTON D M, 1970, Nature (London), V225, P802, DOI 10.1038/225802a0; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; TAKEDA K, 1991, JPN J CANCER RES, V82, P1299, DOI 10.1111/j.1349-7006.1991.tb01796.x; TAKEDA K, 1991, INT J CANCER, V47, P413, DOI 10.1002/ijc.2910470318; TALMADGE JE, 1982, J NATL CANCER I, V69, P975; TALMADGE JE, 1981, J IMMUNOL, V126, P2245; Tyzzer EE, 1913, J MED RES, V28, P309; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WERB Z, 1986, HDB EXPT IMMUNOLOGY, V2; WHITWORTH PW, 1990, CANCER METAST REV, V8, P319, DOI 10.1007/BF00052607; XIE B, 1994, J IMMUNOL, V152, P3637; YOUNG MRI, 1992, INT J CANCER, V50, P628, DOI 10.1002/ijc.2910500424	62	419	451	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					801	810		10.1016/S0092-8674(00)81926-1	http://dx.doi.org/10.1016/S0092-8674(00)81926-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118223	Bronze			2022-12-28	WOS:A1997WQ10000012
J	Little, P; Williamson, I; Warner, G; Gould, C; Gantley, M; Kinmonth, AL				Little, P; Williamson, I; Warner, G; Gould, C; Gantley, M; Kinmonth, AL			Open randomised trial of prescribing strategies in managing sore throat	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOLYTIC STREPTOCOCCAL PHARYNGITIS; ACUTE OTITIS-MEDIA; GENERAL-PRACTICE; RHEUMATIC-FEVER; ANTIBIOTICS; DIAGNOSIS; PENICILLIN; MANAGEMENT; IMMEDIATE	Objective: To assess three prescribing strategies for sore throat Design: Randomised follow up study. Setting: 11 general practices in the South and West region. Subjects: 716 patients aged 4 years and over with sore throat and an abnormal physical sign in the throat; 84% had tonsillitis or pharyngitis. Patients were randomised to three groups: prescription for antibiotics for 10 days (group 1, 246 patients); no prescription (group 2, 230 patients); or prescription for antibiotics if symptoms were not starting to settle after three days (group 3; 238 patients). Main outcome measures: Duration of symptoms; satisfaction and compliance with and perceived efficacy of antibiotics; time off school or work. Outcomes were documented in 582 subjects (81%). Results: Median duration of antibiotic use differed significantly in the three groups (10 v 0 v 0 days, P<0.001); 69% of patients in group 3 did not use their prescription, The proportion of patients better by day 3 did not differ significantly (37% v 35% v 30%, P=0.28), nor did the duration of illness (median 4 v 5 v 5 days, P=0.39), days off work or school (median 2 v 2 v 1, P=0.13), or proportion of patients satisfied (96% v 90% v 93%, P=0.09), although group 1 had fewer days of fever (median 1 v 2 v 2 days, P=0.04). More patients in group 1 thought the antibiotics were effective (87% v 55% v 60%, P<0.001) and intended coming to the doctor in future attacks (79% v 54% v 57%, P<0.001). ''Legitimation'' of illness-to explain to work or school (60%) or family or friends (37%)-was an important reason for consultation. Patients who were more satisfied got better more quickly, and satisfaction related strongly to how well the doctor dealt with patient's concerns. Conclusion: Prescribing antibiotics for sore throat only marginally affects the resolution of symptoms but enhances belief in antibiotics and intention to consult in future when compared with the acceptable strategies of no prescription or delayed prescription. Psychosocial factors are important in the decision to see a general practitioner and in predicting the duration of illness.			Little, P (corresponding author), UNIV SOUTHAMPTON, FAC HLTH MED & BIOL SCI, ALDERMOOR HLTH CTR, SOUTHAMPTON SO16 5ST, HANTS, ENGLAND.			Little, Paul/0000-0003-3664-1873				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BREESE BB, 1977, AM J DIS CHILD, V131, P514, DOI 10.1001/archpedi.1977.02120180028003; BURKE P, 1988, BRIT MED J, V296, P1646, DOI 10.1136/bmj.296.6637.1646; CAPLAN C, 1979, J FAM PRACTICE, V8, P485; CARR NF, 1994, BRIT J GEN PRACT, V44, P515; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; Centor R M, 1981, Med Decis Making, V1, P239, DOI 10.1177/0272989X8100100304; CHANCELLOR AHB, 1965, ANN GEN PRACT, V10, P88; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Dagnelie CF, 1996, BRIT J GEN PRACT, V46, P589; DAY SJ, 1989, BMJ-BRIT MED J, V299, P663, DOI 10.1136/bmj.299.6700.663; DELMAR C, 1992, MED J AUSTRALIA, V156, P572, DOI 10.5694/j.1326-5377.1992.tb121422.x; DELMAR C, 1992, MED J AUSTRALIA, V156, P644, DOI 10.5694/j.1326-5377.1992.tb121463.x; ELDAHER NT, 1991, PEDIATR INFECT DIS J, V10, P126, DOI 10.1097/00006454-199102000-00010; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; FRY J., 1969, MED 3 SOC; GERBER MA, 1990, J PEDIATR-US, V117, P853, DOI 10.1016/S0022-3476(05)80121-0; HERZ MJ, 1988, FAM PRACT, V5, P196, DOI 10.1093/fampra/5.3.196; Howie J G, 1973, J R Coll Gen Pract, V23, P895; HOWIE JGR, 1985, J ROY COLL GEN PRACT, V35, P223; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; Kincey J, 1975, J R Coll Gen Pract, V25, P558; KISELICA D, 1994, AM FAM PHYSICIAN, V49, P1147; LITTLE PS, 1994, BRIT MED J, V309, P1010, DOI 10.1136/bmj.309.6960.1010; Office of Population Censuses and Surveys, 1994, MORB STAT GEN PRACT; Parsons T., 1951, SOCIAL SYSTEM; PICHICHERO ME, 1987, PEDIATR INFECT DIS J, V6, P635, DOI 10.1097/00006454-198707000-00004; PITTS J, 1987, PRACTITIONER, V231, P1232; ROGERS M, 1992, PAED NURS, P4; SCHWARTZMAN P, 1994, BRIT MED J, V309, P1011; SIEGEL AC, 1961, NEW ENGL J MED, V265, P566, DOI 10.1056/NEJM196109212651202; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; TAYLOR JL, 1983, J ROY COLL GEN PRACT, V33, P783; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; VALKENBURG HA, 1971, J INFECT DIS, V124, P348, DOI 10.1093/infdis/124.4.348; WHITFIELD MJ, 1981, PRACTITIONER, V2, P1061; 1995, DRUGS THERAPEUTICS B, V33, P9	37	266	274	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 8	1997	314	7082					722	727		10.1136/bmj.314.7082.722	http://dx.doi.org/10.1136/bmj.314.7082.722			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116551	Green Published			2022-12-28	WOS:A1997WM77600027
J	Stupp, SI; LeBonheur, V; Walker, K; Li, LS; Huggins, KE; Keser, M; Amstutz, A				Stupp, SI; LeBonheur, V; Walker, K; Li, LS; Huggins, KE; Keser, M; Amstutz, A			Supramolecular materials: Self-organized nanostructures	SCIENCE			English	Article							2ND-HARMONIC GENERATION; 2-DIMENSIONAL POLYMERS; THIN-FILMS; STRATEGY	Miniaturized triblock copolymers have been found to self-assemble into nanostructures that are highly regular in size and shape. Mushroom-shaped supramolecular structures of about 200 kilodaltons form by crystallization of the chemically identical blocks and self-organize into films containing 100 or more layers stacked in a polar arrangement. The polar supramolecular material exhibits spontaneous second-harmonic generation from infrared to green photons and has an adhesive tape-like character with nonadhesive-hydrophobic and hydrophilic-sticky opposite surfaces. The films also have reasonable shear strength and adhere tenaciously to glass surfaces on one side only. The regular and finite size of the supramolecular units is believed to be mediated by repulsive forces among some of the segments in the triblock molecules. A large diversity of multifunctional materials could be formed from regular supramolecular units weighing hundreds of kilodaltons.			Stupp, SI (corresponding author), UNIV ILLINOIS,DEPT MAT SCI & ENGN,DEPT CHEM,BECKMAN INST ADV SCI & TECHNOL,1304 W GREEN ST,URBANA,IL 61801, USA.		Stupp, Samuel/AGV-1942-2022; Stupp, Samuel/B-6737-2009					ELMAN JF, 1994, MACROMOLECULES, V27, P5341, DOI 10.1021/ma00097a013; Hoshi H, 1996, PHYS REV B, V53, P12663, DOI 10.1103/PhysRevB.53.12663; HOSHI H, 1995, PHYS REV B, V52, P12335; KATO T, 1989, J AM CHEM SOC, V111, P8533, DOI 10.1021/ja00204a044; KESER M, UNPUB; KUMAGAI K, 1993, PHYS REV B, V48, P14488, DOI 10.1103/PhysRevB.48.14488; KUMAR U, 1992, J AM CHEM SOC, V114, P6630, DOI 10.1021/ja00043a004; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; MANSSON P, 1980, J POLYM SCI POL CHEM, V18, P1945, DOI 10.1002/pol.1980.170180630; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4326, DOI 10.1021/ja00089a022; MISELL DL, 1978, PRACTICAL METHODS EL, V7; MOORE JS, 1990, MACROMOLECULES, V23, P65, DOI 10.1021/ma00203a013; Morton M, 1983, ANIONIC POLYMERIZATI; Pimentel G.C., 1960, HYDROGEN BOND; QUIRK RP, 1989, MACROMOLECULES, V22, P85, DOI 10.1021/ma00191a017; RADZILOWSKI LH, 1994, MACROMOLECULES, V27, P7747, DOI 10.1021/ma00104a033; RADZILOWSKI LH, IN PRESS MACROMOLECU; Rosenfeld A., 1982, DIGITAL PICTURE PROC, V1; Russ J. C., 2016, IMAGE PROCESSING HDB, V7th; SETO CT, 1993, J AM CHEM SOC, V115, P1321, DOI 10.1021/ja00057a015; STUPP SI, 1993, SCIENCE, V259, P59, DOI 10.1126/science.259.5091.59; STUPP SI, 1995, J AM CHEM SOC, V117, P5212, DOI 10.1021/ja00124a005; SZWARC M, 1968, CARBANIONS LIVING PO; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; WILK D, 1995, PHYS REV B, V51, P10057, DOI 10.1103/PhysRevB.51.10057; WU S, 1985, POLYM INTERFACE ADHE; Zimmerman SC, 1996, SCIENCE, V271, P1095, DOI 10.1126/science.271.5252.1095	27	1001	1038	10	383	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					384	389		10.1126/science.276.5311.384	http://dx.doi.org/10.1126/science.276.5311.384			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103190				2022-12-28	WOS:A1997WU47700030
J	Zhang, JR; Hardham, JM; Barbour, AG; Norris, SJ				Zhang, JR; Hardham, JM; Barbour, AG; Norris, SJ			Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes	CELL			English	Article							HUMAN EPITHELIAL-CELLS; NEISSERIA-GONORRHOEAE; SURFACE PROTEIN; IMMUNOCOMPETENT MICE; RELAPSING FEVER; BURGDORFERI; GENES; HERMSII; PILUS; EXPRESSION	We have identified and characterized an elaborate genetic system in the Lyme disease spirochete Borrelia burgdorferi that promotes extensive antigenic variation of a surface-exposed lipoprotein, VlsE. A 28 kb linear plasmid of B. burgdorferi B31 (Ip28-1) was found to contain a vmp-like sequence (vls) locus that closely resembles the variable major protein (vmp) system for antigenic variation of relapsing fever organisms. Portions of several of the 15 nonexpressed (silent) vls cassette sequences located upstream of vlsE recombined into the central vlsE cassette region during infection of C3H/HeN mice, resulting in antigenic variation of the expressed lipoprotein. This combinatorial variation could potentially produce millions of antigenic variants in the mammalian host.	UNIV TEXAS, SCH MED, DEPT MICROBIOL & MOL GENET, HOUSTON, TX 77030 USA; UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOL GENET, IRVINE, CA 92697 USA	University of Texas System; University of California System; University of California Irvine	Zhang, JR (corresponding author), UNIV TEXAS, SCH MED, DEPT PATHOL & LAB MED, HOUSTON, TX 77030 USA.		Norris, Steven James/K-6586-2019; Barbour, Alan/B-3160-2009	Norris, Steven James/0000-0002-2501-8034; Barbour, Alan/0000-0002-0719-5248	NIAID NIH HHS [AI24424, AI37277, R01 AI037277] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037277, R56AI037277, R37AI024424, R01AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barbour A G, 1993, Trends Microbiol, V1, P236, DOI 10.1016/0966-842X(93)90139-I; BARBOUR AG, 1991, MOL MICROBIOL, V5, P489, DOI 10.1111/j.1365-2958.1991.tb02132.x; BARBOUR AG, 1991, INFECT IMMUN, V59, P390, DOI 10.1128/IAI.59.1.390-397.1991; BARTHOLD SW, 1993, INFECT IMMUN, V61, P4955, DOI 10.1128/IAI.61.12.4955-4961.1993; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; Carroll JA, 1996, INFECT IMMUN, V64, P392, DOI 10.1128/IAI.64.2.392-398.1996; CASJENS S, 1995, J BACTERIOL, V177, P2769, DOI 10.1128/jb.177.10.2769-2780.1995; DEMOLIS N, 1995, BIOTECHNIQUES, V18, P453; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; HINNEBUSCH J, 1990, MOL MICROBIOL, V4, P811, DOI 10.1111/j.1365-2958.1990.tb00651.x; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; KOOMEY M, 1987, GENETICS, V117, P391; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; LIVEY I, 1995, MOL MICROBIOL, V18, P257, DOI 10.1111/j.1365-2958.1995.mmi_18020257.x; MARCONI RT, 1993, INFECT IMMUN, V61, P2611, DOI 10.1128/IAI.61.6.2611-2617.1993; MARCONI RT, 1994, J BACTERIOL, V176, P4572, DOI 10.1128/JB.176.15.4572-4582.1994; MEYER TF, 1982, CELL, V30, P45, DOI 10.1016/0092-8674(82)90010-1; NASSIF X, 1993, MOL MICROBIOL, V8, P719, DOI 10.1111/j.1365-2958.1993.tb01615.x; NORRIS SJ, 1995, INFECT IMMUN, V63, P2206, DOI 10.1128/IAI.63.6.2206-2212.1995; NORRIS SJ, 1992, INFECT IMMUN, V60, P4662, DOI 10.1128/IAI.60.11.4662-4672.1992; Pennington PM, 1997, INFECT IMMUN, V65, P285, DOI 10.1128/IAI.65.1.285-292.1997; PERSING DH, 1994, INFECT IMMUN, V62, P3521, DOI 10.1128/IAI.62.8.3521-3527.1994; PLASTERK RHA, 1985, NATURE, V318, P257, DOI 10.1038/318257a0; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; Rosa P, 1996, J BACTERIOL, V178, P5946, DOI 10.1128/jb.178.20.5946-5953.1996; ROSA PA, 1992, MOL MICROBIOL, V6, P3031, DOI 10.1111/j.1365-2958.1992.tb01761.x; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SADZIENE A, 1992, J EXP MED, V176, P799, DOI 10.1084/jem.176.3.799; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMUELS DS, 1994, J BACTERIOL, V176, P6045, DOI 10.1128/jb.176.19.6045-6049.1994; Schutzer S, 1992, LYME DIS MOL IMMUNOL; SCHWAN TG, 1991, CAN J MICROBIOL, V37, P450, DOI 10.1139/m91-074; SCHWAN TG, 1988, INFECT IMMUN, V56, P1831, DOI 10.1128/IAI.56.8.1831-1836.1988; SEAL SE, 1992, APPL ENVIRON MICROB, V58, P3751, DOI 10.1128/AEM.58.11.3751-3758.1992; SEGAL E, 1986, P NATL ACAD SCI USA, V83, P2177, DOI 10.1073/pnas.83.7.2177; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEVENSON B, 1994, INFECT IMMUN, V62, P3568, DOI 10.1128/IAI.62.8.3568-3571.1994; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; Swanson J., 1989, MOBILE DNA, P743; WAINWRIGHT LA, 1994, MOL MICROBIOL, V13, P75, DOI 10.1111/j.1365-2958.1994.tb00403.x; WALKER EM, 1995, J BACTERIOL, V177, P1797, DOI 10.1128/jb.177.7.1797-1804.1995; WILSKE B, 1992, RES MICROBIOL, V143, P583, DOI 10.1016/0923-2508(92)90116-6; WU HC, 1986, CURR TOP MICROBIOL, V125, P127; Xu YN, 1996, INFECT IMMUN, V64, P3870, DOI 10.1128/IAI.64.9.3870-3876.1996	51	492	507	1	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					275	285		10.1016/S0092-8674(00)80206-8	http://dx.doi.org/10.1016/S0092-8674(00)80206-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108482	Bronze			2022-12-28	WOS:A1997WU88800014
J	Guo, L; Lim, KB; Gunn, JS; Bainbridge, B; Darveau, RP; Hackett, M; Miller, SI				Guo, L; Lim, KB; Gunn, JS; Bainbridge, B; Darveau, RP; Hackett, M; Miller, SI			Regulation of lipid a modifications by Salmonella typhimurium virulence genes phoP-phoQ	SCIENCE			English	Article							TANDEM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; STRUCTURAL DETERMINATION; BACTERIAL-ENDOTOXINS; BINDING-PROTEIN; PMRA MUTANTS; SOLUBLE CD14; LIPOPOLYSACCHARIDES; EXPRESSION; RESISTANCE	Bacterial pathogenesis requires proteins that sense host microenvironments and respond by regulating virulence gene transcription. For Salmonellae, one such regulatory system is PhoP-PhoQ, which regulates genes required for intracellular survival and resistance to cationic peptides. Analysis by mass spectrometry revealed that Salmonella typhimurium PhoP-PhoQ regulated structural modifications of lipid A, the host signaling portion of lipopolysaccharide (LPS), by the addition of aminoarabinose and 2-hydroxymyristate. Structurally modified lipid A altered LPS-mediated expression of the adhesion molecule E-selectin by endothelial cells and tumor necrosis factor-alpha expression by adherent monocytes. Thus, altered responses to environmentally induced lipid A structural modifications may represent a mechanism for bacteria to gain advantage within host tissues.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MICROBIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED CHEM, SEATTLE, WA 98195 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, INFLAMMAT DEPT, SEATTLE, WA 98121 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Bristol-Myers Squibb					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI30479] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BRYN K, 1982, J CHROMATOGR, V240, P405, DOI 10.1016/S0021-9673(00)99620-1; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHAN S, 1994, ANAL BIOCHEM, V218, P63, DOI 10.1006/abio.1994.1141; CHWARTZ JC, 1996, METHOD ENZYMOL, V270, P552; DARVEAU RP, 1995, INFECT IMMUN, V63, P1311, DOI 10.1128/IAI.63.4.1311-1317.1995; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; Dole M, 1971, ADV CHEM SER, V125, P73; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Gunn JS, 1996, J BACTERIOL, V178, P6369, DOI 10.1128/jb.178.21.6369-6373.1996; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; HARRATA AK, 1993, BIOL MASS SPECTROM, V22, P59, DOI 10.1002/bms.1200220108; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; JENSEN NJ, 1987, MASS SPECTROM REV, V6, P497, DOI 10.1002/mas.1280060403; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LOURIS JN, 1987, ANAL CHEM, V59, P1677, DOI 10.1021/ac00140a021; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MILLER SI, 1995, SIGNAL TRANSDUCTION, P61; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odham G, 1972, BIOCHEMICAL APPL MAS, P211; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; QURESHI N, 1983, J BIOL CHEM, V258, P2947; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; TAKADA H, 1992, BACTERIAL ENDOTOXIC, V1, P107; TAKAYAMA K, 1983, J BIOL CHEM, V258, P2801; TODD JFJ, 1995, PRACTICAL ASPECTS IO, V3, P4; VAARA M, 1981, J BACTERIOL, V148, P426, DOI 10.1128/JB.148.2.426-434.1981; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H	43	455	473	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					250	253		10.1126/science.276.5310.250	http://dx.doi.org/10.1126/science.276.5310.250			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092473				2022-12-28	WOS:A1997WT92500044
J	Reyburn, HT; Mandelboim, O; ValesGomez, M; Davis, DM; Pazmany, L; Strominger, JL				Reyburn, HT; Mandelboim, O; ValesGomez, M; Davis, DM; Pazmany, L; Strominger, JL			The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells	NATURE			English	Article							ANTI-KP43 MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; EXPRESSION; COMPLEX; RECEPTOR; CHAINS; VIRUS; GENES	Recognition and destruction of virus-infected cells by class I major histocompatibility complex (MHC) restricted cytotoxic T lymphocytes (CTL) is a central part of the immune system's attempts to control and eliminate virus infection. It is therefore not surprising that many viruses have evolved strategies to interfere with the processing and presentation of peptide antigen on class I MHC molecules (reviewed in ref. 1). These mechanisms act to prevent or reduce expression of MHC molecules at the cell surface. However, many natural killer (NK) cells are able to recognize and destroy host cells that no longer express class I MHC molecules (the 'missing self' hypothesis(2)). Thus, any virus-infected cell that has lost cell-surface expression of MHC class I to avoid CTL attack should become susceptible to NK-cell-mediated destruction. We describe here the first example, to our knowledge, of a viral strategy to evade immune surveillance by NK cells.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			Reyburn, Hugh T/B-4338-2009; Valés-Gómez, Mar/F-5351-2012; Vales-Gomez, Mar/ABG-7808-2020	Reyburn, Hugh T/0000-0003-2855-1595; Valés-Gómez, Mar/0000-0001-7424-3206; Vales-Gomez, Mar/0000-0001-7424-3206; Davis, Daniel/0000-0002-9182-291X; Mandelboim, Ofer/0000-0002-9354-1855				Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; ARAMBURU J, 1991, J IMMUNOL, V147, P714; ARAMBURU J, 1990, J IMMUNOL, V144, P3238; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BROCKER T, 1993, EUR J IMMUNOL, V23, P1435, DOI 10.1002/eji.1830230705; BROWNE H, 1990, NATURE, V347, P770, DOI 10.1038/347770a0; FAHNESTOCK ML, 1995, IMMUNITY, V3, P583, DOI 10.1016/1074-7613(95)90129-9; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; Hengel H, 1996, J GEN VIROL, V77, P2287, DOI 10.1099/0022-1317-77-9-2287; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; Lazetic S, 1996, J IMMUNOL, V157, P4741; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Mandelboim O, 1996, J EXP MED, V184, P913, DOI 10.1084/jem.184.3.913; MCGEOCH DJ, 1995, J MOL BIOL, V247, P443, DOI 10.1006/jmbi.1995.0152; PARHAM P, 1983, J BIOL CHEM, V258, P6179; PEREZVILLAR JJ, 1995, J IMMUNOL, V154, P5779; PerezVillar JJ, 1996, J IMMUNOL, V157, P5367; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; SHIMIZU Y, 1988, P NATL ACAD SCI USA, V85, P227, DOI 10.1073/pnas.85.1.227; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILEY D, 1988, NATURE, V331, P209, DOI 10.1038/331209a0	26	257	260	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					514	517		10.1038/386514a0	http://dx.doi.org/10.1038/386514a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087413				2022-12-28	WOS:A1997WR25600057
J	Merke, DP; Cutler, GB				Merke, DP; Cutler, GB			New approaches to the treatment of congenital adrenal hyperplasia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALE PRECOCIOUS PUBERTY; 21-HYDROXYLASE DEFICIENCY; MUTATION; FLUTAMIDE; RECEPTOR; GENE		US PHS,WASHINGTON,DC	United States Public Health Service	Merke, DP (corresponding author), NICHHD,DEV ENDOCRINOL BRANCH,NIH,BLDG 10,ROOM 10N262,10 CTR DR MSC 1862,BETHESDA,MD 20892, USA.							AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; BRISTOW J, 1993, J BIOL CHEM, V268, P1219; CALLEGARI C, 1987, J PEDIATR-US, V111, P240, DOI 10.1016/S0022-3476(87)80075-6; CUTLER GB, 1990, NEW ENGL J MED, V323, P1806; DAVID M, 1994, ARCH PEDIATRIE, V1, P363; GIRARD J, 1977, CONGENITAL ADRENAL H, P217; GOMEZ JL, 1992, AM J MED, V92, P465, DOI 10.1016/0002-9343(92)90741-S; Knorr D, 1988, Acta Paediatr Jpn, V30 Suppl, P89; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; Laue L, 1996, J CLIN ENDOCR METAB, V81, P3535, DOI 10.1210/jc.81.10.3535; LINDER BL, 1990, J PEDIATR-US, V117, P892, DOI 10.1016/S0022-3476(05)80128-3; MOREL Y, 1989, J CLIN INVEST, V83, P527, DOI 10.1172/JCI113914; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; New M I, 1988, Acta Paediatr Jpn, V30 Suppl, P79; SANE K, 1992, J PEDIATR-US, V120, P264, DOI 10.1016/S0022-3476(05)80439-1; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; VanWyk JJ, 1996, J CLIN ENDOCR METAB, V81, P3180, DOI 10.1210/jc.81.9.3180; WYSOWSKI DK, 1993, ANN INTERN MED, V118, P860, DOI 10.7326/0003-4819-118-11-199306010-00006	20	25	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1073	1076		10.1001/jama.277.13.1073	http://dx.doi.org/10.1001/jama.277.13.1073			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091697				2022-12-28	WOS:A1997WQ08900034
J	Quartin, AA; Schein, RMH; Kett, DH; Peduzzi, PN				Quartin, AA; Schein, RMH; Kett, DH; Peduzzi, PN			Magnitude and duration of the effect of sepsis on survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; GRAM-NEGATIVE BACTEREMIA; LONG-TERM SURVIVAL; CONTROLLED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNITS; ACUTE-RENAL-FAILURE; SEPTIC SHOCK; MONOCLONAL-ANTIBODY	Objective.-To determine the magnitude and duration of the effects of sepsis on survival. Design.-Cohort study. Setting.-The 10 Department of Veterans Affairs Medical Centers of the Systemic Sepsis Cooperative Studies Group, which from 1983 to 1986 conducted the Department of Veterans Affairs Cooperative Study of Corticosteroids in Systemic Sepsis. Patients.-The septic population consisted of 1505 patients with evaluable data from the screening log of the Cooperative Study of Corticosteroids in Systemic Sepsis, All 91 830 nonpsychiatric, noninfected patients discharged from the participating medical centers between October 1, 1984, and September 30, 1985, were included in the control population. Main Outcome Measure.-Death through 8 years after the index hospitalization. Results.-On the basis of a proportional hazards model constructed from the demographic and illness characteristics of the control population, the septic population was at significant risk of dying of nonseptic causes (26% predicted 1-year mortality), In the septic population, the daily risk of dying exceeded predictions from this model for 5 years, and the hazard rate rose with increasing severity of the septic episode throughout the first year (P<.05). Among 30-day survivors, sepsis reduced the remaining mean life span from a predicted 8.03 years to 4.08 years. Conclusions.-Sepsis not only causes deaths acutely, but also increases the risk of death for up to 5 years after the septic episode even after comorbidities are accounted for. The risk of late death during the first year is associated with the severity of the septic episode.	UNIV MIAMI, DIV PULM & CRIT CARE MED, MIAMI, FL 33152 USA; DEPT VET AFFAIRS, COOPERAT STUDIES PROGRAM COORDINATING CTR, West Haven, CT USA	University of Miami	Quartin, AA (corresponding author), VET AFFAIRS MED CTR, SECT CRIT CARE 111, 1201 NW 16TH ST, MIAMI, FL 33125 USA.							ALOY DA, 1990, ENFERM INFEC MICR CL, V8, P540; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; BRYANT RE, 1971, ARCH INTERN MED, V127, P120, DOI 10.1001/archinte.127.1.120; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; ELLIOTT CG, 1987, AM REV RESPIR DIS, V135, P634; ELLIOTT CG, 1990, CLIN CHEST MED, V11, P789; FINLAND M, 1959, JAMA-J AM MED ASSOC, V170, P2188, DOI 10.1001/jama.1959.63010180008012; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V272, P1170; GHIO AJ, 1989, AM REV RESPIR DIS, V139, P1158, DOI 10.1164/ajrccm/139.5.1158; GREEN J, 1995, J AM SOC NEPHROL, V5, P1853; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HALL JW, 1970, ANN INTERN MED, V73, P515, DOI 10.7326/0003-4819-73-4-515; HODGIN UG, 1965, AM J MED, V39, P952, DOI 10.1016/0002-9343(65)90118-X; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KOCHANEK KD, 1995, MONTHLY VITAL STAT S, P43; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEIBOVICI L, 1995, JAMA-J AM MED ASSOC, V274, P807, DOI 10.1001/jama.274.10.807; LEIJTEN FSS, 1995, JAMA-J AM MED ASSOC, V274, P1221, DOI 10.1001/jama.274.15.1221; LEWERS DT, 1970, ANN INTERN MED, V73, P523, DOI 10.7326/0003-4819-73-4-523; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; *OFF PLANN EXTR PR, 1990, MMWR-MORBID MORTAL W, V39, P31; PEDUZZI P, 1992, ARCH INTERN MED, V152, P529, DOI 10.1001/archinte.152.3.529; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; PETERS JI, 1989, AM REV RESPIR DIS, V139, P1163, DOI 10.1164/ajrccm/139.5.1163; PITTET D, 1993, INTENS CARE MED, V19, P265, DOI 10.1007/BF01690546; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; RUTENBURG AM, 1959, P SOC EXP BIOL MED, V101, P279, DOI 10.3181/00379727-101-24910; SASSE KC, 1995, CRIT CARE MED, V23, P1040, DOI 10.1097/00003246-199506000-00008; SCHULMAN KA, 1991, JAMA-J AM MED ASSOC, V266, P3466, DOI 10.1001/jama.266.24.3466; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; World Health Organization, 1977, INT CLASS DIS; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	39	293	304	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1058	1063		10.1001/jama.277.13.1058	http://dx.doi.org/10.1001/jama.277.13.1058			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091694				2022-12-28	WOS:A1997WQ08900031
J	Ridker, PM; Glynn, RJ; Miletich, JP; Goldhaber, SZ; Stampfer, MJ; Hennekens, CH				Ridker, PM; Glynn, RJ; Miletich, JP; Goldhaber, SZ; Stampfer, MJ; Hennekens, CH			Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; THROMBOSIS; RESISTANCE; THROMBOPHILIA; RISK	Background: Previous reports suggest that younger carriers of the factor V Leiden mutation are at greater risk for venous thromboembolism than are older carriers. However, available data on thromboembolic risk are limited. Objective: To determine age-specific incidence rates of venous thromboembolism associated with the factor V Leiden mutation. Design: Prospective cohort study. Patients: 14 916 initially healthy men participating in the Physicians' Health Study who were followed from 1982 to August 1994 for the occurrence of deep venous thrombosis or pulmonary embolism. Measurements: Polymerase chain reaction was used to determine factor V Leiden mutation status in 156 study participants who developed venous thromboembolism during follow-up and in 2406 study participants who remained free of vascular disease. Results: Risks for venous thromboembolism in heterozygous carriers of factor V Leiden mutation increased with age at a rate significantly greater than that in noncarriers. Whereas incidence rates of venous thromboembolism were similar in men with and men without the factor V Leiden mutation who were younger than 50 years of age, incidence rate differences (per 1000 person-years of observation) between affected and unaffected men increased significantly from 1.23 (95% CI, -0.4 to 2.9) for those aged 50 to 59 years to 1.61 (CI, -0.5 to 3.7) for those aged 60 to 69 years of age to 5.97 (CI, 0.6 to 11.3) for those aged 70 years or older (P for trend = 0.008). For idiopathic venous thromboembolism, age-specific incidence rate differences between men with and without the factor V Leiden mutation increased significantly with age (P = 0.017). However, no significant relation was found for secondary events (P > 0.2). Conclusions: The findings support the hypothesis that the pathogenesis of venous thromboembolism involves acquired as well as genetic risk factors and indicate that determination of factor V Leiden mutation status should not be limited to young patients.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC DIS, BOSTON, MA 02215 USA; WASHINGTON UNIV, SCH MED, DIV LAB MED, ST LOUIS, MO 63110 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV LAB MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Ridker, PM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA.				NCI NIH HHS [CA-42182] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; GRIZZLE JE, 1969, BIOMETRICS, V25, P489, DOI 10.2307/2528901; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LINDGREN BW, 1976, STATISTICAL THEORY, P130; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; RIDKER PM, 1997, IN PRESS CIRCULATION; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	14	116	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					528	531		10.7326/0003-4819-126-7-199704010-00005	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092318				2022-12-28	WOS:A1997WQ19500014
J	Boulton, RA; Adams, DH				Boulton, RA; Adams, DH			Gallbladder polyps: When to wait and when to act	LANCET			English	Editorial Material							LESIONS; DIAGNOSIS				Boulton, RA (corresponding author), QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Adams, David H/C-9092-2009	Adams, David H/0000-0001-6776-0336				ALBORESSAAVEDRA J, 1993, PATHOL ANNU, V28, P145; ALDRIDGE MC, 1990, BRIT J SURG, V77, P363, DOI 10.1002/bjs.1800770403; JORGENSEN T, 1990, SCAND J GASTROENTERO, V25, P281; KOGA A, 1988, ARCH SURG-CHICAGO, V123, P26; KUBOTA K, 1995, SURGERY, V117, P481, DOI 10.1016/S0039-6060(05)80245-4; Moriguchi H, 1996, GUT, V39, P860, DOI 10.1136/gut.39.6.860; YANG HL, 1992, BRIT J SURG, V79, P227, DOI 10.1002/bjs.1800790312	7	60	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					817	817		10.1016/S0140-6736(05)61744-8	http://dx.doi.org/10.1016/S0140-6736(05)61744-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121250				2022-12-28	WOS:A1997WP40300003
J	Eskes, R; Yang, JA; Lambowitz, AM; Perlman, PS				Eskes, R; Yang, JA; Lambowitz, AM; Perlman, PS			Mobility of yeast mitochondrial group II introns: Engineering a new site specificity and retrohoming via full reverse splicing	CELL			English	Article							DNA; RNA; MATURASE; TRANSPOSITION; INVITRO; GENE	The mobile group II introns al1 and al2 of yeast mtDNA encode endonuclease activities that cleave intronless DNA target sites to initiate mobility by target DNA-primed reverse transcription. For al2, sense-strand cleavage occurs mainly by a partial reverse splicing reaction, whereas for al1, complete reverse splicing occurs, leading to insertion of the linear intron RNA into double-stranded DNA. Here, we show that al1 homing and reverse splicing depend on the EBS1 (RNA)/IBS1(DNA) pairing and that target specificity can be changed by compensatory changes in the target site and the donor intron. Using well-marked strains to follow coconversion of flanking DNA, we show that homing occurs by both RT-dependent and -independent pathways. Remarkably, in mast RT-dependent events, the reverse spliced intron is the initial template for first-strand cDNA synthesis.	OHIO STATE UNIV,DEPT MOL GENET,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Eskes, R (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949, R01GM031480] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37949, GM31480] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONITZ SG, 1980, J BIOL CHEM, V255, P1927; Butow R A, 1996, Methods Enzymol, V264, P265, DOI 10.1016/S0076-6879(96)64026-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Curcio MJ, 1996, CELL, V84, P9, DOI 10.1016/S0092-8674(00)80987-3; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LORSCH JR, 1995, NUCLEIC ACIDS RES, V23, P2811, DOI 10.1093/nar/23.15.2811; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; Sambrook J., 2002, MOL CLONING LAB MANU; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; Sherman F., 1986, METHODS YEAST GENETI; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	24	93	94	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					865	874		10.1016/S0092-8674(00)81932-7	http://dx.doi.org/10.1016/S0092-8674(00)81932-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118229	Bronze			2022-12-28	WOS:A1997WQ10000018
J	Lilford, RJ				Lilford, RJ			Down's syndrome and parity	BRITISH MEDICAL JOURNAL			English	Editorial Material											Lilford, RJ (corresponding author), UNIV BIRMINGHAM,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							CASTILLA EE, 1994, LANCET, V344, P1645, DOI 10.1016/S0140-6736(94)90444-8; HEDDOW JE, 1994, LANCET, V344, P956; HOOK HB, 1983, HUM GENET, V63, P320	3	4	4	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					721	721		10.1136/bmj.314.7082.721	http://dx.doi.org/10.1136/bmj.314.7082.721			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116550	Green Published			2022-12-28	WOS:A1997WM77600025
J	Muntoni, S; Fonte, MT; Stoduto, S; Marietti, G; Bizzarri, C; Crino, A; Ciampalini, P; Multari, G; Suppa, MA; Matteoli, MC; Lucentini, L; Sebastiani, LM; Visalli, N; Pozzilli, P; Boscherini, B; Muntoni, S				Muntoni, S; Fonte, MT; Stoduto, S; Marietti, G; Bizzarri, C; Crino, A; Ciampalini, P; Multari, G; Suppa, MA; Matteoli, MC; Lucentini, L; Sebastiani, LM; Visalli, N; Pozzilli, P; Boscherini, B; Muntoni, S			Incidence of insulin-dependent diabetes mellitus among Sardinian-heritage children born in Lazio region, Italy	LANCET			English	Article							IDDM; POPULATION	Background The relative importance of genetic and environmental factors in causing insulin-dependent diabetes mellitus (IDDM) is unknown. We studied this question by assessing the incidence of the disease in children, born in a region with a low incidence of IDDM (Lazio), but whose parents came from a region with high incidence (Sardinia). Methods We identified all IDDM cases that occurred between 1989 and 1994. We used as the denominator the number of children aged 0-14 born in Lazio of Sardinian parents to calculate incidence. We compared this rate with the incidences of IDDM in the populations of Lazio and Sardinia. Findings The age-adjusted incidence of IDDM in Sardinian-heritage children born and living in Lazio was 33.8 per 100 000 per year (95% CI 7.0-99.0) for those with two Sardinian parents, and 15.9 (8.7-26.6) for those with only one parent from Sardinia. The former incidence was not different from that recorded in Sardinia (34.4, 31.3-37.9), but was fourfold that of Lazio-heritage children (7.9, 7.1-8.8). Interpretation Our results show that two different ethnic groups living in the same region have a fourfold difference in incidence of IDDM. Children of Sardinian-heritage born in Lazio have the same incidence as the population of origin, which is genetically prone to the disease. Moreover, children with one Sardinian parent had a rate half that of Sardinians and double that of the indigenous population. We conclude that in a given population genetic susceptibility determines the frequency of IDDM in response to the environmental challenge.	UNIV ROMA TOR VERGATA, PEDIAT CLIN, ROME, ITALY; CATHOLIC UNIV, PEDIAT CLIN, ROME, ITALY; OSPED BAMBINO GESU, IRCCS, REPARTO ENDOCRINOL, ROME, ITALY; UNIV ROMA LA SAPIENZA, SERV DIABETOL PEDIAT, ROME, ITALY; BAMBIN GESU PALIDORO, CTR DIABETOL PEDIAT, ROME, ITALY; UNIV ROMA LA SAPIENZA, IST IGIENE G SANARELLI, ROME, ITALY; UNIV ROMA LA SAPIENZA, IST CLIN MED 2, ROME, ITALY	University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Bambino Gesu; Sapienza University Rome; IRCCS Bambino Gesu; Sapienza University Rome; Sapienza University Rome	Muntoni, S (corresponding author), ASSOC MEDICO, CTR MALATTIE DISMETABOL & ARTERIOSCLEROSI, 23-29 VIALE MERELLO, I-09123 CAGLIARI, ITALY.		Matteoli, Maria Cristina/AAA-7469-2020; Ciampalini, Paolo/K-4366-2016; Pozzilli, Paolo/A-5235-2010; Bizzarri, Carla/AAI-2429-2019	Ciampalini, Paolo/0000-0002-3273-1778; Bizzarri, Carla/0000-0002-5616-9185; matteoli, maria cristina/0000-0003-1461-6220; Crino, Antonino/0000-0003-3548-7114				BISHOP YMM, 1974, DISCRETE MULTIVARIAT, P229; BODANSKY HJ, 1992, BRIT MED J, V304, P1020, DOI 10.1136/bmj.304.6833.1020; Bruno G, 1996, LANCET, V347, P193, DOI 10.1016/S0140-6736(96)90378-5; COLLE E, 1990, DIABETES METAB REV, V6, P63; CONGIA M, 1994, NATO ADV SCI INST SE, V270, P173; COSTA AM, 1986, INDAGINE CONOSCITIVA; CUCCA F, 1993, HUM IMMUNOL, V37, P85, DOI 10.1016/0198-8859(93)90146-R; DAHLQUIST G, 1995, DIABETES METAB REV, V11, P37, DOI 10.1002/dmr.5610110104; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; HELGASON T, 1981, LANCET, V2, P716; *I NAZ STAT, 1991, ZOP AB REG LAZ; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; LAPORTE RE, 1987, BRIT MED J, V295, P479; LO SSS, 1991, DIABETIC MED, V8, P609, DOI 10.1111/j.1464-5491.1991.tb01666.x; Munro BH, 1986, STAT METHODS HLTH CA; MUNTONI F, 1992, TISSUE ANTIGENS, V39, P262, DOI 10.1111/j.1399-0039.1992.tb01945.x; MUNTONI S, 1992, DIABETES CARE, V15, P1317, DOI 10.2337/diacare.15.10.1317; MUNTONI S, 1995, DIABETES CARE, V18, P1600, DOI 10.2337/diacare.18.12.1600; ORCHARD TJ, 1986, J CHRON DIS, V39, P979, DOI 10.1016/0021-9681(86)90135-9; PUGLIESE A, 1995, DIABETES, V44, P608, DOI 10.2337/diabetes.44.6.608; Sebastiani L, 1996, DIABETES CARE, V19, P70, DOI 10.2337/diacare.19.1.70; SFORZA LLC, 1993, EUR J HUM GENET, V1, P3; SILVETTI M, 1990, J ENDOCRINOL INVE S3, V13, P83; SONGINI M, 1993, DIABETOLOGIA, V36, P547, DOI 10.1007/BF02743272	25	73	74	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					160	162		10.1016/S0140-6736(96)04241-9	http://dx.doi.org/10.1016/S0140-6736(96)04241-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111539				2022-12-28	WOS:A1997WC86100009
J	Delamarche, E; Bernard, A; Schmid, H; Michel, B; Biebuyck, H				Delamarche, E; Bernard, A; Schmid, H; Michel, B; Biebuyck, H			Patterned delivery of immunoglobulins to surfaces using microfluidic networks	SCIENCE			English	Article							COPLANAR MOLECULAR ASSEMBLIES; MONOLAYERS	Microfluidic networks (mu FNs) were used to pattern biomolecules with high resolution on a variety of substrates (gold, glass, or polystyrene). Elastomeric mu FNs localized chemical reactions between the biomolecules and the surface, requiring only microliters of reagent to cover square millimeter-sized areas. The networks were designed to ensure stability and filling of the mu FN and allowed a homogeneous distribution and robust attachment of material to the substrate along the conduits in the mu FN. Immunoglobulins patterned on substrates by means of mu FNs remained strictly confined to areas enclosed by the network with submicron resolution and were viable for subsequent use in assays. The approach is simple and general enough to suggest a practical way to incorporate biological material on technological substrates.	IBM CORP,ZURICH RES LAB,DIV RES,CH-8803 RUSCHLIKON,SWITZERLAND; UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	International Business Machines (IBM); University of Zurich			Delamarche, Emmanuel/G-6342-2013	Delamarche, Emmanuel/0000-0002-8753-8895				BERNARD A, 1995, EUR J BIOCHEM, V230, P416; Delamarche E, 1996, LANGMUIR, V12, P1997, DOI 10.1021/la950836t; DELAMARCHE E, UNPUB; DELAMARCHE E, IN PRESS ADV MAT; DULCEY CS, 1991, SCIENCE, V252, P551, DOI 10.1126/science.2020853; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HARRIS JM, 1992, POLYETHYLENE GLYCOLC; Kim E, 1996, J AM CHEM SOC, V118, P5722, DOI 10.1021/ja960151v; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038; Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; STENGER DA, 1992, J AM CHEM SOC, V114, P8435, DOI 10.1021/ja00048a013; SUNDBERG SA, 1995, J AM CHEM SOC, V117, P12050, DOI 10.1021/ja00154a003; Tender LM, 1996, LANGMUIR, V12, P5515, DOI 10.1021/la960627o; XIA Y, 1996, SCIENCE, V273, P547	16	581	724	3	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					779	781		10.1126/science.276.5313.779	http://dx.doi.org/10.1126/science.276.5313.779			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115199				2022-12-28	WOS:A1997WW90000053
J	Nilsson, C; Jansson, R; Zinko, U				Nilsson, C; Jansson, R; Zinko, U			Long-term responses of river-margin vegetation to water-level regulation	SCIENCE			English	Article							FRAGMENTATION; DYNAMICS	The long-term effect of water-level regulation on riparian plant communities was assessed for storage reservoirs and run-of-river impoundments. Soon after the onset of regulation, there were few species and sparse vegetation cover, regardless of whether the new water level intersected former upland or riparian vegetation, In the longer term, an impoverished vegetation was maintained by storage reservoirs, whereas in run-of-river impoundments, some community characteristics deteriorated and others recovered compared to adjacent free-flowing rivers.			Nilsson, C (corresponding author), UMEA UNIV, DEPT ECOL BOT, RIPARIAN ECOL GRP, S-90187 UMEA, SWEDEN.		Nilsson, Christer/AAI-1354-2019; Jansson, Roland/B-7972-2013	Jansson, Roland/0000-0003-1767-7010				ATTWELL IG, 1970, BIOL CONSERV, V2, P189; Barinaga M, 1996, SCIENCE, V273, P1648, DOI 10.1126/science.273.5282.1648; Blom CWPM, 1996, TRENDS ECOL EVOL, V11, P290, DOI 10.1016/0169-5347(96)10034-3; CONNOR EF, 1979, AM NAT, V113, P791, DOI 10.1086/283438; DECAMPS H, 1993, ECOL APPL, V3, P441, DOI 10.2307/1941913; DUNHAM KM, 1990, AFR J ECOL, V28, P200, DOI 10.1111/j.1365-2028.1990.tb01153.x; DYNESIUS M, 1994, SCIENCE, V266, P753, DOI 10.1126/science.266.5186.753; GILL CJ, 1977, APPLIED BIOL, V2, P129; HANSON JS, 1990, ECOL MODEL, V49, P277, DOI 10.1016/0304-3800(90)90031-B; HORNBERG E, 1974, RIVERS UMEALVEN VI 2; JOHNSON WC, 1976, ECOL MONOGR, V46, P59, DOI 10.2307/1942394; Kozlowski TT., 1984, PHYSL ECOLOGY; KROK TOB, 1984, SVENSK FLORA FANEROG; LUNDQVIST J, 1970, BOTANISKA DATA NORRA; NAIMAN RJ, 1993, ECOL APPL, V3, P209, DOI 10.2307/1941822; NILSSON C, 1989, ECOLOGY, V70, P77, DOI 10.2307/1938414; NILSSON C, 1991, J APPL ECOL, V28, P963, DOI 10.2307/2404220; NILSSON C, 1981, ACTA PHYTOGEOGR SUEC, V69, P1; NILSSON CG, UNPUB; Orians G.H., 1975, UNIFYING CONCEPTS EC; Petts G.E., 1984, IMPOUNDED RIVERS PER, DOI [10.1177/030913338601000116., DOI 10.1016/0006-3207(85)90110-7]; REILY PW, 1982, CAN J BOT, V60, P2410, DOI 10.1139/b82-294; ROOD SB, 1989, CAN J BOT, V67, P1744, DOI 10.1139/b89-221; ROSENBERG DM, 1995, GLOBAL ENVIRON CHANG, V5, P127, DOI 10.1016/0959-3780(95)00018-J; SCHINDLER DW, 1987, CAN J FISH AQUAT SCI, V44, P6; Sjors H., 1973, BOTANISKA SKYDDSVARD; ter Braak C., 1990, UPDATE NOTES CANOCO; TREXLER JC, 1993, ECOLOGY, V74, P1629, DOI 10.2307/1939921; Turner B., 1993, EARTH TRANSFORMED HU, DOI [10.2307/622468, DOI 10.2307/622468]; Wuethrich B, 1996, SCIENCE, V272, P344, DOI 10.1126/science.272.5260.344	30	180	208	3	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					798	800		10.1126/science.276.5313.798	http://dx.doi.org/10.1126/science.276.5313.798			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115205				2022-12-28	WOS:A1997WW90000059
J	Parrish, DM				Parrish, DM			Improving the scientific misconduct hearing process	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								The overturning and withdrawal of several of the Office of Research Integrity's (ORI's) findings of scientific misconduct have called its role into question. The contested findings of scientific misconduct that have been tried before the hearing body have been based on lengthy and expensive ORI investigations. How could ORI have failed to prove its findings of scientific misconduct after the commitment of substantial resources that far exceed those devoted during institutional investigations? One reason may be that the current hearing process makes it difficult or impossible for ORI, institutions, or individuals to prove scientific misconduct. The hearing process has been criticized by discouraged whistleblowers who believe that their allegations of scientific misconduct should have been upheld, and by the accused for the expensive and protracted nature of the proceedings. The following article examines problems in the scientific misconduct hearing process and suggests that the process could be improved by letting administrative law judges, patent attorneys, and a scientific majority decide these cases.	TITUS & MCCONOMY,PITTSBURGH,PA									Department of Health and Human Services, 1995, INT MISC RES REP COM; *OFF RES INT, 1994, COMM RES INT OCT 19; *OFF RES INT, 1994, COMM RES INT NOV 7; *US DHHS, 1989, FED REG         0808, V54; *US DHHS, 1994, FED REG         0606, V59, P29809; *US DHHS, 1992, FED REG         1106, V57, P53125	6	4	4	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1315	1319						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109472				2022-12-28	WOS:A1997WU13500034
J	Ridker, PM; Miletich, JP; Hennekens, CH; Buring, JE				Ridker, PM; Miletich, JP; Hennekens, CH; Buring, JE			Ethnic distribution of factor V Leiden in 4047 men and women - Implications for venous thromboembolism screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED PROTEIN-C; DEEP-VEIN-THROMBOSIS; COAGULATION-FACTOR-V; POOR ANTICOAGULANT RESPONSE; ADDITIONAL RISK FACTOR; ORAL-CONTRACEPTIVES; PULMONARY-EMBOLISM; DEFICIENT FAMILIES; RESISTANCE; MUTATION	Objective.-To estimate ethnic-specific prevalence rates of factor V Leiden, an inherited defect of hemostasis associated with risk of venous thrombosis. Design.-Survey of 4047 American men and women participating in the Physicians' Health Study (PHS) or in the Women's Health Study (WHS). All study participants were free of myocardial infarction, stroke, or venous thrombosis. Main Outcome Measure.-Prevalence of G1691A Leiden mutation in the gene coding for coagulation factor V was determined in the PHS group using polymerase chain reaction techniques and, in the WHS group, a second-generation activated protein C (APC)-resistance screening test with genetic confirmation of all borderline and low-value results. Results.-In 2468 Caucasian Americans, carrier frequency of factor V Leiden was 5.27% (95% confidence interval [CI], 4.42%-6.22%). Carrier frequency was 2.21% in 407 Hispanic Americans, 1.23% in 650 African Americans, 0.45% in 442 Asian Americans, and 1.25% in 80 Native Americans. Thus, prevalence of factor V Leiden was less among minority subjects (P=.001). Carrier frequencies were similar in Caucasian men and women (5.53% vs 4.85% respectively, P=.5). Conclusion.-These data indicate that prevalence of factor V Leiden is greater among Caucasians than minority Americans. These data have implications for clinicians considering whether to screen for factor V Leiden in high-risk groups such as those with prior venous thromboses or coexistent defects of anticoagulation and women at risk for postpartum thrombosis or seeking oral contraceptives.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CARDIOVASC DIS, BOSTON, MA 02215 USA; WASHINGTON UNIV, SCH MED, DIV LAB MED, ST LOUIS, MO 63110 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Washington University (WUSTL)	Ridker, PM (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02215 USA.				NCI NIH HHS [CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-43851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BURKITT DP, 1972, BMJ-BRIT MED J, V2, P556, DOI 10.1136/bmj.2.5813.556; Chan LC, 1996, THROMB HAEMOSTASIS, V75, P522; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Dahlback B, 1996, LANCET, V347, P1346, DOI 10.1016/S0140-6736(96)91004-1; DUTHIE SJ, 1989, BRIT J OBSTET GYNAEC, V96, P4, DOI 10.1111/j.1471-0528.1989.tb01568.x; GOLDHABER SZ, 1985, PULMONARY EMBOLISM D; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOST K, 1991, FAM PLANN PERSPECT, V23, P54, DOI 10.2307/2135450; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; PETERSON LS, 1995, CONTRACEPTIVE USE US, V260, P1; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, CIRCULATION, V95, P1777; ROSEN S, 1994, THROMB HAEMOSTASIS, V72, P255; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TAKAMIYA O, 1995, THROMB HAEMOSTASIS, V74, P996; TSO SC, 1980, BRIT J HAEMATOL, V46, P603, DOI 10.1111/j.1365-2141.1980.tb06018.x; *US BUR CENS, 1996, US POP EST AG SEX RA; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	33	478	495	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1305	1307		10.1001/jama.277.16.1305	http://dx.doi.org/10.1001/jama.277.16.1305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109469				2022-12-28	WOS:A1997WU13500031
J	Pierce, VA; Crawford, DL				Pierce, VA; Crawford, DL			Phylogenetic analysis of glycolytic enzyme expression	SCIENCE			English	Article							FUNDULUS-HETEROCLITUS; CONTROL COEFFICIENTS; PHOSPHOFRUCTOKINASE; CONSTRAINTS; GENETICS; FLUXES	Although differences among species in enzyme maximal activity or concentration are often interpreted as adaptive and important for regulating metabolism, these differences may simply reflect phylogenetic divergence, Phylogenetic analysis of the expression of the glycolytic enzymes among 15 taxa of a North American fish genus (Fundulus) indicated that most variation in enzyme concentration is due to evolutionary distance and may be nonadaptive, However, three enzymes' maximal activities covary with environmental temperature and have adaptive value. Additionally, two pairs of enzymes covary, indicating coevolution. Thus, metabolic flux may be modulated by many different enzymes rather than by a single rate-limiting enzyme.	UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,CHICAGO,IL 60637	University of Chicago				Crawford, Douglas/0000-0002-6239-4012				BERNARDI G, 1995, COPEIA, V2, P469; Cashner R.C., 1993, P421; CHEVERUD JM, 1985, EVOLUTION, V39, P1335, DOI 10.1111/j.1558-5646.1985.tb05699.x; CHEVERUD JM, 1985, AM J PHYS ANTHROPOL, V67, P113, DOI 10.1002/ajpa.1330670206; Cornish-Bowden A., 1990, CONTROL METABOLIC PR; CRABTREE B, 1972, BIOCHEM J, V126, P49, DOI 10.1042/bj1260049; CRABTREE B, 1987, BIOCHEM J, V247, P113, DOI 10.1042/bj2470113; DANGELIS D, 1982, WATER TEMPERATURE GU; DEANGELIS D, 1982, WATER TEMPERATURE GU; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; GARLAND T, 1993, J ZOOL, V229, P133, DOI 10.1111/j.1469-7998.1993.tb02626.x; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; GARLAND T, 1993, SYST BIOL, V42, P265, DOI 10.2307/2992464; GITTLEMAN JL, 1994, PHYLOGENETICS ECOLOG; Hochachka P. W., 1984, BIOCH ADAPTATION; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KRUCKEBERG AL, 1989, BIOCHEM J, V261, P457, DOI 10.1042/bj2610457; LOTRICH VA, 1975, ECOLOGY, V56, P191, DOI 10.2307/1935311; MILES DB, 1992, AM NAT, V139, P848, DOI 10.1086/285361; NEWSHOLME EA, 1986, J EXP ZOOL, V239, P159, DOI 10.1002/jez.1402390203; OROSZ F, 1987, BIOCHEM BIOPH RES CO, V147, P1121, DOI 10.1016/S0006-291X(87)80186-9; Parenti LR, 1981, B AM MUS NAT HIST, V168, P335, DOI DOI 10.1080/00222930210135631; PIERCE VA, 1994, BIOCHEM GENET, V32, P315, DOI 10.1007/BF02426894; Pierce VA, 1996, PHYSIOL ZOOL, V69, P489, DOI 10.1086/physzool.69.3.30164212; PURVIS A, 1994, J THEOR BIOL, V167, P293, DOI 10.1006/jtbi.1994.1071; Rogers J.S., 1987, P251; SAVAGEAU MA, 1989, J THEOR BIOL, V141, P93, DOI 10.1016/S0022-5193(89)80011-6; SOMERO GN, 1990, PHYSIOL ZOOL, V63, P443, DOI 10.1086/physzool.63.3.30156222; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; WATT WB, 1985, AM NAT, V125, P118, DOI 10.1086/284331; WATT WB, 1986, SCIENCE, V233, P1187, DOI 10.1126/science.3738528; WESTNEAT MW, 1995, ENVIRON BIOL FISH, V44, P263, DOI 10.1007/BF00005920; WILEY EO, 1986, AM ZOOL, V26, P121; ZAHNER D, 1993, INT J BIOCHEM, V25, P1303, DOI 10.1016/0020-711X(93)90082-P	35	85	86	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					256	259		10.1126/science.276.5310.256	http://dx.doi.org/10.1126/science.276.5310.256			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092475				2022-12-28	WOS:A1997WT92500046
J	Salo, J; Lehenkari, P; Mulari, M; Metsikko, K; Vaananen, HK				Salo, J; Lehenkari, P; Mulari, M; Metsikko, K; Vaananen, HK			Removal of osteoclast bone resorption products by transcytosis	SCIENCE			English	Article							PROTON PUMP; OSTEOPETROSIS; ACTIN; TETRACYCLINES; EXOCYTOSIS; INVITRO; DEFECT; CELLS; MICE	Osteoclasts are multinucleated cells responsible for bone resorption. During the resorption cycle, osteoclasts undergo dramatic changes in their polarity, and resorbing cells reveal four functionally and structurally different membrane domains. Bone degradation products, both organic and inorganic, were endocytosed from the ruffled border membrane. They were then found to be transported in vesicles through the cell to the plasma membrane domain, located in the middle of the basal membrane, where they were liberated into the extracellular space. These results explain how resorbing osteoclasts can simultaneously remove large amounts of matrix degradation products and penetrate into bone.	UNIV UPPSALA, DEPT MED CELL BIOL, S-75123 UPPSALA, SWEDEN; UNIV OULU, DEPT ANAT, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, SF-90220 OULU, FINLAND	Uppsala University; University of Oulu; University of Oulu			Lehenkari, Petri/O-3009-2016; Salo, Jari/AAH-9112-2019	Lehenkari, Petri/0000-0002-0055-5183; 				BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BOYDE A, 1987, SCANNING MICROSCOPY, V1, P369; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CHOWDHURY MH, 1993, AGENTS ACTIONS, V40, P124, DOI 10.1007/BF01976761; COHLAN SQ, 1963, AM J DIS CHILD, V105, P453, DOI 10.1001/archpedi.1963.02080040455005; FROST HM, 1961, J AM GERIATR SOC, V9, P1078, DOI 10.1111/j.1532-5415.1961.tb00455.x; HOLTROP ME, 1977, CLIN ORTHOP RELAT R, V123, P177; Key L. Lyndon Jr., 1996, P941; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097-0029(19960201)33:2<171::AID-JEMT7>3.0.CO;2-W; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; RIFKIN BR, 1994, ANN NY ACAD SCI, V732, P165, DOI 10.1111/j.1749-6632.1994.tb24733.x; Rodan Gideon A., 1996, P979; Salo J, 1996, J CELL SCI, V109, P301; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAANANEN HK, 1995, J CELL SCI, V108, P2729; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	24	318	328	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					270	273		10.1126/science.276.5310.270	http://dx.doi.org/10.1126/science.276.5310.270			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092479				2022-12-28	WOS:A1997WT92500050
J	Katz, MH; Gerberding, JL				Katz, MH; Gerberding, JL			Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE WORKERS; HIV SEROCONVERSION; ORAL INTERCOURSE; TRANSMISSION; INFECTION; BLOOD; MEN; PROPHYLAXIS; INSURANCE; RAPE		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,SAN FRANCISCO,CA 94102	University of California System; University of California San Francisco; San Francisco Department of Public Health								ALBERT J, 1994, J VIROL, V68, P5918, DOI 10.1128/JVI.68.9.5918-5924.1994; *AM MED ASS, 1996, PHYS GUID HIV PREV; BLAUVELT A, 1995, J INVEST DERMATOL, V105, pS122, DOI 10.1111/1523-1747.ep12316662; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Claydon E, 1991, Int J STD AIDS, V2, P200; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; FAHRNER R, 1994, 34 INT C ANT AG CHEM, P133; FLEISHMAN JA, 1993, INQUIRY-J HEALTH CAR, V30, P180; FOSTER I, 1989, BRIT MED J, V299, P1282, DOI 10.1136/bmj.299.6710.1282; GAUGHWIN MD, 1991, AIDS, V5, P1025, DOI 10.1097/00002030-199108000-00016; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116; KATZ MH, 1995, J ACQ IMMUN DEF SYND, V8, P58; LAFON SW, 1990, 30TH INT C ANT AG CH, P167; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; Lu YC, 1996, J VIROL, V70, P3045, DOI 10.1128/JVI.70.5.3045-3050.1996; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MATHES LE, 1992, ANTIMICROB AGENTS CH, V36, P2715, DOI 10.1128/AAC.36.12.2715; Miller C J, 1994, Curr Top Microbiol Immunol, V188, P107; MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PETERMAN TA, 1989, JAMA-J AM MED ASSOC, V262, P502; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; PURO V, 1992, AIDS, V6, P963, DOI 10.1097/00002030-199209000-00009; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; ROZENBAUM W, 1988, LANCET, V1, P1395; SAMUEL MC, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P423; SPARROW MJ, 1994, CONTRACEPTION, V50, P117, DOI 10.1016/0010-7824(94)90048-5; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; THOMPSON JLP, 1993, AM J PUBLIC HEALTH, V83, P1409, DOI 10.2105/AJPH.83.10.1409; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; Voelker R, 1996, JAMA-J AM MED ASSOC, V276, P585, DOI 10.1001/jama.276.8.585; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; 1993, MMWR-MORBID MORTAL W, V42, P11; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468	42	137	137	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1097	1100		10.1056/NEJM199704103361512	http://dx.doi.org/10.1056/NEJM199704103361512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091810				2022-12-28	WOS:A1997WT16100012
J	Khuroo, MS; Yattoo, GN; Javid, G; Khan, BA; Shah, AA; Gulzar, GM; Sodi, JS				Khuroo, MS; Yattoo, GN; Javid, G; Khan, BA; Shah, AA; Gulzar, GM; Sodi, JS			A comparison of omeprazole and placebo for bleeding peptic ulcer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; VISIBLE VESSELS; HEMORRHAGE; PH	Background The role of medical treatment for patients with bleeding peptic ulcers is uncertain. Methods We conducted a double-blind, placebo-controlled trial in 220 patients with duodenal, gastric, or stomal ulcers and signs of recent bleeding, as confirmed by endoscopy. In 26 patients the ulcers showed arterial spurting, in 34 there was active oozing, in 35 there were nonbleeding, visible vessels, and in 125 there were adherent clots. The patients were randomly assigned to receive omeprazole (40 mg given orally every 12 hours for five days) or placebo. The outcome measures studied were further bleeding, surgery, and death. Results Twelve of the 110 patients treated with omeprazole (10.9 percent) had continued bleeding or further bleeding, as compared with 40 of the 110 patients who received placebo (36.4 percent) (P<0.001). Eight patients in the omeprazole group and 26 in the placebo group required surgery to control their bleeding (P<0.001). Two patients in the omeprazole group and six in the placebo group died. Thirty-two patients in the omeprazole group (29.1 percent) and 78 in the placebo group (70.9 percent) received transfusions (P<0.001). A subgroup analysis showed that omeprazole was associated with significant reductions in recurrent bleeding and surgery in patients with nonbleeding, visible vessels or adherent clots, but not in those with arterial spurting or oozing. Conclusions In patients with bleeding peptic ulcers and signs of recent bleeding, treatment with omeprazole decreases the rate of further bleeding and the need for surgery. (C) 1997, Massachusetts Medical Society.	SHERI KASHMIR INST MED SCI,DEPT GASTROENTEROL,SRINAGAR,JAMMU & KASHMIR,INDIA	Sher-i-Kashmir Institute of Medical Sciences			Khuroo, Mohammad Sultan/N-3571-2014	Khuroo, Mohammad Sultan/0000-0003-2823-8814				Ahmed S Z, 1975, J Assoc Physicians India, V23, P321; BARER D, 1983, NEW ENGL J MED, V308, P1571, DOI 10.1056/NEJM198306303082606; BARKHAM P, 1953, J APPL PHYSIOL, V6, P1; BRANICKI FJ, 1990, ANN SURG, V211, P411, DOI 10.1097/00000658-199004000-00006; CAMPBELL MJ, 1992, MED STAT COMMON SENS; CHRISTIANSEN J, 1989, GASTROENTEROLOGY, V97, P568, DOI 10.1016/0016-5085(89)90626-4; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; DEMUCKADELL OBS, 1995, GASTROENTEROLOGY, V108, pA212; FLEISCHER DE, 1990, J CLIN GASTROENTEROL, V12, pS41, DOI 10.1097/00004836-199000000-00008; FLEISS JL, 1979, J CHRON DIS, V32, P69, DOI 10.1016/0021-9681(79)90015-8; FORREST JAH, 1974, LANCET, V2, P394; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, pS8; GRIFFITHS WJ, 1979, NEW ENGL J MED, V300, P1411, DOI 10.1056/NEJM197906213002503; HAN P, 1974, BRIT J HAEMATOL, V26, P373, DOI 10.1111/j.1365-2141.1974.tb00479.x; JENSEN DM, 1990, GASTROINTEST ENDOSC, V36, pS42; JOHNSTON JH, 1990, GASTROINTEST ENDOSC, V36, pS16; Khuroo M S, 1974, J Indian Med Assoc, V63, P185; KREJS GJ, 1987, NEW ENGL J MED, V316, P1618, DOI 10.1056/NEJM198706253162602; LAINE L, 1989, ANN INTERN MED, V110, P510, DOI 10.7326/0003-4819-110-7-510; LANAS A, 1995, J CLIN GASTROENTEROL, V21, P103, DOI 10.1097/00004836-199509000-00008; LANGMAN MJS, 1990, HEPATO-GASTROENTEROL, V37, P29; LIND T, 1995, GASTROENTEROLOGY, V108, pA150, DOI 10.1016/0016-5085(95)23265-6; OXNER RBG, 1992, LANCET, V339, P966, DOI 10.1016/0140-6736(92)91537-I; PATCHETT SE, 1989, GUT, V30, P1704, DOI 10.1136/gut.30.12.1704; WALT RP, 1992, LANCET, V340, P1058, DOI 10.1016/0140-6736(92)93078-2; ZUCKERMAN G, 1984, AM J MED, V76, P361, DOI 10.1016/0002-9343(84)90652-1; 1989, JAMA-J AM MED ASSOC, V262, P1369	28	248	252	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1054	1058		10.1056/NEJM199704103361503	http://dx.doi.org/10.1056/NEJM199704103361503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091801				2022-12-28	WOS:A1997WT16100003
J	Michalopoulos, GK; DeFrances, MC				Michalopoulos, GK; DeFrances, MC			Liver regeneration	SCIENCE			English	Review							HEPATOCYTE GROWTH-FACTOR; PARTIALLY HEPATECTOMIZED RATS; HEPATIC STIMULATOR SUBSTANCE; FACTOR HEPATOPOIETIN-A; FAT-STORING CELLS; DNA-SYNTHESIS; FACTOR-ALPHA; GENE-EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA	Liver regeneration after the loss of hepatic tissue is a fundamental parameter of liver response to injury. Recognized as a phenomenon from mythological times, it is now defined as an orchestrated response induced by specific external stimuli and involving sequential changes in gene expression, growth factor production, and morphologic structure. Many growth factors and cytokines, most notably hepatocyte growth factor, epidermal growth factor, transforming growth factor-alpha, interleukin-6, tumor necrosis factor-alpha, insulin, and norepinephrine, appear to play important roles in this process. This review attempts to integrate the findings of the last three decades and looks toward clues as to the nature of the causes that trigger this fascinating organ and cellular response.			Michalopoulos, GK (corresponding author), UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15261 USA.				NATIONAL CANCER INSTITUTE [R01CA030241, R37CA030241, R01CA035373] Funding Source: NIH RePORTER; NCI NIH HHS [CA35373, CA30241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPASAMY R, 1993, LAB INVEST, V68, P270; AUGENLICHT LH, 1975, EXP MOL PATHOL, V22, P1, DOI 10.1016/0014-4800(75)90045-3; BEERSTOLZ D, 1997, J CELL PHYSIOL, V170, P57; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; BONNEY RJ, 1973, BIOCHEM J, V136, P115, DOI 10.1042/bj1360115; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; CARR BI, 1986, CANCER RES, V46, P2330; CHARI RS, 1995, AM J SURG, V169, P126, DOI 10.1016/S0002-9610(99)80120-2; CHU RY, 1995, J BIOL CHEM, V270, P29636; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; CORNELL RP, 1981, AM J PHYSIOL, V241, pE428, DOI 10.1152/ajpendo.1981.241.6.E428; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; CRUISE JL, 1985, SCIENCE, V227, P749, DOI 10.1126/science.2982212; CRUISE JL, 1987, HEPATOLOGY, V7, P1189, DOI 10.1002/hep.1840070604; CRUISE JL, 1985, J CELL PHYSIOL, V125, P45, DOI 10.1002/jcp.1041250107; DEHEMPTINNE B, 1985, ACTA GASTRO-ENT BELG, V48, P424; DELAHUNTY TJ, 1970, J LIPID RES, V11, P536; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; FAUSTO N, 1991, CIBA F SYMP, V157, P165; Fausto N, 1986, Symp Fundam Cancer Res, V39, P69; FAUSTO N, 1993, P SOC EXP BIOL MED, V204, P237; FISHER B, 1971, SCIENCE, V171, P575, DOI 10.1126/science.171.3971.575; FLEIG WE, 1989, HEPATOLOGY, V9, P240, DOI 10.1002/hep.1840090213; FLYNN PJ, 1968, ARCH PATHOL, V85, P138; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; FRANCAVILLA A, 1988, TRANSPLANT P, V20, P494; GAULDIE J, 1992, RES IMMUNOL, V143, P755, DOI 10.1016/0923-2494(92)80018-G; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GRESSNER AM, 1995, J HEPATOL, V22, P28; GRISHAM JW, 1962, CANCER RES, V22, P842; GRISHAM JW, 1964, CANCER RES, V24, P1474; Grompe M, 1996, HEPATOLOGY, V24, P519; GUPTA C, 1988, CANCER RES, V48, P1162; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; Higgins GM, 1931, ARCH PATHOL, V12, P186; HORIMOTO M, 1995, J HEPATOL, V23, P174, DOI 10.1016/0168-8278(95)80332-7; HOUCK KA, 1989, J CELL PHYSIOL, V141, P503, DOI 10.1002/jcp.1041410308; HOUSSET CN, 1995, J HEPATOL, V22, P55; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; JIRTLE RL, 1991, DIGEST DIS SCI, V36, P659, DOI 10.1007/BF01297035; JIRTLE RL, 1982, CANCER RES, V42, P3000; JIRTLE RL, UNPUB; JONES DE, 1995, AM J PHYSIOL-GASTR L, V268, pG872, DOI 10.1152/ajpgi.1995.268.5.G872; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAWASAKI S, 1992, LANCET, V339, P580, DOI 10.1016/0140-6736(92)90867-3; Kim TH, 1996, HEPATOLOGY, V24, P30; Kitamura N, 1993, EXS, V65, P49; Kopp JB, 1996, LAB INVEST, V74, P991; KORDULA T, 1991, LYMPHOKINE CYTOK RES, V10, P23; KRAWITT EL, 1969, BIOCHIM BIOPHYS ACTA, V174, P763, DOI 10.1016/0005-2787(69)90308-6; KUMA S, 1990, IMMUNOBIOLOGY, V180, P235, DOI 10.1016/S0171-2985(11)80331-1; LABRECQUE DR, 1987, HEPATOLOGY, V7, P100, DOI 10.1002/hep.1840070121; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LASHINA IN, 1970, B EKSP BIOL MED, V70, P95; LEE GH, 1992, CANCER RES, V52, P5162; LINDROOS P, 1993, CARCINOGENESIS, V14, P731, DOI 10.1093/carcin/14.4.731; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LIU KX, 1992, AM J PHYSIOL, V263, pG642, DOI 10.1152/ajpgi.1992.263.5.G642; LIU ML, 1994, AM J PATHOL, V144, P129; LIU ML, 1994, HEPATOLOGY, V19, P1521; LOYER P, 1994, J BIOL CHEM, V269, P2491; Mars WM, 1996, CANCER RES, V56, P2837; MARS WM, 1993, AM J PATHOL, V143, P949; MARS WM, 1995, HEPATOLOGY, V21, P1695, DOI 10.1016/0270-9139(95)90477-8; MARTINEZHERNANDEZ A, 1995, FASEB J, V9, P1401, DOI 10.1096/fasebj.9.14.7589981; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MATSUMOTO K, 1994, HEPATOLOGY, V20, P376; MATSUNAMI H, 1992, TRANSPLANT P, V24, P1971; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; Michalopoulos GK, 1995, LIVER REGENERATION C, P27; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; Mochida S, 1996, BIOCHEM BIOPH RES CO, V226, P176, DOI 10.1006/bbrc.1996.1329; MOGHUL A, 1994, ONCOGENE, V9, P2045; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOOLTEN FL, 1967, SCIENCE, V158, P272, DOI 10.1126/science.158.3798.272; NADAL C, 1966, EXP CELL RES, V42, P99, DOI 10.1016/0014-4827(66)90324-7; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1991, ONCOGENE, V6, P501; NOGUCHI S, 1991, J ENDOCRINOL, V128, P425, DOI 10.1677/joe.0.1280425; OGAWA K, 1979, BRIT J CANCER, V40, P782, DOI 10.1038/bjc.1979.261; Ohmura T, 1996, LIFE SCI, V58, pPL211, DOI 10.1016/0024-3205(96)00039-2; OLSEN PS, 1985, GUT, V26, P920, DOI 10.1136/gut.26.9.920; OLSEN PS, 1988, HEPATOLOGY, V8, P992, DOI 10.1002/hep.1840080503; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PETERSEN B, 1994, CELL BIOL TOXICOL, V10, P219, DOI 10.1007/BF00756762; RABES HM, 1976, CELL TISSUE KINET, V9, P517; Rai RM, 1996, AM J PHYSIOL-GASTR L, V270, pG909, DOI 10.1152/ajpgi.1996.270.6.G909; REDDY JK, 1986, ENVIRON HEALTH PERSP, V65, P317, DOI 10.2307/3430199; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; Rifkin D B, 1992, Matrix Suppl, V1, P20; ROOS F, 1995, AM J PHYSIOL-GASTR L, V268, pG380, DOI 10.1152/ajpgi.1995.268.2.G380; RUBIN RA, 1982, P NATL ACAD SCI-BIOL, V79, P776, DOI 10.1073/pnas.79.3.776; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Russell WE, 1996, MOL CARCINOGEN, V15, P183; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sargent LM, 1996, CANCER RES, V56, P2137; SCHIRMACHER P, 1992, HEPATOLOGY, V15, P5, DOI 10.1002/hep.1840150103; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHWARZE PE, 1984, CARCINOGENESIS, V5, P1267, DOI 10.1093/carcin/5.10.1267; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; SELL S, 1994, MODERN PATHOL, V7, P105; SHINOZUKA H, 1994, LAB INVEST, V71, P35; SHORT J, 1980, CYTOBIOS, V28, P165; STARZL TE, 1976, LANCET, V1, P821; STARZL TE, 1978, SURG GYNECOL OBSTET, V147, P193; STARZL TE, 1973, SURG GYNECOL OBSTET, V137, P179; STARZL TE, 1993, LANCET, V341, P8853; STHILAIRE RJ, 1983, P NATL ACAD SCI-BIOL, V80, P3797; STOCKER E, 1973, VIRCHOWS ARCH B, V14, P93; Stocker E, 1971, Beitr Pathol, V144, P400; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Thorgeirsson SS, 1996, FASEB J, V10, P1249, DOI 10.1096/fasebj.10.11.8836038; Tomiya T, 1996, HEPATOLOGY, V23, P253; TOMIYA T, 1992, GASTROENTEROLOGY, V103, P1621, DOI 10.1016/0016-5085(92)91186-8; Tomiya T, 1996, CANCER, V77, P1056, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1056::AID-CNCR8>3.0.CO;2-F; TSANEV R, 1975, P197; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Walker P R, 1972, Adv Enzyme Regul, V10, P339, DOI 10.1016/0065-2571(72)90022-2; WEBBER EM, 1994, AM J PATHOL, V145, P398; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; WIDMANN JJ, 1975, LIVER REGENERATION E, P89; XU HS, 1993, ANN SURG, V218, P176, DOI 10.1097/00000658-199308000-00009; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; YANAGI S, 1977, LIFE SCI, V20, P1509, DOI 10.1016/0024-3205(77)90442-8; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; YEE AG, 1975, J CELL BIOL, V66, P200, DOI 10.1083/jcb.66.1.200; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	140	2674	2797	7	296	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					60	66		10.1126/science.276.5309.60	http://dx.doi.org/10.1126/science.276.5309.60			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082986				2022-12-28	WOS:A1997WR38600045
J	Vidal, V; Theolier, A; ThivolleCazat, J; Basset, JM				Vidal, V; Theolier, A; ThivolleCazat, J; Basset, JM			Metathesis of alkanes catalyzed by silica-supported transition metal hydrides	SCIENCE			English	Article							SURFACE ORGANOMETALLIC CHEMISTRY; C-H BONDS; OLEFIN METATHESIS; COMPLEX; ACTIVATION; ZIRCONIUM; METHANE; HYDROGENOLYSIS; MECHANISM; TANTALUM	The silica-supported transition metal hydrides (=Si-O-Si=)(=Si-O-)(2)Ta-H and (=Si-O-)(x)M-H (M, chromium or tungsten) catalyze the metathesis reaction of linear or branched alkanes into the next higher and lower alkanes at moderate temperature (25 degrees to 200 degrees C). With (=Si-O-Si=)(=Si-O-)(2)Ta-H, ethane was transformed at room temperature into an equimolar mixture of propane and methane. Higher and lower homologs were obtained from propane, butane, and pentane as well as from branched alkanes such as isobutane and isopentane. The mechanism of the step leading to carbon-carbon bond cleavage and formation likely involves a four-centered transition state between a tantalum-alkyl intermediate and a carbon-carbon sigma-bond of a second molecule of alkane.	LAB CHIM ORGANOMET SURFACE,UMR CNRS CPE 9986,F-69616 VILLEURBANNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)				basset, jean marie/0000-0003-3166-8882				Ajjou JAN, 1997, ORGANOMETALLICS, V16, P86; BANKS RL, 1964, IND ENG CHEM PROD RD, V3, P170, DOI 10.1021/i360011a002; BHASIN MM, 1995, METHANE ALKANE CONVE; CALDERON N, 1972, ACCOUNTS CHEM RES, V5, P127, DOI 10.1021/ar50052a002; Corker J, 1996, SCIENCE, V271, P966, DOI 10.1126/science.271.5251.966; CRABTREE RH, 1984, J CHEM SOC CHEM COMM, P1260, DOI 10.1039/c39840001260; CRABTREE RH, 1985, CHEM REV, V85, P245, DOI 10.1021/cr00068a002; DAVIDSON PJ, 1973, J ORGANOMET CHEM, V57, P269, DOI 10.1016/S0022-328X(00)86607-3; DUFAUD V, 1995, J AM CHEM SOC, V117, P4288, DOI 10.1021/ja00120a010; ELEUTERIO HS, 1991, J MOL CATAL, V65, P55, DOI 10.1016/0304-5102(91)85082-D; Ivin K J., 1983, OLEFIN METATHESIS; IWSAWA Y, 1986, TAILORED METAL CATAL; LECUYER C, 1991, ANGEW CHEM INT EDIT, V30, P1660, DOI 10.1002/anie.199116601; MIMOUN H, 1987, NEW J CHEM, V11, P513; MORTREUX A, 1978, TETRAHEDRON LETT, V49, P4967; MOWAT W, 1972, J CHEM SOC DALTON, P533, DOI 10.1039/dt9720000533; NATTA G, 1964, ANGEW CHEM INT EDIT, V3, P723, DOI 10.1002/anie.196407231; PERIANA RA, 1984, J AM CHEM SOC, V106, P7272, DOI 10.1021/ja00335a084; PUDDEPHATT RJ, 1980, COORDIN CHEM REV, V33, P149; QUIGNARD F, 1992, INORG CHEM, V31, P928, DOI 10.1021/ic00031a042; QUIGNARD F, 1991, J CHEM SOC CHEM COMM, P1589, DOI 10.1039/c39910001589; QUIGNARD F, 1992, J MOL CATAL, V74, P353, DOI 10.1016/0304-5102(92)80253-D; QUIGNARD F, 1994, J CHEM SOC DALTON, P1153, DOI 10.1039/dt9940001153; SCHROCK RR, 1978, J AM CHEM SOC, V100, P3359, DOI 10.1021/ja00479a019; SCHROCK RR, 1989, INORG SYNTH, V26, P4; STULL DR, 1987, CHEM THERMODYNAMICS; TAKAYA H, 1981, J ORG CHEM, V46, P2854, DOI 10.1021/jo00327a004; TAKAYA H, 1981, J ORG CHEM, V46, P2846, DOI 10.1021/jo00327a003; THOMPSON ME, 1987, J AM CHEM SOC, V109, P203, DOI 10.1021/ja00235a031; Vidal V, 1996, J AM CHEM SOC, V118, P4595, DOI 10.1021/ja953524l; VIDAL V, 1995, J CHEM SOC CHEM COMM, P991, DOI 10.1039/c39950000991; WATSON PL, 1983, J AM CHEM SOC, V105, P6491, DOI 10.1021/ja00359a023; WOO HG, 1992, J AM CHEM SOC, V114, P7047, DOI 10.1021/ja00044a015; 9609033	34	238	242	3	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					99	102		10.1126/science.276.5309.99	http://dx.doi.org/10.1126/science.276.5309.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082995				2022-12-28	WOS:A1997WR38600054
J	Kennedy, M; Firpo, M; Chol, K; Wall, C; Robertson, S; Kabrun, N; Keller, G				Kennedy, M; Firpo, M; Chol, K; Wall, C; Robertson, S; Kabrun, N; Keller, G			A common precursor for primitive erythropoiesis and definitive haematopoiesis	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; YOLK-SAC; FETAL DEVELOPMENT; PROGENITOR CELLS; BLOOD-ISLAND; MOUSE; DIFFERENTIATION; MICE; BINDING; EMBRYO	The generation of blood cells, haematopoiesis, in the mouse embryo begins with the development of primitive nucleated erythroid cells in the yolk sac followed by the appearance of precursors for multiple definitive haematopoietic lineages(1-4) The later developing lineages arise from multipotential stem cells(5,6), but the relationship of primitive erythroid cells to these other haematopoietic populations is unknown. Using an in vitro embryonic stem (ES) cell differentiation system(7), we show that primitive erythrocytes and other haematopoietic lineages arise from a common multipotential precursor that develops within embryoid bodies generated from differentiated ES cells, In response to vascular endothelial growth factor and c-kit Ligand these precursors give rise to colonies containing immature cells (blasts) expressing marker genes characteristic of haematopoietic precursors, Many blast colonies also expressed beta H1 and beta major globins but not Brachyury, a mesodermal marker, Kinetic analysis demonstrated that the blast colony-forming cells represent a transient population, preceding the establishment of the primitive erythroid and other lineage-restricted precursors, This precursor population may represent the earliest stage of embryonic haematopoietic commitment.	NATL JEWISH MED & RES CTR, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Robertson, Scott/B-9018-2013	Keller, Gordon/0000-0001-9309-9297				BARKER JE, 1968, DEV BIOL, V18, P14, DOI 10.1016/0012-1606(68)90020-1; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVIN CI, 1984, J IMMUNOL, V133, P157; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; KAU CL, 1983, J IMMUNOL, V131, P2262; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LIU CP, 1991, DEVELOPMENT, V113, P1315; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; ORKIN SH, 1992, BLOOD, V80, P575; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; WILLIAMS RL, 1988, CELL, V52, P121; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	30	452	477	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	1997	386	6624					488	493		10.1038/386488a0	http://dx.doi.org/10.1038/386488a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087406				2022-12-28	WOS:A1997WR25600050
J	Pelletier, A				Pelletier, A			Deaths among railroad trespassers - The role of alcohol in fatal injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACCIDENTS; TRAIN	Objective.-To describe the characteristics of persons killed by trains while trespassing (ie, using railroad property for activities unrelated to railroad operations). Design.-Case series obtained from records of the state medical examiner. Setting.-North Carolina, 1990 through 1994. Subjects.-One hundred twenty-eight persons ranging in age from 7 to 84 years who were killed in 125 separate incidents. Results.-Of 224 railroad-related deaths during the study period, 128 cases (57%) involved trespassers. Trespasser fatalities typically involved unmarried male pedestrians 20 to 49 years of age with less than a high school education. Eighty-two percent of incidents occurred in the trespassers' county of residence, indicating that few deaths involved transients. Fatalities among railroad trespassers exhibited both geographic and temporal clustering. Seventy-eight percent of trespassers were killed while intoxicated (median alcohol level, 56 mmol/L [260 mg/dL]). Conclusions.-Deaths among trespassers are the leading cause of railroad-related mortality in North Carolina. Greater efforts are needed to reduce this type of preventable injury. Prevention of trespasser fatalities is dependent on control of alcohol abuse, enforcement of existing laws, and education of the public regarding the dangers of railroad trespassing.			Pelletier, A (corresponding author), CTR DIS CONTROL & PREVENT,STATE BRANCH,DIV APPL PUBL HLTH TRAINING,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333, USA.							CINA SJ, 1994, J FORENSIC SCI, V39, P668; DEAN AG, 1994, EPI INF VERS 6 WORD; *FED RAILR ADM, 1994, RAIL HIGHW CROSS SAF; *FED RAILR ADM, 1995, TRESP B, V4; Hilton ME, 1991, ALCOHOL AM DRINKING, P73; IRWIN ST, 1983, BRIT MED J, V286, P522, DOI 10.1136/bmj.286.6364.522; MOORE TJ, 1991, SOUTH MED J, V84, P1097, DOI 10.1097/00007611-199109000-00009; MOORE TJ, 1991, SO MED J, V84, P1102; Murphy G K, 1976, J Forensic Sci, V21, P218; *NAT TRANSP SAF BO, 1978, R782 NAT TRANS SAF B; NIXON J, 1985, ACCIDENT ANAL PREV, V17, P217, DOI 10.1016/0001-4575(85)90054-5; SYMONDS RL, 1985, PSYCHOL MED, V15, P609, DOI 10.1017/S0033291700031469	12	31	31	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1064	1066						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091695				2022-12-28	WOS:A1997WQ08900032
J	Appleby, L; Warner, R; Whitton, A; Faragher, B				Appleby, L; Warner, R; Whitton, A; Faragher, B			A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER; PREVALENCE; COMMUNITY; IMPACT; SCALE	Objective: To study the effectiveness of fluoxetine and cognitive-behavioural counselling in depressive illness in postnatal women: to compare fluoxetine and placebo, six sessions and one session of counselling, and combinations of drugs and counselling. Design: Randomised, controlled treatment trial, double blind in relation to drug treatment, with four treatment cells: fluoxetine or placebo plus one or six sessions of counselling. Subjects: 87 women satisfying criteria for depressive illness 6-8 weeks after childbirth, 61 (70%) of whom completed 12 weeks of treatment Setting: Community based study in south Manchester. Main outcome measures: Psychiatric morbidity after 1, 4, and 12 weeks, measured as mean scores and 95% confidence limits on the revised clinical interview schedule, the Edinburgh postnatal depression scale and the Hamilton depression scale, Results: Highly significant improvement was seen in all four treatment groups. The improvement in subjects receiving fluoxetine was significantly greater than in those receiving placebo. The improvement after six sessions of counselling was significantly greater than after a single session, Interaction between counselling and fluoxetine was not statistically significant These differences were evident after one week, and improvement in all groups was complete after four weeks. Conclusions: Both fluoxetine and cognitive-behavioural counselling given as a course of therapy are effective treatments for non-psychotic depression in postnatal women. After an initial session of counselling, additional benefit results from either fluoxetine or further counselling but there seems to be no advantage in receiving both, The choice of treatment may therefore be made by the women themselves.	UNIV MANCHESTER,SCH MED,RES SUPPORT UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester	Appleby, L (corresponding author), UNIV MANCHESTER,WITHINGTON HOSP,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M20 8LR,LANCS,ENGLAND.							COGILL SR, 1986, BMJ-BRIT MED J, V292, P1165, DOI 10.1136/bmj.292.6529.1165; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; COX JL, 1993, BRIT J PSYCHIAT, V163, P27, DOI 10.1192/bjp.163.1.27; Gregoire AJP, 1996, LANCET, V347, P930, DOI 10.1016/S0140-6736(96)91414-2; Hamilton M., 1976, ECDEU ASSESSMENT MAN, P179; HOLDEN JM, 1989, BRIT MED J, V298, P223, DOI 10.1136/bmj.298.6668.223; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; MURRAY L, 1992, J CHILD PSYCHOL PSYC, V33, P543, DOI 10.1111/j.1469-7610.1992.tb00890.x; MURRAY L, 1990, BRIT J PSYCHIAT, V157, P288, DOI 10.1192/bjp.157.2.288; PAYKEL ES, 1980, BRIT J PSYCHIAT, V136, P339, DOI 10.1192/bjp.136.4.339; PITT B, 1968, BRIT J PSYCHIAT, V114, P1325, DOI 10.1192/bjp.114.516.1325; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; TENNANT C, BRIT J PSYCHIAT, V139, P213; Warner R, 1996, BRIT J PSYCHIAT, V168, P607, DOI 10.1192/bjp.168.5.607; WATSON JP, 1984, BRIT J PSYCHIAT, V144, P453, DOI 10.1192/bjp.144.5.453; Whitton A, 1996, BRIT J GEN PRACT, V46, P427	18	361	367	0	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					932	936		10.1136/bmj.314.7085.932	http://dx.doi.org/10.1136/bmj.314.7085.932			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WQ169	9099116	Green Published			2022-12-28	WOS:A1997WQ16900024
J	Hill, JA; Friedman, PL				Hill, JA; Friedman, PL			Measurement of QT interval and QT dispersion	LANCET			English	Editorial Material											Hill, JA (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,BOSTON,MA 02115, USA.							COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; KAUTZNER J, 1994, PACE, V17, P928, DOI 10.1111/j.1540-8159.1994.tb01435.x; McLaughlin NB, 1996, HEART, V76, P422, DOI 10.1136/hrt.76.5.422; MCLAUGHLIN NB, 1995, BRIT HEART J, V74, P84; MURRAY A, 1994, BRIT HEART J, V71, P386; VOLKA ME, 1996, J INVASIVE CARDIOL, V8, P363	6	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					894	895		10.1016/S0140-6736(05)62692-X	http://dx.doi.org/10.1016/S0140-6736(05)62692-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093246				2022-12-28	WOS:A1997WR25400004
J	White, S				White, S			Ordinary misery should not be mistaken for pathology - Comment	BRITISH MEDICAL JOURNAL			English	Editorial Material											White, S (corresponding author), UNIV MANCHESTER,DEPT SOCIAL POLICY & SOCIAL WORK,MANCHESTER M1 3PL,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					816	817		10.1136/bmj.314.7083.816	http://dx.doi.org/10.1136/bmj.314.7083.816			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081007	Green Published			2022-12-28	WOS:A1997WN64600038
J	Vesterager, V				Vesterager, V			Fortnightly review - Tinnitus - Investigation and management	BRITISH MEDICAL JOURNAL			English	Review											Vesterager, V (corresponding author), BISPEBJERG HOSP,DEPT AUDIOL PHONIATR,REHABIL SECT,DK-2400 COPENHAGEN,DENMARK.							AXELSSON A, 1989, British Journal of Audiology, V23, P53, DOI 10.3109/03005368909077819; Axelsson A, 1995, AUDIOLOGY, V34, P301; AXELSSON A, 1993, J AUDIOLOGICAL MED, V2, P141; CARLSSON SG, 1991, J PSYCHOSOM RES, V35, P509, DOI 10.1016/0022-3999(91)90045-P; COLES R, 1995, P 5 INT TINN SEM POR; COLES RRA, 1990, PRESBYACUSIS OTHER A; ERLANDSSON S, 1987, British Journal of Audiology, V21, P37, DOI 10.3109/03005368709077773; HALLAM R, 1984, CONTRIBUTIONS MED PS; HALLAM RS, 1987, TINNITUS; HAZELL J, 1987, TINNITUS; HAZELL J W P, 1985, British Journal of Audiology, V19, P65, DOI 10.3109/03005368509078966; Hazell J. W. P., 1987, TINNITUS; HINCHCLIFFE R, 1992, J AUDIOLOGICAL MED, V1, P38; JACKSON P, 1983, HEARING BALANCE ELDE; JAKES SC, 1986, BEHAV RES THER, V24, P497, DOI 10.1016/0005-7967(86)90029-X; JASTREBOFF PJ, 1993, BRIT J AUDIOL, V27, P7, DOI 10.3109/03005369309077884; JASTREBOFF PJ, 1990, NEUROSCI RES, V8, P221, DOI 10.1016/0168-0102(90)90031-9; LINDBERG P, 1988, British Journal of Audiology, V22, P265, DOI 10.3109/03005368809076463; MELIN L, 1987, British Journal of Audiology, V21, P91, DOI 10.3109/03005368709077782; SCOTT B, 1985, SCAND AUDIOL, V14, P223, DOI 10.3109/01050398509045945; SCOTT B, 1990, British Journal of Audiology, V24, P51, DOI 10.3109/03005369009077842; SHELDRAKE JB, 1995, P 5 INT TINN SEM	22	26	30	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					728	731		10.1136/bmj.314.7082.728	http://dx.doi.org/10.1136/bmj.314.7082.728			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116552	Green Published			2022-12-28	WOS:A1997WM77600029
J	Naylor, AR; London, NJM; Bell, PRF				Naylor, AR; London, NJM; Bell, PRF			Carotid endarterectomy versus carotid angioplasty	LANCET			English	Editorial Material											Naylor, AR (corresponding author), LEICESTER ROYAL INFIRM,DEPT SURG,CLIN SCI BLDG,LEICESTER LE2 7LX,LEICS,ENGLAND.							Beebe HG, 1996, STROKE, V27, P197, DOI 10.1161/01.STR.27.2.197; Brown MM, 1996, STROKE, V27, P1435; BUCKENHAM T, 1996, P EUR SOC VASC SURG; *CAR VERT ART TRAN, 1996, STROKE, V27, P358; *EUR CAR SURG TRIA, 1991, LANCET, V337, P1235; HSAI DC, 1992, J VASC SURG, V16, P201; *N AM SYMPT CAR EN, 1991, NEW ENGL J MED, V325, P445; Sivaguru A, 1996, J ENDOVASC SURG, V3, P16, DOI 10.1583/1074-6218(1996)003<0016:ECAT>2.0.CO;2	8	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					203	204		10.1016/S0140-6736(96)07181-4	http://dx.doi.org/10.1016/S0140-6736(96)07181-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111559				2022-12-28	WOS:A1997WC86100048
J	Gianni, AM; Bregni, M; Siena, S; Brambilla, C; DiNicola, M; Lombardi, F; Gandola, L; Tarella, C; Pileri, A; Ravagnani, F; Valagussa, P; Bonadonna, G; Stern, AC; Magni, M; Caracciolo, D				Gianni, AM; Bregni, M; Siena, S; Brambilla, C; DiNicola, M; Lombardi, F; Gandola, L; Tarella, C; Pileri, A; Ravagnani, F; Valagussa, P; Bonadonna, G; Stern, AC; Magni, M; Caracciolo, D			High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; NON-HODGKINS-LYMPHOMA; SEQUENTIAL CHEMORADIOTHERAPY; THERAPY; TOXICITY; DISEASE; REGIMEN; MYELOMA; CANCER	Background We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by myeloablative treatment and bone marrow transplantation, with a regimen of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) as initial or salvage treatment for adults with diffuse large-cell lymphoma. Methods Ninety-eight eligible patients with diffuse large-cell lymphoma of the B-cell type were randomly assigned to receive either MACOP-B (50 patients) or high-dose sequential therapy (48 patients). If the assigned treatment failed, the study design allowed patients to cross over to the other treatment group. Results After a median follow-up of 55 months, the patients given high-dose sequential therapy, as compared with those treated with MACOP-B, had significantly higher rates of complete response (96 percent vs. 70 percent, P=0.001), freedom from disease progression (84 percent vs. 49 percent, P<0.001), freedom from relapse (88 percent vs. 70 percent, P=0.055), and event-free survival (76 percent vs. 49 percent, P=0.004). The difference in overall survival at seven years, which also favored the group assigned to high-dose sequential therapy, was marginally significant (81 percent vs. 55 percent, P=0.09). Conclusions High-dose sequential therapy is superior to standard-dose MACOP-B for patients with diffuse diffuse large-cell lymphoma of the B-cell type. (C) 1997, Massachusetts Medical Society.	UNIV MILAN,DEPT MED ONCOL,CRISTINA GANDINI BONE MARROW TRANSPLANTAT UNIT,MILAN,ITALY; IST NAZL STUDIO & CURA TUMORI,DEPT RADIOTHERAPY,I-20133 MILAN,ITALY; UNIV TURIN,CATTEDRA EMATOL,TURIN,ITALY; SANDOZ CLIN RES,BASEL,SWITZERLAND	University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Turin; Novartis; Sandoz			SIENA, SALVATORE/AAC-5806-2019; Magni, Michele/AAC-1310-2020; gandola, lorenza/K-5271-2016; Di Nicola, Massimo/C-7694-2017; Pileri, Alessandro/D-7345-2017	SIENA, SALVATORE/0000-0002-2681-2846; Magni, Michele/0000-0003-0890-7144; gandola, lorenza/0000-0002-7020-1188; Pileri, Alessandro/0000-0002-1025-7171				[Anonymous], 1982, CANCER, V49, P2112; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; DUHRSEN U, 1988, BLOOD, V72, P2074; GIANNI AM, 1989, EUR J CANCER CLIN ON, V25, P1027, DOI 10.1016/0277-5379(89)90382-9; GIANNI AM, 1994, J CLIN ONCOL, V12, P503, DOI 10.1200/JCO.1994.12.3.503; GIANNI AM, 1992, J CLIN ONCOL, V10, P1955, DOI 10.1200/JCO.1992.10.12.1955; GIANNI AM, 1989, LANCET, V2, P580; GIANNI AM, 1993, ANN ONCOL, V4, P889, DOI 10.1093/oxfordjournals.annonc.a058399; GIANNI AM, 1990, J CLIN ONCOL, V8, P768, DOI 10.1200/JCO.1990.8.5.768; GIANNI AM, 1997, NONHODGKINS LYMPHOMA, P1055; GISSELBRECHT C, 1996, ANN ONCOL, V7, P18; Haioun C., 1995, Blood, V86, p457A; *INT NONH LYMPH PR, 1993, NEW ENGL J MED, V329, P987; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; Martelli M, 1996, J CLIN ONCOL, V14, P534, DOI 10.1200/JCO.1996.14.2.534; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SHIPP MA, 1989, J CLIN ONCOL, V7, P613, DOI 10.1200/JCO.1989.7.5.613; SOCINSKI MA, 1988, LANCET, V1, P1194; VERDONCK LF, 1995, NEW ENGL J MED, V332, P1045, DOI 10.1056/NEJM199504203321601; Vitolo U, 1997, J CLIN ONCOL, V15, P491, DOI 10.1200/JCO.1997.15.2.491	25	403	414	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1290	1297		10.1056/NEJM199705013361804	http://dx.doi.org/10.1056/NEJM199705013361804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113932				2022-12-28	WOS:A1997WW26000004
J	Kehl, LJ; Fairbanks, CA; Laughlin, TM; Wilcox, GL				Kehl, LJ; Fairbanks, CA; Laughlin, TM; Wilcox, GL			Neurogenesis in postnatal rat spinal cord: A study in primary culture	SCIENCE			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; ADULT MAMMALIAN FOREBRAIN; NEURON-SPECIFIC ENOLASE; HIPPOCAMPAL-NEURONS; POSTTRANSLATIONAL MODIFICATION; SUBVENTRICULAR ZONE; REACTIVE ASTROCYTES; MEMBRANE-PROPERTIES; BETA-TUBULIN; ION CHANNELS	Spinal cord injuries result in paralysis, because when damaged neurons die they are not replaced. Neurogenesis of electrophysiologically functional neurons occurred in spinal cord cultured from postnatal rats. In these cultures, the numbers of immunocytochemically identified neurons increased over time. Additionally, neurons identified immunocytochemically or electrophysiologically incorporated bromodeoxyuridine, confirming they had differentiated from mitotic cells in vitro. These findings suggest that postnatal spinal cord retains the capacity to generate functional neurons. The presence of neuronal precursor cells in postnatal spinal cord may offer new therapeutic approaches for restoration of function to individuals with spinal cord injuries.	UNIV MINNESOTA,GRAD PROGRAM NEUROSCI,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Wilcox, George/0000-0002-6411-0423; Fairbanks, Carolyn/0000-0003-4252-8586	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K15DE000225] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07097, DA07234] Funding Source: Medline; NIDCR NIH HHS [DE00225] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUGHMAN RW, 1991, CULTURING NERVE CELL, P227; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; GEISERT EE, 1990, P NATL ACAD SCI USA, V87, P3967, DOI 10.1073/pnas.87.10.3967; GONCHOROFF NJ, 1985, CYTOMETRY, V6, P506, DOI 10.1002/cyto.990060604; JOHANSSON S, 1990, NEUROSCI LETT, V118, P155, DOI 10.1016/0304-3940(90)90615-G; JOHANSSON S, 1992, J PHYSIOL-LONDON, V445, P157, DOI 10.1113/jphysiol.1992.sp018917; JOHANSSON S, 1992, J PHYSIOL-LONDON, V445, P129, DOI 10.1113/jphysiol.1992.sp018915; KEHL L, UNPUB J NEUROSCI MET; KEHL L, 1996, THESIS U MINNESOTA M; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; LIN RCS, 1994, NEUROSCIENCE, V60, P11, DOI 10.1016/0306-4522(94)90199-6; LOCKERY SR, 1992, J NEUROSCI, V12, P2268; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MAGNUSON DSK, 1995, DEV BRAIN RES, V84, P130, DOI 10.1016/0165-3806(94)00166-W; MAIER DL, 1995, DEV BRAIN RES, V87, P135, DOI 10.1016/0165-3806(95)00065-L; Martin JH, 1985, PRINCIPLES NEURAL SC, P244; Menezes JRL, 1995, MOL CELL NEUROSCI, V6, P496, DOI 10.1006/mcne.1995.0002; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; PRIVAT A, 1975, INT REV CYTOL, V40, P281, DOI 10.1016/S0074-7696(08)60955-9; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SCHMECHEL DE, 1980, BRAIN RES, V190, P195, DOI 10.1016/0006-8993(80)91169-5; SCHMITT J, 1991, NEUROL CLIN, V9, P779, DOI 10.1016/S0733-8619(18)30279-2; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P1001, DOI 10.1152/jn.1992.68.4.1001; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P985, DOI 10.1152/jn.1992.68.4.985; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VIANA F, 1994, NEUROSCIENCE, V59, P131, DOI 10.1016/0306-4522(94)90105-8; WEBER ED, 1977, BRAIN RES, V125, P241, DOI 10.1016/0006-8993(77)90618-7; Weiss S, 1996, J NEUROSCI, V16, P7599; Zigova T, 1996, DEV BIOL, V173, P459, DOI 10.1006/dbio.1996.0040	35	63	68	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					586	589		10.1126/science.276.5312.586	http://dx.doi.org/10.1126/science.276.5312.586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110976				2022-12-28	WOS:A1997WV72100043
J	Taddio, A; Stevens, B; Craig, K; Rastogi, P; BenDavid, S; Shennan, A; Mulligan, P; Koren, G				Taddio, A; Stevens, B; Craig, K; Rastogi, P; BenDavid, S; Shennan, A; Mulligan, P; Koren, G			Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL CIRCUMCISION; NEWBORN CIRCUMCISION; VACCINATION PAIN; LOCAL-ANESTHESIA; INFANTS; ANALGESIA; RESPONSES; CRY; CHILDREN; SLEEP	Background Neonatal circumcision is a painful surgical procedure often performed without analgesia, We assessed the efficacy and safety of 5 percent lidocaine-prilocaine cream (Emla) in neonates undergoing circumcision. Methods We carried out a double-blind, randomized, controlled trial in 68 full-term male neonates: 38 were assigned to receive lidocaine-prilocaine cream, and 30 to receive placebo, One gram of lidocaine-prilocaine or placebo cream was applied to the penis under an occlusive dressing for 60 to 80 minutes before circumcision. Behavioral (facial activity and time spent crying) and physiologic (heart rate and blood pressure) responses were recorded during the procedure. Blood samples were obtained at various times after drug application for measurements of methemoglobin and plasma lidocaine, prilocaine, and o-toluidine (a metabolite of prilocaine). Results A total of 68 and 59 neonates were included in the safety and efficacy analyses, respectively. Demographic characteristics such as gestational age and birth weight did not differ between the lidocaine-prilocaine and placebo groups. During circumcision, the neonates in the lidocaine-prilocaine group had less facial activity (P=0.01), spent less time crying (P<0.001), and had smaller increases in heart rate (P=0.007) than the neonates in the placebo group, Facial-activity scores were 12 to 49 percent lower during various steps of the procedure in the lidocaine-prilocaine group. As compared with neonates in the placebo group, infants in the lidocaine-prilocaine group cried less than half as much and had heart-rate increases of 10 beats per minute less. Blood methemoglobin concentrations (expressed as a percentage of the hemoglobin concentration) were similar (1.3 percent) in both groups, Lidocaine and prilocaine were detected in plasma in 23 (61 percent) and 21 (55 percent) of the infants treated with lidocaine-prilocaine cream, respectively. Conclusions Lidocaine-prilocaine cream is efficacious and safe for the prevention of pain from circumcision in neonates. (C) 1997, Massachusetts Medical Society.	HOSP SICK CHILDREN,DEPT PAEDIAT,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,FAC PHARM,TORONTO,ON,CANADA; UNIV TORONTO,FAC NURSING,TORONTO,ON,CANADA; UNIV TORONTO,FAC MED,TORONTO,ON,CANADA; UNIV BRITISH COLUMBIA,DEPT PSYCHOL,VANCOUVER,BC,CANADA; WOMENS COLL HOSP,DEPT NEWBORN & DEV PAEDIAT,TORONTO,ON M5S 1B2,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of British Columbia; University of Toronto; University Toronto Affiliates; Womens College Hospital			Craig, Kenneth/I-2738-2018	Craig, Kenneth/0000-0001-8063-2662				ANDERS TF, 1974, PSYCHOSOM MED, V36, P174, DOI 10.1097/00006842-197403000-00009; BENINI F, 1994, JAMA-J AM MED ASSOC, V271, P274; BLASS EM, 1991, PEDIATRICS, V87, P215; CRAIG KD, 1988, CAN J BEHAV SCI, V20, P442, DOI 10.1037/h0079934; DEJONG RH, 1994, LOCAL ANESTHETICS; EMDE RN, 1971, PSYCHOSOM MED, V33, P491, DOI 10.1097/00006842-197111000-00002; ENAD D, 1995, PEDIATR RES, V37, pA204; GARCIA OC, 1995, PEDIATR RES, V37, pA205; GOURRIER E, 1995, ARCH PEDIATRIE, V2, P1041, DOI 10.1016/0929-693X(96)81278-4; GRUNAU RVE, 1990, PAIN, V42, P295, DOI 10.1016/0304-3959(90)91142-6; GRUNAU RVE, 1987, PAIN, V28, P395, DOI 10.1016/0304-3959(87)90073-X; GUNNAR MR, 1984, J AM ACAD CHILD PSY, V23, P34, DOI 10.1097/00004583-198401000-00005; HALPERIN DL, 1989, PEDIATRICS, V84, P281; HOLVE RL, 1983, CLIN PEDIATR, V22, P813, DOI 10.1177/000992288302201205; HOWARD CR, 1994, PEDIATRICS, V93, P641; HOWARD CR, 1996, ARCH PEDIAT ADOLES S, V150, pP42; Hymes JA., 1986, REGION ANESTH, V11, P11, DOI [10.1136/rapm-00115550-198611010-00004, DOI 10.1136/RAPM-00115550-198611010-00004]; JAKOBSON B, 1985, ACTA ANAESTH SCAND, V29, P453, DOI 10.1111/j.1399-6576.1985.tb02232.x; KLEIN J, 1994, J CHROMATOGR B, V655, P83, DOI 10.1016/0378-4347(94)00062-X; Law RMT, 1996, BIOL NEONATE, V70, P213; MARSHALL RE, 1982, EARLY HUM DEV, V7, P367, DOI 10.1016/0378-3782(82)90038-X; MASCIELLO AL, 1990, OBSTET GYNECOL, V75, P834; MAUNUKSELA EL, 1986, BRIT J ANAESTH, V58, P1242, DOI 10.1093/bja/58.11.1242; NIOLOUX C, 1995, ARCH PEDIATRIE, V2, P291, DOI 10.1016/0929-693X(96)81147-X; ROBIEUX I, 1991, J PEDIATR-US, V118, P971, DOI 10.1016/S0022-3476(05)82220-6; STANG HJ, 1988, JAMA-J AM MED ASSOC, V259, P1507, DOI 10.1001/jama.259.10.1507; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; TADDIO A, 1994, J PEDIATR-US, V124, P643, DOI 10.1016/S0022-3476(05)83150-6; Taddio Anna, 1996, Pediatric Research, V39, p80A; Toffler W L, 1990, J Am Board Fam Pract, V3, P171; UHARI M, 1993, PEDIATRICS, V92, P719; WELLINGTON N, 1993, PEDIATRICS, V92, P541	33	185	188	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1197	1201		10.1056/NEJM199704243361701	http://dx.doi.org/10.1056/NEJM199704243361701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110906	Bronze			2022-12-28	WOS:A1997WV33200001
J	Soisson, SM; MacDougallShackleton, B; Schleif, R; Wolberger, C				Soisson, SM; MacDougallShackleton, B; Schleif, R; Wolberger, C			Structural basis for ligand-regulated oligomerization of AraC	SCIENCE			English	Article							ARABAD OPERON PROMOTER; PROTEIN; REPRESSION; OPERATOR; BINDING; MODEL; SITE	The crystal structure of the arabinose-binding and dimerization domain of the Escherchia coli gene regulatory protein AraC was determined in the presence and absence of L-arabinose. The 1.5 angstrom structure of the arabinose-bound molecule shows that the protein adopts an unusual fold, binding sugar within a beta barrel and completely burying the arabinose with the amino-terminal arm of the protein. Dimer contacts in the presence of arabinose are mediated by an antiparallel coiled-coil. In the 2.8 angstrom structure of the uncomplexed protein, the amino-terminal arm is disordered, uncovering the sugar-binding pocket and allowing it to serve as an oligomerization interface. The ligand-gated oligomerization as seen in AraC provides the basis of a plausible mechanism for modulating the protein's DNA-looping properties.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University				Wolberger, Cynthia/0000-0001-8578-2969; Schleif, Robert/0000-0002-4430-7085	NIGMS NIH HHS [GM18277] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018277, R01GM018277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, COMMUNICATION; BRUNGER AT, 1992, XPLOR V3 1 SYSTEM XR; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; CARRA JH, 1993, EMBO J, V12, P35, DOI 10.1002/j.1460-2075.1993.tb05629.x; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; DUYNE GDV, 1996, J MOL BIOL, V256, P377; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; Eustance RJ, 1996, J BACTERIOL, V178, P7025, DOI 10.1128/jb.178.24.7025-7030.1996; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAUBLE H, 1989, EUR J BIOCHEM, V185, P319, DOI 10.1111/j.1432-1033.1989.tb15118.x; LEE N, 1987, P NATL ACAD SCI USA, V84, P8814, DOI 10.1073/pnas.84.24.8814; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MARTIN K, 1986, P NATL ACAD SCI USA, V83, P3654, DOI 10.1073/pnas.83.11.3654; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHLEIF R, 1996, ESCHERICHIA COLI SAL, P1300; SCHLEIF RF, 1982, BIOCHEMISTRY-US, V21, P778, DOI 10.1021/bi00533a031; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WILCOX G, 1974, J BIOL CHEM, V249, P6892; WILCOX G, 1976, MOL GEN GENET, V145, P97, DOI 10.1007/BF00331563; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230	30	173	178	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					421	425		10.1126/science.276.5311.421	http://dx.doi.org/10.1126/science.276.5311.421			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103202				2022-12-28	WOS:A1997WU47700042
J	Strupp, M; Brandt, T				Strupp, M; Brandt, T			Should one reinsert the stylet during lumbar puncture?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											Strupp, M (corresponding author), UNIV MUNICH,MARCHIONINISTR 15,D-81366 MUNICH,GERMANY.							DIETERICH M, 1985, EUR ARCH PSY CLIN N, V235, P71, DOI 10.1007/BF00633475; Fishman RA., 1992, CEREBROSPINAL FLUID; HART JR, 1951, JAMA-J AM MED ASSOC, V147, P657, DOI 10.1001/jama.1951.73670240021006k; KOVANEN J, 1986, HEADACHE, V26, P224, DOI 10.1111/j.1526-4610.1986.hed2605224.x; MULLER B, 1994, J NEUROL, V241, P376, DOI 10.1007/BF02033354	5	24	25	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1190	1190		10.1056/NEJM199704173361616	http://dx.doi.org/10.1056/NEJM199704173361616			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9102578				2022-12-28	WOS:A1997WU00300033
J	Brunell, P				Brunell, P			Diagnosing streptococcal pharyngitis in patients taking antibiotics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Brunell, P (corresponding author), CEDARS SINAI MED CTR,LOS ANGELES,CA 90048, USA.							Cockerill FR, 1997, JAMA-J AM MED ASSOC, V277, P38, DOI 10.1001/jama.277.1.38	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1197	1197		10.1001/jama.277.15.1197	http://dx.doi.org/10.1001/jama.277.15.1197			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103335				2022-12-28	WOS:A1997WT40300016
J	Bhopal, R; Rankin, J; McColl, E; Thomas, L; Kaner, E; Stacy, R; Pearson, P; Vernon, B; Rodgers, H				Bhopal, R; Rankin, J; McColl, E; Thomas, L; Kaner, E; Stacy, R; Pearson, P; Vernon, B; Rodgers, H			The vexed question of authorship: Views of researchers in a British medical faculty	BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess knowledge, views, and behaviour of researchers on criteria for authorship and causes and control of gift authorship. Design: Interview survey of stratified sample of researchers. Setting: University medical faculty. Subjects: 66 staff (94% response rate) comprising several levels of university academic and research appointments. Main outcome measures: Awareness and use of criteria for authorship, views on which contributions to research merit authorship, perceptions about gift authorship and strategies for reducing it, and experiences of authorship problems. Results: 50 (76%) respondents supported criteria for authorship, but few knew about or used available criteria. Of the five people who could specify all three criteria of the International Committee of Medical Journal Editors, only one knew that all criteria had to be met Forty one respondents (62%) disagreed with this stipulation. A range of practical and academic contributions were seen as sufficient for authorship, Gift authorship was perceived as common, promoted by pressure to publish, to motivate research teams, and to maintain working relationships. A signed statement justifying authorship and a published statement of the contribution of each author were perceived as practical ways of tacking gift authorship. Most researchers had experienced problems with authorship, most commonly the perception that authorship had been deserved but not awarded (49%). Conclusion: There seems to be a gap between editors' criteria for authorship and researchers' practice. Lack of awareness of criteria is only a partial explanation. Researchers give more weight than editors to practical research contributions. Future criteria should be agreed by researchers and not be imposed by editors.	UNIV NEWCASTLE,SCH HLTH SCI,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE,SCH HLTH SCI,CTR HLTH SERV RES,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE,SCH HLTH SCI,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE,SCH HLTH SCI,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE,SCH HLTH SCI,DEPT EPIDEMIOL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Kaner, Eileen/ABF-2444-2020	Kaner, Eileen/0000-0002-7169-9344				[Anonymous], 1993, SPSS WINDOWS BASE SY; BURMAN KD, 1982, ANN INTERN MED, V97, P602, DOI 10.7326/0003-4819-97-4-602; DIGIUSTO E, 1993, SOC SCI MED, V38, P55; Eastwood Susan, 1996, Sci Eng Ethics, V2, P89, DOI 10.1007/BF02639320; GOODMAN NW, 1994, BRIT MED J, V309, P1482, DOI 10.1136/bmj.309.6967.1482; HEWITT RM, 1957, PHYSICIAN WRITERS BO; Horton R, 1996, BRIT MED J, V312, P723; HUTH EJ, 1990, WRITE PUBLISH PAPERS; *INT COMM MED J ED, 1985, BRIT MED J, V291, P721; KAPOOR VK, 1994, LANCET, V346, P1039; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; SMITH J, 1994, BRIT MED J, V309, P1456, DOI 10.1136/bmj.309.6967.1456; SMITH R, 1994, BRIT MED J, V309, P143, DOI 10.1136/bmj.309.6948.143; STAHELI LT, 1986, SPEAKING WRITING PHY	14	159	163	1	23	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1009	1012		10.1136/bmj.314.7086.1009	http://dx.doi.org/10.1136/bmj.314.7086.1009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112845	Green Published			2022-12-28	WOS:A1997WT15200023
J	Bourantas, KL; Christou, LG; Dalekos, GN; Barbati, K; Tsianos, EV				Bourantas, KL; Christou, LG; Dalekos, GN; Barbati, K; Tsianos, EV			A 54-year-old stockbreeder with ascites	LANCET			English	Article											Bourantas, KL (corresponding author), UNIV IOANNINA,SCH MED,DEPT INTERNAL MED,IOANNINA 45325,GREECE.							CABALLERIA E, 1992, J HEPATOL, V15, P415, DOI 10.1016/0168-8278(92)90080-9; COLMENERO JD, 1983, MED CLIN-BARCELONA, V80, P748; DALEKOS GN, 1993, GUT, V34, P658, DOI 10.1136/gut.34.5.658; PEDROPONS A, 1950, PATOLOGIA CLIN MED, V4; RUNYON BA, 1992, ANN INTERN MED, V117, P215, DOI 10.7326/0003-4819-117-3-215	5	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					994	994		10.1016/S0140-6736(96)11090-4	http://dx.doi.org/10.1016/S0140-6736(96)11090-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100627				2022-12-28	WOS:A1997WR62100013
J	Albertini, M; Rehling, P; Erdmann, R; Girzalsky, W; Kiel, JAKW; Veenhuis, M; Kunau, WH				Albertini, M; Rehling, P; Erdmann, R; Girzalsky, W; Kiel, JAKW; Veenhuis, M; Kunau, WH			Pex14p, a peroxisomal membrane protein binding both receptors of the two PTS-dependent import pathways	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; 3-OXOACYL-COA THIOLASE; TARGETING SIGNAL; HANSENULA-POLYMORPHA; SHUTTLE VECTORS; YEAST; BIOGENESIS; GENE; MATRIX; ENCODES	Pex14p, an S. cerevisiae peroxin, is attached to the outer face of the peroxisomal membrane and is a component of the protein import machinery. Pex14p interacts with both the PTS1 and PTS2 receptors. It is the only known peroxisomal membrane protein that binds the PTS2 receptor and might thus mediate the membrane docking event of PTS2-dependent protein import. These results suggest that the two import pathways overlap and, furthermore, that Pex14p represents the point of convergence. Pex14p also interacts with two other membrane-bound peroxins including Pex13p, another binding protein for the PTS1 receptor. The data presented here are consistent with the idea of a common translocation machinery for both PTS-dependent protein import pathways in the peroxisomal membrane.	RUHR UNIV BOCHUM,ABT ZELLBIOCHEM,D-44780 BOCHUM,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL CHEM 2,D-44780 BOCHUM,GERMANY; UNIV GRONINGEN,ELECTRON MICROSCOPY LAB,CTR BIOL,NL-9751 NN HAREN,NETHERLANDS	Ruhr University Bochum; Ruhr University Bochum; University of Groningen								Ausubel FM, 1988, MOL REPROD DEV; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P2432; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Harlow E., 1988, ANTIBODIES LAB MANUA; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; HUHSE B, 1995, THESIS RUHR U BOCHUM; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; Lazarow P. B., 1993, TRENDS CELL BIOL, V157, P105; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SIKORSKI RS, 1989, GENETICS, V122, P19; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	45	261	264	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					83	92		10.1016/S0092-8674(00)80185-3	http://dx.doi.org/10.1016/S0092-8674(00)80185-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094717	Green Published, Bronze			2022-12-28	WOS:A1997WR68500012
J	Odum, JR; Jungkamp, TPW; Griffin, RJ; Flagan, RC; Seinfeld, JH				Odum, JR; Jungkamp, TPW; Griffin, RJ; Flagan, RC; Seinfeld, JH			The atmospheric aerosol-forming potential of whole gasoline vapor	SCIENCE			English	Article							OUTDOOR SMOG CHAMBER; ORGANIC-COMPOUNDS; BETA-PINENE; PHOTOOXIDATION; EMISSIONS; NOX; REACTIVITY; TOLUENE; CARBON; GROWTH	A series of sunlight-irradiated, smog-chamber experiments confirmed that the atmospheric organic aerosol formation potential of whole gasoline vapor can be accounted for solely in terms of the aromatic fraction of the fuel. The total amount of secondary organic aerosol produced from the atmospheric oxidation of whole gasoline vapor can be represented as the sum of the contributions of the individual aromatic molecular constituents of the fuel. The urban atmospheric, anthropogenic hydrocarbon profile is approximated well by evaporated whole gasoline, and thus these results suggest that it is possible to model atmospheric secondary organic aerosol formation.	CALTECH,DEPT CHEM ENGN,PASADENA,CA 91125; CALTECH,DEPT ENVIRONM ENGN SCI,PASADENA,CA 91125	California Institute of Technology; California Institute of Technology				Griffin, Robert/0000-0001-7682-8769				ATKINSON R, 1994, J PHYS CHEM REF DATA, V2; Bowman FM, 1995, PROG ENERG COMBUST, V21, P387, DOI 10.1016/0360-1285(95)00008-9; BURNS VR, 1991, 912320 SAE; CALVERT JG, 1993, SCIENCE, V261, P37, DOI 10.1126/science.261.5117.37; GERY MW, 1985, INT J CHEM KINET, V17, P931, DOI 10.1002/kin.550170903; GROSJEAN D, 1989, ATMOS ENVIRON, V23, P1733, DOI 10.1016/0004-6981(89)90058-9; GROSJEAN D, 1992, ATMOS ENVIRON A-GEN, V26, P953, DOI 10.1016/0960-1686(92)90027-I; GROSJEAN D, 1977, OZONE OTHER PHOTOCHE, pCH3; HARLEY RA, 1992, ENVIRON SCI TECHNOL, V26, P2395, DOI 10.1021/es00036a010; HATAKEYAMA S, 1991, J GEOPHYS RES-ATMOS, V96, P947, DOI 10.1029/90JD02341; Hochhauser AM, 1991, 912322 SAE; HOEKMAN SK, 1992, ENVIRON SCI TECHNOL, V26, P1206, DOI 10.1021/es50002a610; IZUMI K, 1990, ATMOS ENVIRON A-GEN, V24, P1433, DOI 10.1016/0960-1686(90)90052-O; KWOK ESC, 1995, ATMOS ENVIRON, V29, P1685, DOI 10.1016/1352-2310(95)00069-B; LEONE JA, 1985, INT J CHEM KINET, V17, P177, DOI 10.1002/kin.550170206; MALLARD WG, 1994, NIST STANDARD REFERE; ODURN JR, 1996, ENVIRON SCI TECHNOL, V30, P2580; PANDIS SN, 1991, ATMOS ENVIRON A-GEN, V25, P997, DOI 10.1016/0960-1686(91)90141-S; PANKOW JF, 1994, ATMOS ENVIRON, V28, P185, DOI 10.1016/1352-2310(94)90093-0; PAUL RH, 1991, 902098 SAE; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; RUSSELL A, 1995, SCIENCE, V269, P491, DOI 10.1126/science.269.5223.491; SCHWARTZ J, 1996, AIR WASTE MANAGE ASS, V46, P927; SHPRENTZ DS, 1996, BREATH TAKING PREMAT; Siegl W. O., 1993, 930142 SAE; STERN JE, 1987, ENVIRON SCI TECHNOL, V21, P1224, DOI 10.1021/es00165a011; TURPIN BJ, 1991, ATMOS ENVIRON A-GEN, V25, P207, DOI 10.1016/0960-1686(91)90291-E; TURPIN BJ, 1991, ENVIRON SCI TECHNOL, V25, P1788, DOI 10.1021/es00022a017; WANG SC, 1992, ATMOS ENVIRON A-GEN, V26, P403, DOI 10.1016/0960-1686(92)90326-G	29	445	486	5	176	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					96	99		10.1126/science.276.5309.96	http://dx.doi.org/10.1126/science.276.5309.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082994				2022-12-28	WOS:A1997WR38600053
J	Vinson, M; Mironov, S; Mulvey, S; Pertsov, A				Vinson, M; Mironov, S; Mulvey, S; Pertsov, A			Control of spatial orientation and lifetime of scroll rings in excitable media	NATURE			English	Article							BELOUSOV-ZHABOTINSKII REACTION; 3-DIMENSIONAL CHEMICAL WAVES; SPIRAL WAVES; ACTIVE MEDIUM; ORGANIZING CENTERS; DYNAMICS; ANNIHILATION; PROPAGATION; FILAMENTS; VORTICES	Excitable media, which range from autocatalytic chemical systems(1-3) to biological cells and tissues(4-7), can maintain organized structures in the form of rotating spiral waves of excitation(8-11). The dynamics of spiral waves in two-dimensional systems have been shown to be susceptible to control by external fields (such as electric, thermal and optical)(12-14). In three dimensions, the analogues of spiral waves are scroll waves(9,15,16), Here we show that an external held-a temperature gradient-can be used to control a particular class of scroll waves called scroll rings. The gradient allows scroll rings to be precisely oriented in space, and their spontaneous shrinkage to be accelerated, decelerated or even reversed (so that the ring expands). The temperature gradient also influences the lifetimes of the scroll rings. We suggest that these dynamics are likely to be generic to other types of field gradients and other excitable media.	SUNY HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210; SHIPPENSBURG UNIV,DEPT PHYS,SHIPPENSBURG,PA 17257; INST CELLULAR BIOPHYS,PUSHCHINO 142292,MOSCOW REGION,RUSSIA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Pennsylvania State System of Higher Education (PASSHE); Shippensburg University of Pennsylvania; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS								AGLADZE KI, 1991, PHYSICA D, V49, P1, DOI 10.1016/0167-2789(91)90186-D; ALIEV RR, 1992, J PHYS CHEM-US, V96, P732, DOI 10.1021/j100181a039; BIKTASHEV VN, 1994, PHILOS T R SOC A, V347, P611, DOI 10.1098/rsta.1994.0070; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; JAHNKE W, 1988, NATURE, V336, P662, DOI 10.1038/336662a0; KEENER JP, 1988, PHYSICA D, V31, P269, DOI 10.1016/0167-2789(88)90080-2; KEENER JP, 1992, SIAM REV, V34, P1, DOI 10.1137/1034001; KEENER JP, 1990, PHYSICA D, V44, P191, DOI 10.1016/0167-2789(90)90055-T; Krinsky V. I., 1984, SELF ORG AUTOWAVES S; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Mironov S, 1996, J PHYS CHEM-US, V100, P1975, DOI 10.1021/jp952556s; MULLER SC, 1985, SCIENCE, V230, P661, DOI 10.1126/science.230.4726.661; Panfilov A. V., 1986, Biophysics, V31, P926; PERTSOV A, 1993, PHYSICA D, V63, P233, DOI 10.1016/0167-2789(93)90157-V; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; PERTSOV AM, 1990, NATURE, V345, P419, DOI 10.1038/345419a0; RUDENKO AN, 1983, STUD BIOPHYS, V98, P183; SCHUTZE J, 1992, NATURE, V356, P45, DOI 10.1038/356045a0; SIEGERT F, 1991, PHYSICA D, V49, P224, DOI 10.1016/0167-2789(91)90210-Z; STEINBOCK O, 1993, NATURE, V366, P322, DOI 10.1038/366322a0; STEINBOCK O, 1992, PHYS REV LETT, V68, P248, DOI 10.1103/PhysRevLett.68.248; SWINNEY HL, 1991, PHYSICA D, V49; WELSH BJ, 1983, NATURE, V304, P611, DOI 10.1038/304611a0; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WINFREE AT, 1984, NATURE, V311, P611, DOI 10.1038/311611a0; Zhabotinsky A, 1971, OSCILLATORY PROCESSE, VII	27	67	70	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					477	480		10.1038/386477a0	http://dx.doi.org/10.1038/386477a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087404				2022-12-28	WOS:A1997WR25600046
J	Barkhof, F; Polman, C				Barkhof, F; Polman, C			Oral or intravenous methylprednisolone for acute relapses of MS?	LANCET			English	Editorial Material							MULTIPLE-SCLEROSIS		VRIJE UNIV AMSTERDAM,ACAD ZIEKENHUIS,DEPT NEUROL,NL-1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	Barkhof, F (corresponding author), VRIJE UNIV AMSTERDAM,ACAD ZIEKENHUIS,DEPT DIAGNOST RADIOL,NL-1081 HV AMSTERDAM,NETHERLANDS.		Barkhof, Frederik/AAJ-6226-2020	Barkhof, Frederik/0000-0003-3543-3706				ALTMAN DG, 1991, PRACTICAL STAT MED R, P457; BARKHOF F, 1992, NEUROLOGY, V42, P63, DOI 10.1212/WNL.42.1.63; Miller DH, 1996, ANN NEUROL, V39, P6, DOI 10.1002/ana.410390104; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; THOMPSON AJ, 1989, NEUROLOGY, V39, P969, DOI 10.1212/WNL.39.7.969	5	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					893	894		10.1016/S0140-6736(05)62691-8	http://dx.doi.org/10.1016/S0140-6736(05)62691-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093245				2022-12-28	WOS:A1997WR25400003
J	Raptis, AE; Spring, MW; Viberti, G				Raptis, AE; Spring, MW; Viberti, G			Comparison of blood pressure measurement methods in adult diabetics	LANCET			English	Article							MONITOR				Raptis, AE (corresponding author), UNITED MED & DENT SCH,GUYS HOSP,METAB MED UNIT,LONDON SE1 9RT,ENGLAND.							GOONASEKERA CDA, 1995, J HUM HYPERTENS, V9, P885; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; PARK MK, 1987, PEDIATRICS, V79, P907	4	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					175	176		10.1016/S0140-6736(05)60976-2	http://dx.doi.org/10.1016/S0140-6736(05)60976-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111545				2022-12-28	WOS:A1997WC86100015
J	Toe, L; Tang, JM; Back, C; Katholi, CR; Unnasch, TR				Toe, L; Tang, JM; Back, C; Katholi, CR; Unnasch, TR			Vector-parasite transmission complexes for onchocerciasis in West Africa	LANCET			English	Article							CONTROL PROGRAM AREA; OCULAR ONCHOCERCIASIS; SIMULIUM-YAHENSE; SEQUENCE FAMILY; VOLVULUS; DIFFERENTIATION; IDENTIFICATION; INTENSITY; INFECTION; COMMUNITY	Background In West Africa, there are two strains of the filarial parasite Onchocerca volvulus, which differ in their ability to induce ocular disease. Transmission studies have suggested that six sibling species of the parasite vector, the black fly Simulium damnosum sensu late, allow development of the two strains of O volvulus with varying efficiency. We aimed to test the hypothesis of parasite-vector complexes, whereby the two parasite strains, known as forest and savanna, are preferentially transmitted by distinct groups of the species of S damnosum s I. Methods During 1993 and 1994, wild black flies were collected from 11 river basins within the area covered by the Onchocerciasis Control Programme (OCP). The flies were dissected and filarial larvae, ovaries, and malpighian tubules removed. Genomic DNA was extracted from larvae, and PCR amplification was used to classify O volvulus parasites as forest or savanna strains. PCR-amplified DNA from ovaries and malpighian tubules was used to distinguish sibling species of S damnosum s I. S yahense and S squamosum were distinguished by body colour. Findings 214 of 105105 flies dissected were infected with filarial larvae; 84 of these were infected with mature O volvulus parasites. Of the 35 savanna-dwelling infected flies, 17 carried forest-strain parasites and 18 savanna-strain parasites. Of the 45 infected flies identified as the forest dwelling sibling species, 20 carried savanna-strain parasites and 25 forest-strain parasites. No significant differences were found in the numbers of mature larvae of each strain carried by the forest-dwelling species of fly or in the number of forest and savanna larvae in savanna-dwelling vector species. Interpretation Vector-parasite transmission complexes do not currently play a part in the biology of O volvulus transmission in the area of the OCP in West Africa. This finding has important strategic implications for the future of efforts to control onchocerciasis in West Africa.	UNIV ALABAMA,DIV GEOG MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOSTAT,BIRMINGHAM,AL 35294; ONCHOCERCIASIS CONTROL PROGRAMME W AFRICA,DNA DIAGNOST LAB,BOUAKE,COTE IVOIRE	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Tang, Jianming "James"/O-4980-2019	Tang, Jianming "James"/0000-0003-0137-7486	NIAID NIH HHS [R01AI33008] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033008] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker RHA, 1990, PHILOS T R SOC L B S, V328, P721; CHRISTENSEN O, 1994, OCP 1974 1994; CIANCHI R, 1985, ACTA TROP, V42, P341; CROSSKEY RW, 1987, ANN TROP MED PARASIT, V81, P181, DOI 10.1080/00034983.1987.11812110; DADZIE KY, 1992, TROP MED PARASITOL, V43, P75; DADZIE KY, 1989, TROP MED PARASITOL, V40, P348; DAVIES JB, 1981, TROPENMED PARASITOL, V32, P17; DUKE BOL, 1981, ANN SOC BELG MED TR, V61, P179; DUKE BOL, 1966, ANN TROP MED PARASIT, V60, P318, DOI 10.1080/00034983.1966.11686422; ERTMANN KD, 1987, NATURE, V327, P415; ERTTMANN KD, 1990, ACT LEIDENS, V59, P253; FIASORGBOR GK, 1992, TROP MED PARASITOL, V43, P72; FLOCKHART HA, 1986, T ROY SOC TROP MED H, V80, P285, DOI 10.1016/0035-9203(86)90037-4; GREENE BM, 1992, J INFECT DIS, V166, P15, DOI 10.1093/infdis/166.1.15; KURTAK DC, 1990, ACT LEIDENS, V59, P95; LOBOS E, 1985, PARASITE IMMUNOL, V7, P333, DOI 10.1111/j.1365-3024.1985.tb00080.x; MEREDITH SEO, 1991, EXP PARASITOL, V73, P335, DOI 10.1016/0014-4894(91)90105-6; PROST A, 1980, ANN PARASIT HUM COMP, V55, P239, DOI 10.1051/parasite/1980552239; REMME J, 1989, TROP MED PARASITOL, V40, P340; TANG J, 1995, INSECT MOL BIOL, V4, P79, DOI 10.1111/j.1365-2583.1995.tb00011.x; TOE L, 1994, AM J TROP MED HYG, V51, P676, DOI 10.4269/ajtmh.1994.51.676; Walsh J.F., 1983, P93; *WHO EXP COMM ONCH, 1987, 3 WHO EXP COMM ONCH; WILSON MD, 1993, ANN TROP MED PARASIT, V87, P65, DOI 10.1080/00034983.1993.11812739; ZIMMERMAN PA, 1994, MOL BIOL EVOL, V11, P384; ZIMMERMAN PA, 1992, J INFECT DIS, V165, P964, DOI 10.1093/infdis/165.5.964; ZIMMERMAN PA, 1993, MOL BIOCHEM PARASIT, V58, P259, DOI 10.1016/0166-6851(93)90047-2	27	28	29	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					163	166		10.1016/S0140-6736(96)05265-8	http://dx.doi.org/10.1016/S0140-6736(96)05265-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111540				2022-12-28	WOS:A1997WC86100010
J	Finlay, BB; Cossart, P				Finlay, BB; Cossart, P			Exploitation of mammalian host cell functions by bacterial pathogens	SCIENCE			English	Article							ACTIN-BASED MOTILITY; PROLINE-RICH REGION; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; LISTERIA-MONOCYTOGENES; LEGIONELLA-PNEUMOPHILA; VIRULENCE GENES; SURFACE PROTEIN; SALMONELLA-TYPHIMURIUM; SIGNAL-TRANSDUCTION	Interest in bacterial pathogenesis has recently increased because of antibiotic resistance, the emergence of new pathogens and the resurgence of old ones, and the lack of effective therapeutics. The molecular and cellular mechanisms of microbial pathogenesis are currently being defined, with precise knowledge of both the common strategies used by multiple pathogenic bacteria and the unique tactics evolved by individual species to help establish infection. What is emerging is a new appreciation of how bacterial pathogens interact with host cells. Many host cell functions, including signal transduction pathways, cytoskeletal rearrangements, and vacuolar trafficking, are exploited, and these are the focus of this review. A bonus of this work is that bacterial virulence factors are providing new tools to study various aspects of mammalian cell functions, in addition to mechanisms of bacterial disease, Together these developments may lead to new therapeutic strategies.	INST PASTEUR,UNITE INTERACT BACTERIES CELLULES,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Finlay, BB (corresponding author), UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER,BC V6T 1Z3,CANADA.							ADAM T, 1995, J CELL BIOL, V129, P367, DOI 10.1083/jcb.129.2.367; Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BERGER KH, 1994, MOL MICROBIOL, V14, P809, DOI 10.1111/j.1365-2958.1994.tb01317.x; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; BOQUET PL, COMMUNICATION; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BRAND BC, 1994, MOL MICROBIOL, V14, P797, DOI 10.1111/j.1365-2958.1994.tb01316.x; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; Contag CH, 1995, MOL MICROBIOL, V18, P593, DOI 10.1111/j.1365-2958.1995.mmi_18040593.x; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Cossart P, 1996, SCIENCE, V271, P315, DOI 10.1126/science.271.5247.315; COSSART P, IN PRESS J CLIN INVE; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Dramsi S, 1996, CURR TOP MICROBIOL, V209, P61; Egile C, 1997, MOL MICROBIOL, V23, P1063, DOI 10.1046/j.1365-2958.1997.2871652.x; Finlay B B, 1994, Curr Top Microbiol Immunol, V192, P163; FINLAY BB, MICROBIOL MOL BIOL R; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; Guzman CA, 1996, MOL MICROBIOL, V20, P119, DOI 10.1111/j.1365-2958.1996.tb02494.x; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; Hofer MF, 1996, P NATL ACAD SCI USA, V93, P5425, DOI 10.1073/pnas.93.11.5425; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1984, CELL, V36, P27, DOI 10.1016/0092-8674(84)90070-9; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; IRETON K, IN PRESS ANN REV GEN; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; KOCKS C, 1993, J CELL SCI, V105, P699; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1996, TRENDS CELL BIOL, V6, P109, DOI 10.1016/0962-8924(96)81001-4; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; LUND B, 1988, MOL MICROBIOL, V2, P255, DOI 10.1111/j.1365-2958.1988.tb00027.x; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; Menard R, 1996, TRENDS MICROBIOL, V4, P220, DOI 10.1016/0966-842X(96)10039-1; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; NHIEU GTV, IN PRESS EMBO J; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PASSADOR L, 1993, SCIENCE, V260, P1127, DOI 10.1126/science.8493556; PERDOMO JJ, 1994, J CLIN INVEST, V93, P633, DOI 10.1172/JCI117015; PERDOMO OJJ, 1994, J EXP MED, V180, P1307, DOI 10.1084/jem.180.4.1307; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Rogers HW, 1996, J IMMUNOL, V156, P679; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; SANSONETTI PJ, 1994, CELL, V76, P829, DOI 10.1016/0092-8674(94)90358-1; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SHAPIRO L, 1997, SCIENCE, V276, P5313; Sheehan B, 1994, Curr Top Microbiol Immunol, V192, P187; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; Strauss EJ, 1997, SCIENCE, V276, P707, DOI 10.1126/science.276.5313.707; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Theriot JA, 1995, ANNU REV CELL DEV BI, V11, P213, DOI 10.1146/annurev.cb.11.110195.001241; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8; VanNhieu GT, 1996, J BIOL CHEM, V271, P7665, DOI 10.1074/jbc.271.13.7665; Virji M, 1996, MOL MICROBIOL, V22, P929, DOI 10.1046/j.1365-2958.1996.01548.x; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234; Zychlinsky A, 1996, INFECT IMMUN, V64, P5357, DOI 10.1128/IAI.64.12.5357-5365.1996; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	94	591	622	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					718	725		10.1126/science.276.5313.718	http://dx.doi.org/10.1126/science.276.5313.718			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115192				2022-12-28	WOS:A1997WW90000038
J	Hawkesworth, CJ; Turner, SP; McDermott, F; Peate, DW; vanCalsteren, P				Hawkesworth, CJ; Turner, SP; McDermott, F; Peate, DW; vanCalsteren, P			U-Th isotopes in arc magmas: Implications for element transfer from the subducted crust	SCIENCE			English	Article							YOUNG VOLCANIC-ROCKS; ISLAND-ARC; DECAY-SERIES; MANTLE EVOLUTION; OCEANIC BASALTS; URANIUM SERIES; LAVAS; CONSTRAINTS; SYSTEMATICS; COMPONENT	Uranium-thorium isotope results from island are volcanic rocks were used to investigate the rates of transfer of fluids and sediments from the downgoing slab. Uranium, but not thorium, is readily mobilized in the fluid. A negative array between thorium/cerium and neodymium-143/neodymium-144 indicates that significant amounts of the thorium in are rocks are derived from subducted sediments, although perhaps only about 30 percent of the thorium in subducted sediments is returned to the crust in this way. The transfer times for fluid through the mantle wedge are about 30,000 to 120,000 years, whereas those for sediment melts may be several million years. The law average uranium/thorium ratios of bulk crust primarily reflect different crustal generation processes in the Archaean.	NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT GEOL,DUBLIN 4,IRELAND	University College Dublin	Hawkesworth, CJ (corresponding author), OPEN UNIV,DEPT EARTH SCI,WALTON HALL,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND.		McDermott, Frank/F-3096-2010; Peate, David W/A-1248-2007; Turner, Simon/0000-0002-6426-6495	McDermott, Frank/0000-0001-7037-7936; Peate, David W/0000-0002-7813-5824; Turner, Simon/0000-0002-6426-6495				ALLEGRE CJ, 1986, CHEM GEOL, V56, P219, DOI 10.1016/0009-2541(86)90005-7; ARCULUS RJ, 1986, J GEOPHYS RES-SOLID, V91, P5913, DOI 10.1029/JB091iB06p05913; BAILEY EH, 1994, EARTH PLANET SC LETT, V124, P119, DOI 10.1016/0012-821X(94)00071-9; BEATTIE P, 1993, NATURE, V363, P63, DOI 10.1038/363063a0; BICKLE MJ, 1992, EARTH PLANET SC LETT, V113, P219, DOI 10.1016/0012-821X(92)90221-G; CAPALDI G, 1983, ISOT GEOSCI, V1, P39; CONDOMINES M, 1993, GEOCHIM COSMOCHIM AC, V57, P4491, DOI 10.1016/0016-7037(93)90498-L; CONDOMINES M, 1988, EARTH PLANET SC LETT, V90, P243, DOI 10.1016/0012-821X(88)90129-X; DAVIES JH, 1992, J GEOPHYS RES-SOL EA, V97, P2037, DOI 10.1029/91JB02571; DAVIES JH, 1997, GEOL SOC AUSTR ABSTR, V45, P17; ELLAM RM, 1989, J GEOPHYS RES-SOLID, V94, P4589, DOI 10.1029/JB094iB04p04589; ELLAM RM, 1988, B VOLCANOL, V50, P386, DOI 10.1007/BF01050638; ELLAM RM, 1990, CHEM GEOL, V83, P165, DOI 10.1016/0009-2541(90)90278-F; ELLAM RM, 1988, CONTRIB MINERAL PETR, V98, P72, DOI 10.1007/BF00371911; ELLIOTT T, IN PRESS J GEOPHYS R; Gill J., 1981, OROGENIC ANDESITES P; GILL JB, 1993, GEOCHIM COSMOCHIM AC, V57, P4269, DOI 10.1016/0016-7037(93)90322-N; GILL JB, 1990, GEOCHIM COSMOCHIM AC, V54, P1427, DOI 10.1016/0016-7037(90)90166-I; HAWKESWORTH CJ, 1993, ANNU REV EARTH PL SC, V21, P175, DOI 10.1146/annurev.ea.21.050193.001135; HAWKESWORTH CJ, 1993, PHILOS T ROY SOC A, V342, P179, DOI 10.1098/rsta.1993.0013; HAWKESWORTH CJ, IN PRESS CHEM GEOL; HEATH E, UNPUB; HEMOND C, 1986, THESIS U PARIS 7; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; HUNTER A, 1994, THESIS OPEN U M KEYN; Hunter AG, 1995, J PETROL, V36, P1579; KAY RW, 1980, J GEOL, V88, P497, DOI 10.1086/628541; Keppler H, 1996, NATURE, V380, P237, DOI 10.1038/380237a0; LATOURRETTE TZ, 1993, SCIENCE, V261, P739, DOI 10.1126/science.261.5122.739; LIN PN, 1990, CONTRIB MINERAL PETR, V105, P381, DOI 10.1007/BF00286826; MCCULLOCH MT, 1991, EARTH PLANET SC LETT, V102, P358, DOI 10.1016/0012-821X(91)90029-H; MCCULLOCH MT, 1993, EARTH PLANET SC LETT, V115, P89, DOI 10.1016/0012-821X(93)90215-U; MCDERMOTT F, 1993, CONTRIB MINERAL PETR, V113, P9, DOI 10.1007/BF00320828; MCDERMOTT F, 1991, EARTH PLANET SC LETT, V104, P1, DOI 10.1016/0012-821X(91)90232-7; MCKENZIE D, 1985, EARTH PLANET SC LETT, V74, P81, DOI 10.1016/0012-821X(85)90168-2; MILLER DM, 1994, NATURE, V368, P514, DOI 10.1038/368514a0; MORRIS JD, 1983, GEOCHIM COSMOCHIM AC, V47, P2015, DOI 10.1016/0016-7037(83)90217-X; MORRIS JD, 1991, ANNU REV EARTH PL SC, V19, P313, DOI 10.1146/annurev.ea.19.050191.001525; MORRIS JD, 1990, NATURE, V344, P31, DOI 10.1038/344031a0; ONIONS RK, 1988, EARTH PLANET SC LETT, V90, P449, DOI 10.1016/0012-821X(88)90142-2; PEARCE JA, 1995, ANNU REV EARTH PL SC, V23, P251, DOI 10.1146/annurev.ea.23.050195.001343; PEARCE JA, 1995, J PETROL, V36, P1073, DOI 10.1093/petrology/36.4.1073; PEATE DW, UNPUB; PEATE DW, 1995, IN  PRESS J PETROL, V36; PLANK T, 1988, EARTH PLANET SC LETT, V90, P349, DOI 10.1016/0012-821X(88)90135-5; PLANK T, 1993, NATURE, V362, P739, DOI 10.1038/362739a0; PLANK T, IN PRESS CHEM GEOL; PLANK T, 1992, EOS, V73, P637; REAGAN MK, 1994, GEOCHIM COSMOCHIM AC, V58, P4199, DOI 10.1016/0016-7037(94)90273-9; RUBIN KH, 1989, J VOLCANOL GEOTH RES, V38, P215, DOI 10.1016/0377-0273(89)90038-3; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; RYAN JG, 1988, GEOCHIM COSMOCHIM AC, V52, P237, DOI 10.1016/0016-7037(88)90073-7; RYAN JG, 1993, GEOCHIM COSMOCHIM AC, V57, P1489, DOI 10.1016/0016-7037(93)90008-K; SIGMARSSON O, 1990, NATURE, V346, P163, DOI 10.1038/346163a0; SPIEGELMAN M, 1993, EARTH PLANET SC LETT, V118, P1, DOI 10.1016/0012-821X(93)90155-3; Staucligel H., 1996, AGU GEOPHYS MONOGR, P19; STOLPER E, 1994, EARTH PLANET SC LETT, V121, P293, DOI 10.1016/0012-821X(94)90074-4; Sun S.-S., 1989, GEOLOGICAL SOC LONDO, V42, P323, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; Taylor S.R., 1985, CONTINENTAL CRUST IT; Turner S, 1996, EARTH PLANET SC LETT, V142, P191, DOI 10.1016/0012-821X(96)00078-7; TURNER S, UNPUB; TURNER SP, 1997, GEOL SOC AUSTR ABSTR, V45, P95; TURNER SP, 1995, EOS, V76, pF537; TURNER SP, UNPUB GEOCHIM COSMOC; TURNER SP, IN PRESS CHEM GEOL; TURNER SP, 1995, T AM GEOPHYS UNION, V76, pF654; VROON PZ, 1995, GEOCHIM COSMOCHIM AC, V59, P2573, DOI 10.1016/0016-7037(95)00151-4; VROON PZ, 1993, J GEOPHYS RES-SOL EA, V98, P22349, DOI 10.1029/93JB01716; WHITE WM, 1986, J GEOPHYS RES-SOLID, V91, P5927, DOI 10.1029/JB091iB06p05927; WILLIAMS RW, 1989, GEOCHIM COSMOCHIM AC, V53, P1607; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	71	741	773	5	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					551	555		10.1126/science.276.5312.551	http://dx.doi.org/10.1126/science.276.5312.551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110968				2022-12-28	WOS:A1997WV72100035
J	Stockx, L; Wilms, G; Baert, AL				Stockx, L; Wilms, G; Baert, AL			Prospects with renal artery stenting	LANCET			English	Editorial Material							LONG-TERM; ANGIOPLASTY; STENOSIS				Stockx, L (corresponding author), KATHOLIEKE UNIV LEUVEN,UNIV HOSP,DEPT RADIOL,B-3000 LOUVAIN,BELGIUM.							BAERT AL, 1990, CARDIOVASC INTER RAD, V13, P22, DOI 10.1007/BF02576933; Blum U, 1997, NEW ENGL J MED, V336, P459, DOI 10.1056/NEJM199702133360702; Henry M, 1996, J VASC INTERV RADIOL, V7, P343, DOI 10.1016/S1051-0443(96)72864-6; PATTYNAMA PMT, 1994, CARDIOVASC INTER RAD, V17, P143; RAYNAUD A, 1994, J RADIOL, V75, P81; REES CR, 1991, RADIOLOGY, V181, P507, DOI 10.1148/radiology.181.2.1924796; VANDEVEN PJG, 1995, LANCET, V346, P672, DOI 10.1016/S0140-6736(95)92283-0; WILMS GE, 1991, RADIOLOGY, V179, P457, DOI 10.1148/radiology.179.2.2014292	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1115	1116		10.1016/S0140-6736(05)63017-6	http://dx.doi.org/10.1016/S0140-6736(05)63017-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113007				2022-12-28	WOS:A1997WU54400005
J	Platt, FM; Neises, GR; Reinkensmeier, G; Townsend, MJ; Perry, VH; Proia, RL; Winchester, B; Dwek, RA; Butters, TD				Platt, FM; Neises, GR; Reinkensmeier, G; Townsend, MJ; Perry, VH; Proia, RL; Winchester, B; Dwek, RA; Butters, TD			Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin	SCIENCE			English	Article							GLYCOLIPID BIOSYNTHESIS; REPLACEMENT THERAPY; TARGETED DISRUPTION; GAUCHER DISEASE; HEXA GENE	The glycosphingolipid (GSL) lysosomal storage diseases result from the inheritance of defects in the genes encoding the enzymes required for catabolism of GSLs within lysosomes. A strategy for the treatment of these diseases, based on an inhibitor of GSL biosynthesis N-butyldeoxynojirimycin, was evaluated in a mouse model of Tay-Sachs disease. When Tay-Sachs mice were treated with N-butyldeoxynojirimycin, the accumulation of G(M2) in the brain was prevented, with the number of storage neurons and the quantity of ganglioside stored per cell markedly reduced. Thus, limiting the biosynthesis of the substrate (G(M2)) for the defective enzyme (beta-hexosaminidase A) prevents GSL accumulation and the neuropathology associated with its lysosomal storage.	MONSANTO CO,ST LOUIS,MO 63198; UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; NIDDKD,NIH,BETHESDA,MD 20892; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	Monsanto; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; University College London	Platt, FM (corresponding author), UNIV OXFORD,GLYCOBIOL INST,DEPT BIOCHEM,S PARKS RD,OXFORD OX1 3QU,ENGLAND.		Platt, Frances/G-1004-2010; Perry, V. Hugh/Y-2935-2019; Proia, Richard L/A-7908-2012	Platt, Frances/0000-0001-7614-0403; Proia, Richard/0000-0003-0456-1270				BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; BEUTLER E, 1991, BLOOD, V78, P1183; BUTTERS T, UNPUB; FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; PLATT FM, 1995, TRENDS GLYCOSCI GLYC, V7, P495, DOI 10.4052/tigg.7.495; PLATT FM, 1994, J BIOL CHEM, V269, P27108; PLATT FM, 1994, J BIOL CHEM, V269, P8362; PLATT FM, UNPUB; Sandhoff K, 1989, METABOLIC BASIS INHE, VII, P1807; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; TANIIKE M, 1995, ACTA NEUROPATHOL, V89, P296; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975	14	301	334	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					428	431		10.1126/science.276.5311.428	http://dx.doi.org/10.1126/science.276.5311.428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103204				2022-12-28	WOS:A1997WU47700044
J	Hwang, SW; Orav, EJ; OConnell, JJ; Lebow, JM; Brennan, TA				Hwang, SW; Orav, EJ; OConnell, JJ; Lebow, JM; Brennan, TA			Causes of death in homeless adults in Boston	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-INFECTION; INNER-CITY; MORTALITY; TUBERCULOSIS; CERTIFICATES; PREVALENCE; DISORDERS; ACCURACY; HEALTH; COHORT	Background: Homeless persons have high mortality rates, Objective: To ascertain causes of death in a group of homeless persons. Design: Cohort study. Patients: 17 292 adults seen by the Boston Health Care for the Homeless Program from 1988 to 1993. Measurements: Cause-specific mortality rates adjusted for race and rate ratios that compare mortality rates in homeless persons with those in the general population of Boston. Results: Homicide was the leading cause of death among men who were 18 to 24 years of age (mortality rate, 242.7 per 100 000 person-years; rate ratio, 4.1). The acquired immunodeficiency syndrome was the major cause of death in men (mortality rate, 336.5 per 100 000 person-years; rate ratio, 2.0) and women (mortality rate, 116.0 per 100 000 person-years; rate ratio, 5.0) who were 25 to 44 years of age. Heart disease and cancer were the leading causes of death in persons who were 45 to 64 years of age. Conclusions: The most common causes of death among homeless adults who have contact with clinicians vary by age group. Efforts to reduce the rate of death among homeless persons should focus on these causes.	BOSTON CITY HOSP, BOSTON HLTH CARE HOMELESS PROGRAM, BOSTON, MA 02118 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Boston Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health			Hwang, Stephen W./D-2297-2011; Hwang, Stephen W./GVR-7773-2022	Hwang, Stephen W./0000-0002-1276-1101; 				ALLEN DM, 1994, AIDS, V8, P1593, DOI 10.1097/00002030-199411000-00011; ALSTROM CH, 1975, BRIT J ADDICT, V70, P245; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BURT M, 1989, AM HOMELESS NUMBER C; FERENCHICK GS, 1991, AM J MED SCI, V301, P379, DOI 10.1097/00000441-199106000-00004; FISCHER PJ, 1991, AM PSYCHOL, V46, P1115, DOI 10.1037/0003-066X.46.11.1115; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; HOMBS ME, 1982, HOMELESSNESS AM FORC; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; LEBOW JM, 1995, J ACQ IMMUN DEF SYND, V8, P292, DOI 10.1097/00042560-199503010-00011; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; *NAT CTR HLTH STAT, 1995, DHHS PUBL; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1987, MMWR-MORBID MORTAL W, V36, P297; 1991, MMWR-MORBID MORTAL W, V40, P877	20	209	209	1	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					625	628		10.7326/0003-4819-126-8-199704150-00007	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WT580	9103130				2022-12-28	WOS:A1997WT58000009
J	Barnes, PJ; Larin, M				Barnes, PJ; Larin, M			Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NITRIC-OXIDE SYNTHASE; DNA-BINDING; GLUCOCORTICOID RECEPTOR; PHORBOL ESTER; ULCERATIVE-COLITIS; HUMAN LUNG; C-JUN; ACTIVATION; EXPRESSION; INHIBITION		UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Barnes, PJ (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, DEPT THORAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ADCOCK IM, 1994, LIFE SCI, V55, P1147, DOI 10.1016/0024-3205(94)00243-6; ADCOCK IM, 1994, EUR RESPIR J, V7, P2117, DOI 10.1183/09031936.94.07122117; ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; ADCOCK IM, 1995, AM J PHYSIOL-CELL PH, V268, pC331, DOI 10.1152/ajpcell.1995.268.2.C331; Adcock IM, 1996, BIOCHEM BIOPH RES CO, V225, P545, DOI 10.1006/bbrc.1996.1209; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARNES PJ, 1995, QJM-MON J ASSOC PHYS, V88, P455; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BRENNAN FM, 1995, BRIT MED BULL, V51, P368, DOI 10.1093/oxfordjournals.bmb.a072967; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; EVANS CH, 1995, CLIN ORTHOP RELAT R, P275; Haddad EB, 1996, FEBS LETT, V379, P265, DOI 10.1016/0014-5793(95)01524-8; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LUNDBERG JON, 1994, LANCET, V344, P1673, DOI 10.1016/S0140-6736(94)90460-X; Marok R, 1996, ARTHRITIS RHEUM, V39, P583, DOI 10.1002/art.1780390407; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PAPAVASSILIOU AG, 1995, NEW ENGL J MED, V332, P45, DOI 10.1056/NEJM199501053320108; RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	53	3935	4163	5	215	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1066	1071		10.1056/NEJM199704103361506	http://dx.doi.org/10.1056/NEJM199704103361506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091804				2022-12-28	WOS:A1997WT16100006
J	Brown, KE; Tisdale, J; Barrett, AJ; Dunbar, CE; Young, NS				Brown, KE; Tisdale, J; Barrett, AJ; Dunbar, CE; Young, NS			Hepatitis-associated aplastic anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SUPPRESSOR LYMPHOCYTES-T; NON-A; NON-B; ANTITHYMOCYTE GLOBULIN; LIVER-TRANSPLANTATION; VIRAL-HEPATITIS; GENE-EXPRESSION; FAILURE; CYCLOSPORINE	Background Hepatitis-associated aplastic anemia is a variant of aplastic anemia in which aplastic anemia follows an acute attack of hepatitis. The aplastic anemia, however, is often fatal if untreated. To characterize the illness, investigate the role of hepatitis viruses, and assess the response to immunosuppressive treatment, we studied patients with the syndrome who were referred to the National Institutes of Health (NIH). Methods Standard hematologic and biochemical tests and measurements of bone marrow cellularity were used to monitor the patients' response to treatment. Serum was assayed for antibodies and antigens related to hepatitis A, B, and C viruses and for the RNA of hepatitis C and GB virus C by the polymerase chain reaction. All patients were treated with antithymocyte globulin and cyclosporine. Results Ten patients with hepatitis-associated aplastic anemia were referred to the NIH between 1990 and 1996; all had the typical features of this syndrome. There was evidence of activated CD8 T lymphocytes in the blood. Serologic tests for hepatitis A, B, and C viruses were negative; RNA of hepatitis C virus was undetectable in all patients, but RNA of GB virus C was detected in three patients. Seven of the patients responded to intensive immunosuppressive treatment; the three who did not respond all died within one year of treatment, two from complications of stem-cell or marrow transplantation. Conclusions The hepatitis of the hepatitis-associated aplastic anemia does not appear to be caused by any of the known hepatitis viruses. We recommend immunosuppressive treatment for patients who do not have an HLA-matched related donor available for bone marrow transplantation. Several features of the syndrome suggest that it is mediated by immunopathologic mechanisms. (C) 1997, Massachusetts Medical Society.			Brown, KE (corresponding author), NHLBI,HEMATOL BRANCH,NIH,BLDG 10,RM 7C218,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Dunbar, Cynthia/0000-0002-7645-838X				BOTTIGER LE, 1972, ACTA MED SCAND, V192, P323; Bradley B A, 1992, Clin Transpl, P91; CAMITTA BM, 1974, BLOOD, V43, P473, DOI 10.1182/blood.V43.4.473.473; CATTRAL MS, 1994, HEPATOLOGY, V20, P813, DOI 10.1002/hep.1840200407; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; FOMINA L G, 1955, Sov Med, V19, P28; Gluckman E, 1979, Haematol Blood Transfus, V24, P171; GLUCKMAN E, 1992, BLOOD, V79, P269; HAGLER L, 1975, MEDICINE, V54, P139, DOI 10.1097/00005792-197554020-00003; HIBBS JR, 1992, JAMA-J AM MED ASSOC, V267, P2051; HIBBS JR, 1992, AM J TROP MED HYG, V46, P564, DOI 10.4269/ajtmh.1992.46.564; KAGAN WA, 1976, P NATL ACAD SCI USA, V73, P2890, DOI 10.1073/pnas.73.8.2890; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KOJIMA S, 1989, BRIT J HAEMATOL, V71, P147, DOI 10.1111/j.1365-2141.1989.tb06289.x; Leary TP, 1996, J VIROL METHODS, V56, P119, DOI 10.1016/0166-0934(95)01956-1; LIANG DC, 1990, BRIT J HAEMATOL, V74, P487, DOI 10.1111/j.1365-2141.1990.tb06339.x; LIAW YF, 1995, HEPATOLOGY, V22, P1368, DOI 10.1016/0270-9139(95)90138-8; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LORENZ E, 1955, Wien Med Wochenschr, V105, P19; MACIEJEWSKI JP, 1994, EXP HEMATOL, V22, P1102; Margolis D, 1996, BRIT J HAEMATOL, V94, P65, DOI 10.1046/j.1365-2141.1996.d01-1772.x; MARY JY, 1990, BLOOD, V75, P1646; MAY WS, 1993, BONE MARROW TRANSPL, V11, P459; NAKAO S, 1992, BLOOD, V79, P2532; NISTICO A, 1994, ANN INTERN MED, V120, P463, DOI 10.7326/0003-4819-120-6-199403150-00003; PASSWEG JR, IN PRESS BLOOD; POL S, 1990, ANN INTERN MED, V113, P435; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; SALLIE R, 1994, J HEPATOL, V20, P580, DOI 10.1016/S0168-8278(05)80343-5; SHANNON K, 1990, CLIN PEDIATR, V29, P25, DOI 10.1177/000992289002900103; Shimokawa T, 1990, Rinsho Ketsueki, V31, P1836; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702; YOUNG NS, 1986, BRIT J HAEMATOL, V62, P1, DOI 10.1111/j.1365-2141.1986.tb02893.x; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501	37	211	226	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1059	1064		10.1056/NEJM199704103361504	http://dx.doi.org/10.1056/NEJM199704103361504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091802				2022-12-28	WOS:A1997WT16100004
J	Colten, HR; Krause, JE				Colten, HR; Krause, JE			Pulmonary inflammation - A balancing act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Colten, HR (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.			Krause, James E./0000-0002-8094-1710				Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0	3	20	22	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1094	1096		10.1056/NEJM199704103361511	http://dx.doi.org/10.1056/NEJM199704103361511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091809				2022-12-28	WOS:A1997WT16100011
J	Col, NF; Eckman, MH; Karas, RH; Pauker, SG; Goldberg, RJ; Ross, EM; Orr, RK; Wong, JB				Col, NF; Eckman, MH; Karas, RH; Pauker, SG; Goldberg, RJ; Ross, EM; Orr, RK; Wong, JB			Patient-specific decisions about hormone replacement therapy in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med			CORONARY HEART-DISEASE; ESTROGEN-PROGESTOGEN REPLACEMENT; ACUTE MYOCARDIAL-INFARCTION; DEVELOPING BREAST-CANCER; POST-MENOPAUSAL WOMEN; HIP FRACTURE; LIFE EXPECTANCY; CONVENIENT APPROXIMATION; CARDIOVASCULAR-DISEASE; COST-EFFECTIVENESS	Objective.-To examine the effect of hormone replacement therapy on life expectancy in postmenopausal women with different risk profiles for heart disease, breast cancer, and hip fracture. Design.-Decision analysis using a Markov model, Published regression models were used to link risk factors to disease incidence and to estimate the lifetime risks of developing coronary heart disease (CHD), breast cancer, hip fracture, and endometrial cancer, The impact of hormone therapy on disease incidence was estimated from published epidemiologic studies. Setting.-Mathematical model applicable to primary care, Interventions.-Treatment with hormone replacement therapy or no hormone replacement therapy. Main Outcome Measure.-Life expectancy. Results.-Hormone replacement therapy should increase life expectancy for nearly all postmenopausal women, with some gains exceeding 3 years, depending mainly on an individual's risk factors for CHD and breast cancer, For women with at least 1 risk factor for CHD, hormone therapy should extend life expectancy, even for women having first-degree relatives with breast cancer, Women without any risk factors for CHD or hip fracture, but who have 2 first-degree relatives with breast cancer, however, should not receive hormone therapy. Conclusions.-The benefit of hormone replacement therapy in reducing the likelihood of developing CHD appears to outweigh the risk of breast cancer for nearly all women in whom this treatment might be considered, Our analysis supports the broader use of hormone replacement therapy.	TUFTS UNIV NEW ENGLAND MED CTR, DIV CARDIOL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, BOSTON, MA 02111 USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA USA; FALLON HLTH CARE SYST, WORCESTER, MA USA	Tufts Medical Center; Tufts Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Col, NF (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV CLIN DECIS MAKING INFORMAT & TELEMED, BOX 302, BOSTON, MA 02111 USA.		Col, Nananda/AAE-3445-2019	Eckman, Mark/0000-0001-8253-269X; Wong, John/0000-0003-4203-9010; Col, Nananda/0000-0001-7106-662X	AHRQ HHS [1 PO1 HS 06503] Funding Source: Medline; NLM NIH HHS [LM 07092] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS006503] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ADAMI HO, 1995, JAMA-J AM MED ASSOC, V274, P178, DOI 10.1001/jama.274.2.178; ALFFRAM PER-AXEL, 1964, ACTA ORTHOPAED SCAND SUPPL, V65, P1; *AM HEART ASS, 1995, HEART STROK FACTS 19; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; BONNIER P, 1995, OBSTET GYNECOL, V85, P11, DOI 10.1016/0029-7844(94)00324-7; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CASPER RF, 1993, AM J OBSTET GYNECOL, V168, P1188, DOI 10.1016/0002-9378(93)90367-R; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; COHEN BJ, 1994, J GEN INTERN MED, V9, P20, DOI 10.1007/BF02599137; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Cupples LA, 1988, NIH PUBLICATION; DAHL E, 1980, ACTA ORTHOP SCAND, V51, P163, DOI 10.3109/17453678008990781; DOREN M, 1995, AM J OBSTET GYNECOL, V173, P1446, DOI 10.1016/0002-9378(95)90631-2; EAKER ED, 1993, CARDIOVASCULAR DIS W; ELBANNA S, 1984, ARCH GERONTOL GERIAT, V3, P311, DOI 10.1016/0167-4943(84)90032-3; ELMERSON S, 1988, GERONTOLOGY, V34, P186, DOI 10.1159/000212951; ELSTEIN AS, 1986, AM J MED, V80, P246, DOI 10.1016/0002-9343(86)90016-1; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; Fisher E S, 1991, Epidemiology, V2, P116, DOI 10.1097/00001648-199103000-00005; FRANKLIN C, 1994, CRIT CARE MED, V22, P1335, DOI 10.1097/00003246-199408000-00019; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GORDON PC, 1971, CAN MED ASSOC J, V105, P47; GORSKY RD, 1994, OBSTET GYNECOL, V83, P161; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; GURA T, 1995, SCIENCE, V269, P771, DOI 10.1126/science.7543696; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; HOLMBERG S, 1986, ACTA ORTHOP SCAND, V57, P8, DOI 10.3109/17453678608993205; HUTCHINSON TA, 1979, LANCET, V2, P705; JACOBS EJ, 1994, CANCER CAUSE CONTROL, V5, P359, DOI 10.1007/BF01804987; JACOBSEN SJ, 1992, AM J PUBLIC HEALTH, V82, P1147, DOI 10.2105/AJPH.82.8.1147; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; KASSIRER JP, 1987, ANN INTERN MED, V106, P275, DOI 10.7326/0003-4819-106-2-275; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; Katelaris AG, 1996, AM J PUBLIC HEALTH, V86, P557, DOI 10.2105/AJPH.86.4.557; KENZORA JE, 1984, CLIN ORTHOP RELAT R, P45; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOVAL KJ, 1994, J BONE JOINT SURG AM, V76A, P751, DOI 10.2106/00004623-199405000-00018; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; KUNTZ KM, 1995, MED DECIS MAKING, V15, P158, DOI 10.1177/0272989X9501500209; LAFFERTY FW, 1994, AM J MED, V97, P66, DOI 10.1016/0002-9343(94)90050-7; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; LERMAN C, 1994, MONOGR NATL CANC I, V16, P171; MACLENNAN SC, 1995, MED J AUSTRALIA, V162, P491, DOI 10.5694/j.1326-5377.1995.tb140014.x; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MILLER BA, 1993, NIH PUBLICATION; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; *NAT CANC I, 1981, NAT CANC I MON, V57, P100; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; *OFF TECHN ASS, 1995, COST EFF ANAL, V1; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; PAUKER SG, 1981, ARCH INTERN MED, V141, P1831, DOI 10.1001/archinte.141.13.1831; PFEFFER RI, 1976, AM J EPIDEMIOL, V103, P445, DOI 10.1093/oxfordjournals.aje.a112246; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; PSATY BM, 1993, ARCH INTERN MED, V153, P1421, DOI 10.1001/archinte.153.12.1421; RENO JH, 1958, AM J SURG, V95, P581, DOI 10.1016/0002-9610(58)90440-9; RIES LG, 1983, JNCI-J NATL CANCER I, V70, P693; RISCH HA, 1995, CANCER EPIDEM BIOMAR, V4, P21; RYAN PJ, 1992, BRIT J OBSTET GYNAEC, V99, P325, DOI 10.1111/j.1471-0528.1992.tb13732.x; Salamone LM, 1996, ARCH INTERN MED, V156, P1293, DOI 10.1001/archinte.156.12.1293; SCHIFFMAN J, 1970, FRAMINGHAM STUDY EPI; Sexson S B, 1987, J Orthop Trauma, V1, P298, DOI 10.1097/00005131-198701040-00005; SONNENBERG FA, 1986, MEDINFO 86, P1152; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STAMPFER MJ, 1995, AM J EPIDEMIOL S, V14, P57; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STRICKLAND DM, 1992, OBSTET GYNECOL, V80, P400; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; TOSTESON ANA, 1991, BAILLIERE CLIN OB GY, V5, P943, DOI 10.1016/S0950-3552(05)80298-6; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; UDOFF L, 1995, OBSTET GYNECOL, V86, P306, DOI 10.1016/0029-7844(95)00115-8; *US C, 1984, PUBL US C; *US DEP HHS, 1993, VIT STAT US VAR YEAR, P2; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WHITE BL, 1987, J BONE JOINT SURG AM, V69A, P1335; Wilkes HC, 1996, BRIT MED J, V312, P473; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676; ZUBIALDE JP, 1993, J FAM PRACTICE, V36, P271; Zuckerman JD, 1996, NEW ENGL J MED, V334, P1519, DOI 10.1056/NEJM199606063342307	114	215	223	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1140	1147		10.1001/jama.277.14.1140	http://dx.doi.org/10.1001/jama.277.14.1140			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WR342	9087469				2022-12-28	WOS:A1997WR34200033
J	VanDamme, P; Kane, M; Meheus, A				VanDamme, P; Kane, M; Meheus, A			Integration of hepatitis B vaccination into national immunisation programmes	BRITISH MEDICAL JOURNAL			English	Article								Hepatitis B is a major public health problem even though safe and effective vaccines have been available for over 10 years. Because hepatitis B infection is largely asymptomatic with long term complications occurring after many years it has not received the attention it deserves. Strategies to immunise those at high risk have failed to control the disease. Delegates to the World Health Assembly of the World Health Organisation recommended in May 1992 that all countries should integrate hepatitis B vaccination into their national immunisation programmes by 1997. Some western European countries remain unconvinced that the burden of disease warrants the expense of universal vaccination, However, epidemiological data and economic evaluation show that universal hepatitis B vaccination is cost effective in countries with low endemicity and that it will control hepatitis B, reinforcing the necessity for action.	WHO,GLOBAL PROGRAMME VACCINES & IMMUNISAT,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization	VanDamme, P (corresponding author), UNIV ANTWERP,CTR EVALUAT VACCINAT EPIDEMIOL & COMMUNITY MED,UNIV PLEIN 1,B-2610 ANTWERP,BELGIUM.		van damme, pierre/I-4846-2013					ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1990, VACCINE, V8, pS74, DOI 10.1016/0264-410X(90)90222-8; BOXALL EH, 1995, BRIT MED J, V311, P1178, DOI 10.1136/bmj.311.7014.1178; CHEN DS, 1996, P TRIENN INT S VIR H, P41; FRANCIS DP, 1995, JAMA-J AM MED ASSOC, V274, P1242, DOI 10.1001/jama.274.15.1242; GROSHEIDE PM, 1995, BRIT MED J, V311, P1197, DOI 10.1136/bmj.311.7014.1197; KANE M, 1995, VACCINE, V13, pS47; KANE MA, 1993, DIS CONTROL PRIORITI, P321; MELE A, 1996, P 9 TRIENN INT S VIR, P21; ROURE C, 1995, VACCINE, V13, pS18; TROISI CL, 1993, HEPATITIS B VACCINES, P179; WAINWRIGHT RB, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P762; World Health Organization, 1992, WHODMPCFD92, Vthird, P11	13	126	130	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1033	1036		10.1136/bmj.314.7086.1033	http://dx.doi.org/10.1136/bmj.314.7086.1033			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112852	Green Published			2022-12-28	WOS:A1997WT15200031
J	Gray, J; Close, PS; Briggs, SP; Johal, GS				Gray, J; Close, PS; Briggs, SP; Johal, GS			A novel suppressor of cell death in plants encoded by the Lls1 gene of maize	CELL			English	Article							DISEASE RESISTANCE; SEARCH TOOL; MUTAGENESIS; SYSTEM; MIMICS	The lls1 (lethal leaf spot1) locus of maize is defined by a recessive mutation characterized by the initiation, in a developmentally programmed manner, of necrotic lesions that expand to kill leaves cell autonomously. The loss-of-function nature of all lls1 mutants implies that the Lls1 gene is required to limit the spread of cell death in mature leaves. We have cloned the Lls1 gene by tagging with Mutator, a transposable element system in maize, and we show that it encodes a novel protein highly conserved in plants. Two consensus binding motifs of aromatic ring-hydroxylating dioxygenases are present in the predicted LLS1 protein, suggesting that it may function to degrade a phenolic mediator of cell death.	HICKMAN HIGH SCH,COLUMBIA,MO 65202; PIONEER HI BRED INT INC,JOHNSTON,IA 50131	DuPont; Pioneer Hi-Bred International, Inc.	Gray, J (corresponding author), UNIV MISSOURI,DEPT AGRON,COLUMBIA,MO 65211, USA.		Gray, John/O-7744-2018; Johal, Guri/F-5056-2017	Gray, John/0000-0003-1352-2900; Johal, Guri/0000-0001-8101-8410				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL HM, 1993, J CHEM ECOL, V19, P1521, DOI 10.1007/BF00984895; BENNETZEN JL, 1993, CRIT REV PLANT SCI, V12, P57, DOI 10.1080/713608042; Bent AF, 1996, PLANT CELL, V8, P1757, DOI 10.1105/tpc.8.10.1757; CHEN Z, 1993, SCIENCE, V242, P883; Close P, 1995, MAIZE GENET NEWSLETT, V69, P48; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Durner J, 1996, J BIOL CHEM, V271, P28492, DOI 10.1074/jbc.271.45.28492; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; GAHAN PB, 1981, CELL DEATH BIOL PATH, P145; GARDINER JM, 1993, GENETICS, V134, P917; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu GS, 1996, PLANT CELL, V8, P1367, DOI 10.1105/tpc.8.8.1367; HULBERT SH, 1991, MOL GEN GENET, V226, P377, DOI 10.1007/BF00260649; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; JOHAL GS, 1994, MAYDICA, V39, P69; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; Jones AM, 1996, TRENDS PLANT SCI, V1, P114, DOI 10.1016/S1360-1385(96)90005-9; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBANNI M, 1994, PHYSIOL MOL PLANT P, V44, P379, DOI 10.1016/S0885-5765(05)80050-5; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; Reinbothe S, 1996, CELL, V86, P703, DOI 10.1016/S0092-8674(00)80144-0; ROBERTSON DS, 1978, MUTAT RES, V51, P21, DOI 10.1016/0027-5107(78)90004-0; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STELLAR H, 1995, SCIENCE, V257, P1445; ULLSTRUP AJ, 1967, PHYTOPATHOLOGY, V57, P1282; WALBOT V, 1992, ANNU REV PLANT PHYS, V43, P49, DOI 10.1146/annurev.pp.43.060192.000405; WEYMAN K, 1996, PLANT CELL, V12, P2013; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	45	202	246	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					25	31		10.1016/S0092-8674(00)80179-8	http://dx.doi.org/10.1016/S0092-8674(00)80179-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094711	Bronze			2022-12-28	WOS:A1997WR68500006
J	Guillemin, K; Krasnow, MA				Guillemin, K; Krasnow, MA			The hypoxic response: Huffing and HIFing	CELL			English	Review							INDUCIBLE FACTOR-1; GENE-EXPRESSION; ERYTHROPOIETIN GENE; OXYGEN SENSOR; ANGIOGENESIS; INHIBITORS; PROTEIN; KINASE				Guillemin, K (corresponding author), STANFORD UNIV,DEPT BIOCHEM,SCH MED,STANFORD,CA 94305, USA.			Guillemin, Karen/0000-0001-6004-9955				Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FANDREY J, 1995, RESP PHYSIOL, V101, P1, DOI 10.1016/0034-5687(95)00013-4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Manning Gerards, 1993, P609; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	20	389	413	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					9	12		10.1016/S0092-8674(00)80176-2	http://dx.doi.org/10.1016/S0092-8674(00)80176-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094708	Bronze			2022-12-28	WOS:A1997WR68500003
J	Bograd, H; Ritzwoller, DP; Calonge, N; Shields, K; Hanrahan, M				Bograd, H; Ritzwoller, DP; Calonge, N; Shields, K; Hanrahan, M			Extending health maintenance organization insurance to the uninsured - A controlled measure of health care utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REGIONAL DIFFERENCES; SURVIVAL ANALYSIS; CONTROLLED TRIAL; AMBULATORY CARE; SERVICES; CHILDREN; ACCESS; TERMINATION; REGRESSION; SELECTION	Objective.-To investigate the utilization of health care services of previously uninsured low-income patients after becoming insured by a health maintenance organization (HMO). Design.-Retrospective study of utilization in a previously uninsured study group compared with an age- and sex-matched randomly selected control group of commercial HMO enrollees. Setting.-Group model HMO. Patients.-A study group of 346 previously uninsured low-income patients and 382 controls. Measures.-Outpatient visits for primary and specialty care, outpatient pharmacy, laboratory, and radiology use, and inpatient admissions and hospital days over a 2-year period. Self-reported health status measures were obtained to control for differences in health status. Principal Findings.-There were no differences between the study and control groups in hospital admissions, hospital days, and measures of outpatient laboratory, pharmacy, and radiology use. The odds of having an outpatient visit per patient per month was 30% higher for the study group. Approximately half the increase in the odds ratio for outpatient visits was related to the worse self-perceived health status of the study group. While both groups utilized more services in the early phase of their enrollment, the intensity of this start-up effect was similar for both groups. Conclusions.-Compared with a commercial group of the same age and sex, the patterns of utilization were similar and the financial costs of care were only moderately more for a previously uninsured group provided with comprehensive HMO insurance. With the growth of managed care, these data should be beneficial in the development of health care programs for the growing number of uninsured Americans.	KAISER PERMANENTE COLORADO,DEPT CLIN PROFILES,DENVER,CO 80205; KAISER PERMANENTE COLORADO,DEPT PREVENT MED,DENVER,CO 80205; KAISER PERMANENTE COLORADO,DEPT COMMUNITY MED,DENVER,CO 80205	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Bograd, H (corresponding author), KAISER PERMANENTE COLORADO,DEPT PEDIAT,2045 FRANKLIN ST,DENVER,CO 80205, USA.							ALLISON PD, 1990, PUBLICATION; ALM J, 1993, NATL TAX J, V46, P463; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; BLUMBERG MS, 1982, MED CARE, V20, P931, DOI 10.1097/00005650-198209000-00006; *C RES SERV, 1988, HLTH INS UN BACKGR D, P1; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; *CO DEP HLTH CAR P, 1995, SURV DAT FAM EMPL HL; CORNELIUS L, 1991, NATL MED EXPENDITURE, V11, P4; Donelan K, 1996, JAMA-J AM MED ASSOC, V276, P1346, DOI 10.1001/jama.276.16.1346; EFRON B, 1988, J AM STAT ASSOC, V83, P414, DOI 10.2307/2288857; FELDMAN R, 1989, INQUIRY-J HEALTH CAR, V26, P381; FREEMAN HE, 1993, HEALTH SERV RES, V28, P531; Greene W. H., 1993, ECONOMETRIC ANAL; HADLEY JP, 1991, HEALTH POLICY, V19, P91, DOI 10.1016/0168-8510(91)90001-E; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HAHN B, 1994, MED CARE, V32, P227, DOI 10.1097/00005650-199403000-00004; HENDERSON T, 1988, INT J ROBOT RES, V7, P114, DOI 10.1177/027836498800700609; KNICKMAN JR, 1984, MED CARE, V22, P971, DOI 10.1097/00005650-198411000-00001; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MCNEIL JM, 1995, CURRENT POPULATION R; MONHEIT AC, 1994, ANNU REV PUBL HEALTH, V15, P461; NEWACHECK PW, 1986, PEDIATRICS, V78, P813; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; Rice T, 1994, Med Care Rev, V51, P235, DOI 10.1177/107755879405100302; RILEY G, 1989, MED CARE, V27, P337, DOI 10.1097/00005650-198904000-00002; Schroeder SA, 1996, NEW ENGL J MED, V334, P1130, DOI 10.1056/NEJM199604253341713; SPILLMAN BC, 1992, INQUIRY-J HEALTH CAR, V29, P457; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; *US BUR CENS, 1994, 1994 STAT ABSTR US, P247; Wilensky G R, 1986, Health Aff (Millwood), V5, P66, DOI 10.1377/hlthaff.5.1.66	34	29	29	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1067	1072		10.1001/jama.277.13.1067	http://dx.doi.org/10.1001/jama.277.13.1067			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WQ089	9091696				2022-12-28	WOS:A1997WQ08900033
J	Nightingale, SL				Nightingale, SL			FDA call for applications for use of certain oral contraceptives for postcoital emergency contraception	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1997, FED REG         0225, V62, P8610	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-28	WOS:A1997WQ08900006
J	Umans, JG				Umans, JG			Less nitric oxide, more pressure, or the converse?	LANCET			English	Editorial Material											Umans, JG (corresponding author), UNIV CHICAGO,NEPHROL SECT,CHICAGO,IL 60637, USA.							FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARLAND CJ, 1995, TRENDS PHARMACOL SCI, V16, P23, DOI 10.1016/S0165-6147(00)88969-5; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011	4	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					816	817		10.1016/S0140-6736(97)22012-X	http://dx.doi.org/10.1016/S0140-6736(97)22012-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121249				2022-12-28	WOS:A1997WP40300002
J	Landick, R				Landick, R			RNA polymerase slides home: Pause and termination site recognition	CELL			English	Review							ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; ELONGATION; CONFORMATIONS				Landick, R (corresponding author), UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706, USA.							CHAMBERLIN MJ, 1995, HARVEY LECT, P1; CHAN C, 1997, IN PRESS J MOL BIOL; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Guerin M, 1996, EMBO J, V15, P5397, DOI 10.1002/j.1460-2075.1996.tb00923.x; KOMISSAROVA N, 1997, IN PRESS P NATL ACAD; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1997, IN PRESS CELL; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; UPTAIN S, 1997, IN PRESS ANN REV BIO; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	20	101	101	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					741	744		10.1016/S0092-8674(00)81919-4	http://dx.doi.org/10.1016/S0092-8674(00)81919-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118216	Bronze			2022-12-28	WOS:A1997WQ10000005
J	Tan, RS				Tan, RS			Prescribing antidepressants in general practice - Low dose tricyclic antidepressants are effective in treating major depression	BRITISH MEDICAL JOURNAL			English	Letter											Tan, RS (corresponding author), TEXAS TECH UNIV,DEPT VET AFFAIRS MED CTR,6010 AMARILLO BLVD,W AMARILLO,TX 79106, USA.							Kendrick T, 1996, BRIT MED J, V313, P829; LAKSHMANAN M, 1986, J AM GERIATR SOC, V34, P421, DOI 10.1111/j.1532-5415.1986.tb03408.x; MacDonald TM, 1996, BRIT MED J, V313, P860; Tan Robert S., 1995, Clinical Gerontologist, V16, P67; TAN RSH, 1994, BRIT J CLIN PHARMACO, V37, P321, DOI 10.1111/j.1365-2125.1994.tb04284.x	5	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					827	827						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN646	9081013				2022-12-28	WOS:A1997WN64600046
J	Baker, B; Zambryski, P; Staskawicz, B; DineshKumar, SP				Baker, B; Zambryski, P; Staskawicz, B; DineshKumar, SP			Signaling in plant-microbe interactions	SCIENCE			English	Review							SYSTEMIC ACQUIRED-RESISTANCE; HYPERSENSITIVE DISEASE RESISTANCE; VIRUS MOVEMENT PROTEIN; LEUCINE-RICH REPEAT; NF-KAPPA-B; ARABIDOPSIS-THALIANA; SALICYLIC-ACID; CLADOSPORIUM-FULVUM; GENE-CLUSTER; INTERLEUKIN-1 RECEPTOR	Analysis of viral and bacterial pathogenesis has revealed common themes in the ways in which plants and animals respond to pathogenic agents, Pathogenic bacteria use macromolecule delivery systems (types III and IV) to deliver microbial avirulence proteins and transfer DNA-protein complexes directly into plant cells, The molecular events that constitute critical steps of plant-pathogen interactions seem to involve ligand-receptor mechanisms for pathogen recognition and the induction of signal transduction pathways in the plant that lead to defense responses. Unraveling the molecular basis of disease resistance pathways has laid a foundation for the rational design of crop protection strategies.	ARS,CTR PLANT GENE EXPRESS,USDA,ALBANY,CA 94710	United States Department of Agriculture (USDA)	Baker, B (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT & MICROBIAL BIOL,BERKELEY,CA 94720, USA.		Baker, Barbara/Z-1108-2019; Baker, Barbara/L-7198-2016	Baker, Barbara/0000-0002-1276-971X; Baker, Barbara/0000-0002-1276-971X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045244] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ANDERSON PA, IN PRESS PLANT CELL; AUSUBEL FM, 1995, P NATL ACAD SCI USA, V92, P4189, DOI 10.1073/pnas.92.10.4189; Barinaga M, 1996, SCIENCE, V272, P1261, DOI 10.1126/science.272.5266.1261; Baron C, 1996, CURR BIOL, V6, P1567, DOI 10.1016/S0960-9822(02)70773-2; Beer S. V., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P53; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Bogdanove AJ, 1996, MOL MICROBIOL, V20, P681, DOI 10.1046/j.1365-2958.1996.5731077.x; BOTELLA MA, UNPUB; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; Cai DG, 1997, SCIENCE, V275, P832, DOI 10.1126/science.275.5301.832; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CARRINGTON JC, 1996, IN PRESS PLANT CELL, V8, P1669; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; CITOVSKY V, 1992, PLANT CELL, V4, P397, DOI 10.1105/tpc.4.4.397; CITOVSKY V, 1991, BIOESSAYS, V13, P373, DOI 10.1002/bies.950130802; CLARK SJ, UNPUB; Crute I, 1994, ARABIDOPSIS, P705; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DANGL JL, 1992, PLANT CELL, V4, P1359, DOI 10.1105/tpc.4.11.1359; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DANGL JL, 1994, BACTERIAL PATHOGENES, V192, P99; Dangl JL, 1993, ADV PLANT PATHOL, V10, P127; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; DINESHKUMAR SP, 1995, P NATL ACAD SCI USA, V92, P4175, DOI 10.1073/pnas.92.10.4175; DINESHKUMAR SP, UNPUB; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; DIXON RA, 1994, ANNU REV PHYTOPATHOL, V32, P479, DOI 10.1146/annurev.py.32.090194.002403; Dwyer SC, 1996, BBA-GEN SUBJECTS, V1289, P231, DOI 10.1016/0304-4165(95)00156-5; Ellis J., UNPUB; FALK A, COMMUNICATION; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Ghoshroy Soumitra, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P27, DOI 10.1146/annurev.arplant.48.1.27; GLAZEBROOK J, 1994, P NATL ACAD SCI USA, V91, P8955, DOI 10.1073/pnas.91.19.8955; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEINLEIN M, 1995, SCIENCE, V270, P1983, DOI 10.1126/science.270.5244.1983; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; Hu GS, 1996, PLANT CELL, V8, P1367, DOI 10.1105/tpc.8.8.1367; HUANG HC, 1988, J BACTERIOL, V170, P4748, DOI 10.1128/jb.170.10.4748-4756.1988; HUANG HC, 1995, MOL PLANT MICROBE IN, V8, P733, DOI 10.1094/MPMI-8-0733; INNES RW, 1993, PLANT J, V4, P813, DOI 10.1046/j.1365-313X.1993.04050813.x; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Jones JDG, 1997, NATURE, V385, P397, DOI 10.1038/385397a0; KATAGIRI F, COMMUNICATION; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kunkel BN, 1996, TRENDS GENET, V12, P63, DOI 10.1016/0168-9525(96)81402-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lamaitre B, 1996, CELL, V86, P973; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; Leister RT, 1996, P NATL ACAD SCI USA, V93, P15497, DOI 10.1073/pnas.93.26.15497; LESSL M, 1994, CELL, V77, P321, DOI 10.1016/0092-8674(94)90146-5; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LINDGREN PB, 1986, J BACTERIOL, V168, P512, DOI 10.1128/jb.168.2.512-522.1986; Long SR, 1996, PLANT CELL, V8, P1885, DOI 10.1105/tpc.8.10.1885; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; McLean BG, 1995, PLANT CELL, V7, P2101, DOI 10.1105/tpc.7.12.2101; MCLEAN BG, IN PRESS PLANT CELL; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Murillo I, 1997, PLANT CELL, V9, P145, DOI 10.1105/tpc.9.2.145; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; Oerke EC., 1994, CROP PRODUCTION CROP; ORI N, IN PRESS PLANT CELL; PADGETT HS, 1993, PLANT CELL, V5, P577, DOI 10.1105/tpc.5.5.577; Parker JE, 1996, PLANT CELL, V8, P2033, DOI 10.1105/tpc.8.11.2033; PARKER JE, IN PRESS PLANT CELL; Pawlowski K, 1996, PLANT CELL, V8, P1899, DOI 10.1105/tpc.8.10.1899; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; PRYOR T, 1993, ADV PLANT PATHOL, V10, P281; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; RICHTER TE, 1995, GENETICS, V141, P373; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SALMOND GPC, 1994, ANNU REV PHYTOPATHOL, V32, P181, DOI 10.1146/annurev.py.32.090194.001145; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schaller A, 1996, BIOESSAYS, V18, P27, DOI 10.1002/bies.950180108; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHULAEV V, 1995, PLANT CELL, V7, P1691, DOI 10.1105/tpc.7.10.1691; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SONG W, UNPUB; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STASKAWICZ B, COMMUNICATION; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433; WANG GR, COMMUNICATION; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WHITHAM S, UNPUB; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	134	741	896	2	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					726	733		10.1126/science.276.5313.726	http://dx.doi.org/10.1126/science.276.5313.726			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115193				2022-12-28	WOS:A1997WW90000039
J	Oro, AE; Higgins, KM; Hu, ZL; Bonifas, JM; Epstein, EH; Scott, MP				Oro, AE; Higgins, KM; Hu, ZL; Bonifas, JM; Epstein, EH; Scott, MP			Basal cell carcinomas in mice overexpressing sonic hedgehog	SCIENCE			English	Article							KERATIN EXPRESSION; BASEMENT-MEMBRANE; GENES; DIFFERENTIATION; DROSOPHILA; PROTEINS; POLARITY; SKIN; TRANSPLANTATION; XENOGRAFTS	Mutations in the tumor suppressor gene PATCHED (PTC) are found in human patients with the basal cell nevus syndrome, a disease causing developmental defects and tumors, including basal cell carcinomas. Gene regulatory relationships defined in the fruit fly Drosophila suggest that overproduction of Sonic hedgehog (SHH), the ligand for PTC, will mimic loss of ptc function. It is shown here that transgenic mice overexpressing SHH in the skin develop many features of basal cell nevus syndrome, demonstrating that SHH is sufficient to induce basal cell carcinomas in mice. These data suggest that SHH may have a role in human tumorigenesis.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT DERMATOL,SAN FRANCISCO,CA 94110; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DERMATOL,STANFORD,CA 94305	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University				hu, zhilan/0000-0003-2925-5595	NIAMS NIH HHS [AR39959] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039959] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arbeit JM, 1996, CANCER SURV, V26, P7; BARLOGIE B, 1983, CANCER RES, V43, P3982; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Chidambaram A, 1996, CANCER RES, V56, P4599; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; COOPER M, 1977, CANCER RES, V37, P2544; Dean M, 1996, NAT GENET, V14, P245, DOI 10.1038/ng1196-245; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANCISWEST PH, 1995, DEV DYNAM, V203, P187, DOI 10.1002/aja.1002030207; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GRIMWOOD RE, 1985, CANCER, V56, P519, DOI 10.1002/1097-0142(19850801)56:3<519::AID-CNCR2820560319>3.0.CO;2-W; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HALES SA, 1989, BRIT J DERMATOL, V120, P351, DOI 10.1111/j.1365-2133.1989.tb04159.x; HALL T, 1996, NATURE, V378, P212; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; IZPISUABELMONTE JC, 1992, DEVELOPMENT, V114, P959; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lazarova Z, 1995, Exp Dermatol, V4, P121, DOI 10.1111/j.1600-0625.1995.tb00235.x; Lever W. F., 1990, HISTOPATHOLOGY SKIN; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; MARKS R, 1988, ARCH DERMATOL, V124, P1039, DOI 10.1001/archderm.124.7.1039; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAVOIA P, 1993, J INVEST DERMATOL, V101, P352, DOI 10.1111/1523-1747.ep12365531; STAMP GWH, 1988, J PATHOL, V156, P213, DOI 10.1002/path.1711560306; STANLEY JR, 1982, CANCER, V50, P1486, DOI 10.1002/1097-0142(19821015)50:8<1486::AID-CNCR2820500807>3.0.CO;2-F; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TingBerreth SA, 1996, DEV DYNAM, V207, P157, DOI 10.1002/(SICI)1097-0177(199610)207:2<157::AID-AJA4>3.0.CO;2-G; Unden AB, 1996, CANCER RES, V56, P4562	52	556	607	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					817	821		10.1126/science.276.5313.817	http://dx.doi.org/10.1126/science.276.5313.817			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115210				2022-12-28	WOS:A1997WW90000064
J	Forni, LG; Hilton, PJ				Forni, LG; Hilton, PJ			Current concepts: Continuous hemofiltration in the treatment of acute renal failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONTINUOUS ARTERIOVENOUS HEMOFILTRATION; CRITICALLY ILL; EPOPROSTENOL PGI2; HEMODIALYSIS; HEMODIAFILTRATION; THERAPIES		ST THOMAS HOSP, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust								BARTON, 1993, Q J MED, V86, P283; Barton I K, 1992, Clin Intensive Care, V3, P196; Barton I K, 1993, Clin Intensive Care, V4, P16; BARTON IK, 1993, Q J MED, V86, P81; BARTON IK, 1991, NEPHROL DIAL TRANSPL, V6, P368, DOI 10.1093/ndt/6.5.368; BELLOMO R, 1993, AM J KIDNEY DIS, V21, P508, DOI 10.1016/S0272-6386(12)80397-0; BRADY HR, 1995, LANCET, V346, P1533, DOI 10.1016/S0140-6736(95)92057-9; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; CLARK WR, 1994, J AM SOC NEPHROL, V4, P1413; Forni LG, 1996, ARCH INTERN MED, V156, P1023, DOI 10.1001/archinte.156.9.1023; GERONEMUS R, 1984, T AM SOC ART INT ORG, V30, P610; JOURNOIS D, 1991, CONTRIB NEPHROL, V93, P202; KIERDORF H, 1991, CONTRIB NEPHROL, V93, P1; KRAMER P, 1977, KLIN WOCHENSCHR, V55, P1121, DOI 10.1007/BF01477940; LAUER A, 1983, ANN INTERN MED, V99, P455, DOI 10.7326/0003-4819-99-4-455; MACIAS WL, 1991, AM J KIDNEY DIS, V18, P451, DOI 10.1016/S0272-6386(12)80113-2; MCDONALD BR, 1991, CONTRIB NEPHROL, V93, P51; MILLER LC, 1985, DIALYSIS TRANSPLANT, V14, P579; Olbricht CJ, 1992, OXFORD TXB CLIN NEPH, V2, P1417; RONCO C, 1993, CLIN NEPHROL, V40, P187; SCHAFER GE, 1991, CONTRIB NEPHROL, V93, P23; SIEBERTH HG, 1992, TXB CLIN NEPHROLOGY, V2, P1026; SWARTZ RD, 1988, J CLIN PHARMACOL, V28, P818, DOI 10.1002/j.1552-4604.1988.tb03222.x; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; van Geelen J A, 1988, Nephrol Dial Transplant, V3, P181; VANBOMMEL EFH, 1995, AM J NEPHROL, V15, P192, DOI 10.1159/000168832; WENDON J, 1989, INTENS CARE MED, V15, P358; WING AJ, 1983, P EUR DIAL TRANS, V20, P2	29	134	142	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1303	1309		10.1056/NEJM199705013361807	http://dx.doi.org/10.1056/NEJM199705013361807			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113935				2022-12-28	WOS:A1997WW26000007
J	Andrews, TC; Cull, DL; Pelton, JJ; Massey, SO; Bostwick, JM				Andrews, TC; Cull, DL; Pelton, JJ; Massey, SO; Bostwick, JM			Self-mutilation and malingering among Cuban migrants detained at Guantanamo Bay	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILITARY				Andrews, TC (corresponding author), WILFORD HALL USAF MED CTR,LACKLAND AFB,TX 78236, USA.							BENNUN I, 1984, SUICIDE LIFE-THREAT, V14, P166; DRUMMOND T, 1994, TIME            1219, P23; GIBBS N, 1994, TIME            0620, P28; GORMAN WF, 1982, J FORENSIC SCI, V27, P401; MARK M, 1987, MIL MED, V152, P260, DOI 10.1093/milmed/152.5.260; PODVOLL E, 1969, BR J MED PSYCHOL, V14, P213; POST T, 1994, NEWSWEEK        0905, P22; ROBINSON L, 1994, US NEWS WORLD R 0926, P55; SHARP TW, 1994, JAMA-J AM MED ASSOC, V272, P386, DOI 10.1001/jama.272.5.386	9	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1251	1253		10.1056/NEJM199704243361712	http://dx.doi.org/10.1056/NEJM199704243361712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110917				2022-12-28	WOS:A1997WV33200012
J	Kyle, RA; Gertz, MA; Greipp, PR; Witzig, TE; Lust, JA; Lacy, MQ; Therneau, TM				Kyle, RA; Gertz, MA; Greipp, PR; Witzig, TE; Lust, JA; Lacy, MQ; Therneau, TM			A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY SYSTEMIC AMYLOIDOSIS; LABORATORY FEATURES; AL	Background Primary systemic amyloidosis is an uncommon disease characterized by the accumulation in vital organs of a fibrillar protein consisting of monoclonal light chains. Methods We treated 220 patients with biopsy-proved amyloidosis. The patients were randomly assigned to receive colchicine (72 patients), melphalan and prednisone (77), or melphalan, prednisone, and colchicine (71). They were stratified according to their chief clinical manifestations: renal disease (105 patients), cardiac involvement (46), peripheral neuropathy (19), or other (50). Results The median duration of survival after randomization was 8.5 months in the colchicine group, 18 months in the group assigned to melphalan and prednisone, and 17 months in the group assigned to melphalan, prednisone, and colchicine (P<0.001). Among patients who had a reduction in serum or urine monoclonal protein at 12 months, the overall length of survival was 50 months, whereas among those without a reduction at 12 months, the overall length of survival was 36 months (P=0.03). Thirty-four patients (15 percent) survived for five years or longer. Conclusions Therapy with melphalan and prednisone results in objective responses and prolonged survival as compared with colchicine in patients with primary amyloidosis. (C) 1997, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic	Kyle, RA (corresponding author), MAYO CLIN & MAYO FDN,DIV HEMATOL & INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.		Gertz, Morie/K-2873-2019		NATIONAL CANCER INSTITUTE [P01CA062242] Funding Source: NIH RePORTER; NCI NIH HHS [CA62242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COHEN AS, 1987, AM J MED, V82, P1182, DOI 10.1016/0002-9343(87)90222-1; Comenzo R. L., 1995, Blood, V86, p206A; Dhodapkar M., 1995, Blood, V86, p442A; GIANNI L, 1995, BLOOD, V86, P855; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; KYLE RA, 1975, MEDICINE, V54, P271; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; KYLE RA, 1985, AM J MED, V79, P708, DOI 10.1016/0002-9343(85)90521-2; KYLE RA, 1978, BLOOD, V52, P818; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9	11	510	538	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1202	1207		10.1056/NEJM199704243361702	http://dx.doi.org/10.1056/NEJM199704243361702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110907	Bronze			2022-12-28	WOS:A1997WV33200002
J	Shibasaki, F; Kondo, E; Akagi, T; McKeon, F				Shibasaki, F; Kondo, E; Akagi, T; McKeon, F			Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2	NATURE			English	Article							PROGRAMMED CELL-DEATH; PROTEIN; GENE; ONCOPROTEIN; EXPRESSION; REGULATOR; SURVIVAL; MEMBERS; FAMILY	It is not known how the protein Bcl-2 inhibits cell death induced by calcium signalling and growth-factor withdrawal(1-3). Here we report that Bcl-2 forms a tight complex with calcineurin, resulting in the targeting of calcineurin to Bcl-2 sites on cytoplasmic membranes, and show that this interaction is dependent on the BH4 domain of Bcl-2. Calcineurin bound to Bcl-2 is an active phosphatase but is unable to promote the nuclear translocation of NF-AT, a transcription-factor required for induction of interleukin-2 expression, suggesting a mechanism by which Bcl-2 suppresses NF-AT activity(4). We also show that Bar, a pro-apoptotic member of the Bcl-2 family, interferes with interactions between calcineurin and Bcl-2. We propose that the ability of Bcl-2 to block NF-AT signalling is due to the sequestering of active calcineurin to the same domain of Bcl-2 which associates with Rad-1 (ref. 5), and that calcineurin may act in Bcl-2-regulated functions.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; OKAYAMA UNIV,SCH MED,DEPT PATHOL 2,OKAYAMA 700,JAPAN	Harvard University; Harvard Medical School; Okayama University								BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRAUN W, 1995, FASEB J, V9, P63, DOI 10.1096/fasebj.9.1.7529736; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; GONZALEZGARCIA M, 1990, DEVELOPMENT, V20, P3033; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; KONDO E, 1992, BLOOD, V80, P2044; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	23	322	327	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					728	731		10.1038/386728a0	http://dx.doi.org/10.1038/386728a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109491				2022-12-28	WOS:A1997WU38700059
J	Rossle, M; Deibert, P; Haag, K; Ochs, A; Olschewski, M; Siegerstetter, V; Hauenstein, KH; Geiger, R; Stiepak, C; Keller, W; Blum, HE				Rossle, M; Deibert, P; Haag, K; Ochs, A; Olschewski, M; Siegerstetter, V; Hauenstein, KH; Geiger, R; Stiepak, C; Keller, W; Blum, HE			Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding	LANCET			English	Article							BLEEDING ESOPHAGEAL-VARICES; DISTAL SPLENORENAL SHUNT; LONG-TERM MANAGEMENT; INJECTION SCLEROTHERAPY; PORTAL-HYPERTENSION; STENT-SHUNT; HEMORRHAGE; ENCEPHALOPATHY; CIRRHOSIS; LIGATION	Background The transjugular-intrahepatic-portosystemic shunt is a new interventional treatment for portal hypertension, The aim of our study was to compare the transjugular shunt with endoscopic treatment for the prophylaxis of recurrent variceal bleeding. Methods Between March, 1993, and March, 1996, 126 patients with variceal bleeding were randomly assigned either transjugular shunt (n=61) or endoscopic treatment (n=65), Patients were followed up for a median of 14 (IQR 8-25) months and 13 (8-25) months, respectively, In 31 (51%) of the shunted patients, simultaneous transjugular-variceal embolisation was done at the time of shunt placement, Endoscopic treatment consisted of sclerotherapy and/or banding ligation and was combined with propranolol medication. Findings Technical success was achieved in all patients assigned to the shunt group. During follow-up, the cumulative 1-year variceal rebleeding rates in the shunted and endoscopically treated patients were 15% and 41% and the 2-year rates were 21% and 52% (p=0.001), respectively. In nine (12%) patients from the endoscopic group treatment failed and the patients received the transjugular-shunt treatment, A total of 19 bleeding episodes from any source occurred in 15 patients in the shunt group compared with 100 episodes in 33 patients in the endoscopic group, There was no difference in survival with estimated 1-year survival rates for shunted and endoscopically treated patients of 90% and 89%, and 2-year survival rates of 79% and 82%, respectively, The incidence of clinically significant hepatic encephalopathy after 1 year was higher in the shunt group (36% vs 18%, p=0.011). Interpretation These results suggest, that the transjugular shunt is more effective than endoscopic treatment in prevention of variceal rebleeding but has a considerable risk of hepatic encephalopathy. Survival is similar in the two groups.	UNIV FREIBURG,UNIV HOSP,INST MED BIOMETRY,D-79106 FREIBURG,GERMANY; UNIV FREIBURG,UNIV HOSP,DEPT RADIOL,D-79106 FREIBURG,GERMANY; GEN HOSP OFFENBURG,DEPT INTERNAL MED,OFFENBURG,GERMANY; GEN HOSP RASTATT,DEPT INTERNAL MED,RASTATT,GERMANY	University of Freiburg; University of Freiburg	Rossle, M (corresponding author), UNIV FREIBURG,UNIV HOSP,DEPT GASTROENTEROL & HEPATOL,HUGSTETTER STR 55,D-79106 FREIBURG,GERMANY.		Deibert, Peter/AAE-4623-2020					Cabrera J, 1996, GASTROENTEROLOGY, V110, P832, DOI 10.1053/gast.1996.v110.pm8608893; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; FLEIG WE, 1987, HEPATOLOGY, V7, P355, DOI 10.1002/hep.1840070224; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; Haag K, 1996, TRANSJUGULAR INTRAHE, P319; Haag Klaus, 1993, Intensivmedizin und Notfallmedizin, V30, P479; HAUENSTEIN KH, 1995, RADIOLOGY, V194, P175, DOI 10.1148/radiology.194.1.7997547; HENDERSON JM, 1990, ANN INTERN MED, V112, P262, DOI 10.7326/0003-4819-112-4-262; INK O, 1992, HEPATOLOGY, V16, P912, DOI 10.1002/hep.1840160410; LABERGE JM, 1995, GASTROENTEROLOGY, V108, P1143, DOI 10.1016/0016-5085(95)90213-9; LAINE L, 1993, ANN INTERN MED, V119, P1, DOI 10.7326/0003-4819-119-1-199307010-00001; LIND CD, 1994, GASTROENTEROLOGY, V106, P1277, DOI 10.1016/0016-5085(94)90020-5; MORIYASU F, 1986, AM J ROENTGENOL, V146, P735, DOI 10.2214/ajr.146.4.735; OCONNOR KW, 1989, GASTROENTEROLOGY, V96, P899; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PERARNAU JM, 1993, GASTROENTEROL CLIN B, V17, P22; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; ROSSLE M, 1988, HEPATOLOGY, V8, P1348; SIMPSON KJ, 1993, GUT, V34, P968, DOI 10.1136/gut.34.7.968; SMITHLAING G, 1981, GASTROENTEROLOGY, V80, P1031; TERBLANCHE J, 1989, ANN SURG, V210, P725, DOI 10.1097/00000658-198912000-00006; TERES J, 1987, HEPATOLOGY, V7, P430, DOI 10.1002/hep.1840070303; VANSTIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1990, HEPATOLOGY, V11, P353, DOI 10.1002/hep.1840110304	30	205	210	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1043	1049		10.1016/S0140-6736(96)08189-5	http://dx.doi.org/10.1016/S0140-6736(96)08189-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107241				2022-12-28	WOS:A1997WU00200007
J	Birmingham, ME; Lee, LA; Ndayimirije, N; Nkurikiye, S; Hersh, BS; Wells, JG; Deming, MS				Birmingham, ME; Lee, LA; Ndayimirije, N; Nkurikiye, S; Hersh, BS; Wells, JG; Deming, MS			Epidemic cholera in Burundi: Patterns of transmission in the Great Rift Valley Lake region	LANCET			English	Article							VIBRIO-CHOLERAE; RISK	Background After a 14-year hiatus, epidemic cholera swept through Burundi between January and May, 1992, The pattern of transmission was similar to that in 1978, when the seventh pandemic first reached this region, Communities affected were limited to those near Lake Tanganyika and the Rusizi River, The river connects Lake Tanganyika with Lake Kivu to the north in Zaire and Rwanda. Methods To identify sources of infection and risk factors for illness, an epidemiological study was carried out in Rumonge, a lake-shore town where 318 people were admited to hospital with cholera between April 9 and May 31, 1992, The investigation included a case-control study of 56 case-patients and 112 matched controls. Findings Attack rates according to street increased with the street's proximity to Lake Tanganyika (chi(2) test for linear trend, p < 0.01) which suggests that exposure to the lake was a risk factor for illness, Comparison of the 56 case-patients with matched controls showed that bathing in the lake (odds ratio 1.6, attributable risk percentage 37%) and drinking its water (2.78, 14%) were independently and significantly (p < 0.05) linked with illness, No food-borne risk factors were identified, Vibrio cholera 01 was isolated from Lake Tanganyiha during, but not after, the outbreak in Rumonge, Isolates from the lake and from patients with acute watery diarrhoea had the same serotype, biotype, and antimicrobial susceptibility profiles, The number of cases rapidly declined when access to the lake was blocked. Interpretation This study identifies bathing in contaminated surface water as a major risk factor for cholera in sub-Saharan Africa, and suggests that improving the quality of drinking water alone will have only limited impact on the transmission of the disease in the Great Rift Valley Lake region. The similarity in the patterns of transmission during the 1978 and 1992 epidemics suggests that extensive use of the Great Lakes and connecting rivers for transportation and domestic purposes may be the reason for the explosive cholera outbreaks that occur sporadically in this region.	CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,NATL CTR INFECT DIS,ATLANTA,GA 30333; MINIST PUBL HLTH,BUJUMBURA,BURUNDI	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1995, Wkly Epidemiol Rec, V70, P201; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CASH RA, 1974, J INFECT DIS, V129, P45, DOI 10.1093/infdis/129.1.45; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; FIELDS PI, 1992, J CLIN MICROBIOL, V30, P2118, DOI 10.1128/JCM.30.8.2118-2121.1992; GANGAROSA EJ, 1974, CHOLERA, P381; Global Task Force on Cholera Control, 1993, GUID CHOL CONTR; *GOM EP GROUP, 1994, LANCET, V345, P339; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; HUGHES JM, 1982, B WORLD HEALTH ORGAN, V60, P395; MINTZ ED, 1995, JAMA-J AM MED ASSOC, V273, P948, DOI 10.1001/jama.273.12.948; *NAT COMM CLIN LAB, 1990, PERF STAND ANT SUSC, V10, pM2; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; *SAS I INC, 1993, P229 SAS I INC, P465; SCHHYNS C, 1979, ANN SOC BELG MED TR, P391; SINCLAIR GS, 1982, S AFR MED J, V62, P753; SPIRA WM, 1981, APPL ENVIRON MICROB, V42, P730, DOI 10.1128/AEM.42.4.730-733.1981; STLOUIS ME, 1990, AM J EPIDEMIOL, V131, P719; STORME B, 1979, ANN SOC BELG MED TR, V59, P413; Swerdlow David L., 1994, P297; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418; WEBBER RH, 1983, E AFR MED J, V60, P848; WEST PA, 1989, EPIDEMIOL INFECT, V103, P1, DOI 10.1017/S0950268800030326; *WHO, 1987, CCC833 WHO	24	49	51	3	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					981	985		10.1016/S0140-6736(96)08478-4	http://dx.doi.org/10.1016/S0140-6736(96)08478-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100624				2022-12-28	WOS:A1997WR62100010
J	Kawachi, I; Kennedy, BP				Kawachi, I; Kennedy, BP			Socioeconomic determinants of health .2. Health and social cohesion: Why care about income inequality?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIFE EXPECTANCY; ALAMEDA COUNTY; MORTALITY	Throughout the world, wealth and income are becoming more concentrated. Growing evidence suggests that the distribution of income-in addition to the absolute standard of living enjoyed by the poor-is a key determinant of population health. A large gap between rich people and poor people leads to higher mortality through the breakdown of social cohesion. The recent surge in income inequality in many countries has been accompanied by a marked increase in the residential concentration of poverty and affluence. Residential segregation diminishes the opportunities for social cohesion. Income inequality has spillover effects on society at large, including increased rates of crime and violence, impeded productivity and economic growth, and the impaired functioning of representative democracy. The extent of inequality in society is often a consequence of explicit policies and public choice. Reducing income inequality offers the prospect of greater social cohesiveness and better population health.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health	Kawachi, I (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH & SOCIAL BEHAV, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.							BenShlomo Y, 1996, BRIT MED J, V312, P1013; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Bruhn J, 1979, ROSETO STORY; Durkheim E, 1897, SUICIDE ETUDE SOCIOL; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; Hahn RA, 1996, INT J HEALTH SERV, V26, P673, DOI 10.2190/967K-LC4F-DU66-W5P9; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; JUDGE K, 1995, BRIT MED J, V311, P1282, DOI 10.1136/bmj.311.7015.1282; Kaplan GA, 1996, BRIT MED J, V312, P999; Kaplan GA, 1996, INT J HEALTH SERV, V26, P507, DOI 10.2190/4CUU-7B3G-G4XR-0K0B; Kawachi I, 1996, J EPIDEMIOL COMMUN H, V50, P245, DOI 10.1136/jech.50.3.245; KAWACHI I, IN PRESS AM J PUBLIC; Kawachi I., 1994, INCOME INEQUALITY LI; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; MACINTYRE S, 1993, J SOC POLICY, V22, P213, DOI 10.1017/S0047279400019310; Massey D., 1993, AM APARTHEID SEGREGA; Massey DS, 1996, DEMOGRAPHY, V33, P395, DOI 10.2307/2061773; Putnam R.D., 1994, MAKING DEMOCRACY WOR, DOI DOI 10.2307/206637; PUTNAM RD, 1995, J DEMOCRACY, V0006; Shouls S, 1996, J EPIDEMIOL COMMUN H, V50, P366, DOI 10.1136/jech.50.3.366; SLOGGETT A, 1994, BRIT MED J, V309, P1470, DOI 10.1136/bmj.309.6967.1470; Tumin MM, 1953, AM SOCIOL REV, V18, P387, DOI 10.2307/2087551; *UN, 1996, HUM DEV REP 1996; Verba Sidney, 1995, VOICE AND EQUALITY; WACQUANT LJD, 1989, ANN AM ACAD POLIT SS, V501, P8, DOI 10.1177/0002716289501001001; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilson R., 1987, TRULY DISADVANTAGED	28	438	447	3	114	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	1997	314	7086					1037	1040		10.1136/bmj.314.7086.1037	http://dx.doi.org/10.1136/bmj.314.7086.1037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WT152	9112854	Green Published			2022-12-28	WOS:A1997WT15200033
J	Redlich, CA; Sparer, J; Cullen, MR				Redlich, CA; Sparer, J; Cullen, MR			Sick-building syndrome	LANCET			English	Article							OFFICE BUILDINGS; INDOOR AIR; SUSCEPTIBILITY; CONTAMINANTS; SENSITIVITY; ILLNESS; HOME	Sick-building syndrome (SBS) is an increasingly common problem. Although objective physiological abnormalities are not generally found and permanent sequelae are rare, the symptoms of SBS can be uncomfortable, even disabling, and whole workplaces can be rendered non-functional. In assessment of patients with SBS complaints, specific building-related illnesses suggested by history or physical examination should be ruled out. On-site assessment of buildings is extremely useful. Treatment involves both the patient and the building. Whenever possible, changes such as ventilation improvements and reduction of sources of environmental contamination should be initiated even if specific aetiological agents have not been identified.			Redlich, CA (corresponding author), YALE UNIV,SCH MED,YALE OCCUPAT & ENVIRONM MED PROGRAM,135 COLL ST,NEW HAVEN,CT 06510, USA.							APTER A, 1994, J ALLERGY CLIN IMMUN, V94, P277, DOI 10.1016/0091-6749(94)90087-6; *ASHRAE, 62189 ASHRAE; BACHMANN MO, 1995, SOC SCI MED, V40, P245, DOI 10.1016/0277-9536(94)E0068-4; BASCOM R, 1995, OCCUP MED, V10, P119; BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013; Herrick R., 1994, TXB CLIN OCCUPATIONA, P169; HODGSON M, 1994, J ALLERGY CLIN IMMUN, V94, P296, DOI 10.1053/ai.1994.v94.a56008; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5, DOI 10.5271/sjweh.103; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755, DOI 10.1093/oxfordjournals.aje.a117498; LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P275, DOI 10.1016/0091-6749(94)90086-8; LEVIN H, 1995, OCCUP MED, V10, P59; LOCKEY JE, 1994, J ALLERGY CLIN IMMUN, V94, P310, DOI 10.1053/ai.1994.v94.a56010; MEGGS WJ, 1993, ENVIRON HEALTH PERSP, V101, P234, DOI 10.2307/3431548; Mendell MJ., 1993, INDOOR AIR, V3, P227, DOI DOI 10.1111/J.1600-0668.1993.00003.X; *OCC SAF HLTH ADM, 1994, FED REGISTER, V59, P15968; PERSHAGEN G, 1994, EPIDEMIOLOGY LUNG CA, P109; QUINLAN P, 1989, OCCUP MED, V4, P771; SALVAGGIO JE, 1994, J ALLERGY CLIN IMMUN, V94, P304, DOI 10.1053/ai.1994.v94.a56009; SALVAGGIO JE, 1994, J ALLERGY CLIN IMMUN, V94, P366, DOI 10.1016/0091-6749(94)90098-1; SAMIMI BS, 1995, OCCUP MED, V10, P95; Seltzer J.M., 1995, OCCUP MED, V10, P26; SELTZER JM, 1995, OCCUP MED, V10, P1; STENBERG B, 1994, INT J EPIDEMIOL, V23, P1190, DOI 10.1093/ije/23.6.1190; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339	24	298	309	3	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					1013	1016		10.1016/S0140-6736(96)07220-0	http://dx.doi.org/10.1016/S0140-6736(96)07220-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100639	hybrid			2022-12-28	WOS:A1997WR62100042
J	Martin, P				Martin, P			Wound healing - Aiming for perfect skin regeneration	SCIENCE			English	Review							KERATINOCYTE GROWTH-FACTOR; ACTIN STRESS FIBERS; FACTOR-BETA; PLASMINOGEN-ACTIVATOR; INTEGRIN EXPRESSION; COLLAGEN MATRICES; UROKINASE-TYPE; FACTOR-ALPHA; TGF-ALPHA; EPIDERMAL-KERATINOCYTES	The healing of an adult skin wound is a complex process requiring the collaborative efforts of many different tissues and cell lineages. The behavior of each of the contributing cell types during the phases of proliferation, migration, matrix synthesis, and contraction, as well as the growth factor and matrix signals present at a wound site, are now roughly understood. Details of how these signals control wound cell activities are beginning to emerge, and studies of healing in embryos have begun to show how the normal adult repair process might be readjusted to make it less like patching up and more like regeneration.	UNIV LONDON UNIV COLL, DEPT SURG, DIV PLAST & RECONSTRUCT SURG, LONDON WC1E 6BT, ENGLAND	University of London; University College London	Martin, P (corresponding author), UNIV LONDON UNIV COLL, DEPT ANAT & DEV BIOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.			Martin, Paul/0000-0002-2665-5086	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; ADZICK NS, 1985, J PEDIATR SURG, V20, P315; Adzick NS, 1992, FETAL WOUND HEALING, Vxv; ARMSTRONG JR, 1995, DEV BIOL, V169, P242, DOI 10.1006/dbio.1995.1141; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BEMENT WM, 1993, J CELL BIOL, V121, P565, DOI 10.1083/jcb.121.3.565; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; BREUSS JM, 1995, J CELL SCI, V108, P2241; BROADLEY KN, 1989, LAB INVEST, V61, P571; Brock J, 1996, CELL MOTIL CYTOSKEL, V35, P358, DOI 10.1002/(SICI)1097-0169(1996)35:4<358::AID-CM7>3.0.CO;2-2; Brock J, 1996, J CELL BIOL, V135, P1097, DOI 10.1083/jcb.135.4.1097; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROWN GL, 1986, J EXP MED, V163, P1319; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1993, AM J PATHOL, V142, P793; BUCHMAN VL, 1994, DEVELOPMENT, V120, P1621; BURGESS LPA, 1990, ARCH OTOLARYNGOL, V116, P798; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CLARK RAF, 1989, J CLIN INVEST, V84, P1036, DOI 10.1172/JCI114227; Clark RAF, 1996, AM J PATHOL, V148, P1407; COMPTON CC, 1989, LAB INVEST, V60, P600; CONSTANTINOU J, 1994, NEUROREPORT, V5, P2281, DOI 10.1097/00001756-199411000-00019; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; Eckes B., 1996, MOL CELLULAR BIOL WO, P493; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ESTES JM, 1994, DIFFERENTIATION, V56, P173, DOI 10.1046/j.1432-0436.1994.5630173.x; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRANK S, IN PRESS ONCOGENE; GALLIT J, 1994, J INVEST DERMATOL, V103, P221; GARLICK JA, 1994, LAB INVEST, V70, P916; GIPSON IK, 1988, DEV BIOL, V126, P253, DOI 10.1016/0012-1606(88)90136-4; GOLIGER JA, 1995, MOL BIOL CELL, V6, P1491, DOI 10.1091/mbc.6.11.1491; GREILING D, IN PRESS J CELL SCI; GRINNELL F, 1992, J CELL SCI, V101, P1; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HE YJ, 1994, J CELL BIOL, V126, P457, DOI 10.1083/jcb.126.2.457; HE YJ, 1995, J CELL BIOL, V130, P1197, DOI 10.1083/jcb.130.5.1197; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Heldin CH., 1996, MOL CELLULAR BIOL WO, P249; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HERTLE MD, 1995, J INVEST DERMATOL, V104, P260, DOI 10.1111/1523-1747.ep12612801; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JAHODA CAB, 1992, DEVELOPMENT, V115, P1103; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; KRAWCZYK WS, 1971, J CELL BIOL, V49, P247, DOI 10.1083/jcb.49.2.247; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LIN YC, 1993, J CELL BIOL, V122, P663, DOI 10.1083/jcb.122.3.663; LONGAKER MT, 1990, SURG FORUM, V41, P639; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MARTIN P, 1992, MECH DEVELOP, V38, P209, DOI 10.1016/0925-4773(92)90054-N; MARTIN P, 1992, NATURE, V360, P179, DOI 10.1038/360179a0; MARTIN P, 1993, DEV GENET, V14, P225, DOI 10.1002/dvg.1020140309; Martin P, 1996, CURR TOP DEV BIOL, V32, P175, DOI 10.1016/S0070-2153(08)60428-7; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Mast Bruce A., 1996, Wound Repair and Regeneration, V4, P411, DOI 10.1046/j.1524-475X.1996.40404.x; MATOLTSY AG, 1970, J INVEST DERMATOL, V55, P20, DOI 10.1111/1523-1747.ep12290488; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCCALLION RL, IN PRESS LANCET; McCallion RL, 1996, MOL CELLULAR BIOL WO, P561; McClain SA, 1996, AM J PATHOL, V149, P1257; MCCLUSKEY J, 1995, DEV BIOL, V170, P102, DOI 10.1006/dbio.1995.1199; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894; MUELLER RV, 1994, ARCH SURG-CHICAGO, V129, P262; Mullen LM, 1996, DEVELOPMENT, V122, P3487; Nanney LB, 1996, MOL CELLULAR BIOL WO, P171; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nodder S, 1997, ANAT EMBRYOL, V195, P215, DOI 10.1007/s004290050041; NOHNO T, 1995, BIOCHEM BIOPH RES CO, V206, P33, DOI 10.1006/bbrc.1995.1005; O'Kane S., 1996, Molecular Biology of the Cell, V7, p543A; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; PAWAR S, 1995, J CELL PHYSIOL, V165, P556, DOI 10.1002/jcp.1041650314; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; Riches DWH, 1996, MOL CELLULAR BIOL WO, P95; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SALO T, 1994, LAB INVEST, V70, P176; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SENGEL P, 1986, BIOL INTEGUMENT; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; Tarnuzzer Roy W., 1996, Wound Repair and Regeneration, V4, P321, DOI 10.1046/j.1524-475X.1996.40307.x; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; Uitto J., 1996, MOL CELLULAR BIOL WO, P513; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WHITBY DJ, 1991, DEVELOPMENT, V112, P651; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Yamada K.M., 1996, MOL CELLULAR BIOL WO, P51; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	133	3484	3717	46	1050	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					75	81		10.1126/science.276.5309.75	http://dx.doi.org/10.1126/science.276.5309.75			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082989				2022-12-28	WOS:A1997WR38600048
J	Seiff, A; Kirk, DB; Knight, TCD; Young, LA; Milos, FS; Venkatapathy, E; Mihalov, JD; Blanchard, RC; Young, RE; Schubert, G				Seiff, A; Kirk, DB; Knight, TCD; Young, LA; Milos, FS; Venkatapathy, E; Mihalov, JD; Blanchard, RC; Young, RE; Schubert, G			Thermal structure of Jupiter's upper atmosphere derived from the Galileo probe	SCIENCE			English	Article								Temperatures in Jupiter's atmosphere derived from Galileo Probe deceleration data increase from 109 kelvin at the 175-millibar level to 900 +/- 40 kelvin at 1 nanobar, consistent with Voyager remote sensing data. Wavelike oscillations are present at all levels. Vertical wavelengths are 10 to 25 kilometers in the deep isothermal layer, which extends from 12 to 0.003 millibars. Above the 0.003-millibar level, only 90- to 270-kilometer vertical wavelengths survive, suggesting dissipation of wave energy as the probable source of upper atmosphere heating.	UNIV OREGON,PLEASANT HILL,OR 97455; BOSTON UNIV,CTR SPACE PHYS,BOSTON,MA 02215; NASA,AMES RES CTR,MS 234 1,MOFFETT FIELD,CA 94035; AMES RES CTR,ELORET INST,MOFFETT FIELD,CA 94035; NASA,LANGLEY RES CTR,HAMPTON,VA 23681; UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90024; AMES RES CTR,MS 245 1,MOFFETT FIELD,CA 94035	University of Oregon; Boston University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Aeronautics & Space Administration (NASA); NASA Langley Research Center; University of California System; University of California Los Angeles; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Seiff, A (corresponding author), SAN JOSE STATE UNIV FDN,DEPT METEOROL,MOFFETT FIELD,CA 94035, USA.							ATREYA SK, 1979, GEOPHYS RES LETT, V6, P795, DOI 10.1029/GL006i010p00795; ATREYA SK, 1981, ASTROPHYS J, V247, pL43, DOI 10.1086/183586; ATREYA SK, 1986, ATMOSPHERES IONOSPHE, P89; BROADFOOT AL, 1989, SCIENCE, V246, P1459, DOI 10.1126/science.246.4936.1459; FESTOU MC, 1981, J GEOPHYS RES-SPACE, V86, P5715, DOI 10.1029/JA086iA07p05715; HANEL R, 1979, SCIENCE, V204, P972, DOI 10.1126/science.204.4396.972-a; HERBERT F, 1987, J GEOPHYS RES, V92, P15093, DOI 10.1029/JA092iA13p15093; HUNTEN DM, 1977, PLANET SPACE SCI, V25, P817, DOI 10.1016/0032-0633(77)90035-6; KUNDE V, 1982, ASTROPHYS J, V263, P443, DOI 10.1086/160516; MILOS FS, 1996, 31 AIAA THERM C NEW; MOSS JN, 1983, PROGR ASTRONAUTICS A, P419; NEFF JM, COMMUNICATION; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; NISHIDA A, 1981, J GEOPHYS RES-SPACE, V86, P9945, DOI 10.1029/JA086iA12p09945; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SEIFF A, 1992, SPACE SCI REV, V60, P203, DOI 10.1007/BF00216855; SEIFF A, 1991, J GEOPHYS RES-SPACE, V96, P11021, DOI 10.1029/91JA01101; SEIFF A, 1982, ICARUS, V49, P45; SEIFF A, 1996, 14 AIAA APPL AER C N; SMITH GR, 1983, J GEOPHYS RES-SPACE, V88, P8667, DOI 10.1029/JA088iA11p08667; STROBEL DF, 1973, J ATMOS SCI, V30, P718, DOI 10.1175/1520-0469(1973)030<0718:OTTOTJ>2.0.CO;2; VERVACK RJ, 1995, ICARUS, V114, P163, DOI 10.1006/icar.1995.1051; vonZahn U, 1996, SCIENCE, V272, P849, DOI 10.1126/science.272.5263.849; Yelle RV, 1996, J GEOPHYS RES-PLANET, V101, P2149, DOI 10.1029/95JE03384; Young LA, 1997, SCIENCE, V276, P108, DOI 10.1126/science.276.5309.108; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837	27	67	67	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					102	104		10.1126/science.276.5309.102	http://dx.doi.org/10.1126/science.276.5309.102			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082977				2022-12-28	WOS:A1997WR38600055
J	Brahams, D				Brahams, D			Expert witnesses under scrutiny	LANCET			English	Editorial Material											Brahams, D (corresponding author), OLD SQ CHAMBERS,LONDON WC1R 5LQ,ENGLAND.								0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					896	896		10.1016/S0140-6736(05)62694-3	http://dx.doi.org/10.1016/S0140-6736(05)62694-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093248				2022-12-28	WOS:A1997WR25400006
J	Gillespie, ND; McNeill, G; Pringle, T; Ogston, S; Struthers, AD; Pringle, SD				Gillespie, ND; McNeill, G; Pringle, T; Ogston, S; Struthers, AD; Pringle, SD			Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-FAILURE; ECHOCARDIOGRAPHY	Objective: To assess the comparative contribution of clinical assessment, electrocardiography, and chest radiography to the diagnosis of left ventricular systolic dysfunction in patients admitted to a general medical ward with acute dyspnoea Design: Prospective cross sectional study. Setting: Acute medical admissions ward of a teaching hospital. Subjects: 71 randomly selected patients admitted with acute dyspnoea. Main outcome measures: Sensitivity and specificity of each investigation and logistic regression analysis of each variable in identifying left ventricular systolic dysfunction, Results: Clinical assessment in this cohort of patients with severe dyspnoea was generally sensitive (sensitivity 81%), Patients were divided into three groups on the basis of clinical assessment In the first group (37 patients) the diagnosis of systolic dysfunction was clear, in the second (22) it was in doubt, and in the third (12) it was unlikely. The sensitivity of clinical assessment in identifying left ventricular systolic dysfunction was 81% and the specificity was 41%, The specificity of diagnosis was improved by electrocardiography (69%) and chest radiography (92%), Logistic regression analysis showed that isolated pulmonary crepitations were a comparatively poor predictor of left ventricular systolic dysfunction (chi(2)=10.215, P=0.0014) but that a full clinical examination had reasonable predictive value (chi(2)=24.82, P<0.00001). The combination of clinical assessment and chest radiography improved the accuracy of diagnosis (chi(2)=28.08, P<0.00001), as did the combination of clinical assessment and electrocardiography (chi(2)=32.41, P<0.00001), Conclusion: Clinical assessment in patients admitted with acute dyspnoea is comparatively accurate, Patients with abnormal results on chest radiography, electrocardiography, and clinical examination have a high likelihood of having left ventricular systolic dysfunction. Echocardiography contributes little more to the diagnosis in these patients and may be more efficiently directed towards patients in whom the diagnosis is still in doubt after clinical assessment, chest radiography, and electrocardiography.			Gillespie, ND (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, SECT AGEING & HLTH, DUNDEE DD1 9SY, SCOTLAND.			Struthers, Allan/0000-0002-2926-2528				CLARKE KW, 1994, BRIT HEART J, V71, P584; CLELAND JG, 1995, EUR HEART J, V16, P741; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; Davie AP, 1996, BRIT MED J, V312, P222; Gillespie N D, 1996, Health Bull (Edinb), V54, P395; HEGER JJ, 1979, CIRCULATION, V60, P531, DOI 10.1161/01.CIR.60.3.531; HOBBS R, 1995, BRIT MED J, V310, P207, DOI 10.1136/bmj.310.6974.207; ISOM OW, 1975, CIRCULATION, V52, P119; MONAGHAN M, 1994, BRIT HEART J, V71, P2; PARAMESHWAR J, 1992, J ROY COLL PHYS LOND, V26, P139; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; SLOVICK DI, 1995, BRIT MED J, V311, P327, DOI 10.1136/bmj.311.7000.327; STRUTHERS AD, 1994, CURR OPIN CARDIOL, V9, pS12, DOI 10.1097/00001573-199407000-00003; WHEELDON NM, 1993, Q J MED, V86, P17; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZARIFIS J, 1995, BRIT MED J, V311, P326, DOI 10.1136/bmj.311.7000.326a	16	64	64	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	1997	314	7085					936	940		10.1136/bmj.314.7085.936	http://dx.doi.org/10.1136/bmj.314.7085.936			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099117	Green Published			2022-12-28	WOS:A1997WQ16900025
J	OConnor, H; Broadbent, JAM; Magos, AL; McPherson, K				OConnor, H; Broadbent, JAM; Magos, AL; McPherson, K			Medical Research Council randomised trial of endometrial resection versus hysterectomy in management of menorrhagia	LANCET			English	Article							ABDOMINAL HYSTERECTOMY; ABLATION; SURGERY; WOMEN	Background The most frequent indication for hysterectomy is menorrhagia, even though the uterus is normal in a large number of patients. Transcervical resection of the endometrium (TCRE) is a less drastic alternative, but success rates have varied and menorrhagia can recur. We have tested the hypothesis that the difference in the proportion of women dissatisfied and requiring further surgery within 3 years of TCRE or hysterectomy would be no more than 15%. Methods 202 women with symptomatic menorrhagia were recruited to a multicentre, randomised, controlled trial to compare the two interventions. TCRE and hysterectomy were randomly assigned in a ratio of two to one. The primary endpoints were women's satisfaction and need for further surgery. The patients' psychological and Social states were monitored before surgery, then annually with a questionnaire. Analysis was by intention to treat. Findings Data were available for 172 women (56 hysterectomy, 116 TCRE); 26 withdrew before surgery and four were lost to follow-up. Satisfaction scores were higher for hysterectomy than for TCRE throughout follow-up (median 2 years), but the differences were not significant (at 3 years 27 [96%] of 28 in hysterectomy group vs 46 [85%] of 54 in TCRE group were satisfied; p=0.16). 25 (22%) women in the TCRE group and five (9%) in the hysterectomy group required further surgery (relative risk 0.46 [95% CI 0.2-1.1], p=0.053). TCRE had the benefits of shorter operating time, fewer complications, and faster rates of recovery. Interpretation TCRE is an acceptable alternative to hysterectomy in the treatment of menorrhagia for many women with no other serious disorders.	UNIV LONDON ROYAL FREE HOSP,DEPT OBSTET & GYNAECOL,MINIMALLY INVAS THERAPY UNIT,LONDON NW3 2QG,ENGLAND; UNIV LONDON ROYAL FREE HOSP,DEPT OBSTET & GYNAECOL,ENDOSCOPY TRAINING CTR,LONDON NW3 2QG,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND	University of London; University College London; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine								BRIDGMAN SA, 1994, LANCET, V344, P893, DOI 10.1016/S0140-6736(94)92868-1; COOPER P, 1982, BRIT J PSYCHIAT, V141, P68, DOI 10.1192/bjp.141.1.68; COULTER A, 1994, LANCET, V344, P1367, DOI 10.1016/S0140-6736(94)90727-7; DANIELL JF, 1986, COLP GYNECOL LAS SUR, V2, P43; DERMAN SG, 1991, OBSTET GYNECOL, V77, P591; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; GATH D, 1982, BRIT J PSYCHIAT, V140, P335, DOI 10.1192/bjp.140.4.335; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDRATH MH, 1981, AM J OBSTET GYNECOL, V140, P14, DOI 10.1016/0002-9378(81)90251-9; GRANT JM, 1984, BRIT J OBSTET GYNAEC, V91, P73, DOI 10.1111/j.1471-0528.1984.tb05282.x; GREENBERG M, 1983, J PSYCHOSOM RES, V27, P209, DOI 10.1016/0022-3999(83)90024-7; MAGOS AL, 1990, BRIT MED J, V300, P1537, DOI 10.1136/bmj.300.6739.1537; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; MAGOS AL, 1989, LANCET, V2, P925; MAGOS AL, 1989, BRIT MED J, V298, P1209, DOI 10.1136/bmj.298.6682.1209; MAHER PJ, 1990, AUST NZ J OBSTET GYN, V30, P357, DOI 10.1111/j.1479-828X.1990.tb02029.x; MCNAIR DM, 1964, J ABNORM SOC PSYCH, V69, P620, DOI 10.1037/h0040902; OConnor H, 1996, NEW ENGL J MED, V335, P151, DOI 10.1056/NEJM199607183350302; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RAIGA J, 1995, J GYNECOL SURG, V11, P1, DOI 10.1089/gyn.1995.11.1; *ROYAL COLL OBST G, 1995, BRIT J OBSTET GYNAEC, V102, P249; SCULPHER MJ, 1993, BRIT J OBSTET GYNAEC, V100, P244, DOI 10.1111/j.1471-0528.1993.tb15238.x; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; WORTMAN M, 1994, OBSTET GYNECOL, V83, P295	27	137	138	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					897	901		10.1016/S0140-6736(96)07285-6	http://dx.doi.org/10.1016/S0140-6736(96)07285-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093249				2022-12-28	WOS:A1997WR25400008
J	Jones, SE; Smith, RH				Jones, SE; Smith, RH			Drug points - Quinolones may induce hepatitis	BRITISH MEDICAL JOURNAL			English	Letter							CIPROFLOXACIN				Jones, SE (corresponding author), N TEES GEN HOSP,STOCKTON ON TEES TS19 8PE,CLEVELAND,ENGLAND.							BLUM A, 1991, SOUTHERN MED J, V84, P1158, DOI 10.1097/00007611-199109000-00027; DAVOREN P, 1993, MED J AUSTRALIA, V159, P423; FUCHS S, 1994, LANCET, V343, P738, DOI 10.1016/S0140-6736(94)91624-1; HODSON ME, 1987, LANCET, V1, P235	4	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					869	869						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093098				2022-12-28	WOS:A1997WQ02800029
J	Metzlaff, M; ODell, M; Cluster, PD; Flavell, RB				Metzlaff, M; ODell, M; Cluster, PD; Flavell, RB			RNA-mediated RNA degradation and chalcone synthase A silencing in Petunia	CELL			English	Article							GENE-EXPRESSION; TRANSGENIC PLANTS; CO-SUPPRESSION; VIRUS-RESISTANCE; CLEAVAGE; PATHWAY; HYBRIDA; DNA	Transgenic Petunia plants with a chsA coding sequence under the control of a 35S promoter sometimes lose endogene and transgene chalcone synthase activity and purple flower pigment through posttranscriptional chsA RNA degradation. In these plants, shorter poly(A)(+) and poly(A)(-) chsA RNAs are found, and a 3' end-specific RNA fragment from the endogene is more resistant to degradation. The termini of this RNA fragment are located in a region of complementarity between the chsA 3' coding region and its 3' untranslated region. Equivalent chsA RNA fragments remain in the white flower tissue of a nontransgenic Petunia variety. We present a model involving cycles of RNA-RNA pairing between complementary sequences followed by endonucleolytic RNA cleavages to describe how RNA degradation is likely to be promoted.			Metzlaff, M (corresponding author), JOHN INNES CTR PLANT SCI RES, NORWICH RES PK, NORWICH NR4 7UH, NORFOLK, ENGLAND.							Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; DE CARVALHO-NIEBEL F, 1995, PLANT CELL, V7, P347, DOI 10.2307/3869856; Depicker A., 1996, MECH APPL GENE SILEN, P71; DOUGHERTY WG, 1994, MOL PLANT MICROBE IN, V7, P544, DOI 10.1094/MPMI-7-0554; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P3998; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; GRIERSON D, 1991, TRENDS BIOTECHNOL, V9, P122, DOI 10.1016/0167-7799(91)90042-G; HAMILTON AJ, 1996, MECH APPL GENE SILEN, P105; Jorgensen RA, 1996, STADLER GEN, P159; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; MARTIN CR, 1993, INT REV CYTOL, V147, P233, DOI 10.1016/S0074-7696(08)60770-6; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Meins F. Jr., 1994, Homologous recombination and gene silencing in plants., P335; MEYER P, 1994, MOL GEN GENET, V243, P390, DOI 10.1007/BF00280469; MEYER P, 1995, GENE SILENCING HIGHE; MOL J, 1991, TRENDS BIOTECHNOL, V9, P182, DOI 10.1016/0167-7799(91)90060-U; MOL JNM, 1983, MOL GEN GENET, V192, P424, DOI 10.1007/BF00392185; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Scheper W, 1996, NUCLEIC ACIDS RES, V24, P1000, DOI 10.1093/nar/24.6.1000; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	31	240	273	1	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	1997	88	6					845	854		10.1016/S0092-8674(00)81930-3	http://dx.doi.org/10.1016/S0092-8674(00)81930-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118227	Bronze			2022-12-28	WOS:A1997WQ10000016
J	Pazin, MJ; Kadonaga, JT				Pazin, MJ; Kadonaga, JT			SW12/SNF2 and related proteins: ATP-Driven motors that disrupt protein-DNA interactions?	CELL			English	Review							TRANSCRIPTION; HELICASES; BINDING; COMPLEX; FAMILY		UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego				Pazin, Michael/0000-0002-7561-3640				Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	20	265	270	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					737	740		10.1016/S0092-8674(00)81918-2	http://dx.doi.org/10.1016/S0092-8674(00)81918-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118215	Bronze			2022-12-28	WOS:A1997WQ10000004
J	Washburn, T; Schweighoffer, E; Gridley, T; Chang, D; Fowlkes, BJ; Cado, D; Robey, E				Washburn, T; Schweighoffer, E; Gridley, T; Chang, D; Fowlkes, BJ; Cado, D; Robey, E			Notch activity influences the alpha beta versus gamma delta T cell lineage decision	CELL			English	Article							DROSOPHILA-NOTCH; THYMOCYTE DEVELOPMENT; RAG-1-DEFICIENT MICE; CD8 EXPRESSION; RECEPTOR GENE; HOMOLOG; DIFFERENTIATION; REARRANGEMENT; COMMITMENT; PRECURSOR	The choice between the alpha beta or gamma delta T cell fates is influenced by the production of functional, in-frame rearrangements of the TCR genes, but the mechanism that controls the lineage choice is not known. Here, we show that T cells that are heterozygous for a mutation of the Notch1 gene are more likely to develop as gamma delta T cells than as alpha beta T cells, implying that reduced Notch activity favors the ya T cell fate over the alpha beta T cell fate. A constitutively activated form of Notch produces a reciprocal phenotype and induces thymocytes that have functional gamma delta TCR gene rearrangements to adopt the alpha beta T cell fate. Our data indicate that Notch acts together with the newly formed T cell antigen receptor to direct the alpha beta versus gamma delta T cell lineage decision.	JACKSON LAB,BAR HARBOR,ME 04609; NIAID,CELLULAR & MOL IMMUNOL LAB,NIH,BETHESDA,MD 20892	Jackson Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Washburn, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.							ALLISON JP, 1993, CURR OPIN IMMUNOL, V5, P241, DOI 10.1016/0952-7915(93)90011-G; ALLISON JP, 1987, IMMUNOL TODAY, V8, P293, DOI 10.1016/0167-5699(87)90014-4; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BLUESTONE JA, 1991, IMMUNOL REV, V120, P5, DOI 10.1111/j.1600-065X.1991.tb00585.x; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; Coligan JE., 1994, CURRENT PROTOCOLS IM; CONLON RA, 1995, DEVELOPMENT, V121, P1533; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DUDLEY EC, 1995, CURR BIOL, V5, P659, DOI 10.1016/S0960-9822(95)00131-X; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; KANG J, 1995, EUR J IMMUNOL, V25, P2706, DOI 10.1002/eji.1830250946; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KERSH GJ, 1995, J IMMUNOL, V154, P5706; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LIVAK F, 1995, IMMUNITY, V2, P617, DOI 10.1016/1074-7613(95)90006-3; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PARDOLL DM, 1987, NATURE, V326, P79, DOI 10.1038/326079a0; PETRIE HT, 1992, EUR J IMMUNOL, V22, P2185, DOI 10.1002/eji.1830220836; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Schweighoer E, 1996, J EXP MED, V183, P2033, DOI 10.1084/jem.183.5.2033; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SIM GK, 1995, J IMMUNOL, V154, P5821; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	44	353	368	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					833	843		10.1016/S0092-8674(00)81929-7	http://dx.doi.org/10.1016/S0092-8674(00)81929-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118226	Bronze			2022-12-28	WOS:A1997WQ10000015
J	Holby, N; Jarlov, JO; Kemp, M; Tvede, M; Bangsborg, JM; Kjerulf, A; Pers, C; Hansen, H				Holby, N; Jarlov, JO; Kemp, M; Tvede, M; Bangsborg, JM; Kjerulf, A; Pers, C; Hansen, H			Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis	LANCET			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; PSEUDOMONAS-AERUGINOSA; RESISTANT; SKIN; UNIT	Background Staphylococcus epidermidis develops resistance to ciprofloxacin rapidly. That this antibiotic is excreted in apocrine and eccrine sweat of healthy individuals might be the reason for the development of such resistance. We assessed whether S epidermidis isolated from the axilla and nasal flora of healthy people could develop resistance to ciprofloxacin after a 1-week course of this antibiotic. Methods The concentration of ciprofloxacin in sweat was measured in seven volunteers after oral administration of 750 mg ciprofloxacin twice daily for 7 days, and the development of resistance in S epidermidis from axilla and nostrils was monitored during and 2 months after the treatment. Genotyping of S epidermidis was done by restriction fragment length polymorphism. Findings The mean concentration of ciprofloxacin in sweat increased during the 7 days of treatment-from 2.2 mu g/mL 2.5 h after the first tablet to 2.5 mu g/mL after the fifth tablet, and 5.5 mu g/mL after the 13th tablet. All persons harboured susceptible S epidermidis (minimal inhibitory concentration [MIC] 0.25 mu g/ml) in axilla and nostrils before treatment. Four resistant drains were detected, two intermediate level (MIC 4-12 mu g/ml) and two high-level (MI >32 mu g/mL). Three of these strains were found in all the participants, and a ciprofloxacin-sensitive variant of one of the high-level resistant strains was also found before the start of the treatment. The high-level resistant strains were also resistant to methicillin, erythromycin, gentamicin, sulphonamide, and trimethoprim. A mean of 2 7 days after the start of the treatment, development of ciprofloxacin resistance was detected in S epidermidis from the axilla of all persons, compared with 11 days for the appearance of resistant S epidermidis in nostrils. The resistant strains persisted for an average of 37 and 39 days in axilla and nostrils, respectively, after the end of the treatment. Interpretation The rapid development of resistance to ciprofloxacin due to excretion of this drug into the sweat might be involved in the development of multiresistant S epidermidis and possibly other shin bacteria in hospitals and in communities with high use of ciprofloxacin or related drugs.			Holby, N (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN MICROBIOL 9301,JULIANE MARIES VEJ 22,DK-2100 COPENHAGEN O,DENMARK.		Kemp, Michael/HGU-4170-2022; Kemp, Michael/AAY-3017-2021	Kemp, Michael/0000-0001-5989-0421; Kemp, Michael/0000-0001-5989-0421; Hoiby, Niels/0000-0002-1347-725X				ARCHER GL, 1991, REV INFECT DIS S10, V13, P805; COYLE MB, 1990, CLIN MICROBIOL REV, V3, P227, DOI 10.1128/CMR.3.3.227-246.1990; DALHOFF A, 1994, INFECTION, V22, pS111, DOI 10.1007/BF01793575; Davis R, 1996, DRUGS, V51, P1019, DOI 10.2165/00003495-199651060-00010; DRYDEN MS, 1992, EPIDEMIOL INFECT, V109, P97; FORSTALL GJ, 1991, ANTIMICROB AGENTS CH, V35, P1679, DOI 10.1128/AAC.35.8.1679; HARRIS R, 1983, ANTIMICROB AGENTS CH, V24, P876, DOI 10.1128/AAC.24.6.876; HEDIN G, 1991, J HOSP INFECT, V17, P95, DOI 10.1016/0195-6701(91)90173-6; HOIBY N, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92946-0; IMAYAMA S, 1994, J ALLERGY CLIN IMMUN, V94, P195, DOI 10.1016/0091-6749(94)90040-X; Jarlov JO, 1996, J HOSP INFECT, V32, P217, DOI 10.1016/S0195-6701(96)90148-6; JARLOV JO, 1994, APMIS, V102, P272, DOI 10.1111/j.1699-0463.1994.tb04875.x; JONES HE, 1990, J AM ACAD DERMATOL, V23, P779, DOI 10.1016/0190-9622(90)70287-R; MONTES LF, 1970, ARCH DERMATOL, V101, P145, DOI 10.1001/archderm.101.2.145; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; OJENIYI B, 1991, APMIS, V99, P492, DOI 10.1111/j.1699-0463.1991.tb05181.x; OPPENHEIM BA, 1989, BRIT MED J, V299, P294, DOI 10.1136/bmj.299.6694.294; ROTH RR, 1988, ANNU REV MICROBIOL, V42, P441, DOI 10.1146/annurev.mi.42.100188.002301; SATO K, 1987, DERMATOLOGY GEN MED, P195; SHAH VP, 1974, J CLIN INVEST, V53, P1673, DOI 10.1172/JCI107718; Sloos Jacobus H., 1996, Clin Microbiol Infect, V2, P44, DOI 10.1111/j.1469-0691.1996.tb00199.x; SORGEL F, 1988, J ANTIMICROB CHEMOTH, V22, P155, DOI 10.1093/jac/22.Supplement_D.155; SORGEL F, 1991, AM J MED, V91, P51; STRAUSBAUGH LJ, 1976, ANTIMICROB AGENTS CH, V10, P450, DOI 10.1128/AAC.10.3.450; Takenouchi T, 1996, ANTIMICROB AGENTS CH, V40, P1835, DOI 10.1128/AAC.40.8.1835; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995	27	103	104	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					167	169		10.1016/S0140-6736(96)09229-X	http://dx.doi.org/10.1016/S0140-6736(96)09229-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111541				2022-12-28	WOS:A1997WC86100011
J	Scamarcio, G; Capasso, F; Sirtori, C; Faist, J; Hutchinson, AL; Sivco, DL; Cho, AY				Scamarcio, G; Capasso, F; Sirtori, C; Faist, J; Hutchinson, AL; Sivco, DL; Cho, AY			High-power infrared (8-micrometer wavelength) superlattice lasers	SCIENCE			English	Article							QUANTUM CASCADE LASER; MU-M; WELL; ELECTRONS	A quantum-cascade long-wavelength infrared laser based on superlattice active regions has been demonstrated. In this source, electrons injected by tunneling emit photons corresponding to the energy gap (minigap) between two superlattice conduction bands (minibands). A distinctive design feature is the high oscillator strength of the optical transition. Pulsed operation at a wavelength of about 8 micrometers with peak powers ranging from similar to 0.80 watt at 80 kelvin to 0.2 watt at 200 kelvin has been demonstrated in a superlattice with 1-nanometer-thick AllnAs barriers and 4.3-nanometer-thick GalnAs quantum wells grown by molecular beam epitaxy. These results demonstrate the potential of strongly coupled superlattices as infrared laser materials for high-power sources in which the wavelength can be tailored by design.	AT&T BELL LABS,LUCENT TECHNOL,MURRAY HILL,NJ 07974	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs			Faist, Jerome/A-7339-2013; Scamarcio, Gaetano/I-7674-2014	Faist, Jerome/0000-0003-4429-7988; Scamarcio, Gaetano/0000-0003-0808-4336; Sirtori, Carlo/0000-0003-1817-4554				BELTRAM F, 1990, PHYS REV LETT, V64, P3167, DOI 10.1103/PhysRevLett.64.3167; Bhattacharya P, 1994, SEMICONDUCTOR OPTOEL; CAPASSO F, 1994, SURF SCI, V299, P878, DOI 10.1016/0039-6028(94)90704-8; Capasso F, 1996, J MATH PHYS, V37, P4775, DOI 10.1063/1.531669; CHOI HK, 1995, APPL PHYS LETT, V66, P3543, DOI 10.1063/1.113810; DINGLE R, 1975, PHYS REV LETT, V34, P1327, DOI 10.1103/PhysRevLett.34.1327; ESAKI L, 1970, IBM J RES DEV, V14, P61, DOI 10.1147/rd.141.0061; Faist J, 1996, PHYS REV LETT, V76, P411, DOI 10.1103/PhysRevLett.76.411; FAIST J, 1994, APPL PHYS LETT, V65, P94, DOI 10.1063/1.113086; FAIST J, 1994, SCIENCE, V264, P553, DOI 10.1126/science.264.5158.553; Faist J, 1996, APPL PHYS LETT, V68, P3680, DOI 10.1063/1.115741; FERREIRA R, 1989, PHYS REV B, V40, P1074, DOI 10.1103/PhysRevB.40.1074; HELM M, 1995, SEMICOND SCI TECH, V10, P557, DOI 10.1088/0268-1242/10/5/001; HERBERT DC, 1988, SEMICOND SCI TECH, V3, P101, DOI 10.1088/0268-1242/3/2/005; Malin JI, 1996, APPL PHYS LETT, V68, P2976, DOI 10.1063/1.116374; Scamarcio G, 1997, APPL PHYS LETT, V70, P1796, DOI 10.1063/1.118695; SHI Z, 1995, APPL PHYS LETT, V66, P2537, DOI 10.1063/1.113159; Sirtori C, 1997, IEEE PHOTONIC TECH L, V9, P294, DOI 10.1109/68.556051; SIRTORI C, 1995, APPL PHYS LETT, V66, P3242, DOI 10.1063/1.113391; SIRTORI C, 1994, PHYS REV B, V50, P8663, DOI 10.1103/PhysRevB.50.8663; SIRTORI C, 1996, APPL PHYS LETT, V68, P1746; TACKE M, 1996, INFRARED PHYS TECHN, V36, P1745; WASCHKE C, 1993, PHYS REV LETT, V70, P3319, DOI 10.1103/PhysRevLett.70.3319	23	147	157	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					773	776		10.1126/science.276.5313.773	http://dx.doi.org/10.1126/science.276.5313.773			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115197				2022-12-28	WOS:A1997WW90000051
J	McAdoo, D; Laxon, S				McAdoo, D; Laxon, S			Antarctic tectonics: Constraints from an ERS-1 satellite marine gravity field	SCIENCE			English	Article							PLATE MOTIONS; WEDDELL SEA; GEOSAT DATA; PACIFIC; OCEAN; GONDWANALAND; EVOLUTION; HISTORY; MODEL; FLOOR	A high-resolution gravity field of poorly charted and ice-covered ocean near West Antarctica, from the Ross Sea east to the Weddell Sea, has been derived with the use of satellite altimetry, including ERS-1 geodetic phase, wave-form data. This gravity field reveals regional tectonic fabric, such as gravity lineations, which are the expression of fracture zones left by early (65 to 83 million years ago) Pacific-Antarctic sea-floor spreading that separated the Campbell Plateau and New Zealand continent from West Antarctica. These lineations constrain plate motion history and confirm the hypothesis that Antarctica behaved as two distinct plates, separated from each other by an extensional Bellingshausen plate boundary active in the Amundsen Sea before about 61 million years ago.	UCL, MULLARD SPACE SCI LAB, DEPT SPACE & CLIMATE PHYS, DORKING RH5 6NT, SURREY, ENGLAND	University of London; University College London	McAdoo, D (corresponding author), NATL OCEAN SERV, GEOSCI LAB, NATL OCEAN & ATMOSPHER ADM, SILVER SPRING, MD 20910 USA.		McAdoo, Dave/F-5612-2010; Laxon, Seymour/C-1644-2008	McAdoo, Dave/0000-0002-7533-5564; 				ACTON GD, 1994, SCIENCE, V263, P1246, DOI 10.1126/science.263.5151.1246; [Anonymous], 1991, GEOLOGICAL EVOLUTION; BARKER PF, 1982, J GEOL SOC LONDON, V139, P787, DOI 10.1144/gsjgs.139.6.0787; BELL RE, 1990, ANTARCT RES SER, V50, P91; BRADSHAW JD, 1991, GEOLOGICAL EVOLUTION, P581; CANDE SC, 1995, SCIENCE, V270, P947, DOI 10.1126/science.270.5238.947; DALZIEL IWD, 1982, TECTONICS, V1, P3, DOI 10.1029/TC001i001p00003; Davey F. J., 1987, ANTARCT RES SER, V68, P167, DOI DOI 10.1029/AR068P0167; DIVINERE VJ, 1996, GEOL SOC SPEC PUB, V108, P31; du Toit A.L, 1937, OUR WANDERING CONTIN; GOHL K, 1996, ANN GEOPHYS       S1, V14, pC202; GRUNOW AM, 1993, GEOLOGY, V21, P647, DOI 10.1130/0091-7613(1993)021<0647:CADOWS>2.3.CO;2; KING EC, 1996, GEOL SOC SPEC PUB, V108, P1; LARTER RD, 1996, ANN GEOPHYS, V14, pC202; Lawver L. A, 1991, GEOLOGICAL EVOLUTION, P533; LAWVER LA, 1994, TERRA ANTARCT, V2, P375; LAXON S, 1994, INT J REMOTE SENS, V15, P915, DOI 10.1080/01431169408954124; LAXON S, 1994, SCIENCE, V265, P621, DOI 10.1126/science.265.5172.621; LAXON S, UNPUB; LIVEMORE RA, 1996, GEOL SOC SPEC PUBL, V103, P227; LIVERMORE RA, 1993, EARTH PLANET SC LETT, V117, P475, DOI 10.1016/0012-821X(93)90098-T; Marks K.M., 1993, EOS T AM GEOPHYS UNI, V74, P81, DOI [10.1029/93EO00249, DOI 10.1029/93EO00249]; MARKS KM, 1994, J GEOPHYS RES-SOL EA, V99, P531, DOI 10.1029/93JB02760; Marks KM, 1996, GEOPHYS RES LETT, V23, P2069, DOI 10.1029/96GL02059; MARKS KM, 1994, EOS, V75, P154; MCADOO DC, 1992, J GEOPHYS RES-SOL EA, V97, P3247, DOI 10.1029/91JB02797; MCADOO DC, 1992, J GEOPHYS RES-SOL EA, V97, P17709, DOI 10.1029/92JB02155; MCADOO DC, 1996, GEOL SOC LOND SPEC P, V108, P155, DOI DOI 10.1144/GSL.SP.1996.108.01.11; MOLNAR P, 1975, GEOPHYS J ROY ASTR S, V40, P383, DOI 10.1111/j.1365-246X.1975.tb04139.x; NEREM RS, 1994, J GEOPHYS RES-OCEANS, V99, P24421, DOI 10.1029/94JC01376; NORTON IO, 1979, J GEOPHYS RES, V84, P6803, DOI 10.1029/JB084iB12p06803; SANDWELL DT, IN PRESS J GEOPHYS R; SMITH AG, 1970, NATURE, V225, P139, DOI 10.1038/225139a0; Smith W. H. F., 1995, EOS T AM GEOPHYS UN, V76, P156; STOCK J, 1987, NATURE, V325, P495, DOI 10.1038/325495a0; STOCK JM, 1996, EOS, V77, P647; SUTHERLAND R, 1995, TECTONICS, V14, P819, DOI 10.1029/95TC00930	37	69	72	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					556	560		10.1126/science.276.5312.556	http://dx.doi.org/10.1126/science.276.5312.556			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110969				2022-12-28	WOS:A1997WV72100036
J	Weiser, P; Muller, R; Braun, U; Reth, M				Weiser, P; Muller, R; Braun, U; Reth, M			Endosomal targeting by the cytoplasmic tail of membrane immunoglobulin	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; IG-ALPHA; SIGNAL-TRANSDUCTION; BETA; ACTIVATION; INTERNALIZATION; LYMPHOCYTES; ASSOCIATION; MUTATION; PROTEINS	Membrane-bound immunoglobulin (mlg) of the IgG, IgA, and IgE classes have conserved cytoplasmic tails. To investigate the function of these tails, a B cell line was transfected with truncated or mutated gamma 2a heavy chains. Transport to the endosomal compartment of antigen bound by the B cell antigen receptor did not occur in the absence of the cytoplasmic tail; and one or two mutations, respectively, in the Tyr-X-X-Met motif of the tail partially or completely interrupted the process. Experiments with chimeric antigen receptors confirmed these findings. Thus, a role for the cytoplasmic tail of mlg heavy chains in endosomal targeting of antigen is revealed.	MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY	Max Planck Society								Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; AMIGORENA S, 1992, NATURE, V358, P37; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BROCKER T, 1993, EUR J IMMUNOL, V23, P1435, DOI 10.1002/eji.1830230705; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Kaisho T, 1997, SCIENCE, V276, P412, DOI 10.1126/science.276.5311.412; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; MITCHELL RN, 1995, J EXP MED, V181, P1705, DOI 10.1084/jem.181.5.1705; NEUBERGER MS, 1993, IMMUNOL REV, V132, P147, DOI 10.1111/j.1600-065X.1993.tb00841.x; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; STEVENS TL, 1994, J IMMUNOL, V152, P4397; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; Watts C, 1990, Semin Immunol, V2, P247; WEISER P, 1994, EUR J IMMUNOL, V24, P665, DOI 10.1002/eji.1830240327	22	34	36	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					407	409		10.1126/science.276.5311.407	http://dx.doi.org/10.1126/science.276.5311.407			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103197				2022-12-28	WOS:A1997WU47700037
J	Hollingsworth, H				Hollingsworth, H			Preventing insect sting anaphylaxis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HYPERSENSITIVITY				Hollingsworth, H (corresponding author), BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA.			Hollingsworth, Helen/0000-0001-9007-9012				Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; HOLLINGSWORTH HM, 1996, INTENS CARE MED, P2401; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; VALENTINE MD, 1992, JAMA-J AM MED ASSOC, V268, P2830, DOI 10.1001/jama.268.20.2830	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1196	1197		10.1001/jama.1997.03540390026016	http://dx.doi.org/10.1001/jama.1997.03540390026016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103334				2022-12-28	WOS:A1997WT40300015
J	Anker, SD; Ponikowski, P; Varney, S; Chua, TP; Clark, AL; WebbPeploe, KM; Harrington, D; Kox, WJ; PooleWilson, PA; Coats, AJS				Anker, SD; Ponikowski, P; Varney, S; Chua, TP; Clark, AL; WebbPeploe, KM; Harrington, D; Kox, WJ; PooleWilson, PA; Coats, AJS			Wasting as independent risk factor for mortality in chronic heart failure	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; IDIOPATHIC DILATED CARDIOMYOPATHY; SURVIVAL; MALNUTRITION; CACHEXIA; AIDS	Background Wasting in chronic heart failure (CHF) has long been known but is little investigated. We sought to find out whether the cachectic state in CHF provides additional prognostic information about all-cause mortality. Methods Between June, 1993, and May, 1995, we studied 171 consecutive patients with CHF (mean age 60 years [SD 11; range 27-86]; 17 female). We assessed exercise capacity (peak oxygen consumption; mean 17.5 mL kg(-1) min(-1) [6.7]), functional status (New York Heart Association [NYHA] class: 21 class I, 63 class II, 68 class III, 19 class IV), and left-ventricular ejection fraction (mean 30% [SD 15]; n=115). The cachectic status was defined prospectively as a non-intentional documented weight loss of at least 75% of previous normal weight (28 patients; range 9-36% or 6-30 kg) during at least 6 months. The Cox proportional-hazards model was used to assess the association of variables with survival, and Kaplan-Meier cumulative survival plots were constructed to estimate the influence of risk factors. Findings At the end of follow-up in November, 1996, 49 patients had died (after a mean 324 days [SD 283]). The mean follow-up of the survivors was 834 days (SD 186; range 549-1269). The cachectic state was predictive of 18-month mortality independent of age, NYHA class, left-ventricular ejection fraction, and peak oxygen consumption. Mortality in the cachectic patients (n=28) was 18% at 3 months, 29% at 6 months, 39% at 12 months, and 50% at 18 months. Patients who had a peak oxygen consumption below 14 mL kg(-1) min(-1) (n=53) had mortality at 3, 6, 12, and 18 months of 19%, 30%, 40%, and 51%. 18-month survival was 23% (95% CI 0-46) for the 13 patients with both of these risk factors (cachexia and low peak oxygen consumption) compared with 93% (88-98) in those (n=103) with neither risk factor (p<0.0001). Interpretation The cachectic state is a strong independent risk factor for mortality in patients with CHF. Combined with a low peak oxygen consumption, it identifies a subset of patients at extremely high risk of death. Assessment of cachexia should be included in transplant programmes and studies that investigate the effect of interventions by survival analyses.	UNIV HALLE WITTENBERG,DEPT INTERNAL MED CARDIOL 3,HALLE,GERMANY; UNIV GLASGOW,WESTERN INFIRM,GLASGOW G11 6NT,LANARK,SCOTLAND; HUMBOLDT UNIV BERLIN,UNIV HOSP CHARITE,DEPT ANAESTHESIOL & INTENS CARE MED,BERLIN,GERMANY	Martin Luther University Halle Wittenberg; University of Glasgow; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Anker, SD (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012; Ponikowski, Piotr/O-6454-2015	Coats, Andrew J Stewart/0000-0002-2771-4260; Ponikowski, Piotr/0000-0002-3391-7064				ABEL RM, 1976, ARCH SURG-CHICAGO, V111, P45; Anker SD, 1996, LANCET, V348, P1530, DOI 10.1016/S0140-6736(05)66163-6; ANKER SD, IN PRESS CIRCULATION; CARR JG, 1989, AM J CARDIOL, V63, P709, DOI 10.1016/0002-9149(89)90256-7; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; FERRARI R, 1995, CIRCULATION, V92, P1479, DOI 10.1161/01.CIR.92.6.1479; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; FRANCIS GS, 1993, CIRCULATION, V87, P40; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MADSEN BK, 1994, EUR HEART J, V15, P303, DOI 10.1093/oxfordjournals.eurheartj.a060495; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; OTAKI M, 1994, CHEST, V105, P1347, DOI 10.1378/chest.105.5.1347; Pacher R, 1996, J AM COLL CARDIOL, V27, P633, DOI 10.1016/0735-1097(95)00520-X; PARAMESHWAR J, 1992, AM HEART J, V123, P421, DOI 10.1016/0002-8703(92)90656-G; ROUL G, 1995, EUR HEART J, V16, P1387, DOI 10.1093/oxfordjournals.eurheartj.a060747; SOUHAMI RL, 1996, OXFORD TXB MED, P240; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; TSUTAMOTO T, 1995, AM J CARDIOL, V76, P803, DOI 10.1016/S0002-9149(99)80231-8	24	1006	1028	1	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1050	1053		10.1016/S0140-6736(96)07015-8	http://dx.doi.org/10.1016/S0140-6736(96)07015-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107242				2022-12-28	WOS:A1997WU00200008
J	Mortimer, PP; Miller, E				Mortimer, PP; Miller, E			Antenatal screening and targeting should be sufficient in some countries - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,IMMUNISAT DIV,LONDON NW9 5EQ,ENGLAND; CENT PUBL HLTH LAB,HEPATITIS & RETROVIRUS LAB,LONDON NW9 5HT,ENGLAND	Public Health England; Public Health England								BHATTI N, 1991, BRIT MED J, V303, P97, DOI 10.1136/bmj.303.6794.97; BOXALL EH, 1987, BRIT MED J, V294, P57, DOI 10.1136/bmj.294.6563.57; Collins M, 1994, Commun Dis Rep CDR Rev, V4, pR153; Fenn P, 1996, J INFECTION, V32, P197, DOI 10.1016/S0163-4453(96)80019-3; HESKETH LM, IN PRESS COMM DIS RE; Jefferson T, 1996, BRIT MED J, V313, P768; MANGTANI P, 1995, J EPIDEMIOL COMMUN H, V49, P238, DOI 10.1136/jech.49.3.238; *UK DEP HLTH, 1996, IMM INF DIS; Wong VS, 1996, BRIT MED J, V312, P1336, DOI 10.1136/bmj.312.7042.1336; 1996, SCIEH WEEKLY REPORT, P89; 1996, MMWR-MORBID MORTAL W, V45, P584	11	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1036	1037		10.1136/bmj.314.7086.1036	http://dx.doi.org/10.1136/bmj.314.7086.1036			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112853	Green Published			2022-12-28	WOS:A1997WT15200032
J	Prockop, DJ				Prockop, DJ			Marrow stromal cells as steam cells for nonhematopoietic tissues	SCIENCE			English	Article							HUMAN-BONE-MARROW; I PROCOLLAGEN COL1A1; HEMATOPOIETIC MICROENVIRONMENT; TRANSGENIC MICE; HOST ORIGIN; OSTEOGENIC PRECURSORS; DIFFUSION-CHAMBERS; PROGENITOR CELLS; HOMEOBOX GENES; MURINE MARROW	Marrow stromal cells can be isolated from other cells in marrow by their tendency to adhere to tissue culture plastic: The cells have many df the characteristics of stem cells for tissues that can roughly be defined as mesenchymal, because they can be differentiated in culture into osteoblasts, chondrocytes, adipocytes, and even myoblasts. Therefore, marrow stromal cells present an intriguing model for examining the differentiation of stem cells. Also, they have several characteristics that make them potentially useful for cell and gene therapy.			Prockop, DJ (corresponding author), ALLEGHENY UNIV HLTH SCI, CTR GENE THERAPY, MCP HAHNEMANN SCH MED, 245 N 15 ST, MAIL STOP 421, PHILADELPHIA, PA 19102 USA.							ANDERSON WF, 1994, HUM GENE THER, V5, P755, DOI 10.1089/hum.1994.5.6-755; ANKLESARIA P, 1989, BLOOD, V74, P1144; ANKLESARIA P, 1987, P NATL ACAD SCI USA, V84, P7681, DOI 10.1073/pnas.84.21.7681; ATHANASOU NA, 1990, BRIT J CANCER, V61, P385, DOI 10.1038/bjc.1990.84; BARON RE, 1966, PRIMER METABOLIC BON, P3; BENNETT JH, 1991, J CELL SCI, V99, P131; BERESFORD JN, 1992, J CELL SCI, V102, P341; BLENZIE D, 1994, P NATL ACAD SCI USA, V91, P350; BRENNER M, 1994, BR J CANC S, V23, P56; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; BUIJA J, 1994, ANN PLAST SURG, V21, P26; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; CAPLAN AI, 1990, BIOMATERIALS, V11, P44; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; Cohnheim J, 1867, PATH ANAT PHYSL KLIN, V40, P1, DOI 10.1007/BF02968135; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; DERYUGINA EI, 1993, CRIT REV IMMUNOL, V13, P115; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DEXTER TM, 1982, J CELL PHYSIOL, P87; EAVES CJ, 1991, BLOOD, V78, P110; FRIEDENSTEIN AJ, 1978, EXP HEMATOL, V6, P440; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; GARTNER S, 1980, P NATL ACAD SCI-BIOL, V77, P4756, DOI 10.1073/pnas.77.8.4756; GILBERT SF, 1994, DEV BIOL, P335; GOLDBERG VM, 1994, ORTHOPEDICS, V17, P819; Gordon MY, 1996, LEUKEMIA, V10, P1347; Gronthos S, 1996, J Hematother, V5, P15, DOI 10.1089/scd.1.1996.5.15; GRONTHOS S, 1994, BLOOD, V84, P4164, DOI 10.1182/blood.V84.12.4164.bloodjournal84124164; GRONTHOS S, 1995, BLOOD, V85, P929, DOI 10.1182/blood.V85.4.929.bloodjournal854929; Guinn B, 1996, BLOOD, V88, P3921; HALL BK, 1988, AM SCI, V76, P174; Hay E., 1966, REGENERATION; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; Horwitz EM, 1996, MATRIX BIOL, V15, P188; HOWLETT CR, 1986, CLIN ORTHOP RELAT R, V213, P251; ISCOVE N, 1990, NATURE, V347, P126, DOI 10.1038/347126a0; KEATING A, 1984, BLOOD, V64, P1159; Keating A, 1996, EXP HEMATOL, V24, P180; KEATING A, 1982, NATURE, V298, P280, DOI 10.1038/298280a0; KEATING A, 1990, EXP HEMATOL, V18, P99; KHILLAN JS, 1991, J BIOL CHEM, V266, P23373; KITTLER ELW, 1992, BLOOD, V79, P3168; KLEIN G, 1995, EXPERIENTIA, V51, P914, DOI 10.1007/BF01921741; LAVER J, 1987, BLOOD, V70, P1966; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; Lemieux ME, 1996, BLOOD, V88, P1639; LONG MW, 1990, J CLIN INVEST, V86, P1387, DOI 10.1172/JCI114852; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MARDON HJ, 1987, CELL TISSUE RES, V250, P157, DOI 10.1007/BF00214667; MARSHALL MJ, 1984, EXPERIENTIA, V40, P385, DOI 10.1007/BF01952566; Moen JK, 1935, J EXP MED, V61, P247, DOI 10.1084/jem.61.2.247; MORETTI P, 1994, GENE, V144, P213, DOI 10.1016/0378-1119(94)90380-8; NIENHUIS AW, 1994, BLOOD CELLS, V20, P141; OTSUKA T, 1991, J CELL PHYSIOL, V148, P370, DOI 10.1002/jcp.1041480307; OWEN M, 1988, CIBA F SYMP, V136, P42; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pereira RF, 1996, MATRIX BIOL, V15, P188, DOI 10.1016/S0945-053X(96)90085-2; PETRAKIS NL, 1961, BLOOD, V17, P109, DOI 10.1182/blood.V17.1.109.109; PIERSMA AH, 1983, BRIT J HAEMATOL, V54, P285, DOI 10.1111/j.1365-2141.1983.tb02097.x; PLERSMA AH, 1983, BRIT J HAEMATOL, V54, P285; PLERSMA AH, 1985, EXP HEMATOL, V13, P237; QUESENBERRY PJ, 1994, BLOOD CELLS, V20, P348; QUESENBERRY PJ, 1992, CANCER, V70, P909; RANGAN SRS, 1967, EXP CELL RES, V46, P477, DOI 10.1016/0014-4827(67)90374-6; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; Rickard DJ, 1996, J BONE MINER RES, V11, P312; ROSS R, 1970, Journal of Cell Biology, V44, P645, DOI 10.1083/jcb.44.3.645; SANTUCCI MA, 1992, BONE MARROW TRANSPL, V10, P255; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHUENING FG, 1992, CURR TOP MICROBIOL, V177, P237; SIMMONS PJ, 1991, BLOOD, V78, P55; SIMMONS PJ, 1987, NATURE, V328, P429, DOI 10.1038/328429a0; SOKOLOV BP, 1995, J BIOL CHEM, V270, P9622, DOI 10.1074/jbc.270.16.9622; SOKOLOV BP, 1993, BIOCHEMISTRY-US, V32, P9242, DOI 10.1021/bi00086a033; STEWART FM, 1993, BLOOD, V81, P2566; SUTHERLAND DR, 1993, STEM CELLS, V11, P50, DOI 10.1002/stem.5530110914; TANAKA J, 1994, BRIT J HAEMATOL, V86, P436, DOI 10.1111/j.1365-2141.1994.tb04764.x; VACANTI CA, 1994, AM J SPORT MED, V22, P485, DOI 10.1177/036354659402200408; VACANTI CA, 1994, OTOLARYNG CLIN N AM, V27, P263; VANZANT G, 1990, J EXP MED, V171, P1547, DOI 10.1084/jem.171.5.1547; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; WAKITANI S, 1994, J BONE JOINT SURG AM, V76A, P579, DOI 10.2106/00004623-199404000-00013; WALLER EK, 1995, BLOOD, V86, P710, DOI 10.1182/blood.V86.2.710.bloodjournal862710; WALLER EK, 1995, BLOOD, V85, P2422, DOI 10.1182/blood.V85.9.2422.bloodjournal8592422; WU DD, 1991, EXP HEMATOL, V19, P585	89	3573	4070	8	265	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					71	74		10.1126/science.276.5309.71	http://dx.doi.org/10.1126/science.276.5309.71			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082988				2022-12-28	WOS:A1997WR38600047
J	White, KP; Hurban, P; Watanabe, T; Hogness, DS				White, KP; Hurban, P; Watanabe, T; Hogness, DS			Coordination of Drosophila metamorphosis by two ecdysone-induced nuclear receptors	SCIENCE			English	Article							SEQUENTIAL GENE ACTIVATION; SUPERFAMILY MEMBERS; INDUCIBLE GENE; EARLY PUFF; ENCODES 2; TRANSCRIPTION; ULTRASPIRACLE; MELANOGASTER; EXPRESSION; PROTEINS	The functions of the ecdysone-induced DHR3 and E75B orphan nuclear receptors in the early stages of Drosophila metamorphosis were investigated, DHR3 represses the ecdysone induction of early genes turned on by the pulse of ecdysone that triggers metamorphosis. It also induces beta FTZF1, an orphan nuclear receptor that is essential for the appropriate response to the subsequent prepupal pulse of ecdysone. The E75B receptor, which lacks a complete DNA binding domain, inhibits this inductive function by forming a complex with DHR3 on the beta FTZF1 promoter, thereby providing a timing mechanism for beta FTZF1 induction that is dependent on the disappearance of E75B.	STANFORD UNIV,DEPT DEV BIOL,SCH MED,BECKMAN CTR B300,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOCHEM,SCH MED,BECKMAN CTR B300,STANFORD,CA 94305	Stanford University; Stanford University								ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ARBEITMAN MN, UNPUB; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; BERNARD HU, 1987, EMBO J, V6, P133, DOI 10.1002/j.1460-2075.1987.tb04730.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; BURTIS KC, 1985, THESIS STANFORD U; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Fristrom D, 1993, DEV DROSOPHILA MELAN, P843; HARPER JW, 1993, CELL, V75, P805; HORNER MA, 1995, DEV BIOL, V168, P490, DOI 10.1006/dbio.1995.1097; HUET F, 1995, DEVELOPMENT, V121, P1195; JOHANSEN H, 1989, GENE DEV, V3, P882, DOI 10.1101/gad.3.6.882; KAGEYAMA Y, COMMUNICATION; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U; LAM GT, IN PRESS DEVELOPMENT; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARONI G, 1983, DROS INFORM SERV, V59, P142; RICHARDS G, 1976, DEV BIOL, V54, P264, DOI 10.1016/0012-1606(76)90304-3; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Skaer H., 1993, DEV DROSOPHILA MELAN, V2, P941; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; WATANABE T, UNPUB; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	36	240	247	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					114	117		10.1126/science.276.5309.114	http://dx.doi.org/10.1126/science.276.5309.114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082981				2022-12-28	WOS:A1997WR38600059
J	Ishihara, H; Connolly, AJ; Zeng, DW; Kahn, ML; Zheng, YW; Timmons, C; Tram, T; Coughlin, SR				Ishihara, H; Connolly, AJ; Zeng, DW; Kahn, ML; Zheng, YW; Timmons, C; Tram, T; Coughlin, SR			Protease-activated receptor 3 is a second thrombin receptor in humans	NATURE			English	Article							MOLECULAR-CLONING; AGONIST PEPTIDES; HUMAN PLATELETS; ALPHA-THROMBIN; SPECIFICITY; MECHANISM; CLEAVAGE; HIRUDIN; CELLS	Thrombin is a coagulation protease that activates platelets, leukocytes, endothelial and mesenchymal cells at sites of vascular injury, acting partly through an unusual proteolytically activated G-protein-coupled receptor(1-3). Knockout of the gene encoding this receptor provided definitive evidence for a second thrombin receptor in mouse platelets and for tissue-specific roles for different thrombin receptors(4) We now report the cloning and characterization of a new human thrombin receptor, designated protease-activated receptor 3 (PAR3). PAR3 can mediate thrombin-triggered phosphoinositide hydrolysis and is expressed in a variety of tissues, including human bone marrow and mouse megakaryocytes, making it a candidate for the sought-after second platelet thrombin receptor. PAR3 provides a new tool for understanding thrombin signalling and a possible target for therapeutics designed selectively to block thrombotic, inflammatory and proliferative responses to thrombin.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHEN J, 1994, J BIOL CHEM, V269, P16041; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOODWIN CA, 1994, BIOCHEM BIOPH RES CO, V202, P321, DOI 10.1006/bbrc.1994.1930; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1993, J BIOL CHEM, V268, P9780; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; LIU LW, 1991, J BIOL CHEM, V266, P16977; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RATHBONE RK, 1993, THROMB HAEMOSTASIS, V70, P1019; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1994, J BIOL CHEM, V269, P22000; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SOIFER SJ, 1994, AM J PATHOL, V144, P60; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939	30	775	800	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					502	506		10.1038/386502a0	http://dx.doi.org/10.1038/386502a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087410				2022-12-28	WOS:A1997WR25600054
J	Kempermann, G; Kuhn, HG; Gage, FH				Kempermann, G; Kuhn, HG; Gage, FH			More hippocampal neurons in adult mice living in an enriched environment	NATURE			English	Article							DENTATE GYRUS; RAT; BRAIN; NEUROGENESIS	Neurogenesis occurs in the dentate gyrus of the hippocampus throughout the life of a rodent(1-4), but the function of these new neurons and the mechanisms that regulate their birth are unknown, Here we show that significantly more new neurons exist in the dentate gyrus of mice exposed to an enriched environment compared with littermates housed in standard cages. We also show, using unbiased stereology, that the enriched mice have a larger hippocampal granule cell layer and 15 per cent more granule cell neurons in the dentate gyrus.	SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037	Salk Institute			Kempermann, Gerd/F-5416-2010; Kuhn, Hans-Georg/L-8127-2014	Kempermann, Gerd/0000-0002-5304-4061; Kuhn, Hans-Georg/0000-0003-4247-5613				ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALTMAN J, 1964, NATURE, V204, P1161, DOI 10.1038/2041161a0; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Craig CG, 1996, J NEUROSCI, V16, P2649; CUMMINS RA, 1977, SCIENCE, V197, P692, DOI 10.1126/science.877587; CUMMINS RA, 1973, NATURE, V243, P516, DOI 10.1038/243516a0; DELRIO JA, 1989, DEV BRAIN RES, V49, P311, DOI 10.1016/0165-3806(89)90033-3; FIALA BA, 1978, EXP NEUROL, V59, P372, DOI 10.1016/0014-4886(78)90229-7; GREENOUGH WT, 1975, AM SCI, V63, P37; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kuhn HG, 1996, J NEUROSCI, V16, P2027; McEwen BS, 1996, CELL MOL NEUROBIOL, V16, P103, DOI 10.1007/BF02088170; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; PACTEAU C, 1989, BEHAV BRAIN RES, V34, P79, DOI 10.1016/S0166-4328(89)80092-0; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; WAINWRIGHT PE, 1994, BEHAV BRAIN RES, V60, P125, DOI 10.1016/0166-4328(94)90139-2; WALSH RN, 1979, INT J NEUROSCI, V9, P209, DOI 10.3109/00207457909147675; WALSH RN, 1969, J COMP NEUROL, V137, P361, DOI 10.1002/cne.901370309; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; WIMER RE, 1978, BRAIN RES, V157, P105, DOI 10.1016/0006-8993(78)90999-X	28	2647	2742	5	192	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					493	495		10.1038/386493a0	http://dx.doi.org/10.1038/386493a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087407				2022-12-28	WOS:A1997WR25600051
J	Nightingale, SL				Nightingale, SL			Request for information on therapeutic switches	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-28	WOS:A1997WQ08900008
J	ORahilly, S				ORahilly, S			Science, medicine, and the future - Non-insulin dependent diabetes mellitus: The gathering storm	BRITISH MEDICAL JOURNAL			English	Review							HYPERTENSION; GENE	A massive increase in the global prevalence of non-insulin dependent diabetes is likely to occur as ''Westernisation'' of dietary habits and patterns of physical activity becomes more widespread. Advances in molecular and cellular science may provide some useful insights and therapeutic tools to assist in the fight against the severe consequences of this epidemic. These will include the better identification of specific aetiological subtypes of the disease; the identification of new drugs through the better understanding of the biology of insulin secretion and action; and the targeting of therapies to specific subtypes of the disease. In addition, knowledge of the precise mode of action and antidiabetes drugs may facilitate the design of more effective non-pharmacological manipulations; the genetic identification of ''high risk'' asymptomatic people may allow us to target screening and preventive strategies more effectively; and investigations into the mechanisms that underlie the link between low birth weight and later diabetes should provide new routes towards treatment and prevention. Barriers to the implementation of the global measures required to stem the predicted flood of non-insulin dependent diabetes may prove insuperable, but if we are to have any success, then close collaboration between clinicians, epidemiologists, public health physicians, and laboratory scientists will be essential.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Addenbrooke's Hospital; University of Cambridge	ORahilly, S (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,BOX 157,CAMBRIDGE CB2 2QR,ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449				BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; DAVIES M, 1994, BRIT MED J, V308, P1160, DOI 10.1136/bmj.308.6937.1160b; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HODGE AM, 1995, OBES RES S2, V3, P77; Krook A, 1996, BAILLIERE CLIN ENDOC, V10, P97, DOI 10.1016/S0950-351X(96)80330-2; Maassen JA, 1996, DIABETOLOGIA, V39, P375; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TURNER RC, 1985, HYPERTENSION, V7, P8; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	17	72	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					955	959		10.1136/bmj.314.7085.955	http://dx.doi.org/10.1136/bmj.314.7085.955			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099123	Green Published			2022-12-28	WOS:A1997WQ16900032
J	Burke, W; Daly, M; Garber, J; Botkin, J; Kahn, MJE; Lynch, P; McTierman, A; Offit, K; Perlman, J; Petersen, G; Thomson, E; Varricchio, C				Burke, W; Daly, M; Garber, J; Botkin, J; Kahn, MJE; Lynch, P; McTierman, A; Offit, K; Perlman, J; Petersen, G; Thomson, E; Varricchio, C			Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BREAST SELF-EXAMINATION; SERUM CA-125 LEVELS; HORMONE REPLACEMENT THERAPY; FAMILIAL OVARIAN-CANCER; RANDOMIZED CONTROLLED TRIAL; ORAL-CONTRACEPTIVE USE; FECAL OCCULT BLOOD; WOMEN AGED 40; SUBCUTANEOUS MASTECTOMY; POSTMENOPAUSAL WOMEN	Objective.-To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations in the BRCA1 or BRCA2 genes. Participants.-A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by National Human Genome Research Institute (previously the National Center for Human Genome Research). Evidence.-Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to breast and ovarian cancer were identified using MEDLINE (National Library of Medicine) and from bibliographies of articles thus identified. Indexing terms used were ''genetics'' in combination with ''breast cancer, ''ovarian cancer,'' and ''screening,'' or ''surveillance'' in combination with ''cancer family'' and ''BRCA1'' and ''BRCA2.'' For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. Consensus Process.-The task force developed recommendations through discussions over a 14-month period. Conclusions.-Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown. Based on expert opinion concerning presumptive benefit, early breast cancer and ovarian cancer screening are recommended for individuals with BRCA1 mutations and early breast cancer screening for those with BRCA2 mutations. No recommendation is made for or against prophylactic surgery (eg, mastectomy, oophorectomy); these surgeries are an option for mutation carriers, but evidence of benefit is lacking, and case reports have documented the occurrence of cancer following prophylactic surgery. It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; DANA FARBER CANC INST,BOSTON,MA 02115; UNIV UTAH,ECCLES INST HUMAN GENET,UTAH CTR HUMAN GENOME RES,SALT LAKE CITY,UT; NATL BREAST CANC COALIT,RICHMOND,VA; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; MEM SLOAN KETTERING INST CANC RES,NEW YORK,NY; NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,DEPT EPIDEMIOL,BALTIMORE,MD 21218; NATL HUMAN GENOME RES INST,ETH LEGAL & SOCIAL IMPLICAT BRANCH,BETHESDA,MD	Fox Chase Cancer Center; Harvard University; Dana-Farber Cancer Institute; Utah System of Higher Education; University of Utah; University of Texas System; UTMD Anderson Cancer Center; Fred Hutchinson Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Burke, W (corresponding author), UNIV WASHINGTON 354765,DEPT MED,4245 ROOSEVELT WAY NE,SEATTLE,WA 98105, USA.							Beam CA, 1996, ARCH INTERN MED, V156, P209, DOI 10.1001/archinte.156.2.209; BENNETT SE, 1983, JAMA-J AM MED ASSOC, V249, P488, DOI 10.1001/jama.249.4.488; BERNSTEIN L, 1994, J NATL CANCER I, V86, P1403, DOI 10.1093/jnci/86.18.1403; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BILIMORIA MM, 1995, CA-CANCER J CLIN, V45, P263, DOI 10.3322/canjclin.45.5.263; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; BURHENNE HJ, 1994, AM J ROENTGENOL, V162, P1067, DOI 10.2214/ajr.162.5.8165983; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CAMPBELL HS, 1991, AM J PREV MED, V7, P1; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; *COLL GROUP HORM F, 1996, LANCET, V347, P1713; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; DALY MB, 1992, HEMATOL ONCOL CLIN N, V6, P729; *DIV CANC PREV CON, 1993, CLIN TRIALS HORM REP; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; ELDAR S, 1984, AM J SURG, V148, P692, DOI 10.1016/0002-9610(84)90352-0; EVANS JS, 1986, NEW ENGL J MED, V315, P810, DOI 10.1056/NEJM198609253151306; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; FLETCHER SW, 1995, RADIOL CLIN N AM, V33, P1259; FLETCHER SW, 1985, JAMA-J AM MED ASSOC, V253, P2224, DOI 10.1001/jama.253.15.2224; FLETCHER SW, 1990, ANN INTERN MED, V112, P772, DOI 10.7326/0003-4819-112-10-772; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FOSTER RS, 1978, NEW ENGL J MED, V299, P265, DOI 10.1056/NEJM197808102990601; GARGANO G, 1990, Clinical and Experimental Obstetrics and Gynecology, V17, P23; GOLDMAN LD, 1973, PLAST RECONSTR SURG, V51, P501, DOI 10.1097/00006534-197305000-00002; GOODNIGHT JE, 1984, J SURG ONCOL, V26, P198, DOI 10.1002/jso.2930260313; GORSKY RD, 1994, OBSTET GYNECOL, V83, P161; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENWALD P, 1978, NEW ENGL J MED, V299, P271, DOI 10.1056/NEJM197808102990602; GROSS TP, 1994, OBSTET GYNECOL, V83, P419; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HARTGE P, 1994, OBSTET GYNECOL, V84, P760; HELZLSOUER KJ, 1993, JAMA-J AM MED ASSOC, V269, P1123, DOI 10.1001/jama.269.9.1123; Hicken NF, 1940, ARCH SURG-CHICAGO, V40, P6, DOI 10.1001/archsurg.1940.04080010009002; HIGGINS RV, 1989, GYNECOL ONCOL, V34, P402, DOI 10.1016/0090-8258(89)90181-9; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; HUMPHREY LJ, 1983, AM J SURG, V145, P311, DOI 10.1016/0002-9610(83)90188-5; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; HYLAND WT, 1985, SURG CLIN N AM, V65, P373; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; JACOBS I, 1989, HUM REPROD, V4, P1; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JOHN EM, 1993, EPIDEMIOL REV, V15, P157, DOI 10.1093/oxfordjournals.epirev.a036099; KELSEY JL, 1993, EPIDEMIOL REV, V15, P37; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1992, OBSTET GYNECOL, V80, P700; KIEBACK DG, 1986, BREAST CANCER RES TR, V7, P119, DOI 10.1007/BF01806797; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; KOPANS DB, 1995, RADIOL CLIN N AM, V33, P1273; KOPANS DB, 1995, AM J ROENTGENOL, V164, P1298, DOI 10.2214/ajr.164.5.7717258; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, CANCER, V71, P589; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; KURJAK A, 1991, J ULTRAS MED, V10, P295; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LITTRUP PJ, 1994, CANCER-AM CANCER SOC, V74, P2016, DOI 10.1002/1097-0142(19941001)74:7+<2016::AID-CNCR2820741705>3.0.CO;2-J; LYNCH HT, 1993, ARCH INTERN MED, V153, P1979; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; McTiernan A, 1996, EPIDEMIOLOGY, V7, P598, DOI 10.1097/00001648-199611000-00006; Mettler FA, 1996, CANCER, V77, P903, DOI 10.1002/(SICI)1097-0142(19960301)77:5<903::AID-CNCR15>3.0.CO;2-7; METTLIN C, 1994, CA-CANCER J CLIN, V44, P248, DOI 10.3322/canjclin.44.4.248; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MIES C, 1993, AM J SURG PATHOL, V17, P715, DOI 10.1097/00000478-199307000-00009; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER AB, 1991, CAN J PUBLIC HEALTH, V82, P162; MUTO MG, 1993, GYNECOL ONCOL, V51, P12, DOI 10.1006/gyno.1993.1239; National Cancer Institute, 1987, WORK GUID EARL CANC; *NCI CANC GEN NETW, 1996, SCIENTIST, V10, P8; *NCI CANC GEN NETW, 1996, SCIENTIST       0722, V10, P1; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; NEWCOMB PA, 1991, J NATL CANCER I, V83, P260, DOI 10.1093/jnci/83.4.260; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; NGUYEN HN, 1994, CANCER-AM CANCER SOC, V74, P545, DOI 10.1002/1097-0142(19940715)74:2<545::AID-CNCR2820740204>3.0.CO;2-Q; *NIH CONS DEV PAN, 1995, JAMA-J AM MED ASSOC, V273, P491; NILOFF JM, 1992, PRINCIPLES PRACTICE, P137; OShaughnessy JA, 1996, JAMA-J AM MED ASSOC, V275, P1349, DOI 10.1001/jama.275.17.1349; PENNISI VR, 1989, AESTHET PLAST SURG, V13, P15, DOI 10.1007/BF01570320; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; PIVER MS, 1993, CANCER, V71, P2651; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; Report of the Working Group to Review the National Cancer Institute, 1979, JNCI-J NATL CANCER I, V62, P639; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; RUBIN LR, 1984, CLIN PLAST SURG, V11, P369; SCHUURMAN AG, 1995, CANCER CAUSE CONTROL, V6, P416, DOI 10.1007/BF00052181; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, ANN INTERN MED, V118, P1, DOI 10.7326/0003-4819-118-1-199301010-00001; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SKATES SJ, 1995, CANCER, V76, P2004, DOI 10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G; SLADE CL, 1984, PLAST RECONSTR SURG, V73, P84, DOI 10.1097/00006534-198401000-00019; SNYDERMAN RK, 1984, CANCER, V53, P803, DOI 10.1002/1097-0142(19840201)53:3+<803::AID-CNCR2820531332>3.0.CO;2-6; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; Struewing J P, 1995, J Natl Cancer Inst Monogr, P33; TAVTIGIAN SV, 1996, NAT GENET, V12, P10; TEMPLE WJ, 1991, AM J SURG, V161, P413, DOI 10.1016/0002-9610(91)91100-W; THOMAS DB, IN PRESS J NATL CANC; THORLACIUS S, 1995, LANCET, V346, P544, DOI 10.1016/S0140-6736(95)91383-1; TOBACMAN JK, 1982, LANCET, V2, P795; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4; VASEN HFA, 1994, ANN MED, V26, P185, DOI 10.3109/07853899409147888; VASILEV SA, 1988, OBSTET GYNECOL, V71, P751; WAPNIR IL, 1990, SURG GYNECOL OBSTET, V171, P171; WOODS JE, 1986, MAYO CLIN PROC, V61, P579, DOI 10.1016/S0025-6196(12)62008-4; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507	121	726	744	0	72	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					997	1003		10.1001/jama.277.12.997	http://dx.doi.org/10.1001/jama.277.12.997			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091675				2022-12-28	WOS:A1997WN99200037
J	Baldwin, PJ; Newton, RW; Buckley, G; Roberts, MA; Dodd, M				Baldwin, PJ; Newton, RW; Buckley, G; Roberts, MA; Dodd, M			Senior house officers in medicine: Postal survey of training and work experience	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To describe working conditions for senior house officers in medicine in Scotland and to relate these to the quality of clinical training they receive. Design: Postal questionnaire survey. Subjects: All senior house officers in medicine and related specialties in past in Scotland in October 1995 (n=437); 252 (58%) respondents. Main outcome measures: Questionnaires covered hours, working patterns, measures of workload, an attitudes to work scale, and experience of education and training. Results: In the week before the questionnaire, doctors on rotas had worked a mean of 7.4 (95% confidence interval 5.8 to 9.0) hours in excess of their contracts, compared with 3.7 (2.0 to 5.5) hours for those on partial shifts. The most common reason for this was ''the needs of the patients or the service.'' Those on partial shifts reported significantly less continuity of care with patients than those on rotas (Mann-Whitney U test, z=-4.2, P<0.0001) or full shifts (z=-2.08, P=0.03). Doctors in general medicine reported significantly higher measures of workload (number of acute admissions, number of times called out, and fewest hours' uninterrupted sleep) than those in subspecialties. Consultants' clinical teaching and style of conducting a ward round were significantly related to factors extracted from the attitudes to work scale. Conclusions: The quality of senior house officers' training is detrimentally affected by a variety of conditions, especially the need for closer support and supervision, the need for greater feedback, and the lack of time that consultants have to dedicate to clinical training. Efforts should be made to improve these conditions and to reinforce a dose working relationship between trainee and supervising consultant.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND; SCOTTISH COUNCIL POSTGRAD MED & DENT EDUC,EDINBURGH EH2 1JE,MIDLOTHIAN,SCOTLAND; VICTORIA GERIATR UNIT,GLASGOW G41 3DX,LANARK,SCOTLAND	University of Dundee	Baldwin, PJ (corresponding author), ASTLEY AINSLIE HOSP,WORKING MINDS PROJECT,BLACKFORD PAVIL,GRANGE LOAN,EDINBURGH EH9 2HL,MIDLOTHIAN,SCOTLAND.							FIRTHCOZENS J, 1992, J OCCUP ORGAN PSYCH, V65, P61, DOI 10.1111/j.2044-8325.1992.tb00484.x; *JUN DOCT COMM, 1994, SHIFT WORK PRACT GUI; *JUN DOCT COMM, 1993, JUN DOCT NEW DEAL; *ROYAL COLL PHYS F, 1997, REV WORK PATT TRAIN	4	50	50	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					740	743		10.1136/bmj.314.7082.740	http://dx.doi.org/10.1136/bmj.314.7082.740			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116556	Green Published			2022-12-28	WOS:A1997WM77600033
J	Sano, T; Maruyama, K				Sano, T; Maruyama, K			Commentary: Japanese point of view	BRITISH MEDICAL JOURNAL			English	Editorial Material											Sano, T (corresponding author), NATL CANC CTR,DEPT SURG ONCOL,DIV GASTR,1-1 TSUKIJI 5 CHOME,TOKYO,JAPAN.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					470	471		10.1136/bmj.314.7079.470	http://dx.doi.org/10.1136/bmj.314.7079.470			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9081573	Green Published			2022-12-28	WOS:A1997WJ41900022
J	Cohen, D; Ashkenazi, S; Green, MS; Gdalevich, M; Robin, G; Slepon, R; Yavzori, M; Orr, N; Block, C; Ashkenazi, I; Shemer, J; Taylor, DN; Hale, TL; Sadoff, JC; Pavliakova, D; Schneerson, R; Robbins, JB				Cohen, D; Ashkenazi, S; Green, MS; Gdalevich, M; Robin, G; Slepon, R; Yavzori, M; Orr, N; Block, C; Ashkenazi, I; Shemer, J; Taylor, DN; Hale, TL; Sadoff, JC; Pavliakova, D; Schneerson, R; Robbins, JB			Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults	LANCET			English	Article							LIPOPOLYSACCHARIDE O-ANTIGEN; SERUM ANTIBODIES; ORAL VACCINATION; FLEXNERI; POLYSACCHARIDE; TRANSMISSION; IMMUNIZATION; CANDIDATE; IMMUNITY; ISRAEL	Background The aim of this double-blind randomised vaccine-controlled trial was to assess the efficacy of a conjugate vaccine composed of Shigella sonnei O-specific polysaccharide bound to Pseudomonas aeruginosa recombinant exoprotein A (S sonnei-rEPA) and of an oral, live-attenuated Escherichia coli/S flexneri 2a (EcSf2a-2) hybrid vaccine among military recruits in Israel at high risk of exposure to Shigella spp. We report here our preliminary findings on the efficacy of S sonnei-rEPA; we have not documented sufficient cases to assess the efficacy of EcSf2a-2. Methods Between April, 1993, and August, 1994, male Israeli military recruits aged 18-22 years were asked to take part in our study. We enrolled 1446 soldiers from seven separate field sites (groups A-G). Soldiers were randomly allocated one injection of S sonnei-rEPA and four doses of oral placebo (n=576), four oral doses of EcSf2a-2 and one injection of saline placebo (n=580), or one injection of meningococcal tetravalent control vaccine and four doses of oral placebo (n=290). Because there were no cases of S flexneri 2a, the EcSf2a-2 and meningococcal vaccines were the control group. We defined S sonnei shigellosis as diarrhoea with a positive faecal culture for S sonnei. Each group of soldiers was followed up for 2.5-7.0 months. The primary endpoint was protective efficacy of S sonnei-rEPA against S sonnei shigellosis. Findings Cases of culture-proven S sonnei shigellosis occurred in four groups of soldiers (groups A-D), which comprised 787 volunteers (312 received S sonnei-rEPA, 316 received EcSf2a-2, and 159 received meningococcal control vaccine). In groups A-C, cases of shigellosis occurred 70-155 days after vaccination, whereas in group D cases occurred after 1-17 days. In groups A-C, the attack rate of shigellosis was 2.2% in recipients of S sonnei-rEPA compared with 8.6% in controls (protective efficacy 74% [95% CI 28-100], p=0.006). S sonnei-rEPA also showed significant protection against shigellosis in group D (43% [4-82], p=0.039). Prevaccination and postvaccination ELISA measurements of antibody to S sonnei lipopolysaccharide among recipients of S sonnei-rEPA showed that the vaccinees who developed S sonnei shigellosis had significantly lower serum IgG and IgA responses to the homologous lipopolysaccharide than those who did not (p=<0.05). Interpretation One injection of S sonnei-rEPA confers type specific protection against S sonnei shigellosis. The high antibody concentration induced by the conjugate vaccine in volunteers who did not develop shigellosis suggests that there is an association between serum antibody titre and protection.	TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL; WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,WASHINGTON,DC 20307; NICHHD,DEV & MOL IMMUN LAB,NIH,BETHESDA,MD	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Cohen, D (corresponding author), CHAIM SHEBA MED CTR,ISRAEL DEF FORCES MED CORPS,MIL POST 02149,IL-52621 TEL HASHOMER,ISRAEL.		Ashkenazi, Shai/V-7996-2019	Ashkenazi, Shai/0000-0001-7244-0679; Green, Manfred S./0000-0002-9753-5612; Cohen, Daniel/0000-0003-2664-2303				ASHKENAZI S, 1993, CLIN INFECT DIS, V17, P897, DOI 10.1093/clinids/17.5.897; CHU CY, 1991, INFECT IMMUN, V59, P4450, DOI 10.1128/IAI.59.12.4450-4458.1991; COHEN D, 1994, VACCINE, V12, P1436, DOI 10.1016/0264-410X(94)90153-8; COHEN D, 1989, J CLIN MICROBIOL, V27, P162, DOI 10.1128/JCM.27.1.162-167.1989; COHEN D, 1988, J INFECT DIS, V157, P1068, DOI 10.1093/infdis/157.5.1068; COHEN D, 1991, J CLIN MICROBIOL, V29, P386, DOI 10.1128/JCM.29.2.386-389.1991; COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N; Cohen D, 1996, INFECT IMMUN, V64, P4074, DOI 10.1128/IAI.64.10.4074-4077.1996; Cohen D, 1996, CLIN DIAGN LAB IMMUN, V3, P451, DOI 10.1128/CDLI.3.4.451-455.1996; DEMARIA A, 1988, J INFECT DIS, V158, P301, DOI 10.1093/infdis/158.2.301; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; DUPONT HL, 1969, J INFECT DIS, V119, P296, DOI 10.1093/infdis/119.3.296; FORMAL SB, 1984, INFECT IMMUN, V46, P465, DOI 10.1128/IAI.46.2.465-469.1984; GREEN MS, 1987, ISRAEL J MED SCI, V23, P811; HENRY FJ, 1987, HUM NUTR-CLIN NUTR, V41C, P243; HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3; HIGGINS AR, 1955, AM J TROP MED HYG, V4, P281, DOI 10.4269/ajtmh.1955.4.281; *I MED, 1986, NEW VACC DEV EST PRI, V2, P329; KAUPPI M, 1995, PEDIATR INFECT DIS J, V14, P286, DOI 10.1097/00006454-199504000-00008; KEUSCH GT, 1991, BACTERIAL INFECTIONS, P593; KHAU MU, 1982, T R SOC TROP MED HYG, V76, P164; LINDBERG AA, 1990, NEW GENERATION VACCI, P677; MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2; ROBBINS JB, 1992, CLIN INFECT DIS, V15, P346, DOI 10.1093/clinids/15.2.346; ROBBINS JB, 1985, J INFECT DIS, V171, P1378; SANSONETTI PJ, 1989, VACCINE, V7, P443, DOI 10.1016/0264-410X(89)90160-6; SCHWARTZER TA, 1988, J INFECT DIS, V158, P1135, DOI 10.1093/infdis/158.5.1135; TAYLOR DN, 1993, INFECT IMMUN, V61, P3678, DOI 10.1128/IAI.61.9.3678-3687.1993	28	193	212	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					155	159		10.1016/S0140-6736(96)06255-1	http://dx.doi.org/10.1016/S0140-6736(96)06255-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111538				2022-12-28	WOS:A1997WC86100008
J	Chong, I; Hiroi, Z; Izumi, M; Shimoyama, J; Nakayama, Y; Kishio, K; Terashima, T; Bando, Y; Takano, M				Chong, I; Hiroi, Z; Izumi, M; Shimoyama, J; Nakayama, Y; Kishio, K; Terashima, T; Bando, Y; Takano, M			High critical-current density in the heavily Pb-doped Bi2Sr2CaCu2O8+delta superconductor: Generation of efficient pinning centers	SCIENCE			English	Article							HIGH-TC SUPERCONDUCTORS; CU-O SYSTEM; SINGLE-CRYSTALS; ION IRRADIATION; OXIDE SUPERCONDUCTORS; ELECTRON-MICROSCOPY; COLUMNAR DEFECTS; BI; TEMPERATURE; VORTICES	Critical-current density (J(c)) is a parameter of primary importance for potential applications of high-temperature copper oxide superconductors. It is limited principally by the breakdown of zero-resistive current due to thermally activated flux flow at high temperatures and high magnetic fields. One promising method to overcome this limitation is to introduce efficient pinning centers into crystals that can suppress the flux flow, A marked increase in J(c) was observed in B(2)iSr(2)CaCu(2)O(8+delta) (Bi-2212) single crystals doped with a large amount of Pb. By electron microscopy, characteristic microstructures were revealed that probably underlie the observed enhancement in J(c): thin (10 to 50 nanometers), platelike domains having a modulation-free structure appeared with spacings of 50 to 100 nanometers along the b axis.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN; UNIV TOKYO,DEPT APPL CHEM,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Kishio, Kohji/AAL-2904-2020	Nakayama, Yuri/0000-0003-1705-5078; Kishio, Kohji/0000-0002-2759-8618				BEAN CP, 1964, REV MOD PHYS, V36, P31, DOI 10.1103/RevModPhys.36.31; BISHOP DJ, 1992, SCIENCE, V255, P165, DOI 10.1126/science.255.5041.165; BLATTER G, 1994, REV MOD PHYS, V66, P1125, DOI 10.1103/RevModPhys.66.1125; BRANDT EH, 1989, PHYS REV LETT, V63, P1106, DOI 10.1103/PhysRevLett.63.1106; CIVALE L, 1991, PHYS REV LETT, V67, P648, DOI 10.1103/PhysRevLett.67.648; CLEM JR, 1991, PHYS REV B, V43, P7837, DOI 10.1103/PhysRevB.43.7837; Fournier P, 1996, PHYSICA C, V257, P291, DOI 10.1016/0921-4534(95)00671-0; FUKUSHIMA N, 1989, PHYSICA C, V159, P777, DOI 10.1016/0921-4534(89)90148-2; GAMMEL PL, 1988, PHYS REV LETT, V61, P1666, DOI 10.1103/PhysRevLett.61.1666; GERHAUSER W, 1992, PHYS REV LETT, V68, P879, DOI 10.1103/PhysRevLett.68.879; IKEDA Y, 1989, PHYSICA C, V165, P189; ITO H, 1991, J JPN SOC POWDER POW, V38, P171; KADOWAKI K, 1991, 4 INT S SUP ISS 91 T, P395; KISHIO K, 1994, PHYSICA C, V235, P2775, DOI 10.1016/0921-4534(94)92608-5; KLEINER R, 1994, PHYS REV B, V49, P1327, DOI 10.1103/PhysRevB.49.1327; KONCZYKOWSKI M, 1991, PHYS REV B, V44, P7167, DOI 10.1103/PhysRevB.44.7167; KOTAKA Y, 1994, PHYSICA C, V235, P1529, DOI 10.1016/0921-4534(94)91989-5; KUMAKURA H, 1993, J APPL PHYS, V74, P451, DOI 10.1063/1.355279; KUMAKURA H, 1991, APPL PHYS LETT, V58, P2830, DOI 10.1063/1.104749; MAJEWSKI P, 1994, PHYSICA C, V221, P295, DOI 10.1016/0921-4534(94)90235-6; MATSUI Y, 1988, JPN J APPL PHYS 2, V27, pL361, DOI 10.1143/JJAP.27.L361; MOCHIKU T, 1996, BISMUTH BASED HIGH T, P227; Pradhan AK, 1996, PHYS REV B, V53, P2269, DOI 10.1103/PhysRevB.53.2269; TAKANO M, 1988, JPN J APPL PHYS 2, V27, pL1041, DOI 10.1143/JJAP.27.L1041; TALLON JL, 1989, PHYSICA C, V158, P247, DOI 10.1016/0921-4534(89)90325-0; THOMPSON JR, 1992, APPL PHYS LETT, V60, P2306, DOI 10.1063/1.107012; WERDER DJ, 1989, J MATER RES, V4, P748, DOI 10.1557/JMR.1989.0748; YANG G, 1993, PHYS REV B, V48, P4054, DOI 10.1103/PhysRevB.48.4054; Yang PD, 1996, SCIENCE, V273, P1836, DOI 10.1126/science.273.5283.1836	29	191	192	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					770	773		10.1126/science.276.5313.770	http://dx.doi.org/10.1126/science.276.5313.770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115196				2022-12-28	WOS:A1997WW90000050
J	Waxman, HS				Waxman, HS			The patient as physician	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Waxman, HS (corresponding author), AMER COLL PHYSICIANS, INDEPENDENCE MALL W, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA.								0	1	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					656	657		10.7326/0003-4819-126-8-199704150-00013	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103136				2022-12-28	WOS:A1997WT58000015
J	Gabrieli, JDE; Brewer, JB; Desmond, JE; Glover, GH				Gabrieli, JDE; Brewer, JB; Desmond, JE; Glover, GH			Separate neural bases of two fundamental memory processes in the human medial temporal lobe	SCIENCE			English	Article							HIPPOCAMPAL-FORMATION; CORTICAL AFFERENTS; ALZHEIMERS-DISEASE; ENTORHINAL CORTEX; HUMAN BRAIN; IMPAIRMENT; MONKEYS; LESIONS; TRANSECTION; RECOGNITION	The participation of medial temporal-lobe structures in memory performance was examined by functional magnetic resonance imaging of local blood oxygenation level-dependent signals. Signals were measured during encoding into memory complex scenes or line drawings and during retrieval from memory of previously studied line drawings or words. Encoding tasks yielded increased signals for unfamiliar information in a posterior medial-temporal region that were focused in the parahippocampal cortex. Retrieval tasks yielded increased signals for successfully remembered information in an anterior medial-temporal region that were focused in the subiculum. These results indicate that separate components of the human medial temporal-lobe memory system are active during distinct memory processes.	STANFORD UNIV,PROGRAM NEUROSCI,STANFORD,CA 94305; STANFORD UNIV,DEPT RADIOL,STANFORD,CA 94305	Stanford University; Stanford University	Gabrieli, JDE (corresponding author), STANFORD UNIV,DEPT PSYCHOL,STANFORD,CA 94305, USA.		Gabrieli, John/AAJ-2869-2020		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Amaral DG, 1990, HUMAN NERVOUS SYSTEM, P711; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; DAVIES DC, 1988, NEUROSCI LETT, V94, P228, DOI 10.1016/0304-3940(88)90300-X; Duvernoy HM, 1988, HUMAN HIPPOCAMPUS; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; GAFFAN D, 1994, EXP BRAIN RES, V99, P411; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; INSAUSTI R, 1987, J COMP NEUROL, V264, P356, DOI 10.1002/cne.902640306; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JARRARD LE, 1990, PSYCHOBIOLOGY, V18, P68; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEONARD BW, 1995, J NEUROSCI, V15, P5637; MANDLER G, 1980, PSYCHOL REV, V87, P252, DOI 10.1037/0033-295X.87.3.252; MEUNIER M, 1993, J NEUROSCI, V13, P5418, DOI 10.1523/JNEUROSCI.13-12-05418.1993; Murray EA, 1996, SEMIN NEUROSCI, V8, P13, DOI 10.1006/smns.1996.0003; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; Nyberg L, 1996, NATURE, V380, P715, DOI 10.1038/380715a0; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P4355; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	34	457	462	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					264	266		10.1126/science.276.5310.264	http://dx.doi.org/10.1126/science.276.5310.264			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092477				2022-12-28	WOS:A1997WT92500048
J	Maroto, M; Reshef, R; Munsterberg, AE; Koester, S; Goulding, M; Lassar, AB				Maroto, M; Reshef, R; Munsterberg, AE; Koester, S; Goulding, M; Lassar, AB			Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue	CELL			English	Article							BHLH GENE-EXPRESSION; RETROVIRAL VECTORS; MUSCLE DEVELOPMENT; SKELETAL-MUSCLE; SONIC HEDGEHOG; AVIAN EMBRYOS; CHICK-EMBRYO; FLOOR PLATE; SOMITE; CELLS	To understand how the skeletal muscle lineage is induced during vertebrate embryogenesis, we have sought to identify the regulatory molecules that mediate induction of the myogenic regulatory factors MyoD and Myf-5. In this work, we demonstrate that either signals from the overlying ectoderm or Wnt and Sonic hedgehog signals can induce semitic expression of the paired box transcription factors, Pax-3 and Pax-7, concomitant with expression of Myf-5 and prior to that of MyoD. Moreover, infection of embryonic tissues in vitro with a retrovirus encoding Pax-3 is sufficient to induce expression of MyoD, Myf-5, and myogenin in both paraxial and lateral plate mesoderm in the absence of inducing tissues as well as in the neural tube. Together, these findings imply that Pax-3 may mediate activation of MyoD and Myf-5 in response to muscle-inducing signals from either the axial tissues or overlying ectoderm and identify Pax-3 as a key regulator of semitic myogenesis.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; SALK INST BIOL STUDIES, MOL NEUROBIOL LAB, LA JOLLA, CA 92037 USA	Harvard University; Harvard Medical School; Salk Institute			Munsterberg, Andrea E/E-2205-2011	Munsterberg, Andrea E/0000-0002-4577-4240				BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cossu G, 1996, DEVELOPMENT, V122, P429; Daston G, 1996, DEVELOPMENT, V122, P1017; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; Gamel AJ, 1995, DEV BIOL, V172, P625, DOI 10.1006/dbio.1995.8028; GEORGEWEINSTEIN M, 1994, EXP CELL RES, V211, P263, DOI 10.1006/excr.1994.1086; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KAEHN K, 1988, ANAT EMBRYOL, V177, P191, DOI 10.1007/BF00321131; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KRENN V, 1988, ANAT EMBRYOL, V179, P49, DOI 10.1007/BF00305099; MUNSTERBERG AE, 1995, DEVELOPMENT, V121, P651; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; POURQUIE O, 1995, P NATL ACAD SCI USA, V92, P3219, DOI 10.1073/pnas.92.8.3219; Pownall ME, 1996, DEVELOPMENT, V122, P1475; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; STERN HM, 1995, DEVELOPMENT, V121, P3675; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tremblay P, 1996, DEVELOPMENT, V122, P2555; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; Weinberg ES, 1996, DEVELOPMENT, V122, P271; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YANG XM, 1996, CELL, V122, P2171	44	357	359	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					139	148		10.1016/S0092-8674(00)80190-7	http://dx.doi.org/10.1016/S0092-8674(00)80190-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094722	Bronze			2022-12-28	WOS:A1997WR68500017
J	Waite, JH; Gladstone, GR; Lewis, WS; Drossart, P; Cravens, TE; Maurellis, AN; Mauk, BH; Miller, S				Waite, JH; Gladstone, GR; Lewis, WS; Drossart, P; Cravens, TE; Maurellis, AN; Mauk, BH; Miller, S			Equatorial X-ray emissions: Implications for Jupiter's high exospheric temperatures	SCIENCE			English	Article							JOVIAN AURORAL ELECTRONS; UPPER-ATMOSPHERE; RADIO SCIENCE; PRECIPITATION; THERMOSPHERE; IONOSPHERE; VOYAGER-1; PROFILES; PLANETS; OXYGEN	Observations with the High Resolution Imager on the Rontgensatellit reveal x-ray emissions from Jupiter's equatorial latitudes. The observed emissions probably result from the precipitation of energetic (>300 kiloelectron volts per atomic mass unit) sulfur and oxygen ions out of Jupiter's inner radiation belt, Model calculations of the energy deposition by such heavy ion precipitation and of the resulting atmospheric heating rates indicate that this energy source can contribute to the high exospheric temperatures (>800 kelvin at 0.01 microbar) measured by the Galileo probe's Atmospheric Structure Instrument. Low-latitude energetic particle precipitation must therefore be considered, in addition to other proposed mechanisms such as gravity waves and soft electron precipitation, as an important source of heat for Jupiter's thermosphere.	OBSERV PARIS,DESPA,F-92195 MEUDON,FRANCE; UNIV KANSAS,DEPT PHYS & ASTRON,LAWRENCE,KS 66045; JOHNS HOPKINS UNIV,APPL PHYS LAB,LAUREL,MD 20723; UNIV LONDON UNIV COLL,DEPT HIST PHILOSOPHY & COMMUN SCI,LONDON WC1E 6BT,ENGLAND	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Kansas; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University of London; University College London	Waite, JH (corresponding author), SW RES INST,DEPT SPACE SCI,POB 28510,SAN ANTONIO,TX 78228, USA.		Drossart, Pierre/H-8670-2013; Mauk, Barry H/E-8420-2017	Mauk, Barry H/0000-0001-9789-3797; Miller, Steven/0000-0002-7159-6871				APPLEBY JF, 1990, ICARUS, V85, P355, DOI 10.1016/0019-1035(90)90123-Q; ATREYA SK, 1976, JUPITER, P304; BALLESTER GE, 1994, ICARUS, V107, P189, DOI 10.1006/icar.1994.1015; BARBOSA DD, 1990, J GEOPHYS RES-SPACE, V95, P14969, DOI 10.1029/JA095iA09p14969; BROADFOOT AL, 1981, J GEOPHYS RES-SPACE, V86, P8259, DOI 10.1029/JA086iA10p08259; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; CRAVENS TE, 1995, J GEOPHYS RES-SPACE, V100, P17153, DOI 10.1029/95JA00970; CRAVENS TE, 1987, J GEOPHYS RES, V92, P11083, DOI 10.1029/JA092iA10p11083; DAVID LP, 1995, ROSAT HIGH RESOLUTIO, P6; DROSSART P, 1993, J GEOPHYS RES-PLANET, V98, P18803, DOI 10.1029/93JE01801; Encrenaz T, 1996, ASTRON ASTROPHYS, V315, pL397; ESHLEMAN VR, 1979, SCIENCE, V204, P976, DOI 10.1126/science.204.4396.976; ESHLEMAN VR, 1979, SCIENCE, V206, P959, DOI 10.1126/science.206.4421.959; Fischer HM, 1996, SCIENCE, V272, P856, DOI 10.1126/science.272.5263.856; FRENCH RG, 1974, J ATMOS SCI, V31, P1707, DOI 10.1175/1520-0469(1974)031<1707:WITJUA>2.0.CO;2; GEHRELS N, 1983, J GEOPHYS RES-SPACE, V88, P5537, DOI 10.1029/JA088iA07p05537; Gladstone GR, 1996, ICARUS, V119, P1, DOI 10.1006/icar.1996.0001; HANLEY HJM, 1970, J RES NBS A PHYS CH, VA 74, P331, DOI 10.6028/jres.074A.029; HENRY RJW, 1969, J ATMOS SCI, V26, P912, DOI 10.1175/1520-0469(1969)026<0912:TAOEUS>2.0.CO;2; HORANYI M, 1988, J GEOPHYS RES, V93, P7251, DOI 10.1029/JA093iA07p07251; HUNTEN DM, 1977, PLANET SPACE SCI, V23, P817; LAM HA, 1995, THESIS U COLLEGE LON; Lanzerotti L. J., 1974, PARTICLE DIFFUSION R, DOI DOI 10.1007/978-3-642-65675-0; LIVENGOOD TA, 1992, ICARUS, V97, P26, DOI 10.1016/0019-1035(92)90055-C; Mauk BH, 1996, J GEOPHYS RES-SPACE, V101, P7685, DOI 10.1029/96JA00006; METZGER AE, 1983, J GEOPHYS RES-SPACE, V88, P7731, DOI 10.1029/JA088iA10p07731; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; Seiff A, 1997, SCIENCE, V276, P102, DOI 10.1126/science.276.5309.102; SOMMERIA J, 1995, ICARUS, V119, P2; SPELDVIK WN, 1985, HDB GEOPHYSICS SPACE; STROBEL DF, 1973, J ATMOS SCI, V30, P718, DOI 10.1175/1520-0469(1973)030<0718:OTTOTJ>2.0.CO;2; Waite J. H.  Jr., 1996, Rontgenstrahlung from the Universe. International Conference on X-Ray Astronomy and Astrophysics. Conference Proceedings (MPE Report 263), P641; WAITE JH, 1988, J GEOPHYS RES, V93, P7244, DOI 10.1029/JA093iA07p07244; WAITE JH, 1983, J GEOPHYS RES-SPACE, V88, P6143, DOI 10.1029/JA088iA08p06143; WAITE JH, 1991, J GEOPHYS RES-SPACE, V96, P19529, DOI 10.1029/91JA02143; WAITE JH, 1995, SCIENCE, V268, P1598, DOI 10.1126/science.268.5217.1598; WAITE JH, 1981, THESIS U MICHIGAN AN; WAITE JH, 1994, J GEOPHYS RES, V99, P14788; WAITED JH, 1996, 31 COSPAR SIC ASS BI; Yelle RV, 1996, J GEOPHYS RES-PLANET, V101, P2149, DOI 10.1029/95JE03384; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837	41	83	83	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					104	108		10.1126/science.276.5309.104	http://dx.doi.org/10.1126/science.276.5309.104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082978				2022-12-28	WOS:A1997WR38600056
J	Fleming, MF; Barry, KL; Manwell, LB; Johnson, K; London, R				Fleming, MF; Barry, KL; Manwell, LB; Johnson, K; London, R			Brief physician advice for problem alcohol drinkers - A randomized controlled trial in community-based primary care practices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-REPORT ISSUES; OF-THE-ART; FUTURE-DIRECTIONS; GENERAL-PRACTICE; INTERVENTION; VALIDITY; QUESTIONNAIRE; CONSUMPTION; RELIABILITY; DRINKING	Objective.-Project TrEAT (Trial for Early Alcohol Treatment) was designed to test the efficacy of brief physician advice in reducing alcohol use and health care utilization in problem drinkers. Design.-Randomized controlled clinical trial with 12-month follow-up. Setting.-A total of 17 community-based primary care practices (64 physicians) located in 10 Wisconsin counties. Participants.-Of the 17 695 patients screened for problem drinking, 482 men and 292 women met inclusion criteria and were randomized into a control (n=382) or an experimental (n=392) group. A total of 723 subjects (93%) participated in the 12-month follow-up procedures. Intervention.-The intervention consisted of two 10- to 15-minute counseling visits delivered by physicians using a scripted workbook that included advice, education, and contracting information. Main Outcome Measures.-Alcohol use measures, emergency department visits, and hospital days. Results.-There were no significant differences between groups at baseline on alcohol use, age, socioeconomic status, smoking status, rates of depression or anxiety, frequency of conduct disorders, lifetime drug use, or health care utilization. At the time of the 12-month follow-up, there were significant reductions in 7-day alcohol use (mean number of drinks in previous 7 days decreased from 19.1 at baseline to 11.5 at 12 months for the experimental group vs 18.9 at baseline to 15.5 at 12 months for controls; t=4.33; P<.001), episodes of binge drinking (mean number of binge drinking episodes during previous 30 days decreased from 5.7 at baseline to 3.1 at 12 months for the experimental group vs 5.3 at baseline to 4.2 at 12 months for controls; t=2.81; P<.001), and frequency of excessive drinking (percentage drinking excessively in previous 7 days decreased from 47.5% at baseline to 17.8% at 12 months for the experimental group vs 48.1% at baseline to 32.5% at 12 months for controls; t=4.53; P<.001). The chi(2) test of independence revealed a significant relationship between group status and length of hospitalization over the study period for men (P<.01). Conclusions.-This study provides the first direct evidence that physician intervention with problem drinkers decreases alcohol use and health resource utilization in the US health care system.	UNIV WISCONSIN, SCH MED, DEPT FAMILY MED, MADISON, WI USA; UNIV WISCONSIN, SCH MED, CTR ADDICT RES & EDUC, MADISON, WI USA; UNIV MICHIGAN, DEPT VET AFFAIRS, SERIOUS MENTAL ILLNESS TREATMENT RES & EVALUAT CT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PSYCHIAT, ANN ARBOR, MI 48109 USA; FAMILY HLTH PLAN COOPERAT, MILWAUKEE, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008512] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 08512-01A] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; [Anonymous], 1996, Am J Public Health, V86, P948; BABOR TF, 1990, CAN MED ASSOC J, V143, P1070; BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; CHICK J, 1991, ALCOHOL ALCOHOLISM, P477; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FLEMING MF, 1991, ALCOHOL ALCOHOLISM, V26, P81; HEATHER N, 1987, J ROY COLL GEN PRACT, V37, P358; HOLDER HD, 1992, J STUD ALCOHOL, V53, P293, DOI 10.15288/jsa.1992.53.293; *I MED, 1996, COMM STUD FET ALC SY; KAHAN M, 1995, CAN MED ASSOC J, V152, P851; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; MAISTO SA, 1990, BEHAV ASSESS, V12, P117; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; Miller W R, 1987, Recent Dev Alcohol, V5, P425; Moos RH., 1994, FAMILY ENV SCALE MAN, V3; *NAT I ALC ABUS AL, 1995, NIH PUBL; RICE DP, 1983, VITAL HLTH STATE, V23, P1; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; *US HHS, 1993, PUBL US DEP HLTH HUM; WALLACE P, 1985, BRIT MED J, V290, P1949, DOI 10.1136/bmj.290.6486.1949; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663	28	654	660	1	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1039	1045						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WQ089	9091691				2022-12-28	WOS:A1997WQ08900028
J	Curhan, GC; Willett, WC; Speizer, FE; Spiegelman, D; Stampfer, MJ				Curhan, GC; Willett, WC; Speizer, FE; Spiegelman, D; Stampfer, MJ			Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women	ANNALS OF INTERNAL MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; OXALATE NEPHROLITHIASIS; EXCRETION; FORMERS; REPRODUCIBILITY; HYPERCALCIURIA; MAGNESIUM; VALIDITY	Background: Calcium intake is believed to play an important role in the formation of kidney stones, but data on the risk factors for stone formation in women are limited. Objective: To examine the association between intake of dietary and supplemental calcium and the risk for kidney stones in women. Design: Prospective cohort study with 12-year follow-up. Setting: Several U.S. states. Participants: 91 731 women participating in the Nurses' Health Study I who were 34 to 59 years of age in 1980 and had no history of kidney stones, Measurements: Self-administered food-frequency questionnaires were used to assess diet in 1980, 1984, 1986, and 1990. The main outcome measure was incident symptomatic kidney stones. Results: During 903 849 person-years of follow-up, 864 cases of kidney stones were documented. After adjustment for potential risk factors, intake of dietary calcium was inversely associated with risk for kidney stones and intake of supplemental calcium was positively associated with risk. The relative risk for stone formation in women in the highest quintile of dietary calcium intake compared with women in the lowest quintile was 0.65 (95% CI, 0.50 to 0.83). The relative risk in women who took supplemental calcium compared with women who did not was 1.20 (CI, 1.02 to 1.41), In 67% of women who took supplemental calcium, the calcium either was not consumed with a meal or was consumed with meals whose oxalate content was probably low. Other dietary factors showed the following relative risks among women in the highest quintile of intake compared with those in the lowest quintile: sucrose, 1.52 (CI, 1.18 to 1.96); sodium, 1.30 (CI, 1.05 to 1.62); fluid, 0.61 (CI, 0.48 to 0.78); and potassium, 0.65 (CI, 0.51 to 0.84). Conclusions: High intake of dietary calcium appears to decrease risk for symptomatic kidney stones, whereas intake of supplemental calcium may increase risk. Because dietary calcium reduces the absorption of oxalate, the apparently different effects caused by the type of calcium may be associated with the timing of calcium ingestion relative to the amount of oxalate consumed. However, other factors present in dairy products (the major source of dietary calcium) could be responsible for the decreased risk seen with dietary calcium.	BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CAMBRIDGE, MA 02138 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Massachusetts General Hospital	Curhan, GC (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NCI NIH HHS [CA55075, CA40356] Funding Source: Medline; NIDDK NIH HHS [DK45362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356, P01CA055075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, JAMA, V272, P1942; BARILLA DE, 1978, AM J MED, V64, P579, DOI 10.1016/0002-9343(78)90576-4; BATAILLE P, 1983, J UROLOGY, V130, P218, DOI 10.1016/S0022-5347(17)51073-3; BATAILLE P, 1991, KIDNEY INT, V39, P1193, DOI 10.1038/ki.1991.151; BORSATTI A, 1991, KIDNEY INT, V39, P1283, DOI 10.1038/ki.1991.162; BRESLAU NA, 1995, J BONE MINER RES, V10, P394; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; CARROLI G, 1994, BRIT J OBSTET GYNAEC, V101, P753, DOI 10.1111/j.1471-0528.1994.tb11940.x; COE FL, 1976, J CHRON DIS, V29, P793, DOI 10.1016/0021-9681(76)90053-9; COE FL, 1988, NEPHROLOLITHIASIS PA; Colditz G A, 1995, J Am Med Womens Assoc (1972), V50, P40; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; GOLDFARB S, 1988, KIDNEY INT, V34, P544, DOI 10.1038/ki.1988.216; HIATT RA, 1982, AM J EPIDEMIOL, V115, P255, DOI 10.1093/oxfordjournals.aje.a113297; JOHANSSON G, 1980, J UROLOGY, V124, P770, DOI 10.1016/S0022-5347(17)55655-4; JOHNSON CM, 1979, KIDNEY INT, V16, P624, DOI 10.1038/ki.1979.173; LARSSON L, 1987, MINER ELECTROL METAB, V13, P242; LEMANN J, 1993, NEW ENGL J MED, V328, P880, DOI 10.1056/NEJM199303253281212; LEMANN J, 1991, KIDNEY INT, V39, P973, DOI 10.1038/ki.1991.123; LEMANN J, 1969, NEW ENGL J MED, V280, P232, DOI 10.1056/NEJM196901302800502; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARSHALL RW, 1972, CLIN SCI, V43, P91, DOI 10.1042/cs0430091; MULDOWNEY FP, 1982, KIDNEY INT, V22, P292, DOI 10.1038/ki.1982.168; PAK CYC, 1986, ANN INTERN MED, V104, P33, DOI 10.7326/0003-4819-104-1-33; RAO PN, 1982, BRIT J UROL, V54, P578, DOI 10.1111/j.1464-410X.1982.tb13600.x; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROBERTSON WG, 1979, J CHRON DIS, V32, P469, DOI 10.1016/0021-9681(79)90107-3; Rothman K, 1986, MODERN EPIDEMIOLOGY; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; ZAREMBSK.PM, 1969, CLIN CHIM ACTA, V25, P1, DOI 10.1016/0009-8981(69)90218-6	33	454	471	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					497	+		10.7326/0003-4819-126-7-199704010-00001	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092314				2022-12-28	WOS:A1997WQ19500010
J	Nakayama, JI; Saito, M; Nakamura, H; Matsuura, A; Ishikawa, F				Nakayama, JI; Saito, M; Nakamura, H; Matsuura, A; Ishikawa, F			TLP1: A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; TETRAHYMENA TELOMERASE; CHROMATIN STRUCTURE; MOUSE TELOMERASE; END-REPLICATION; RNA COMPONENT; DNA; SEQUENCES; TEMPLATE	We have cloned and characterized the rat telomerase protein component 1 gene (TLP1), which is related to the gene for Tetrahymena p80. The cDNA encodes a 2629 amino acid sequence and produces the TLP1 proteins p240 and p230. The anti-TLP1 antibody specifically immunoprecipitated the telomerase activity. Moreover, p240 and p230 were copurified with telomerase activity in a series of extensive purification experiments. These results strongly suggest that the TLP1 proteins are components of, or are closely associated with, the rat telomerase. A pulse-chase experiment showed that p240 is modified to p230 in vivo. p230 was the dominant form in telomerase-positive cells, suggesting that modification of the TLP1 protein may regulate telomerase activity in vivo.	MITSUBISHI CHEM CORP,YOKOHAMA RES CTR,PHARMACEUT LAB 2,AOBA KU,YOKOHAMA,KANAGAWA 227,JAPAN	Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Nakayama, JI (corresponding author), TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,4259 NAGATSUTA,YOKOHAMA,KANAGAWA 226,JAPAN.		Matsuura, Akira/J-3864-2017; Matsuura, Akira/AAO-1572-2021; Nakayama, Jun-ichi/C-6003-2011	Matsuura, Akira/0000-0002-2300-7227; Matsuura, Akira/0000-0002-2300-7227; Nakayama, Jun-ichi/0000-0002-5597-8239; Ishikawa, Fuyuki/0000-0002-5580-2305				Avilion AA, 1996, CANCER RES, V56, P645; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FANG G, 1995, TELOMERES, P69; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HO PLC, 1994, SCIENCE, V266, P2011; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RILEY JH, 1994, CURRENT PROTOCOLS HU; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tatematsu K, 1996, ONCOGENE, V13, P2265; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	47	366	389	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					875	884		10.1016/S0092-8674(00)81933-9	http://dx.doi.org/10.1016/S0092-8674(00)81933-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118230	Bronze			2022-12-28	WOS:A1997WQ10000019
J	Hattersley, AT				Hattersley, AT			Genes versus environment in insulin-dependent diabetes: The phoney war	LANCET			English	Editorial Material							MELLITUS				Hattersley, AT (corresponding author), POSTGRAD MED SCH,DEPT VASC MED & DIABET RES,EXETER EX2 5AX,DEVON,ENGLAND.			Hattersley, Andrew/0000-0001-5620-473X				CUCCA F, 1993, HUM IMMUNOL, V37, P85, DOI 10.1016/0198-8859(93)90146-R; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DORMAN JS, 1990, P NATL ACAD SCI USA, V87, P7370, DOI 10.1073/pnas.87.19.7370; FRAYLING T, IN PRESS DIABETES; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; Lounamaa R., 1996, BAILLIERES CLIN PAED, V4, P609; TODD JA, 1995, P NATL ACAD SCI USA, V92, P8560, DOI 10.1073/pnas.92.19.8560; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					147	148		10.1016/S0140-6736(05)60972-5	http://dx.doi.org/10.1016/S0140-6736(05)60972-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111533				2022-12-28	WOS:A1997WC86100003
J	Kushi, LH; Fee, RM; Folsom, AR; Mink, PJ; Anderson, KE; Sellers, TA				Kushi, LH; Fee, RM; Folsom, AR; Mink, PJ; Anderson, KE; Sellers, TA			Physical activity and mortality in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; UNITED-STATES RAILROAD; CARDIOVASCULAR-DISEASE; FOLLOW-UP; OLDER ADULTS; RISK; MEN; FITNESS; HEALTH; DEATH	Objective.-To evaluate the association between physical activity and all-cause mortality in postmenopausal women. Design.-Prospective cohort study with 7 years of follow-up through December 31, 1992. Setting and Participants.-Subjects were 40 417 postmenopausal Iowa women, aged 55 to 69 years at baseline in 1986. Physical activity was assessed by mailed questionnaire. Main Outcome Measure.-All-cause mortality (n=2260). Results.-After adjustment for potential confounders and excluding women who reported having cancer or heart disease and those who died in the first 3 years of follow-up, women who reported regular physical activity were at significantly reduced risk of death during follow-up compared with women who did not (relative risk [RR], 0.77; 95% confidence interval [CI], 0.66-0.90). Increasing frequency of moderate physical activity was associated with reduced risk of death during followup (from rarely or never engaging in activity to activity at least 4 times per week, RRs, 1.0 [referent], 0.76, 0.70, and 0.62; P value for trend < .001). A similar pattern was seen for vigorous physical activity (corresponding RRs, 1.0, 0.89, 0.74, and 0.57; P value for trend = .06). Reduced risks of death with increased physical activity were evident for cardiovascular diseases (n = 729) and respiratory illnesses (n = 147). Women who engaged only in moderate but not vigorous physical activity also benefited, with moderate activity as infrequently as once per week demonstrating a reduced mortality risk of 0.78 (95% CI, 0.64-0.96). Conclusions.-These results demonstrate a graded, inverse association between physical activity and all-cause mortality in postmenopausal women. These findings strengthen the confidence that population recommendations to engage in regular physical activity are applicable to postmenopausal women.			Kushi, LH (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Kushi, Lawrence/0000-0001-9136-1175	NCI NIH HHS [CA 39742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CHANGCLAUDE J, 1993, INT J EPIDEMIOL, V22, P228, DOI 10.1093/ije/22.2.228; DAVIS MA, 1994, PREV MED, V23, P369, DOI 10.1006/pmed.1994.1051; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; *GALL POLL, 1988, PUBL OP 1987, P316; HARRIS SS, 1989, JAMA-J AM MED ASSOC, V261, P3588, DOI 10.1001/jama.261.24.3588; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LEE DJ, 1990, J GERONTOL, V45, pS39, DOI 10.1093/geronj/45.1.S39; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LEON AS, 1991, INT J EPIDEMIOL, V20, P690, DOI 10.1093/ije/20.3.690; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; MARCUS R, 1992, MED SCI SPORT EXER, V24, pS301; Mensink GBM, 1996, EPIDEMIOLOGY, V7, P391, DOI 10.1097/00001648-199607000-00009; PAFFENBARGER RS, 1991, ANN MED, V23, P319, DOI 10.3109/07853899109148067; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P325; RAKOWSKI W, 1992, J GERONTOL, V47, pM122, DOI 10.1093/geronj/47.4.M122; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHERMAN SE, 1994, AM HEART J, V128, P879, DOI 10.1016/0002-8703(94)90583-5; SHERMAN SE, 1993, AM HEART J, V83, P1443; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; STENDER M, 1993, INT J EPIDEMIOL, V22, P644, DOI 10.1093/ije/22.4.644; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; WEYERER S, 1993, PERCEPT MOTOR SKILL, V77, P499, DOI 10.2466/pms.1993.77.2.499	33	271	276	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1287	1292		10.1001/jama.277.16.1287	http://dx.doi.org/10.1001/jama.277.16.1287			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109466				2022-12-28	WOS:A1997WU13500028
J	Kharbanda, S; Pandey, P; Jin, SF; Inoue, S; Bharti, A; Yuan, ZM; Weichselbaum, R; Weaver, D; Kufe, D				Kharbanda, S; Pandey, P; Jin, SF; Inoue, S; Bharti, A; Yuan, ZM; Weichselbaum, R; Weaver, D; Kufe, D			Functional interaction between DNA-PK and c-Abl in response to DNA damage	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; STRAND-BREAK REPAIR; V(D)J RECOMBINATION; TYROSINE KINASE; KU-AUTOANTIGEN; SH3 DOMAINS; COMPLEMENTATION; SENSITIVITY; BINDING; ANTIGEN	How DNA damage is converted into intracellular signals that can control cell behaviour is unknown. The c-Abl protein tyrosine kinase is activated by ionizing radiation and certain other DNA-damaging agents(1-5), whereas the DNA-dependent protein kinase (DNA-PK), consisting of a serine/threonine kinase and Ku DNA-binding subunits, requires DNA double-strand breaks or other DNA lesions for activation(6-8). Here we demonstrate that c-Abl interacts constitutively with DNA-PK. Ionizing radiation stimulates binding of c-Abl to DNA-PK and induces an association of c-Abl with Ku antigen. We show that DNA-PK phosphorylates and activates c-Abl in vitro. Cells deficient in DNA-PK are defective in c-Abl activation induced by ionizing radiation. In a potential feedback mechanism, c-Abl phosphorylates DNA-PK, but not Ku, in vitro. Phosphorylation of DNA-PK by c-Abl inhibits the ability of DNA-PK to form a complex with DNA. We also show that treatment of cells with ionizing radiation results in phosphorylation of DNA-PK that is dependent on c-Abl. Our results support the hypothesis that there are functional interactions between c-Abl and DNA-PK in the response to DNA damage.	HARVARD UNIV,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; University of Chicago								BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; REN R, 1994, GENE DEV, V8, P73; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	23	224	230	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					732	735		10.1038/386732a0	http://dx.doi.org/10.1038/386732a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109492				2022-12-28	WOS:A1997WU38700060
J	Yates, CR; Krynetski, EY; Loennechen, T; Fessing, MY; Tai, HL; Pui, CH; Relling, MV; Evans, WE				Yates, CR; Krynetski, EY; Loennechen, T; Fessing, MY; Tai, HL; Pui, CH; Relling, MV; Evans, WE			Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance	ANNALS OF INTERNAL MEDICINE			English	Article						thiopurine; S-methyltransferase deficiency; azathioprine; mercaptopurine; thioguanine; pharmacogenetics	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEART-TRANSPLANT RECIPIENT; INDUCED MYELOSUPPRESSION; 6-MERCAPTOPURINE; PHARMACOGENETICS; DISEASE	Background: Thiopurine 5-methyltransferase (TPMT) catalyzes the S-methylation (that is, inactivation) of mercaptopurine, azathioprine, and thioguanine and exhibits genetic polymorphism. About 10% of patients have intermediate TPMT activity because of heterozygosity, and about 1 in 300 inherit TPMT deficiency as an autosomal recessive trait. if they receive standard doses of thiopurine medications (for example, 75 mg/m(2) body surface area per day), TPMT-deficient patients accumulate excessive thioguanine nucleotides in hematopoietic tissues, which leads to severe and possibly fatal myelosuppression. Objective: To elucidate the genetic basis and develop molecular methods for the diagnosis of TPMT deficiency and heterozygosity. Design: Diagnostic test evaluation. Setting: Research hospital. Patients: The TPMT phenotype was determined in 282 unrelated white persons, and TPMT genotype was determined in all persons who had intermediate TPMT activity (heterozygotes) and a randomly selected, equal number of persons who had high activity. In addition, genotype was determined in 6 TPMT-deficient patients. Measurements: Polymerase chain reaction (PCR) assays were developed to detect the G238C transversion in TPMT*Z and the G460A and A719G transitions in TPMT*3 alleles; Radiochemical assay was used to measure TPMT activity. Mutations of TPMT were identified in genomic DNA, and the concordance of TPMT genotype and phenotype was determined. Results: 21 patients who had a heterozygous phenotype were identified (7.4% of sample [95% Cl, 4.7% to 11.2%]). TPMT*3A was the most prevalent mutant allele (18 of 21 mutant alleles in heterozygotes; 85%); TPMT*2 and TPMT*3C were more rare(about: 5% each). All 6 patients who had TPMT deficiency had two mutant alleles, 20 of 21 patients (95% [CI, 76% to 99.9%]) who had intermediate TPMT activity had one mutant allele, and 21 of 21 patients (100% [CI, 83% to 100%]) who had high activity had no known TPMT mutation. Detection of TPMT mutations in genomic DNA by PCR coincided perfectly with genotypes detected by complementary DNA sequencing. Conclusions: The major inactivating mutations at the human TPMT locus have been identified and can be reliably detected by PCR-based methods, which show an excellent concordance between genotype and phenotype. The detection of TPMT mutations provides a molecular diagnostic method for prospectively identifying TPMT-deficient and heterozygous patients.	ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Evans, William E./C-2069-2012; Pui, Ching-Hon/N-8076-2018; Relling, Mary/N-5032-2018	Evans, William E./0000-0002-9333-5322; Pui, Ching-Hon/0000-0003-0303-5658; Fessing, Michael/0000-0002-3120-8707	NATIONAL CANCER INSTITUTE [P01CA020180, R37CA036401, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA20180, R37 CA36401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cosi V, 1993, Acta Neurol (Napoli), V15, P123; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; GRANT DM, 1993, PHARMACOGENETICS, V3, P45, DOI 10.1097/00008571-199302000-00005; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; HOLLANDER AAMJ, 1995, LANCET, V345, P610, DOI 10.1016/S0140-6736(95)90520-0; JOHNSON PJ, 1995, NEW ENGL J MED, V333, P958, DOI 10.1056/NEJM199510123331502; KERSTENS PJSM, 1994, ANN RHEUM DIS, V53, P608, DOI 10.1136/ard.53.9.608; Kreiner T, 1996, AM LAB, V28, P39; Krynetski EY, 1996, PHARMACOGENETICS, V6, P279, DOI 10.1097/00008571-199608000-00001; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; LEE D, 1995, DRUG METAB DISPOS, V23, P398; LENNARD L, 1993, ARCH DIS CHILD, V69, P577, DOI 10.1136/adc.69.5.577; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; MCLEOD HL, 1993, LANCET, V341, P1151, DOI 10.1016/0140-6736(93)93168-Z; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; MILANESE C, 1993, J NEUROL, V240, P295, DOI 10.1007/BF00838165; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; SCHUTZ E, 1993, LANCET, V341, P436, DOI 10.1016/0140-6736(93)93028-Y; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; Tai HL, 1996, AM J HUM GENET, V58, P694; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEINSHILBOUM RM, 1978, CLIN CHIM ACTA, V85, P323, DOI 10.1016/0009-8981(78)90311-X; WILLOUGHBY JM, 1971, LANCET, V2, P944	26	622	660	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					608	+		10.7326/0003-4819-126-8-199704150-00003	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103127				2022-12-28	WOS:A1997WT58000006
J	Mas, A; Rodes, J				Mas, A; Rodes, J			Fulminant hepatic failure	LANCET			English	Article							ACUTE LIVER-FAILURE; CEREBRAL EDEMA; TRANSPLANTATION; COMPLICATION; MANAGEMENT; INFECTION; VIRUS		UNIV BARCELONA, HOSP CLIN & PROV, DEPT MED, LIVER UNIT, E-08036 BARCELONA, SPAIN	University of Barcelona; Hospital Clinic de Barcelona								AGGARWAL S, 1994, HEPATOLOGY, V19, P80, DOI 10.1002/hep.1840190114; BERNUAU J, 1993, LANCET, V342, P252, DOI 10.1016/0140-6736(93)91809-Z; BERNUAU J, 1991, HEPATOLOGY, V14, pA49; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; Bernuau J, 1991, OXFORD TXB CLIN HEPA, P923; BILIARI DJ, 1986, SEMIN LIVER DIS, V6, P119; BISMUTH H, 1995, ANN SURG, V222, P109, DOI 10.1097/00000658-199508000-00002; BISMUTH H, 1987, ANN INTERN MED, V107, P337, DOI 10.7326/0003-4819-107-2-337; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; CARACENI P, 1995, LANCET, V345, P163, DOI 10.1016/S0140-6736(95)90171-X; CASTELLS A, 1993, GASTROENTEROLOGY, V105, P532, DOI 10.1016/0016-5085(93)90731-Q; ChenardNeu MP, 1996, HEPATOLOGY, V23, P1119; DEKNEGT RJ, 1991, NETH J MED, V38, P131; EDE RJ, 1986, SEMIN LIVER DIS, V6, P107, DOI 10.1055/s-2008-1040594; FERENCI P, 1994, J HEPATOL, V21, P487, DOI 10.1016/S0168-8278(94)80090-1; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; GIMSON AES, 1992, THERAPY IN LIVER DISEASES, P407; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; KONDRUP J, 1992, INT J ARTIF ORGANS, V15, P669, DOI 10.1177/039139889201501110; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395; NAVASA M, 1986, GASTROENTEROL HEPATO, V9, P221; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OGRADY JG, 1992, GASTROINTESTINAL EME, P104; ROLANDO N, 1991, J HEPATOL, V12, P1, DOI 10.1016/0168-8278(91)90900-V; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1016/0270-9139(93)90076-Y; Sallie R, 1996, LANCET, V347, P1552, DOI 10.1016/S0140-6736(96)90704-7; SALMERON JM, 1992, J HEPATOL, V14, P280, DOI 10.1016/0168-8278(92)90171-K; SCHAFER DF, 1989, SEMIN LIVER DIS, V9, P189, DOI 10.1055/s-2008-1040512; SHERLOCK S, 1993, ADV INTERNAL MED, V38, P245; SUSSMAN NL, 1996, HEPATOLOGY TXB LIVER, P618; TREY C, 1970, Progress in Liver Diseases, P282; VANTHIEL DH, 1993, J HEPATOL, V17, P1, DOI 10.1016/S0168-8278(05)80512-4; WARE AJ, 1971, GASTROENTEROLOGY, V61, P877; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1016/0270-9139(94)90235-6; WILLIAMS R, 1991, DIGEST DIS SCI, V36, P820, DOI 10.1007/BF01311243; WILLIAMS R, 1995, TREATMENTS HEPATOLOG, P365; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	44	100	112	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	1997	349	9058					1081	1085		10.1016/S0140-6736(96)08054-3	http://dx.doi.org/10.1016/S0140-6736(96)08054-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107258				2022-12-28	WOS:A1997WU00200039
J	Rietschel, RL				Rietschel, RL			Occupational contact dermatitis	LANCET			English	Article							ECZEMA	The two commonest forms of occupational skin disease are irritant and allergic contact dermatitis. Morphology and history are used to establish the diagnosis and the relation of the disorder to work exposure, respectively. Diagnostic patch tests are used to define further the diagnosis and aetiology of the dermatitis.			Rietschel, RL (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT DERMATOL,NEW ORLEANS,LA 70121, USA.							ADAMS RM, 1986, J AM ACAD DERMATOL, V14, P951, DOI 10.1016/S0190-9622(86)70119-9; ADAMS RM, 1990, OCCUPATIONAL SKIN DI; De Groot AC, 1994, PATCH TESTING TEST C; Fregert S, 1975, Contact Dermatitis, V1, P96, DOI 10.1111/j.1600-0536.1975.tb05334.x; Fregert S., 1975, INT CONTACT DERMATIT, P8; HANNUKSELA M, 1987, OCCUPATIONAL IND DER, P168; LANTINGA H, 1984, CONTACT DERMATITIS, V10, P135, DOI 10.1111/j.1600-0536.1984.tb00018.x; MALTEN KE, 1981, CONTACT DERMATITIS, V7, P238, DOI 10.1111/j.1600-0536.1981.tb04059.x; MEDING B, 1990, CONTACT DERMATITIS, V23, P154, DOI 10.1111/j.1600-0536.1990.tb04776.x; MOURSIDEN HT, 1973, T ST JOHNS HOSP DERM, V59, P230; RIETSCHEL, 1988, DERMATOL CLIN, V6, P43; RIETSCHEL RL, 1988, J AM ACAD DERMATOL, V18, P42, DOI 10.1016/S0190-9622(88)70006-7; RIETSCHEL RL, 1995, FISHERS CONTACT DERM, P23; RIETSCHEL RL, 1990, IRRITANT CONTACT DER, P167; RIETSCHELL RL, 1982, J SOC COSMET CHEM, V33, P309; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; WILKINSON M, 1995, J AM ACAD DERMATOL, V33, P963, DOI 10.1016/0190-9622(95)90287-2; [No title captured]	18	8	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1093	1095		10.1016/S0140-6736(96)07216-9	http://dx.doi.org/10.1016/S0140-6736(96)07216-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107260				2022-12-28	WOS:A1997WU00200041
J	Hudson, N				Hudson, N			Excess long-term mortality in patients with ulcer complications	LANCET			English	Editorial Material							PEPTIC-ULCER				Hudson, N (corresponding author), CITY HOSP NHS TRUST,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; HOSKING S W, 1992, Gastroenterology, V102, pA85; HUDSON N, 1995, GUT, V37, P177, DOI 10.1136/gut.37.2.177; JASPERSEN D, 1995, GASTROINTEST ENDOSC, V41, P5, DOI 10.1016/S0016-5107(95)70267-9; KATSCHINSKI BD, 1989, POSTGRAD MED J, V65, P913, DOI 10.1136/pgmj.65.770.913; Kubba AK, 1997, BRIT J SURG, V84, P265; REINBACH DH, 1993, GUT, V34, P1344, DOI 10.1136/gut.34.10.1344; RORBAEKMADSEN M, 1994, SCAND J GASTROENTERO, V29, P983, DOI 10.3109/00365529409094874; Svanes C, 1996, J CLIN EPIDEMIOL, V49, P1363, DOI 10.1016/S0895-4356(96)00278-8; SVANES C, 1993, GUT, V34, P1666, DOI 10.1136/gut.34.12.1666; WALT R, 1986, LANCET, V1, P489; 1974, BRIT MED J, V2, P760	12	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					968	969		10.1016/S0140-6736(05)62889-9	http://dx.doi.org/10.1016/S0140-6736(05)62889-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100620				2022-12-28	WOS:A1997WR62100005
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			An 85-year-old woman with a history of falls, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																			0	0	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					996	996		10.1001/jama.277.12.996	http://dx.doi.org/10.1001/jama.277.12.996			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091674				2022-12-28	WOS:A1997WN99200036
J	StevensSimon, C; Dolgan, JI; Kelly, L; Singer, D				StevensSimon, C; Dolgan, JI; Kelly, L; Singer, D			The effect of monetary incentives and peer support groups on repeat adolescent pregnancies - A randomized trial of the dollar-a-day program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	65th Annual Meeting of the Society-for-Pediatric-Research	MAY 02-10, 1996	WASHINGTON, DC	Soc Pediat Res			TEENAGE MOTHERS; PREVENTION; CHILDBEARING; EDUCATION; CHILDREN; SERVICES; LESSONS; INFANTS; IMPACT; BIRTH	Objectives.-To test the hypotheses that (1) a monetary incentive promotes peer-support group participation; and (2) peer-support group participation decreases repeat adolescent pregnancies. Design.-Two-year, prospective, randomized controlled trial. Setting.-Denver, Cole. Participants.-A total of 286 primiparous girls younger than 18 years, whose infants were younger than 5 months. Intervention.-Participants were randomized to 4 interventions: monetary incentive and peer-support group, peer-support group only, monetary incentive only, or no intervention. Main Outcome Measures.-Consistency of participation in planned intervention and repeat pregnancy. Results.-Participation in interventions was generally low. Hypothesis I was supported: 58% of those offered a monetary incentive participated in the peer-support groups, compared with 9% of those who were not offered the incentive, Hypothesis 2 was rejected: the peer-support group experience failed to prevent repeat pregnancies. The incidence of second pregnancies at 6 months (9%, 22/248), at 12 months (20%, 49/248), at 18 months (29%, 72/248), and at 24 months (39%, 97/248) following delivery did not vary significantly in relation to intervention strategy. Background sociodemographic characteristics significantly affected the timing of subsequent conceptions but not intervention participation. Conclusion.-A monetary incentive draws adolescent mothers to sites where they can discuss the costs and benefits of contraception and conception with knowledgeable adults and supportive peers. These discussions do not prevent repeat pregnancies. Further studies are needed to determine if an intervention that produces substantive changes in the daily living environment will eliminate the sexual practices that are responsible for the high rate of repeat pregnancy in this population.	UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80218; CHILDRENS HOSP,DEPT PSYCHOL & BEHAV SCI,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	StevensSimon, C (corresponding author), UNIV COLORADO,CHILDRENS HOSP,HLTH SCI CTR,DIV ADOLESCENT MED,1056 E 19TH ST,DENVER,CO 80218, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NCRR NIH HHS [5 M01 RR00069] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAHAMSE AF, 1988, FAM PLANN PERSPECT, V20, P13, DOI 10.2307/2135591; BILLEWICZ WZ, 1973, BRIT J PREV SOC MED, V27, P49; BRAYDEN RM, 1993, J PEDIATR-US, V122, P511, DOI 10.1016/S0022-3476(05)83528-0; DEAN AG, 1990, EPI INFO VERSION 5; DOLGAN JI, 1989, DOLLAR A DAY TEENAGE; ERICKSON PI, 1994, FAM PLANN PERSPECT, V26, P174, DOI 10.2307/2136243; FIELD T, 1982, PEDIATRICS, V69, P703; FIRESTONE WA, 1994, FAM PLANN PERSPECT, V26, P125, DOI 10.2307/2136038; FROST JJ, 1995, FAM PLANN PERSPECT, V27, P188, DOI 10.2307/2136274; FURSTENBERG FF, 1987, FAM PLANN PERSPECT, V19, P142, DOI 10.2307/2135159; HERCEGBARON R, 1986, FAM PLANN PERSPECT, V18, P61, DOI 10.2307/2135030; HOWARD M, 1990, FAM PLANN PERSPECT, V22, P21, DOI 10.2307/2135434; HUGHES ME, 1995, FAM PLANN PERSPECT, V27, P60, DOI 10.2307/2135906; KALMUSS DS, 1994, FAM PLANN PERSPECT, V26, P149, DOI 10.2307/2136238; KLERMAN LV, 1993, J ADOLESCENT HEALTH, V14, P553, DOI 10.1016/1054-139X(93)90140-K; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; MATSUHASHI Y, 1989, J ADOLESCENT HEALTH, V10, P409, DOI 10.1016/0197-0070(89)90220-9; Miller B C, 1992, J Fam Econ Issues, V13, P467, DOI 10.1007/BF01018927; Mott FL, 1996, FAM PLANN PERSPECT, V28, P13, DOI 10.2307/2135957; NORUSIS MJ, 1990, STAT PACKAGE SOCIAL; OLDS DL, 1990, PEDIATRICS, V86, P108; Patton GC, 1996, AM J PUBLIC HEALTH, V86, P225, DOI 10.2105/AJPH.86.2.225; RAINEY DY, 1993, AM J DIS CHILD, V147, P1053, DOI 10.1001/archpedi.1993.02160340039010; STEVENSSIMON C, 1994, ARCH PEDIAT ADOL MED, V148, P23, DOI 10.1001/archpedi.1994.02170010025005; STEVENSSIMON C, 1995, J ADOLESCENT HEALTH, V16, P350, DOI 10.1016/S1054-139X(94)00048-J; StevensSimon C, 1996, ARCH PEDIAT ADOL MED, V150, P1037, DOI 10.1001/archpedi.1996.02170350039006; STEVENSSIMON C, 1991, PEDIATR ANN, V20, P322, DOI 10.3928/0090-4481-19910601-09; STEVENSSIMON C, 1993, ADOLESCENT PEDIAT G, V6, P83, DOI 10.1016/S0932-8610(12)80222-2; STEVENSSIMON C, 1995, ARCH PEDIAT ADOL MED, V149, P912, DOI 10.1001/archpedi.1995.02170210086015; STEVENSSIMON C, 1990, J ADOLESCENT HEALTH, V11, P114, DOI 10.1016/0197-0070(90)90019-X; STEVENSSIMON C, 1994, J ADOLESCENT HEALTH, V15, P396, DOI 10.1016/1054-139X(94)90263-1; STEVENSSIMON C, 1989, CLIN PEDIATR, V28, P282, DOI 10.1177/000992288902800609; STEVENSSIMON C, 1995, J MATERN FETAL MED, V4, P186; STEVENSSIMON C, IN PRESS J ADOLESC H; STOUT JW, 1989, PEDIATRICS, V83, P375; Zabin L S, 1993, J Res Adolesc, V3, P67, DOI 10.1207/s15327795jra0301_4; ZABIN LS, 1991, J ADOLESCENT HEALTH, V12, P225, DOI 10.1016/0197-0070(91)90015-E	37	58	59	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					977	982		10.1001/jama.277.12.977	http://dx.doi.org/10.1001/jama.277.12.977			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN992	9091670				2022-12-28	WOS:A1997WN99200032
J	Wright, J; Johns, R; Watt, I; Melville, A; Sheldon, T				Wright, J; Johns, R; Watt, I; Melville, A; Sheldon, T			Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: A systematic review of the research evidence	BRITISH MEDICAL JOURNAL			English	Review							LEFT-VENTRICULAR HYPERTROPHY; CARDIOVASCULAR RISK-FACTORS; AMBULATORY BLOOD-PRESSURE; APNEA HYPOPNEA SYNDROME; NASAL CPAP TREATMENT; LONG-TERM COMPLIANCE; PULMONARY-HYPERTENSION; AUTOMOBILE ACCIDENTS; CARDIAC-ARRHYTHMIAS; APNOEA/HYPOPNOEA SYNDROME	Objective: To examine the research evidence for the health consequences of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure. Design: A systematic review of published research, studies being identified by searching Medline (1966-96), Embase (1974-96), and CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1982-95); scanning citations; and consulting experts. Studies in all languages were considered which either investigated the association between obstructive sleep apnoea in adults and key health outcomes or evaluated the effectiveness of treatment of obstructive sleep apnoea with continuous positive airways pressure in adults. Main outcome measures: Mortality, systematic hypertension, cardiac arrhythmias, ischaemic heart disease, left ventricular hypertrophy, pulmonary hypertension, stroke, vehicle accidents, measures of daytime sleepiness, and quality of life. Results: 54 epidemiological studies examined the association between sleep apnoea and health related outcomes. Most were poorly designed and only weak or contradictory evidence was found of an association with cardiac arrhythmias, ischaemic heart disease, cardiac failure, systemic or pulmonary hypertension, and stroke. Evidence of a link with sleepiness and road traffic accidents was stronger but inconclusive. Only one small randomised controlled trial evaluated continuous positive airways pressure. Five non-randomised controlled trials and 38 uncontrolled trials were identified. Small changes in objectively measured daytime sleepiness were consistently found, but improvements in morbidity, mortality, and quality of life indicators were not adequately assessed. Conclusions: The relevance of sleep apnoea to public health has been exaggerated. The effectiveness of continuous positive airways pressure in improving health outcomes has been poorly evaluated. There is enough evidence suggesting benefit in reducing daytime sleepiness in some patients to warrant large randomised placebo controlled trials of continuous positive airways pressure versus an effective weight reduction programme and other interventions.	N YORKSHIRE HLTH AUTHOR,YORK YO3 4XF,N YORKSHIRE,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YOU DD,N YORKSHIRE,ENGLAND	University of York - UK	Wright, J (corresponding author), BRADFORD ROYAL INFIRM,BRADFORD BD9 6RJ,W YORKSHIRE,ENGLAND.		Wright, John/H-1624-2012; Sheldon, Trevor/AAK-7088-2021	Wright, John/0000-0001-9572-7293; Sheldon, Trevor/0000-0002-7479-5913				ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; *AM SLEEP DIS ASS, 1992, SLEEP, V15, P268; ANCOLIISRAEL S, 1994, SLEEP, V17, P77, DOI 10.1093/sleep/17.1.77; ANCOLIISRAEL S, 1989, CHEST, V96, P1054, DOI 10.1378/chest.96.5.1054; BEARPARK H, 1987, SLEEP RES, V16, P303; BEDARD MA, 1993, J CLIN EXP NEUROPSYC, V15, P330, DOI 10.1080/01688639308402567; BLIWISE DL, 1988, AM J PUBLIC HEALTH, V78, P544, DOI 10.2105/AJPH.78.5.544; Borak J, 1993, Psychiatr Pol, V27, P43; BOUDOULAS H, 1983, J MED, V14, P223; BRADLEY TD, 1985, AM REV RESPIR DIS, V131, P835; CARLSON JT, 1994, AM J RESP CRIT CARE, V150, P72, DOI 10.1164/ajrccm.150.1.8025776; CHARBONNEAU M, 1992, American Review of Respiratory Disease, V145, pA168; COOK DJ, 1992, CHEST S4, V102, P305; DAVIES RJO, 1993, AM REV RESPIR DIS, V147, P630, DOI 10.1164/ajrccm/147.3.630; DAVIES RJO, 1994, CLIN SCI, V86, P417, DOI 10.1042/cs0860417; DEEKS J, 1996, 4 NHS CTR REV DISS; Denzel K, 1993, Pneumologie, V47 Suppl 1, P155; DERIDERIAN SS, 1988, CHEST, V94, P1023; DIPHILLIPO MA, 1988, SLEEP RES, V17, P167; DOUGLAS NJ, 1994, LANCET, V344, P653, DOI 10.1016/S0140-6736(94)92088-5; Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401; ELIGULASHVILI TS, 1994, ZH NEVROPATOL PSIKH, V94, P76; ENGLEMAN HM, 1994, THORAX, V49, P263, DOI 10.1136/thx.49.3.263; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; ENGLEMAN HM, 1993, THORAX, V48, P911, DOI 10.1136/thx.48.9.911; ENGLEMAN HM, 1993, SLEEP, V16, pS114, DOI 10.1093/sleep/16.suppl_8.S114; ENGLEMAN HM, 1996, SELF REPORTED USE CP; ESCOURROU P, 1990, CHEST, V98, P1362, DOI 10.1378/chest.98.6.1362; Ferguson KA, 1996, CHEST, V109, P1269, DOI 10.1378/chest.109.5.1269; FINDLEY L, 1995, CHEST, V108, P619, DOI 10.1378/chest.108.3.619; FINDLEY LJ, 1989, NEW ENGL J MED, V320, P868; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; Fischer J, 1995, Pneumologie, V49 Suppl 1, P131; FLEMONS WW, 1993, SLEEP, V16, pS71, DOI 10.1093/sleep/16.suppl_8.S71; FLEMONS WW, 1993, AM REV RESPIR DIS, V148, P618, DOI 10.1164/ajrccm/148.3.618; FLETCHER EC, 1991, AM REV RESPIR DIS, V143, P936, DOI 10.1164/ajrccm/143.5_Pt_1.936; GADDY JR, 1991, SLEEP RES, V20, P245; GONZALEZROTHI RJ, 1988, CHEST, V94, P531, DOI 10.1378/chest.94.3.531; GRUNSTEIN R, 1993, INT J OBESITY, V17, P533; GUILLEMINAULT C, 1983, AM J CARDIOL, V52, P490, DOI 10.1016/0002-9149(83)90013-9; GUILLEMINAULT C, 1992, SLEEP, V15, pS20; HANLY P, 1992, CHEST, V102, P100, DOI 10.1378/chest.102.1.100; HARALDSSON PO, 1990, ACTA OTO-LARYNGOL, V110, P136, DOI 10.3109/00016489009122528; HARALDSSON PO, 1990, ORL J OTO-RHINO-LARY, V52, P57, DOI 10.1159/000276104; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HEDNER J, 1990, J HYPERTENS, V8, P941, DOI 10.1097/00004872-199010000-00009; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HOFFSTEIN V, 1994, CHEST, V106, P466, DOI 10.1378/chest.106.2.466; HOFFSTEIN V, 1992, AM REV RESPIR DIS, V145, P841, DOI 10.1164/ajrccm/145.4_Pt_1.841; HOFFSTEIN V, 1994, LANCET, V344, P643, DOI 10.1016/S0140-6736(94)92084-2; HOFFSTEIN V, 1992, CHEST, V101, P379, DOI 10.1378/chest.101.2.379; HOFFSTEIN V, 1988, LANCET, V2, P992; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; INGRAM F, 1994, SLEEP, V17, P248, DOI 10.1093/sleep/17.3.248; Jennum, 1992, J Sleep Res, V1, P240; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; JENNUM P, 1989, AM J HYPERTENS, V2, P847, DOI 10.1093/ajh/2.11.847; KATSANTONIS GP, 1988, LARYNGOSCOPE, V98, P304; KEENAU SP, 1991, AM REV RESPIR DIS, V143, pA603; KISELAK J, 1993, CHEST, V104, P775, DOI 10.1378/chest.104.3.775; KOEHLER U, 1994, KLIN WOCHENSCHR, V69, P474; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; KRIEGER J, 1989, CHEST, V96, P729, DOI 10.1378/chest.96.4.729; KRIEGER J, 1988, EUR RESPIR J, V1, P436; KRIEGER J, 1992, SLEEP, V15, pS42, DOI 10.1093/sleep/15.suppl_6.S42; KRIEGER J, 1991, CHEST, V100, P917, DOI 10.1378/chest.100.4.917; LAKS L, 1995, EUR RESPIR J, V8, P537; LAMPHERE J, 1989, CHEST, V96, P1364, DOI 10.1378/chest.96.6.1364; LAVIE P, 1993, CHEST, V103, P717, DOI 10.1378/chest.103.3.717; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; LEVINSON PD, 1993, CHEST, V103, P1336, DOI 10.1378/chest.103.5.1336; LEVINSON PD, 1991, ARCH INTERN MED, V151, P544; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; MAUT A, 1995, SLEEP, V18, P433; MAYER J, 1991, CARDIOLOGY, V79, P84, DOI 10.1159/000174864; MAYER J, 1993, CARDIOLOGY, V82, P69, DOI 10.1159/000175907; MAYER J, 1991, NIEREN HOCHDRUKKR, V10, P531; MENDELSON WB, 1992, CHEST, V101, P903, DOI 10.1378/chest.101.4.903; MENDELSON WB, 1995, CHEST, V108, P966, DOI 10.1378/chest.108.4.966; MEURICE JC, 1994, CHEST, V105, P429, DOI 10.1378/chest.105.2.429; MEURICE JC, 1995, REV MAL RESPIR, V12, P283; Miles PG, 1996, AM J ORTHOD DENTOFAC, V109, P163, DOI 10.1016/S0889-5406(96)70177-4; MILLER WP, 1982, AM J MED, V73, P317, DOI 10.1016/0002-9343(82)90716-1; MILLMAN RP, 1991, CHEST, V99, P861, DOI 10.1378/chest.99.4.861; MINEMURA H, 1993, JPN J THORAC MED, V31, P1103; MOHSENIN V, 1995, ARCH PHYS MED REHAB, V76, P71, DOI 10.1016/S0003-9993(95)80046-8; Mooe T, 1996, CHEST, V109, P659, DOI 10.1378/chest.109.3.659; NAUGHTON M, 1992, AUST NZ J MED, V21, P917; NINOMURCIA G, 1989, WESTERN J MED, V150, P165; NODA A, 1993, CHEST, V103, P1343, DOI 10.1378/chest.103.5.1343; NORUP PW, 1996, UGESKRIFT LAEGER, V157, P2315; OVESEN J, 1992, ACTA OTO-LARYNGOL, P119; PALOMAKI H, 1991, STROKE, V22, P1021, DOI 10.1161/01.STR.22.8.1021; PHILLIPS BA, 1990, CHEST, V98, P325, DOI 10.1378/chest.98.2.325; PHILLIPSON EA, 1993, NEW ENGL J MED, V328, P1271, DOI 10.1056/NEJM199304293281712; PINILLA CF, 1994, MED CLIN-BARCELONA, V103, P165; PRZYBYLOWSKI T, 1994, ATEMWEG LUNGENKRANK, V20, P358; RAJAGOPAL KR, 1986, CHEST, V90, P172, DOI 10.1378/chest.90.2.172; RAUSCHER H, 1993, THORAX, V48, P529, DOI 10.1136/thx.48.5.529; RAUSCHER H, 1991, CHEST, V100, P1019, DOI 10.1378/chest.100.4.1019; RAUSCHER H, 1992, CHEST, V102, P367, DOI 10.1378/chest.102.2.367; RAUSCHER H, 1993, CHEST, V103, P1675, DOI 10.1378/chest.103.6.1675; REEVESHOCHE MK, 1994, AM J RESP CRIT CARE, V149, P149, DOI 10.1164/ajrccm.149.1.8111574; ROLFE I, 1991, AM REV RESPIR DIS, V144, P1130, DOI 10.1164/ajrccm/144.5.1130; *ROYAL COLL PHYS, 1993, SLEEP APN REL COND R; RUFFIN JM, 1969, NEW ENGL J MED, V281, P16, DOI 10.1056/NEJM196907032810104; SAJKOV D, 1994, AM J RESP CRIT CARE, V149, P416, DOI 10.1164/ajrccm.149.2.8306039; SANGAL RB, 1992, CHEST, V102, P699, DOI 10.1378/chest.102.3.699; SCHECHTMAN KB, 1995, SLEEP, V18, P659, DOI 10.1093/sleep/18.8.659; SCHMIDTNOWARA WW, 1990, PROG CLIN BIOL RES, V345, P377; SFORZA E, 1992, J NEUROL SCI, V110, P21, DOI 10.1016/0022-510X(92)90004-5; SFORZA E, 1992, EUR RESPIR J, V5, P858; SFORZA E, 1995, SLEEP, V18, P195; SFORZA E, 1994, EUR RESPIR J, V7, P1765, DOI 10.1183/09031936.94.07101765; SFORZA E, 1990, AM REV RESPIR DIS, V141, P866, DOI 10.1164/ajrccm/141.4_Pt_1.866; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; Shinozaki T, 1995, Nihon Kyobu Shikkan Gakkai Zasshi, V33, P1073; SIMONDS AK, 1994, BRIT MED J, V309, P35, DOI 10.1136/bmj.309.6946.35; SIRELING LI, 1983, J ROY SOC MED, V76, P131, DOI 10.1177/014107688307600209; SMITH IE, 1995, J SLEEP RES, V4, P183, DOI 10.1111/j.1365-2869.1995.tb00167.x; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; STOOHS RA, 1994, SLEEP, V17, P619; STOOHS RA, 1993, SLEEP, V16, pS141, DOI 10.1093/sleep/16.suppl_8.S141; STOOHS RA, 1993, SLEEP, V16, P511; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; STRADLING JR, 1990, LANCET, V336, P1378, DOI 10.1016/0140-6736(90)92929-C; STROHL KP, 1994, SLEEP, V17, P614, DOI 10.1093/sleep/17.7.614; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; SUZUKI M, 1993, SLEEP, V16, P545, DOI 10.1093/sleep/16.6.545; Thalhofer S, 1991, Pneumologie, V45 Suppl 1, P293; TILKIAN AG, 1977, AM J MED, V63, P348, DOI 10.1016/0002-9343(77)90272-8; Vazquez Oliva R, 1995, ARCH BRONCONEUMOL, V31, P18; WALDHORN RE, 1990, CHEST, V97, P33, DOI 10.1378/chest.97.1.33; WALLER PC, 1989, LANCET, V1, P143; Weissenberg A, 1995, Wien Med Wochenschr, V145, P523; WEITZENBLUM E, 1988, AM REV RESPIR DIS, V138, P345, DOI 10.1164/ajrccm/138.2.345; WILCOX I, 1993, SLEEP, V16, P539, DOI 10.1093/sleep/16.6.539; WITTIG R, 1986, SLEEP RES, V15, P185; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZORICK FJ, 1990, H FORD HOSP MED J, V38, P233	144	322	342	1	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					851	860						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093094				2022-12-28	WOS:A1997WQ02800022
J	Bonn, D				Bonn, D			Anticipating the future by counting DNA triplet repeats	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					782	782		10.1016/S0140-6736(05)60212-7	http://dx.doi.org/10.1016/S0140-6736(05)60212-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9091755				2022-12-28	WOS:A1997WN12400029
J	Bradley, CP; Taylor, RJ; Blenkinsopp, A				Bradley, CP; Taylor, RJ; Blenkinsopp, A			Primary care - Opportunities and threats - Developing prescribing in primary care	BRITISH MEDICAL JOURNAL			English	Article								The latest white papers on the NHS focus on stimulating innovation in the delivery of primary care and removing barriers to further development. Some of this innovation relates directly to prescribing in primary care, and in this article the authors speculate on what might happen if the prescribing initiatives referred to in the white papers were extended and disseminated more widely. The initiatives which might have the biggest impact are those encouraging closer collaboration between general practitioners and community pharmacists and those aiding extension of the current nurse prescribing scheme in primary care. Both offer considerable opportunities to improve primary care, but both bear some potential risks.	UNIV ABERDEEN,DEPT GEN PRACTICE,ABERDEEN AB9 2AY,SCOTLAND; UNIV KEELE,DEPT MED MANAGEMENT,KEELE ST5 5BG,STAFFS,ENGLAND	University of Aberdeen; Keele University	Bradley, CP (corresponding author), UNIV BIRMINGHAM,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Bradley, Colin/0000-0002-3595-9567; Blenkinsopp, Alison/0000-0001-8872-2769				BALINT M, 1964, DOCTOR HIS PATIENT I, P60; BRADLEY C, 1993, HORIZONS, V7, P115; BRADLEY M, 1996, VFM UPDATE, V2, P27; CHAPMAN S, 1996, VFM UPDATE, V2, P8; Coulter A, 1997, BRIT MED J, V314, P510; GOODYER L, 1996, PHARM J, V256, P723; HULME H, 1996, PHARM J, V257, pR7; MARSH GN, 1991, EFFICIENT CARE GEN P; MCCORMICK J, 1992, BRIT J GEN PRACT, V42, P493; *NHS EX SCOTL PRIM, 1996, PRIM CAR DEV FUND PR; PURVIS I, 1996, PRODIGY INTERIM REPO; *ROYAL PHARM SOC G, 1996, PHARM NEW AG; SCHNEIDER JS, 1996, PHARM J, V256, P524; *SECR STAT HLTH SC, 1996, CM3512 SECR STAT HLT; *SECR STAT HLTH SC, 1996, NAT HLTH SERV SERV A; *SECR STAT HLTH SC, 1996, CM3390 SECR STAT HLT; WOOD KM, IN PRESS INT J PHARM; [No title captured]; [No title captured]	19	23	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					744	747		10.1136/bmj.314.7082.744	http://dx.doi.org/10.1136/bmj.314.7082.744			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116557	Green Published			2022-12-28	WOS:A1997WM77600035
J	Lingner, J; Hughes, TR; Shevchenko, A; Mann, M; Lundblad, V; Cech, TR				Lingner, J; Hughes, TR; Shevchenko, A; Mann, M; Lundblad, V; Cech, TR			Reverse transcriptase motifs in the catalytic subunit of telomerase	SCIENCE			English	Article							DEPENDENT DNA POLYMERASE; SACCHAROMYCES-CEREVISIAE; TETRAHYMENA TELOMERASE; TERMINAL TRANSFERASE; MAURICEVILLE PLASMID; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; RNA COMPONENT; STRANDED-DNA	Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Telomerase RNA components have been identified from many organisms, but no protein component has been demonstrated to catalyze telomeric DNA extension. Telomerase was purified from Euplotes aediculatus, a ciliated protozoan, and one of its proteins was partially sequenced by nanoelectrospray tandem mass spectrometry. Cloning and sequence analysis of the corresponding gene revealed that this 123-kilodalton protein (p123) contains reverse transcriptase motifs. A yeast (Saccharomyces cerevisiae) homolog was found and subsequently identified as EST2 (ever shorter telomeres), deletion of which had independently been shown to produce telomere defects. Introduction of single amino acid substitutions within the reverse transcriptase motifs of Est2 protein led to telomere shortening and senescence in yeast, indicating that these motifs are important for catalysis of telomere elongation in vivo. In vitro telomeric DNA extension occurred with extracts from wild-type yeast but not from est2 mutants or mutants deficient in telomerase RNA. Thus, the reverse transcriptase protein fold, previously known to be involved in retroviral replication and retrotransposition, is essential for normal chromosome telomere replication in diverse eukaryotes.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	European Molecular Biology Laboratory (EMBL); Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Baylor College of Medicine			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Lingner, Joachim/0000-0002-2853-5803	NATIONAL INSTITUTE ON AGING [R01AG011728, R37AG011728] Funding Source: NIH RePORTER; NIA NIH HHS [AG11728] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; EVANS S, UNPUB; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; HARRINGTON L, 1997, SCIENCE, V275, P673; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE M, 1994, ANN REV BIOCH, V63, P777; KENNELL JC, 1994, MOL CELL BIOL, V14, P3094, DOI 10.1128/MCB.14.5.3094; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lendvay TS, 1996, GENETICS, V144, P1399; LEVIS RW, 1993, CELL, V75, P1; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LINGNER J, UNPUB BLAST SEARCH P; LINGNER J, UNPUB; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MAIZELS N, 1993, RNA WORLD, P577; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; NUGENT CI, UNPUB; OLLIS DL, 1985, NATURE, V313, P765; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P791; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; Strahl C, 1996, MOL CELL BIOL, V16, P53; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TEMIN HM, 1974, ANNU REV GENET, V8, P155, DOI 10.1146/annurev.ge.08.120174.001103; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	67	965	1031	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					561	567		10.1126/science.276.5312.561	http://dx.doi.org/10.1126/science.276.5312.561			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110970				2022-12-28	WOS:A1997WV72100037
J	Russell, VA; Evans, CC; Li, WJ; Ward, MD				Russell, VA; Evans, CC; Li, WJ; Ward, MD			Nanoporous molecular sandwiches: Pillared two-dimensional hydrogen-bonded networks with adjustable porosity	SCIENCE			English	Article							INCLUSION-COMPOUNDS; DESIGN; BIPHENYL; CONSTRUCTION; PHOSPHONATES; STATE; ACID	Crystal engineering of molecular materials is commonly frustrated by the absence of reliable structural paradigms that are needed for systematic design of crystal lattices with predictable structure and desirable function. This problem can be attributed, at least partially, to the absence of robust supramolecular motifs that serve as synthons for the assembly of crystal lattices. A novel class of molecular crystals based on two-dimensional hydrogen (H)-bonded networks comprising guanidinium ions and the sulfonate groups of alkane- or arenedisulfonate ions is described. The disulfonate ions act as pillars that connect opposing H-bonded sheets and form nanoporous galleries with one-dimensional channels. The flexibility of the H-bonded network allows the galleries to adapt to changes in the steric requirements of guest molecules that occupy the channels. This robustness reduces crystal engineering to the last remaining dimension, enabling rational adjustment of the gallery heights by choice of the disulfonate pillar.	UNIV MINNESOTA,DEPT CHEM ENGN & MAT SCI,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								ASHTON PR, 1995, ANGEW CHEM INT EDIT, V34, P1862, DOI 10.1002/anie.199518621; ATWOOD JL, 1996, COMPREHENSIVE SUPRAM, V6; BASTIANSEN O, 1985, J MOL STRUCT, V128, P115, DOI 10.1016/0022-2860(85)85044-4; BROCK CP, 1989, J AM CHEM SOC, V111, P4586, DOI 10.1021/ja00195a010; CAO G, 1991, J SOLID STATE CHEM, V94, P59, DOI 10.1016/0022-4596(91)90221-3; CAO G, 1992, ACCOUNTS CHEM RES, V25, P420, DOI 10.1021/ar00021a007; CASALONE G, 1968, MOL PHYS, V15, P339, DOI 10.1080/00268976800101191; CHARBONNEAU GP, 1977, ACTA CRYSTALLOGR B, V33, P1586, DOI 10.1107/S0567740877006566; Davis ME, 1996, CHEM MATER, V8, P1820, DOI 10.1021/cm960019u; Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111; ERMER O, 1991, HELV CHIM ACTA, V74, P825, DOI 10.1002/hlca.19910740417; ERMER O, 1988, J AM CHEM SOC, V110, P3747, DOI 10.1021/ja00220a005; GARDNER GB, 1995, NATURE, V374, P792, DOI 10.1038/374792a0; GAVEZZOTTI A, 1982, NOUV J CHIM, V6, P443; GOODGAME DML, 1995, ANGEW CHEM INT EDIT, V34, P574, DOI 10.1002/anie.199505741; Hollingsworth MD, 1996, SCIENCE, V273, P1355, DOI 10.1126/science.273.5280.1355; HOSKINS BF, 1990, J AM CHEM SOC, V112, P1546, DOI 10.1021/ja00160a038; HULLIGER J, 1995, ADV MATER, V7, P719, DOI 10.1002/adma.19950070807; Kitaigorodskii A. I., 1973, MOL CRYSTALS MOL; KOTOTUCHIN SV, 1995, ANGEW CHEM INT EDIT, V34, P2654; RAMAMURTHY V, 1994, CHEM MATER, V6, P1128, DOI 10.1021/cm00044a011; Reis KP, 1996, J CATAL, V161, P62, DOI 10.1006/jcat.1996.0162; Russell VA, 1996, CHEM MATER, V8, P1654, DOI 10.1021/cm9600743; RUSSELL VA, 1994, CHEM MATER, V6, P1206, DOI 10.1021/cm00044a019; Russell VA, 1996, ACTA CRYSTALLOGR B, V52, P209, DOI 10.1107/S0108768195009980; RUSSELL VA, 1994, J AM CHEM SOC, V116, P1941, DOI 10.1021/ja00084a039; SCHMIDT G M J, 1971, Pure and Applied Chemistry, V27, P647; THOMPSON ME, 1994, CHEM MATER, V6, P1168, DOI 10.1021/cm00044a015; VENKATARAMAN D, 1994, NATURE, V371, P591, DOI 10.1038/371591a0; WANG X, 1994, J AM CHEM SOC, V116, P12119, DOI 10.1021/ja00105a089; ZHANG YP, 1992, INORG CHEM, V31, P2821, DOI 10.1021/ic00039a029	32	547	561	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					575	579		10.1126/science.276.5312.575	http://dx.doi.org/10.1126/science.276.5312.575			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110973				2022-12-28	WOS:A1997WV72100040
J	Wallen, EB; Youngberg, GA				Wallen, EB; Youngberg, GA			Blastomycosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									JAMES QUILLEN VET AFFAIRS MED CTR,JOHNSON CITY,TN 37684		Wallen, EB (corresponding author), E TENNESSEE STATE UNIV,JOHNSON CITY,TN 37614, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1223	1223		10.1056/NEJM199704243361705	http://dx.doi.org/10.1056/NEJM199704243361705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110910				2022-12-28	WOS:A1997WV33200005
J	Webb, A; Cunningham, D; Cotter, F; Clarke, PA; diStefano, F; Ross, P; Corbo, M; Dziewanowska, Z				Webb, A; Cunningham, D; Cotter, F; Clarke, PA; diStefano, F; Ross, P; Corbo, M; Dziewanowska, Z			BCL-2 antisense therapy in patients with non-Hodgkin lymphoma	LANCET			English	Article							CELL-DEATH; HAIR; OLIGONUCLEOTIDES; EXPRESSION; PROTEIN	Background Overexpression of BCL-2 is common in non-Hodgkin lymphoma and leads to resistance to programmed cell death (apoptosis) and promotes tumorigenesis. Antisense oligonucleotides targeted at the open reading frame of the BCL-2 mRNA cause a specific down-regulation of BCL-2 expression which leads to increased apoptosis. Lymphoma grown in laboratory animals responds to BCL-2 antisense oligonucleotides with few toxic effects. We report the first study of BCL-2 antisense therapy in human beings. Methods A daily subcutaneous infusion of 18-base, fully phosporothioated antisense oligonucleotide was administered for 2 weeks to nine patients who had BCL-2-positive relapsed non-Hodgkin lymphoma. Toxicity was scored by the common toxicity criteria, and tumour response was assessed by computed tomography scan. Efficacy was also assessed by quantification of BCL-2 expression; BCL-2 protein levels were measured by flow cytometry in samples from patients. Findings During the course of the study, the daily dose of BCL-2 antisense was increased incrementally from 4.6 mg/m(2) to 73.6 mg/m(2) No treatment-related toxic effects occurred, apart from local inflammation at the infusion site. In two patients, computed tomography scans showed a reduction in tumour size (one minor, one complete response). In two patients, the number of circulating lymphoma cells decreased during treatment. In four patients, serum concentrations of lactate dehydrogenase fell, and in two of these patients symptoms improved. We were able to measure BCL-2 levels by flow cytometry in the samples of five patients, two of whom had reduced levels of BCL-2 protein. Interpretation In patients with relapsing non-Hodgkin lymphoma, BCL-2 antisense therapy led to an improvement in symptoms, objective biochemical and radiological evidence of tumour response, and down-regulation of the BCL-2 protein in some patients. Our findings are encouraging and warrant further investigations of BCL-2 antisense therapy in cancer treatment.	ROYAL MARSDEN HOSP,LYMPHOMA UNIT,SUTTON SM2 5PT,SURREY,ENGLAND; INST CANC RES,CRC,CTR CANC THERAPEUT,SUTTON,SURREY,ENGLAND; INST CHILD HLTH,LONDON,ENGLAND; GENTA INC,SAN DIEGO,CA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London				Clarke, Paul/0000-0001-9342-1290; Cunningham, David/0000-0001-5158-1069				Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Bishop MR, 1996, J CLIN ONCOL, V14, P1320, DOI 10.1200/JCO.1996.14.4.1320; COTTER FE, 1994, ONCOGENE, V9, P3049; COTTER FE, 1996, ANN ONCOL, V7, P32; *EUR ORG RES TREAT, 1994, PRACT GUID EORTC STU; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAMADA S, 1995, CANCER RES, V55, P354; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MIYASHITA T, 1992, CANCER RES, V52, P5407; *NCI, 1988, GUID REP ADV DRUG RE; PARK JR, 1995, BLOOD, V86, P868; PEZZELLA F, 1992, BRIT J CANCER, V65, P87, DOI 10.1038/bjc.1992.16; RAYNAUD F, 1997, IN PRESS J PHARM EXP; SELBY P, 1990, BRIT J CANCER, V62, P279, DOI 10.1038/bjc.1990.278; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M	19	442	482	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1137	1141		10.1016/S0140-6736(96)11103-X	http://dx.doi.org/10.1016/S0140-6736(96)11103-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113013				2022-12-28	WOS:A1997WU54400011
J	Coquelle, A; Pipiras, E; Toledo, F; Buttin, G; Debatisse, M				Coquelle, A; Pipiras, E; Toledo, F; Buttin, G; Debatisse, M			Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons	CELL			English	Article							CHINESE-HAMSTER CELLS; DNA STRAND BREAKS; CHROMOSOME BREAKAGE; AMPLIFIED GENES; INSITU HYBRIDIZATION; DOUBLE MINUTES; 11Q13 REGION; CAD GENES; SEQUENCES; CANCER	Drug-selected intrachromosomal gene amplification by breakage-fusion-bridge (BFB) cycles is well documented in mammalian cells, but factors governing this mechanism are not clear. Here, we show that only some clastogenic drugs induce drug resistance through intrachromosomal amplification. We strictly correlate triggering of BFB cycles to induction of fragile site expression. We demonstrate a dual role for fragile sites in intrachromosomal amplification: a site telomeric to the selected gene is involved in initiation, while a centromeric site defines the size and organization of early amplified units. The positions of fragile sites relative to boundaries of amplicons found in human cancers support the hypothesis that fragile sites play a key role in the amplification of at least some oncogenes during tumor progression.	INST PASTEUR, UNITE GENET SOMAT, CNRS, UNITE RECH ASSOCIEE 1960, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Coquelle, Arnaud/AAE-5425-2020	Toledo, Franck/0000-0003-3798-4106				BALABANMALENBAUM G, 1980, CANCER GENET CYTOGEN, V2, P339, DOI 10.1016/0165-4608(80)90065-5; BAN S, 1995, MUTAT RES-ENVIR MUTA, V334, P197, DOI 10.1016/0165-1161(95)90011-X; BARRETT M, 1992, GENE AMPLIFICATION M, P119; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; BIEDLER JL, 1988, CANCER RES, V48, P3179; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CARROLL SM, 1987, MOL CELL BIOL, V7, P1740, DOI 10.1128/MCB.7.5.1740; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P128, DOI 10.1002/gcc.2870120207; CHEN ATL, 1989, ENVIRON MOL MUTAGEN, V13, P319, DOI 10.1002/em.2850130407; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DEBATISSE M, 1988, MOL CELL BIOL, V8, P17, DOI 10.1128/MCB.8.1.17; DEBATISSE M, 1982, MOL CELL BIOL, V2, P1346, DOI 10.1128/MCB.2.11.1346; DEBATISSE M, 1984, EMBO J, V3, P3123, DOI 10.1002/j.1460-2075.1984.tb02268.x; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; EVANS HJ, 1974, CHROMOSOMES CANCER, P191; FRITSCHE M, 1993, ONCOGENE, V8, P307; GEORGE DL, 1982, P NATL ACAD SCI-BIOL, V79, P1597, DOI 10.1073/pnas.79.5.1597; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KAOSHAN CS, 1987, CANCER RES, V47, P6278; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; LI JC, 1984, P NATL ACAD SCI-BIOL, V81, P5694, DOI 10.1073/pnas.81.18.5694; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MARTINS MB, 1993, MUTAT RES, V285, P229, DOI 10.1016/0027-5107(93)90111-R; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MOORE RC, 1990, CHROMOSOMAL ABERRATI, P41; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; RATH H, 1984, CANCER RES, V44, P3303; ROBINSON TJ, 1987, CHROMOSOMA, V96, P45, DOI 10.1007/BF00285882; ROELOFS H, 1993, GENE CHROMOSOME CANC, V7, P74, DOI 10.1002/gcc.2870070203; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SEABRIGH.M, 1971, LANCET, V2, P971; SEN S, 1987, CHROMOSOMA, V95, P117, DOI 10.1007/BF00332184; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SPRIGGS AI, 1962, BRIT MED J, P1431, DOI 10.1136/bmj.2.5317.1431; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; TISTY TD, 1984, MOL CELL BIOL, V4, P1050; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TOLEDO F, 1992, MUTAT RES, V276, P261, DOI 10.1016/0165-1110(92)90012-X; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Veinot L., 1992, Gene amplification in mammalian cells: a comprehensive guide., P287; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	67	333	338	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					215	225		10.1016/S0092-8674(00)80201-9	http://dx.doi.org/10.1016/S0092-8674(00)80201-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108477	Bronze			2022-12-28	WOS:A1997WU88800009
J	Graff, JM				Graff, JM			Embryonic patterning: To BMP or not to BMP, that is the question	CELL			English	Review							EARLY XENOPUS EMBRYO; NEURAL INDUCTION; MESODERM; SIGNALS; EXPRESSION; ORGANIZER				Graff, JM (corresponding author), UNIV TEXAS,SW MED CTR,CTR DEV BIOL,DEPT MOL BIOL & ONCOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							Camac G., 1996, DEVELOPMENT, V122, P3055; COOKE J, 1983, NATURE, V306, P423, DOI 10.1038/306423a0; GAMER LW, 1995, DEV BIOL, V171, P240, DOI 10.1006/dbio.1995.1275; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Henry GL, 1996, DEVELOPMENT, V122, P1007; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	20	184	187	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					171	174		10.1016/S0092-8674(00)80196-8	http://dx.doi.org/10.1016/S0092-8674(00)80196-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108472	Bronze			2022-12-28	WOS:A1997WU88800004
J	McKay, CP; Borucki, WJ				McKay, CP; Borucki, WJ			Organic synthesis in experimental impact shocks	SCIENCE			English	Article							LASER-INDUCED PLASMAS; PLANETARY-ATMOSPHERES; NITROGEN-FIXATION; TITAN; CARBON; ORIGIN; RATES	Laboratory simulations of shocks created with a high-energy laser demonstrate that the efficacy of organic production depends on the molecular, not just the elemental composition of the shocked gas. In a methane-rich mixture that simulates a low-temperature equilibrium mixture of cometary material, hydrogen cyanide and acetylene were produced with yields of 5 x 10(17) molecules per joule. Repeated shocking of the methane-rich mixture produced amine groups, suggesting the possible synthesis of amino acids, No organic molecules were produced in a carbon dioxide-rich mixture, which is at odds with thermodynamic equilibrium approaches to shock chemistry and has implications for the modeling of shock-produced organic molecules on early Earth.			McKay, CP (corresponding author), NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035, USA.							BORUCKI WJ, 1987, APPL OPTICS, V26, P4319, DOI 10.1364/AO.26.004319; BORUCKI WJ, 1984, REV GEOPHYS, V22, P363, DOI 10.1029/RG022i004p00363; BORUCKI WJ, 1985, ICARUS, V64, P221, DOI 10.1016/0019-1035(85)90087-9; BORUCKI WJ, 1987, NATURE, V328, P509, DOI 10.1038/328509a0; BORUCKI WJ, 1988, ICARUS, V76, P125, DOI 10.1016/0019-1035(88)90145-5; CHAMEIDES WL, 1981, ORIGINS LIFE EVOL B, V11, P291, DOI 10.1007/BF00931483; CHAMEIDES WL, 1979, NATURE, V277, P123, DOI 10.1038/277123a0; DAVIES AM, 1980, J PHYS OCEANOGR, V10, P237, DOI 10.1175/1520-0485(1980)010<0237:OACMTC>2.0.CO;2; DELSEMME AH, 1988, PHILOS T R SOC A, V325, P509, DOI 10.1098/rsta.1988.0064; FEGLEY B, 1986, NATURE, V319, P305, DOI 10.1038/319305a0; Gordon S, 1971, NASA; Holland HD., 1984, CHEM EVOLUTION ATMOS; JEBENS DS, 1992, GEOPHYS RES LETT, V19, P273, DOI 10.1029/91GL02937; KISSEL J, 1987, NATURE, V326, P755, DOI 10.1038/326755a0; Lewis J. S., 1982, SPEC PAP GEOL SOC AM, V190, P215; Maker P D, 1964, P 3 INT C QUANT EL P, V2, P1559; MCKAY CP, 1988, NATURE, V332, P520, DOI 10.1038/332520a0; MUKHIN LM, 1989, NATURE, V340, P46, DOI 10.1038/340046a0; POLLACK JB, 1980, ANNU REV EARTH PL SC, V8, P425, DOI 10.1146/annurev.ea.08.050180.002233; RADZIEMSKI LJ, 1983, ANAL CHEM, V55, P1246, DOI 10.1021/ac00259a016; RAIZER YP, 1966, SOV PHYS USPEKHI, V8, P650, DOI 10.1070/PU1966v008n05ABEH003027; SCATTERGOOD TW, 1989, ICARUS, V81, P413, DOI 10.1016/0019-1035(89)90061-4; SIMONELLI DP, 1989, ICARUS, V82, P1, DOI 10.1016/0019-1035(89)90020-1; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963; ZAHNLE K, 1995, GEOPHYS RES LETT, V22, P1593, DOI 10.1029/95GL01190	25	80	81	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					390	392		10.1126/science.276.5311.390	http://dx.doi.org/10.1126/science.276.5311.390			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103191				2022-12-28	WOS:A1997WU47700031
J	Tesmer, JJG; Berman, DM; Gilman, AG; Sprang, SR				Tesmer, JJG; Berman, DM; Gilman, AG; Sprang, SR			Structure of RGS4 bound to AlF4--activated G(i alpha 1): Stabilization of the transition state for GTP hydrolysis	CELL			English	Article							PROTEIN ALPHA-SUBUNITS; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; RAS PROTEINS; GS-ALPHA; MECHANISM; MUTANTS; P21; REFINEMENT; MUTATIONS	RGS proteins are GTPase activators for heterotrimeric G proteins. We report here the 2.8 Angstrom resolution crystal structure of the RGS protein RGS4 complexed with G(i alpha 1)-Mg2+-GDP0AlF(4)(-). Only the core domain of RGS4 is visible in the crystal. The core domain binds to the three switch regions of G(i alpha 1), but does not contribute catalytic residues that directly interact with either GDP or AlF4-. Therefore, RGS4 appears to catalyze rapid hydrolysis of GTP primarily by stabilizing the switch regions of G(i alpha 1), although the conserved Asn-128 from RGS4 could also play a catalytic role by interacting with the hydrolytic water molecule or the side chain of Gln-204. The binding site for RGS4 on G(i alpha 1) is also consistent with the activity of RGS proteins as antagonists of G(alpha) effectors.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Tesmer, John/0000-0003-1125-3727	NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM07062, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Berghuis AM, 1996, STRUCTURE, V4, P1277, DOI 10.1016/S0969-2126(96)00136-0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOLIN JT, 1993, AM CRYST ASS, V21, P51; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HAMM HE, 1996, CURR OPIN CELL BIOL, V8, P615; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1994, METHOD ENZYMOL, V237, P146; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0	62	680	690	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					251	261		10.1016/S0092-8674(00)80204-4	http://dx.doi.org/10.1016/S0092-8674(00)80204-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108480	Bronze			2022-12-28	WOS:A1997WU88800012
J	Dong, BJ; Hauck, WW; Gambertoglio, JG; Gee, L; White, JR; Bubp, JL; Greenspan, FS				Dong, BJ; Hauck, WW; Gambertoglio, JG; Gee, L; White, JR; Bubp, JL; Greenspan, FS			Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE; THERAPY; BIOAVAILABILITY; TABLET	Objective.-To compare relative bioavailability of Synthroid, Levoxine (Levoxine has been renamed Levoxyl), and 2 generic levothyroxine sodium preparations. Design.-Single-blind (primary investigators blinded), randomized, 4-way crossover trial. Setting.-Ambulatory care. Patients.-Twenty-two women with hypothyroidism who were clinically and chemically euthyroid and were receiving levothyroxine sodium, 0.1 or 0.15 mg. Interventions.-All patients received each of the 4 levothyroxine products for 6-week periods in the same dosage as their prestudy regimen with no washout period. The order of the drug sequences was randomly determined before study initiation. Main Outcome Measures.-Area under the curve, time to peak serum concentrations, and peak serum concentrations of thyroxine, triiodothyronine, and free thyroxine index for all 4 products. Results.-All data analyses were completed prior to unblinding of the product codes. No significant differences between the 4 products were found in area under the curve or peak serum concentrations of total thyroxine, total triiodothyronine, or free thyroxine index, Although Synthroid produced a more rapid rise in total serum triiodothyronine concentration and a higher total peak serum triiodothyronine concentration than the other products, these differences were not statistically significant (P=.08). The Food and Drug Administration criterion for relative bioequivalence within 90% confidence intervals (0.8-1.25) was demonstrated (P<.05) for all pairs of products, Relative bioequivalence of 0.95 to 1.07 was demonstrated, tighter than the current bioequivalence criterion for oral formulations. Conclusions.-The 4 generic and brand-name levothyroxine preparations studied are different but are bioequivalent by current Food and Drug Administration criteria and are interchangeable in the majority of patients receiving thyroxine replacement therapy. Further investigation is required to determine whether our results are equally applicable to all existing levothyroxine preparations.	UNIV CALIF SAN FRANCISCO,MED CTR,DEPT BIOSTAT & EPIDEMIOL,DIV BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Dong, BJ (corresponding author), UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT CLIN PHARM,MED CTR,C-152,521 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.							AIN KB, 1993, THYROID, V3, P81, DOI 10.1089/thy.1993.3.81; ANDERSON S, 1990, J PHARMACOKINET BIOP, V18, P259, DOI 10.1007/BF01062202; BERG JA, 1992, J CLIN PHARMACOL, V32, P1135; BERG JA, 1989, DICP ANN PHARMAC, V23, P812, DOI 10.1177/106002808902301018; BLOUIN RA, 1989, CLIN PHARMACY, V8, P588; BROWER JF, 1984, J PHARM SCI, V73, P1315, DOI 10.1002/jps.2600730937; CARMEYER NR, 1991, AM J HOSP PHARM, V48, P735; Chow S, 1992, DESIGN ANAL BIOAVAIL; Cochran W.G., 1957, EXPT DESIGNS, p[117, 132, 244]; CURRY SH, 1988, DRUG INTEL CLIN PHAR, V22, P589, DOI 10.1177/106002808802200715; DAVIS HA, 1962, BLOOD VOLUME DYNAMIC; Dong B J, 1991, J Am Board Fam Pract, V4, P167; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; HAUCK WW, 1992, INT J CLIN PHARM TH, V30, P181; HENNESSEY JV, 1985, ANN INTERN MED, V102, P770, DOI 10.7326/0003-4819-102-6-770; HENNESSEY JV, 1986, ANN INTERN MED, V105, P11, DOI 10.7326/0003-4819-105-1-11; *IMS AM LTD, 1988, NAT PRESCR AUD BAS D; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; Neter J., 1974, J R STAT SOC C-APPL; SAWIN CT, 1984, ANN INTERN MED, V100, P641, DOI 10.7326/0003-4819-100-5-641; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TOFT AD, 1994, NEW ENGL J MED, V331, P174; *US PHARM, 1985, OFF MON LEV SOD LEV; Waterfield RL, 1931, J PHYSIOL-LONDON, V72, P110, DOI 10.1113/jphysiol.1931.sp002765; WESTLAKE WJ, 1981, BIOMETRICS, V37, P589	26	143	147	1	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1205	1213		10.1001/jama.277.15.1205	http://dx.doi.org/10.1001/jama.277.15.1205			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103344				2022-12-28	WOS:A1997WT40300031
J	Montaner, JSG; Hogg, RS; OShaughnessy, MV				Montaner, JSG; Hogg, RS; OShaughnessy, MV			Emerging international consensus for use of antiretroviral therapy	LANCET			English	Editorial Material									UNIV BRITISH COLUMBIA,ST PAULS HOSP,VANCOUVER,BC V6Z 1Y6,CANADA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Montaner, JSG (corresponding author), CANADIAN HIV TRIALS NETWORK,CTR EXCELLENCE HIV AIDS,VANCOUVER,BC V6Z 1Y6,CANADA.		Hogg, Robert S/B-2783-2012; Montaner, Julio/K-7621-2012	Hogg, Robert S/0000-0003-3463-5488; 				*ACTG 320 PROT TEA, 1997, RAND DOUBL BLIND PHR; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; KEMPF D, 1997, 4 C RETR OPP INF JAN; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MONTANER JSG, 1996, 11 INT C AIDS VANC J; MONTANER JSG, 1996, ICAAC NEW ORL SEPT 1; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; SCHECHTER MT, 1993, LANCET, V341, P658, DOI 10.1016/0140-6736(93)90421-C; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	10	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1042	1042		10.1016/S0140-6736(05)62289-1	http://dx.doi.org/10.1016/S0140-6736(05)62289-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107240				2022-12-28	WOS:A1997WU00200006
J	Benoist, C; Mathis, D				Benoist, C; Mathis, D			Cell death mediators in autoimmune diabetes - No shortage of suspects	CELL			English	Review							DISEASE; MICE				Benoist, C (corresponding author), CNRS INSERM ULP, INST GENET & BIOL MOL & CELLULAIRE, 1 RUE LAURENT FRIES, F-67404 ILLKIRCH GRAFFENSTADEN, CU STRASBOURG, FRANCE.							ANDRE I, 1996, P NATL ACAD SCI USA, V6, P2239; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; CHU JL, 1995, J EXP MED, V181, P393, DOI 10.1084/jem.181.1.393; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Kagi D, 1996, J EXP MED, V183, P2143, DOI 10.1084/jem.183.5.2143; MOLLER G, 1990, IMMUNOL REV, V115, P5, DOI 10.1111/j.1600-065X.1990.tb00782.x; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PAKALA SV, 1997, J ALLERGY CLIN IMMUN, V99, P6380; Sarvetnick N, 1996, J EXP MED, V184, P1597, DOI 10.1084/jem.184.5.1597; Spencer DM, 1996, TRENDS GENET, V12, P181, DOI 10.1016/0168-9525(96)10013-5; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang B, 1996, EUR J IMMUNOL, V26, P1762, DOI 10.1002/eji.1830260815; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67	15	105	107	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					1	3		10.1016/S0092-8674(00)80174-9	http://dx.doi.org/10.1016/S0092-8674(00)80174-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094706	Bronze			2022-12-28	WOS:A1997WR68500001
J	Thiel, S; VorupJensen, T; Stover, CM; Schwaeble, W; Laursen, SB; Poulsen, K; Willis, AC; Eggleton, P; Hansen, S; Holmskov, U; Reid, KB; Jensenius, JC				Thiel, S; VorupJensen, T; Stover, CM; Schwaeble, W; Laursen, SB; Poulsen, K; Willis, AC; Eggleton, P; Hansen, S; Holmskov, U; Reid, KB; Jensenius, JC			A second serine protease associated with mannan-binding lectin that activates complement	NATURE			English	Article							RA-REACTIVE FACTOR; BACTERICIDAL FACTOR; SERUM LECTIN; SEQUENCE; CDNA; C1S; MUTATIONS; PATHWAY; OPSONIN; CLONING	The complement system comprises a complex array of enzymes and non-enzymatic proteins that is essential for the operation of the innate as well as the adaptive immune defence(1). The complement system can be activated in three ways: by the classical pathway which is initiated by antibody-antigen complexes, by the alternative pathway initiated by certain structures on microbial surfaces, and by an antibody-independent pathway(2) that is initiated by the binding of mannan-binding lectin (MEL; first described as mannan-binding protein(3)) to carbohydrates. MBL is structurally related to the complement C1 subcomponent, C1q, and seems to activate the complement system through an associated serine protease known as MASP (ref. 4) or p100 (ref. 5), which is similar to C1r and C1s of the classical pathway. MBL binds to specific carbohydrate structures found on the surface of a range of microorganisms, including bacteria, yeasts, parasitic protozoa and viruses(6), and exhibits antibacterial activity through killing mediated by the terminal, lytic complement components(7) or by promoting phagocytosis(8), The level of MBL in plasma is genetically determinedg-(9-11), and deficiency is associated with frequent infections in childhood(12,13), and possibly also in adults(14,15) (for review, see ref. 6), We have now identified a new MBL-associated serine protease (MASP-2) which shows a striking homology with the previously reported MASP (MASP-1) and the two C1q-associated serine proteases C1r and C1s. Thus complement activation through MBL, like the classical pathway, involves two serine proteases and may antedate the development of the specific immune system of vertebrates.	UNIV LEICESTER, DEPT MICROBIOL & IMMUNOL, LEICESTER LE1 9HN, LEICS, ENGLAND; UNIV OXFORD, MRC, IMMUNOCHEM UNIT, OXFORD OX1 3QU, ENGLAND; ODENSE UNIV, DEPT MED MICROBIOL, DK-5000 ODENSE, DENMARK	University of Leicester; University of Oxford; University of Southern Denmark	Thiel, S (corresponding author), AARHUS UNIV, DEPT MED MICROBIOL & IMMUNOL, DK-8000 AARHUS, DENMARK.		Holmskov, Uffe/AAA-3056-2022; Vorup-Jensen, Thomas/N-9082-2016	Holmskov, Uffe/0000-0002-2391-9445; Hansen, Soren/0000-0002-8186-4630; Vorup-Jensen, Thomas/0000-0002-4140-6563; Schwaeble, Wilhelm/0000-0001-8927-0864; Thiel, Steffen/0000-0002-4817-155X; Eggleton, Paul/0000-0001-8244-2125; Stover, Cordula/0000-0002-0125-4868	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAATRUP G, 1987, SCAND J IMMUNOL, V26, P355, DOI 10.1111/j.1365-3083.1987.tb02267.x; Endo Y, 1996, INT IMMUNOL, V8, P1355, DOI 10.1093/intimm/8.9.1355; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; JI YH, 1993, J IMMUNOL, V150, P571; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KAWASAKI T, 1978, BIOCHEM BIOPH RES CO, V81, P1018, DOI 10.1016/0006-291X(78)91452-3; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAW SKA, 1996, COMPLEMENT, P1; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; NIELSEN SL, 1995, CLIN EXP IMMUNOL, V100, P219; SATO T, 1994, INT IMMUNOL, V6, P665, DOI 10.1093/intimm/6.4.665; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; [No title captured]	26	713	768	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	1997	386	6624					506	510		10.1038/386506a0	http://dx.doi.org/10.1038/386506a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087411				2022-12-28	WOS:A1997WR25600055
J	Bates, DW; Miller, E; Bernstein, SJ; Hauptman, PJ; Leape, LL				Bates, DW; Miller, E; Bernstein, SJ; Hauptman, PJ; Leape, LL			Coronary angiography and angioplasty after acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Review							OUTPATIENT CARDIAC-CATHETERIZATION; EXERCISE TESTING SOON; THROMBOLYTIC THERAPY; RANDOMIZED TRIAL; PLASMINOGEN-ACTIVATOR; PHASE-II; RISK STRATIFICATION; UNITED-STATES; INTRACORONARY STREPTOKINASE; IMMEDIATE ANGIOPLASTY	Purpose: To assess the data that support the use of coronary angiography and angioplasty after acute myocardial infarction, that identify the risks of these procedures, and that analyze their use and costs. Data Sources: English-language articles published between 1970 and June 1995 identified through a search of the MEDLINE database. Study Selection: Studies that contained information about benefits, risks, use, and costs of coronary angiography and angioplasty after acute myocardial infarction. Data Extraction: Descriptive and analytic data from each study were collected. Data Synthesis: The outcome for patients who have complications of myocardial infarction (such as shock) is poor. Such patients usually undergo angiography, although the evidence that supports this practice is weak. Preliminary data suggest that patients who immediately have angiography and angioplasty after acute myocardial infarction have better outcomes than do patients who receive thrombolytic therapy with angioplasty only for specific indications in experienced centers. After the acute phase of myocardial infarction, patients who have noninvasive evidence of persistent or recurrent ischemia are believed to benefit from angiography. In the remaining patients, however, angiography after myocardial infarction has not been shown to be beneficial. Coronary angiography is done in 30% to 81% of patients after acute myocardial infarction in different settings and regions; for many of these patients, the benefit is questionable. Better outcomes are not always associated with more frequent use of the procedure. In the United States, catheterizations after myocardial infarction cost approximately $1 billion per year. Conclusions: Although many patients benefit from angiography and angioplasty after myocardial infarction, others probably do not. Substantial resources are at stake.	UNIV MICHIGAN, MED CTR, DIV GEN MED, TAUBMAN CTR 3116, ANN ARBOR, MI 48109 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Bates, DW (corresponding author), BRIGHAM & WOMENS HOSP, DIV GEN MED & PRIMARY CARE, 75 FRANCIS ST, BOSTON, MA 02115 USA.			Bernstein, Steven/0000-0003-3359-7168	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008071] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS08071-02] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AGUIRRE FV, 1995, CIRCULATION, V91, P2541, DOI 10.1161/01.CIR.91.10.2541; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1993, Lancet, V342, P767; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], CORONARY ANGIOGRAPHY; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ARNOLD AER, 1992, CIRCULATION, V86, P111, DOI 10.1161/01.CIR.86.1.111; ARNOLD AER, 1993, EUR HEART J, V14, P306, DOI 10.1093/eurheartj/14.3.306; BAIM DS, 1990, J AM COLL CARDIOL, V15, P1188, DOI 10.1016/0735-1097(90)90263-O; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BEAUCHAMP PK, 1981, HOSPITALS, V55, P62; BELENKIE I, 1992, CAN J CARDIOL, V8, P357; Bittl JA, 1996, NEW ENGL J MED, V335, P1290, DOI 10.1056/NEJM199610243351707; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; BRODIE BR, 1991, AM J CARDIOL, V67, P7, DOI 10.1016/0002-9149(91)90090-8; BROWN KA, 1986, AM J CARDIOL, V58, P359, DOI 10.1016/0002-9149(86)90078-0; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CHAITMAN B R, 1990, Journal of the American College of Cardiology, V15, p251A; CHARLES ED, 1989, J AM COLL CARDIOL, V13, pA152; DEBELDER MA, 1988, BRIT HEART J, V60, P377; DEBOER MJ, 1993, CIRCULATION, V88, P106; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; DEBUSK RF, 1980, AM J CARDIOL, V45, P547, DOI 10.1016/S0002-9149(80)80003-8; DEBUSK RF, 1983, AM J CARDIOL, V52, P1161, DOI 10.1016/0002-9149(83)90567-2; DESERVI S, 1986, EUR HEART J, V7, P69, DOI 10.1093/eurheartj/7.suppl_C.69; DeWood M A, 1984, Cardiol Clin, V2, P113; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DEWOOD MA, 1989, CIRCULATION S2, V80, P418; DEWOOD MA, 1983, CIRCULATION 2, V68, P16; DIETHRICH EB, 1981, CARDIOVASC DIS, V8, P195; ECKMAN MH, 1992, ANN INTERN MED, V117, P667, DOI 10.7326/0003-4819-117-8-667; ELIZAGA J, 1993, CIRCULATION, V88, P411; ELLIS S, 1996, P AM COLL CARD SCI S; ELLIS SG, 1992, CIRCULATION, V86, P1400, DOI 10.1161/01.CIR.86.5.1400; Ellis SG, 1996, CIRCULATION, V93, P431, DOI 10.1161/01.CIR.93.3.431; ELLIS SG, 1995, CIRCULATION, V92, P741, DOI 10.1161/01.CIR.92.4.741; ELLIS SG, 1993, CIRCULATION, V88, P106; ERBEL R, 1986, J AM COLL CARDIOL, V8, P485, DOI 10.1016/S0735-1097(86)80172-3; ERBEL R, 1989, J AM COLL CARDIOL, V14, P276, DOI 10.1016/0735-1097(89)90173-3; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FIERENS E, 1984, CATHETER CARDIO DIAG, V10, P27, DOI 10.1002/ccd.1810100106; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FULLER CM, 1981, ANN INTERN MED, V94, P734, DOI 10.7326/0003-4819-94-6-734; GARDNER TJ, 1989, CIRCULATION, V79, P79; GELTMAN EM, 1979, CIRCULATION, V60, P805, DOI 10.1161/01.CIR.60.4.805; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRAVES EJ, 1994, VITAL HLTH STAT, P1; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grines CL, 1996, NEW ENGL J MED, V335, P1313; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HAMPTON J, 1993, LANCET, V342, P759; HILBORNE LH, 1991, PERCUTANEOUS TRANSLU; HIMBERT D, 1993, AM J CARDIOL, V71, P377, DOI 10.1016/0002-9149(93)90435-F; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; JONES EL, 1981, ANN THORAC SURG, V32, P33, DOI 10.1016/S0003-4975(10)61371-9; JULIARD JM, 1992, AM J CARDIOL, V69, P1383, DOI 10.1016/0002-9149(92)90886-4; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; KIMMEL SE, 1995, J AM COLL CARDIOL, V26, P931, DOI 10.1016/0735-1097(95)00294-4; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; KOSHAL A, 1988, CIRCULATION, V78, P171; KRONE RJ, 1989, J AM COLL CARDIOL, V14, P31, DOI 10.1016/0735-1097(89)90049-1; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; Lange RA, 1996, NEW ENGL J MED, V335, P1311; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LEE JC, 1990, J AM COLL CARDIOL, V15, P378, DOI 10.1016/S0735-1097(10)80066-X; MAHRER PR, 1981, CATHETER CARDIO DIAG, V7, P355, DOI 10.1002/ccd.1810070407; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; McKendall G.R, 1991, CIRCULATION S2, V84, pII; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; MULLER DWM, 1990, AM HEART J, V119, P224, DOI 10.1016/S0002-8703(05)80008-0; MULLER DWM, 1991, J AM COLL CARDIOL, V18, P1594, DOI 10.1016/0735-1097(91)90490-Z; MULLER DWM, 1991, AM HEART J, V121, P1042, DOI 10.1016/0002-8703(91)90661-Z; MURRAY DP, 1987, EUR J NUCL MED, V13, P274; NASHEF SAM, 1992, BRIT MED J, V305, P1066, DOI 10.1136/bmj.305.6861.1066; NESKOVIC AN, 1995, AM HEART J, V129, P31, DOI 10.1016/0002-8703(95)90039-X; NORRIS RM, 1981, CIRCULATION, V63, P785, DOI 10.1161/01.CIR.63.4.785; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; OROURKE RA, 1994, CURR PROB CARDIOLOGY, V19, P179; OZBEK C, 1990, Journal of the American College of Cardiology, V15, p63A; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PEART I, 1989, BRIT HEART J, V61, P231; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; RENTROP KP, 1984, NEW ENGL J MED, V311, P1457, DOI 10.1056/NEJM198412063112301; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; ROGERS WJ, 1994, AM J CARDIOL, V74, P111, DOI 10.1016/0002-9149(94)90082-5; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROGERS WJ, 1996, ATHEROSCLEROSIS CORO; ROSS J, 1989, CIRCULATION, V79, P292, DOI 10.1161/01.CIR.79.2.292; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; RUOCCO NA, 1992, J AM COLL CARDIOL, V20, P1445, DOI 10.1016/0735-1097(92)90435-P; SCHULZE RA, 1977, AM J MED, V62, P192, DOI 10.1016/0002-9343(77)90314-X; SCHUSTER EH, 1981, NEW ENGL J MED, V305, P1101, DOI 10.1056/NEJM198111053051901; SERRUYS PW, 1982, EUR HEART J, V3, P404, DOI 10.1093/oxfordjournals.eurheartj.a061326; SILVA P, 1993, AM J CARDIOL, V71, P1142, DOI 10.1016/0002-9149(93)90636-Q; SILVERMAN KJ, 1980, CIRCULATION, V61, P996, DOI 10.1161/01.CIR.61.5.996; SIMOONS M L, 1988, Lancet, V1, P197; STONE GW, 1990, J AM COLL CARDIOL, V15, P534, DOI 10.1016/0735-1097(90)90621-U; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; TOPOL EJ, 1991, ANN INTERN MED, V114, P877, DOI 10.7326/0003-4819-114-10-877; TOPOL EJ, 1990, CIRCULATION, V82, P539; TOPOL EJ, 1992, CIRCULATION, V85, P2090, DOI 10.1161/01.CIR.85.6.2090; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; TOPOL EJ, 1987, CIRCULATION, V75, P420, DOI 10.1161/01.CIR.75.2.420; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; VANDENBRAND MJ, 1992, CORONARY ARTERY DIS, V3, P393, DOI 10.1097/00019501-199205000-00007; Verrilli D, 1996, JAMA-J AM MED ASSOC, V275, P1189, DOI 10.1001/jama.275.15.1189; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WELD FM, 1981, CIRCULATION, V64, P306, DOI 10.1161/01.CIR.64.2.306; WILLIAMS DO, 1992, CIRCULATION, V85, P533, DOI 10.1161/01.CIR.85.2.533; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1995, DRG HDB COMP CLIN FI; 1994, STAT B METROP INSUR, V75, P21	121	24	25	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					539	550		10.7326/0003-4819-126-7-199704010-00007	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092320				2022-12-28	WOS:A1997WQ19500016
J	Thune, I; Brenn, T; Lunk, E; Gaard, M				Thune, I; Brenn, T; Lunk, E; Gaard, M			Physical activity and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENSTRUAL-CYCLE PATTERNS; DIETARY-FAT; EXERCISE; WOMEN; PROGESTERONE; RESTRICTION; MORTALITY; MENARCHE; OVARIAN; WEIGHT	Background Because physical activity may affect hormonal concentrations and energy balance, we decided to investigate whether everyday exercise is related to the risk of breast cancer. Methods During 1974 to 1978 and 1977 to 1983, a total of 25,624 women, 20 to 54 years of age at entry, enrolled in health surveys and answered questionnaires about leisure-time and work activity. Results During a median follow-up of 13.7 years, we identified 351 cases of invasive breast cancer among the 25,624 women in the cohort. Greater leisure-time activity was associated with a reduced risk of breast cancer, after adjustments for age, body mass index (the weight in kilograms divided by the square of the height in meters), height, parity, and county of residence (relative risk, 0.63; 95 percent confidence interval, 0.42 to 0.95), among women who exercised regularly, as compared with sedentary women (P for trend = 0.04). In regularly exercising women, the reduction in risk was greater in premenopausal women than in postmenopausal women, and greater in younger women (<45 years at study entry) than in older women (greater than or equal to 45 years) (relative risk, 0.38; 95 percent confidence interval, 0.19 to 0.79). In stratified analyses the risk of breast cancer was lowest in lean women (body-mass index, <22.8) who exercised at least four hours per week (relative risk, 0.28; 95 percent confidence interval, 0.11 to 0.70). The risk was also reduced with higher levels of activity at work, and again there was a more pronounced effect among premenopausal than postmenopausal women. Conclusions Physical activity during leisure time and at work is associated with a reduced risk of breast cancer. (C) 1997, Massachusetts Medical Society.	CANC REGISTRY NORWAY,OSLO,NORWAY	University of Oslo	Thune, I (corresponding author), UNIV TROMSO,INST COMMUNITY MED,N-9037 TROMSO,NORWAY.		Brenn, Tormod/AAY-5357-2021	Brenn, Tormod/0000-0003-3717-8323; Lund, Eiliv/0000-0002-8071-8711				ALBANES D, 1989, AM J PUBLIC HEALTH, V79, P744, DOI 10.2105/AJPH.79.6.744; BEITINS IZ, 1991, J CLIN ENDOCR METAB, V72, P1350, DOI 10.1210/jcem-72-6-1350; BERNSTEIN L, 1987, BRIT J CANCER, V55, P681, DOI 10.1038/bjc.1987.139; BERNSTEIN L, 1994, J NATL CANCER I, V86, P1403, DOI 10.1093/jnci/86.18.1403; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BROOCKS A, 1990, J APPL PHYSIOL, V68, P2083, DOI 10.1152/jappl.1990.68.5.2083; BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103; COHEN LA, 1988, CANCER RES, V48, P4276; *COLL GROUP HORM F, 1996, LANCET, V347, P1713; DAvanzo B, 1996, CANCER EPIDEM BIOMAR, V5, P155; DORGAN JF, 1994, AM J EPIDEMIOL, V139, P662, DOI 10.1093/oxfordjournals.aje.a117056; DOSEMECI M, 1993, CANCER CAUSE CONTROL, V4, P313, DOI 10.1007/BF00051333; ELLISON PT, 1986, AM J OBSTET GYNECOL, V154, P1000, DOI 10.1016/0002-9378(86)90737-4; Freni SC, 1996, CANCER CAUSE CONTROL, V7, P358, DOI 10.1007/BF00052942; FRIEDENREICH CM, 1995, EUR J CANCER PREV, V4, P145, DOI 10.1097/00008469-199504000-00004; FRISCH RE, 1981, JAMA-J AM MED ASSOC, V246, P1559, DOI 10.1001/jama.246.14.1559; FRISCH RE, 1985, BRIT J CANCER, V52, P885, DOI 10.1038/bjc.1985.273; GAARD M, 1996, 1 CANC REG NORW; HAFFNER SM, 1991, INT J OBESITY, V15, P471; HARLOW SD, 1991, AM J EPIDEMIOL, V133, P38, DOI 10.1093/oxfordjournals.aje.a115800; HENDERSON BE, 1985, CANCER, V56, P1206, DOI 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9; HOLME I, 1981, ACTA MED SCAND, V209, P277; KRITCHEVSKY D, 1992, ADV EXP MED BIOL, V322, P131; KVALE G, 1988, CANCER-AM CANCER SOC, V62, P1625, DOI 10.1002/1097-0142(19881015)62:8<1625::AID-CNCR2820620828>3.0.CO;2-K; LOCHEN ML, 1992, J EPIDEMIOL COMMUNIT, V26, P103; LOKEN EB, 1987, VAR FODA S, V1, P33; LOUCKS AB, 1989, J CLIN ENDOCR METAB, V68, P402, DOI 10.1210/jcem-68-2-402; MERZENICH H, 1993, AM J EPIDEMIOL, V138, P217, DOI 10.1093/oxfordjournals.aje.a116850; Meyer F, 1990, Epidemiology, V1, P377, DOI 10.1097/00001648-199009000-00007; MITTENDORF R, 1995, CANCER CAUSE CONTROL, V6, P347, DOI 10.1007/BF00051410; MOISAN J, 1991, Medicine and Science in Sports and Exercise, V23, P1170; *NAT HLTH SCREEN S, 1988, CARD DIS STUD NORW C; PAFFENBARGER RS, 1987, AM J CLIN NUTR, V45, P312, DOI 10.1093/ajcn/45.1.312; PERUSSE L, 1989, AM J EPIDEMIOL, V129, P1012, DOI 10.1093/oxfordjournals.aje.a115205; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; PRIOR JC, 1990, NEW ENGL J MED, V323, P1221, DOI 10.1056/NEJM199011013231801; PRIOR JC, 1993, NEW ENGL J MED, V328, P1724; RUSSELL JB, 1984, OBSTET GYNECOL, V63, P452; SLATTERY ML, 1992, AM J CLIN NUTR, V55, P943, DOI 10.1093/ajcn/55.5.943; TAIOLI E, 1995, EUR J CANCER, V31A, P723, DOI 10.1016/0959-8049(95)00046-L; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; VENA JE, 1987, AM J CLIN NUTR, V45, P318, DOI 10.1093/ajcn/45.1.318; VIHKO VJ, 1992, ACTA ONCOL, V31, P201, DOI 10.3109/02841869209088903; WALBERGRANKIN J, 1992, INT J SPORTS MED, V13, P542, DOI 10.1055/s-2007-1021313; WARREN MP, 1980, J CLIN ENDOCR METAB, V51, P1150, DOI 10.1210/jcem-51-5-1150; WELSCH CW, 1985, CANCER RES, V45, P6147; WHELAN EA, 1994, AM J EPIDEMIOL, V140, P1081, DOI 10.1093/oxfordjournals.aje.a117208; Wilhelmsen L, 1976, Adv Cardiol, V18, P217; ZHENG W, 1993, CANCER-AM CANCER SOC, V71, P3620, DOI 10.1002/1097-0142(19930601)71:11<3620::AID-CNCR2820711125>3.0.CO;2-S; Ziegler RG, 1996, J NATL CANCER I, V88, P650, DOI 10.1093/jnci/88.10.650	51	408	413	3	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1269	1275		10.1056/NEJM199705013361801	http://dx.doi.org/10.1056/NEJM199705013361801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113929				2022-12-28	WOS:A1997WW26000001
J	Brozovic, N; Burbank, DW; Meigs, AJ				Brozovic, N; Burbank, DW; Meigs, AJ			Climatic limits on landscape development in the northwestern Himalaya	SCIENCE			English	Article							MOUNTAINS; CALIFORNIA; EVOLUTION; EROSION; RANGES; UPLIFT	The interaction between tectonism and erosion produces rugged landscapes in actively deforming regions. In the northwestern Himalaya, the form of the landscape was found to be largely independent of exhumation rates, but regional trends in mean and modal elevations, hypsometry (frequency distribution of altitude), and slope distributions were correlated with the extent of glaciation. These observations imply that in mountain belts that intersect the snowline, glacial and periglacial processes place an upper limit on altitude, relief, and the development of topography irrespective of the rate of tectonic processes operating.	UNIV SO CALIF,DEPT EARTH SCI,LOS ANGELES,CA 90089	University of Southern California			Meigs, Andrew/A-6230-2011	Brozovic, Nicholas/0000-0002-2218-4934				ANDERSON RS, 1994, J GEOPHYS RES-SOL EA, V99, P20161, DOI 10.1029/94JB00713; BENXING Z, 1989, Z GEOMORPH S, V76, P89; BROECKER WS, 1990, SCI AM, V262, P48, DOI 10.1038/scientificamerican0190-48; Burbank DW, 1996, NATURE, V379, P505, DOI 10.1038/379505a0; DAWSON GM, 1896, GEOL SURV CAN, V7, P11; DERBYSHIRE E, 1984, INT KARAKORAM PROJEC, V2, P456; FERGUSON RI, 1984, INT KARAKORAM PROJEC, V2, P581; FIELDING E, 1994, GEOLOGY, V22, P163, DOI 10.1130/0091-7613(1994)022<0163:HFIT>2.3.CO;2; FURBISH DJ, 1984, J GLACIOL, V30, P199, DOI 10.3189/S0022143000005931; Gerrard AJ, 1990, MOUNTAIN ENV EXAMINA; Hallet B, 1996, GLOBAL PLANET CHANGE, V12, P213, DOI 10.1016/0921-8181(95)00021-6; Hewitt, 1989, Z GEOMORPHOL S, V76, P9; HEWITT K, 1988, SCIENCE, V242, P64, DOI 10.1126/science.242.4875.64; Holmes J.A., 1993, HIMALAYA SEA GEOLOGY, P72; HUMPHREY NF, 1994, J GLACIOL, V40, P539, DOI 10.1017/S0022143000012429; KELSEY HM, 1994, J GEOPHYS RES-SOL EA, V99, P12245, DOI 10.1029/93JB03236; Kuhle M., 1986, GeoJournal, V13, P331, DOI 10.1007/BF00224590; Kuhle M., 1988, GeoJournal, V17, P545; LIFTON NA, 1992, GEOMORPHOLOGY, V5, P77, DOI 10.1016/0169-555X(92)90059-W; MERCER J.H., 1975, MOUNTAIN GLACIERS NO, V1, P371; MOLNAR P, 1990, NATURE, V346, P29, DOI 10.1038/346029a0; Molnar P., 1988, GEOL SOC AM SPEC PAP, V218, P179; OWEN LA, 1989, TECTONOPHYSICS, V163, P227, DOI 10.1016/0040-1951(89)90260-6; PENCK A, 1886, SCHR VER VEBR NATURW, V27; PORTER SC, 1989, QUATERNARY RES, V32, P245, DOI 10.1016/0033-5894(89)90092-6; PORTER SC, 1970, GEOL SOC AM BULL, V81, P1421, DOI 10.1130/0016-7606(1970)81[1421:QGRISK]2.0.CO;2; SCHMIDT KM, 1995, SCIENCE, V270, P617, DOI 10.1126/science.270.5236.617; SCOTT CH, 1992, THESIS U LEICESTER E; SEARLE M. P., 1991, GEOLOGY TECTONICS KA; Sharma MC, 1996, QUATERNARY SCI REV, V15, P335, DOI 10.1016/0277-3791(95)00061-5; Shroder J. F., 1993, HIMALAYA SEA GEOLOGY, P1; Shroder JF, 1993, HIMALAYA SEA GEOLOGY, P132; SLAYMAKER O, 1990, MT RES DEV, V10, P171, DOI 10.2307/3673427; Small EE, 1995, GEOMORPHOLOGY, V14, P109, DOI 10.1016/0169-555X(95)00052-3; TROLL C., 1972, GEOECOLOGY HIGH MOUN, P264; VONWISSMANN H, 1959, AKAD WISS LIT MAI MN, V14, P4; WEIERS S., 1995, BONN GEOGR ABH, V92, P1; Winslow DM, 1996, TECTONICS, V15, P1292, DOI 10.1029/96TC00032; Zeitler P.K., 1989, GEOL SOC AM SPEC PAP, V232, DOI 10.1130/SPE232-p1; [No title captured], DOI DOI 10.3112/ERDKUNDE.1956.01.01; [No title captured]	41	301	315	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					571	574		10.1126/science.276.5312.571	http://dx.doi.org/10.1126/science.276.5312.571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110972				2022-12-28	WOS:A1997WV72100039
J	Retallack, GJ				Retallack, GJ			Early forest soils and their role in Devonian global change	SCIENCE			English	Article							FOSSIL RECORD; LAND; COMPLETENESS; EVOLUTION; PALEOSOLS; ANIMALS; PLANTS	A paleosol in the Middle Devonian Aztec Siltstone of Victoria Land, Antarctica, is the most ancient known soil of well-drained forest ecosystems. Clay enrichment and chemical weathering of subsurface horizons in this and other Devonian forested paleosols culminate a long-term increase initiated during the Silurian. From Silurian into Devonian time, red clayey calcareous paleosols show a greater volume of roots and a concomitant decline in the density of animal burrows. These trends parallel the decline in atmospheric carbon dioxide determined from isotopic records of pedogenic carbonate in these same paleosols. The drawdown of carbon dioxide began well before the Devonian appearance of coals, large logs, and diverse terrestrial plants and animals, and it did not correlate with temporal variation in volcanic or metamorphic activity. The early Paleozoic greenhouse may have been curbed by the evolution of rhizospheres with an increased ratio of primary to secondary production and by more effective silicate weathering during Silurian time.			Retallack, GJ (corresponding author), UNIV OREGON,DEPT GEOL SCI,EUGENE,OR 97403, USA.							Algeo T.J., 1995, GSA TODAY, V5, P64; ASKIN RA, 1971, VICTORIA U WELLINGTO, V2; BECK CB, 1964, MEM TORREY BOT CLUB, V21, P26; BERNER RA, 1993, SCIENCE, V261, P68, DOI 10.1126/science.261.5117.68; BINNEY EW, 1845, PHIL MAG J SCI, V3, P241; BINNEY EW, 1846, P GEOL SOC LONDON, V2, P390; Cai CY, 1996, NATURE, V379, P592, DOI 10.1038/379592a0; Chaloner W.G., 1979, SPEC PAP PALAEONTOL, V23, P145; Cleal C.J., 1995, PALAEOZOIC PALAEOBOT; Dimichele William A., 1992, P205; DRIESE SG, 1992, J SEDIMENT PETROL, V62, P825; DRIESE SG, 1993, U TENN DEP GEOL SCI, V22, P91; Embleton B.J.J., 1984, PHANEROZOIC EARTH HI, P11; *FAO, 1974, WORLD MAP SOILS, V1; Frakes L. A, 1992, CLIMATE MODES PHANER; GRAY J, 1993, PALAEOGEOGR PALAEOCL, V104, P153, DOI 10.1016/0031-0182(93)90127-5; Harland W.B., 1990, GEOLOGIC TIME SCALE; JOECKEL RM, 1995, PALAEOGEOGR PALAEOCL, V118, P159, DOI 10.1016/0031-0182(95)00005-8; JOHNSON EW, 1994, GEOL MAG, V131, P395, DOI 10.1017/S0016756800011146; JONGMANS MJ, 1955, ASS ETUD PALEONT STR, V21, P63; KUMP LR, 1986, AM J SCI, V286, P337, DOI 10.2475/ajs.286.5.337; MAXWELL WD, 1990, PALEOBIOLOGY, V16, P322, DOI 10.1017/S0094837300010022; MCPHERSON JG, 1979, SEDIMENT GEOL, V22, P267, DOI 10.1016/0037-0738(79)90056-3; MCPHERSON JG, 1980, SEDIMENT GEOL, V27, P119, DOI 10.1016/0037-0738(80)90033-0; Miller K.B., 1993, KANSAS GEOLOGICAL SU, V235, P1; MPORA CI, 1996, SCIENCE, V271, P1105; MURTHY RS, 1982, BENCHMARK SOILS INDI; NIKLAS K.J., 1985, Phanerozoic Diversity Patterns: Profiles in Macroevolution, P143, DOI DOI 10.1515/9781400855056.97; PLAYFORD G, 1990, ANTARCTIC PALEOBIOLOGY, P51; RETALLACK G, 1984, PALEOBIOLOGY, V10, P59, DOI 10.1017/S0094837300008022; Retallack G. J., 1992, Weathering, soils & paleosols., P543; Retallack G. J., 1993, U TENN DEP GEOL SCI, V22, P33; Retallack G.J., 1990, SOILPAST, P20; RETALLACK GJ, 1994, SCIENCE, V265, P499, DOI 10.1126/science.265.5171.499; RETALLACK GJ, 1985, PHILOS T ROY SOC B, V309, P105, DOI 10.1098/rstb.1985.0074; Retallack GJ, 1996, GEOL SOC AM BULL, V108, P195, DOI 10.1130/0016-7606(1996)108<0195:GCGBPT>2.3.CO;2; RETALLACK GJ, 1987, SCIENCE, V235, P61, DOI 10.1126/science.235.4784.61; RETALLACK GJ, 1996, ANTARCT J US, V30, P62; Retallack GJ, 1991, MIOCENE PALEOSOLS AP; Retallack Gregory J., 1992, Palaios, V7, P508, DOI 10.2307/3514848; ROBINSON JM, 1990, GEOLOGY, V18, P607, DOI 10.1130/0091-7613(1990)015<0607:LLPAFB>2.3.CO;2; Sepkoski J.J. Jr, 1985, P11; Seward, 1917, FOSSIL PLANTS, VIII; Soil Survey Staff, 1990, KEYS SOIL TAX; SRIVASTAVA P, 1994, SEDIMENT GEOL, V94, P129, DOI 10.1016/0037-0738(94)90151-1; SWAIN T, 1981, PALEOBOTANY PALEOECO, V1, P103; YAPP CJ, 1994, NATURE, V368, P49, DOI 10.1038/368049a0; YAPP CS, 1992, NATURE, V355, P2395; YOUNG G C, 1988, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V202, P1; YOUNG GC, 1993, PALAEOZOIC VERTEBRAT, P206; ZIMMER C, 1993, DISCOVER, V14, P16	51	155	166	2	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					583	585		10.1126/science.276.5312.583	http://dx.doi.org/10.1126/science.276.5312.583			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110975				2022-12-28	WOS:A1997WV72100042
J	Bezzubova, O; Silbergleit, A; YamaguchiIwai, Y; Takeda, S; Buerstedde, JM				Bezzubova, O; Silbergleit, A; YamaguchiIwai, Y; Takeda, S; Buerstedde, JM			Reduced X-ray resistance and homologous recombination frequencies in a RAD54(-/-) mutant of the chicken DT40 cell line	CELL			English	Article							STRAND-BREAK REPAIR; ESCHERICHIA-COLI RECA; LIGHT CHAIN GENE; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; DNA-REPAIR; YEAST RECOMBINATION; SENSITIVE MUTANTS; HIGHER EUKARYOTES; MOUSE HOMOLOG	rad54 mutants of the yeast Saccharomyces cerevisiae are extremely X-ray sensitive and have decreased mitotic recombination frequencies because of a defect in double-strand break repair. A RAD54 homolog was disrupted in the chicken B cell line DT40, which undergoes immunoglobulin gene conversion and exhibits unusually high ratios of targeted to random integration after DNA transfection. Homozygous RAD54(-/-) mutant clones were highly X-ray sensitive compared to wildtype cells. The rate of immunoglobulin gene conversion was 6- to 8-fold reduced, and the frequency of targeted integration was at least two orders of magnitude decreased in the mutant clones. Reexpression of the RAD54 cDNA restored radiation resistance and targeted integration activity. The reported phenotype provides the first genetic evidence of a link between double-strand break repair and homologous recombination in vertebrate cells.	KYOTO UNIV, SCH MED, BAYER CHAIR DEPT MOL IMMUNOL, KYOTO 606, JAPAN	Kyoto University	Bezzubova, O (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.			Takeda, Shunichi/0000-0002-7924-7991				BENDIXEN C, 1994, GENOMICS, V23, P300, DOI 10.1006/geno.1994.1503; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BUDD M, 1982, MUTAT RES, V103, P19, DOI 10.1016/0165-7992(82)90080-X; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CALDERON IL, 1983, CURR GENET, V7, P93, DOI 10.1007/BF00365632; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; CONTOPOULOU CR, 1987, YEAST, V3, P71, DOI 10.1002/yea.320030203; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Luria SE, 1943, GENETICS, V28, P491; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; Muris DFR, 1996, J CELL SCI, V109, P73; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; MURIS DFR, 1997, IN PRESS CURR GENET; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAEKI T, 1980, MUTAT RES, V73, P251, DOI 10.1016/0027-5107(80)90192-X; SHINOHARA A, 1993, NAT GENET, V5, P312, DOI 10.1038/ng1193-312c; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAKEDA S, 1992, P NATL ACAD SCI USA, V89, P4023, DOI 10.1073/pnas.89.9.4023; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0	49	233	239	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					185	193		10.1016/S0092-8674(00)80198-1	http://dx.doi.org/10.1016/S0092-8674(00)80198-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108474	Bronze			2022-12-28	WOS:A1997WU88800006
J	Volterrani, M; Desenzani, P; Lorusso, R; dAloia, A; Manelli, F; Giustina, A				Volterrani, M; Desenzani, P; Lorusso, R; dAloia, A; Manelli, F; Giustina, A			Haemodynamic effects of intravenous growth hormone in congestive heart failure	LANCET			English	Article									IRCCS,INST REHABIL,DIV CARDIOL,SALVATORE MAUGERI FDN,GUSSAGO,ITALY	Istituti Clinici Scientifici Maugeri IRCCS	Volterrani, M (corresponding author), UNIV BRESCIA,ENDOCRINE SECT,I-25123 BRESCIA,ITALY.		Giustina, Andrea/AAN-5938-2020; Lorusso, Roberto/ABB-9275-2020; Manelli, Filippo/AAL-8616-2020; volterrani, maurizio/K-5919-2016	Lorusso, Roberto/0000-0002-1777-2045; Manelli, Filippo/0000-0003-0797-0360; volterrani, maurizio/0000-0002-2624-9213; Manelli, Filippo/0000-0001-6766-9428				Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; GIUSTINA A, 1995, AM J CARDIOL, V75, P1042, DOI 10.1016/S0002-9149(99)80721-8; GIUSTINA A, 1996, AM HEART J, V131, P629; GROSE R, 1986, J AM COLL CARDIOL, V7, P1107, DOI 10.1016/S0735-1097(86)80231-5; Turner H, 1996, NEW ENGL J MED, V335, P672	5	95	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1067	1068		10.1016/S0140-6736(97)24015-8	http://dx.doi.org/10.1016/S0140-6736(97)24015-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107247				2022-12-28	WOS:A1997WU00200013
J	Isozaki, Y				Isozaki, Y			Permo-triassic boundary superanoxia and stratified superocean: Records from lost deep sea	SCIENCE			English	Article							MASS EXTINCTION; OCEAN	Pelagic cherts of Japan and British Columbia, Canada, recorded a long-term and worldwide deep-sea anoxic (oxygen-depleted) event across the Permo-Triassic (or Paleozoic and Mesozoic) boundary (251 +/- 2 million years ago). The symmetry in lithostratigraphy and redox condition of the boundary sections suggest that the superocean Panthalassa became totally stratified for nearly 20 million years across the boundary. The timing of onset, climax, and termination of the oceanic stratification correspond to global biotic events including the end-Guadalupian decline, the end-Permian extinction, and mid-Triassic recovery.			Isozaki, Y (corresponding author), TOKYO INST TECHNOL, DEPT EARTH & PLANETARY SCI, MEGURO KU, O OKAYAMA, TOKYO 152, JAPAN.		Isozaki, Yukio/A-1806-2009	Isozaki, Yukio/0000-0002-3596-581X				BAUD A, 1989, GEOL RUNDSCH, V78, P649, DOI 10.1007/BF01776196; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Cordey F., 1986, 861A CURR RES A GEOL, P595, DOI 10.4095/120430; Erwin D. H, 1993, GREAT PALEOZOIC CRIS; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; Flugel Erik, 1994, Geological Society of America Special Paper, V288, P247; Grotzinger JP, 1995, PALAIOS, V10, P578, DOI 10.2307/3515096; Hallam A., 1994, Canadian Society of Petroleum Geologists Memoir, V17, P797; HAY WW, 1988, GEOL SOC AM BULL, V100, P1934, DOI 10.1130/0016-7606(1988)100<1934:PARFTG>2.3.CO;2; HOLSER WT, 1989, NATURE, V337, P39, DOI 10.1038/337039a0; Ishiga H, 1996, ISL ARC, V5, P180; ISIIIGA II, 1990, PRECRETACEOUS TERRAN, V224, P285; Isozaki Y, 1997, ISL ARC, V6, P25, DOI 10.1111/j.1440-1738.1997.tb00039.x; Isozaki Y., 1996, ISL ARC, V5, P289, DOI [DOI 10.1111/J.1440-1738.1996.TB00033.X, 10.1111/j.1440-1738.1996.tb00033.x]; ISOZAKI Y, 1996, GEOLOGY PALEONTOLOGY, P245; Isozaki Yukio, 1994, Canadian Society of Petroleum Geologists Memoir, V17, P805; JENKYNS HC, 1988, AM J SCI, V288, P101, DOI 10.2475/ajs.288.2.101; JENKYNS HC, 1980, J GEOL SOC LONDON, V137, P171, DOI 10.1144/gsjgs.137.2.0171; KAJIWARA Y, 1994, PALAEOGEOGR PALAEOCL, V111, P367, DOI 10.1016/0031-0182(94)90072-8; Kakuwa Y, 1996, PALAEOGEOGR PALAEOCL, V121, P35, DOI 10.1016/0031-0182(95)00070-4; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; Kubo K., 1996, J GEOL SOC JPN, V102, P40; Kuwahara K., 1991, Journal of the Geological Society of Japan, V97, P1005; MAGARITZ M., 1980, CONTRIB SEDIMENTOL, V9, P269; MATSUDA T, 1991, TECTONICS, V10, P475, DOI 10.1029/90TC02134; Nakao K., 1994, MINO BELT SW JAPAN J, V100, P505; ORCHARD MJ, 1984, 841B PAP GEOL SURV C, P197; ROSS CA, 1994, CANADIAN SOC PETROLE, V17, P81; SCOTESE C.R., 1995, PERMIAN NO PANGEA PA, P3; SEPKOSKI JJ, 1984, J GEOL SOC LONDON, V146, P7; Sepkoski Jr J. J., 1986, GLOBAL BIOEVENTS, P47; STANLEY SM, 1994, SCIENCE, V266, P1340, DOI 10.1126/science.266.5189.1340; Sugiyama K., 1992, Transactions and Proceedings of the Palaeontological Society of Japan New Series, P1180; SUGIYAMA K, 1995 ANN M PAL SOC J, P124; TYSON RV, 1979, NATURE, V277, P377, DOI 10.1038/277377a0; WIGNALL PB, 1992, PALAEOGEOGR PALAEOCL, V93, P21, DOI 10.1016/0031-0182(92)90182-5; Wignall PB, 1996, SCIENCE, V272, P1155, DOI 10.1126/science.272.5265.1155; WIGNALL PB, 1993, PALAEOGEOGR PALAEOCL, V102, P215, DOI 10.1016/0031-0182(93)90068-T; YAMAKITA S, 1987, Journal of the Geological Society of Japan, V93, P145; YAMAKITA S, 1993 ANN M GEOL SOC, P65; [No title captured]	41	632	690	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					235	238		10.1126/science.276.5310.235	http://dx.doi.org/10.1126/science.276.5310.235			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092467				2022-12-28	WOS:A1997WT92500038
J	Schlozman, S				Schlozman, S			The Bard in his outcast state	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1118	1118						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087460				2022-12-28	WOS:A1997WR34200015
J	Hampton, JR; vanVeldhuisen, DJ; Kleber, FX; Cowley, AJ; Ardia, A; Block, P; Cortina, A; Cserhalmi, L; Follath, F; Jensen, G; Kayanakis, J; Lie, KI; Mancia, G; Skene, AM				Hampton, JR; vanVeldhuisen, DJ; Kleber, FX; Cowley, AJ; Ardia, A; Block, P; Cortina, A; Cserhalmi, L; Follath, F; Jensen, G; Kayanakis, J; Lie, KI; Mancia, G; Skene, AM			Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure	LANCET			English	Article							CONVERTING ENZYME-INHIBITOR; LONG-TERM THERAPY; TRIAL; CATECHOLAMINES; HEMODYNAMICS; DIGOXIN	Background Drugs that improve symptoms in patients with heart failure must also be assessed for their effects on survival. Ibopamine stimulates DA-1 and DA-2 receptors and causes peripheral and renal vasodilatation; the drug improves symptoms of heart failure. We assessed the effect of ibopamine on survival in patients with advanced heart failure in a multicentre, randomised placebo-controlled study. Methods Patients with advanced severe heart failure (New York Heart Association classes III and IV) and evidence of severe left-ventricular disease, who were already receiving optimum treatment for heart failure, were randomly allocated oral ibopamine 100 mg three times daily or placebo. The primary endpoint was all-cause mortality. The study was designed to recruit 2200 patients, and the minimum duration of treatment would be 6 months. We did intention-to-treat and on-treatment analyses; a post-hoc subgroup analysis was also done. Findings After we had recruited 1906 patients the trial was stopped early, because of an excess of deaths among patients in the ibopamine group. 232 (25%) of 953 patients in the ibopamine group died, compared with 193 (20%) of 953 patients in the placebo group (relative risk 1.26 [95% CI 1.04-1.53], p=0.017). The average length of follow-up was 347 days in the ibopamine group and 363 days in the placebo group. In multivariate analysis, only the use of antiarrhythmic drugs at baseline was a significant independent predictor of increased fatality in ibopamine-treated patients. Interpretation Ibopamine seems to increase the risk of death among patients with advanced heart failure who are already receiving optimum therapy, but the reasons for this increase are not clear. Our finding that antiarrhythmic treatment was a significant predictor of increased mortality in ibopamine-treated patients may be important, but exploratory analyses must be interpreted with caution.	UNIV GRONINGEN HOSP,GRONINGEN,NETHERLANDS; UNIV KLINIKUM CHARITE,BERLIN,GERMANY; DEPT BIOSTAT,ZAMBON GRP,MILAN,ITALY; ACAD ZIEKENHUIS,BRUSSELS,BELGIUM; UNIV OVIEDO,HOSP CENT ASTURIAS,E-33080 OVIEDO,SPAIN; HUNGARIAN INST CARDIOL,BUDAPEST,HUNGARY; UNIV SPITAL ZURICH,ZURICH,SWITZERLAND; UNIV COPENHAGEN,HVIDOVRE HOSP,DK-2650 HVIDOVRE,DENMARK; UNIV AMSTERDAM,ACAD MED CTR,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV MILAN,MILAN,ITALY; NOTTINGHAM CLIN TRIAL DATA CTR,NOTTINGHAM,ENGLAND	University of Groningen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Zambon; Central University Hospital Asturias; University of Oviedo; University of Zurich; University Zurich Hospital; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; University of Milan	Hampton, JR (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.		van Veldhuisen, Dirk Jan/E-8967-2014					BARABINO A, 1991, CARDIOLOGY, V78, P243, DOI 10.1159/000174791; COWLEY AJ, 1994, BRIT HEART J, V72, P226; Dohmenon Henk J. M., 1995, European Heart Journal, V16, P181; Hunt SM, 1991, NOTTINGHAM HLTH PROF; ITOH H, 1991, AM J MED, V90, pS36, DOI 10.1016/0002-9343(91)90272-Y; MASSIE BM, 1993, CIRCULATION, V88, P492, DOI 10.1161/01.CIR.88.2.492; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; ROUSSEAU MF, 1992, J CARDIOVASC PHARM, V19, P155, DOI 10.1097/00005344-199202000-00001; ROUSSEAU MF, 1994, AM J CARDIOL, V73, P488, DOI 10.1016/0002-9149(94)90680-7; VANVELDHUISEN DJ, 1991, AM J CARDIOL, V68, P1194, DOI 10.1016/0002-9149(91)90193-O; VANVELDHUISEN DJ, 1993, AM J CARDIOL, V71, P992, DOI 10.1016/0002-9149(93)90920-8; VANVELDHUISEN DJ, 1993, J AM COLL CARDIOL, V22, P1564, DOI 10.1016/0735-1097(93)90579-P	12	253	266	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					971	977		10.1016/S0140-6736(96)10488-8	http://dx.doi.org/10.1016/S0140-6736(96)10488-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100622	Green Submitted			2022-12-28	WOS:A1997WR62100008
J	Wallace, SJ				Wallace, SJ			First tonic-clonic seizures in childhood	LANCET			English	Article							1ST UNPROVOKED SEIZURE; STATUS EPILEPTICUS; FEBRILE CONVULSION; FOLLOW-UP; EPILEPSY; CHILDREN; MANAGEMENT; RECURRENCE; RISK; ABSENCES				Wallace, SJ (corresponding author), UNIV WALES HOSP, DEPT CHILD HLTH, CARDIFF CF4 4XW, S GLAM, WALES.							AICARDI J, 1994, EPILEPSY CHILDREN; Aicardi Jean, 1992, P97; ALDENKAMP AP, 1995, EPILEPSY CHILDREN AD; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; APPLETON RE, 1995, ARCH DIS CHILD, V72, P386, DOI 10.1136/adc.72.5.386; APPLETON RE, 1993, J NEUROL NEUROSUR PS, V56, P1312, DOI 10.1136/jnnp.56.12.1312; BALSLEV T, 1991, ACTA PAEDIATR SCAND, V80, P466, DOI 10.1111/j.1651-2227.1991.tb11883.x; BAUMER JH, 1981, DEV MED CHILD NEUROL, V23, P462; Beck-Mannagetta G, 1989, GENETICS EPILEPSIES; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; BITTENCOURT PRM, 1988, RECENT ADV EPILEPSY, V4, P123; CAMFIELD P, 1994, DEV MED CHILD NEUROL, V36, P887; DAHL J, 1992, EPILEPSY BEHAV MED A; DESILVA M, 1989, ROY SOC MED INT CONG, V152, P81; Doose Hermann, 1992, P103; Dravet Charlotte, 1992, P75; Ferrie CD, 1996, ARCH DIS CHILD, V75, P102, DOI 10.1136/adc.75.2.102; FISHER RS, 1994, IMITATORS EPILEPSY; GASTAUT H., 1966, EPILESPSIA, V7, P139; GEAUMANOIR A, 1989, REFLEX SEIZURES REFL; GENTON P, 1994, EPILEPTIC SEIZURES S, P241; GOOSSENS LAZ, 1990, NEUROLOGY, V40, P1171, DOI 10.1212/WNL.40.8.1171; GRAM L, 1990, EPILEPSY LANCET REV; GUERRINI R, 1995, EPILEPSIA, V36, P883, DOI 10.1111/j.1528-1157.1995.tb01631.x; Harding G., 1994, PHOTOSENSITIVE EPILE; HARDING GFA, 1994, PHOTOSENSITIVE EPILE, P5; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HOLMES GL, 1987, ANN NEUROL, V21, P268, DOI 10.1002/ana.410210308; JANZ D, 1985, ACTA NEUROL SCAND, V72, P449; Janz D, 1997, EPILEPSIA, V38, P4, DOI 10.1111/j.1528-1157.1997.tb01073.x; JANZ D, 1994, EPILEPTIC SEIZURES S, P213; KIESLICH M, 1995, LANCET, V345, P187, DOI 10.1016/S0140-6736(95)90188-4; KIRKHAM FJ, 1995, RECENT ADV EPILEPSY, P139; KUNZE J, 1980, NEUROPEDIATRICS, V11, P203, DOI 10.1055/s-2008-1071392; KUZNIECKY R, 1993, NEUROLOGY, V43, P681, DOI 10.1212/WNL.43.4.681; LAIDLAW J, 1993, TXB EPILEPSY; Livingston John, 1996, P429; LOISEAU P, 1973, EPILEPSIA, V14, P381, DOI 10.1111/j.1528-1157.1973.tb03977.x; LOISEAU P, 1978, LANCET, V2, P1070; Malafosse A, 1994, IDIOPATHIC GEN EPILE; MANONMANI V, 1994, ARCH DIS CHILD, V70, P288, DOI 10.1136/adc.70.4.288; MAYTAL J, 1989, PEDIATRICS, V83, P323; MAYTAL J, 1990, PEDIATRICS, V86, P611; Meldrum B, 1985, RECENT ADV EPILEPSY, V2, P239; NIEDERMEYER Ernst, 1982, ELECTROEN CLIN NEURO; Okumura A, 1996, ARCH DIS CHILD, V74, P19, DOI 10.1136/adc.74.1.19; Oller-Daurella Luis, 1992, P161; OTSUBO H, 1993, PEDIATR NEUROL, V9, P101, DOI 10.1016/0887-8994(93)90043-C; PANAYIOTOPOULOS CP, 1989, ANN NEUROL, V26, P51, DOI 10.1002/ana.410260108; PANAYIOTOPOULOS CP, 1994, EPILEPTIC SEIZURES S, P143; SCHWARTZKROIN PA, 1995, BRAIN DEV EPILEPSY; SHINNAR S, 1990, PEDIATRICS, V85, P1076; Shorvon S, 1994, STATUS EPILEPTICUS; SJORS K, 1993, ACTA PAEDIATR, V82, P66, DOI 10.1111/j.1651-2227.1993.tb12519.x; STEPHENSON JBP, 1992, CURR PAEDIAT, V2, P63; Taylor David C., 1996, P601; TREIMAN DM, 1990, NEUROLOGY, V40, P32; TRENITE DGAK, 1987, J NEUROL NEUROSUR PS, V50, P1546, DOI 10.1136/jnnp.50.11.1546; TRENITE DGAKN, 1994, LANCET, V344, P1102, DOI 10.1016/S0140-6736(94)90625-4; TUNIK MG, 1992, PEDIATR CLIN N AM, V39, P1007; VONWENDT L, 1985, EUR J PEDIATR, V144, P149; WALLACE S, 1996, EPILEPSY CHILDREN; Wallace S J, 1994, Seizure, V3, P177, DOI 10.1016/S1059-1311(05)80186-4; WALLACE SJ, 1988, CHILD FEBRILE SEIZUR, P54; WILLIAMS BA, 1992, J CHILD NEUROL, V7, P291, DOI 10.1177/088307389200700309; WOLF P, 1994, EPILEPTIC SEIZURES S, P67	67	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	1997	349	9057					1009	1012		10.1016/S0140-6736(96)09023-X	http://dx.doi.org/10.1016/S0140-6736(96)09023-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100638				2022-12-28	WOS:A1997WR62100041
J	Hegde, AN; Inokuchi, K; Pei, WZ; Casadio, A; Ghirardi, M; Chain, DG; Martin, KC; Kandel, ER; Schwartz, JH				Hegde, AN; Inokuchi, K; Pei, WZ; Casadio, A; Ghirardi, M; Chain, DG; Martin, KC; Kandel, ER; Schwartz, JH			Ubiquitin C-terminal hydrolase is an immediate-early gene essential for long-term facilitation in Aplysia	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SIPHON-WITHDRAWAL REFLEX; CAMP-RESPONSIVE ELEMENT; SENSORY NEURONS; REGULATORY SUBUNITS; TRANSMITTER RELEASE; MOLECULAR MECHANISM; CYCLIC-AMP; DEGRADATION; PROTEOLYSIS	The switch from short-term to long-term facilitation of the synapses between sensory and motor neurons mediating gill and tail withdrawal reflexes in Aplysia requires CREB-mediated transcription and new protein synthesis. We isolated several downstream genes, one of which encodes a neuron-specific ubiquitin C-terminal hydrolase. This rapidly induced gene encodes an enzyme that associates with the proteasome and increases its proteolytic activity. This regulated proteolysis is essential for long-term facilitation. Inhibiting the expression or function of the hydrolase blocks induction of long-term but not short-term facilitation. We suggest that the enhanced proteasome activity increases degradation of substrates that normally inhibit long-term facilitation. Thus, through induction of the hydrolase and the resulting up-regulation of the ubiquitin pathway, learning recruits a regulated form of proteolysis that removes inhibitory constraints on long-term memory storage.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,HOWARD HUGHES MED INST,NEW YORK,NY 10032; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; UNIV TURIN,DIPARTIMENTO NEUROSCI,I-10125 TURIN,ITALY	Columbia University; Howard Hughes Medical Institute; New York State Psychiatry Institute; University of Turin	Hegde, AN (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		Schwartz, John/AAO-8158-2021; Inokuchi, Kaoru/AAI-9693-2020; ghirardi, mirella/AEQ-0420-2022	Schwartz, John/0000-0002-1660-8681; Inokuchi, Kaoru/0000-0002-5393-3133; 	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029255, R55NS029255] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00921] Funding Source: Medline; NINDS NIH HHS [NS29255] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BEERS EP, 1993, J BIOL CHEM, V268, P21645; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BERNIER L, 1982, J NEUROSCI, V2, P1682; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; Byrne JH, 1996, J NEUROSCI, V16, P425; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; CHAIN DG, 1995, J NEUROSCI, V15, P7592; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DALE N, 1987, J NEUROSCI, V7, P2232; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; HADARI T, 1992, J BIOL CHEM, V267, P719; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KREUTZERSCHMID C, 1990, FEBS LETT, V267, P142, DOI 10.1016/0014-5793(90)80309-7; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MONTAROLO PG, 1988, NATURE, V333, P171, DOI 10.1038/333171a0; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; OH CE, 1994, J NEUROSCI, V14, P3166; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SCHWARTZ JH, 1971, J NEUROPHYSIOL, V34, P939, DOI 10.1152/jn.1971.34.6.939; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; TAMURA T, 1991, FEBS LETT, V292, P154, DOI 10.1016/0014-5793(91)80856-X; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	55	305	313	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					115	126		10.1016/S0092-8674(00)80188-9	http://dx.doi.org/10.1016/S0092-8674(00)80188-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094720	hybrid			2022-12-28	WOS:A1997WR68500015
J	Giardiello, FM; Brensinger, JD; Luce, MC; Petersen, GM; Cayouette, MC; Krush, AJ; Bacon, JA; Booker, SV; Bufill, JA; Hamilton, SR				Giardiello, FM; Brensinger, JD; Luce, MC; Petersen, GM; Cayouette, MC; Krush, AJ; Bacon, JA; Booker, SV; Bufill, JA; Hamilton, SR			Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene	ANNALS OF INTERNAL MEDICINE			English	Article							GERM-LINE MUTATIONS; APC GENE; ATTENUATED FORM; CANCER; IDENTIFICATION; LOCUS; FAP; CHROMOSOME-5Q21; VARIANT	Background: Germline mutation in a gene on chromosome 5 (the adenomatous polyposis coli gene) causes familial adenomatous polyposis of the colorectum. Phenotypic manifestations of this condition vary, but the exact relation of the phenotype to the mutation site along the gene has not been fully described. Objective: To determine how the location of mutations along a gene that is associated with multiple colorectal polyps (the adenomatous polyposis coli gene) is related to the phenotypic expression of the syndrome in families. Design: Prospective cohort study. Setting: Polyposis registry. Patients: 20 patients from 7 families that had mutations in the adenomatous polyposis coli gene that were located toward the 5' end of codon 158 (proximal 5' families), were compared with 52 patients from 7 families that had mutations downstream from codon 158, in codons 179 to 625 (distal 5' families). Measurements: Sex, age at diagnosis of familial adenomatous polyposis, number of polyps at first examination of the colon, distribution of polyps, age at diagnosis of colorectal cancer, and location of colorectal cancer. Results: Mutations that were proximal to codon 158 were found in 7 of 112 families (6%). At the first examination of the colon, 8 of 17 (47%) patients in proximal 5' families and 9 of 48 (19%) patients of similar ages in distal 5' families were found to have fewer than 100 adenomas (P = 0.029). The distribution of polyps was frequently right-sided in patients in proximal 5' families (P = 0.001). The cumulative probability of survival without colorectal cancer was greater for patients in proximal 5' families (P = 0.041). Conclusions: Families with adenomatous polyposis that have proximal 5' mutations of the adenomatous polyposis coli gene are more likely to have a heterogeneous phenotype with delayed development of colonic polyposis and colorectal cancer than are families with distal 5' mutations of the gene. Management should include genotyping of patients who are at risk, colonoscopic surveillance of genotypically positive persons, and prophylactic colectomy if several adenomas are found.	JOHNS HOPKINS HEREDITARY COLORECTAL CANC REGISTRY, BALTIMORE, MD 21205 USA; MYRIAD GENET, SALT LAKE CITY, UT 84108 USA; JOHNS HOPKINS UNIV, SCH PUBL HLTH, BALTIMORE, MD 21205 USA; LABCORP, RES TRIANGLE PK, NC 27709 USA; ELKHART CLIN, ELKHART, IN 46514 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, DIV GASTROINTESTINAL LIVER PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Myriad Genetics, Inc; Johns Hopkins University; Johns Hopkins University	Giardiello, FM (corresponding author), JOHNS HOPKINS UNIV HOSP, 600 N WOLFE ST, BLALOCK 935, BALTIMORE, MD 21287 USA.				NCI NIH HHS [CA 63721, CA 53801, CA 62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063721, P50CA062924, U01CA053801] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURT RW, 1995, GASTROENTEROLOGY, V108, pA453; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GIARDIELLO FM, 1994, GASTROENTEROLOGY, V106, P1542, DOI 10.1016/0016-5085(94)90408-1; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LYNCH HT, 1990, CANCER, V66, P909, DOI 10.1002/1097-0142(19900901)66:5<909::AID-CNCR2820660516>3.0.CO;2-H; LYNCH HT, 1988, J NATL CANCER I, V80, P278, DOI 10.1093/jnci/80.4.278; LYNCH HT, 1995, CANCER, V76, P2427, DOI 10.1002/1097-0142(19951215)76:12<2427::AID-CNCR2820761205>3.0.CO;2-B; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Nagase H., 1992, American Journal of Human Genetics, V51, pA39; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; TALBOT IC, 1994, FAMILIAL ADENOMATOUS, P15	20	65	65	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					514	+		10.7326/0003-4819-126-7-199704010-00003	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092316				2022-12-28	WOS:A1997WQ19500012
J	King, P				King, P			A partnership to resolve the conundrum	BRITISH MEDICAL JOURNAL			English	Article											King, P (corresponding author), ROCHE PROD LTD,POB 8,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					890	891						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093108				2022-12-28	WOS:A1997WQ02800039
J	Liesner, RJ; Goldstone, AH				Liesner, RJ; Goldstone, AH			ABC of clinical haematology - The acute leukaemias	BRITISH MEDICAL JOURNAL			English	Article											Liesner, RJ (corresponding author), UCL HOSP NHS TRUST, DEPT HAEMATOL, LONDON, ENGLAND.								0	7	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					733	736		10.1136/bmj.314.7082.733	http://dx.doi.org/10.1136/bmj.314.7082.733			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116554	Green Published			2022-12-28	WOS:A1997WM77600031
J	Stowell, MHB; McPhillips, TM; Rees, DC; Soltis, SM; Abresch, E; Feher, G				Stowell, MHB; McPhillips, TM; Rees, DC; Soltis, SM; Abresch, E; Feher, G			Light-induced structural changes in photosynthetic reaction center: Implications for mechanism of electron-proton transfer	SCIENCE			English	Article							SPHAEROIDES REACTION CENTERS; BACTERIAL REACTION CENTERS; RHODOBACTER-SPHAEROIDES; RHODOPSEUDOMONAS-SPHAEROIDES; CRYOGENIC TEMPERATURES; PARAMAGNETIC-RESONANCE; TRANSFER KINETICS; FREE-ENERGY; RESOLUTION; PATHWAY	High resolution x-ray diffraction data from crystals of the Rhodobacter sphaeroides photosynthetic reaction center (RC) have been collected at cryogenic temperature in the dark and under illumination, and the structures were refined at 2.2 and 2.6 angstrom resolution, respectively. In the charge-separated D(+)Q(A)Q(B)(-) state (where D is the primary electron donor (a bacteriochlorophyll dimer), and Q(A) and Q(B) are the primary and secondary quinone accepters, respectively), Q(B)(-) is located approximately 5 angstroms from the Q(B) position in the charge-neutral (DQ(A)Q(B)) slate, and has undergone a 180 degrees propeller twist around the isoprene chain. A model based on the difference between the two structures is proposed to explain the observed kinetics of electron transfer from Q(A)-Q(B) to Q(A)Q(B)(-) and the relative binding affinities of the different ubiquinone species in the Q(B) pocket. In addition, several water channels (putative proton pathways) leading from the Q(B) pocket to the surface of the RC were delineated, one of which leads directly to the membrane surface.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125; STANFORD SYNCHROTRON RADIAT LAB,STANFORD,CA 94309; UNIV CALIF SAN DIEGO,DEPT PHYS,LA JOLLA,CA 92093	California Institute of Technology; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of California System; University of California San Diego			Feher, George/E-3050-2010	STOWELL, MICHAEL/0000-0001-7250-1419	NIGMS NIH HHS [GM13191, GM45162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, R37GM013191, R37GM045162, R01GM013191] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALLEN JP, 1994, PROTEINS, V20, P283, DOI 10.1002/prot.340200309; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ALLEN JP, 1986, P NATL ACAD SCI USA, V83, P8589, DOI 10.1073/pnas.83.22.8589; ARATA H, 1981, BIOCHIM BIOPHYS ACTA, V636, P70, DOI 10.1016/0005-2728(81)90077-3; ARATA H, 1981, BIOCHIM BIOPHYS ACTA, V638, P201, DOI 10.1016/0005-2728(81)90228-0; ARNOUX B, 1995, ACTA CRYSTALLOGR D, V51, P368, DOI 10.1107/S0907444994013120; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARBER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P253, DOI 10.1016/0304-4173(80)90003-8; BELLAMY HD, 1994, J APPL CRYSTALLOGR, V27, P967, DOI 10.1107/S0021889894006357; BEROZA P, 1992, PHOTOSYNTHETIC BACTE, V2, P363; BLANKENSHIP RE, 1995, ANOXYGENIC PHOTOSYNT; Breton J, 1996, BBA-BIOENERGETICS, V1275, P84, DOI 10.1016/0005-2728(96)00054-0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brzezinski P, 1992, PHOTOSYNTHETIC BACTE, P321; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; Cramer W.A., 1990, ENERGY TRANSDUCTION; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DINER BA, 1984, BIOCHIM BIOPHYS ACTA, V776, P9; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; Ermler Ulrich, 1992, P341; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRAIGE M, 1996, BIOPHYS J, V70; HARTSEL SC, 1986, BIOCHEMISTRY-US, V25, P8214, DOI 10.1021/bi00373a014; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HOPE H, 1995, STANF SYNCHR RAD LAB; ISAACSON RA, 1995, BIOPHYS J, V69, P311, DOI 10.1016/S0006-3495(95)79936-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABBANI OE, 1986, BIOCHEMISTRY-US, V30, P5352; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KIRMAIER C, 1985, BIOCHIM BIOPHYS ACTA, V810, P33, DOI 10.1016/0005-2728(85)90204-X; KLEINFELD D, 1984, BIOCHEMISTRY-US, V23, P5780, DOI 10.1021/bi00319a017; KLEINFELD D, 1984, BIOCHIM BIOPHYS ACTA, V766, P126, DOI 10.1016/0005-2728(84)90224-X; LANCASTER CRD, 1995, REACTION CTR PHOTOSY, P23; MANCINO LJ, 1984, BIOCHIM BIOPHYS ACTA, V764, P46, DOI 10.1016/0005-2728(84)90139-7; MCELROY JD, 1974, BIOCHIM BIOPHYS ACTA, V333, P261, DOI 10.1016/0005-2728(74)90010-3; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; MCPHERSON PH, 1990, BIOCHIM BIOPHYS ACTA, V1016, P289, DOI 10.1016/0005-2728(90)90071-B; NABEDRYK E, 1990, FEBS LETT, V266, P59, DOI 10.1016/0014-5793(90)81506-J; NOKS P P, 1977, Molekulyarnaya Biologiya (Moscow), V11, P1090; OKAMURA MY, 1975, P NATL ACAD SCI USA, V72, P3491, DOI 10.1073/pnas.72.9.3491; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; OKAMURA MY, 1982, FUNCTION QUINONES EN, V5, P99; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PADDOCK ML, 1994, BIOCHEMISTRY-US, V33, P734, DOI 10.1021/bi00169a015; PADDOCK ML, 1990, P NATL ACAD SCI USA, V87, P6803, DOI 10.1073/pnas.87.17.6803; PADDOCK ML, 1997, BIOPHYS J, V72; PAROT P, 1988, PHOTOSYNTHETIC BACTE, P251; Rongey S. H., 1995, Biophysical Journal, V68, pA247; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; SINNING I, 1989, BIOCHEMISTRY-US, V28, P5544, DOI 10.1021/bi00439a031; STOWELL MHB, UNPUB; Takahashi E, 1996, P NATL ACAD SCI USA, V93, P2640, DOI 10.1073/pnas.93.7.2640; TAKAHASHI E, 1990, BIOCHIM BIOPHYS ACTA, V1020, P107, DOI 10.1016/0005-2728(90)90100-I; WINISKI AP, 1986, BIOCHEMISTRY-US, V23, P8206; WOODBURY NWT, 1984, BIOCHIM BIOPHYS ACTA, V767, P345, DOI 10.1016/0005-2728(84)90205-6; WRAIGHT CA, 1981, ISRAEL J CHEM, V21, P348; WRAIGHT CA, 1983, OXYGEN EVOLVING SYST, V2, P383	64	725	751	3	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					812	816		10.1126/science.276.5313.812	http://dx.doi.org/10.1126/science.276.5313.812			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115209				2022-12-28	WOS:A1997WW90000063
J	Daly, I				Daly, I			Mania	LANCET			English	Article							BIPOLAR AFFECTIVE-DISORDER; LITHIUM TREATMENT; MOOD DISORDERS; FOLLOW-UP; PSYCHIATRIC-DISORDERS; AFFECTIVE-ILLNESS; FAMILY; STATES; DISCONTINUATION; SCHIZOPHRENIA				Daly, I (corresponding author), ST LOMANS HOSP, DUBLIN 20, IRELAND.							ABOUSALEH MT, 1993, BRIT J PSYCHIAT, V163, P20, DOI 10.1192/S0007125000292441; AKISKAL HS, 1983, ARCH GEN PSYCHIAT, V40, P801; BAUER MS, 1990, ARCH GEN PSYCHIAT, V47, P427; BEBBINGTON P, 1995, SOC PSYCH PSYCH EPID, V30, P279, DOI 10.1007/BF00805795; BLACK DW, 1989, PSYCHOPATHOLOGY, V22, P28, DOI 10.1159/000284576; BOWDEN CL, 1994, JAMA-J AM MED ASSOC, V271, P918, DOI 10.1001/jama.271.12.918; Brockington IF, 1982, MOTHERHOOD MENTAL IL, P37; CHOU JCY, 1993, PSYCHIAT QUART, V54, P331; CORYELL W, 1992, ARCH GEN PSYCHIAT, V49, P126; CORYELL W, 1993, AM J PSYCHIAT, V150, P720; CORYELL W, 1989, AM J PSYCHIAT, V146, P983; CORYELL W, 1990, ARCH GEN PSYCHIAT, V47, P658; DEAN C, 1989, PSYCHOL MED, V19, P637, DOI 10.1017/S0033291700024235; DILSAVER SC, 1994, AM J PSYCHIAT, V151, P1312; DUNNER DL, 1976, BIOL PSYCHIAT, V11, P31; DUPONT RM, 1995, ARCH GEN PSYCHIAT, V52, P747; ELKIS H, 1995, ARCH GEN PSYCHIAT, V52, P735; FAEDDA GL, 1993, ARCH GEN PSYCHIAT, V50, P17; FAEDDA GL, 1993, ARCH GEN PSYCHIAT, V50, P448; FOGARTY F, 1994, ACTA PSYCHIAT SCAND, V89, P16, DOI 10.1111/j.1600-0447.1994.tb05787.x; GARZATREVINO ES, 1992, AM J PSYCHIAT, V149, P121; GERNER RH, 1992, J CLIN PSYCHOPHARM, V12, pS57, DOI 10.1097/00004714-199202001-00009; GLOVER V, 1994, BRIT J PSYCHIAT, V164, P517, DOI 10.1192/bjp.164.4.517; GOLDBERG JF, 1995, AM J PSYCHIAT, V152, P379; Goodwin F, 1990, MANIC DEPRESSIVE ILL; GOODWIN GM, 1994, BRIT J PSYCHIAT, V164, P149, DOI 10.1192/bjp.164.2.149; GROF P, 1993, BRIT J PSYCHIAT, V163, P16, DOI 10.1192/S000712500029243X; HIRSCHFELD RMA, 1986, J AFFECT DISORDERS, V11, P81, DOI 10.1016/0165-0327(86)90064-9; JAMPALA VC, 1989, AM J PSYCHIAT, V146, P459; JENSEN HV, 1995, ACTA PSYCHIAT SCAND, V92, P69, DOI 10.1111/j.1600-0447.1995.tb09545.x; KANBA S, 1994, PROG NEURO-PSYCHOPH, V18, P707; KELLER MB, 1986, JAMA-J AM MED ASSOC, V255, P3138, DOI 10.1001/jama.255.22.3138; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; KRAUTHAMMER C, 1978, ARCH GEN PSYCHIAT, V35, P1333; LASCH K, 1990, PSYCHIAT RES, V33, P31, DOI 10.1016/0165-1781(90)90146-V; Leibenluft E, 1996, AM J PSYCHIAT, V153, P163; LESSER AL, 1983, CAN J PSYCHIAT, V28, P362, DOI 10.1177/070674378302800506; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; MCELROY SL, 1992, J CLIN PSYCHOPHARM, V12, pS42, DOI 10.1097/00004714-199202001-00007; MCELROY SL, 1993, CURRENT PSYCHIAT THE, P226; MCGLASHAN TH, 1988, AM J PSYCHIAT, V145, P221; MCGUFFIN P, 1994, SEMINARS PSYCHIAT GE, P110; MCGUFFIN P, 1986, BIOL DEPRESSION, P26; MCKENNA PJ, 1985, AM J PSYCHIAT, V142, P895; MUKHERJEE S, 1994, AM J PSYCHIAT, V151, P169; MULLEROERLINGHAUSEN B, 1992, ACTA PSYCHIAT SCAND, V86, P218, DOI 10.1111/j.1600-0447.1992.tb03255.x; Parker I., 1995, HDB AFFECTIVE DISORD; PLATZ C, 1988, BRIT J PSYCHIAT, V153, P90, DOI 10.1192/bjp.153.1.90; POST RM, 1989, ARCH GEN PSYCHIAT, V46, P353; POST RM, 1992, AM J PSYCHIAT, V149, P1727; POST RM, 1984, NEUROBIOLOGY MOOD DI, V1, P432; POST RM, 1990, REV PSYCHIATRY, V9, P170; RIFKIN A, 1990, PSYCHOPHARMACOL BULL, V26, P144; *ROYAL COLL PSYCH, 1992, CR26 ROYAL COLL PSYC; ROYBYRNE P, 1985, ACTA PSYCHIAT SCAND, V71, P1, DOI 10.1111/j.1600-0447.1985.tb10510.x; SCOTT J, 1995, BRIT J PSYCHIAT, V167, P581, DOI 10.1192/bjp.167.5.581; SHELLEY R, 1995, CLIN PSYCHOPHARMACOL, P193; SIMPSON SG, 1993, AM J PSYCHIAT, V150, P901; SMALL JG, 1988, ARCH GEN PSYCHIAT, V45, P727; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; STOLL AL, 1994, AM J PSYCHIAT, V151, P1642; STRAKOWSKI SM, 1994, INT J PSYCHIAT MED, V24, P305, DOI 10.2190/CM8E-46R5-9AJL-03FN; STRUVE FA, 1979, PSYCHOPATHOLOGY BRAI, P199; TOHEN M, 1994, AM J PSYCHIAT, V151, P130; TRIMBLE MR, 1996, BIOL PSYCHIAT, P226; WEHR TA, 1987, AM J PSYCHIAT, V144, P1403; WEHR TA, 1987, AM J PSYCHIAT, V144, P201; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; WHITE E, 1993, INT CLIN PSYCHOPHARM, V8, P119, DOI 10.1097/00004850-199300820-00007; WINOKUR G, 1995, AM J PSYCHIAT, V152, P365; WINOKUR G, 1994, ACTA PSYCHIAT SCAND, V89, P102, DOI 10.1111/j.1600-0447.1994.tb01495.x; Winokur G., 1996, NATURAL HIST MANIA D; Winokur G., 1991, MANIA DEPRESSION CLA; WOZNIAK J, 1995, J AM ACAD CHILD PSY, V34, P1577, DOI 10.1097/00004583-199512000-00007	74	16	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	1997	349	9059					1157	1160		10.1016/S0140-6736(96)07253-4	http://dx.doi.org/10.1016/S0140-6736(96)07253-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WU544	9113023				2022-12-28	WOS:A1997WU54400040
J	Enting, R				Enting, R			Dexamethasone for bacterial meningitis: We need the answer	LANCET			English	Letter											Enting, R (corresponding author), UNIV AMSTERDAM,ACAD MED CTR H2 214,DEPT NEUROL,NL-1105 AZ AMSTERDAM,NETHERLANDS.							PFISTER HW, 1993, ARCH NEUROL-CHICAGO, V50, P575, DOI 10.1001/archneur.1993.00540060015010; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; Tunkel AR, 1995, LANCET, V346, P1675, DOI 10.1016/S0140-6736(95)92844-8	4	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1179	1180		10.1016/S0140-6736(05)63063-2	http://dx.doi.org/10.1016/S0140-6736(05)63063-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113042				2022-12-28	WOS:A1997WU54400062
J	Vandenbroucke, JP; Rosendaal, FR				Vandenbroucke, JP; Rosendaal, FR			End of the line for ''third-generation-pill'' controversy?	LANCET			English	Editorial Material							THROMBOSIS; RISK		LEIDEN UNIV HOSP,THROMBOSIS & HAEMOSTASIS RES CTR,NL-3200 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	Vandenbroucke, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,NL-3200 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496				BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Farley TMM, 1996, CONTRACEPTION, V54, P193, DOI 10.1016/S0010-7824(96)00166-7; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Rosing J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/j.1365-2141.1997.192707.x	4	58	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1113	1114		10.1016/S0140-6736(05)63015-2	http://dx.doi.org/10.1016/S0140-6736(05)63015-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113005				2022-12-28	WOS:A1997WU54400003
J	Essers, J; Hendriks, RW; Swagemakers, SMA; Troelstra, C; deWit, J; Bootsma, D; Hoeijmakers, JHJ; Kanaar, R				Essers, J; Hendriks, RW; Swagemakers, SMA; Troelstra, C; deWit, J; Bootsma, D; Hoeijmakers, JHJ; Kanaar, R			Disruption of mouse RAD54 reduces ionizing radiation resistance	CELL			English	Article							STRAND-BREAK-REPAIR; DEPENDENT PROTEIN-KINASE; V(D)J RECOMBINATION; SCID MUTATION; DNA; RECA; MICE; GENE; SACCHAROMYCES; DEFICIENCY	Double-strand DNA break (DSB) repair by homologous recombination occurs through the RAD52 pathway in Saccharomyces cerevisiae. Its biological importance is underscored by the conservation of many RAD52 pathway genes, including RAD54, from fungi to humans. We have analyzed the phenotype of mouse RAD54(-/)- (mRAD54(-/-)) cells. Consistent with a DSB repair defect, these cells are sensitive to ionizing radiation, mitomycin C, and methyl methanesulfonate, but not to ultraviolet light. Gene targeting experiments demonstrate that homologous recombination in mRAD54(-/-) cells is reduced compared to wild-type cells. These results imply that, besides DNA end-joining mediated by DNA-dependent protein kinase, homologous recombination contributes to the repair of DSBs in mammalian cells. Furthermore, we show that mRAD54(-/-) mice are viable and exhibit apparently normal V(D)J and immunoglobulin class-switch recombination. Thus, mRAD54 is not required for the recombination processes that generate functional immunoglobulin and T cell receptor genes.	DR DANIEL DEN HOED CANC CTR, DEPT RADIOTHERAPY, DIV CLIN RADIOTHERAPY, NL-3075 EA ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Essers, J (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, CTR MED GENET, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.		Hoeijmakers, Jan/AAX-6972-2021					Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CLEVER B, 1997, IN PRESS EMBO J; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Eki T, 1996, YEAST, V12, P177; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gellert M, 1996, GENES CELLS, V1, P269, DOI 10.1046/j.1365-2443.1996.22023.x; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Hendriks RW, 1996, EMBO J, V15, P4862, DOI 10.1002/j.1460-2075.1996.tb00867.x; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MEYN MS, 1995, CANCER RES, V55, P5991; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muris DFR, 1996, J CELL SCI, V109, P73; MURIS DFR, 1997, IN PRESS CURR GENET; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PETRINI JHJ, 1997, IN PRESS SEMIN IMMUN; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; STAYTON CL, 1994, HUM MOL GENET, V3, P1957, DOI 10.1093/hmg/3.11.1957; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VANDERHORST GTJ, 1997, IN PRESS CELL, V89; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	49	363	370	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					195	204		10.1016/S0092-8674(00)80199-3	http://dx.doi.org/10.1016/S0092-8674(00)80199-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108475	Green Published, Bronze			2022-12-28	WOS:A1997WU88800007
J	Blendon, RJ; Benson, JM; Brodie, M; Altman, DE; Rowland, D; Neuman, P; James, M				Blendon, RJ; Benson, JM; Brodie, M; Altman, DE; Rowland, D; Neuman, P; James, M			Voters and health care in the 1996 election	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HENRY J KAISER FAMILY FDN,MENLO PK,CA	Harvard University	Blendon, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							BERENSON RA, 1989, NEW ENGL J MED, V321, P908; BLENDON RJ, 1995, JAMA-J AM MED ASSOC, V274, P1645, DOI 10.1001/jama.274.20.1645; BLENDON RJ, 1989, HEALTH AFFAIR, V8, P6, DOI 10.1377/hlthaff.8.3.6; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V268, P3371, DOI 10.1001/jama.268.23.3371; FIORINA MORRIS P., 1981, RETROSPECTIVE VOTING, P89; JOHNSON H, 1996, SYSTEM AM WAY POLITI; LADD EC, 1997, PUBLIC PERSPECT, V8, P4; MARKUS GB, 1993, CLASSICS VOTING BEHA; Morris D., 1997, OVAL OFFICE WINNING; PENN MJ, 1996, POLLING REPORT, V12, P6; *ROP CTR PUBL OP R, 1996, HARR POLL; Swartz K, 1996, ANN INTERN MED, V124, P442, DOI 10.7326/0003-4819-124-4-199602150-00009; 1996, LOS ANGELES TIM 1105; 1997, PUBLIC PERSPECT, V8, P37	14	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1253	1258		10.1001/jama.277.15.1253	http://dx.doi.org/10.1001/jama.277.15.1253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WT403	9103352				2022-12-28	WOS:A1997WT40300044
J	Weigner, MJ; Caulfield, TA; Danias, PG; Silverman, DI; Manning, WJ				Weigner, MJ; Caulfield, TA; Danias, PG; Silverman, DI; Manning, WJ			Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours	ANNALS OF INTERNAL MEDICINE			English	Article						atrial fibrillation; thromboembolism; electric countershock; time factors; cardiac output, low	DIRECT-CURRENT CARDIOVERSION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANTITHROMBOTIC THERAPY; ANTICOAGULATION; COMPLICATIONS; RECOMMENDATIONS; MANAGEMENT; THROMBUS; TRIAL	Background: It has been assumed that cardioversion in patients with atrial fibrillation lasting less than 48 hours is associated with a low risk for thromboembolism. However, no clinical data support this assumption. Objective: To determine the incidence of cardioversion-related clinical thromboembolism among patients presenting with atrial fibrillation lasting less than 48 hours. Design: Patients were prospectively identified on admission, and clinical data on the duration of atrial fibrillation were recorded. Data on cardioversion and thromboembolism were obtained retrospectively from hospital and outpatient records. Setting: Academic medical center. Patients: 1822 consecutive patients admitted to the hospital for atrial fibrillation were screened. Three hundred seventy-five adults (mean age +/- SD, 68 +/- 16 years) with atrial fibrillation that had lasted less than 48 hours were identified. One hundred eighty-one patients (48.3%) had a history of atrial fibrillation; 23 (6.1%) had a history of thromboembolism. Results: 357 patients (95.2%) converted to sinus rhythm during the index admission; spontaneous conversion occurred in 250 patients (66.7%) and active pharmacologic or electrical conversion was done in 107 patients (28.5%). Three patients (0.8% [95% CI, 0.2% to 2.4%]), all of whom had converted spontaneously after ventricular rate control was begun, had a clinical thromboembolic event: One had a stroke, 1 had a transient ischemic attack, and 1 had a peripheral embolus. None of these 3 patients had a history of atrial fibrillation or thromboembolism, and all had normal left ventricular systolic function. Conclusion: Among patients presenting with atrial fibrillation that was clinically estimated to have lasted less than 48 hours, the likelihood of cardioversion-related clinical thromboembolism is low. These data support the current recommendation for early cardioversion in these patients.	BETH ISRAEL DEACONESS MED CTR, DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; JOHN DEMPSEY HOSP, FARMINGTON, CT USA; UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Connecticut					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RRO6192] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM HEART ASS, 1996, HEART STROK FACTS ST, P14; [Anonymous], 1995, J STROKE CEREBROVASC, V5, P147, DOI [DOI 10.1016/S1052-3057(10)80166-1, 10.1016/S10523057(10)80166-1]; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; ASPLUND K, 1993, EUR HEART J, V14, P1427; ATWOOD JE, 1987, J AM COLL CARDIOL, V10, P314; BAER M, 1995, GERIATRICS, V50, P22; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; COLLINS LJ, 1995, CIRCULATION, V92, P160, DOI 10.1161/01.CIR.92.2.160; DALY L, 1992, COMPUT BIOL MED, V22, P351, DOI 10.1016/0010-4825(92)90023-G; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FATKIN D, 1994, J AM COLL CARDIOL, V23, P307, DOI 10.1016/0735-1097(94)90412-X; GOLDMAN MJ, 1960, PROG CARDIOVASC DIS, V2, P465, DOI 10.1016/S0033-0620(60)80005-9; Golzari H, 1996, ANN INTERN MED, V125, P311, DOI 10.7326/0003-4819-125-4-199608150-00010; GRIMM RA, 1995, AM HEART J, V130, P174, DOI 10.1016/0002-8703(95)90253-8; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LOWN B, 1963, NEW ENGL J MED, V269, P325, DOI 10.1056/NEJM196308152690701; MANCINI GBJ, 1982, AM HEART J, V104, P617; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MANNING WJ, 1995, ARCH INTERN MED, V155, P2193, DOI 10.1001/archinte.155.20.2193; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SCHAMROTH L, 1971, CARDIOVASC RES, V5, P419, DOI 10.1093/cvr/5.4.419; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; STODDARD MF, 1995, AM HEART J, V129, P1204, DOI 10.1016/0002-8703(95)90405-0; THEISEN K, 1985, AM J CARDIOL, V55, P98, DOI 10.1016/0002-9149(85)90307-8; WEINBERG DM, 1989, AM J CARDIOL, V63, P745, DOI 10.1016/0002-9149(89)90264-6	35	166	167	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					615	+		10.7326/0003-4819-126-8-199704150-00005	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103128				2022-12-28	WOS:A1997WT58000007
J	Bowden, N; Terfort, A; Carbeck, J; Whitesides, GM				Bowden, N; Terfort, A; Carbeck, J; Whitesides, GM			Self-assembly of mesoscale objects into ordered two-dimensional arrays	SCIENCE			English	Article							COLLOIDAL PARTICLES; CAPILLARY FORCES; SURFACE	Regular arrays of topologically complex, millimeter-scale objects were prepared by self-assembly, with the shapes of the assembling objects and the wettability of their surfaces determining the structure of the arrays. The system was composed of solid objects floating at the interface between perfluorodecalin and water and interacting by lateral capillary forces; patterning of the wettability of the surfaces of the objects directs these forces. Self-assembly results from minimization of the interfacial free energy of the liquid-liquid interface. Calculations suggest that this strategy for self-assembly can be applied to objects on a micrometer scale.	HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138	Harvard University								ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653; DASHKIN CD, 1996, LANGMUIR, V12, P641; Davis H.T., 1996, STAT MECH PHASES INT; FAKES DW, 1988, SURF INTERFACE ANAL, V13, P233, DOI 10.1002/sia.740130411; KRALCHEVSKY PA, 1993, J COLLOID INTERF SCI, V155, P420, DOI 10.1006/jcis.1993.1056; KRALCHEVSKY PA, 1994, LANGMUIR, V10, P23, DOI 10.1021/la00013a004; OWEN MJ, 1981, J COATING TECHNOL, V53, P49; PAUNOV VN, 1993, J COLLOID INTERF SCI, V157, P100, DOI 10.1006/jcis.1993.1163; SCHOBER T, 1992, J APPL PHYS, V71, P2206, DOI 10.1063/1.351118; SIMPSON AW, 1972, NATURE, V237, P320, DOI 10.1038/237320a0; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; TU JK, 1995, ELECTRON LETT, V31, P1448, DOI 10.1049/el:19950989; YAMAKI M, 1995, LANGMUIR, V11, P2975, DOI 10.1021/la00008a021; ZISMAN WA, 1962, ADHESION COHESION, P176	14	532	584	4	254	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					233	235		10.1126/science.276.5310.233	http://dx.doi.org/10.1126/science.276.5310.233			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092466				2022-12-28	WOS:A1997WT92500037
J	Wolfe, SF; Gurevitch, AW				Wolfe, SF; Gurevitch, AW			Fish-tank granuloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Wolfe, SF (corresponding author), UNIV CALIF LOS ANGELES,HARBOR MED CTR,TORRANCE,CA 90509, USA.								0	1	1	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1065	1065		10.1056/NEJM199704103361505	http://dx.doi.org/10.1056/NEJM199704103361505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091803				2022-12-28	WOS:A1997WT16100005
J	Yip, R; Limburg, PJ; Ahlquist, DA; Carpenter, HA; ONeill, A; Kruse, D; Stitham, S; Gold, BD; Gunter, EW; Looker, AC; Parkinson, AJ; Nobmann, ED; Petersen, KM; Ellefson, M; Schwartz, S				Yip, R; Limburg, PJ; Ahlquist, DA; Carpenter, HA; ONeill, A; Kruse, D; Stitham, S; Gold, BD; Gunter, EW; Looker, AC; Parkinson, AJ; Nobmann, ED; Petersen, KM; Ellefson, M; Schwartz, S			Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency - Role of Helicobacter pylori gastritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1995 Swedish-Society-of-Medicine Berzeliuos Symposium XXXI on Iron Nutrition in Health and Disease	SEP, 1995	STOCKHOLM, SWEDEN	Swedish soc Med			PEPTIC-ULCER DISEASE; CAMPYLOBACTER-PYLORI; INFECTION; HEMOQUANT; BLOOD; SEROEPIDEMIOLOGY; HEMOGLOBIN; ESKIMOS; ADULTS; HEME	Objective.-To confirm prevalent iron deficiency among Yupik Eskimos living in Alaska and to explore the frequency of and potential lesions accounting for occult gastrointestinal bleeding. Design.-Descriptive survey. Setting.-Rural Arctic community. Subjects.-A total of 140 adult volunteers from 3 villages in the Yukon-Kuskokwim Delta region of western Alaska. Main Outcome Measures.-Daily iron intake, hematologic and biochemical indexes of iron status, fecal hemoglobin levels, stool parasites, and endoscopic findings. Results.-While dietary iron intake by Yupiks was similar to that of a reference population, iron deficiency prevalence was increased 13-fold in Yupik men and 4-fold in Yupik women, Fecal hemoglobin levels were elevated in 90% of subjects contrasted with only 4% of a reference group; median levels were 5.9 and 0.5 mg of hemoglobin per gram of stool, respectively, Among 70 Yupik subjects with elevated fecal hemoglobin levels who had endoscopy performed, 68 (97%) had an abnormal gastric appearance consisting of erythema, mucosal thickening, diffuse mucosal hemorrhages, erosions, or ulcerations. Gastric biopsies revealed chronic active gastritis with associated Helicobacter pylori in 68 (99%) of 69. No other hemorrhagic gastrointestinal disease was detected. Conclusions.-Based on this study sample, occult gastrointestinal bleeding appears to be pervasive in the Yupik population and likely underlies the prevalent iron deficiency. An atypical hemorrhagic gastritis associated with H pylori infection is present almost universally and may represent the bleeding source.	MAYO CLIN, DIV GASTROENTEROL, DEPT INTERNAL MED, ROCHESTER, MN 55905 USA; CTR DIS CONTROL & PREVENT, DIV NUTR, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, NATL CTR INFECT DIS, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV ENVIRONM HLTH LAB SCI, NATL CTR ENVIRONM HLTH, ATLANTA, GA USA; YUKON KUSKOKWIM HLTH CORP, BETHEL, AK USA; EMORY UNIV, SCH MED, DEPT PEDIAT, ATLANTA, GA USA; CDC, DIV HLTH EXAMINAT STAT, NATL CTR HLTH STAT, HYATTSVILLE, MD USA; CDC, ARCTIC INVEST PROGRAM, NATL CTR INFECT DIS, ANCHORAGE, AK USA; ALASKA AREA NATIVE HLTH SERV, INDIAN HLTH SERV, ANCHORAGE, AK USA; ELLEFSON ANALYT INC, LINO LAKES, MN USA; MINNEAPOLIS MED RES FDN INC, MINNEAPOLIS, MN USA; MAYO CLIN, DEPT LAB MED & PATHOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Minneapolis Medical Research Foundation; Mayo Clinic								AHLQUIST DA, 1988, ANN INTERN MED, V108, P609, DOI 10.7326/0003-4819-108-4-609; AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; ANDERSEN LP, 1988, SCAND J GASTROENTERO, V23, P760, DOI 10.3109/00365528809093946; BORSCH G, 1988, EUR J CLIN INVEST, V18, P133; CDC, 1989, MMWR-MORBID MORTAL W, V38, P400; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; Garby L., 1973, Clinics in Haematology, V2, P245; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HOLCOMBE C, 1992, AM J GASTROENTEROL, V87, P28; Ito A, 1996, J GASTROENTEROL, V31, P1, DOI 10.1007/BF01211179; KERLIN P, 1979, AUST NZ J MED, V9, P402, DOI 10.1111/j.1445-5994.1979.tb04167.x; KHANNA B, 1995, GASTROENTEROLOGY, V108, pA130; KUWAYAMA H, 1995, GASTROENTEROLOGY, V108, pA139; LANIER AP, 1989, PUBLIC HEALTH REP, V104, P658; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MONSON RR, 1969, NEW ENGL J MED, V281, P11, DOI 10.1056/NEJM196907032810103; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; NOBMANN ED, 1992, AM J CLIN NUTR, V55, P1024, DOI 10.1093/ajcn/55.5.1024; ORMAND JE, 1990, DIGEST DIS SCI, V35, P879, DOI 10.1007/BF01536802; Peek RM, 1995, LAB INVEST, V73, P760; Petersen KM, 1996, J NUTR, V126, P2774; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; PORTER VS, 1953, SCI ALASKA, P217; RAED AK, 1995, GASTROENTEROLOGY, V108, pA199; ROCHE M, 1966, AM J TROP MED HYG, V15, P1032, DOI 10.4269/ajtmh.1966.15.1032; SASSA S, 1973, BIOCHEM MED METAB B, V8, P135, DOI 10.1016/0006-2944(73)90017-3; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; SCHWARTZ S, 1985, GASTROENTEROLOGY, V89, P19, DOI 10.1016/0016-5085(85)90740-1; SCOTT EM, 1964, AM J CLIN NUTR, V15, P282, DOI 10.1093/ajcn/15.5.282; SCOTT EM, 1955, J NUTR, V55, P137, DOI 10.1093/jn/55.1.137; SCOTT EM, 1954, SCI ALASKA, P92; TYTGAT GNJ, 1990, GASTROENTEROL CLIN N, V19, P183; WARD JI, 1981, LANCET, V1, P1281; Weel JFL, 1996, J INFECT DIS, V173, P1171, DOI 10.1093/infdis/173.5.1171; Yamada, 1995, TXB GASTROENTEROLOGY, V1, P699; YOSHIMURA HH, 1993, DIGEST DIS SCI, V38, P1128, DOI 10.1007/BF01295731; 1988, MMWR MORB MORTAL WEE, V37, P200	41	122	126	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1135	1139		10.1001/jama.277.14.1135	http://dx.doi.org/10.1001/jama.277.14.1135			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WR342	9087468				2022-12-28	WOS:A1997WR34200032
J	Niebauer, J; Coats, AJS				Niebauer, J; Coats, AJS			Treating, chronic heart failure: Time to take stock	LANCET			English	Editorial Material									ROYAL BROMPTON HOSP,LONDON SW3 6LY,ENGLAND	Royal Brompton Hospital	Niebauer, J (corresponding author), NATL HEART & LUNG INST,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				DIES F, 1986, CIRCULATION S2, V74, P138; HARVEY CA, 1983, BRIT J PHARMACOL, V78, pP127; KULLBERG MP, 1981, CLIN PHARMACOL THER, V29, P394, DOI 10.1038/clpt.1981.54; METRA M, 1995, CLIN CARDIOL S, V18, P22; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103	5	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					966	967		10.1016/S0140-6736(97)22014-3	http://dx.doi.org/10.1016/S0140-6736(97)22014-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100617				2022-12-28	WOS:A1997WR62100002
J	Tajbakhsh, S; Rocancourt, D; Cossu, G; Buckingham, M				Tajbakhsh, S; Rocancourt, D; Cossu, G; Buckingham, M			Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD	CELL			English	Article							REGULATORY FACTOR PROTEINS; MUSCLE DEVELOPMENT; PRECURSOR CELLS; MESSENGER-RNA; EXPRESSION; MICE; DIFFERENTIATION; RECEPTOR; MUTATION; SPECIFICATION	We analyzed Pax-3 (splotch), Myf-5 (targeted with nlacZ), and splotch/Myf-5 homozygous mutant mice to investigate the roles that these genes play in programming skeletal myogenesis. In splotch and Myf-5 homozygous embryos, myogenic progenitor cell perturbations and early muscle defects are distinct. Remarkably, splotch/Myf-5 double homozygotes have a dramatic phenotype not seen in the individual mutants: body muscles are absent. MyoD does not rescue this double mutant phenotype since activation of this gene proves to be dependent on either Pax-3 or Myf-5. Therefore, Pax-3 and Myf-5 define two distinct myogenic pathways, and MyoD acts genetically downstream of these genes for myogenesis in the body. This genetic hierarchy does not appear to operate for head muscle formation.	UNIV ROMA LA SAPIENZA, DEPT HISTOL & MED EMBRYOL, I-00161 ROME, ITALY	Sapienza University Rome	Tajbakhsh, S (corresponding author), INST PASTEUR, DEPT MOL BIOL, CNRS, URA 1947, F-75724 PARIS 15, FRANCE.				Telethon [A.067] Funding Source: Medline	Telethon(Fondazione Telethon)		BATE M, 1992, SEMIN DEV BIOL, V3, P267; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; Braun T, 1996, EMBO J, V15, P310, DOI 10.1002/j.1460-2075.1996.tb00361.x; BRAUN T, 1994, DEVELOPMENT, V120, P3083; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cossu G, 1996, DEVELOPMENT, V122, P429; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Daston G, 1996, DEVELOPMENT, V122, P1017; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; Gamel AJ, 1995, DEV BIOL, V172, P625, DOI 10.1006/dbio.1995.8028; GOULDING M, 1994, DEVELOPMENT, V120, P957; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Mansouri A, 1996, DEVELOPMENT, V122, P831; MARCELLE C, 1995, DEV BIOL, V172, P100, DOI 10.1006/dbio.1995.0008; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; PICARD JK, 1994, TRANSGENICS, V1, P241; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; SMITH TH, 1993, DEVELOPMENT, V117, P1125; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Tajbakhsh S, 1995, DEVELOPMENT, V121, P4077; Tajbakhsh S, 1996, NATURE, V384, P266, DOI 10.1038/384266a0; Tajbakhsh S, 1996, DEV DYNAM, V206, P291, DOI 10.1002/(SICI)1097-0177(199607)206:3<291::AID-AJA6>3.0.CO;2-D; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAJBAKHSH S, 1995, TRENDS GENET, V11, P42, DOI 10.1016/S0168-9525(00)88994-5; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Wachtler F., 1992, SEMIN DEV BIOL, V3, P217; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Yang XM, 1996, DEVELOPMENT, V122, P2163	49	638	652	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					127	138		10.1016/S0092-8674(00)80189-0	http://dx.doi.org/10.1016/S0092-8674(00)80189-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094721	Bronze			2022-12-28	WOS:A1997WR68500016
J	Zhang, YH; Yao, B; Delikat, S; Bayoumy, S; Lin, XH; Basu, S; McGinley, M; ChanHui, PY; Lichenstein, H; Kolesnick, R				Zhang, YH; Yao, B; Delikat, S; Bayoumy, S; Lin, XH; Basu, S; McGinley, M; ChanHui, PY; Lichenstein, H; Kolesnick, R			Kinase suppressor of Ras is ceramide-activated protein kinase	CELL			English	Article							NECROSIS-FACTOR-ALPHA; KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-ELEGANS; RAF-1; SPHINGOMYELINASE; PHOSPHORYLATION; IDENTIFICATION; STIMULATION; C-RAF-1	A proline-directed serine/threonine ceramide-activated protein (CAP) kinase mediates transmembrane signaling through the sphingomyelin pathway. CAP kinase reportedly initiates proinflammatory TNF alpha action by phosphorylating and activating Raf-1. The present studies delineate kinase suppressor of Ras (KSR), identified genetically in Caenorhabditis elegans and Drosophila, as CAP kinase. Mouse KSR, like CAP kinase, renatures and autophosphorylates as a 100-kDa membrane-bound polypeptide. KSR overexpression constitutively activates Raf-1. TNF alpha or ceramide analogs markedly enhance KSR autophosphorylation and its ability to complex with, phosphorylate, and activate Raf-1. In vitro, low nanomolar concentrations of natural ceramide stimulate KSR to autophosphorylate, and transactivate Raf-1. Other lipid second messengers were ineffective. Moreover, Thr(269), the Raf-1 site phosphorylated by CAP kinase, is also recognized by KSR. Thus, by previously established criteria, KSR appears to be CAP kinase.	MEM SLOAN KETTERING CANC CTR,LAB SIGNAL TRANSDUCT,NEW YORK,NY 10021; AMGEN INC,BOULDER,CO 80301	Memorial Sloan Kettering Cancer Center; Amgen					NCI NIH HHS [CA42385] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; RAPP UR, 1991, ONCOGENE, V6, P495; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	33	376	387	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					63	72		10.1016/S0092-8674(00)80183-X	http://dx.doi.org/10.1016/S0092-8674(00)80183-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094715	Bronze			2022-12-28	WOS:A1997WR68500010
J	Seckl, JR; Miller, WL				Seckl, JR; Miller, WL			How safe is long-term prenatal glucocorticoid treatment?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONGENITAL ADRENAL-HYPERPLASIA; TYPE-2 11-BETA-HYDROXYSTEROID DEHYDROGENASE; 21-HYDROXYLASE DEFICIENCY; ADULT HYPERTENSION; SEXUAL-BEHAVIOR; BLOOD-PRESSURE; BIRTH-WEIGHT; DIAGNOSIS; DEXAMETHASONE; MANAGEMENT		UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV EDINBURGH,WESTERN GEN HOSP,MOL MED CTR,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of California System; University of California San Francisco; University of Edinburgh			Seckl, Jonathan R/C-3555-2013; Miller, Walter L/J-3696-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922, R01DK042154] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37922, DK42154] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BEITINS IZ, 1973, PEDIATR RES, V7, P509, DOI 10.1203/00006450-197305000-00004; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BENEDIKTSSON R, 1995, CLIN ENDOCRINOL, V42, P551, DOI 10.1111/j.1365-2265.1995.tb02676.x; Brown RW, 1996, BIOCHEM J, V313, P1007, DOI 10.1042/bj3131007; Brown RW, 1996, ENDOCRINOLOGY, V137, P794, DOI 10.1210/en.137.2.794; BUESCHER MA, 1992, OBSTET GYNECOL, V79, P130; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; DIAZ R, 1995, NEUROSCIENCE, V66, P467, DOI 10.1016/0306-4522(94)00605-5; DITTMANN RW, 1992, PSYCHONEUROENDOCRINO, V17, P153, DOI 10.1016/0306-4530(92)90054-B; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; FOREST MG, 1993, J STEROID BIOCHEM, V45, P75, DOI 10.1016/0960-0760(93)90125-G; FOREST MG, 1989, ENDOCR RES, V15, P277, DOI 10.1080/07435808909039101; HAAN EA, 1992, MED J AUSTRALIA, V156, P132; HOLSON RR, 1995, NEUROTOXICOL TERATOL, V17, P393, DOI 10.1016/0892-0362(94)00074-N; KUHNLE U, 1993, J STEROID BIOCHEM, V45, P123, DOI 10.1016/0960-0760(93)90131-F; LEVINE RS, 1994, BMJ-BRIT MED J, V308, P298, DOI 10.1136/bmj.308.6924.298; Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200; Lindsay RS, 1996, DIABETOLOGIA, V39, P1299, DOI 10.1007/s001250050573; MAGIAKOU MA, 1994, J CLIN ENDOCR METAB, V79, P1082, DOI 10.1210/jc.79.4.1082; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MERCADO AB, 1995, J CLIN ENDOCR METAB, V80, P2014, DOI 10.1210/jc.80.7.2014; MILLER WL, 1994, J CLIN ENDOCR METAB, V78, P241, DOI 10.1210/jc.78.2.241; Miller WL., 1995, ENDOCRINOL METAB, P555; Morel Y, 1991, Adv Hum Genet, V20, P1; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; NOVY MJ, 1983, AM J OBSTET GYNECOL, V145, P920, DOI 10.1016/0002-9378(83)90841-4; PANG SY, 1992, J CLIN ENDOCR METAB, V75, P249, DOI 10.1210/jc.75.1.249; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; SECKL JR, 1994, Q J MED, V87, P259; SPEISER PW, 1994, CLIN PERINATOL, V21, P631, DOI 10.1016/S0095-5108(18)30335-X; STEWART PM, 1994, J CLIN ENDOCR METAB, V78, P1529, DOI 10.1210/jc.78.6.1529; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P885, DOI 10.1210/jc.80.3.885; STYNE DM, 1984, NEW ENGL J MED, V310, P889, DOI 10.1056/NEJM198404053101405; TRAUTMAN PD, 1995, PSYCHONEUROENDOCRINO, V20, P439, DOI 10.1016/0306-4530(94)00070-0; VanWyk JJ, 1996, J CLIN ENDOCR METAB, V81, P3180, DOI 10.1210/jc.81.9.3180; WARD RM, 1994, CLIN PERINATOL, V21, P523, DOI 10.1016/S0095-5108(18)30330-0; WEINSTOCK M, 1992, BRAIN RES, V595, P195, DOI 10.1016/0006-8993(92)91049-K; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773	40	86	89	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1077	1079		10.1001/jama.277.13.1077	http://dx.doi.org/10.1001/jama.277.13.1077			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091698				2022-12-28	WOS:A1997WQ08900035
J	Nassimbeni, G; DelSanto, M; Buri, L; Ventura, A				Nassimbeni, G; DelSanto, M; Buri, L; Ventura, A			Persisting abdominal pain in an 11-year-old without an appendix	LANCET			English	Article							MECKELS-DIVERTICULUM; CROHNS-DISEASE; CHILDREN		OSPED S CHIARA,IST CLIN PEDIAT,I-56100 PISA,ITALY; OSPED CATTINARA,DIV GASTROENTEROL,TRIESTE,ITALY; IST INFANZIA,TRIESTE,ITALY					Ventura, Alessandro/0000-0002-4657-1760				ANDREYEV HJN, 1994, AM J GASTROENTEROL, V89, P1552; ANDREYEV HJN, 1994, GUT, V35, P788, DOI 10.1136/gut.35.6.788; KONG MS, 1994, J PEDIATR GASTR NUTR, V18, P284, DOI 10.1097/00005176-199404000-00006; MACKEY WC, 1983, SURG GYNECOL OBSTET, V156, P56; STVIL D, 1991, J PEDIATR SURG, V26, P1289, DOI 10.1016/0022-3468(91)90601-O	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					920	920		10.1016/S0140-6736(96)12296-0	http://dx.doi.org/10.1016/S0140-6736(96)12296-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093254				2022-12-28	WOS:A1997WR25400013
J	Burke, GAA; Chambers, TL				Burke, GAA; Chambers, TL			Musculoskeletal side-effects of varicella	LANCET			English	Editorial Material							CHILDREN				Burke, GAA (corresponding author), SOUTHMEAD GEN HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND.		Burke, Amos/AAT-1358-2021	Burke, Amos/0000-0003-2671-9972				BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; DOCTOR A, 1995, PEDIATRICS, V96, P428; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; GIVNER LB, 1991, J PEDIATR-US, V118, P341, DOI 10.1016/S0022-3476(05)82144-4; SCHRECK P, 1996, J BONE JOINT SURG, V11, P1713	5	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					818	819		10.1016/S0140-6736(05)61746-1	http://dx.doi.org/10.1016/S0140-6736(05)61746-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121252				2022-12-28	WOS:A1997WP40300005
J	Riese, J; Yu, XN; Munnerlyn, A; Eresh, S; Hsu, SC; Grosschedl, R; Bienz, M				Riese, J; Yu, XN; Munnerlyn, A; Eresh, S; Hsu, SC; Grosschedl, R; Bienz, M			LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic	CELL			English	Article							SEGMENT POLARITY GENE; HOMEOTIC DROSOPHILA GENE; ALPHA-ENHANCER; HMG DOMAIN; NUCLEOPROTEIN STRUCTURES; ACTIVATION DOMAIN; DORSAL MESODERM; CELL-ADHESION; BETA-CATENIN; PROTEIN	wingless and decapentaplegic signal during endoderm induction in Drosophila to regulate expression of the homeotic gene Ultrabithorax. Here, we define a minimal wingless response sequence in the midgut enhancer of Ultrabithorax. We show that this sequence is recognized by the murine transcription factor LEF-1 (lymphocyte enhancer binding factor 1) in a ternary complex with armadillo protein, the cytoplasmic target of the wingless signaling pathway. In stable transformants, transcriptional stimulation of the Ultrabithorax enhancer by LEF-1 depends on armadillo. Furthermore, overexpression of LEF-1 bypasses the need for wingless signaling and causes phenotypes in the midgut, notum, and wing that mimic wingless hyperstimulation. Finally, efficient transcriptional stimulation by LEF-1 in the midgut depends also on the decapentaplegic response sequence and is limited spatially by decapentaplegic signaling. Thus, LEF-1 coordinates inputs from multiple positional signals, consistent with its architectural role in regulating the assembly of multiprotein enhancer complexes.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Riese, J (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1996, SEMIN CELL DEV BIOL, V7, P113, DOI 10.1006/scdb.1996.0016; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHRISTEN B, 1995, THESIS U ZURICH SWIT; COUSO JP, 1994, DEVELOPMENT, V120, P621; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; ERESH S, 1997, IN PRESS EMBO J; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Grobstein C, 1967, Natl Cancer Inst Monogr, V26, P279; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morimura S, 1996, DEV BIOL, V177, P136, DOI 10.1006/dbio.1996.0151; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SIMPSON P, 1988, DEVELOPMENT, V103, P391; SIMPSON P, 1989, DEVELOPMENT, V106, P57; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu X, 1996, DEVELOPMENT, V122, P849	61	388	390	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					777	787		10.1016/S0092-8674(00)81924-8	http://dx.doi.org/10.1016/S0092-8674(00)81924-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118221	Bronze			2022-12-28	WOS:A1997WQ10000010
J	Daines, B				Daines, B			The medical model is unhelpful - Comment	BRITISH MEDICAL JOURNAL			English	Editorial Material											Daines, B (corresponding author), E SUSSEX CTY COUNCIL,CTY PSYCHOL SERV,BRIGHTON BN2 2JA,E SUSSEX,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					815	816		10.1136/bmj.314.7083.815	http://dx.doi.org/10.1136/bmj.314.7083.815			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081006	Green Published			2022-12-28	WOS:A1997WN64600037
J	Chua, E; Garvey, C; Kingsnorth, AN; Rhodes, JM				Chua, E; Garvey, C; Kingsnorth, AN; Rhodes, JM			A 49-year-old with a duodenal ulcer and a mass in the head of her pancreas	LANCET			English	Article									UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,DEPT RADIOL,LIVERPOOL,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT MED & SURG,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Liverpool			Rhodes, Jonathan M/C-2496-2009					PARKER N, 1992, CANCER, V70, P1062, DOI 10.1002/1097-0142(19920901)70:5<1062::AID-CNCR2820700509>3.0.CO;2-P; SHEPPARD MC, 1977, GUT, V18, P524, DOI 10.1136/gut.18.7.524; SMITH CD, 1994, BRIT J SURG, V81, P585, DOI 10.1002/bjs.1800810435; TREDE M, 1990, ANN SURG, V211, P447, DOI 10.1097/00000658-199004000-00011	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					174	174						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111543				2022-12-28	WOS:A1997WC86100013
J	LaMontagne, JR				LaMontagne, JR			RSV pneumonia, a community-acquired infection in adults	LANCET			English	Editorial Material							RESPIRATORY SYNCYTIAL VIRUS; YOUNG-CHILDREN; INFANTS; RISK				LaMontagne, JR (corresponding author), NIAID,DIV MICROBIOL & INFECT DIS,ROCKVILLE,MD 20892, USA.							COLLINS PL, 1995, FIELDS VIROLOGY, V1, P1313; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; HEMMING VG, 1987, ANTIMICROB AGENTS CH, V31, P1882, DOI 10.1128/AAC.31.12.1882	7	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					149	150		10.1016/S0140-6736(05)60974-9	http://dx.doi.org/10.1016/S0140-6736(05)60974-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111535				2022-12-28	WOS:A1997WC86100005
J	FitzSimmons, SC; Burkhart, GA; Borowitz, D; Grand, RJ; Hammerstrom, T; Durie, PR; LloydStill, JD; Lowenfels, AB				FitzSimmons, SC; Burkhart, GA; Borowitz, D; Grand, RJ; Hammerstrom, T; Durie, PR; LloydStill, JD; Lowenfels, AB			High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONIC STRICTURES; EPIDEMIOLOGY; DISEASE	Background Fibrosing colonopathy has been reported in young children with cystic fibrosis, the majority of whom take high-strength pancreatic-enzyme supplements to control intestinal malabsorption. We conducted a case-control study in the United States to investigate the relation between dose and type of pancreatic-enzyme supplement and fibrosing colonopathy. Methods Children with histopathologically con firmed cases of fibrosing colonopathy who required colectomy for colonic strictures from January 1, 1990, through December 31, 1994, were identified. Each of these patients was matched according to age at the time of surgery and medical center with up to four controls with cystic fibrosis who did not have fibrosing colonopathy. Results We studied 29 patients (mean age, 5.0 years) with fibrosing colonopathy (case patients) and 105 controls (mean age, 5.2 years). The mean dose of pancreatic-enzyme supplement was 50,046 units of lipase per kilogram of body weight per day for the case patients and 18,985 units per kilogram per day for the controls. A history of gastrointestinal complications attributed to cystic fibrosis and the use of histamine H-2-receptor blockers, corticosteroids, or recombinant human DNase (dornase alfa) were associated with a higher incidence of fibrosing colonopathy. After adjustment for a history of such complications and the use of these medicines, the relative risk of fibrosing colonopathy that was associated with a dose of 24,001 to 50,000 units of lipase per kilogram per day, as compared with a close of 0 to 24,000 units per kilogram per day, was 10.9 (95 percent confidence interval, 1.6 to 71.8), and that associated with a dose of more than 50,000 units per kilogram per day was 199.5 (95 percent confidence interval, 9.9 to 4026.0). The strength, coating, and manufacturer of the products used were not associated with the risk of fibrosing colonopathy. Conclusions In young children with cystic fibrosis, we found a strong relation between high daily doses of pancreatic-enzyme supplements and the development of fibrosing colonopathy. Our findings support recommendations that the daily dose of pancreatic enzymes for most patients should remain below 10,000 units of lipase per kilogram. (C) 1997, Massachusetts Medical Society.	US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA; CHILDRENS HOSP BUFFALO, DEPT PEDIAT PULMONOL, BUFFALO, NY USA; TUFTS UNIV, SCH MED, DIV PEDIAT GASTROENTEROL & NUTR, BOSTON, MA 02111 USA; HOSP SICK CHILDREN, DIV PEDIAT GASTROENTEROL & NUTR, TORONTO, ON M5G 1X8, CANADA; RUSH MED COLL, DEPT PEDIAT, CHICAGO, IL 60612 USA; NEW YORK MED COLL, DEPT SURG & COMMUNITY & PREVENT MED, VALHALLA, NY 10595 USA; EUROPEAN INST ONCOL, MILAN, ITALY	US Food & Drug Administration (FDA); Tufts University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Rush University; New York Medical College; IRCCS European Institute of Oncology (IEO)	FitzSimmons, SC (corresponding author), CYST FIBROSIS FDN, DEPT MED, 6931 ARLINGTON RD, BETHESDA, MD 20814 USA.		Lowenfels, Albert/ABD-8388-2021		NIAID NIH HHS [AI06331] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOROWITZ DS, 1995, J PEDIATR-US, V127, P681, DOI 10.1016/S0022-3476(95)70153-2; BRIARS G, 1994, LANCET, V343, P600; CROFT NM, 1995, LANCET, V346, P1265; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Freiman JP, 1996, J PEDIATR GASTR NUTR, V22, P153, DOI 10.1097/00005176-199602000-00005; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; KNABE N, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92443-0; LEBENTHAL E, 1994, J PEDIATR GASTR NUTR, V18, P423, DOI 10.1097/00005176-199405000-00002; LLOYDSTILL JD, 1995, J CLIN GASTROENTEROL, V21, P2, DOI 10.1097/00004836-199507000-00001; MACSWEENEY EJ, 1995, LANCET, V345, P752; MAHONY MJ, 1994, LANCET, V343, P599; PETTEI MJ, 1994, J PEDIATR-US, V125, P587, DOI 10.1016/S0022-3476(94)70014-1; Prestridge L, 1996, J PEDIATR GASTR NUTR, V22, P219, DOI 10.1097/00005176-199602000-00016; SCHWARZENBERG SJ, 1995, J PEDIATR-US, V127, P565, DOI 10.1016/S0022-3476(95)70113-3; SMYTH RL, 1995, LANCET, V346, P1247, DOI 10.1016/S0140-6736(95)91860-4; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; TAYLOR CJ, 1995, LANCET, V346, P1106, DOI 10.1016/S0140-6736(95)91783-7; VANVELZEN D, 1996, POSTGRAD MED J S2, V72, P39; ZERIN JM, 1995, RADIOLOGY, V194, P223, DOI 10.1148/radiology.194.1.7997557; 1995, LANCET, V346, P499; 1994, LANCET, V343, P109	21	158	190	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1283	1289		10.1056/NEJM199705013361803	http://dx.doi.org/10.1056/NEJM199705013361803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113931				2022-12-28	WOS:A1997WW26000003
J	Haneji, N; Nakamura, T; Takio, K; Yanagi, K; Higashiyama, H; Saito, I; Noji, S; Sugino, H; Hayashi, Y				Haneji, N; Nakamura, T; Takio, K; Yanagi, K; Higashiyama, H; Saito, I; Noji, S; Sugino, H; Hayashi, Y			Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome	SCIENCE			English	Article							NONERYTHROID SPECTRIN; CELLS; CYTOSKELETON; PROTEOLYSIS; SECRETION; CRITERIA; BINDING; PROTEIN; ANTIGEN; MODEL	It is unclear whether organ-specific autoantigens are critical for the development of primary Sjogren's syndrome (SS). A 120-kilodalton organ-specific autoantigen was purified from salivary gland tissues of an NFS/sld mouse model of human SS. The amino-terminal residues were identical to those of the human cytoskeletal protein alpha-fodrin. The purified antigen induced proliferative T cell responses and production of interleukin-2 and interferon-gamma in vitro. Neonatal immunization with the 120-kilodalton antigen prevented the disease in mice. Sera from patients with SS reacted positively with purified antigen and recombinant human alpha-fodrin protein, whereas those from patients with systemic lupus erythematosus and rheumatoid arthritis did not. Thus, the immune response to 120-kilodalton alpha-fodrin could be important in the initial development of primary SS.	UNIV TOKUSHIMA,SCH DENT,DEPT PATHOL,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; INST PHYS & CHEM RES,DIV BIOMOL CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN; UNIV TOKUSHIMA,DIV BIOL IND,TOKUSHIMA 770,JAPAN	Tokushima University; Tokushima University; RIKEN; Tokushima University			Noji, Sumihare/E-3047-2010					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BACKKESKOV S, 1990, NATURE, V347, P151; BIRKENMEIER CS, 1985, P NATL ACAD SCI USA, V82, P5671, DOI 10.1073/pnas.82.17.5671; BLOCH KJ, 1965, MEDICINE, V44, P187, DOI 10.1097/00005792-196505000-00001; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; FOX RI, 1986, ARTHRITIS RHEUM-US, V29, P577, DOI 10.1002/art.1780290501; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; HANEJI N, 1994, J IMMUNOL, V153, P2769; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HOOPER DC, 1987, IMMUNOL TODAY, V8, P327, DOI 10.1016/0167-5699(87)90005-3; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KRUIZE AA, 1995, IMMUNOL TODAY, V16, P557, DOI 10.1016/0167-5699(95)80075-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1989, J BIOL CHEM, V264, P5826; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MOON RT, 1990, J BIOL CHEM, V265, P4427; OADRI I, 1995, P NATL ACAD SCI USA, V92, P1003; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; PERRIN D, 1992, J CELL BIOL, V116, P127, DOI 10.1083/jcb.116.1.127; PORTMANN L, 1985, J CLIN ENDOCR METAB, V61, P1001, DOI 10.1210/jcem-61-5-1001; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; STETLER DA, 1982, P NATL ACAD SCI USA, V79, P6499; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; VANDEWATER J, 1988, J EXP MED, V167, P1791, DOI 10.1084/jem.167.6.1791; WHITE SC, 1974, J IMMUNOL, V112, P178	28	330	356	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					604	607		10.1126/science.276.5312.604	http://dx.doi.org/10.1126/science.276.5312.604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110981				2022-12-28	WOS:A1997WV72100048
J	Stebbins, CE; Russo, AA; Schneider, C; Rosen, N; Hartl, FU; Pavletich, NP				Stebbins, CE; Russo, AA; Schneider, C; Rosen, N; Hartl, FU; Pavletich, NP			Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent	CELL			English	Article							HEAT-SHOCK PROTEIN; CELL-FREE SYSTEM; STEROID-RECEPTOR; TYROSINE KINASE; PROGESTERONE-RECEPTOR; MUTATIONAL ANALYSIS; HERBIMYCIN-A; HSP90; GELDANAMYCIN; BINDING	The Hsp90 chaperone is required for the activation of several families of eukaryotic protein kinases and nuclear hormone receptors, many of which are protooncogenic and play a prominent role in cancer. The geldanamycin antibiotic has antiproliferative and antitumor effects, as it binds to Hsp90, inhibits the Hsp90-mediated conformational maturation/refolding reaction, and results in the degradation of Hsp90 substrates. The structure of the geldanamycin-binding domain of Hsp90 (residues 9-232) reveals a pronounced pocket, 15 Angstrom deep, that is highly conserved across species. Geldanamycin binds inside this pocket, adopting a compact structure similar to that of a polypeptide chain in a turn conformation. This, and the pocket's similarity to substrate-binding sites, suggest that the pocket binds a portion of the polypeptide substrate and participates in the conformational maturation/refolding reaction.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; CORNELL UNIV, GRAD SCH MED SCI, DEPT BIOCHEM & STRUCT BIOL, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Stebbins, Erec/N-2565-2018; Rosen, Neal/ABF-2677-2020; Hartl, F. Ulrich/Y-8206-2019	Stebbins, Erec/0000-0001-6229-5308; 				ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOHEN SP, 1994, BIOL HEAT SHOCK PROT; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUNGER AT, 1991, X PLOR SYSTEM XRAY C; Chavany C, 1996, J BIOL CHEM, V271, P4974; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FURUSAKI A, 1980, J ANTIBIOT, V33, P781, DOI 10.7164/antibiotics.33.781; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISAACS JT, 1979, UICC MONOGRAPH PROST, V48, P112; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KIMURA Y, 1994, MOL GEN GENET, V242, P517, DOI 10.1007/BF00285275; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER P, 1994, CANCER RES, V54, P2724; MILLER SJ, 1995, DISS ABSTR INT B, V55, P3313; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; ONO Y, 1982, GANN, V73, P938; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; Rinehart K L Jr, 1976, Fortschr Chem Org Naturst, V33, P231; SASAKI K, 1979, J ANTIBIOT, V32, P849, DOI 10.7164/antibiotics.32.849; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHNUR RC, 1995, J MED CHEM, V38, P3813, DOI 10.1021/jm00019a011; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	61	1183	1253	2	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					239	250		10.1016/S0092-8674(00)80203-2	http://dx.doi.org/10.1016/S0092-8674(00)80203-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108479	hybrid			2022-12-28	WOS:A1997WU88800011
J	deAngelis, MH; McIntyre, J; Gossler, A				deAngelis, MH; McIntyre, J; Gossler, A			Maintenance of somite borders in mice requires the Delta homologue DII1	NATURE			English	Article							CHICK-EMBRYO; CELLS; SEGMENTATION; NEUROGENESIS; MECHANISMS; EXPRESSION; GROWTH	During vertebrate embryonic development, the paraxial mesoderm is subdivided into metameric subunits called somites. The arrangement and cranio-caudal polarity of the somites governs the metamerism of all somite-derived tissues and spinal ganglia. Little is known about the molecular mechanisms underlying somite formation, segment polarity, maintenance of segment borders, and the interdependency of these processes. The mouse Delta homologue Dll1, a member of the DSL gene family, is expressed in the presomitic mesoderm and posterior halves of somites(1). Here we report that, in Dll1-deficient mouse embryos, a primary metameric pattern is established in mesoderm, and cytodifferentiation is apparently normal, but the segments have no cranio-caudal polarity, and no epithelial somites form. Caudal sclerotome halves do not condense, and the pattern of spinal ganglia and nerves is perturbed, indicating loss of segment polarity. Myoblasts span segment borders, demonstrating that these borders are not maintained. These results show that Dll1 is involved in compartmentalization of somites, that dermomyotome and sclerotome differentiation are independent of formation of epithelia and subdivision of somites in cranial and caudal halves, and that compartmentalization is essential for the maintenance of s0egment borders in paraxial mesoderm-derived structures.	JACKSON LAB,BAR HARBOR,ME 04609	Jackson Laboratory			de Angelis, Martin Hrabe/F-5531-2012	de Angelis, Martin Hrabe/0000-0002-7898-2353				BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Burgess R, 1996, NATURE, V384, P570, DOI 10.1038/384570a0; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CHRIST B, 1986, SOMITES DEV EMBRYOS, P261; CONLON RA, 1995, DEVELOPMENT, V121, P1533; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; GOLDSTEIN RS, 1990, P NATL ACAD SCI USA, V87, P4476, DOI 10.1073/pnas.87.12.4476; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KEYNES RJ, 1984, NATURE, V310, P786, DOI 10.1038/310786a0; KOSEKI H, 1993, DEVELOPMENT, V119, P649; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; MONTARRAS D, 1991, NEW BIOL, V3, P592; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Sambrook J., 2002, MOL CLONING LAB MANU; STERN CD, 1986, J EMBRYOL EXP MORPH, V91, P209; STERN CD, 1987, DEVELOPMENT, V99, P261; TEILLET MA, 1987, DEV BIOL, V120, P329, DOI 10.1016/0012-1606(87)90236-3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	24	523	535	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					717	721		10.1038/386717a0	http://dx.doi.org/10.1038/386717a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109488				2022-12-28	WOS:A1997WU38700056
J	Gulbrandsen, P; Hjortdahl, P; Fugelli, P				Gulbrandsen, P; Hjortdahl, P; Fugelli, P			General practitioners' knowledge of their patients' psychosocial problems: Multipractice questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							CARE; MEDICINE	Objectives: To evaluate general practitioners' knowledge of a range of psychosocial problems among their patients and to explore whether doctors' recognition of psychosocial problems depends on previous general knowledge about the patient or the type of problem or on certain characteristics of the doctor or the patient. Design: Multipractice survey of consecutive adult patients consulting general practitioners. Doctors and patients answered written questions. Setting: Buskerud county, Norway. Subjects: 1401 adults attending 89 general practitioners during one regular working day in March 1995. Main outcome measures: Doctors' knowledge of nine predefined psychosocial problems in patients; these problems were assessed by the patients as affecting their health on the day of consultation; odds ratios for the doctor's recognition of each problem, adjusted for characteristics of patients, doctors, and practices; and the doctor's assessment of previous general knowledge about the patient. Results: Doctors' knowledge of the problems ranged from 53% (108/203) of ''stressful working conditions' to 19% (12/63) of a history of ''violence or threats.'' Good previous knowledge of the patient increased the odds for the doctor's recognition of ''sorrow,'' ''violence or threats,'' ''substance misuse in close friend or relative,'' and ''difficult conflict with close friend or relative.'' Age and sex of doctor and patient, patient's educational level and living situation, and location of practice influenced the doctor's awareness. Conclusions: Variation in the patients' communication abilities, the need for confidence in the doctor-patient relationship before revealing intimate problems, and a tendency for the doctors to be entrapped by their expectations may explain these findings.			Gulbrandsen, P (corresponding author), INST GEN PRACTICE & COMMUNITY MED,POB 1130 BLINDERN,N-0317 OSLO,NORWAY.							BARBOUR A, 1995, CARING PATIENTS CRIT, P81; CHEN CY, 1989, FAM PRACT, V6, P259, DOI 10.1093/fampra/6.4.259; EIDE R, 1982, PSYCHOTHER PSYCHOSOM, V37, P218, DOI 10.1159/000287576; GOLDBERG RJ, 1992, SOC SCI MED, V35, P261, DOI 10.1016/0277-9536(92)90022-I; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1992, THESIS U OSLO OSLO; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; JONES I, 1995, FAM PRACT, V12, P49, DOI 10.1093/fampra/12.1.49; KUSHNER K, 1986, J FAM PRACTICE, V23, P463; LAMBERTS H, 1989, INT CLASSIFICATION P, P68; LEEFLANG RLI, 1992, SOC SCI MED, V34, P351, DOI 10.1016/0277-9536(92)90295-2; Leopold N, 1996, J FAM PRACTICE, V42, P129; MARTIN FJ, 1989, FAM PRACT, V6, P254, DOI 10.1093/fampra/6.4.254; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MCWHINNEY IR, 1989, TXB FAMILY MED, P12; MILLER PM, 1984, ACTA PSYCHIAT SCAND, V70, P417, DOI 10.1111/j.1600-0447.1984.tb01229.x; OGG J, 1992, BRIT MED J, V305, P998, DOI 10.1136/bmj.305.6860.998; PENDLETON D, 1984, CONSULTATION APPROAC, P1; QUERIDO A, 1963, EFFICIENCY MED CARE, P46; ROSENBERG EE, 1985, FAM PRACT, V2, P23, DOI 10.1093/fampra/2.1.23; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P19; SCHMELINGKLUDAS C, 1994, PSYCHOTHER PSYCH MED, V44, P372; SCHWENK TL, 1982, J FAM PRACTICE, V15, P339; Smilkstein G, 1994, Fam Med, V26, P111; STEWART MA, 1977, MED CARE, V15, P578, DOI 10.1097/00005650-197707000-00005; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P357; TELLNES G, 1990, THESIS U OSLO OSLO; *WONCA CLASS COMM, 1981, FAM PRACT, V13, P671; YAFFE MJ, 1985, MED CARE, V23, P1276, DOI 10.1097/00005650-198511000-00006	30	70	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1014	1018		10.1136/bmj.314.7086.1014	http://dx.doi.org/10.1136/bmj.314.7086.1014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WT152	9112847	Green Published			2022-12-28	WOS:A1997WT15200026
J	Darling, RS; Chou, IM; Bodnar, RJ				Darling, RS; Chou, IM; Bodnar, RJ			An occurrence of metastable cristobalite in high-pressure garnet granulite	SCIENCE			English	Article							PHASE-TRANSITION; FLUID INCLUSIONS; RE-EQUILIBRATION; CENTRAL CHINA; COESITE; QUARTZ; METAMORPHISM; BEHAVIOR; KBAR	High-pressure (0.8 gigapascals) granulite facies garnet from Gore Mountain, New York, hosts multiple solid inclusions containing the low-pressure silica polymorph cristobalite along with albite and minor ilmenite. Identification of cristobalite is based on Raman spectra, electron microprobe analysis, and microthermometric measurements on the alpha/beta phase transformation. The cristobalite plus albite inclusions may have originated as small, trapped samples of hydrous sodium-aluminum-siliceous melt. Diffusive loss of water from these inclusions under isothermal, isochoric conditions may have resulted in a large enough internal pressure decrease to promote the metastable crystallization of cristobalite.	US GEOL SURVEY,RESTON,VA 20192; VIRGINIA POLYTECH INST & STATE UNIV,DEPT GEOL SCI,BLACKSBURG,VA 24061	United States Department of the Interior; United States Geological Survey; Virginia Polytechnic Institute & State University	Darling, RS (corresponding author), SUNY COLL CORTLAND,DEPT GEOL,CORTLAND,NY 13045, USA.		Bodnar, Robert J/A-1916-2009					BATES JB, 1972, J CHEM PHYS, V57, P4042, DOI 10.1063/1.1678878; Beljankin DS, 1938, AM MINERAL, V23, P153; BERMAN RG, 1988, J PETROL, V29, P445, DOI 10.1093/petrology/29.2.445; BOHLEN SR, 1985, J PETROL, V26, P971, DOI 10.1093/petrology/26.4.971; CHOPIN C, 1984, CONTRIB MINERAL PETR, V86, P107, DOI 10.1007/BF00381838; COHEN LH, 1979, PHILOS MAG A, V39, P399, DOI 10.1080/01418617908239280; DEWAARD D, 1967, J PETROL, V8, P210, DOI 10.1093/petrology/8.2.210; Frondel C., 1962, SYSTEM MINERALOGY SI, P77; HILL VG, 1958, J AM CERAM SOC, V41, P532, DOI 10.1111/j.1151-2916.1958.tb12911.x; HOLLOWAY JR, 1973, GEOCHIM COSMOCHIM AC, V37, P651, DOI 10.1016/0016-7037(73)90225-1; HOSIENI KR, 1985, AM MINERAL, V70, P782; KLASIK JA, 1975, SCIENCE, V189, P631, DOI 10.1126/science.189.4203.631; Luther F., 1976, THESIS LEHIGH U BETH; MEZGER K, 1991, J GEOL, V99, P415, DOI 10.1086/629503; OKAY AI, 1989, EUR J MINERAL, V1, P595; RINGWOOD AE, 1966, TECTONOPHYSICS, V3, P383, DOI 10.1016/0040-1951(66)90009-6; SCHAIRER JF, 1956, AM J SCI, V254, P129, DOI 10.2475/ajs.254.3.129; SCHMAHL WW, 1992, Z KRISTALLOGR, V201, P125, DOI 10.1524/zkri.1992.201.1-2.125; SCHMAHL WW, 1993, EUR J MINERAL, V5, P377; SPEAR FS, IN PRESS J PETROL; STERNER SM, 1989, J METAMORPH GEOL, V7, P243, DOI 10.1111/j.1525-1314.1989.tb00587.x; VANVALKENBURG A, 1945, AM MINERAL, V30, P526; VITYK MO, 1995, EUR J MINERAL, V7, P1071; Wang LP, 1996, AM MINERAL, V81, P706; WANG XM, 1989, GEOLOGY, V17, P1085, DOI 10.1130/0091-7613(1989)017<1085:CBEFTD>2.3.CO;2; WEN SX, 1994, AM MINERAL, V79, P316	26	37	44	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					91	93		10.1126/science.276.5309.91	http://dx.doi.org/10.1126/science.276.5309.91			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082992				2022-12-28	WOS:A1997WR38600051
J	Gaudreau, L; Schmid, A; Blaschke, D; Ptashne, M; Horz, W				Gaudreau, L; Schmid, A; Blaschke, D; Ptashne, M; Horz, W			RNA polymerase II holoenzyme recruitment is sufficient to remodel chromatin at the yeast PHO5 promoter	CELL			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; NUCLEOSOME DISRUPTION; IN-VIVO; POSITIONED NUCLEOSOMES; GAL11 PROTEIN; DNA; GENE; COMPLEX	We examine transcriptional activation and chromatin remodeling at the PHO5 promoter in yeast by fusion proteins that are thought to act by recruiting the RNA polymerase II holoenzyme to DNA in the absence of a classic activating region. These hybrid proteins (e.g., Gal11+Pho4 or Gal4(58-97)+Pho4 in the presence of a GAL11P allele) efficiently activated transcription and remodeled chromatin. Similar chromatin remodeling was observed at a PHO5 promoter deleted for TATA and thus unable to support transcription. We conclude that recruitment of the holoenzyme or associated proteins suffices for chromatin remodeling. We also show that the SWI/SNF complex is required neither for efficient transcription of the wild-type PHO5 nor the GAL1 promoters, and we observe nearly complete chromatin remodeling at PHO5 in the absence of Snf2.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	University of Munich; Harvard University								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Bunker CA, 1996, P NATL ACAD SCI USA, V93, P10820, DOI 10.1073/pnas.93.20.10820; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; RUDOLPH H, 1987, P NATL ACAD SCI USA, V84, P1340, DOI 10.1073/pnas.84.5.1340; Sakurai H, 1996, P NATL ACAD SCI USA, V93, P9488, DOI 10.1073/pnas.93.18.9488; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; SUZUKI Y, MOL CELL BIOL, V12, P4806; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; SVAREN J, 1995, METH MOL G, V6, P153; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; XIAO H, 1995, MOL CELL BIOL, V15, P5757	49	113	113	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					55	62		10.1016/S0092-8674(00)80182-8	http://dx.doi.org/10.1016/S0092-8674(00)80182-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094714	Bronze			2022-12-28	WOS:A1997WR68500009
J	Vossler, MR; Yao, H; York, RD; Pan, MG; Rim, CS; Stork, PJS				Vossler, MR; Yao, H; York, RD; Pan, MG; Rim, CS; Stork, PJS			cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway	CELL			English	Article							DEPENDENT PROTEIN-KINASE; NERVE GROWTH-FACTOR; PC12 CELLS; CYCLIC-AMP; CATALYZED PHOSPHORYLATION; IDENTIFICATION; DOMAIN; DIFFERENTIATION; FIBROBLASTS; EXPRESSION	Cyclic adenosine monophosphate (cAMP) has tissue-specific effects on growth, differentiation, and gene expression. We show here that cAMP can activate the transcription factor Elk-1and induce neuronal differentiation of PC12 cells via its activation of the MAP kinase cascade. These cell type-specific actions of cAMP require the expression of the serine/threonine kinase B-Raf and activation of the small G protein Rap1. Rap1, activated by mutation or by the cAMP-dependent protein kinase PKA, is a selective activator of B-Raf and an inhibitor of Raf-1. Therefore, in B-Raf-expressing cells, the activation of Rap1 provides a mechanism for tissue-specific regulation of cell growth and differentiation via MAP kinase.	OREGON HLTH SCI UNIV L474,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DIV CARDIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT MOL MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,GRAD PROGRAM NEUROSCI,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT CELL & DEV BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HATA Y, 1991, J BIOL CHEM, V266, P6571; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada T, 1996, J BIOL CHEM, V271, P4671; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAN MG, 1995, ONCOGENE, V11, P2005; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	44	928	953	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					73	82		10.1016/S0092-8674(00)80184-1	http://dx.doi.org/10.1016/S0092-8674(00)80184-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094716	Bronze			2022-12-28	WOS:A1997WR68500011
J	Dickens, BM				Dickens, BM			Legal aspects of the dementias	LANCET			English	Article											Dickens, BM (corresponding author), UNIV TORONTO,FAC LAW,84 QUEENS PK,TORONTO,ON M5S 2C5,CANADA.							BATTIN MP, 1994, LEAST WORST DEATH; BRAZIER M, 1992, MED PATIENTS LAW, P100; *BRIT MED ASS, 1993, MED ETH TOD ITS PRAC, P160; CULVER CM, 1982, PHILOS MED, P143; GRENE R, 1992, SEXUAL SCI LAW; Jones Michael A, 1996, Med Law Int, V2, P107	6	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					948	950		10.1016/S0140-6736(96)07513-7	http://dx.doi.org/10.1016/S0140-6736(96)07513-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093265				2022-12-28	WOS:A1997WR25400047
J	Watanabe, Y; Yamada, N; Yokoi, H; Fujiwara, Y; Mokuno, H; Daida, H; Yamaguchi, H				Watanabe, Y; Yamada, N; Yokoi, H; Fujiwara, Y; Mokuno, H; Daida, H; Yamaguchi, H			Relationship between HLA-C locus and restenosis after coronary artery balloon angioplasty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To determine the relationship between human leukocyte antigen (HLA) loci and restenosis after percutaneous transluminal coronary angioplasty (PTCA). Design and Setting.-Cross-sectional study in patients treated by PTCA at Juntendo University Hospital, Tokyo, Japan. Patients.-A total of 65 patients (58 males and 7 females) with coronary artery stenosis who were consecutively selected between October 1994 and June 1995. Main Outcome Measures.-Significant relationships between the restenosis and the HLA-Cw1. Results.-Among HLA-C locus, Cw1 was negatively related to restenosis (multivariate adjusted odds ratio, 0.19; 95% confidence interval, 0.06-0.63; P=.007). Conclusions-In HLA typing, Cw1 may be a useful marker for the prediction of restenosis after PTCA.	UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN; JUNTENDO UNIV, DEPT CARDIOL, TOKYO, JAPAN	University of Tokyo; Juntendo University								FALK K, 1993, P NATL ACAD SCI USA, V90, P12005, DOI 10.1073/pnas.90.24.12005; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103; TSUJI K, 1991, P 11 INT HIST WORKSH, P1065	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					983	984		10.1001/jama.277.12.983	http://dx.doi.org/10.1001/jama.277.12.983			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091671				2022-12-28	WOS:A1997WN99200033
J	Busse, P				Busse, P			Strident, but essential: The voices of people with AIDS	BRITISH MEDICAL JOURNAL			English	Article											Busse, P (corresponding author), NAPWA S AFRICA,POB 27262,PO RHINE RD 8050,WESTERN CAPE,SOUTH AFRICA.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					888	889						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093105				2022-12-28	WOS:A1997WQ02800037
J	Emery, S; Cooper, DA				Emery, S; Cooper, DA			Drug companies have a duty to continue treatment	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW 2010,AUSTRALIA	University of New South Wales Sydney; Kirby Institute			Emery, Sean/O-9122-2019; Emery, Sean/J-3825-2017	Emery, Sean/0000-0001-6072-8309; Emery, Sean/0000-0001-6072-8309				*WORLD MED ASS, 1964, WORLD MED ASS HDB DE	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					889	889						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093106				2022-12-28	WOS:A1997WQ02800038
J	Pace, NR				Pace, NR			A molecular view of microbial diversity and the biosphere	SCIENCE			English	Article							RIBOSOMAL-RNA SEQUENCES; YELLOWSTONE-NATIONAL-PARK; TATA-BINDING PROTEIN; PHYLOGENETIC ANALYSIS; TRANSCRIPTION FACTOR; DEEP-SEA; ARCHAEA; EUKARYOTES; COMMUNITY; ENDOSYMBIONTS	Over three decades of molecular-phylogenetic studies, researchers have compiled an increasingly robust map of evolutionary diversification showing that the main diversity of life is microbial, distributed among three primary relatedness groups or domains: Archaea, Bacteria, and Eucarya. The general properties of representatives of the three domains indicate that the earliest life was based on inorganic nutrition and that photosynthesis and use of organic compounds for carbon and energy metabolism came comparatively later. The application of molecular-phylogenetic methods to study natural microbial ecosystems without the traditional requirement for cultivation has resulted in the discovery of many unexpected evolutionary lineages; members of some of these lineages are only distantly related to known organisms but are sufficiently abundant that they are likely to have impact on the chemistry of the biosphere.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Pace, NR (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT & MICROBIAL BIOL,BERKELEY,CA 94720, USA.							AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Barns SM, 1996, P NATL ACAD SCI USA, V93, P9188, DOI 10.1073/pnas.93.17.9188; BARNS SM, 1994, P NATL ACAD SCI USA, V91, P1609, DOI 10.1073/pnas.91.5.1609; Bintrim SB, 1997, P NATL ACAD SCI USA, V94, P277, DOI 10.1073/pnas.94.1.277; Brock T.D., 1978, THERMOPHILIC MICROOR; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; BULL AT, 1992, ANNU REV MICROBIOL, V46, P219, DOI 10.1146/annurev.micro.46.1.219; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CHATTON E, 1937, TITRES TRAVOUX SCI; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; DOOLITTLE WF, 1994, P NATL ACAD SCI USA, V91, P6721, DOI 10.1073/pnas.91.15.6721; EMBLEY TM, 1994, MICROBIOL-SGM, V140, P225, DOI 10.1099/13500872-140-2-225; FENCHEL T, 1989, OPHELIA, V30, P75; FENCHEL T, 1995, ECOLOGY EVOLUTION AN; Fredrickson JK, 1996, SCI AM, V275, P68, DOI 10.1038/scientificamerican1096-68; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Ghiorse WC, 1997, SCIENCE, V275, P789, DOI 10.1126/science.275.5301.789; GOLD T, 1992, P NATL ACAD SCI USA, V89, P6045, DOI 10.1073/pnas.89.13.6045; Hershberger KL, 1996, NATURE, V384, P420, DOI 10.1038/384420a0; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; Hugenholtz P, 1996, TRENDS BIOTECHNOL, V14, P190, DOI 10.1016/0167-7799(96)10025-1; HUGENHOLTZ P, UNPUB; Jurgens G, 1997, APPL ENVIRON MICROB, V63, P803, DOI 10.1128/AEM.63.2.803-805.1997; KANDLER O, 1993, NOBEL S, V84, P152; Kates M, 1993, BIOCH ARCHAEA ARCHAE; LOVELY DR, 1995, REV GEOPHYS, V33, P365; LUTZ RA, 1994, NATURE, V371, P663, DOI 10.1038/371663a0; Madigan M. T., 1996, BROCK BIOL MICROORGA; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; MARSH TL, 1994, P NATL ACAD SCI USA, V91, P4180, DOI 10.1073/pnas.91.10.4180; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PACE NR, 1985, ASM NEWS, V51, P4; Palmer JD, 1997, SCIENCE, V275, P790, DOI 10.1126/science.275.5301.790; PEDERSEN K, 1993, EARTH-SCI REV, V34, P243, DOI 10.1016/0012-8252(93)90058-F; PIERSON BK, 1993, NOBEL S, V84, P161; PITULLE C, 1994, INT J SYST BACTERIOL, V44, P620, DOI 10.1099/00207713-44-4-620; REYSENBACH AL, 1994, APPL ENVIRON MICROB, V60, P2113, DOI 10.1128/AEM.60.6.2113-2119.1994; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; SALKI RK, 1988, SCIENCE, V239, P487; Sapp Jan., 1994, EVOLUTION ASS HIST S; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; Smith DC, 1987, BIOL SYMBIOSIS; SOGIN ML, 1994, NOBEL S, V84, P181; STAHL DA, 1985, APPL ENVIRON MICROB, V49, P1379, DOI 10.1128/AEM.49.6.1379-1384.1985; Stein JL, 1996, J BACTERIOL, V178, P591, DOI 10.1128/jb.178.3.591-599.1996; STETTER KO, 1995, ASM NEWS, V61, P285; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; Swofford David L., 1996, P407; TUNNICLIFFE V, 1992, AM SCI, V80, P336; UEDA T, 1995, EUR J SOIL SCI, V46, P415, DOI 10.1111/j.1365-2389.1995.tb01337.x; WHITTAKER RH, 1969, SCIENCE, V163, P150, DOI 10.1126/science.163.3863.150; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	61	1825	2008	9	528	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					734	740		10.1126/science.276.5313.734	http://dx.doi.org/10.1126/science.276.5313.734			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115194				2022-12-28	WOS:A1997WW90000040
J	Shapiro, L; Losick, R				Shapiro, L; Losick, R			Protein localization and cell fate in bacteria	SCIENCE			English	Review							DEVELOPMENTAL TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION PATHWAY; ANTI-SIGMA FACTOR; BACILLUS-SUBTILIS; GENE-EXPRESSION; CAULOBACTER-CRESCENTUS; MOTHER-CELL; 2-COMPONENT REGULATORS; ASYMMETRIC DIVISION; PREDIVISIONAL CELL	A major breakthrough in understanding the bacterial cell is the discovery that the cell is highly organized at the level of protein localization. Proteins are positioned at particular sites in bacteria, including the cell pole, the incipient division plane, and the septum. Differential protein localization can control DNA replication, chromosome segregation, and cytokinesis and is responsible for generating daughter cells with different fates upon cell division. Recent discoveries have revealed that progression through the cell cycle and communication between cellular compartments are mediated by two-component signal transduction systems and signaling pathways involving transcription factor activation by proteolytic processing. Asymmetric cell division in Caulobacter crescentus and sporulation in Bacillus subtilis are used as paradigms for the control of the cell cycle and cellular morphogenesis in bacterial cells.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138	Harvard University	Shapiro, L (corresponding author), STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM51426, GM-32506, GM18568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568, R01GM032506, R37GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDENALL SG, 1996, J BACTERIOL, V178, P7167; Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; BALDUS JM, 1994, J BACTERIOL, V176, P296, DOI 10.1128/JB.176.2.296-306.1994; Barak I, 1996, MOL MICROBIOL, V19, P1047, DOI 10.1046/j.1365-2958.1996.433963.x; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BRAMUCCI MG, 1995, J BACTERIOL, V177, P1630, DOI 10.1128/jb.177.6.1630-1633.1995; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; CHUNG JD, 1994, J BACTERIOL, V176, P1977, DOI 10.1128/jb.176.7.1977-1984.1994; CUTTING S, 1991, J MOL BIOL, V221, P1237; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; DRIKS A, 1994, GENE DEV, V8, P234, DOI 10.1101/gad.8.2.234; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; ELY B, 1993, P NATL ACAD SCI USA, V90, P630; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GLASER P, 1997, CELL, V88, P675; GOBER JW, 1992, MOL BIOL CELL, V3, P913, DOI 10.1091/mbc.3.8.913; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; GOMEZ M, 1995, J BACTERIOL, V177, P4825, DOI 10.1128/jb.177.16.4825-4827.1995; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HOFMEISTER AEM, 1995, CELL, V83, P219, DOI 10.1016/0092-8674(95)90163-9; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; Jenal U, 1996, EMBO J, V15, P2393, DOI 10.1002/j.1460-2075.1996.tb00597.x; KAROW ML, 1995, P NATL ACAD SCI USA, V92, P2012, DOI 10.1073/pnas.92.6.2012; KELLY AJ, UNPUB; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; KOCKS C, 1993, J CELL SCI, V105, P699; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KUTSUKAKE K, 1994, EMBO J, V13, P4568, DOI 10.1002/j.1460-2075.1994.tb06778.x; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LANE T, 1995, 2 COMPONENT SIGNAL T, P296; LEVIN PA, 1994, J BACTERIOL, V176, P1451, DOI 10.1128/jb.176.5.1451-1459.1994; Levin PA, 1996, GENE DEV, V10, P478, DOI 10.1101/gad.10.4.478; Lewis PJ, 1996, GENES CELLS, V1, P881, DOI 10.1046/j.1365-2443.1996.750275.x; LIN D, IN PRESS P NATL ACAD; LONDONOVALLEJO JA, 1995, GENE DEV, V9, P503, DOI 10.1101/gad.9.4.503; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCZYNSKI GT, 1995, GENE DEV, V9, P1543, DOI 10.1101/gad.9.12.1543; MILHAUSEN M, 1983, NATURE, V302, P630, DOI 10.1038/302630a0; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; MUKHERJEE A, 1994, J BACTERIOL, V176, P2764; MULLIN DA, 1994, J BACTERIOL, V176, P5971, DOI 10.1128/jb.176.19.5971-5981.1994; NATHAN P, 1986, J MOL BIOL, V191, P433, DOI 10.1016/0022-2836(86)90138-5; OHTA N, 1992, P NATL ACAD SCI USA, V89, P10297, DOI 10.1073/pnas.89.21.10297; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; POGLIANO K, 1995, MOL MICROBIOL, V18, P459, DOI 10.1111/j.1365-2958.1995.mmi_18030459.x; POGLIANO K, IN PRESS J BACTERIOL; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; PREGO M, 1994, CELL, V79, P1047; Quardokus E, 1996, P NATL ACAD SCI USA, V93, P6314, DOI 10.1073/pnas.93.13.6314; QUON K, UNPUB; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; Resnekov O, 1996, GENES CELLS, V1, P529, DOI 10.1046/j.1365-2443.1996.d01-262.x; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SATOLA SW, 1992, J BACTERIOL, V174, P1448, DOI 10.1128/jb.174.5.1448-1453.1992; SHAPIRO L, 1993, CELL, V73, P841, DOI 10.1016/0092-8674(93)90266-S; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHAZAND K, 1995, EMBO J, V14, P1439, DOI 10.1002/j.1460-2075.1995.tb07130.x; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; Stephens C, 1996, P NATL ACAD SCI USA, V93, P1210, DOI 10.1073/pnas.93.3.1210; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WEBB CD, 1995, J BACTERIOL, V177, P5906, DOI 10.1128/jb.177.20.5906-5911.1995; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Wingrove JA, 1996, SCIENCE, V274, P597, DOI 10.1126/science.274.5287.597; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014; Wu LJ, 1997, EMBO J, V16, P2161, DOI 10.1093/emboj/16.8.2161; WU LJ, 1995, GENE DEV, V9, P1306; Zhang L, 1996, J BACTERIOL, V178, P2813, DOI 10.1128/jb.178.10.2813-2817.1996; ZWEIGER G, 1994, J MOL BIOL, V235, P472, DOI 10.1006/jmbi.1994.1007	101	96	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					712	718		10.1126/science.276.5313.712	http://dx.doi.org/10.1126/science.276.5313.712			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115191				2022-12-28	WOS:A1997WW90000037
J	Davis, A; Daley, J; Hartman, EE				Davis, A; Daley, J; Hartman, EE			A 21-year-old woman with menstrual irregularity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FUNCTIONAL HYPOTHALAMIC AMENORRHEA; DISTINCT ENTITY; NATURAL-HISTORY; YOUNG-WOMEN; BLOOD-LOSS; WEIGHT; CYCLE; CONTRACEPTIVES; DYSFUNCTION; EXERCISE		BETH ISRAEL MED CTR,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02215; BETH ISRAEL MED CTR,DEPT REPROD BIOL,BOSTON,MA 02215; BETH ISRAEL MED CTR,DEPT OBSTET & GYNECOL,BOSTON,MA 02215; CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital								*AM COLL OBST GYN, 1989, TECHN B DYSF UT BLEE; BAYER SR, 1993, JAMA-J AM MED ASSOC, V269, P1823; BERGA SL, 1989, J CLIN ENDOCR METAB, V68, P301, DOI 10.1210/jcem-68-2-301; CHIMBIRA TH, 1980, BRIT J OBSTET GYNAEC, V87, P603, DOI 10.1111/j.1471-0528.1980.tb05013.x; CONSTANTINI NW, 1995, J CLIN ENDOCR METAB, V80, P2740, DOI 10.1210/jc.80.9.2740; DREW FL, 1968, OBSTET GYNECOL, V32, P47; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; GARZAFLORES J, 1985, CONTRACEPTION, V31, P361, DOI 10.1016/0010-7824(85)90004-6; GILES DE, 1993, FERTIL STERIL, V60, P486; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HARLAP S, 1991, PREVENTING PREGNANCY; HARLOW SD, 1991, J CLIN EPIDEMIOL, V44, P1015, DOI 10.1016/0895-4356(91)90003-R; HULL MGR, 1979, BRIT J OBSTET GYNAEC, V86, P799, DOI 10.1111/j.1471-0528.1979.tb10696.x; JONES KP, 1986, OBSTET GYNECOL, V66, P55; KRETTEK JE, 1993, OBSTET GYNECOL, V81, P728; LOBO RA, 1995, FERTIL STERIL, V63, P1158, DOI 10.1016/S0015-0282(16)57589-X; LOUCKS AB, 1989, J CLIN ENDOCR METAB, V68, P401; PIRKE KM, 1989, FERTIL STERIL, V51, P263; PIRKE KM, 1985, J CLIN ENDOCR METAB, V60, P1174, DOI 10.1210/jcem-60-6-1174; PIRKE KM, 1987, CLIN ENDOCRINOL, V27, P245, DOI 10.1111/j.1365-2265.1987.tb01150.x; PIRKE KM, 1986, FERTIL STERIL, V46, P1083; SCHEDLOWSKI M, 1992, LIFE SCI, V50, P1201, DOI 10.1016/0024-3205(92)90319-K; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; SCHWALLIE PC, 1974, CONTRACEPTION, V10, P181, DOI 10.1016/0010-7824(74)90073-0; SCHWARTZ B, 1981, AM J OBSTET GYNECOL, V141, P662, DOI 10.1016/S0002-9378(15)33308-1; SCHWEIGER U, 1987, FERTIL STERIL, V48, P746; SCHWEIGER U, 1995, FERTIL STERIL, V57, P771; SHANGOLD M, 1990, JAMA-J AM MED ASSOC, V263, P1665, DOI 10.1001/jama.263.12.1665; SHELDRAKE P, 1976, J PSYCHOSOM RES, V20, P169, DOI 10.1016/0022-3999(76)90017-9; SISAM DA, 1987, FERTIL STERIL, V48, P67; Speroff L, 1994, CLIN GYNECOLOGIC END, V5th; SUH BY, 1988, J CLIN ENDOCR METAB, V66, P773; TREOLAR AE, 1967, INT J FERTIL, V12, P77; WARREN MP, 1980, J CLIN ENDOCR METAB, V51, P1150, DOI 10.1210/jcem-51-5-1150; YEN SSC, 1992, FERTIL STERIL, V58, P37	36	7	7	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1308	1314		10.1001/jama.277.16.1308	http://dx.doi.org/10.1001/jama.277.16.1308			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109470				2022-12-28	WOS:A1997WU13500032
J	Grupp, DE; Goldman, AM				Grupp, DE; Goldman, AM			Giant piezoelectric effect in strontium titanate at cryogenic temperatures	SCIENCE			English	Article							SRTIO3	Piezoelectric materials have many applications at cryogenic temperatures. However, the piezoelectric response below 10 kelvin is diminished, making the use of these materials somewhat marginal. Results are presented on strontium titanate (SrTiO3), which exhibits a rapidly increasing piezoelectric response with decreasing 'temperature below 50 kelvin; the magnitude of its response around 1 kelvin is comparable to that of the best materials at room temperature. This ''giant'' piezoelectric response may open the way for a broad class of applications including use in ultralow-temperature scanning microscopies and in a magnetic field-insensitive thermometer. These observations, and the possible divergence of the mechanical response to electric fields at even lower temperatures, may arise from an apparent quantum critical point at absolute zero.	UNIV MINNESOTA,SCH PHYS & ASTRON,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								GRUPP DE, UNPUB; HEHLEN B, 1995, PHYS REV LETT, V75, P2416, DOI 10.1103/PhysRevLett.75.2416; HELFRICH JA, 1995, REV SCI INSTRUM, V66, P4880, DOI 10.1063/1.1146169; HEMBERGER J, 1995, PHYS REV B, V52, P13159, DOI 10.1103/PhysRevB.52.13159; LAWLESS WN, 1974, FERROELECTRICS, V7, P379, DOI 10.1080/00150197408238053; MANZANARES C, 1995, REV SCI INSTRUM, V66, P2644, DOI 10.1063/1.1145603; Meyer G, 1996, REV SCI INSTRUM, V67, P2960, DOI 10.1063/1.1147080; MUGELE F, 1996, REV SCI INSTRUM, V67, P4880; MULLER KA, 1979, PHYS REV B, V19, P3593, DOI 10.1103/PhysRevB.19.3593; MULLER KA, 1970, SOLID STATE COMMUN, V8, P549, DOI 10.1016/0038-1098(70)90302-9; SAWAGUCHI E, 1971, FERROELECTRICS, V2, P37, DOI 10.1080/00150197108243943; SAWAGUCHI E, 1963, J PHYS SOC JPN, V18, P459, DOI 10.1143/JPSJ.18.459; SCHMIDT G, 1963, PHYS STATUS SOLIDI, V3, P329, DOI 10.1002/pssb.19630030216; SIEGEL J, 1995, REV SCI INSTRUM, V66, P2520, DOI 10.1063/1.1145652; SONDHI SL, IN PRESS REV MOD PHY; UWE H, 1976, PHYS REV B, V13, P271, DOI 10.1103/PhysRevB.13.271; WALDNER KA, 1968, PHYS REV LETT, V21, P814; YAMADA Y, 1969, J PHYS SOC JPN, V26, P396, DOI 10.1143/JPSJ.26.396; ZHELUDEV IS, 1971, P0HYSICS CRYSTALLINE, V2; Zhong W, 1996, PHYS REV B, V53, P5047, DOI 10.1103/PhysRevB.53.5047	20	120	122	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					392	394		10.1126/science.276.5311.392	http://dx.doi.org/10.1126/science.276.5311.392			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103192				2022-12-28	WOS:A1997WU47700032
J	Cahill, MR; Newland, AC				Cahill, MR; Newland, AC			Is it refractory idiopathic thrombocytopenic purpura?	LANCET			English	Article							DEAFNESS; MACROTHROMBOCYTOPATHIA; NEPHRITIS				Cahill, MR (corresponding author), ROYAL LONDON HOSP,DEPT HAEMATOL,LONDON E1 1BB,ENGLAND.							BERNHEIM J, 1976, AM J MED, V61, P145, DOI 10.1016/0002-9343(76)90058-9; ECKSTEIN JD, 1975, ANN INTERN MED, V82, P639, DOI 10.7326/0003-4819-82-5-639; EPSTEIN CJ, 1972, AM J MED, V52, P299, DOI 10.1016/0002-9343(72)90017-4; NAJEAN Y, 1995, SEMIN THROMB HEMOST, V21, P294, DOI 10.1055/s-2007-1000650	4	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1066	1066		10.1016/S0140-6736(97)02257-5	http://dx.doi.org/10.1016/S0140-6736(97)02257-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107246				2022-12-28	WOS:A1997WU00200012
J	Polzin, KL; Toole, JM; Ledwell, JR; Schmitt, RW				Polzin, KL; Toole, JM; Ledwell, JR; Schmitt, RW			Spatial variability of turbulent mixing in the abyssal ocean	SCIENCE			English	Article							ANTARCTIC BOTTOM WATER; MAIN THERMOCLINE; BRAZIL BASIN; DISSIPATION; TRACER; FLOW; CIRCULATION; WAVES; FLUX	Ocean microstructure data show that turbulent mixing in the deep Brazil Basin of the South Atlantic Ocean is weak at all depths above smooth abyssal plains and the South American Continental Rise. The diapycnal diffusivity there was estimated to be less than or approximately equal to 0.1 x 10(-4) meters squared per second. In contrast, mixing rates are large throughout the water column above the rough Mid-Atlantic Ridge, and the diffusivity deduced for the bottom-most 150 meters exceeds 5 x 10(-4) meters squared per second. Such patterns in vertical mixing imply that abyssal circulations have complex spatial structures that are linked to the underlying bathymetry.			Polzin, KL (corresponding author), WOODS HOLE OCEANOG INST,WOODS HOLE,MA 02543, USA.		Schmitt, Raymond W/B-7451-2011	Toole, John/0000-0003-2905-0637				BAINES PG, 1982, DEEP-SEA RES, V29, P307, DOI 10.1016/0198-0149(82)90098-X; BARTON ED, 1989, DEEP-SEA RES, V36, P1121, DOI 10.1016/0198-0149(89)90082-4; BELL TH, 1975, J FLUID MECH, V67, P705, DOI 10.1017/S0022112075000560; BELL TH, 1975, J GEOPHYS RES, V80, P320, DOI 10.1029/JC080i003p00320; CAIRNS JL, 1976, J GEOPHYS RES-OC ATM, V81, P1943, DOI 10.1029/JC081i012p01943; DEMADRON XD, 1994, J MAR RES, V52, P583; ERIKSEN CC, 1982, J GEOPHYS RES-OCEANS, V87, P525, DOI 10.1029/JC087iC01p00525; GARGETT AE, 1984, J MAR RES, V42, P359, DOI 10.1357/002224084788502756; GARRETT C, 1975, J GEOPHYS RES, V80, P291, DOI 10.1029/JC080i003p00291; GARRETT C, 1988, J GEOPHYS RES, P405; GREGG MC, 1977, J PHYS OCEANOGR, V7, P436, DOI 10.1175/1520-0485(1977)007<0436:VITIOS>2.0.CO;2; GREGG MC, 1989, J GEOPHYS RES-OCEANS, V94, P9686, DOI 10.1029/JC094iC07p09686; HALL MB, COMMUNICATION; Hogg N, 1982, J MAR RES, V40, P231; HOTCHKISS FS, 1982, DEEP-SEA RES, V29, P415, DOI 10.1016/0198-0149(82)90068-1; Kunze E, 1996, J PHYS OCEANOGR, V26, P2286, DOI 10.1175/1520-0485(1996)026<2286:AMWIIN>2.0.CO;2; LAW CS, 1994, MAR CHEM, V48, P57, DOI 10.1016/0304-4203(94)90062-0; LEDWELL JR, 1995, J GEOPHYS RES-OCEANS, V100, P20681, DOI 10.1029/95JC02164; LEDWELL JR, 1993, NATURE, V364, P701, DOI 10.1038/364701a0; MCDOUGALL T, 1991, SOEST SPECIAL PUBLIC, P355; MERCIER HPA, UNPUB; MOUM JN, 1986, J PHYS OCEANOGR, V16, P1250, DOI 10.1175/1520-0485(1986)016<1250:MITMT>2.0.CO;2; MUNK WH, 1966, DEEP-SEA RES, V13, P207; Osborn T. R., 1972, Geophysical Fluid Dynamics, V3, P321, DOI 10.1080/03091927208236085; OSBORN TR, 1980, J PHYS OCEANOGR, V10, P83, DOI 10.1175/1520-0485(1980)010<0083:EOTLRO>2.0.CO;2; Phillips O.M., 1977, DYNAMICS UPPER OCEAN, V2nd ed.; Polzin KL, 1996, NATURE, V380, P54, DOI 10.1038/380054a0; POLZIN KL, 1995, J PHYS OCEANOGR, V25, P306, DOI 10.1175/1520-0485(1995)025<0306:FPOTD>2.0.CO;2; Roemmich D, 1996, J GEOPHYS RES-OCEANS, V101, P14039, DOI 10.1029/96JC00797; SAUNDERS PM, 1987, J PHYS OCEANOGR, V17, P631, DOI 10.1175/1520-0485(1987)017<0631:FTDG>2.0.CO;2; Schmitt R. W., 1988, Journal of Atmospheric and Oceanic Technology, V5, P484, DOI 10.1175/1520-0426(1988)005<0484:TDOAFA>2.0.CO;2; SJOBERG B, 1992, DEEP-SEA RES, V39, P269, DOI 10.1016/0198-0149(92)90109-7; SPALL MA, 1994, J MAR RES, V52, P1051, DOI 10.1357/0022240943076830; SPEER KG, 1993, J PHYS OCEANOGR, V23, P2667, DOI 10.1175/1520-0485(1993)023<2667:TFOABW>2.0.CO;2; STOMMEL H, 1960, DEEP-SEA RES, V6, P140; Thompson L, 1996, DEEP-SEA RES PT I, V43, P193, DOI 10.1016/0967-0637(96)00095-7; THORPE SA, 1995, P ROY SOC LOND A MAT, V439, P115; TOOLE JM, 1994, SCIENCE, V264, P1120, DOI 10.1126/science.264.5162.1120; Toole JM, 1997, J GEOPHYS RES-OCEANS, V102, P947, DOI 10.1029/96JC03160; WHITEHEAD JA, 1982, J GEOPHYS RES-OCEANS, V87, P7903, DOI 10.1029/JC087iC10p07903; WUNSCH C, 1970, DEEP-SEA RES, V17, P293, DOI 10.1016/0011-7471(70)90022-7; WYRTKI K, 1961, DEEP-SEA RES, V8, P39, DOI 10.1016/0146-6313(61)90014-4	42	810	832	0	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					93	96		10.1126/science.276.5309.93	http://dx.doi.org/10.1126/science.276.5309.93			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082993				2022-12-28	WOS:A1997WR38600052
J	Steeghs, K; Benders, A; Oerlemans, F; deHaan, A; Heerschap, A; Ruitenbeek, W; Jost, C; vanDeursen, J; Perryman, B; Pette, D; Bruckwilder, M; Koudijs, J; Jap, P; Veerkamp, J; Wieringa, B				Steeghs, K; Benders, A; Oerlemans, F; deHaan, A; Heerschap, A; Ruitenbeek, W; Jost, C; vanDeursen, J; Perryman, B; Pette, D; Bruckwilder, M; Koudijs, J; Jap, P; Veerkamp, J; Wieringa, B			Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies	CELL			English	Article							CELLULAR-ENERGY METABOLISM; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; MICE; COMPARTMENTATION; PHOSPHORYLATION; HOMEOSTASIS; CONTRACTION; RELAXATION; PHOSPHATE	We have blocked creatine kinase (CK)-mediated phosphocreatine (PCr) reversible arrow ATP transphosphorylation in skeletal muscle by combining targeted mutations in the genes encoding mitochondrial and cytosolic CK in mice. Contrary to expectation, the PCr level was only marginally affected, but the compound was rendered metabolically inert. Mutant muscles in vivo showed significantly impaired tetanic force output, increased relaxation times, altered mitochondrial volume and location, and conspicuous tubular aggregates of sarcoplasmic reticulum membranes, as seen in myopathies with electrolyte disturbances. In depolarized myotubes cultured in vitro, CK absence influenced both the release and sequestration of Ca2+. Our data point to a direct link between the CK-PCr system and Ca2+-flux regulation during the excitation and relaxation phases of muscle contraction.	UNIV NIJMEGEN,FAC MED SCI,DEPT CELL BIOL & HISTOL,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,FAC MED SCI,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,FAC MED SCI,DEPT DIAGNOST RADIOL,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,FAC MED SCI,DEPT PEDIAT,NL-6500 HB NIJMEGEN,NETHERLANDS; FREE UNIV AMSTERDAM,DEPT MUSCLE & EXERCISE PHYSIOL,FAC HUMAN MOVEMENT SCI,NL-1081 BT AMSTERDAM,NETHERLANDS; UNIV COLORADO,HLTH SCI CTR,DIV CARDIOL,DENVER,CO 80262; UNIV KONSTANZ,DEPT BIOL,D-7834 CONSTANCE,GERMANY	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Vrije Universiteit Amsterdam; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Konstanz			Heerschap, Arend/G-5228-2010; Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020				BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377; BENDERS AAGM, 1994, J CLIN INVEST, V94, P741, DOI 10.1172/JCI117393; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P69, DOI 10.1007/BF01267948; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; CRAIG ID, 1980, MUSCLE NERVE, V3, P134, DOI 10.1002/mus.880030206; DEHAAN A, 1989, PFLUG ARCH EUR J PHY, V413, P422, DOI 10.1007/BF00584493; DIDONATO S, 1978, NEUROLOGY, V28, P1110, DOI 10.1212/WNL.28.11.1110; Donoso P, 1996, BIOCHEMISTRY-US, V35, P13419, DOI 10.1021/bi9616209; DOWN WH, 1983, DRUG RES, V1, P552; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; EBASHI S, 1976, ANNU REV PHYSIOL, V38, P293, DOI 10.1146/annurev.ph.38.030176.001453; EDWARDS RHT, 1975, J PHYSIOL-LONDON, V251, P287, DOI 10.1113/jphysiol.1975.sp011093; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAN JW, 1992, BIOCHEMISTRY-US, V31, P377, DOI 10.1021/bi00117a010; Heerschap A, 1988, NMR Biomed, V1, P27, DOI 10.1002/nbm.1940010106; Hidalgo C, 1995, BIOSCIENCE REP, V15, P387, DOI 10.1007/BF01788370; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; KORETSKY AP, 1995, PHYSIOL REV, V75, P667, DOI 10.1152/physrev.1995.75.4.667; KORGE P, 1994, AM J PHYSIOL, V267, pC357, DOI 10.1152/ajpcell.1994.267.2.C357; KUNCL RW, 1989, ACTA NEUROPATHOL, V78, P615, DOI 10.1007/BF00691288; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; MEYER RA, 1982, AM J PHYSIOL, V242, pC1, DOI 10.1152/ajpcell.1982.242.1.C1; MILLER DS, 1986, J BIOL CHEM, V261, P13911; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; Owen VJ, 1996, J PHYSIOL-LONDON, V493, P309, DOI 10.1113/jphysiol.1996.sp021385; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROSENBERG NL, 1985, ARCH NEUROL-CHICAGO, V42, P973, DOI 10.1001/archneur.1985.04060090055014; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SALVIATI G, 1985, MUSCLE NERVE, V8, P299, DOI 10.1002/mus.880080406; Sata M, 1996, CIRCULATION, V93, P310, DOI 10.1161/01.CIR.93.2.310; STEEGHS K, 1996, IN PRESS J NEUROSCI, V20; STEEGHS K, 1995, THESIS U NIJMEGEN NI; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1994, P NATL ACAD SCI USA, V91, P9091, DOI 10.1073/pnas.91.19.9091; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	48	206	211	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					93	103		10.1016/S0092-8674(00)80186-5	http://dx.doi.org/10.1016/S0092-8674(00)80186-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094718	Bronze, Green Published			2022-12-28	WOS:A1997WR68500013
J	Stephens, LR; Eguinoa, A; ErdjumentBromage, H; Lui, M; Cooke, F; Coadwell, J; Smrcka, AS; Thelen, M; Cadwallader, K; Tempst, P; Hawkins, PT				Stephens, LR; Eguinoa, A; ErdjumentBromage, H; Lui, M; Cooke, F; Coadwell, J; Smrcka, AS; Thelen, M; Cadwallader, K; Tempst, P; Hawkins, PT			The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101	CELL			English	Article							MYELOID-DERIVED CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATED NEUTROPHILS; KINASE; SUBUNIT; WORTMANNIN; CLONING; IDENTIFICATION	Two highly similar, PtdIns(4,5)P-2-selective, G beta gamma-activated PI3Ks were purified from pig neutrophil cytosol. Both were heterodimers, were composed of a 101 kDa protein and either a 120 kDa or a 117 kDa catalytic subunit, and were activated greater than 100-fold by G beta gamma s. Peptide sequence-based oligonucleotide probes were used to clone cDNAs for the p120 and p101 species. The cDNA of p120 is highly related to p110 gamma, while the cDNA of p101 is not substantially related to anything in current databases. The proteins were expressed in and purified from insect and mammalian cells. They bound tightly to one another, both in vivo and in vitro, and in so doing, p101 amplified the effect of G beta gamma s on the PI3K activity of p120 from less than 2-fold to greater than 100-fold.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA; UNIV ROCHESTER, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV BERN, THEODOR KOCHER INST, CH-3000 BERN 9, SWITZERLAND; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Memorial Sloan Kettering Cancer Center; University of Rochester; University of Bern	Stephens, LR (corresponding author), BABRAHAM INST, INOSITIDE LAB, DEPT SIGNALLING, CAMBRIDGE CB2 4AT, ENGLAND.			Hawkins, Phillip/0000-0002-6979-0464; Erdjument-Bromage, Hediye/0000-0003-0224-3594; stephens, len/0000-0002-2771-3487	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; LEE SB, 1995, CURR BIOL, V7, P193; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TEMPST P, 1994, METH COMPANION METH, V6, P284; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	37	489	528	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					105	114		10.1016/S0092-8674(00)80187-7	http://dx.doi.org/10.1016/S0092-8674(00)80187-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094719	hybrid			2022-12-28	WOS:A1997WR68500014
J	Groll, M; Ditzel, L; Lowe, J; Stock, D; Bochtler, M; Bartunik, HD; Huber, R				Groll, M; Ditzel, L; Lowe, J; Stock, D; Bochtler, M; Bartunik, HD; Huber, R			Structure of 20S proteasome from yeast at 2.4 angstrom resolution	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN-DEGRADATION; SUBUNIT; PEPTIDES; PRODUCTS; CELL; LMP2; GENE; PROTEOLYSIS; ACIDOPHILUM	The crystal structure of the 20S proteasome from the yeast Saccharomyces cerevisiae shows that its 28 protein subunits are arranged as an (alpha 1...alpha 7, beta 1...beta 7)(2) complex in four stacked rings and occupy unique locations. The interior of the particle, which harbours the active sites, is only accessible by some very narrow side entrances, The beta-type subunits are synthesized as proproteins before being proteolytically processed for assembly into the particle, The proforms of three of the seven different beta-type subunits, beta 1/PRE3, beta 2/PUP1 and beta 5/PRE2, are cleaved between the threonlne at position 1 and the last glycine of the pro-sequence, with release of the active-site residue Thr 1. These three beta-type subunlts have inhibitor-binding sites, indicating that PRE2 has a chymotrypsin-like and a trypsin-like activity and that PRE3 has peptidylglutamyl peptide hydrolytlc specificity, Other beta-type subunits are processed to an intermediate form, indicating that an additional nonspecific endopeptidase activity may exist which is important for peptide hydrolysis and for the generation of ligands for class I molecules of the major histocompatibility complex.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK GESELL,ARBEITSGRP STRUKTURELLE MOL BIOL,D-22603 HAMBURG,GERMANY	Max Planck Society; Max Planck Society			Groll, Michael/C-1174-2010; Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019; Groll, Michael/F-5572-2015; Bochtler, Matthias/A-4514-2010	Lowe, Jan/0000-0002-5218-6615; Bochtler, Matthias/0000-0001-7884-4463				ACHSTATTER T, 1994, J BIOL CHEM, V259, P13344; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kania MA, 1996, EUR J BIOCHEM, V236, P510, DOI 10.1111/j.1432-1033.1996.00510.x; KOPP F, 1995, J MOL BIOL, V248, P264; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; LESLIE AGW, 1994, ACTA CRYSTALLOGR D, V50, P760; LORD M, 1996, CURR BIOL, V6, P1067; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SIBILLE C, 1995, CURR BIOL, V5, P923, DOI 10.1016/S0960-9822(95)00182-5; Stock D, 1996, CURR OPIN BIOTECH, V7, P376, DOI 10.1016/S0958-1669(96)80111-X; Stock D, 1995, COLD SPRING HARB SYM, V60, P525, DOI 10.1101/SQB.1995.060.01.056; Stohwasser R, 1996, FEBS LETT, V383, P109, DOI 10.1016/0014-5793(96)00110-X; TURK D, 1992, THESIS TU MUNCHEN; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VONENGELHARD H, 1994, CURR OPIN IMMUNOL, V6, P13; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	55	1865	1927	2	100	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					463	471		10.1038/386463a0	http://dx.doi.org/10.1038/386463a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087403				2022-12-28	WOS:A1997WR25600043
J	Mashru, M; Lant, A				Mashru, M; Lant, A			Interpractice audit of diagnosis and management of hypertension in primary care: Educational intervention and review of medical records	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; BLOOD-PRESSURE; GUIDELINES; HALVES; RULE	Objective: To determine whether peer review medical audit in a primary care setting changes clinical behaviour in relation to the management of hypertension. Design: Review of medical records in general practices to identify hypertensive patients followed up by assessment of the pre-educational and post-educational management of interventions. Setting: Six general practices in north west London picked at random within defined criteria of geography and size. Subjects: 740 hypertensive patients managed by 25 different general practitioners. Main outcome measures:Improved level of care in terms of better diagnosis by having at least three blood pressure readings before the start of drug treatment, better level of recordings of lifestyle parameters as shown by the level of recordings of body mass index and total lipid values, and better control of blood pressure and harm minimisation as shown by the level of recordings of urea and electrolyte values. Results:Improvement was noted in the level of recordings of body mass index, total lipid concentrations, and urea and electrolyte values but not in better diagnosis or blood pressure control. Conclusion: Clinical behaviour of general practitioners can be changed by peer review but more complex behavioural changes which require the cooperation of the patients and cognitive actions by the general practitioners need further investigation.	CHELSEA & WESTMINSTER HOSP, CHARING CROSS & WESTMINSTER MED SCH, DEPT CLIN PHARMACOL & THERAPEUT, LONDON SW10 9NH, ENGLAND	Imperial College London								BANDURA A, 1991, NEBR SYM MOTIV, V38, P69; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; BUTLER C, 1995, BMJ-BRIT MED J, V310, P784, DOI 10.1136/bmj.310.6982.784; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Department of Health, 1992, HLTH NAT STRAT HLTH; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HART JT, 1992, BRIT J GEN PRACT, V42, P116; HART JT, 1993, HYPERTENSION COMMUNI, P1; Hopkins A, 1996, J ROY COLL PHYS LOND, V30, P415; Humphrey C, 1993, Qual Health Care, V2, P232, DOI 10.1136/qshc.2.4.232; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JOHNSON R, 1994, BRIT MED J, V309, P98, DOI 10.1136/bmj.309.6947.98; MAYNARD A, 1993, HLTH SERV J, V193, P21; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; *NHS MAN EX, 1993, EL93115 NHS MAN EX D; *ROYAL COLL GEN PR, 1985, 23 ROYAL COLL GEN PR; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STEWART A, 1994, AUDIT TRENDS, V2, P80; TABENKIN H, 1996, J FAM PRACTICE, V12, P309; *U LEEDS, 1995, EFF HLTH CARE, V8; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541	25	39	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	1997	314	7085					942	946		10.1136/bmj.314.7085.942	http://dx.doi.org/10.1136/bmj.314.7085.942			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099120	Green Published			2022-12-28	WOS:A1997WQ16900028
J	Looker, AC; Dallman, PR; Carroll, MD; Gunter, EW; Johnson, CL				Looker, AC; Dallman, PR; Carroll, MD; Gunter, EW; Johnson, CL			Prevalence of iron deficiency in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECLINING PREVALENCE; ANEMIA; POPULATION; NHANES	Objective.-To determine the prevalence of iron deficiency and iron deficiency anemia in the US population. Design.-Nationally representative cross-sectional health examination survey that included venous blood measurements of iron status. Main Outcome Measures.-Iron deficiency, defined as having an abnormal value for at least 2 of 3 laboratory tests of iron status (erythrocyte protoporphyrin, transferrin saturation, or serum ferritin); and iron deficiency anemia, defined as iron deficiency plus low hemoglobin. Participants.-A total of 24 894 persons aged 1 year and older examined in the third National Health and Nutrition Examination Survey (1988-1994). Results.-Nine percent of toddlers aged 1 to 2 years and 9% to 11% of adolescent girls and women of childbearing age were iron deficient; of these, iron deficiency anemia was found in 3% and 2% to 5%, respectively. These prevalences correspond to approximately 700 000 toddlers and 7.8 million women with iron deficiency; of these, approximately 240 000 toddlers and 3.3 million women have iron deficiency anemia. Iron deficiency occurred in no more than 7% of older children or those older than 50 years, and in no more than 1% of teenage boys and young men. Among women of childbearing age, iron deficiency was more likely in those who are minority, low income, and multiparous. Conclusion.-Iron deficiency and iron deficiency anemia are still relatively common in toddlers, adolescent girls, and women of childbearing age.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,SAN FRANCISCO,CA 94143; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA	University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Looker, AC (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,6525 BELCREST RD,HYATTSVILLE,MD 20782, USA.							[Anonymous], 1984, ASSESSMENT IRON NUTR; [Anonymous], JAMA; CDC, 1989, MMWR-MORBID MORTAL W, V38, P400; COOK JD, 1976, BLOOD, V48, P449; Dallman Peter R., 1996, P65; DALLMAN PR, 1986, ANNU REV NUTR, V6, P13, DOI 10.1146/annurev.nu.06.070186.000305; Ekblom Bjorn, 1996, P195; *EXP SCI WORK GROU, 1985, AM J CLIN NUTR, V42, P1318; EZZATI T, 1992, NONRESPONSE ADJUSTME, P339; *FOOD NUTR BOARD I, 1993, IR DEF AN REC GUID P; GUNTER EW, 1989, CLIN CHEM, V35, P1601; Gunter EW, 1996, LAB PROCEDURES USED; *INT COMM STAND HA, 1988, J CLIN PATHOL, V41, P1203; Kim I, 1992, MMWR-MORBID MORTAL W, V41, P26; LOOKER AC, 1989, AM J CLIN NUTR, V49, P553, DOI 10.1093/ajcn/49.3.553; LOOKER AC, 1995, NUTR REV, V53, P246, DOI 10.1111/j.1753-4887.1995.tb05481.x; MOHADJER L, 1996, NATL HLTH NUTR EXAMI; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; REES JM, 1985, CLIN PEDIATR, V24, P707, DOI 10.1177/000992288502401207; SHAH BV, 1991, SUDAAN USERS MANUAL; STOCKMAN JA, 1987, JAMA-J AM MED ASSOC, V258, P1645, DOI 10.1001/jama.258.12.1645; VAZQUEZSEOANE P, 1985, NEW ENGL J MED, V313, P1239, DOI 10.1056/NEJM198511073131936; YIP R, 1987, JAMA-J AM MED ASSOC, V258, P1619, DOI 10.1001/jama.258.12.1619; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; YIP R, 1987, PEDIATRICS, V80, P330	26	911	935	0	73	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					973	976		10.1001/jama.277.12.973	http://dx.doi.org/10.1001/jama.277.12.973			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091669				2022-12-28	WOS:A1997WN99200031
J	Mendelson, W; Delbanco				Mendelson, W; Delbanco			A 96-year-old woman with insomnia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SLEEP; TRIAZOLAM; MELATONIN; MULTICENTER; ZOLPIDEM		UNIV CHICAGO, SLEEP RES LAB, CHICAGO, IL 60637 USA	University of Chicago								ANCOLIISRAEL S, 1991, SLEEP, V14, P496, DOI 10.1093/sleep/14.6.496; AncoliIsrael S, 1996, SLEEP, V19, P277, DOI 10.1093/sleep/19.4.277; ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; BLIWISE DL, 1994, PRINCIPLES PRACTICE, P26; BONNET MH, 1987, BIOL PSYCHOL, V25, P153, DOI 10.1016/0301-0511(87)90035-4; Daley, 1996, JAMA-J AM MED ASSOC, V276, P1832; Ellis CM, 1996, J SLEEP RES, V5, P61, DOI 10.1046/j.1365-2869.1996.00003.x; FEINBERG I, 1967, J PSYCHIAT RES, V5, P107, DOI 10.1016/0022-3956(67)90027-1; FEINBERG I, 1977, AGING BRAIN SENILE D, P5; FERINISTRAMBI L, 1993, SLEEP, V16, P744, DOI 10.1093/sleep/16.8.744; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FREDRICKSON PA, 1994, PRINCIPLES PRACTICE, P523; *GALLUP ORG, 1995, SLEEP AMER; *GALLUP ORG, 1991, SLEEP AMER; GRUNSTEIN RR, 1988, AM J MED, V85, P775; HORNE JA, 1987, SLEEP, V10, P383, DOI 10.1093/sleep/10.4.383; JAIN B, 1996, INTERN MED WORLD REP, V11, P13; JAMES SP, 1990, NEUROPSYCHOPHARMACOL, V3, P19; JAMES SP, 1987, NEUROPSYCHOPHARMACOL, V1, P41, DOI 10.1016/0893-133X(87)90008-X; Johnson LC, 1983, SLEEP WAKE DISORDERS, P13; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; LEIGH JP, 1991, SOC SCI MED, V33, P127, DOI 10.1016/0277-9536(91)90173-A; MCCLUSKY HY, 1991, AM J PSYCHIAT, V148, P121; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; MENDELSON WB, 1995, CLIN DRUG INVEST, V10, P276, DOI 10.2165/00044011-199510050-00004; Mendelson WB, 1996, SLEEP, V19, P219, DOI 10.1093/sleep/19.3.219; MENDELSON WB, 1991, SLEEP RESPIRATION AG, P49; MENDELSON WB, 1995, CONNS CURRENT THERAP, P33; Mendelson WB, 1987, HUMAN SLEEP RES CLIN, P323; Middleton BA, 1996, LANCET, V348, P551, DOI 10.1016/S0140-6736(05)64715-0; MILBY JB, 1993, AM J PSYCHIAT, V150, P1259; RAJAGOPAL KR, 1984, ANN INTERN MED, V101, P491, DOI 10.7326/0003-4819-101-4-491; REDIEHS MH, 1990, SLEEP, V13, P410; Reppert SM, 1995, CELL, V83, P1059, DOI 10.1016/0092-8674(95)90131-0; SCHARF MB, 1994, J CLIN PSYCHIAT, V55, P192; SCHLICH D, 1991, J INT MED RES, V19, P271, DOI 10.1177/030006059101900313; Schweitzer PK, 1992, SLEEP RES, V21, P260; STEPANSKI EJ, 1994, PRINCIPLES PRACTICE, P535; TERMAN M, 1994, PRINCIPLES PRACTICE, P1012; Turek FW, 1996, NATURE, V379, P295, DOI 10.1038/379295a0; VOGEL G, 1988, SLEEP RES, V17, P80; Walsh J. K., 1994, SLEEP DISORDERS MED, P219; Weekley L B, 1993, Clin Auton Res, V3, P45, DOI 10.1007/BF01819143; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3; Zhdanova IV, 1996, SLEEP, V19, P423, DOI 10.1093/sleep/19.5.423; 1997, CONSUM REP, V62, P10	46	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					990	996		10.1001/jama.277.12.990	http://dx.doi.org/10.1001/jama.277.12.990			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091673				2022-12-28	WOS:A1997WN99200035
J	Ohayon, MM; Guilleminault, C; Priest, RG; Caulet, M				Ohayon, MM; Guilleminault, C; Priest, RG; Caulet, M			Snoring and breathing pauses during sleep: Telephone interview survey of a United Kingdom population sample	BRITISH MEDICAL JOURNAL			English	Article							APNEA; DISTURBANCES; HYPERTENSION; MEN	Objectives: To determine the prevalence of snoring, breathing pauses during sleep, and obstructive sleep apnoea syndrome and determine the relation between these events and sociodemographic variables, other health problems, driving accidents, and consumption of healthcare resources. Design: Telephone interview survey directed by a previously validated computerised system (Sleep-Eval). Setting: United Kingdom. Subjects: 2894 women and 2078 men aged 15-100 years who formed a representative sample of the non-institutionalised population. Main outcome measures: Interview responses. Results: Forty per cent of the population reported snoring regularly and 3.8% reported breathing pauses during sleep, Regular snoring was significantly associated with male sex, age 25 or more, obesity, daytime sleepiness or naps, night time awakenings, consuming large amounts of caffeine, and smoking. Breathing pauses during sleep were significantly associated with obstructive airways or thyroid disease, male sex, age 35-44 years, consumption of anxiety reducing drugs, complaints of non-restorative sleep, and consultation with a doctor in the past year. The two breathing symptoms were also significantly associated with drowsiness while driving. Based on minimal criteria of the International Classification of Sleep Disorders (1990), 1.9% of the sample had obstructive sleep apnoea syndrome, In the 35-64 year age group 1.5% of women (95% confidence interval 0.8% to 2.2%) and 3.5% of men (2.4% to 4.6%) had obstructive sleep apnoea syndrome. Conclusions: Disordered breathing during sleep is widely underdiagnosed in the United Kingdom. The condition is linked to increased use of medical resources and a greater risk of daytime sleepiness, which augments the risk of accidents. Doctors should ask patients and bed partners regularly about snoring and breathing pauses during sleep.	STANFORD UNIV,SLEEP DISORDERS CLIN & RES CTR,SCH MED,STANFORD,CA 94305; UNIV LONDON,ST MARYS,IMPERIAL COLL SCH MED,PATERSON CTR,ACAD DEPT PSYCHIAT,LONDON W2 1PD,ENGLAND	Stanford University; Imperial College London; University of London	Ohayon, MM (corresponding author), CTR RECH PHILIPPE PINEL MONTREAL,MONTREAL,PQ H1C 1H1,CANADA.		Ohayon, Maurice M/A-1338-2007	Ohayon, Maurice/0000-0002-2757-5440				American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; CROSBY J, 1989, THORAX, V344, P353; GISLASON T, 1993, J INTERN MED, V234, P31, DOI 10.1111/j.1365-2796.1993.tb00701.x; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HOSMER DW, 1989, APPL LOGISTIC REGRES; Kish L, 1965, SURVEY SAMPLING; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; MENDELSON WB, 1992, CHEST, V101, P903, DOI 10.1378/chest.101.4.903; Ohayon M., 1992, MEDINFO 92. Proceedings of the Seventh World Congress on Medical Informatics, P615; OHAYON M, 1994, SLEEP DISORDERS QUES; OHAYON M, 1994, P 12 INT C EUR FED M, P90; OHAYON M, 1994, P 12 INT C EUR FED M, P174; PARISH JM, 1990, CHEST, V97, P1220, DOI 10.1378/chest.97.5.1220; REDLINE S, 1994, SLEEP BREATH, P363; SHAPIRO CM, 1981, LANCET, V2, P523; SMIRNE S, 1993, EUR RESPIR J, V6, P1347; STRADLING JR, 1989, BRIT MED J, V298, P904, DOI 10.1136/bmj.298.6678.904; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; TELAKIVI T, 1987, ACTA NEUROL SCAND, V76, P69, DOI 10.1111/j.1600-0404.1987.tb03547.x; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	21	212	217	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					860	863						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093095				2022-12-28	WOS:A1997WQ02800023
J	DiGuiseppi, C; Roberts, I; Li, L				DiGuiseppi, C; Roberts, I; Li, L			Influence of changing travel patterns on child death rates from injury: Trend analysis	BRITISH MEDICAL JOURNAL			English	Article							OBESITY	Objectives: To examine trends in child mortality from unintentional injury between 1985 and 1992 and to find how changes in modes of travel contributed to these trends. Design: Poisson regression modelling using data from death certificates, censuses, and national travel surveys. Setting: England and Wales. Subjects: Resident children aged 0-14. Main outcome measures: Deaths from unintentional injury and poisoning. Results: Child deaths from injury declined by 34% (95% confidence interval 28% to 40%) per 100 000 population between 1985 and 1992. Substantial decreases in each of the leading causes of death from injury contributed to this overall decline. On average, children walked and cycled less distance and travelled substantially more miles by car in 1992 compared with 1985. Deaths from road traffic accidents declined for pedestrians by 24% per mile walked and for cyclists by 20% per mile cycled, substantially less than the declines per 100 000 population of 37% and 38% respectively. In contrast, deaths of occupants of motor vehicles declined by 42% per mile travelled by car compared with a 21% decline per 100 000 population. Conclusions: if trends in child mortality from injury continue the government's target to reduce the rate by 33% by the year 2005 will be achieved. A substantial proportion of the decline in pedestrian traffic and pedal cycling deaths, however, seems to have been achieved at the expense of children's walking and cycling activities. Changes in travel patterns may exact a considerable price in terms of future health problems.			DiGuiseppi, C (corresponding author), UNIV LONDON,INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND.		DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817				Bly Robert., 1993, RAG BONE SHOP HEART; CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; *DEP TRANSP, 1995, TRANSP STAT REP NAT; Department of Health, 1992, HLTH NAT STRAT HLTH; DIGUISEPPI C, 1992, IN PRESS INJURY PREV; FIFE D, 1987, AM J EPIDEMIOL, V126, P936, DOI 10.1093/oxfordjournals.aje.a114731; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GARROW JS, 1992, LANCET, V340, P409, DOI 10.1016/0140-6736(92)91481-M; HULLMAN M, 1990, ONE FALSE MOVE STUDY; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; ROBERTS I, 1993, BRIT MED J, V306, P1737, DOI 10.1136/bmj.306.6894.1737; Roberts I, 1996, BRIT MED J, V313, P784; ROBERTS I, IN PRESS BMJ; TAYLOR SB, 1996, 156 TRL; TOWNER EML, 1994, BRIT MED J, V308, P449, DOI 10.1136/bmj.308.6926.449; WHO, 1977, MAN INT STAT CLASS D, V1; WOODROFFE G, 1993, CHILDREN TEENAGERS H	17	63	63	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					710	713		10.1136/bmj.314.7082.710	http://dx.doi.org/10.1136/bmj.314.7082.710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116546	Green Published			2022-12-28	WOS:A1997WM77600021
J	Westendorp, RGJ; Langermans, JAM; Huizinga, TWJ; Elouali, AH; Verweij, CL; Boomsma, DI; Vandenbroucke, JP				Westendorp, RGJ; Langermans, JAM; Huizinga, TWJ; Elouali, AH; Verweij, CL; Boomsma, DI; Vandenbroucke, JP			Genetic influence on cytokine production and fatal meningococcal disease	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; TNF-ALPHA; PEDIGREE ANALYSIS; PROMOTER; RELEASE; DEATH	Background To assess the genetic influence on cytokine production and its contribution to fatal outcome, we determined the capacity to produce tumour necrosis factor-alpha (TNF alpha) and interleukin-10 (IL-10) in families of patients who had had meningococcal disease. Methods We studied 190 first-degree relatives of 61 patients with meningococcal disease; we also studied 26 monozygotic twins. Production of cytokines was determined during endotoxin stimulation of whole-blood samples ex-vivo. Heritability was estimated in a pedigree-based maximum-likelihood model. DNA was typed for the G to A transition polymorphisms at position -308 and -238 in the TNF gene promoter. Findings Heritability in monozygotic twins was 0 . 60 for the production of TNF and 0 . 75 for the production of IL-10, Families with low TNF production had a tenfold increased risk for fatal outcome (OR 8 . 9, 95% Cl 1 . 8-45), whereas high IL-10 production increased the risk 20-fold (19 . 5, 2 . 3-165). Families with both characteristics had the greatest risk. The transition polymorphisms in the TNF gene promoter were not associated with outcome. Interpretation Genetic factors substantially influence production of cytokines. An innate anti-inflammatory cytokine profile may contribute to fatal meningococcal disease.	UNIV LEIDEN HOSP, DEPT GEN INTERNAL MED, NL-2300 RC LEIDEN, NETHERLANDS; UNIV LEIDEN HOSP, DEPT INFECT DIS, NL-2300 RC LEIDEN, NETHERLANDS; UNIV LEIDEN HOSP, DEPT RHEUMATOL, NL-2300 RC LEIDEN, NETHERLANDS; FREE UNIV AMSTERDAM, DEPT PSYCHONOM, AMSTERDAM, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Vrije Universiteit Amsterdam	Westendorp, RGJ (corresponding author), UNIV LEIDEN HOSP, DEPT CLIN EPIDEMIOL, CO-P, NL-2300 RC LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Boomsma, Dorret I/AAX-4470-2020	Vandenbroucke, Jan/0000-0001-5668-6716; Langermans, Jan/0000-0002-4806-4412				ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; Brinkman BMN, 1996, J INFLAMM, V46, P32; DEGROOTE D, 1992, CYTOKINE, V4, P239, DOI 10.1016/1043-4666(92)90062-V; DERKX HHF, 1992, MONONUCLEAR PHAGOCYTES, P355; Entzian P, 1996, AM J RESP CRIT CARE, V153, P1080, DOI 10.1164/ajrccm.153.3.8630548; FERNANDES DM, 1995, INFECT IMMUN, V63, P1130, DOI 10.1128/IAI.63.3.1130-1133.1995; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; LANGE K, 1976, ANN HUM GENET, V39, P485, DOI 10.1111/j.1469-1809.1976.tb00156.x; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; POCIOT F, 1995, SCAND J IMMUNOL, V42, P501, DOI 10.1111/j.1365-3083.1995.tb03686.x; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057	19	650	673	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1997	349	9046					170	173		10.1016/S0140-6736(96)06413-6	http://dx.doi.org/10.1016/S0140-6736(96)06413-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111542				2022-12-28	WOS:A1997WC86100012
J	Crosthwaite, SK; Dunlap, JC; Loros, JJ				Crosthwaite, SK; Dunlap, JC; Loros, JJ			Neurospora wc-1 and wc-2: Transcription, photoresponses, and the origins of circadian rhythmicity	SCIENCE			English	Article							CLOCK-CONTROLLED GENE; PHYTOCHROME-A; SUPRACHIASMATIC NUCLEUS; SIGNAL-TRANSDUCTION; REGULATORY ACTIVITY; DROSOPHILA PERIOD; BIOLOGICAL CLOCK; LIGHT INDUCTION; TERMINAL-DOMAIN; CRASSA	Circadian rhythmicity is universally associated with the ability to perceive light, and the oscillators (''clocks'') giving rise to these rhythms, which are feedback loops based on transcription and translation, are reset by light. Although such loops must contain elements of positive and negative regulation, the clock genes analyzed to date-frq in Neurospora and per and tim in Drosophila-are associated only with negative feedback and their biochemical functions are largely inferred. The white collar-1 and white collar-2 genes, both global regulators of photoresponses in Neurospora, encode DNA binding proteins that contain PAS domains and are believed to act as transcriptional activators. Data shown here suggest that wc-1 is a clock-associated gene and wc-2 is a clock component; both play essential roles in the assembly or operation of the Neurospora circadian oscillator. Thus DNA binding and transcriptional activation can now be associated with a clock gene that may provide a positive element in the feedback loop. In addition, similarities between the PAS-domain regions of molecules involved in light perception and circadian rhythmicity in several organisms suggest an evolutionary link between ancient photoreceptor proteins and more modern proteins required for circadian oscillation.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College			Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; 	NIGMS NIH HHS [GM 34985] Funding Source: Medline; NIMH NIH HHS [MH44651, MH01186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651, K05MH001186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ARPAIA G, 1993, PLANT PHYSIOL, V102, P1299, DOI 10.1104/pp.102.4.1299; ARPAIA G, 1995, MOL GEN GENET, V247, P157, DOI 10.1007/BF00705645; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; BELLPEDERSEN D, 1992, GENE DEV, V6, P2382, DOI 10.1101/gad.6.12a.2382; BELLPEDERSEN D, IN PRESS J GENET; BLOCK G, 1995, CIBA F SYMP, V183, P51; BLOCK GD, 1995, SEMIN NEUROSCI, V7, P37, DOI 10.1016/1044-5765(95)90015-2; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CHIANG TY, 1994, BIOCHEMISTRY-US, V33, P576, DOI 10.1021/bi00168a024; CORROCHANO LM, 1995, DEV BIOL, V167, P190, DOI 10.1006/dbio.1995.1016; COSTA R, 1992, P ROY SOC B-BIOL SCI, V250, P43, DOI 10.1098/rspb.1992.0128; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; Degli Innocenti F, 1984, BLUE LIGHT EFFECTS B, P213; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; ELICH TD, 1994, PLANT MOL BIOL, V26, P1315, DOI 10.1007/BF00016477; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; GARCEAU N, IN PRESS CELL; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; GOLDBETTER A, 1996, BIOCH OSCILLATIONS C; GOOCH VD, 1994, J BIOL RHYTHM, V9, P83, DOI 10.1177/074873049400900108; Goodwin B., 1963, TEMPORAL ORG CELLS; Grace MS, 1996, J COMP NEUROL, V367, P575; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, EMBO J, V12, P1; Harding R, 1983, PLANT PHYSIOL, V72, P745; HARDING RW, 1980, ANNU REV PLANT PHYS, V31, P217, DOI 10.1146/annurev.pp.31.060180.001245; HASTINGS MH, 1995, CIBA F SYMP, V183, P175; HOTZVITATERNA M, 1994, SCIENCE, V264, P719; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Koh M, 1996, BIOCHEMISTRY-US, V35, P2526, DOI 10.1021/bi951494t; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; LANKINEN P, 1993, BEHAV GENET, V23, P359, DOI 10.1007/BF01067437; LAUTER FR, 1991, NUCLEIC ACIDS RES, V19, P6883, DOI 10.1093/nar/19.24.6883; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; LIU Y, IN PRESS CELL; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; MACINO G, COMMUNICATION; MARZLUF GA, 1994, ADV GENET, V31, P187, DOI 10.1016/S0065-2660(08)60398-3; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; MERROW M, IN PRESS P NATL ACAD; MERROW M, UNPUB; MOORE RY, 1995, CIBA F SYMP, V183, P88; MOORE RY, 1992, DISCUSS NEUROSCI, V8, P26; NEWBY LM, 1993, GENETICS, V135, P1077; ORKIN SH, 1992, BLOOD, V80, P575; PALETTA J, 1981, P NATL ACAD SCI USA, V78, P5573; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; PERKINS DD, 1962, CAN J GENET CYTOL, V4, P187, DOI 10.1139/g62-024; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; ROENNBERG T, 1995, CIBA FDN S, V183, P177; RUSSO VEA, 1988, J PHOTOCH PHOTOBIO B, V2, P59, DOI 10.1016/1011-1344(88)85037-1; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SCHWARTZ WJ, 1995, SEMIN NEUROSCI, V7, P53, DOI 10.1016/1044-5765(95)90017-9; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; SIWICKI KK, 1995, SEMIN NEUROSCI, V7, P1, DOI 10.1016/1044-5765(95)90011-X; SOMMER T, 1989, NUCLEIC ACIDS RES, V17, P5713, DOI 10.1093/nar/17.14.5713; SWEENEY BM, 1960, COLD SPRING HARB SYM, V25, P87, DOI 10.1101/SQB.1960.025.01.009; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; WAGNER D, 1995, P NATL ACAD SCI USA, V92, P8596, DOI 10.1073/pnas.92.19.8596; Worden, 1974, NEUROSCIENCES 3RD ST, P437; XU Y, 1995, PLANT CELL, V7, P1433, DOI 10.1105/tpc.7.9.1433; YARDEN O, 1992, EMBO, V11, P259; ZATZ M, 1992, CIRCADIAN RHYTHMS DI, V8; ZATZ M, 1993, BRAIN RES REV, V18, P326; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	84	418	433	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					763	769		10.1126/science.276.5313.763	http://dx.doi.org/10.1126/science.276.5313.763			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115195				2022-12-28	WOS:A1997WW90000049
J	Wu, ZR; Ebrahimian, S; Zawrotny, ME; Thornburg, LD; PerezAlvarado, GC; Brothers, P; Pollack, RM; Summers, MF				Wu, ZR; Ebrahimian, S; Zawrotny, ME; Thornburg, LD; PerezAlvarado, GC; Brothers, P; Pollack, RM; Summers, MF			Solution structure of 3-oxo-Delta(5)-steroid isomerase	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; SITE-DIRECTED MUTAGENESIS; CHEMICAL-SHIFT INDEX; DELTA-5-3-KETOSTEROID ISOMERASE; NMR-SPECTROSCOPY; PSEUDOMONAS-TESTOSTERONI; 3-OXO-DELTA-5-STEROID ISOMERASE; ESCHERICHIA-COLI; PROTON-TRANSFER; CATALYSIS	The three-dimensional structure of the enzyme 3-oxo-Delta(5)-steroid isomerase (E.C. 5.3.3.1), a 28-kilodalton symmetrical dimer, was solved by multidimensional heteronuclear magnetic resonance spectroscopy. The two independently folded monomers pack together by means of extensive hydrophobic and electrostatic interactions. Each monomer comprises three alpha helices and a six-strand mixed beta-pleated sheet arranged to form a deep hydrophobic cavity. Catalytically important residues Tyr(14) (general acid) and Asp(38) (general base) are located near the bottom of the cavity and positioned as expected from mechanistic hypotheses. An unexpected acid group (Asp(99)) is also located in the active site adjacent to Tyr(14), and kinetic and binding studies of the Asp(99) to Ala mutant demonstrate that Asp(99) contributes to catalysis by stabilizing the intermediate.	UNIV MARYLAND,HOWARD HUGHES MED INST,BALTIMORE,MD 21250; UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21250	Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NIGMS NIH HHS [GM49082, GM38155] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038155] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1992, J MAGN RESON, V96, P432; BENISEK WF, 1980, ANN NY ACAD SCI, V346, P115; BOUNDS PL, 1987, BIOCHEMISTRY-US, V26, P2263, DOI 10.1021/bi00382a029; BROTHERS PN, 1995, BIOCHEMISTRY-US, V34, P15453, DOI 10.1021/bi00047a009; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CHOI KY, 1988, GENE, V69, P121; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FALCOZKELLY F, 1968, BIOCHEMISTRY-US, V7, P4119, DOI 10.1021/bi00851a047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HAWKINSON DC, 1993, BIOCHEMISTRY-US, V32, P694, DOI 10.1021/bi00053a038; HAWKINSON DC, 1994, BIOCHEMISTRY-US, V33, P12172, DOI 10.1021/bi00206a021; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P10849, DOI 10.1021/bi00109a007; HOLMAN CM, 1995, BIOCHEMISTRY-US, V34, P14245, DOI 10.1021/bi00043a032; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULIOPULOS A, 1987, P NATL ACAD SCI USA, V84, P8893, DOI 10.1073/pnas.84.24.8893; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; KULIOPULOS A, 1991, BIOCHEMISTRY-US, V30, P3169, DOI 10.1021/bi00227a003; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLLACK RM, 1979, BIOCHEM BIOPH RES CO, V91, P783, DOI 10.1016/0006-291X(79)91948-X; POLLACK RM, 1986, BIOCHEMISTRY-US, V25, P1905, DOI 10.1021/bi00356a011; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Sambrook J., 2002, MOL CLONING LAB MANU; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; Shan SO, 1996, J AM CHEM SOC, V118, P5515, DOI 10.1021/ja954205x; SHAND RF, 1991, BIOCHEMISTRY-US, V30, P3082, DOI 10.1021/bi00226a015; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; TALALAY P, 1955, BIOCHIM BIOPHYS ACTA, V18, P300, DOI 10.1016/0006-3002(55)90079-2; TIVOL WF, 1975, J BIOL CHEM, V250, P271; VENTERS RA, 1991, BIOCHEMISTRY-US, V30, P4491, DOI 10.1021/bi00232a017; VIGER A, 1981, J AM CHEM SOC, V103, P451, DOI 10.1021/ja00392a034; WEINTRAUB H, 1970, EUR J BIOCHEM, V12, P217, DOI 10.1111/j.1432-1033.1970.tb00840.x; WESTBROOK EM, 1976, J MOL BIOL, V103, P665, DOI 10.1016/0022-2836(76)90225-4; WESTBROOK EM, 1984, J BIOL CHEM, V259, P9096; WESTBROOK EM, 1976, J MOL BIOL, V103, P659, DOI 10.1016/0022-2836(76)90224-2; WILSON NA, 1995, BIOCHEMISTRY-US, V34, P8931, DOI 10.1021/bi00028a001; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zawrotny ME, 1996, BIOCHEMISTRY-US, V35, P6438, DOI 10.1021/bi953025x; ZAWROTNY ME, 1994, BIOCHEMISTRY-US, V33, P13896, DOI 10.1021/bi00250a044; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220	61	134	135	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					415	418		10.1126/science.276.5311.415	http://dx.doi.org/10.1126/science.276.5311.415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103200				2022-12-28	WOS:A1997WU47700040
J	Campos, SM; Walden, T				Campos, SM; Walden, T			Images in clinical medicine - Spigelian hernia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Campos, SM (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1149	1149		10.1056/NEJM199704173361605	http://dx.doi.org/10.1056/NEJM199704173361605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099659				2022-12-28	WOS:A1997WU00300005
J	Calvert, GM; Steenland, K; Palu, S				Calvert, GM; Steenland, K; Palu, S			End-stage renal disease among silica-exposed gold miners - A new method for assessing incidence among epidemiologic cohorts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LUNG-CANCER MORTALITY; GRANITE WORKERS; NEPHROPATHY; MERCURY; GLOMERULONEPHRITIS; NEPHROTOXICITY; FAILURE	Objective.-To examine the association between silica exposure and end-stage renal disease (ESRD). Design.-Retrospective cohort study. Participants.-A cohort of 2412 white male gold miners was studied. Eligible gold miners worked underground for at least 1 year between 1940 and 1965 in a South Dakota gold mine and were alive on January 1, 1977. Of primary interest was exposure to silica. Methods.-The ESRD Program Management and Medical Information System (PMMIS) was used to identify members of the gold mine cohort who had treated ESRD and to create a US rate file for treated ESRD. The ESRD incidence among the gold miners was compared with that in the US population. Results.-Based on the 11 cohort members identified with treated ESRD, the risk for ESRD in the cohort was elevated (standardized incidence ratio [SIR], 1.37; 95% confidence interval [CI], 0.68-2.46). The risk was greatest for nonsystemic ESRD (ESRD caused by glomerulonephritis or interstitial nephritis) for which the SIR was 4.22 (95% CI, 1.54-9.19), increasing to 7.70 (95% CI, 1.59-22.48) among workers with 10 or more years of employment underground. Conclusions.-To our knowledge this is the first epidemiologic study to examine ESRD incidence in an occupational cohort. This study provides evidence that silica exposure is associated with an increased risk for ESRD, especially ESRD caused by glomerulonephritis. This study also demonstrates the usefulness of the ESRD PMMIS to assess ESRD risk among cohorts exposed to potential nephrotoxins.			Calvert, GM (corresponding author), CTR DIS CONTROL & PREVENT,NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,CINCINNATI,OH 45226, USA.							BANKS DE, 1983, AM J NEPHROL, V3, P279, DOI 10.1159/000166730; BARREGARD L, 1990, BRIT J IND MED, V47, P99; BOLTON WK, 1981, AM J MED, V71, P823; BROWN DP, 1986, SILICA SILICOSIS CAN, P335; CARTA P, 1994, AM J IND MED, V25, P489, DOI 10.1002/ajim.4700250404; COCCO PL, 1994, J OCCUP ENVIRON MED, V36, P894; CRAGLE DL, 1984, J OCCUP ENVIRON MED, V26, P817, DOI 10.1097/00043764-198411000-00011; DAVIS LK, 1983, AM J IND MED, V4, P705, DOI 10.1002/ajim.4700040604; ELLINGSEN DG, 1993, BRIT J IND MED, V50, P881; GERHARDT RE, 1978, ARCH INTERN MED, V138, P1267, DOI 10.1001/archinte.138.8.1267; GILBERSON A, 1976, ARCH INTERN MED, V136, P1303; GILES RD, 1978, AM J MED, V64, P336, DOI 10.1016/0002-9343(78)90063-3; GREENBERGER JS, 1982, CANC KIDNEY, P814; HANDKE J, 1981, HLTH HAZARD EVALUATI; HAUGLUSTAINE D, 1980, NEPHRON, V26, P219, DOI 10.1159/000181988; Kolev K, 1970, Med Lav, V61, P205; KOSKELA RS, 1987, SCAND J WORK ENV HEA, V13, P18, DOI 10.5271/sjweh.2085; LANDRIGAN PJ, 1984, ARCH ENVIRON HEALTH, V39, P225, DOI 10.1080/00039896.1984.9939529; NAJDA J, 1994, BIOL TRACE ELEM RES, V42, P63, DOI 10.1007/BF02990489; *NAT I OCC SAF HLT, 1992, DHHS NIOSH PUBL; NG TP, 1992, BRIT J IND MED, V49, P35; NG TP, 1993, BRIT J IND MED, V50, P907; *NIH, 1996, US REN DAT SYST 1996; NUYTS GD, 1995, NEPHROL DIAL TRANSPL, V10, P1162, DOI 10.1093/ndt/10.7.1162; NUYTS GD, 1995, LANCET, V346, P7, DOI 10.1016/S0140-6736(95)92648-8; OSORIO AM, 1987, AM J KIDNEY DIS, V9, P224, DOI 10.1016/S0272-6386(87)80059-8; Rothman KJ, 1979, DHEW PUBLICATION, P79; SAITA G., 1951, MED LAVORO, V42, P41; SALDANHA LF, 1975, AM J MED, V59, P95, DOI 10.1016/0002-9343(75)90326-5; SHERSON D, 1989, BRIT J IND MED, V46, P675; STEENLAND K, 1995, AM J IND MED, V27, P217, DOI 10.1002/ajim.4700270207; STEENLAND K, 1990, J OCCUP ENVIRON MED, V32, P1091, DOI 10.1097/00043764-199011000-00008; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; WEDEEN RP, 1992, OCCUP MED, V7, P449; WYNDHAM CH, 1986, BRIT J IND MED, V43, P677; Zumwalde R, 1981, IND HYGIENE REPORT H; 1989, FED REG         0119, V54, P2521	37	54	54	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1219	1223		10.1001/jama.277.15.1219	http://dx.doi.org/10.1001/jama.277.15.1219			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103346				2022-12-28	WOS:A1997WT40300033
J	Ong, ACM; Harris, PC				Ong, ACM; Harris, PC			Molecular basis of renal cyst formation - One hit or two?	LANCET			English	Editorial Material							POLYCYSTIC KIDNEY-DISEASE				Ong, ACM (corresponding author), UNIV OXFORD,MRC,INST MOL MED,MOL HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Ong, Albert/AAN-9430-2021	Ong, Albert/0000-0002-7211-5400				[Anonymous], 1994, CELL, V77, P881; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; GENGL, 1996, J CLIN INVEST, V98, P2674; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; *INT POL KIDN DIS, 1995, CELL, V81, P289; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Peral B, 1996, HUM MOL GENET, V5, P539, DOI 10.1093/hmg/5.4.539; Peral B, 1996, AM J HUM GENET, V58, P86; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; WARD CJ, 1996, NATL ACAD SCI US, V93, P1524	13	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1039	1040		10.1016/S0140-6736(05)62286-6	http://dx.doi.org/10.1016/S0140-6736(05)62286-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107237				2022-12-28	WOS:A1997WU00200003
J	Ligi, M; Bonatti, E; Bortoluzzi, G; Carrara, G; Fabretti, P; Penitenti, D; Gilod, D; Peyve, AA; Skolotnev, S; Turko, N				Ligi, M; Bonatti, E; Bortoluzzi, G; Carrara, G; Fabretti, P; Penitenti, D; Gilod, D; Peyve, AA; Skolotnev, S; Turko, N			Death and transfiguration of a triple junction in the South Atlantic	SCIENCE			English	Article							RIDGE; OCEAN; EVOLUTION; PLUMES	Three major lithospheric plates-Antarctic, South American, and African-meet in the South Atlantic near Bouvet Island where the Mid-Atlantic Ridge (MAR), the Southwest Indian Ridge (SWIR), and the American Antarctic Ridge converge toward a fast evolving triple junction. A major magmatic pulse has recently built a new, swollen segment of the SWIR (Spiess Ridge) that is propagating toward the MAR at a rate of 4 to 5 centimeters per year, disrupting a former ridge-ridge-ridge (RRR) triple junction. A new triple junction will be established about 70 kilometers to the north when the propagating SWIR/Spiess segment will impact with the MAR, probably within the next 1 million years. The American Antarctic Ridge will take advantage of the MAR/SWIR duel by capturing an approximately 70-kilometer stretch of MAR, whereas the Antarctic plate will increase its size.	CNR, IST GEOL MARINA, I-40126 BOLOGNA, ITALY; COLUMBIA UNIV, LAMONT DOHERTY EARTH OBSERV, PALISADES, NY 10964 USA; MOSCOW MV LOMONOSOV STATE UNIV, MOSCOW, RUSSIA; RUSSIAN ACAD SCI, INST GEOL, MOSCOW V71, RUSSIA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze Marine (ISMAR-CNR); Columbia University; Lomonosov Moscow State University; Geological Institute, Russian Academy of Sciences; Russian Academy of Sciences			Ligi, Marco/G-4853-2012; Carrara, Gabriela/AAC-3824-2019; Peyve, Alexander A/J-5724-2013; Cipriani, Anna/A-2797-2012	Ligi, Marco/0000-0002-5098-5907; Cipriani, Anna/0000-0001-8457-0147; Bonatti, Enrico/0000-0001-6162-9572				DOUGLASS J, 1995, GEOPHYS RES LETT, V22, P2893, DOI 10.1029/95GL02665; FORSYTH DW, 1975, J GEOPHYS RES, V80, P1429, DOI 10.1029/JB080i011p01429; HARTNADY CJH, 1985, EARTH PLANET SC LETT, V75, P245, DOI 10.1016/0012-821X(85)90106-2; HEY R, 1980, J GEOPHYS RES, V85, P3647, DOI 10.1029/JB085iB07p03647; Johnson G. L., 1973, Marine Geophysical Researches, V2, P23, DOI 10.1007/BF00451868; LEROEX AP, 1982, EARTH PLANET SC LETT, V60, P437, DOI 10.1016/0012-821X(82)90079-6; LEROEX AP, 1987, S AFR J ANTARCT RES, V17, P90; MACDONALD KC, 1983, NATURE, V302, P55, DOI 10.1038/302055a0; MCKENZIE DP, 1969, NATURE, V224, P125, DOI 10.1038/224125a0; MITCHELL NC, 1995, EOS S, V76, pF542; MOREIRA M, 1995, EARTH PLANET SC LETT, V133, P367, DOI 10.1016/0012-821X(95)00080-V; MORGAN JP, 1993, NATURE, V364, P706, DOI 10.1038/364706a0; MORGAN WJ, 1972, AM ASSOC PETR GEOL B, V56, P203; MUNSCHY M, 1989, MAR GEOPHYS RES, V11, P1, DOI 10.1007/BF00286244; PATRIAT P, 1984, TECTONICS, V3, P317, DOI 10.1029/TC003i003p00317; SCLATER JG, 1976, J GEOPHYS RES, V81, P1857, DOI 10.1029/JB081i011p01857; SHOBERG T, 1994, EARTH PLANET SC LETT, V122, P195, DOI 10.1016/0012-821X(94)90060-4; Simonov VA, 1996, TERRA NOVA, V8, P415, DOI 10.1111/j.1365-3121.1996.tb00766.x; SINTON JM, 1983, EARTH PLANET SC LETT, V62, P193, DOI 10.1016/0012-821X(83)90083-3; SMALL C, 1995, J GEOPHYS RES-SOL EA, V100, P17931, DOI 10.1029/95JB01377	20	36	39	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					243	245		10.1126/science.276.5310.243	http://dx.doi.org/10.1126/science.276.5310.243			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092470				2022-12-28	WOS:A1997WT92500041
J	Simmons, G; Clapham, PR; Picard, L; Offord, RE; Rosenkilde, MM; Schwartz, TW; Buser, R; Wells, TNC; Proudfoot, AEI				Simmons, G; Clapham, PR; Picard, L; Offord, RE; Rosenkilde, MM; Schwartz, TW; Buser, R; Wells, TNC; Proudfoot, AEI			Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TROPIC HIV-1; FUSION; CELLS; ENTRY; RECEPTOR; RANTES; IDENTIFICATION; MIP-1-ALPHA; MIP-1-BETA	The chemokine receptors CXCR4 and CCR5 have recently been shown to act as coreceptors, in concert with CD4, for human immunodeficiency virus-type 1 (HIV-1) infection. RANTES and other chemokines that interact with CCR5 and block infection of peripheral blood mononuclear cell cultures inhibit infection of primary macrophages inefficiently at best. If used to treat HIV-1-infected individuals, these chemokines could fail to influence HIV replication in nonlymphocyte compartments while promoting unwanted inflammatory side effects. A derivative of RANTES that was created by chemical modification of the amino terminus, aminooxypentane (AOP)-RANTES, did not induce chemotaxis and was a subnanomolar antagonist of CCR5 function in monocytes. It potently inhibited infection of diverse cell types (including macrophages and lymphocytes) by nonsyncytium-inducing, macrophage-tropic HIV-1 strains. Thus, activation of cells by chemokines is not a prerequisite for the inhibition of viral uptake and replication. Chemokine receptor antagonists like AOP-RANTES that achieve full receptor occupancy at nanomolar concentrations are strong candidates for the therapy of HIV-1-infected individuals.	INST CANC RES,CHESTER BEATTY LABS,VIROL GRP,LONDON SW3 6JB,ENGLAND; CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND; GRYPHON SCI,S SAN FRANCISCO,CA 94080; RIGSHOSP 6321,MOL PHARMACOL LAB,DK-2100 COPENHAGEN,DENMARK; GLAXOWELLCOME RES & DEV SA,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Geneva; Rigshospitalet			Simmons, Graham/G-3523-2012	Simmons, Graham/0000-0002-9615-7023; Wells, Timothy/0000-0001-9796-847X; Rosenkilde, Mette Marie/0000-0001-9600-3254; Schwartz, Thue W./0000-0002-0261-6904				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; ENDRES MJ, 1996, CELL, V87, P1; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GAERTNER HF, 1992, BIOCONJUGATE CHEM, V3, P262, DOI 10.1021/bc00015a010; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; MCKNIGHT A, 1995, J VIROL, V69, P3167, DOI 10.1128/JVI.69.5.3167-3170.1995; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; SIMMONS G, 1995, VIROLOGY, V209, P696, DOI 10.1006/viro.1995.1307; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996	20	557	619	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					276	279		10.1126/science.276.5310.276	http://dx.doi.org/10.1126/science.276.5310.276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092481				2022-12-28	WOS:A1997WT92500052
J	Daviglus, ML; Stamler, J; Orencia, AJ; Dyer, AR; Liu, K; Greenland, P; Walsh, MK; Morris, D; Shekelle, RB				Daviglus, ML; Stamler, J; Orencia, AJ; Dyer, AR; Liu, K; Greenland, P; Walsh, MK; Morris, D; Shekelle, RB			Fish consumption and the 30-year risk of fatal myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; N-3 FATTY-ACIDS; SUDDEN-DEATH; CARDIOVASCULAR-DISEASE; DIETARY-INTAKE; MORTALITY; MINNESOTA; DECLINE; HEALTH; OILS	Background Epidemiologic data on the possible benefit of eating fish to reduce the risk of coronary heart disease have been inconsistent. We used data from the Chicago Western Electric Study to examine the relation between base-line fish consumption and the 30-year risk of death from coronary heart disease. Methods The study participants were 1822 men who were 40 to 55 years old and free of cardiovascular disease at base line. Fish consumption, as determined from a detailed dietary history, was stratified (0, 1 to 17, 18 to 34, and greater than or equal to 35 g per day). Mortality from coronary heart disease, ascertained from death certificates, was classified as death from myocardial infarction (sudden or nonsudden) or death from other coronary causes. Results During 47,153 person-years of follow-up, there were 430 deaths from coronary heart disease; 293 were due to myocardial infarctions (196 were sudden, 94 were nonsudden, and 3 were not classifiable). Cox proportional-hazards regression showed that for men who consumed 35 g or more of fish dally as compared with those who consumed none, the relative risks of death from coronary heart disease and from sudden or nonsudden myocardial infarction were 0.62 (95 percent confidence interval, 0.40 to 0.94) and 0.56 (95 percent confidence interval, 0.33 to 0.93), respectively, with a graded relation between the relative risks and the strata of fish consumption (P for trend = 0.04 and 0.02, respectively). These findings were accounted for by the relation of fish consumption to nonsudden death from myocardial infarction (relative risk, 0.33; 95 percent confidence interval, 0.12 to 0.91; P for trend = 0.007). Conclusions These data show an inverse association between fish consumption and death from coronary heart disease, especially nonsudden death from myocardial infarction. (C) 1997, Massachusets Medical Society.	INDIANA UNIV, SCH MED, DEPT NEUROL, INDIANAPOLIS, IN 46202 USA; UNIV TEXAS, HLTH SCI CTR, SCH PUBL HLTH, DEPT EPIDEMIOL, HOUSTON, TX USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Daviglus, ML (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, 680 N LAKE SHORE DR, SUITE 1102, CHICAGO, IL 60611 USA.		Greenland, Philip/ABD-5528-2021; Walsh, Molly/AAG-3274-2021	Walsh, Molly/0000-0002-0656-2050	NHLBI NIH HHS [HL 03387, HL 15174, HL 21010] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021010, K14HL003387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERT CM, 1996, CIRCULATION S1, V94, P578; ANASTASIOUNANA M, 1982, CIRCULATION, V66, P236; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BAIRATI I, 1992, CIRCULATION, V85, P950, DOI 10.1161/01.CIR.85.3.950; BILLMAN GE, 1996, CIRCULATION S1, V94, P307; BOWES ADP, 1956, FOOD VALUES PORTIONS; Burke Bertha S., 1947, JOUR AMER DIETETIC ASSOC, V23, P1041; BURR ML, 1989, LANCET, V2, P757; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, NEW ENGL J MED, V313, P821; *DEP HLTH ED WELF, 1967, PHS DHEW PUBL, V1693; DREVON CA, 1992, NUTR REV, V50, P38; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GILLUM RF, 1983, NEW ENGL J MED, V309, P1353, DOI 10.1056/NEJM198312013092203; GILLUM RF, 1984, AM J MED, V76, P1055, DOI 10.1016/0002-9343(84)90857-X; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; HARDINGE MARVYN, 1958, JOUR AMER DIETETIC ASSOC, V34, P1065; HARRIS WS, 1989, J LIPID RES, V30, P785; HAYES OLIVE B., 1957, JOUR AMER DIETETIC ASSOC, V33, P26; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KINSELLA JE, 1990, AM J CLIN NUTR, V52, P1; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; Kjelsberg MO, 1996, CIRCULATION, V94, P946; Kromhout D, 1996, NUTR METAB CARDIOVAS, V6, P65; KROMHOUT D, 1995, INT J EPIDEMIOL, V24, P340, DOI 10.1093/ije/24.2.340; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KROMHOUT D, 1989, J INTERN MED, V225, P47, DOI 10.1111/j.1365-2796.1989.tb01435.x; KULLER LH, 1986, J CHRON DIS, V39, P1001, DOI 10.1016/0021-9681(86)90136-0; KULLER LH, 1987, J CHRON DIS, V40, P1071; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; *MULT RISK FACT IN, 1990, JAMA-J AM MED ASSOC, V263, P3151; *NAT CTR HLTH STAT, 1995, MON VIT STAT REP S, V43; *NAT I HLTH, 1981, NIH PUBL, P175; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; SCHMIDT EB, 1994, DRUGS, V47, P405, DOI 10.2165/00003495-199447030-00003; SEIDELIN KN, 1992, AM J CLIN NUTR, V55, P1117, DOI 10.1093/ajcn/55.6.1117; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SHEKELLE RB, 1993, NUTR METAB CARDIOVAS, V3, P46; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; TRAVEN ND, 1995, AM J EPIDEMIOL, V142, P45, DOI 10.1093/oxfordjournals.aje.a117544; VANHOUWELINGEN AC, 1989, ATHEROSCLEROSIS, V75, P157, DOI 10.1016/0021-9150(89)90172-X; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; WAHLQVIST ML, 1989, LANCET, V2, P944; WOOD DA, 1987, LANCET, V1, P177	50	670	694	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1046	1053		10.1056/NEJM199704103361502	http://dx.doi.org/10.1056/NEJM199704103361502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091800				2022-12-28	WOS:A1997WT16100002
J	Royce, RA; Sena, A; Cates, W; Cohen, MS				Royce, RA; Sena, A; Cates, W; Cohen, MS			Current concepts - Sexual transmission of HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; TRANSMITTED DISEASES; HETEROSEXUAL TRANSMISSION; TYPE-1 HIV-1; CONCURRENT PARTNERSHIPS; GENITAL SECRETIONS; SEROPOSITIVE MEN; CONTROLLED TRIAL; SAN-FRANCISCO		UNIV N CAROLINA, DIV INFECT DIS, CHAPEL HILL, NC 27599 USA; FAMILY HLTH INT, RES TRIANGLE PK, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill	Royce, RA (corresponding author), UNIV N CAROLINA, DEPT EPIDEMIOL, CB 7400, CHAPEL HILL, NC 27599 USA.		Franzeck, Fabian C/B-5055-2011; Royce, Rachel A/A-7964-2012		PHS HHS [R0 49381] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHLGREN DJ, 1990, J ACQ IMMUN DEF SYND, V3, P631; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; ANDERSON R M, 1991; [Anonymous], 1992, BMJ, V304, P809; Aral SO, 1996, J INFECT DIS, V174, pS127, DOI 10.1093/infdis/174.Supplement_2.S127; Atkins MC, 1996, BRIT MED J, V313, P341, DOI 10.1136/bmj.313.7053.341; BAGASRA O, 1994, AIDS, V8, P1669, DOI 10.1097/00002030-199412000-00005; BARNETT T, 1996, AIDS WORLD 2 GLOBAL, P444; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; CACERES CF, 1994, AIDS, V8, P1051, DOI 10.1097/00002030-199408000-00004; CAMERON DW, 1989, LANCET, V2, P403; CHAO A, 1994, INT J EPIDEMIOL, V23, P371, DOI 10.1093/ije/23.2.371; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017; COHEN MS, 1994, ANN INTERN MED, V120, P340, DOI 10.7326/0003-4819-120-4-199402150-00014; CRITCHLOW CW, 1995, AM J OBSTET GYNECOL, V173, P534, DOI 10.1016/0002-9378(95)90279-1; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DALY CC, 1994, GENITOURIN MED, V70, P110; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feldblum P J, 1995, AIDS, V9 Suppl A, pS85; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; GILLIAM BL, 1996, 1U INT C AIDS VANC B, V1, P69; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GUIMARAES MDC, 1995, AM J EPIDEMIOL, V142, P538, DOI 10.1093/oxfordjournals.aje.a117672; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; HOFFMAN I, 1996, 11 INT C AIDS VANC B, P15; Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210; HUNTER DJ, 1993, EPIDEMIOLOGY, V4, P63, DOI 10.1097/00001648-199301000-00012; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; *JOINT UN PROGR HI, 1996, HIV AIDS SIT MID 199; KAPIGA SH, 1994, J ACQ IMMUN DEF SYND, V7, P301; KAPLAN EH, 1990, J ACQ IMMUN DEF SYND, V3, P55; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P1367; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Koopman JS, 1996, AM J PUBLIC HEALTH, V86, P630, DOI 10.2105/AJPH.86.5.630; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; KRIEGER JN, 1995, J UROLOGY, V154, P1035, DOI 10.1016/S0022-5347(01)66969-6; KRIEGER JN, 1995, J INFECT DIS, V171, P1018, DOI 10.1093/infdis/171.4.1018; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; KRIESS JK, 1993, J INFECT DIS, V168, P1404, DOI 10.1093/infdis/168.6.1404; KROODSMA KL, 1994, J INFECT DIS, V170, P1292, DOI 10.1093/infdis/170.5.1292; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; Lu YC, 1996, J VIROL, V70, P3045, DOI 10.1128/JVI.70.5.3045-3050.1996; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MATI JKG, 1995, INT J GYNECOL OBSTET, V48, P61; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P68, DOI 10.2105/AJPH.78.1.68; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; MORRIS M, 1995, SOC NETWORKS, V17, P299, DOI 10.1016/0378-8733(95)00268-S; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; NAGACHINTA T, 1996, 11 INT C AIDS VANC B, V1, P42; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; NUOVO GJ, 1993, AM J PATHOL, V143, P40; OCONNOR TJ, 1995, INT J STD AIDS, V6, P267, DOI 10.1177/095646249500600409; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PETERMAN TA, 1989, JAMA-J AM MED ASSOC, V262, P502; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PLOURDE PJ, 1994, J INFECT DIS, V170, P313, DOI 10.1093/infdis/170.2.313; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; Rasheed S, 1996, AM J OBSTET GYNECOL, V175, P122, DOI 10.1016/S0002-9378(96)70261-2; Royce Rachel, 1992, P645; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SEIDLIN M, 1993, AIDS, V7, pU1541; SEIDLIN M, 1993, AIDS, V7, P1247, DOI 10.1097/00002030-199309000-00015; Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0; Sinei SKA, 1996, INT J STD AIDS, V7, P65, DOI 10.1258/0956462961917104; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; Tovo PA, 1996, J ACQ IMMUN DEF SYND, V11, P88, DOI 10.1097/00042560-199601010-00012; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; VOGT MW, 1987, ANN INTERN MED, V106, P380, DOI 10.7326/0003-4819-106-3-380; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WATTS CH, 1992, MATH BIOSCI, V108, P89, DOI 10.1016/0025-5564(92)90006-I; WAWER M, 1996, 11 INT C AIDS VANC B, V1, P39; Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996; 1995, MMWR-MORBID MORTAL W, V44, P929; 1994, MMWR-MORBID MORTAL W, V43, P285	100	779	807	0	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1072	1078		10.1056/NEJM199704103361507	http://dx.doi.org/10.1056/NEJM199704103361507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091805				2022-12-28	WOS:A1997WT16100007
J	Henning, KJ; White, MH; Sapkowitz, KA; Armstrong, D				Henning, KJ; White, MH; Sapkowitz, KA; Armstrong, D			A national survey of immunization practices following allogeneic bone marrow transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYSACCHARIDE ANTIBODY DEFICIENCY; HEPATITIS-B VIRUS; RECIPIENTS; VACCINATION; IMMUNITY; RECOMMENDATIONS; INFECTIONS; MEASLES; RUBELLA; MUMPS	Objectives.-To describe the frequency and patterns of use of routine childhood and hepatitis B, pneumococcal, influenza, and meningococcal vaccines following allogeneic bone marrow transplantation (BMT). Design, Setting, and Participants.-Survey of all US transplantation centers participating in the National Marrow Donor Program (NMDP) during 1994. Main Outcome Measures.-Use, timing, and total doses of selected vaccines given to patients younger than 7 years and patients aged 7 years or older following allogeneic BMT. Results.-Of 66 centers associated with the NMDP, 45 (68%) responded. A total of 97% of centers performing transplants on patients younger than 7 years and 88% of centers performing transplants on patients aged 7 years or older gave either the diphtheria-tetanus vaccine or the diphtheria-tetanus-pertussis vaccine compared with 77% and 58% usage, respectively, of Haemophilus influenza type b conjugate vaccine (P=.03 and .003, respectively). Centers were more likely to administer inactivated poliovirus and measles-mumps-rubella vaccines to patients younger than 7 years than to the older age group (94% vs 73% for poliovirus, P=.02; and 94% vs 70% for measles-mumps-rubella, P=.01). About one half of centers routinely administer hepatitis B vaccine and approximately three quarters immunize with pneumococcal and influenza vaccines. Few programs, regardless of age of bone marrow recipient, use multiple vaccine (greater than or equal to 2) doses. The number of schedules reported for specific vaccines varied widely (3-11 schedules per vaccine). Conclusions.-Despite convincing evidence that patients lose protective antibodies to vaccine-preventable diseases following allogeneic BMT and accumulating data showing the safety and efficacy of many vaccines after BMT, vaccines are underutilized and schedules vary widely at US transplant centers. National guidelines for optimal doses and timing of vaccines after BMT are warranted.	MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Henning, KJ (corresponding author), THOMAS JEFFERSON UNIV,DIV INFECT DIS,1015 CHESTNUT ST,SUITE 610,PHILADELPHIA,PA 19107, USA.							AMBROSINO DM, 1993, HEMATOL ONCOL CLIN N, V7, P1027, DOI 10.1016/S0889-8588(18)30216-8; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; ASCHAN J, 1989, SCAND J INFECT DIS, V21, P349, DOI 10.3109/00365548909035710; AUCOUTURIER P, 1987, BLOOD, V70, P779; BRANDT L, 1994, ARCH DIS CHILD, V71, P529, DOI 10.1136/adc.71.6.529; DEAN AD, 1990, EPI INFO VRSION 5; ENGELHARD D, 1993, BONE MARROW TRANSPL, V11, P1; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GIEBINK GS, 1986, J INFECT DIS, V154, P590, DOI 10.1093/infdis/154.4.590; GUINAN EC, 1994, TRANSPLANTATION, V57, P667; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; HOROWITZ MM, 1995, IBMTR NEWSLETTER JUL, V2, P3; ILAN Y, 1994, CLIN EXP IMMUNOL, V97, P299, DOI 10.1111/j.1365-2249.1994.tb06084.x; ILAN Y, 1993, HEPATOLOGY, V18, P246, DOI 10.1002/hep.1840180204; LJUNGMAN P, 1994, BLOOD, V84, P657; LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610; LJUNGMAN P, 1995, BONE MARROW TRANSPL, V15, P455; LJUNGMAN P, 1991, BONE MARROW TRANSPL, V7, P89; LJUNGMAN P, 1990, J INFECT DIS, V162, P496, DOI 10.1093/infdis/162.2.496; LJUNGMAN P, 1994, 8 INT S INF IMM HOST; LUM LG, 1986, BLOOD, V67, P582; LUM LG, 1988, BONE MARROW TRANSPL, V3, P399; *NAT MARR DON PROG, 1995, TRANSPL CTR ACC DIR; QUINTI I, 1990, J CLIN IMMUNOL, V10, P160, DOI 10.1007/BF00917916; ROSENDAHL C, 1985, EXP HEMATOL, V13, P104; SOMANI J, 1995, AM J MED, V98, P389, DOI 10.1016/S0002-9343(99)80319-2; VOLTI SL, 1994, BONE MARROW TRANSPL, V14, P225; WHIMBEY E, 1994, BONE MARROW TRANSPL, V13, P437; WINGARD JR, 1990, BONE MARROW TRANSPL, V6, P371; WINSTON DJ, 1983, ARCH INTERN MED, V143, P1735, DOI 10.1001/archinte.143.9.1735; WINSTON DJ, 1979, ANN INTERN MED, V91, P835, DOI 10.7326/0003-4819-91-6-835	31	40	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1148	1151		10.1001/jama.277.14.1148	http://dx.doi.org/10.1001/jama.277.14.1148			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087470				2022-12-28	WOS:A1997WR34200034
J	Peterson, ED; Shaw, LJ; Califf, RM				Peterson, ED; Shaw, LJ; Califf, RM			Clinical guideline .2. Risk stratification after myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR FUNCTION; CORONARY-ARTERY DISEASE; ST-SEGMENT ELEVATION; CARDIAC TROPONIN-T; SIGNAL-AVERAGED ELECTROCARDIOGRAM; EMISSION COMPUTED-TOMOGRAPHY; ISCHEMIC HEART-DISEASE; RECEIVING THROMBOLYTIC THERAPY; RANDOMIZED CONTROLLED TRIAL; ACUTE REPERFUSION THERAPY	Purpose: To review the literature on risk stratification after acute myocardial infarction in the reperfusion era and to propose an algorithm for early and continual risk assessment. Data Sources: A MEDLINE search of the English-language literature on humans was done using the terms myocardial infarction, prospective studies, and prognosis. This search was supplemented by narrowed searches for subheadings (such as cardiogenic shock, thrombolytic therapy, and stress testing) and surveys of references cited in review articles and book chapters. Study Selection: Literature on prognosis and myocardial infarction published from 1981 to 1996 was considered. From the literature on stress testing methods, studies that enrolled patients before 1980, enrolled patients for indications other than myocardial infarction, tested patients more than 6 weeks after infarction, were missing outcome data, or had inadequate follow-up were excluded. Data Extraction: Because too few randomized trials were available to allow the cross-comparison of risk stratification methods, the available observational data were synthesized and supplemented with clinical judgments to produce recommendations. Data Synthesis: Risk stratification must begin when acute myocardial infarction is diagnosed. High-risk patients (such as those with cardiogenic shock) and candidates for reperfusion therapy must be identified quickly if ideal emergency care is to be given. At specific points during hospitalization, specialized tests may be useful if they add incremental information to the results of clinical evaluations. High-risk patients who have complications after infarction or significant left ventricular dysfunction probably benefit from early angiography; patients without these conditions are at low risk for recurrent events and should have noninvasive stress testing for further risk stratification. Conclusions: Physicians should continually reappraise risk throughout hospitalization to optimize both patient outcomes and cost containment.	DUKE UNIV, MED CTR, DURHAM, NC 27706 USA	Duke University			Peterson, Eric David/ABF-5033-2021					ABBOTTSMITH CW, 1990, J AM COLL CARDIOL, V16, P770, DOI 10.1016/S0735-1097(10)80320-1; ABE S, 1994, J AM COLL CARDIOL, V23, P1382, DOI 10.1016/0735-1097(94)90381-6; ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; AGUIRRE FV, 1991, AM J CARDIOL, V68, P1410, DOI 10.1016/0002-9149(91)90272-M; ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; *AM HEART ASS, 1994, HEART STROK FACTS; ANDERSON WD, 1988, AM J CARDIOL, V61, P729, DOI 10.1016/0002-9149(88)91056-9; [Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARBAGELATA A, 1995, AM J CARDIOL, V76, P1007, DOI 10.1016/S0002-9149(99)80285-9; BARBASH GI, 1995, J AM COLL CARDIOL, V26, P1222, DOI 10.1016/0735-1097(95)00299-5; BARBASH GI, 1990, BRIT HEART J, V64, P241; BARBASH GI, 1990, J AM COLL CARDIOL, V16, P779, DOI 10.1016/S0735-1097(10)80321-3; BATES ER, 1991, J AM COLL CARDIOL, V18, P1077, DOI 10.1016/0735-1097(91)90770-A; BATES ER, 1990, J AM COLL CARDIOL, V16, P1538, DOI 10.1016/0735-1097(90)90297-3; BATES ER, 1988, J AM COLL CARDIOL, V12, pA44, DOI 10.1016/0735-1097(88)92640-X; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BEHAR S, 1993, AM J CARDIOL, V72, P1366, DOI 10.1016/0002-9149(93)90181-B; BENGTSON JR, 1992, J AM COLL CARDIOL, V20, P1482, DOI 10.1016/0735-1097(92)90440-X; BERNING J, 1992, AM J CARDIOL, V69, P1538, DOI 10.1016/0002-9149(92)90699-Y; BETRIU A, 1992, J AM COLL CARDIOL, V19, P1659, DOI 10.1016/0735-1097(92)90633-X; BHANDARI AK, 1989, BRIT HEART J, V61, P410; BIGGER JT, 1986, AM J CARDIOL, V58, P1151, DOI 10.1016/0002-9149(86)90374-7; BILBAO FJ, 1987, CIRCULATION, V75, P733, DOI 10.1161/01.CIR.75.4.733; BINDER MJ, 1955, AM J MED, V18, P622, DOI 10.1016/0002-9343(55)90463-0; BITTL JA, 1991, CHEST, V99, pS150, DOI 10.1378/chest.99.4.150S; BLUMENTHAL JA, 1989, J AM COLL CARDIOL, V14, P1034, DOI 10.1016/0735-1097(89)90486-5; BOSSAERT L, 1991, EUR HEART J, V12, P357, DOI 10.1093/oxfordjournals.eurheartj.a059902; BOSTROM PA, 1992, CLIN PHYSIOL, V12, P679, DOI 10.1111/j.1475-097X.1992.tb00371.x; BOUWELS L, 1992, INT J CARDIOL, V35, P355, DOI 10.1016/0167-5273(92)90234-T; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; BRAUNWALD E, 1992, HEART DISEASE TXB CA; BRAUNWALD E, 1994, UNSTABLE ANGINA DIAG, P1; BROTT T, 1986, STROKE, V17, P1078, DOI 10.1161/01.STR.17.6.1078; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1994, NEW ENGL J MED, V330, P1724, DOI 10.1056/NEJM199406163302406; CALIFF RM, 1992, CIRCULATION, V85, P839, DOI 10.1161/01.CIR.85.2.839; Califf RM, 1996, CIRCULATION, V93, P403, DOI 10.1161/01.CIR.93.3.403; CALIFF RM, 1995, ACUTE CORONARY CARE; CANDELLRIERA J, 1991, J AM COLL CARDIOL, V18, P1207, DOI 10.1016/0735-1097(91)90537-J; CAPONE RJ, 1991, J AM COLL CARDIOL, V18, P1434, DOI 10.1016/0735-1097(91)90671-U; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; CERQUEIRA MD, 1992, J AM COLL CARDIOL, V20, P1452, DOI 10.1016/0735-1097(92)90436-Q; CHARLES ED, 1989, J AM COLL CARDIOL, V13, pA152; CHRISTIAN TF, 1991, CIRCULATION, V83, P1615, DOI 10.1161/01.CIR.83.5.1615; CHRISTIAN TF, 1991, ANN INTERN MED, V114, P264, DOI 10.7326/0003-4819-114-4-264; CHRISTIAN TF, 1992, CIRCULATION, V86, P81, DOI 10.1161/01.CIR.86.1.81; CLEMMENSEN P, 1990, AM J CARDIOL, V66, P1407, DOI 10.1016/0002-9149(90)90524-5; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; COLLINS R, 1995, LANCET, V345, P669; CONNOLLY SJ, 1992, AM J CARDIOL, V69, P408, DOI 10.1016/0002-9149(92)90243-R; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; CORBETT JR, 1984, AM J CARDIOL, V54, P1231, DOI 10.1016/S0002-9149(84)80072-7; CORBETT JR, 1981, CIRCULATION, V64, P535, DOI 10.1161/01.CIR.64.3.535; CORNEL JH, 1994, HERZ, V19, P19; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; CRIPPS T, 1989, J AM COLL CARDIOL, V14, P289, DOI 10.1016/0735-1097(89)90175-7; CURRIE P, 1993, BRIT HEART J, V69, P303; DEBOER MJ, 1994, CIRCULATION, V90, P753, DOI 10.1161/01.CIR.90.2.753; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; DEBUSK RF, 1989, ANN INTERN MED, V110, P470, DOI 10.7326/0003-4819-110-6-470; DECOSTER PM, 1990, CIRCULATION, V82, P2152, DOI 10.1161/01.CIR.82.6.2152; DENES P, 1994, AM J CARDIOL, V74, P216, DOI 10.1016/0002-9149(94)90359-X; DENNISS AR, 1986, CIRCULATION, V74, P731, DOI 10.1161/01.CIR.74.4.731; DENNISS AR, 1985, AM J CARDIOL, V56, P213, DOI 10.1016/0002-9149(85)90837-9; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DUBOIS C, 1988, AM J CARDIOL, V61, P216, DOI 10.1016/0002-9149(88)90918-6; EDDY DM, 1990, MED DECIS MAKING, V10, P15, DOI 10.1177/0272989X9001000104; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; Eisenstein Eric L., 1996, Journal of the American College of Cardiology, V27, p244A; ELDAR M, 1992, ANN INTERN MED, V117, P31, DOI 10.7326/0003-4819-117-1-31; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; ELLIS SG, 1994, CIRCULATION, V90, P2280, DOI 10.1161/01.CIR.90.5.2280; FALLEN EL, 1991, CAN MED ASSOC J, V144, P1015; FARRELL TG, 1992, BRIT HEART J, V67, P129; Ferguson JJ, 1996, CIRCULATION, V94, P1; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISCH GR, 1980, PROG CARDIOVASC DIS, V23, P187, DOI 10.1016/0033-0620(80)90021-3; FLEISCHMANN KE, 1994, J AM COLL CARDIOL, V23, P1390, DOI 10.1016/0735-1097(94)90382-4; FLETCHER WO, 1993, AM HEART J, V126, P526, DOI 10.1016/0002-8703(93)90400-4; FORRESTER JS, 1976, NEW ENGL J MED, V295, P1356, DOI 10.1056/NEJM197612092952406; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; GADSBOLL N, 1987, EUR HEART J, V8, P1201, DOI 10.1093/oxfordjournals.eurheartj.a062193; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GIBBONS RJ, 1989, CIRCULATION, V80, P1277, DOI 10.1161/01.CIR.80.5.1277; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; GOLDBERG RJ, 1990, AM HEART J, V119, P996, DOI 10.1016/S0002-8703(05)80227-3; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDMAN L, 1982, INT J CARDIOL, V2, P284, DOI 10.1016/0167-5273(82)90046-8; GOLDMAN L, 1989, CLIN RES, V37, pA524; GOMES JA, 1987, J AM COLL CARDIOL, V10, P349; GONZALEZ R, 1988, PACE, V11, P283, DOI 10.1111/j.1540-8159.1988.tb05005.x; GOTTLIEB S, 1992, AM J CARDIOL, V69, P977, DOI 10.1016/0002-9149(92)90850-X; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENBERG H, 1984, J AM COLL CARDIOL, V4, P867, DOI 10.1016/S0735-1097(84)80045-5; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; GRIFFIN BP, 1991, AM J CARDIOL, V68, P707, DOI 10.1016/0002-9149(91)90640-7; GRINES CL, 1995, CIRCULATION, V91, P298, DOI 10.1161/01.CIR.91.2.298; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GRINES CL, 1995, ACTURE CORONARY CARE, P215; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Gunnar R M, 1990, Circulation, V82, P664; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; HAMBY RI, 1985, AM HEART J, V109, P338, DOI 10.1016/0002-8703(85)90604-0; HAMER A, 1982, AM J CARDIOL, V50, P223, DOI 10.1016/0002-9149(82)90170-9; HAMPTON JR, 1990, AM J CARDIOL, V66, pC3, DOI 10.1016/0002-9149(90)90756-Q; HANDS ME, 1989, J AM COLL CARDIOL, V14, P40, DOI 10.1016/0735-1097(89)90051-X; HARRIS P, 1994, CARDIOVASC DRUG THER, V8, P447, DOI 10.1007/BF00877921; HEIDBUCHEL H, 1994, CIRCULATION, V89, P1051, DOI 10.1161/01.CIR.89.3.1051; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HOGG KJ, 1988, BRIT HEART J, V60, P275; HOHNLOSER SH, 1994, CIRCULATION, V90, P1747, DOI 10.1161/01.CIR.90.4.1747; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; HONG M, 1991, AM J CARDIOL, V68, P1403, DOI 10.1016/0002-9149(91)90271-L; HOWARTH D, 1995, CLIN NUCL MED, V20, P1, DOI 10.1097/00003072-199501000-00001; HUBER KC, 1992, J AM COLL CARDIOL, V19, P67, DOI 10.1016/0735-1097(92)90053-P; KAN G, 1986, BRIT HEART J, V56, P422; KATUS HA, 1991, AM J CARDIOL, V67, P1360, DOI 10.1016/0002-9149(91)90466-X; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KLEIMAN NS, 1994, CIRCULATION, V90, P2658, DOI 10.1161/01.CIR.90.6.2658; KLEIMAN NS, 1992, J AM COLL CARDIOL, V19, P1129; KLEIN J, 1989, J AM COLL CARDIOL, V14, P305, DOI 10.1016/0735-1097(89)90178-2; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KONSTAM MA, 1993, CIRCULATION, V88, P2277, DOI 10.1161/01.CIR.88.5.2277; KOSTIS JB, 1987, J AM COLL CARDIOL, V10, P231, DOI 10.1016/S0735-1097(87)80001-3; KOWEY PR, 1984, J AM COLL CARDIOL, V3, P690, DOI 10.1016/S0735-1097(84)80244-2; KRONE RJ, 1983, AM J CARDIOL, V52, P234, DOI 10.1016/0002-9149(83)90114-5; KRUCOFF MW, 1993, CIRCULATION, V88, P437, DOI 10.1161/01.CIR.88.2.437; KRUMHOLZ HM, 1993, J AM COLL CARDIOL, V22, P1697, DOI 10.1016/0735-1097(93)90598-U; KRUMHOLZ HM, 1989, WESTERN J MED, V151, P304; KUCHAR DL, 1986, CIRCULATION, V74, P1280, DOI 10.1161/01.CIR.74.6.1280; KULICK DL, 1991, AM HEART J, V121, P641, DOI 10.1016/0002-8703(91)90747-6; La Rovere M T, 1992, G Ital Cardiol, V22, P639; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; LEE TH, 1987, ARCH INTERN MED, V147, P115, DOI 10.1001/archinte.147.1.115; LEMBO NJ, 1986, CIRCULATION, V74, P56, DOI 10.1161/01.CIR.74.1.56; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; LIU LS, 1995, LANCET, V345, P686; LOMBOY CT, 1995, J AM COLL CARDIOL, V25, P210, DOI 10.1016/0735-1097(94)00350-Y; LOTTO A, 1990, HAEMOSTASIS, V20, P132; LOW KG, 1994, WOMEN HEALTH, V22, P79, DOI 10.1300/J013v22n01_05; LOWN B, 1967, J AMER MED ASSOC, V199, P188, DOI 10.1001/jama.199.3.188; MACIEIRACOELHO E, 1993, CLIN CARDIOL, V16, P879, DOI 10.1002/clc.4960161208; MADSEN EB, 1984, AM HEART J, V107, P1241, DOI 10.1016/0002-8703(84)90284-9; MAGGIONI AP, 1993, CIRCULATION, V87, P312, DOI 10.1161/01.CIR.87.2.312; MAHMARIAN JJ, 1991, J AM COLL CARDIOL, V17, P355, DOI 10.1016/S0735-1097(10)80099-3; MARCHLINSKI FE, 1983, AM J CARDIOL, V52, P1190, DOI 10.1016/0002-9149(83)90572-6; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARK DB, 1996, CIRCULATION, V94, P168; MARK DB, 1994, TXB INTERVENTIONAL C, P1323; MAVRIC Z, 1990, AM HEART J, V119, P823; MCCALLISTER BD, 1993, CIRCULATION, V88, P1470, DOI 10.1161/01.CIR.88.4.1470; MCCLEMENTS BM, 1993, J AM COLL CARDIOL, V21, P1419, DOI 10.1016/0735-1097(93)90319-V; MCCOMB JM, 1988, AM J CARDIOL, V62, P186, DOI 10.1016/0002-9149(88)90209-3; MEADE TW, 1988, EUR HEART J, V9, P836, DOI 10.1093/oxfordjournals.eurheartj.a062576; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEYER J, 1982, AM HEART J, V103, P132, DOI 10.1016/0002-8703(82)90540-3; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MOSS AJ, 1983, AM J CARDIOL, V52, P667, DOI 10.1016/0002-9149(83)90394-6; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; MULLER DWM, 1991, J AM COLL CARDIOL, V18, P1594, DOI 10.1016/0735-1097(91)90490-Z; *MULT POST INF RES, 1989, NEW ENGL J MED, V309, P321; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; NICOD P, 1983, AM J CARDIOL, V52, P30, DOI 10.1016/0002-9149(83)90064-4; NICOD P, 1988, AM J CARDIOL, V61, P1165, DOI 10.1016/0002-9149(88)91148-4; NIEMEYER MG, 1992, ANGIOLOGY, V43, P720, DOI 10.1177/000331979204300902; NISHIMURA RA, 1984, J AM COLL CARDIOL, V4, P1080, DOI 10.1016/S0735-1097(84)80125-4; NORRIS RM, 1969, LANCET, V1, P274; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OHMAN EM, 1993, CORONARY ARTERY DIS, V4, P957, DOI 10.1097/00019501-199311000-00002; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; OLDRIDGE N, 1993, AM J CARDIOL, V72, P154, DOI 10.1016/0002-9149(93)90152-3; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; OLSSON G, 1992, EUR HEART J, V13, P28, DOI 10.1093/oxfordjournals.eurheartj.a060043; ONEILL WW, 1992, J AM COLL CARDIOL, V19, P915, DOI 10.1016/0735-1097(92)90270-W; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PATTERSON RE, 1983, AM J CARDIOL, V51, P361, DOI 10.1016/S0002-9149(83)80066-6; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDRETTI R, 1993, AM J CARDIOL, V71, P1131, DOI 10.1016/0002-9149(93)90635-P; PELLIKKA PA, 1990, J NUCL MED, V31, P1269; Peterson ED, 1996, J AM COLL CARDIOL, V28, P305, DOI 10.1016/0735-1097(96)00133-7; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PIRELLI S, 1988, EUR HEART J, V9, P1324, DOI 10.1093/oxfordjournals.eurheartj.a062450; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; Rackley C E, 1981, Cardiovasc Clin, V11, P15; REMPPIS A, 1994, BRIT HEART J, V71, P242; RICH MW, 1988, AM J CARDIOL, V62, P714, DOI 10.1016/0002-9149(88)91208-8; RICHARDS DA, 1983, AM J CARDIOL, V51, P75, DOI 10.1016/S0002-9149(83)80014-9; RICHARDS DAB, 1991, CIRCULATION, V83, P756, DOI 10.1161/01.CIR.83.3.756; RICHARDSON SG, 1988, AM J CARDIOL, V61, P961, DOI 10.1016/0002-9149(88)90106-3; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; ROBIN ED, 1985, ANN INTERN MED, V103, P445, DOI 10.7326/0003-4819-103-3-445; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROUBIN GS, 1994, INTERVENTIONAL CARDI; ROY D, 1985, CIRCULATION, V72, P487, DOI 10.1161/01.CIR.72.3.487; SABIA P, 1991, CIRCULATION, V84, P1615, DOI 10.1161/01.CIR.84.4.1615; SANTARELLI P, 1985, AM J CARDIOL, V55, P391, DOI 10.1016/0002-9149(85)90382-0; SANZ G, 1993, J AM COLL CARDIOL, V22, P1795, DOI 10.1016/0735-1097(93)90759-T; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SARAN RK, 1990, BRIT HEART J, V64, P113; SCHEIDT S, 1970, AM J CARDIOL, V26, P556, DOI 10.1016/0002-9149(70)90407-8; Schreiber Theodore, 1996, Journal of the American College of Cardiology, V27, p83A; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; SERRUYS PW, 1986, J AM COLL CARDIOL, V7, P729, DOI 10.1016/S0735-1097(86)80330-8; SHAH PK, 1993, J AM COLL CARDIOL, V21, P55, DOI 10.1016/0735-1097(93)90716-E; Shaw LJ, 1996, AM J CARDIOL, V78, P1327, DOI 10.1016/S0002-9149(96)00653-4; SHAW LJ, 1996, 13 ANN M ASS HLTH SE; SHIMADA T, 1994, CLIN CARDIOL, V17, P184, DOI 10.1002/clc.4960170408; SIEGEL D, 1988, ANN INTERN MED, V109, P213, DOI 10.7326/0003-4819-109-3-213; SILVER MT, 1994, ANN INTERN MED, V121, P750, DOI 10.7326/0003-4819-121-10-199411150-00004; SILVERMAN KJ, 1980, CIRCULATION, V61, P996, DOI 10.1161/01.CIR.61.5.996; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1993, AM J CARDIOL, V71, P524, DOI 10.1016/0002-9149(93)90506-8; Singh N, 1996, CIRCULATION, V93, P1388, DOI 10.1161/01.CIR.93.7.1388; SMEETS JP, 1981, CARDIOLOGY, V68, P67, DOI 10.1159/000173319; SOTOLONGO RP, 1990, TEX HEART I J, V17, P31; SRIDHARA BS, 1994, EUR J NUCL MED, V21, P1094; STEINBERG JS, 1992, AM J CARDIOL, V69, P13, DOI 10.1016/0002-9149(92)90669-P; STGIBSON W, 1992, J NUCL MED, V33, P2080; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; SUTTON JM, 1991, CIRCULATION, V83, P1278, DOI 10.1161/01.CIR.83.4.1278; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; SWAN H J C, 1970, Progress in Cardiovascular Diseases, V12, P568, DOI 10.1016/0033-0620(70)90022-8; TAMAKI S, 1984, BRIT HEART J, V52, P30; TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960; TOFIER GH, 1987, J AM COLL CARDIOL, V9, P473; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; Topol EJ, 1996, NEW ENGL J MED, V335, P775; TOPOL EJ, 1987, CIRCULATION, V75, P420, DOI 10.1161/01.CIR.75.2.420; VAAGENILSEN M, 1991, J CARDIOVASC PHARM, V18, pS26; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; VALETTE H, 1988, EUR J NUCL MED, V13, P551, DOI 10.1007/BF02574766; VANDEWERF F, 1990, LANCET, V336, P71; VANHEMEL NM, 1989, EUR HEART J, V10, P304, DOI 10.1093/oxfordjournals.eurheartj.a059487; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; WACKERS FJT, 1989, J AM COLL CARDIOL, V13, P998, DOI 10.1016/0735-1097(89)90250-7; WAGNER I, 1993, CORONARY ARTERY DIS, V4, P537, DOI 10.1097/00019501-199306000-00008; WAKSMAN R, 1993, EUR HEART J, V14, P71, DOI 10.1093/eurheartj/14.1.71; WALAMIES M, 1994, EUR J NUCL MED, V21, P968; WALL TC, 1989, AM J CARDIOL, V63, P423, DOI 10.1016/0002-9149(89)90312-3; WALL TC, 1991, MODERN MANAGEMENT AC, P103; WASPE LE, 1985, J AM COLL CARDIOL, V5, P1292, DOI 10.1016/S0735-1097(85)80339-9; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WHITE HD, 1990, BRIT HEART J, V64, P177; WILLEMS AR, 1990, J AM COLL CARDIOL, V16, P521, DOI 10.1016/0735-1097(90)90336-N; WILLEMS JL, 1990, CIRCULATION, V82, P1147, DOI 10.1161/01.CIR.82.4.1147; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1993, J HYPERTENS, V11, pS61; ZABEL KM, 1995, J AM COLL CARDIOL, V25, pA342; ZABEL M, 1994, J CARDIOVASC ELECTR, V5, P211, DOI 10.1111/j.1540-8167.1994.tb01158.x; ZABEL M, 1992, EUR HEART J, V13, P1619, DOI 10.1093/oxfordjournals.eurheartj.a060114; ZAMAN AG, 1993, CIRCULATION, V88, P905, DOI 10.1161/01.CIR.88.3.905; ZBILUT JP, 1988, CRIT CARE MED, V16, P64, DOI 10.1097/00003246-198801000-00014; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401; ZHANG YZ, 1992, JPN HEART J, V33, P15	280	113	126	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					561	582		10.7326/0003-4819-126-7-199704010-00012	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00012			22	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092324				2022-12-28	WOS:A1997WQ19500020
J	Bruzzi, P; Dogliotti, L; Naldoni, C; Bucchi, L; Costantini, M; Cicognani, A; Torta, M; Buzzi, GF; Angeli, A				Bruzzi, P; Dogliotti, L; Naldoni, C; Bucchi, L; Costantini, M; Cicognani, A; Torta, M; Buzzi, GF; Angeli, A			Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	4th Cherasco Meeting on Gross Cystic Disease of the Breast	JUN 23, 1995	CHERASCO, ITALY				FLUID; SUBSEQUENT; HISTORY	Objective: To assess correlation between type of breast cyst and risk of breast cancer in women with gross cystic disease of the breast. Design: Cohort study of women with breast cysts aspirated between 1983 and 1993 who were followed up until December 1994 for occurrence of breast cancer. Setting: Major cancer prevention centre. Subjects: 802 women with aspirated breast cysts. Main outcome measures: Type of breast cyst based on cationic content of cyst fluid: type I (potassium:sodium ratio > 1.5), type II (potassium:sodium ratio < 1.5), or mixed (both types). Subsequent occurrence and type of breast cancer. Results: After median follow up of six years (range 2-12 years) 15 cases of invasive breast cancer and two ductal carcinomas in situ were diagnosed in the cohort: 12 invasive cancers (and two carcinomas in situ) among the 417 women with type I cysts, two cancers among the 325 women with type II cysts, and one among the 60 women with mixed cysts. The incidence of breast cancer in women with type I cysts was significantly higher than that in women with type II cysts (relative risk 4.62 (95% confidence interval 1.26 to 29.7)). These results were confirmed after adjustment for several risk factors for breast cancer (relative risk 4.24 (1.12 to 27.5)). Conclusions: The increased risk of breast cancer of women with breast cysts seems to be concentrated among women with type I breast cysts.	ST LUIGI HOSP, UNIV TURIN, DEPT CLIN & BIOL SCI, I-10043 ORBASSANO, TORINO, ITALY; ST MARIA CROCI HOSP, CANC PREV CTR, I-48100 RAVENNA, ITALY	University of Turin	Bruzzi, P (corresponding author), IST NAZL RIC CANC, UNIT CLIN EPIDEMIOL & TRIALS, LARGO ROSANNA BENZI 10, I-16132 GENOA, ITALY.		Bucchi, Lauro/W-5033-2018; Bruzzi, Paolo/AAU-3363-2021; costantini, massimo/AAK-5388-2021	Bucchi, Lauro/0000-0002-6771-8119; costantini, massimo/0000-0002-5293-7079; Bruzzi, Paolo/0000-0002-7874-2077				AMADORI D, 1992, REGISTRO TUMORI ROMA; ANGELI A, 1990, ANN NY ACAD SCI, V586, P49, DOI 10.1111/j.1749-6632.1990.tb17788.x; ANGELI A, 1994, J STEROID BIOCHEM, V49, P333, DOI 10.1016/0960-0760(94)90276-3; BELANGER A, 1990, EUR J CANCER, V26, P277, DOI 10.1016/0277-5379(90)90222-F; BOCCARDO F, 1988, CANCER RES, V48, P5860; BODIAN CA, 1993, CANCER, V71, P3896, DOI 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I; BODIAN CA, 1993, EPIDEMIOL REV, V15, P177, DOI 10.1093/oxfordjournals.epirev.a036103; BODIAN CA, 1992, CANCER DETECT PREV, V16, P7; BRADLOW HL, 1983, ENDOCRINOLOGY CYSTIC, P197; BUCCHI L, 1995, J CLIN EPIDEMIOL, V48, P969, DOI 10.1016/0895-4356(94)00226-G; BUNDRED NJ, 1991, BRIT J CANCER, V64, P953, DOI 10.1038/bjc.1991.433; BUNDRED NJ, 1992, BREAST DIS, V5, P21; CIATTO S, 1990, EUR J CANCER, V26, P555, DOI 10.1016/0277-5379(90)90074-4; DIXON JM, 1985, EUR J CANCER CLIN ON, V21, P1047, DOI 10.1016/0277-5379(85)90289-5; DIXON JM, 1983, BRIT J SURG, V70, P604, DOI 10.1002/bjs.1800701012; DOGLIOTTI L, 1986, EUR J CANCER CLIN ON, V22, P1301, DOI 10.1016/0277-5379(86)90137-9; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EBBS SR, 1988, BRIT J SURG, V75, P702, DOI 10.1002/bjs.1800750726; HAAGENSEN CD, 1981, BREAST CARCINOMA RIS; HARRINGTON E, 1981, BREAST, V7, P13; Hills, 1993, STAT MODELS EPIDEMIO; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; JONES BM, 1980, BRIT J SURG, V67, P669, DOI 10.1002/bjs.1800670922; LAI LC, 1995, J CLIN ENDOCR METAB, V80, P711, DOI 10.1210/jc.80.2.711; LAI LC, 1993, CANCER, V24, P668; MILLER B, 1983, J ACAD LIBR, V9, P227; MILLER WR, 1992, CANCER DETECT PREV, V16, P99; NALDONI C, 1992, CANCER RES, V52, P1791; NALDONI C, 1990, ANN NY ACAD SCI, V586, P272, DOI 10.1111/j.1749-6632.1990.tb17816.x; NESS JC, 1993, AM J SURG, V166, P237, DOI 10.1016/S0002-9610(05)80965-1; ROBERTS MM, 1984, BRIT MED J, V288, P275, DOI 10.1136/bmj.288.6413.275	31	39	39	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	1997	314	7085					925	928		10.1136/bmj.314.7085.925	http://dx.doi.org/10.1136/bmj.314.7085.925			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WQ169	9099114	Green Published			2022-12-28	WOS:A1997WQ16900022
J	Slawson, DC; Shaughnessy, AF				Slawson, DC; Shaughnessy, AF			Obtaining useful information from expert based sources	BRITISH MEDICAL JOURNAL			English	Article							MASTER	Clinicians rely heavily on expert based systems-consultation with colleagues,journal reviews and textbooks, and continuing education activities-to obtain new information. The usefulness of sources such as these depends on the relevance and validity of the information and the work it takes to obtain it Useful information can be distinguished from the useless by asking three questions: Does the information focus on an outcome that my patients care about? Is the issue common to my practice, and is the intervention feasible? If the information is true, will it require me to change my practice? If the answer to all three questions is yes, then the information is a common POEM (patient oriented evidence that matters), capable of improving the lives of your patients and must be evaluated for validity. Conclusions based on results of well designed clinical trials are more likely to be valid than those drawn from observations based on experience in clinical practice. Both members of the team, clinicians and experts, must take responsibility for their respective roles.	HARRISBURG FAMILY PRACTICE RESIDENCY PROGRAM,HARRISBURG,PA		Slawson, DC (corresponding author), UNIV VIRGINIA,DEPT FAMILY MED,CHARLOTTESVILLE,VA 22908, USA.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; DONNENFELD ED, 1995, OPHTHALMOLOGY, V102, P976; DUNN EV, 1994, DISSEMINATING RES CH, P156; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GRODBERG MG, 1978, ADV COMM M FOOD DRUG; Harris LL, 1996, JAMA-J AM MED ASSOC, V275, P837, DOI 10.1001/jama.1996.03530350019020; HULBERT MFG, 1991, LANCET, V337, P643, DOI 10.1016/0140-6736(91)92454-A; Kaiser PK, 1995, OPHTHALMOLOGY, V102, P1936, DOI 10.1016/S0161-6420(95)30772-5; KIRKPATRICK JNP, 1993, EYE, V7, P468, DOI 10.1038/eye.1993.95; NEIHOUSE PF, 1989, DICP ANN PHARMAC, V23, P594, DOI 10.1177/1060028089023007-813; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; Riffenburgh RH, 1996, ARCH OTOLARYNGOL, V122, P600; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SANFORD JP, 1996, SANFORD GUIDE ANTIMI, P6; SHAUGHNESSY AF, 1994, J FAM PRACTICE, V39, P489; SLAWSON DC, 1994, J FAM PRACTICE, V38, P505; Slawson DC, 1996, JAMA-J AM MED ASSOC, V275, P837, DOI 10.1001/jama.1996.03530350019019; Smith R, 1996, BRIT MED J, V313, P1062	20	47	48	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					947	949		10.1136/bmj.314.7085.947	http://dx.doi.org/10.1136/bmj.314.7085.947			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099121	Green Published			2022-12-28	WOS:A1997WQ16900029
J	Stollerman, GH				Stollerman, GH			Rheumatic fever	LANCET			English	Article							STREPTOCOCCAL M-PROTEIN; ACUTE GLOMERULONEPHRITIS; HEART-DISEASE; UNITED-STATES; INFECTIONS; CARDITIS; EPIDEMIOLOGY; IMMUNIZATION; AUTOIMMUNITY; PHARYNGITIS		BOSTON UNIV,DEPT MED,BOSTON,MA 02215	Boston University								ALBERT DA, 1995, MEDICINE, V74, P1, DOI 10.1097/00005792-199501000-00001; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BERRIOS X, 1993, ANN INTERN MED, V118, P401, DOI 10.7326/0003-4819-118-6-199303150-00001; BESSEN D, 1989, J EXP MED, V169, P269, DOI 10.1084/jem.169.1.269; Bessen DE, 1996, J INFECT DIS, V173, P896, DOI 10.1093/infdis/173.4.896; BESSEN DE, 1995, J INFECT DIS, V172, P1608, DOI 10.1093/infdis/172.6.1608; Bisno A.L., 1980, STREPTOCOCCAL DISEAS, P789; BISNO AI, 1977, J INFECT DIS, V136, P78; BISNO AL, 1970, NEW ENGL J MED, V283, P561, DOI 10.1056/NEJM197009102831103; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Bisno AL, 1996, PEDIATRICS, V97, P949; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; *CDC, 1987, MMWR-MORBID MORTAL W, V36, P108; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P519; CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998; Dale JB, 1996, VACCINE, V14, P944, DOI 10.1016/0264-410X(96)00050-3; DALE JB, 1995, J INFECT DIS, V171, P1038, DOI 10.1093/infdis/171.4.1038; DALE JB, IN PRESS STREPTOCOCC; DJANI A, 1995, PEDIATRICS, V96, P758; DJANI AS, 1993, CIRCULATION, V87, P302; FISCHETTI VA, IN PRESS STREPTOCOCC; GARY BM, 1991, BACTERIAL INFECT HUM, P652; HARTAS J, 1995, MICROB PATHOGENESIS, V18, P345, DOI 10.1006/mpat.1995.0031; KAPLAN EL, 1989, J INFECT DIS, V159, P101, DOI 10.1093/infdis/159.1.101; KAPLAN EL, 1993, CIRCULATION, V88, P1964, DOI 10.1161/01.CIR.88.4.1964; KHANNA AK, 1989, J CLIN INVEST, V83, P1710, DOI 10.1172/JCI114071; KRAUSE RM, 1962, J CLIN INVEST, V41, P575, DOI 10.1172/JCI104511; LAND MA, 1983, JAMA-J AM MED ASSOC, V249, P895, DOI 10.1001/jama.249.7.895; LITTLE PS, 1994, BRIT MED J, V309, P1010, DOI 10.1136/bmj.309.6960.1010; MARCUS RH, 1994, ANN INTERN MED, V120, P177, DOI 10.7326/0003-4819-120-3-199402010-00001; MAXTED WR, 1969, J MED MICROBIOL, V2, P199, DOI 10.1099/00222615-2-3-199; MCLAREN MJ, 1994, ANN INTERN MED, V120, P243, DOI 10.7326/0003-4819-120-3-199402010-00012; NARULA J, 1993, CIRCULATION, V88, P2198, DOI 10.1161/01.CIR.88.5.2198; PARKER MT, 1968, J HYG-CAMB, V66, P657, DOI 10.1017/S0022172400028394; PICHERERO ME, 1993, PEDIATR INFECT DIS J, V123, P268; POTTER EV, 1978, J PEDIATR-US, V92, P325, DOI 10.1016/S0022-3476(78)80036-5; PRUKSAKORN S, 1994, LANCET, V344, P639, DOI 10.1016/S0140-6736(94)92083-4; Rammelkamp C.H., 1952, RHEUMATIC FEVER, P72; RAMMELKAMP CH, 1952, T ASSOC AM PHYSICIAN, V65, P168; RAZ R, 1995, INFECT DIS CLIN PRAC, V4, P50, DOI 10.1097/00019048-199501000-00015; ROTHBARD S, 1948, J EXP MED, V87, P521, DOI 10.1084/jem.87.6.521; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; SIEGEL AC, 1961, NEW ENGL J MED, V265, P559, DOI 10.1056/NEJM196109212651201; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STOLLERMAN G, 1975, RHEUAMTIC FEVER STRE; Stollerman G H, 1990, Adv Intern Med, V35, P1; STOLLERMAN GH, 1995, HOSP PRACT, V30, P80, DOI 10.1080/21548331.1995.11443168; STOLLERMAN GH, 1995, LANCET, V346, P390, DOI 10.1016/S0140-6736(95)92776-X; STOLLERMAN GH, 1991, CLIN IMMUNOL IMMUNOP, V61, P131, DOI 10.1016/S0090-1229(05)80019-4; STOLLERMAN GH, 1992, HEART DIS TXB CARDIO, P1721; STOLLERMAN GH, 1996, MT SINAI J MED, V653, P144; TARANTA A, 1956, AM J MED, V20, P170, DOI 10.1016/0002-9343(56)90186-3; Taranta A, 1989, RHEUMATIC FEVER; Vasan RS, 1996, CIRCULATION, V94, P73, DOI 10.1161/01.CIR.94.1.73; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WANNAMAKER LW, 1970, NEW ENGL J MED, V282, P23, DOI 10.1056/NEJM197001082820206; WANNAMAKER LW, 1973, CIRCULATION, V48, P9, DOI 10.1161/01.CIR.48.1.9; WATANABEOHNISHI R, 1994, J IMMUNOL, V152, P2066; WILSON NJ, 1995, INT J CARDIOL, V50, P1, DOI 10.1016/0167-5273(95)02325-Q	59	171	177	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					935	942		10.1016/S0140-6736(96)06364-7	http://dx.doi.org/10.1016/S0140-6736(96)06364-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093263				2022-12-28	WOS:A1997WR25400045
J	Wyatt, JP; McLeod, L; Beard, D; Busuttil, A; Beattie, TF; Robertson, CE				Wyatt, JP; McLeod, L; Beard, D; Busuttil, A; Beattie, TF; Robertson, CE			Timing of paediatric deaths after trauma	BRITISH MEDICAL JOURNAL			English	Article									ROYAL EDINBURGH INFIRM,SCOTTISH TRAUMA AUDIT GRP,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,FORENS MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ROYAL EDINBURGH INFIRM,DEPT ACCID & EMERGENCY,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh	Wyatt, JP (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT ACCID & EMERGENCY MED,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND.							Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; *CHILD ACC PREV TR, 1989, BAS PRINC CHILD ACC; *SECR STAT HLTH, 1992, HLTH NAT, P102; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; WYATT J, 1995, BRIT MED J, V310, P1502, DOI 10.1136/bmj.310.6993.1502	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					868	868						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093097				2022-12-28	WOS:A1997WQ02800027
J	Jacobs, C; Frere, JM; Normark, S				Jacobs, C; Frere, JM; Normark, S			Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria	CELL			English	Article							CITROBACTER-FREUNDII AMPR; L-ALANINE AMIDASE; ESCHERICHIA-COLI; MUREIN HYDROLASES; DIVISION CYCLE; INDUCTION; EXPRESSION; REGULATOR; BINDING; PROTEIN	beta-lactam induction of chromosomal beta-lactamase in gram-negative bacteria requires the transcriptional regulator AmpR and the transport of murein breakdown products (muropeptides) into the cytoplasm. In vitro transcription shows that purified AmpR acts as an activator for ampC beta-lactamase synthesis. The murein precursor, UDP-MurNAc-pentapeptide, decreases AmpR-mediated transcriptional activation in vitro, but has no effect on an AmpR(G102E) mutant that mediates constitutive activation of ampC in vivo. Addition of the muropeptide, anhMurNAc-tripeptide, which accumulates in beta-lactamase-overproducing mutants, counteracts the negative effect of UDP-MurNAc-pentapeptide, restoring the innate ability of AmpR to induce ampC expression in vitro. Cytosolic intermediates of murein biosynthesis and degradation thus act antagonistically to control beta-lactamase expression, thereby operating as a cell-wall sensing device.	KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	Jacobs, C (corresponding author), UNIV LIEGE,CTR INGN PROT,INST CHEM,BATIMENT B6,B-4000 SART 1,BELGIUM.							BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BARTOWSKY E, 1991, MOL MICROBIOL, V5, P1715, DOI 10.1111/j.1365-2958.1991.tb01920.x; BECK BD, 1976, J BACTERIOL, V126, P1250, DOI 10.1128/JB.126.3.1250-1260.1976; BISHOP RE, 1993, EUR J BIOCHEM, V213, P405, DOI 10.1111/j.1432-1033.1993.tb17775.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DJORDJEVIC MA, 1987, EMBO J, V6, P1173, DOI 10.1002/j.1460-2075.1987.tb02351.x; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; GEIS A, 1978, BIOCHIM BIOPHYS ACTA, V527, P414, DOI 10.1016/0005-2744(78)90355-8; GOODELL EW, 1985, J BACTERIOL, V163, P305, DOI 10.1128/JB.163.1.305-310.1985; HAKENBECK R, 1977, J BACTERIOL, V129, P1239, DOI 10.1128/JB.129.3.1239-1244.1977; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HINKS RP, 1978, J BACTERIOL, V133, P822, DOI 10.1128/JB.133.2.822-829.1978; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; HOLTJE JV, 1994, FEMS MICROBIOL LETT, V122, P159, DOI 10.1111/j.1574-6968.1994.tb07159.x; JACOBS C, 1995, MOL MICROBIOL, V15, P553, DOI 10.1111/j.1365-2958.1995.tb02268.x; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; KORFMANN G, 1989, ANTIMICROB AGENTS CH, V33, P1946, DOI 10.1128/AAC.33.11.1946; LINDBERG F, 1987, J BACTERIOL, V169, P1923, DOI 10.1128/jb.169.5.1923-1928.1987; LINDBERG F, 1985, P NATL ACAD SCI USA, V82, P4620, DOI 10.1073/pnas.82.14.4620; LINDQUIST S, 1989, J BACTERIOL, V171, P3746, DOI 10.1128/jb.171.7.3746-3753.1989; LINDQUIST S, 1993, MOL MICROBIOL, V9, P703, DOI 10.1111/j.1365-2958.1993.tb01731.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MENGINLECREULX D, 1989, J BACTERIOL, V171, P3282, DOI 10.1128/jb.171.6.3282-3287.1989; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; NORMARK S, 1994, N COMP BIOC, V27, P485; OGAWA J, 1995, GENE DEV, V9, P714, DOI 10.1101/gad.9.6.714; OLIJHOEK AJM, 1982, J BACTERIOL, V152, P1248; OSTROWSKI J, 1990, J BACTERIOL, V172, P779, DOI 10.1128/jb.172.2.779-785.1990; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315	35	259	268	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					823	832		10.1016/S0092-8674(00)81928-5	http://dx.doi.org/10.1016/S0092-8674(00)81928-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118225	Bronze			2022-12-28	WOS:A1997WQ10000014
J	Rittmaster, RS				Rittmaster, RS			Hirsutism	LANCET			English	Review							CYPROTERONE-ACETATE; 21-HYDROXYLASE DEFICIENCY; SPIRONOLACTONE THERAPY; ADRENAL-HYPERPLASIA; WOMEN; HYPERANDROGENISM; FLUTAMIDE; HAIR; FINASTERIDE; ESTROGEN				Rittmaster, RS (corresponding author), DALHOUSIE UNIV, DEPT MED, 5303 MORRIS ST, HALIFAX, NS B3J 1B6, CANADA.							AZZIZ R, 1995, J CLIN ENDOCR METAB, V80, P3406, DOI 10.1210/jc.80.12.3406; AZZIZ R, 1989, J CLIN ENDOCR METAB, V69, P577, DOI 10.1210/jcem-69-3-577; CHETKOWSKI RJ, 1984, J CLIN ENDOCR METAB, V58, P595, DOI 10.1210/jcem-58-4-595; CROSBY PDA, 1991, FERTIL STERIL, V55, P1076; CUSAN L, 1994, FERTIL STERIL, V61, P281; DUNAIF A, 1991, J CLIN ENDOCR METAB, V73, P590, DOI 10.1210/jcem-73-3-590; DUNAIF A, 1992, ENDOCRINOLOGIST, V2, P248; EIL C, 1984, J CLIN ENDOCR METAB, V59, P51, DOI 10.1210/jcem-59-1-51; ERENUS M, 1994, FERTIL STERIL, V61, P613; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; GROVES TD, 1995, AM J OBSTET GYNECOL, V172, P1655, DOI 10.1016/0002-9378(95)90549-9; HEINER JS, 1995, J CLIN ENDOCR METAB, V80, P3412, DOI 10.1210/jc.80.12.3412; HELFER EL, 1988, J CLIN ENDOCR METAB, V66, P208, DOI 10.1210/jcem-66-1-208; LOBO RA, 1985, FERTIL STERIL, V43, P200; LUNDE O, 1984, AM J PHYS ANTHROPOL, V64, P179, DOI 10.1002/ajpa.1330640211; MAUVAISJARVIS P, 1986, CLIN ENDOCRINOL META, V15, P307, DOI 10.1016/S0300-595X(86)80027-5; MCKNIGHT E, 1964, LANCET, V1, P410; MILLER JA, 1986, CLIN ENDOCRINOL META, V15, P373, DOI 10.1016/S0300-595X(86)80031-7; NEW MI, 1989, METABOLIC BASIS INHE, P1881; OBRIEN RC, 1991, J CLIN ENDOCR METAB, V72, P1008, DOI 10.1210/jcem-72-5-1008; RITTMASTER RS, 1994, NEW ENGL J MED, V330, P120; RITTMASTER RS, 1993, CLIN OBSTET GYNECOL, V36, P679, DOI 10.1097/00003081-199309000-00024; RITTMASTER RS, 1991, INFERTIL REPROD MED, V2, P511; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SPRITZER P, 1990, J CLIN ENDOCR METAB, V70, P642, DOI 10.1210/jcem-70-3-642; STEINBERGER E, 1990, BAILLIERE CLIN OB GY, V4, P457, DOI 10.1016/S0950-3552(05)80304-9; TAGATZ GE, 1979, OBSTET GYNECOL, V54, P562; UNO H, 1986, SEMIN REPROD ENDOCR, V4, P131, DOI 10.1055/s-2007-1022494; WONG IL, 1995, J CLIN ENDOCR METAB, V80, P233, DOI 10.1210/jc.80.1.233; WYSOWSKI DK, 1994, FERTIL STERIL, V62, P1089	30	65	69	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1997	349	9046					191	195		10.1016/S0140-6736(96)07252-2	http://dx.doi.org/10.1016/S0140-6736(96)07252-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111556				2022-12-28	WOS:A1997WC86100045
J	Rao, SC; Rainer, G; Miller, EK				Rao, SC; Rainer, G; Miller, EK			Integration of what and where in the primate prefrontal cortex	SCIENCE			English	Article							INFERIOR TEMPORAL CORTEX; SHORT-TERM-MEMORY; RHESUS-MONKEYS; UNIT-ACTIVITY; TASK; PERFORMANCE; PROJECTIONS; PARIETAL; NEURONS	The visual system separates processing of an object's form and color (''what'') from its spatial location (''where''). In order to direct action to objects, the identity and location of those objects must somehow be integrated. To examine whether this process occurs within the prefrontal (PF) cortex, the activity of 195 PF neurons was recorded during a task that engaged both what and where working memory. Some neurons showed either object-tuned (what) or location-tuned (where) delay activity. However, over half (52 percent, or 64/123) of the PF neurons with delay activity showed both what and where tuning. These neurons may contribute to the linking of object information with the spatial information needed to guide behavior.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Rainer, Gregor/B-5876-2012; Miller, Earl K./AAE-8187-2019	Miller, Earl K./0000-0002-0582-6958; Rainer, Gregor/0000-0002-5805-2220				Baddeley A.D., 1986, WORKING MEMORY THOUG; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BRAVER TS, 1995, P COGNIT NEUROSCI SO, V2, P95; Bullier J, 1996, BEHAV BRAIN RES, V76, P89, DOI 10.1016/0166-4328(95)00182-4; Courtney SM, 1996, CEREB CORTEX, V6, P39, DOI 10.1093/cercor/6.1.39; DIPELLEGRINO G, 1993, J NEUROSCI, V13, P227; FERRERA VP, 1994, J NEUROSCI, V14, P6171; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; FUSTER JM, 1982, EXP NEUROL, V77, P679, DOI 10.1016/0014-4886(82)90238-2; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; Fuster JM, 1995, MEMORY CEREBRAL CORT; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MILLER EK, 1993, J NEUROSCI, V13, P1460; Miller EK, 1996, J NEUROSCI, V16, P5154; Perecman E., 1987, FRONTAL LOBES REVISI, P41; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057, DOI 10.1152/jn.1992.67.5.1057; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SERENO AB, 1995, INVEST OPHTH VISUAL, V36, P692; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1989, EXP BRAIN RES, V76, P473, DOI 10.1007/BF00248903; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	25	613	619	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					821	824		10.1126/science.276.5313.821	http://dx.doi.org/10.1126/science.276.5313.821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115211				2022-12-28	WOS:A1997WW90000065
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			A 76-year-old woman considering total hip replacement, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Callaghan JJ, 1996, JAMA-J AM MED ASSOC, V276, P486	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1314	1314						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109471				2022-12-28	WOS:A1997WU13500033
J	Chen, CC; Herhold, AB; Johnson, CS; Alivisatos, AP				Chen, CC; Herhold, AB; Johnson, CS; Alivisatos, AP			Size dependence of structural metastability in semiconductor nanocrystals	SCIENCE			English	Article							HIGH-PRESSURE PHASE; ROCK-SALT PHASE; CDSE NANOCRYSTALS; TRANSITION; WURTZITE; TRANSFORMATION; NITRIDE; SURFACE; GAP	The kinetics of a first-order, solid-solid phase transition were investigated in the prototypical nanocrystal system CdSe as a function of crystallite size. In contrast to extended solids, nanocrystals convert from one structure to another by single nucleation events, and the transformations obey simple unimolecular kinetics. Barrier heights were observed to increase with increasing nanocrystal size, although they also depend on the nature of the nanocrystal surface. These results are analogous to magnetic phase transitions in nanocrystals and suggest general rules that may be of use in the discovery of new metastable phases.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Alivisatos, Paul/N-8863-2015; Chen, Chia-Chun/F-7939-2012	Alivisatos, Paul/0000-0001-6895-9048; 				AWSCHALOM DD, 1995, PHYS TODAY, V48, P43, DOI 10.1063/1.881448; BARNETT JD, 1973, REV SCI INSTRUM, V44, P1, DOI 10.1063/1.1685943; BESSON JM, 1991, PHYS REV B, V44, P4214, DOI 10.1103/PhysRevB.44.4214; BODKER F, 1994, PHYS REV LETT, V72, P282, DOI 10.1103/PhysRevLett.72.282; Brus LE, 1996, J AM CHEM SOC, V118, P4834, DOI 10.1021/ja954166p; Chen C., UNPUB; CHEN JP, 1995, PHYS REV B, V51, P11527, DOI 10.1103/PhysRevB.51.11527; EDWARDS AL, 1961, PHYS REV, V122, P1149, DOI 10.1103/PhysRev.122.1149; GOLDSTEIN AN, 1992, SCIENCE, V256, P1425, DOI 10.1126/science.256.5062.1425; HERRON N, 1993, SCIENCE, V259, P1426, DOI 10.1126/science.259.5100.1426; JAMIESON JC, 1963, SCIENCE, V139, P762, DOI 10.1126/science.139.3556.762; KATARI JEB, 1994, J PHYS CHEM-US, V98, P4109, DOI 10.1021/j100066a034; LI T, 1995, PHYS REV LETT, V74, P5232, DOI 10.1103/PhysRevLett.74.5232; LIN J, 1994, J AM CHEM SOC, V116, P4738, DOI 10.1021/ja00090a021; MIZUSHIMA K, 1994, PHYS REV B, V50, P14952, DOI 10.1103/PhysRevB.50.14952; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Neel L., 1949, ANN GEOPHYS, V5, P99; NGUYEN JH, 1993, REV SCI INSTRUM, V64, P3456, DOI 10.1063/1.1144267; ONODERA A, 1969, REV PHYS CHEM JPN, V39, P65; SHIANG JJ, 1995, J PHYS CHEM-US, V99, P17417, DOI 10.1021/j100048a017; STONER EC, 1948, PHILOS TR R SOC S-A, V240, P599, DOI 10.1098/rsta.1948.0007; TOLBERT SH, 1994, PHYS REV LETT, V73, P3266, DOI 10.1103/PhysRevLett.73.3266; TOLBERT SH, 1995, J CHEM PHYS, V102, P4642, DOI 10.1063/1.469512; Tolbert SH, 1996, PHYS REV LETT, V76, P4384, DOI 10.1103/PhysRevLett.76.4384; TOLBERT SH, 1995, ANNU REV PHYS CHEM, V46, P595, DOI 10.1146/annurev.pc.46.100195.003115; TOLBERT SH, 1994, SCIENCE, V265, P373, DOI 10.1126/science.265.5170.373; TURNBULL D, 1952, J CHEM PHYS, V20, P411, DOI 10.1063/1.1700435; TURNBULL D, 1956, SOLID STATE PHYS, V3, P225; VENKATESWARAN UD, 1992, PHYS REV B, V45, P9237, DOI 10.1103/PhysRevB.45.9237; WEINSTEIN BA, 1975, PHYS REV B, V12, P1172, DOI 10.1103/PhysRevB.12.1172; XIA H, 1993, PHYS REV B, V47, P12925, DOI 10.1103/PhysRevB.47.12925; XIA Q, 1993, J APPL PHYS, V73, P8198, DOI 10.1063/1.353435; Xie Y, 1996, SCIENCE, V272, P1926, DOI 10.1126/science.272.5270.1926; YU WC, 1971, MATER RES BULL, V6, P621, DOI 10.1016/0025-5408(71)90011-0	34	522	529	5	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					398	401		10.1126/science.276.5311.398	http://dx.doi.org/10.1126/science.276.5311.398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103194				2022-12-28	WOS:A1997WU47700034
J	Mahler, H; Pasi, A; Kramer, JM; Schulte, P; Scoging, AC; Bar, W; Krahenbuhl, S				Mahler, H; Pasi, A; Kramer, JM; Schulte, P; Scoging, AC; Bar, W; Krahenbuhl, S			Fulminant liver failure in association with the emetic toxin of Bacillus cereus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEP-2 CELL; TRANSPLANTATION; HEPATOTOXICITY; INHIBITION; METABOLISM; OXIDATION; PATIENT; ACID	Background A 17-year-old boy and his father had acute gastroenteritis after eating spaghetti and pesto that had been prepared four days earlier. Within two days, fulminant liver failure and rhabdomyolysis developed in the boy and he died. The father had hyperbilirubinemia and rhabdomyolysis but recovered. We investigated the cause of these illnesses. Methods Bacteria were isolated and characterized by conventional methods, and bacterial toxins were quantified by immunoassays and cell-culture techniques. The effect of the isolated toxin on the rates of oxidation of various substrates was analyzed in rat-liver mitochondria. Results Autopsy of the boy's liver revealed diffuse microvesicular steatosis and midzonal necrosis that suggested impaired beta-oxidation of liver mitochondria due to a mitochondrial toxin. There was no evidence of ingestion of heavy metals, halogenated compounds, hepatotoxic drugs, or staphylococcal enterotoxin. However, high concentrations of Bacillus cereus emetic toxin were found both in the residue from the pan used to reheat the food and in the boy's liver and bile. B. cereus was cultured from the intestinal contents and the pan residue. The emetic toxin isolated from the B. cereus cultures was found to be a mitochondrial toxin. Conclusions Fulminant liver failure developed after the ingestion of food contaminated with the B. cereus emetic toxin, The toxin inhibits hepatic mitochondrial fatty-acid oxidation, indicating that it caused liver failure in this patient. (C) 1997, Massachusetts Medical Society.	UNIV ZURICH,INST LEGAL MED,GRP MED TOXICOL,ENDORPHIN RES LABS,CH-8057 ZURICH,SWITZERLAND; UNIV DUSSELDORF,INST LEGAL MED,D-4000 DUSSELDORF,GERMANY; CENT PUBL HLTH LAB,FOOD HYG LAB,LONDON NW9 5HT,ENGLAND; UNIV ZURICH HOSP,DEPT INTERNAL MED,DIV CLIN PHARMACOL & TOXICOL,ZURICH,SWITZERLAND	University of Zurich; Heinrich Heine University Dusseldorf; Public Health England; University of Zurich; University Zurich Hospital			Krähenbühl, Stephan/Z-4744-2019					Agata N, 1996, CURR MICROBIOL, V33, P67, DOI 10.1007/s002849900076; AGATA N, 1994, FEMS MICROBIOL LETT, V121, P31, DOI 10.1016/0378-1097(94)90141-4; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BOUWERHERTZBERG.SA, 1982, ISOLATION IDENTIFICA, P255; CARACENI P, 1995, LANCET, V345, P163, DOI 10.1016/S0140-6736(95)90171-X; COHEN ML, 1978, NEW ENGL J MED, V299, P459, DOI 10.1056/NEJM197808312990906; DESCHAMPS D, 1991, J PHARMACOL EXP THER, V259, P894; DIRNHOFER R, 1977, Z RECHTSMED, V80, P139, DOI 10.1007/BF01160201; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FERMANIAN C, 1993, J RAPID METH AUT MIC, V2, P83, DOI DOI 10.1111/J.1745-4581.1993.TB00282.X; FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6; Hennessy TW, 1996, NEW ENGL J MED, V334, P1281, DOI 10.1056/NEJM199605163342001; HOPPEL C, 1979, J BIOL CHEM, V254, P4164; HUGHES S, 1988, FEMS MICROBIOL LETT, V52, P7, DOI 10.1016/S0378-1097(97)00175-4; *INT COMM MICR SPE, 1978, MICR FOODS, V1, P119; KLEIN AS, 1989, AM J MED, V86, P187, DOI 10.1016/0002-9343(89)90267-2; KOPPEL C, 1993, TOXICON, V31, P1513, DOI 10.1016/0041-0101(93)90337-I; KRAHENBUHL S, 1994, HEPATOLOGY, V19, P1272, DOI 10.1016/0270-9139(94)90877-X; KRAHENBUHL S, 1995, GUT, V37, P140, DOI 10.1136/gut.37.1.140; Kramer J. M., 1989, Foodborne bacterial pathogens., P21; Kramer J. M., 1982, ISOLATION IDENTIFICA, P261; LEVY G, 1982, NEW ENGL J MED, V307, P676, DOI 10.1056/NEJM198209093071109; MEUNIER B, 1994, LIVER, V14, P158, DOI 10.1111/j.1600-0676.1994.tb00066.x; MICHELOT D, 1991, J APPL TOXICOL, V11, P235, DOI 10.1002/jat.2550110403; MOWAT AP, 1987, ADVERSE DRUG REACT T, V6, P211; SAKURAI N, 1994, MICROBIOL IMMUNOL, V38, P337, DOI 10.1111/j.1348-0421.1994.tb01788.x; SANDVIG K, 1982, J BIOL CHEM, V257, P7495; TAKABE F, 1976, Forensic Science, V7, P97, DOI 10.1016/0300-9432(76)90024-8; Temper K., 1963, Z GESAMTE HYG GRENZG, V9, P481; TERRANOVA W, 1978, NEW ENGL J MED, V298, P143, DOI 10.1056/NEJM197801192980306; TREEM WR, 1994, SEMIN LIVER DIS, V14, P236, DOI 10.1055/s-2007-1007315	31	274	283	2	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1142	1148		10.1056/NEJM199704173361604	http://dx.doi.org/10.1056/NEJM199704173361604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099658	Bronze			2022-12-28	WOS:A1997WU00300004
J	Karpf, DB; Shapiro, DR; Seeman, E; Ensrud, KE; Johnston, CC; Adami, S; Harris, ST; Santora, AC; Hirsch, LJ; Oppenheimer, L; Thompson, D				Karpf, DB; Shapiro, DR; Seeman, E; Ensrud, KE; Johnston, CC; Adami, S; Harris, ST; Santora, AC; Hirsch, LJ; Oppenheimer, L; Thompson, D			Prevention of nonvertebral fractures by alendronate - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	17th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research	SEP 09-13, 1995	BALTIMORE, MD	Amer Soc Bone & Mineral Res			POSTMENOPAUSAL OSTEOPOROSIS; BONE MASS; ELDERLY WOMEN; BIOCHEMICAL MARKERS; ORAL ALENDRONATE; HIP-FRACTURES; THERAPY; TURNOVER; FLUORIDE; CALCIUM	Objective.-To evaluate the effect of treatment with alendronate sodium, a potent aminobisphosphonate, on the incidence of nonvertebral fractures in postmenopausal women with osteoporosis. Data Sources.-Published data and data on fi le at Merck Research Laboratories. Study Selection.-All completed prospective, randomized, placebo-controlled alendronate trials of at least 2 years' duration (5 studies). Data Extraction.-All subjects were women with osteoporosis between the ages of 42 and 85 years, postmenopausal at least 4 years, with lumbar spine bone mineral density (measured using dual-energy x-ray absorptiometry) at least 2.0 SD below the mean for young adult women. All women randomized to treatment with placebo or alendronate at a dose higher than 1 mg per day for at least 2 years were included. Data Synthesis.-In the placebo group (n=590), 60 women reported nonvertebral fractures during 1347 patient-years at risk (overall rate, 4.45 women with fractures per 100 patient-years at risk), In the alendronate group (n=1012), 73 women reported nonvertebral fractures during 2240 patient-years at risk (overall rate, 3.26 women with fractures per 100 patient-years at risk). The estimated cumulative incidence of nonvertebral fractures after 3 years was 12.6% in the placebo group and 9.0% in alendronate group. The relative risk for nonvertebral fracture estimated using the Cox proportional hazards model was 0.71 (95% confidence interval, 0.502-0.997) (P=.048). A reduction in risk was consistent across each of the studies and at each major site of osteoporotic fracture, including the hip and wrist. Conclusion.-In postmenopausal women with osteoporosis, treatment with alendronate reduces the risk of nonvertebral fractures over at least 3 years.	MERCK RES LABS,RAHWAY,NJ 07065; AUSTIN HOSP,HEIDELBERG,VIC 3084,AUSTRALIA; UNIV MINNESOTA,MINNEAPOLIS,MN 55455; VET ADM MED CTR,MINNEAPOLIS,MN; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN; CTR OSPED CLINICIZZATO VALEGGIO,VERONA,ITALY; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	Merck & Company; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California San Francisco			Seeman, Ego/AAC-3656-2019	Seeman, Ego/0000-0002-9692-048X; Ensrud, Kristine/0000-0002-9069-3036				ADAMI S, 1995, BONE, V17, P383, DOI 10.1016/S8756-3282(95)00262-6; ARLOT MC, 1995, J BONE MINER RES, V10, pS199; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BLACK DM, 1993, OSTEOPOROSIS INT, V3, P29; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002-9343(99)80134-X; CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1990, CLIN ORTHOPAEDICS, V252, P163; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; *NAT OST FDN WORK, 1995, J BONE MINER RES, V10, P518; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; PAK CYC, 1995, ANN INTERN MED, V123, P401, DOI 10.7326/0003-4819-123-6-199509150-00001; PHILLIPS S, 1988, BONE, V9, P271, DOI 10.1016/8756-3282(88)90009-9; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEINSTEIN RS, 1994, J BONE MINER RES  S1, V9, pS144; 1987, BRIT MED J, V295, P914	34	230	235	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1159	1164						6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087473				2022-12-28	WOS:A1997WR34200037
J	Campbell, H; Gibson, A				Campbell, H; Gibson, A			Health targets in the NHS: Lessons learned from experience with breast feeding targets in Scotland	BRITISH MEDICAL JOURNAL			English	Article							SERVICE SUPPORT; CHILDREN; MILK; SUCCESS		MARKINCH CLIN,FIFE HEALTHCARE NHS TRUST,MARKINCH KY7 6AA,FIFE,SCOTLAND		Campbell, H (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Campbell, Harry/E-2959-2010	Campbell, Harry/0000-0002-6169-6262				BEEKEN S, 1992, BRIT MED J, V305, P285, DOI 10.1136/bmj.305.6848.285; BRUCE NG, 1991, PUBLIC HEALTH, V105, P357, DOI 10.1016/S0033-3506(05)80595-5; Campbell H, 1995, J PUBLIC HEALTH MED, V17, P450; CAMPBELL H, 1994, BREAST FEEDING SCOTL; CATFORD JC, 1991, BRIT MED J, V302, P980, DOI 10.1136/bmj.302.6783.980; Chalmers J W, 1991, Midwifery, V7, P162, DOI 10.1016/S0266-6138(05)80194-9; *COMM SERV AG INF, 1989, HLTH ALL YEAR 2000 T; *DEP HLTH, 1991, HLTH NAT CONS DOC H; ENDERSON EH, 1995, ACTA PAEDIAT, V84, P719; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; FERGUSON AE, 1994, BRIT MED J, V308, P824, DOI 10.1136/bmj.308.6932.824; FLOREY CV, 1995, INT J EPIDEMIOL, V24, P521; FRANK DA, 1987, PEDIATRICS, V80, P845; GLASS RI, 1983, NEW ENGL J MED, V308, P1389, DOI 10.1056/NEJM198306093082304; GROSSMAN LK, 1990, AM J DIS CHILD, V144, P471, DOI 10.1001/archpedi.1990.02150280093019; HELDING E, 1990, INT J GYN OBS S1, V31, P69; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JACOBSON B, 1991, NATIONS HLTH STRATEG; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; *MAN EX, 1994, MEL1994110 MAN EX SC; MOSETLANSON A, 1994, BREAT FEEDING SHOULD; NARAYAN I, 1984, LANCET, V2, P111; *NAT AUD OFF, 1996, HLTH NAT PROGR REP; *NEW ZEAL GOV, 1989, NEW REL; Neyzi O, 1991, Paediatr Perinat Epidemiol, V5, P299, DOI 10.1111/j.1365-3016.1991.tb00714.x; *NHS MAN EX, 1993, HLTH NAT LOC TARG SE; PEREZESCAMILLA R, 1994, AM J PUBLIC HEALTH, V84, P89, DOI 10.2105/AJPH.84.1.89; RIGHARD L, 1990, LANCET, V336, P1105, DOI 10.1016/0140-6736(90)92579-7; Scottish Office, 1992, SCOTL HLTH CHALL US; VICTORA CG, 1989, INT J EPIDEMIOL, V18, P918, DOI 10.1093/ije/18.4.918; WHITE AS, 1992, INFANT FEEDING 1990; WHO World Health Organisation, 1985, TARG HLTH ALL; WILLIAMS SP, 1992, BRIT MED J, V305, P522, DOI 10.1136/bmj.305.6852.522-c; *WORK PART CHIEF M, 1993, SCOTT DIET; YAMAUCHI Y, 1990, ACTA PAEDIATR SCAND, V79, P1017, DOI 10.1111/j.1651-2227.1990.tb11377.x	36	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1030	1033		10.1136/bmj.314.7086.1030	http://dx.doi.org/10.1136/bmj.314.7086.1030			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112851	Green Published			2022-12-28	WOS:A1997WT15200030
J	Nudler, E; Mustaev, A; Lukhtanov, E; Goldfarb, A				Nudler, E; Mustaev, A; Lukhtanov, E; Goldfarb, A			The RNA-DNA hybrid maintains the register of transcription by preventing backtracking of RNA polymerase	CELL			English	Article							ESCHERICHIA-COLI; TERNARY COMPLEXES; 3-DIMENSIONAL STRUCTURE; ELONGATION COMPLEXES; CHAIN ELONGATION; TERMINATION; CLEAVAGE; ENZYME; CONFORMATIONS; INITIATION	An 8-9 bp RNA-DNA hybrid in the transcription elongation complex is essential for keeping the RNA 3' terminus engaged with the active site of E. coli RNA polymerase (RNAP). Destabilization of the hybrid leads to detachment of the transcript terminus, RNAP backtracking, and shifting of the hybrid upstream. Eventually, the exposed 3' segment of RNA can be removed through transcript cleavage. At certain sites, cycles of unwinding-rewinding of the hybrid are coupled to reverse-forward sliding of the transcription elongation complex. This explains apparent discontinuous elongation, which was previously interpreted as contraction and expansion of an RNAP molecule (inch-worming). Thus, the 3'-proximal RNA-DNA hybrid plays the dual role of keeping the active site in register with the template and sensing the helix-destabilizing mismatches in RNA, launching correction through backtracking and cleavage.	EPOCH PHARMACEUT INC, BOTHELL, WA 98021 USA		Nudler, E (corresponding author), PUBL HLTH RES INST, NEW YORK, NY 10016 USA.			Nudler, Evgeny/0000-0002-8811-3071	NIGMS NIH HHS [GM49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BUROVA E, 1995, J BACTERIOL, V177, P1388, DOI 10.1128/jb.177.5.1388-1392.1995; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Chan Cathleen L., 1994, V3, P297; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; Gall A. A., 1979, IZV SIB OTD AN KHIM, V4, P99; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KOMISARROVA N, 1997, IN PRESS P NATL ACAD, V94; KOMISARROVA N, 1997, IN PRESS J BIOL CHEM, V272; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MASON SW, 1992, J BIOL CHEM, V267, P19418; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; PLATT T, 1997, IN PRESS RNA STRUCTU; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WIEST DK, 1992, J BIOL CHEM, V267, P7733; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	53	358	364	3	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					33	41		10.1016/S0092-8674(00)80180-4	http://dx.doi.org/10.1016/S0092-8674(00)80180-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094712	Bronze			2022-12-28	WOS:A1997WR68500007
J	Visser, M				Visser, M			Energy conditions in the epoch of galaxy formation	SCIENCE			English	Article								The energy conditions of Einsteinian gravity (classical general relativity) do not require one to fix a specific equation of state. In a Friedmann-Robertson-Walker universe where the equation of state for the cosmological fluid is uncertain, the energy conditions provide simple, model-independent, and robust bounds on the behavior of the density and look-back time as a function of red shift. Current observations suggest that the ''strong energy condition'' was violated sometime between the epoch of galaxy formation and the present. This implies that no possible combination of ''normal'' matter is capable of fitting the observational data.			Visser, M (corresponding author), WASHINGTON UNIV,DEPT PHYS,ST LOUIS,MO 63130, USA.		Visser, Matt/Q-5084-2019	Visser, Matt/0000-0003-1088-6485				Birrell N. D., 1982, Quantum fields in curved space; Fulling, 1989, ASPECTS QUANTUM FIEL; Hawkind S.W, 1973, LARGE SCALE STRUCTUR, P95; Hawking S. W., 1987, 300 YEARS GRAVITATIO; HAWKING SW, 1973, LARGE SCALE STRUCTUR, P88; HAWKING SW, 1973, LARE SCALE STRUCTURE, P263; HAWKING SW, 1979, GENERAL RELATIVITY E; KOLB EW, 1990, EARLY UNIVERSE; LEONARD S, 1995, ASTROPHYS J, V441, pL55, DOI 10.1086/187788; Linde A. D., 1990, INFLATION QUANTUM CO; Moss I. G., 1996, QUANTUM THEORY BLACK; *PART DAT GROUP, 1996, PHYS REV D, V54, P112; PEEBLES PJ, 1972, GRAVITATION COSMOLOG, P433; PEEBLES PJE, 1993, PRINCIPLES PHYSICAL, P106; PEEBLES PJE, 1993, PRINICPLES PHYSICAL; VISSER M, 1995, LORENTZIAN WORMHOLES, P128; VISSER M, 1995, LORENTZIAN WORMHOLES, P118; VISSER M, 1995, LORENTZIAN WORMHOLES, P121; VISSER M, 1995, LORENTIZAN WORMHOLES, P120; VISSER M, 1995, LORENTZIAN WORMHOLES, P53; VISSER M, 1995, LORENTZIAN WORMHOLES, P115; WALD RM, 1984, GEN RELAT GRAVIT, P226; WALD RM, 1984, GEN RELAT GRAVIT, P218; WEINBERG S, 1972, GRAVITATION COSMOLOG, P412; WEINBERG S, 1972, GRAVITATION COSMOLOG, P441	25	118	122	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					88	90		10.1126/science.276.5309.88	http://dx.doi.org/10.1126/science.276.5309.88			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082991	Green Submitted			2022-12-28	WOS:A1997WR38600050
J	Pahlman, L; Glimelius, B; Cedermark, B; Lundell, G; Rubio, C; Rutqvist, LE; Wilking, N; Ost, A; Brismar, B; Ewerth, S; Forsgren, L; Johansson, C; Magnusson, I; Sundelin, P; Svensson, C; Tornberg, B; Theve, T; Fenyo, G; Svensson, SO; Goldman, S; Molin, K; Bark, S; Sundblad, M; Dalen, J; Lindholmer, C; Robertsson, B; Ohman, U; Nilsson, SE; Dahlberg, M; Graf, W; JanssonFrykholm, G; Lindmark, G; Westman, M; Liljeholm, H; Bendtsen, O; Ljungquist, U; Nihlberg, A; Heuman, R; Lorentz, T; BisgaardPedersen, A; Bergstrom, S; Krog, M; Tuvesson, T; Edman, P; Lindstrom, C; Sandhammar, B; Tyden, G; Bergman, L; Enander, LK; Underskog, I; Sellstrom, H; Armatys, P; Moell, P; Hellberg, R; Stenstam, B; Dafnis, G; Hojer, H; Baldetorp, L; Hatschek, T; Sjodahl, R; Arbman, G; Nilsson, E; StorgrenFordell, V; Hugander, A; Lagerberg, F; Simert, G; delaRue, RA; Aldman, A; Lannerstad, O; Gullstrand, P; Arwidi, A; Bohe, M; Ekelund, G; Jiborn, H; Landberg, T; Graffman, S; Jansson, O; Jeppson, B; Sorbris, R; Ohlsson, E; Lenninger, S; Hallden, K; Norryd, C; Adamsen, S; Hultborn, R; Nilsson, S; Magnusson, O; Soderberg, HE; Lindberg, B; Tveit, E; Jansson, R; Svensson, JH; Gustafsson, A; Almskog, B; Salander, H; Holmlund, D; Filipsson, S; Laino, R; Athlin, L; Bengtsson, NO; Groman, G; Lundegard, G; Dedorson, S; Henriksson, G; Nordahl, A; Ryd, G; Edlund, G; Svensson, JO; Rutegard, J; Fagerberg, M; Edin, K				Pahlman, L; Glimelius, B; Cedermark, B; Lundell, G; Rubio, C; Rutqvist, LE; Wilking, N; Ost, A; Brismar, B; Ewerth, S; Forsgren, L; Johansson, C; Magnusson, I; Sundelin, P; Svensson, C; Tornberg, B; Theve, T; Fenyo, G; Svensson, SO; Goldman, S; Molin, K; Bark, S; Sundblad, M; Dalen, J; Lindholmer, C; Robertsson, B; Ohman, U; Nilsson, SE; Dahlberg, M; Graf, W; JanssonFrykholm, G; Lindmark, G; Westman, M; Liljeholm, H; Bendtsen, O; Ljungquist, U; Nihlberg, A; Heuman, R; Lorentz, T; BisgaardPedersen, A; Bergstrom, S; Krog, M; Tuvesson, T; Edman, P; Lindstrom, C; Sandhammar, B; Tyden, G; Bergman, L; Enander, LK; Underskog, I; Sellstrom, H; Armatys, P; Moell, P; Hellberg, R; Stenstam, B; Dafnis, G; Hojer, H; Baldetorp, L; Hatschek, T; Sjodahl, R; Arbman, G; Nilsson, E; StorgrenFordell, V; Hugander, A; Lagerberg, F; Simert, G; delaRue, RA; Aldman, A; Lannerstad, O; Gullstrand, P; Arwidi, A; Bohe, M; Ekelund, G; Jiborn, H; Landberg, T; Graffman, S; Jansson, O; Jeppson, B; Sorbris, R; Ohlsson, E; Lenninger, S; Hallden, K; Norryd, C; Adamsen, S; Hultborn, R; Nilsson, S; Magnusson, O; Soderberg, HE; Lindberg, B; Tveit, E; Jansson, R; Svensson, JH; Gustafsson, A; Almskog, B; Salander, H; Holmlund, D; Filipsson, S; Laino, R; Athlin, L; Bengtsson, NO; Groman, G; Lundegard, G; Dedorson, S; Henriksson, G; Nordahl, A; Ryd, G; Edlund, G; Svensson, JO; Rutegard, J; Fagerberg, M; Edin, K			Improved survival with preoperative radiotherapy in resectable rectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL TISSUE REACTION; A-WEEK FRACTIONATION; ADJUVANT THERAPY; POSTOPERATIVE RADIOTHERAPY; RANDOMIZED MULTICENTER; RECTOSIGMOID CARCINOMA; HUMAN-SKIN; IRRADIATION; TRIAL; ADENOCARCINOMA	Background Adjuvant radiotherapy for rectal cancer has been extensively studied, but no trial has unequivocally demonstrated improved overall survival with radiotherapy, despite a reduction in the rate of local recurrence. Methods Between March 1987 and February 1990, we randomly assigned 1168 patients younger than 80 years of age who had resectable rectal cancer to undergo preoperative irradiation (25 Gy delivered in five fractions in one week) followed by surgery within one week or to have surgery alone. Results The irradiation did not increase postoperative mortality. After five years of follow-up, the rate of local recurrence was 11 percent (63 of 553 patients) in the group that received radiotherapy before surgery and 27 percent (150 of 557) in the group treated with surgery alone (P<0.001). This difference was found in all subgroups defined according to Dukes' stage. The overall five-year survival rate was 58 percent in the radiotherapy-plus-surgery group and 48 percent in the surgery-alone group (P=0.004). The cancer-specific survival rates at nine years among patients treated with curative resection were 74 percent and 65 percent, respectively (P=0.002). Conclusions A short-term regimen of high-dose preoperative radiotherapy reduces rates of local recurrence and improves survival among patients with resectable rectal cancer. (C) 1997, Massachusetts Medical Society.	KAROLINSKA HOSP, S-10401 STOCKHOLM, SWEDEN; HUDDINGE HOSP, S-14186 HUDDINGE, SWEDEN; DANDERYD HOSP, S-18288 DANDERYD, SWEDEN; SODERSJUKHUSET HOSP, STOCKHOLM, SWEDEN; SABBATSBERGS HOSP, S-11382 STOCKHOLM, SWEDEN; NACKA SJUKHUS, NACKA, SWEDEN; LOWENSTROMSKA HOSP, UPPLANDS VASBY, SWEDEN; VISBY HOSP, VISBY, SWEDEN; ST GORANS UNIV HOSP, STOCKHOLM, SWEDEN; SODERTALJE HOSP, SODERTALJE, SWEDEN; NORRTALJE HOSP, NORRTALJE, SWEDEN; AKAD HOSP, UPPSALA, SWEDEN; SAMARITERHEMMET HOSP, UPPSALA, SWEDEN; ENKOPING HOSP, ENKOPING, SWEDEN; FALUN CENT HOSP, FALUN, SWEDEN; MORA HOSP, MORA, SWEDEN; LUDVIKA HOSP, LUDVIKA, SWEDEN; AVESTA HOSP, AVESTA, SWEDEN; GAVLE CENT HOSP, S-80187 GAVLE, SWEDEN; SANDVIKEN HOSP, SANDVIKEN, SWEDEN; SODERHAMN HOSP, SODERHAMN, SWEDEN; BOLLNAS HOSP, BOLLNAS, SWEDEN; HUDIKSVALL HOSP, HUDIKSVALL, SWEDEN; KARLSTAD HOSP, KARLSTAD, SWEDEN; SAFFLE HOSP, SAFFLE, SWEDEN; KRISTINEHAMN HOSP, KRISTINEHAMN, SWEDEN; ARVIKA HOSP, ARVIKA, SWEDEN; ESKILSTUNA HOSP, ESKILSTUNA, SWEDEN; KULLBERGSKA HOSP, KATRINEHOLM, SWEDEN; NYKOPING HOSP, LUND, SWEDEN; LINKOPING UNIV HOSP, S-58185 LINKOPING, SWEDEN; NORRKOPING HOSP, NORRKOPING, SWEDEN; MOTALA HOSP, MOTALA, SWEDEN; FINSPANG HOSP, FINSPANG, SWEDEN; JONKOPING HOSP, JONKOPING, SWEDEN; EKSJO NASSJO HOSP, EKSJO, SWEDEN; VARNAMO HOSP, STOCKHOLM, SWEDEN; VASTERVIK HOSP, VASTERVIK, SWEDEN; KALMAR HOSP, KALMAR, SWEDEN; OSKARHAMN HOSP, OSKARHAMN, SWEDEN; MALMO GEN HOSP, S-21401 MALMO, SWEDEN; UNIV LUND HOSP, S-22185 LUND, SWEDEN; LANDSKRONA HOSP, LANDSKRONA, SWEDEN; TRELLEBORG HOSP, TRELLEBORG, SWEDEN; YSTAD HOSP, YSTAD, SWEDEN; HALMSTAD CTY HOSP, HALMSTAD, SWEDEN; GOTHENBURG UNIV, SAHLGRENS HOSP, S-41345 GOTHENBURG, SWEDEN; OSTRA HOSP, S-41685 GOTHENBURG, SWEDEN; UDDEVALLA CENT HOSP, UDDEVALLA, SWEDEN; KUNGALV HOSP, GOTHENBURG, SWEDEN; BORAS HOSP, BORAS, SWEDEN; ALINGSAS HOSP, ALINGSAS, SWEDEN; TROLLHATTAN HOSP, TROLLHATTAN, SWEDEN; CENT HOSP SKOVDE, S-54185 SKOVDE, SWEDEN; LIDKOPING HOSP, LINKOPING, SWEDEN; FALKOPING HOSP, FALKOPING, SWEDEN; UMEA UNIV HOSP, S-90185 UMEA, SWEDEN; SKELLEFTEA HOSP, SKELLEFTEA, SWEDEN; BODEN HOSP, BODEN, SWEDEN; LULEA HOSP, LULEA, SWEDEN; GALLIVARE HOSP, GALLIVARE, SWEDEN; PITEA HOSP, PITEA, SWEDEN; KALIX HOSP, KALIX, SWEDEN; OSTERSUND HOSP, OSTERSUND, SWEDEN; SUNDSVALL HOSP, SUNDSVALL, SWEDEN; ORNSKOLDSVIK HOSP, ORNSKOLDSVIK, SWEDEN; HARNOSAND HOSP, HARNOSAND, SWEDEN; SOLLEFTEA HOSP, SOLLEFTEA, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Danderyds Hospital; Sodersjukhuset Hospital; Saint Goran's Hospital; Uppsala University; Uppsala University Hospital; Falun Hospital; Linkoping University; Lund University; Skane University Hospital; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; Voestalpine AG; Umea University	Pahlman, L (corresponding author), UNIV UPPSALA, AKAD SJUKHUSET, DEPT SURG, S-75185 UPPSALA, SWEDEN.							[Anonymous], 1990, Cancer, V66, P49; [Anonymous], 1985, NEW ENGL J MED, V312, P1465; BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO;2-Q; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; DUKES CE, 1958, BRIT J CANCER, V12, P309, DOI 10.1038/bjc.1958.37; DUNCAN W, 1985, BRIT J SURG, V72, pS59, DOI 10.1002/bjs.1800721333; ELLIS F, 1969, Clinical Radiology, V20, P1, DOI 10.1016/S0009-9260(69)80043-7; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; FLETCHER GH, 1991, RADIOTHER ONCOL, V20, P10, DOI 10.1016/0167-8140(91)90106-Q; FOWLER JF, 1989, BRIT J RADIOL, V62, P679, DOI 10.1259/0007-1285-62-740-679; FRYKHOLM GJ, 1993, DIS COLON RECTUM, V36, P564, DOI 10.1007/BF02049863; Frykholm GJ, 1996, INT J RADIAT ONCOL, V35, P1039, DOI 10.1016/0360-3016(96)00229-5; GERARD A, 1988, ANN SURG, V208, P606, DOI 10.1097/00000658-198811000-00011; GLIMELIUS B, 1995, ACTA ONCOL, V34, P565, DOI 10.3109/02841869509094030; GLIMELIUS B, 1982, ACTA RADIOL ONCOL, V21, P373, DOI 10.3109/02841868209134315; GLIMELIUS B, IN PRESS INT J RAD O; GOLDBERG PA, 1994, EUR J CANCER, V30A, P1602, DOI 10.1016/0959-8049(94)00312-S; Graf W, 1996, DIS COLON RECTUM, V39, P744, DOI 10.1007/BF02054438; GRAF W, IN PRESS RADIOTHER O; Holm T, 1996, CANCER, V78, P968, DOI 10.1002/(SICI)1097-0142(19960901)78:5<968::AID-CNCR5>3.0.CO;2-8; HORN A, 1990, DIS COLON RECTUM, V33, P823, DOI 10.1007/BF02051916; JONES DJ, 1989, BRIT J SURG, V76, P1172, DOI 10.1002/bjs.1800761120; KIRK J, 1971, Clinical Radiology, V22, P145, DOI 10.1016/S0009-9260(71)80044-2; KLIGERMAN MM, 1972, AM J ROENTGENOL, V114, P498, DOI 10.2214/ajr.114.3.498; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LABIANCA R, 1995, LANCET, V345, P939; LEWIS WG, 1995, INT J COLORECTAL DIS, V10, P133, DOI 10.1007/BF00298533; LINDMARK G, 1992, INT J COLORECTAL DIS, V7, P162, DOI 10.1007/BF00360359; MACFARLANE JK, 1993, LANCET, V341, P457, DOI 10.1016/0140-6736(93)90207-W; MARSH PJ, 1994, DIS COLON RECTUM, V37, P1205, DOI 10.1007/BF02257783; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; *NAT CANC I, 1991, CLIN ANN 1991 ADJ TH; Pahlman L, 1996, EUR J SURG, V162, P397; PAHLMAN L, 1990, ANN SURG, V211, P187, DOI 10.1097/00000658-199002000-00011; PAHLMAN L, 1993, BRIT J SURG, V80, P1333, DOI 10.1002/bjs.1800801040; PAHLMAN L, 1995, EUR J CANCER, V31A, P1347, DOI 10.1016/0959-8049(95)91268-H; RIDER WD, 1977, CAN J SURG, V20, P335; TURESSON I, 1984, INT J RADIAT ONCOL, V10, P593, DOI 10.1016/0360-3016(84)90289-X; TURESSON I, 1984, INT J RADIAT ONCOL, V10, P599, DOI 10.1016/0360-3016(84)90290-6	39	1879	1932	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					980	987						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9091798				2022-12-28	WOS:A1997WR38500002
J	Nightingale, SL				Nightingale, SL			Simplified labeling for OTC drugs proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1997, FED REG         0227, V62, P9024	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-28	WOS:A1997WQ08900007
J	Reifler, BV				Reifler, BV			Seeds of reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		WEINER J, BEAK FINCH	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1021	1021						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091676				2022-12-28	WOS:A1997WQ08900001
J	Ramzan, NN; Loftus, E; Burgart, LJ; Rooney, M; Batts, KP; Wiesner, RH; Fredricks, DN; Relman, DA; Persing, DH				Ramzan, NN; Loftus, E; Burgart, LJ; Rooney, M; Batts, KP; Wiesner, RH; Fredricks, DN; Relman, DA; Persing, DH			Diagnosis and monitoring of whipple disease by polymerase chain reaction	ANNALS OF INTERNAL MEDICINE			English	Article							AMPLIFICATION; BACILLUS; IDENTIFICATION; DNA	Background: Whipple disease is a chronic, multisystem disorder associated with infection with Tropheryma whippelii, an organism that has not yet been grown on artificial media. In some cases, the diagnosis of Whipple disease is uncertain if it is based on histology alone. Although antibiotic regimens of various durations have been used, the disease recurs in about one third of cases. No test for cure is available. Objective: To develop a test that is more sensitive and specific than histologic examination to diagnose Whipple disease and monitor the effects of antibiotic therapy. Design: Retrospective, laboratory-based evaluations of stored tissue specimens. Patients: 30 patients with clinically diagnosed, histologically confirmed Whipple disease and 8 patients in whom Whipple disease was clinically suspected but who did not have definitive histologic evidence. Measurements: Pretreatment and post-treatment biopsy specimens of the small bowel and lymph node were tested by polymerase chain reaction for the presence of T. whippeli DNA. Results: Results on PCR were positive in 29 of the 30 specimens from patients with histologically confirmed disease (sensitivity, 96.6%; specificity, 100%) and in 7 of the 8 specimens from patients in whom disease was clinically suspected. Small-bowel biopsy specimens were obtained after treatment from 17 patients (median duration of follow-up, 119 months); specimens from 12 of these patients had positive results on PCR. When these cases were correlated with therapeutic outcome, it was found that 7 of the 12 patients had clinical relapse during subsequent follow-up or had never responded to treatment (positive predictive value, 58% [95% CI, 28% to 85%]). In contrast, none of the 5 patients whose post-treatment biopsy specimens had negative results on PCR had relapse (negative predictive value, 100% [CI, 48% to 100%]; P = 0.044). No correlation was found between post-treatment histology and clinical outcome (P > 0.2). Conclusions: Polymerase chain reaction is highly sensitive and specific when used to confirm the diagnosis of Whipple disease, to identify inconclusive and suspicious cases, and to monitor response to therapy. A negative result on PCR may predict a low likelihood of clinical relapse; a positive test result that remains positive despite therapy may be associated with a poor clinical outcome. Histopathologic evaluation of post-treatment specimens does not predict clinical cure or relapse.	MAYO CLIN & MAYO GRAD SCH MED, DEPT LAB MED, MOL MICROBIOL LAB, ROCHESTER, MN 55905 USA; SUNY SYRACUSE, HLTH SCI CTR, DEPT ANAT PATHOL, SYRACUSE, NY 13210 USA; STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA; VET AFFAIRS PALO ALTO HLTH CARE SYST, PALO ALTO, CA USA	Mayo Clinic; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System			Loftus, Edward V/E-8304-2011	Loftus, Edward V/0000-0001-7199-6851; Fredricks, David/0000-0003-2735-6800; Relman, David A./0000-0001-8331-1354	NIAID NIH HHS [AI32403, AI45253] Funding Source: Medline; NIDDK NIH HHS [DK07198] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, N01AI045253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007198] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CIMINO GD, 1991, NUCLEIC ACIDS RES, V19, P99, DOI 10.1093/nar/19.1.99; CLARRIDGE JE, 1993, J CLIN MICROBIOL, V31, P2049, DOI 10.1128/JCM.31.8.2049-2056.1993; DOBBINS WO, 1995, NEW ENGL J MED, V332, P390, DOI 10.1056/NEJM199502093320611; DOBBINS WO, 1988, MAYO CLIN PROC, V63, P623, DOI 10.1016/S0025-6196(12)64892-7; FEURLE GE, 1979, NEW ENGL J MED, V300, P907, DOI 10.1056/NEJM197904193001607; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; GEBOES K, 1990, GASTROINTEST ENDOSC, V36, P247, DOI 10.1016/S0016-5107(90)71016-4; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; KEINATH RD, 1985, GASTROENTEROLOGY, V88, P1867, DOI 10.1016/0016-5085(85)90012-5; LOWSKY R, 1994, NEW ENGL J MED, V331, P1343, DOI 10.1056/NEJM199411173312004; MANSBACH CM, 1978, ANN INTERN MED, V89, P64, DOI 10.7326/0003-4819-89-1-64; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; RELMAN DA, 1993, J INFECT DIS, V168, P1; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Relman David A., 1993, P496; RICKMAN LS, 1995, NEW ENGL J MED, V332, P363, DOI 10.1056/NEJM199502093320604; RIEMANN JF, 1978, ENDOSCOPY, V10, P98, DOI 10.1055/s-0028-1098273; RYS PN, 1993, J CLIN MICROBIOL, V31, P2356, DOI 10.1128/JCM.31.9.2356-2360.1993; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPAPEN HDM, 1989, DIGEST DIS SCI, V34, P640, DOI 10.1007/BF01536345; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WROE SJ, 1991, J NEUROL NEUROSUR PS, V54, P989, DOI 10.1136/jnnp.54.11.989; 1983, NEW ENGL J MED, V24, P1323	25	149	154	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					520	+		10.7326/0003-4819-126-7-199704010-00004	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092317				2022-12-28	WOS:A1997WQ19500013
J	Costello, A				Costello, A			Should mother and child health services in developing countries be free? Comment	BRITISH MEDICAL JOURNAL			English	Editorial Material											Costello, A (corresponding author), INST CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							Abel-Smith B., 1993, NU Nytt om U-landshalsovard, V7, P8; CARRHILL RA, 1994, SOC SCI MED, V39, P1189, DOI 10.1016/0277-9536(94)90351-4; COSTELLO A, 1994, HUMAN FACE HUMAN F 2; COSTELLO A, 1994, HUMAN FACE HUMAN F 1; MCPAKE B, 1993, SOC SCI MED, V36, P1397, DOI 10.1016/0277-9536(93)90382-E; World Bank, 1993, INV HLTH WORLD DEV R	6	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					941	941		10.1136/bmj.314.7085.941	http://dx.doi.org/10.1136/bmj.314.7085.941			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WQ169	9099119	Green Published			2022-12-28	WOS:A1997WQ16900027
J	Penson, RT; Rudd, RM				Penson, RT; Rudd, RM			Poor recruitment to lung cancer trials	BRITISH MEDICAL JOURNAL			English	Letter											Penson, RT (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND.							Hancock BW, 1997, BRIT MED J, V314, P36, DOI 10.1136/bmj.314.7073.36; *NONSM CELL LUNG C, 1995, BRIT MED J, V311, P899	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					974	975		10.1136/bmj.314.7085.974a	http://dx.doi.org/10.1136/bmj.314.7085.974a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099129	Green Published			2022-12-28	WOS:A1997WQ16900040
J	Smith, KA; Fairburn, CG; Cowen, PJ				Smith, KA; Fairburn, CG; Cowen, PJ			Relapse of depression after rapid depletion of tryptophan	LANCET			English	Article							5-HYDROXYINDOLEACETIC ACID; PLASMA TRYPTOPHAN; SEROTONIN; REMISSION; DISORDERS; MALES; MODEL; AGE	Background Major depression is a common disorder but. the pathophysiology is poorly understood. Current hypotheses implicate deficient function of brain serotonin pathways because drugs that selectively increase brain serotonin activity are effective antidepressants. However, there is no direct evidence that lowered serotonin function causes major depression. We aimed to assess whether lowering of brain serotonin activity by depletion of its aminoacid precursor, tryptophan, could provoke a short-term relapse of clinically significant symptoms in women vulnerable to major depressive disorder. Methods We studied 15 women who had suffered recurrent episodes of major depression but had recovered and were no longer on drug treatment. Patients received two aminoacid mixtures in a double-blind crossover design. One of the mixtures was nutritionally balanced and contained tryptophan and the other was identical except it contained no tryptophan. Participants were scored on the Hamilton rating scale for depression (HAM-D) before and 7 h after drinking each mixture. They also completed hourly self-rated measures of mood during this period. Blood samples were also taken at baseline and 7 h for measurement of plasma tryptophan. Findings The tryptophan-free mixture produced a 75% reduction in plasma tryptophan concentration. After drinking the tryptophan-free mixture, ten of the 15 women experienced temporary but clinically significant depressive symptoms. The mean difference in total HAM-D scores (7 h minus baseline) were significantly higher after the tryptophan-free mixture than after the nutritionally balanced mixture (7.3 vs 0.15 [95% CI 4.5-9.9]; p<0.001). No changes in mood were seen after taking the nutritionally balanced mixture. Interpretation We conclude that rapid lowering of brain serotonin function can precipitate clinical depressive symptoms in well, untreated individuals who are Vulnerable to major depressive disorder. The findings support a hey role for deficient serotonin function in the aetiology of depression.	UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND	University of Oxford			Fairburn, Christopher/AAM-9792-2020; Fairburn, Christopher/AAG-6234-2019	Fairburn, Christopher/0000-0002-9673-9795; Cowen, Philip/0000-0001-5518-6138; Smith, Katharine/0000-0003-2679-1472	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; BECH P, 1992, HDB AFFECTIVE DISORD, P3; BENKELFAST C, 1995, AM COLL NEUROPYSCHOP, V34, P124; BIGGIO G, 1974, LIFE SCI, V14, P1321, DOI 10.1016/0024-3205(74)90440-8; COOPER Z, 1987, INT J EAT DISORDER, V6, P1, DOI 10.1002/1098-108X(198701)6:1<1::AID-EAT2260060102>3.0.CO;2-9; COWEN PJ, 1995, NATURE, V376, P557, DOI 10.1038/376557a0; COWEN PJ, 1996, SELECTIVE SEROTONIN, P63; DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411; DELGADO PL, 1994, ARCH GEN PSYCHIAT, V51, P865; Delgado PL, 1992, HDB AFFECTIVE DISORD, P219; Fairburn Christopher G., 1993, P317; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; GARTSIDE SE, 1992, BRIT J PHARMACOL, V107, pP448; Gelder M, 1996, OXFORD TXB PSYCHIAT, P197; HALLEM DJ, 1990, J NEURAL TRANSM, V79, P93; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Kasper S, 1992, Drugs, V43 Suppl 2, P11; KENDLER KS, 1993, AM J PSYCHIAT, V150, P1139; KENNETT GA, 1986, BRAIN RES, V382, P416, DOI 10.1016/0006-8993(86)91355-7; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; LINNOILA M, 1992, J CLIN PSYCHIAT, V53, P46; MCBRIDE PA, 1990, BIOL PSYCHIAT, V27, P1143, DOI 10.1016/0006-3223(90)90051-3; MENKES DB, 1994, J AFFECT DISORDERS, V32, P37, DOI 10.1016/0165-0327(94)90059-0; MORENO FL, 1995, SOC NEUR, V21; PARKER G, 1994, BRIT J PSYCHIAT, V164, P316, DOI 10.1192/bjp.164.3.316; Smith A., 1992, HDB AFFECTIVE DISORD, P111; SMITH KA, 1997, IN PRESS HUMAN PSYCH; Spitzer RL, 1990, STRUCTURED CLIN INTE; Teasdale JD, 1988, COGNITION EMOTION, V2, P247, DOI 10.1080/02699938808410927; VANPRAAG HM, 1991, PSYCHOL MED, V21, P15, DOI 10.1017/S0033291700014604; WELTZIN TE, 1994, BIOL PSYCHIAT, V35, P388, DOI 10.1016/0006-3223(94)90005-1; YOUNG SN, 1980, J NEUROL NEUROSUR PS, V43, P438, DOI 10.1136/jnnp.43.5.438; YOUNG SN, 1989, PSYCHOPHARMACOLOGY, V98, P508, DOI 10.1007/BF00441950; YOUNG SN, 1985, PSYCHOPHARMACOLOGY, V87, P173, DOI 10.1007/BF00431803	35	309	316	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					915	919		10.1016/S0140-6736(96)07044-4	http://dx.doi.org/10.1016/S0140-6736(96)07044-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093253				2022-12-28	WOS:A1997WR25400012
J	CleatonJones, PE				CleatonJones, PE			An ethical dilemma - Availability of antiretroviral therapy after clinical trials with HIV infected patients are ended	BRITISH MEDICAL JOURNAL			English	Article											CleatonJones, PE (corresponding author), UNIV WITWATERSRAND,COMM RES HUMAN SUBJECTS MED,JOHANNESBURG,SOUTH AFRICA.		Cleaton-Jones, Peter E/L-4090-2016					*CPMP WORK PART EF, 1990, GOOD CLIN PRACT TRIA; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; *S AFR MED RES COU, 1983, GUID ETH MED RES; Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354; Volberding PA, 1996, NEW ENGL J MED, V334, P729, DOI 10.1056/NEJM199603143341113; 1995, EPIDEMIOL COMMENTS, V22, P90	6	19	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					887	888						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093104	Green Published			2022-12-28	WOS:A1997WQ02800036
J	Werner, MH; Burley, SK				Werner, MH; Burley, SK			Architectural transcription factors: Proteins that remodel DNA	CELL			English	Review							CRYSTAL-STRUCTURE; COMPLEX; SITE		HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute	Werner, MH (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.			Burley, Stephen K./0000-0002-2487-9713				EBRIGHT R, 1995, MOL MICROBIOL, V8, P797; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Nash Howard A., 1996, P149; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PATIKOGLOU G, 1997, ANNU REV BIOPH BIOM, V26, P287; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	19	96	97	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					733	736		10.1016/S0092-8674(00)81917-0	http://dx.doi.org/10.1016/S0092-8674(00)81917-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118214	Bronze			2022-12-28	WOS:A1997WQ10000003
J	Hogerzeil, HV; Couper, MR; Gray, R				Hogerzeil, HV; Couper, MR; Gray, R			Guidelines for drug donations	BRITISH MEDICAL JOURNAL			English	Article								Drug donations are usually given in response to acute emergencies, but they can also be part of development aid. Donations may be given directly by governments, by non-governmental organisations, as corporate donations (direct or through private voluntary organisations), or as private donations to single health facilities. Although there are legitimate differences between these donations, basic rules should apply to them all. This common core of ''good donation practice'' is the basis for new guidelines which have recently been issued by the World Health Organisation after consultation with all relevant United Nations agencies, the Red Cross, and other major international agencies active in humanitarian emergency relief. This article summarises the need for such guidelines, the development process, the core principles, and the guidelines themselves and gives practical advice to recipients and donor agencies.	WHO,DIV DRUG MANAGEMENT & POLICIES,CH-1211 GENEVA,SWITZERLAND; WHO,DIV EMERGENCY & HUMANITARIAN ACT,CH-1211 GENEVA,SWITZERLAND	World Health Organization; World Health Organization	Hogerzeil, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA,SWITZERLAND.							AUTIER P, 1990, LANCET, V335, P1388; *CHRIST MED COMM, 1990, GUID DON REC PHARM D; COHEN S, 1990, LANCET, V335, P745; FORTE GB, 1994, OUNCE PREVENTION WOR; HOEN E, 1993, LANCET, V342, P308; HOGERZEIL HV, 1990, LANCET, V336, P1194, DOI 10.1016/0140-6736(90)92812-V; *WHO, 1990, NEW EM HLTH KIT, P5; *WHO, 1992, WHO TECH REP SER, V825, P13; *WHO, 1996, GUID DRUG DON; *WHO, 1994, MED SUPPL DON GUID W; WOLDEYESUS K, 1994, LANCET, V344, P879, DOI 10.1016/S0140-6736(94)92845-2	11	22	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					737	740		10.1136/bmj.314.7082.737	http://dx.doi.org/10.1136/bmj.314.7082.737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116555	Green Published			2022-12-28	WOS:A1997WM77600032
J	Williams, S; Dale, J; Glucksman, E; Wellesley, A				Williams, S; Dale, J; Glucksman, E; Wellesley, A			Senior house officers' work related stressors, psychological distress, and confidence in performing clinical tasks in accident and emergency: A questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							SATISFACTION; MEDICINE; DOCTORS	Objective: To investigate the relation between accident and emergency senior house officers' psychological distress and confidence in performing clinical tasks and to describe work related stressors. Design: Questionnaire survey with data collected at four points during senior house officers' six month attachment to accident and emergency departments. Subjects: 171 newly appointed accident and emergency senior house officers from 27 hospitals in the South Thames region. Main outcome measures: Psychological distress measured with a 25 item questionnaire; confidence in performing a range of 35 clinical and practical activities (visual analogue scales); reported consultation stress factors, other work related stressors, and personal stressors. Results: Overall confidence scores in carrying out a range of clinical and practical activities increased significantly between the end of the first and the end of the fourth month (Z=-6.05, P<0.001). Senior house officers with higher psychological distress scores at the end of their first and fourth month had significantly lower confidence scores (Z=-3.20, P<0.001; Z=-1.90, P<0.05). Senior house officers with lower increases in confidence between the first and fourth month had significantly higher distress than those with greater increases (Z=-2.62, P<0.001), Factors identified as causing stress during consultations included difficulties with communication, certain clinical presentations, and department organisational factors (particularly tile intensity of workload). Conclusions: Psychological distress is linked to confidence in senior house officers. This supports the need to monitor and build confidence in senior house officers and to address work related stressors. Additional communication skills training needs to be considered.	KINGS COLL HOSP,DEPT ACCID & EMERGENCY MED,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital	Williams, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SE5 9PJ,ENGLAND.			Dale, Jeremy/0000-0001-9256-3553				BEECHAM L, 1995, BRIT MED J, V310, P31; COHEN A, 1990, MED TEACH, V12, P47, DOI 10.3109/01421599009010561; COLES C, 1994, MED EDUC, V28, P18, DOI 10.1111/j.1365-2923.1994.tb02680.x; *COMM POSTGR MED D, 1995, SHO TRAIN TACKL ISS; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; DALE J, IN PRESS MED ED; Dowling S, 1990, BRIT MED J, V295, P926; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; GARRUD P, 1990, BRIT MED J, V300, P445, DOI 10.1136/bmj.300.6722.445; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; HALE R, 1992, BRIT J HOSP MED, V47, P452; HEYWORTH J, 1993, ARCH EMERG MED, V10, P279; LUM G, 1995, ANN EMERG MED, V25, P81, DOI 10.1016/S0196-0644(95)70360-8; Miles M, 1994, QUALITATIVE DATA ANA, Vsecond; MORGAN DR, 1992, STRESS MED PROFESSIO; Norusis M.J, 1985, SPSSX ADV STAT GUIDE; RAMIREZ AJ, 1995, BRIT J CANCER, V71, P1263, DOI 10.1038/bjc.1995.244; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; Ware J. E, 1979, CONCEPTUALIZATION ME, V3	19	75	76	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					713	718		10.1136/bmj.314.7082.713	http://dx.doi.org/10.1136/bmj.314.7082.713			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM776	9116547	Green Published			2022-12-28	WOS:A1997WM77600022
J	Stradling, J				Stradling, J			Sleep apnoea and the misuse of evidence-based medicine	LANCET			English	Editorial Material							AIRWAY PRESSURE TREATMENT; APNEA; PERFORMANCE				Stradling, J (corresponding author), CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD RADCLIFFE TRUST,OXFORD OX3 7LJ,ENGLAND.							CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; FERGUSON KA, 1995, THORAX, V50, P998, DOI 10.1136/thx.50.9.998; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GRUNSTEIN RR, 1995, THORAX, V50, P1106, DOI 10.1136/thx.50.10.1106; GUILLEMINAULT C, 1976, ANNU REV MED, V27, P465, DOI 10.1146/annurev.me.27.020176.002341; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; ISSA FG, 1986, ELECTROEN CLIN NEURO, V63, P10, DOI 10.1016/0013-4694(86)90056-8; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SMITH IE, 1995, J SLEEP RES, V4, P183, DOI 10.1111/j.1365-2869.1995.tb00167.x; SULLIVAN CE, 1981, LANCET, V1, P862; WRIGHT J, 1996, SYSTEMATIC REV OBSTR	14	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					201	202		10.1016/S0140-6736(96)08166-4	http://dx.doi.org/10.1016/S0140-6736(96)08166-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111558				2022-12-28	WOS:A1997WC86100047
J	Yoo, MJ; Fulton, TA; Hess, HF; Willett, RL; Dunkleberger, LN; Chichester, RJ; Pfeiffer, LN; West, KW				Yoo, MJ; Fulton, TA; Hess, HF; Willett, RL; Dunkleberger, LN; Chichester, RJ; Pfeiffer, LN; West, KW			Scanning single-electron transistor microscopy: Imaging individual charges	SCIENCE			English	Article							FORCE MICROSCOPY; RESOLUTION	A single-electron transistor scanning electrometer (SETSE)-a scanned probe microscope capable of mapping static electric fields and charges with 100-nanometer spatial resolution and a charge sensitivity of a small fraction of an electron-has been developed. The active sensing element of the SETSE, a single-electron transistor fabricated. at the end of a sharp glass tip, is scanned in close proximity across the sample surface. Images of the surface electric fields of a GaAs/AlxGa1-xAs heterostructure sample show individual photo-ionized charge sites and fluctuations in the dopant and surface-charge distribution on a length scale of 100 nanometers. The SETSE has been used to image and measure depleted regions, local capacitance, band bending, and contact potentials at submicrometer length scales on the surface of this semiconductor sample.	BELL LABS,LUCENT TECHNOL,MURRAY HILL,NJ 07974	Alcatel-Lucent; Lucent Technologies; AT&T								Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; Averin D., 1991, MESOSCOPIC PHENOMENA, P173, DOI DOI 10.1016/B978-0-444-88454-1.50012-7; BETZIG E, 1991, SCIENCE, V251, P1468, DOI 10.1126/science.251.5000.1468; CHLOVSKII DB, 1993, PHYS REV B, V47, P12605; DOMANSKY K, 1993, APPL PHYS LETT, V63, P1513, DOI 10.1063/1.110759; Eyring CF, 1928, PHYS REV, V31, P0900, DOI 10.1103/PhysRev.31.900; FULTON TA, 1987, PHYS REV LETT, V59, P109, DOI 10.1103/PhysRevLett.59.109; GRABERT H, 1992, SINGLE CHARGE TUNNEL; HENNING AK, 1995, J APPL PHYS, V77, P1888, DOI 10.1063/1.358819; KUZMIN LS, 1987, JETP LETT, V45, P389; LARKIN IA, 1990, PHYS LETT A, V151, P335, DOI 10.1016/0375-9601(90)90293-W; MARTIN Y, 1988, APPL PHYS LETT, V52, P1103, DOI 10.1063/1.99224; MARTIN Y, 1995, SCANNED PROBE MICROS; NONNENMACHER M, 1991, APPL PHYS LETT, V58, P2921, DOI 10.1063/1.105227; SCHONENBERGER C, 1990, PHYS REV LETT, V65, P3162, DOI 10.1103/PhysRevLett.65.3162; SCHONENBERGER C, 1992, PHYS REV B, V45, P3861, DOI 10.1103/PhysRevB.45.3861; WILLIAMS CC, 1989, APPL PHYS LETT, V55, P1662, DOI 10.1063/1.102312	17	223	241	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					579	582		10.1126/science.276.5312.579	http://dx.doi.org/10.1126/science.276.5312.579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110974				2022-12-28	WOS:A1997WV72100041
J	Deyo, RA; Psaty, BM; Simon, G; Wagner, EH; Omenn, GS				Deyo, RA; Psaty, BM; Simon, G; Wagner, EH; Omenn, GS			The messenger under attack - Intimidation of researchers by special-interest groups	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION; NIFEDIPINE; DISEASE; RISK		UNIV WASHINGTON,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,SEATTLE,WA 98101	University of Washington; University of Washington Seattle; Group Health Cooperative	Deyo, RA (corresponding author), CTR COST & OUTCOMES RES,146 N CANAL ST,SUITE 300,SEATTLE,WA 98103, USA.			Omenn, Gilbert S./0000-0002-8976-6074				Angell M, 1996, NEW ENGL J MED, V334, P1513, DOI 10.1056/NEJM199606063342306; Black B, 1997, NEW ENGL J MED, V336, P725, DOI 10.1056/NEJM199703063361011; CANAN P, 1992, J LAW POLIT, V8, P539; Daniell WE, 1996, REGUL TOXICOL PHARM, V24, pS152, DOI 10.1006/rtph.1996.0091; DEYO RA, 1993, SPINE, V18, P1463; DEYO RA, 1992, J BONE JOINT SURG AM, V74A, P536, DOI 10.2106/00004623-199274040-00009; DONALDSON MS, 1991, PATIENT OUTCOMES RES; *EARL TREATM UNST, 1986, BRIT HEART J, V56, P400; FEINSTEIN AR, 1967, CLIN JUDGMENT, P220; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; Hershey N, 1996, CONTROL CLIN TRIALS, V17, P183, DOI 10.1016/0197-2456(95)00250-2; HORTON R, 1995, LANCET, V346, P891, DOI 10.1016/S0140-6736(95)92717-4; KASSIRER JP, 1995, NEW ENGL J MED, V333, P793, DOI 10.1056/NEJM199509213331209; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; *NAT HEART LUNG BL, 1995, STAT CALC CHANN BLOC; *NAT HEART LUNG BL, 1995, STAT NEW AN REG SAF; NEEDLEMAN HL, 1994, NEW ENGL J MED, V331, P616, DOI 10.1056/NEJM199409013310915; NEEDLEMAN HL, 1992, PEDIATRICS, V90, P977; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; PRING GW, 1992, BRIDGEPORT L REV, V12, P937; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BZ, 1995, CIRCULATION, V91, P925; SILBERGELD EK, 1995, AM J PUBLIC HEALTH, V85, P165, DOI 10.2105/AJPH.85.2.165; SIMON GE, 1993, ANN INTERN MED, V119, P97, DOI 10.7326/0003-4819-119-2-199307150-00001; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907	27	107	108	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1176	1180		10.1056/NEJM199704173361611	http://dx.doi.org/10.1056/NEJM199704173361611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099665				2022-12-28	WOS:A1997WU00300011
J	Lamb, GC				Lamb, GC			Loading dose of warfarin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							INDUCTION				Lamb, GC (corresponding author), MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226, USA.							FENNERTY A, 1984, BRIT MED J, V288, P1268, DOI 10.1136/bmj.288.6426.1268; HARRISON J, 1997, ANN INTERN MED, V126, P133; HIRSH J, 1995, AM J CARDIOL, V75, pB39, DOI 10.1016/0002-9149(95)80009-H; HIRSH J, 1992, CHEST S, V102, pS313; IGUCHI A, 1994, THORAC CARDIOV SURG, V42, P222, DOI 10.1055/s-2007-1016492; OREILLY RA, 1968, CIRCULATION, V38, P169, DOI 10.1161/01.CIR.38.1.169	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1196	1196		10.1001/jama.1997.03540390026015	http://dx.doi.org/10.1001/jama.1997.03540390026015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103333				2022-12-28	WOS:A1997WT40300014
J	Hartmann, O; LeCorroller, AG; Blaise, D; Michon, J; Philip, I; Norol, F; Janvier, M; Pico, JL; Baranzelli, MC; Rubie, H; Coze, C; Pinna, A; Meresse, V; Benhamou, E				Hartmann, O; LeCorroller, AG; Blaise, D; Michon, J; Philip, I; Norol, F; Janvier, M; Pico, JL; Baranzelli, MC; Rubie, H; Coze, C; Pinna, A; Meresse, V; Benhamou, E			Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						hematopoietic stem cell transplantation; bone marrow transplantation; leukapheresis; cost-benefit analysis; lymphoma	COLONY-STIMULATING FACTOR; HIGH-DOSE CHEMOTHERAPY; PROGENITOR CELLS; G-CSF; PLATELET RECOVERY; AUTOLOGOUS TRANSPLANTATION; GRANULOCYTE; THERAPY; MOBILIZATION; CHILDREN	Background: Previous studies have suggested that peripheral blood stem cell (PBSC) transplantation has an advantage over autologous bone marrow transplantation. Objective: To compare the hematologic recovery and costs associated with PBSC transplantation with those associated with autologous bone marrow transplantation in patients receiving high-dose chemotherapy for solid tumors or lymphomas. Design: Multicenter, randomized, controlled clinical trial. Setting: French Federation of Cancer Centers, located in cancer facilities or public hospitals with transplantation units. Patients: Children and adults with solid tumors or lymphomas who were candidates for high-dose chemotherapy. Interventions: Bone marrow or filgrastim-mobilized PBSCs. Measurement: The major end point was the duration of thrombocytopenia (platelet count < 50 x 10(9)/L). An economic evaluation of both types of transplantation was done prospectively to measure costs and cost-effectiveness. Results: 129 patients entered the trial; 64 had PBSC transplantation, and 65 had bone marrow transplantation. The median duration of thrombocytopenia was 16 days in the PBSC group and 36 days in the bone marrow group (P < 0.001). All of the other clinical end points studied (time to last platelet transfusion, duration of granulocytopenia, number of transfusion episodes, and duration of hospitalization) favored PBSC transplantation. A cost analysis showed that total cost was decreased by 17% in adults and 29% in children with PBSC transplantation; thus, PBSC transplantation was clearly more cost-effective than bone marrow transplantation for both platelet and granulocyte recovery. Conclusion: Transplantation of PBSCs is associated with more rapid hematologic recovery than is bone marrow transplantation after high-dose chemotherapy for solid tumors or lymphomas. Furthermore, global costs are lower and cost-effectiveness ratios are better with PBSC transplantation.	INSERM U379, MARSEILLE, FRANCE; INST PAOLI CALMETTES, MARSEILLE, FRANCE; INST CURIE, PARIS, FRANCE; CTR LEON BERARD, F-69373 LYON, FRANCE; GIP SUDEST FRANCILIEN, CRETEIL, FRANCE; CTR RENE HUGUENIN, ST CLOUD, FRANCE; LAB AMGEN, NEUILLY SUR SEINE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard; Rene Huguenin Hospital	Hartmann, O (corresponding author), INST GUSTAVE ROUSSY, RUE CAMILLE DESMOULINS, F-94800 VILLEJUIF, FRANCE.		Blaise, Didier/R-2483-2016; Le Corroller, Anne-Gaëlle/S-3006-2019; Le Corroller Soriano, Anne-Gaelle/D-7302-2016	Blaise, Didier/0000-0002-5684-9447; Le Corroller, Anne-Gaëlle/0000-0003-0072-9910; Le Corroller Soriano, Anne-Gaelle/0000-0003-0072-9910				BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; Bender J G, 1992, J Hematother, V1, P329, DOI 10.1089/scd.1.1992.1.329; BENSINGER W, 1993, BLOOD, V81, P3158; BEYER J, 1995, J CLIN ONCOL, V13, P1328, DOI 10.1200/JCO.1995.13.6.1328; BOLWELL BJ, 1993, BONE MARROW TRANSPL, V12, P609; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BRICE P, 1995, PHARMACOECONOMICS, V7, P238, DOI 10.2165/00019053-199507030-00007; BRUGGER W, 1993, BRIT J HAEMATOL, V84, P402, DOI 10.1111/j.1365-2141.1993.tb03093.x; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; CHAO NJ, 1993, BLOOD, V81, P2031; DELUCA E, 1992, BRIT J CANCER, V66, P893, DOI 10.1038/bjc.1992.381; DEMEOCQ F, 1994, BONE MARROW TRANSPL, V13, P43; EISENBERG JM, 1984, REV INFECT DIS, V6, pS905; FAUCHER C, 1994, BONE MARROW TRANSPL, V14, P895; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FUKUDA M, 1992, BRIT J HAEMATOL, V80, P327, DOI 10.1111/j.1365-2141.1992.tb08140.x; HAAS R, 1994, BLOOD, V83, P3787; HENON P, 1992, INT J CELL CLONING, V10, P1, DOI 10.1002/stem.5530100702; HOHAUS S, 1993, EXP HEMATOL, V21, P508; Janssen W E, 1995, J Hematother, V4, P139, DOI 10.1089/scd.1.1995.4.139; KAWANO Y, 1993, EXP HEMATOL, V21, P103; KESSINGER A, 1991, EXP HEMATOL, V19, P1013; KORBLING M, 1986, BLOOD, V67, P529; Lowenthal RM, 1996, LANCET, V347, P1125, DOI 10.1016/S0140-6736(96)90327-X; Moss T J, 1992, J Hematother, V1, P225, DOI 10.1089/scd.1.1992.1.225; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PETTENGELL R, 1993, BLOOD, V82, P3770; REIFFERS J, 1983, EXP HEMATOL, V11, P148; REIFFERS J, 1992, INT J CELL CLONING, V10, P1; RILL DR, 1994, BLOOD, V84, P380; ROTHMAN KJ, 1978, J CHRON DIS, V31, P557, DOI 10.1016/0021-9681(78)90043-7; Schmitz N, 1996, LANCET, V347, P353, DOI 10.1016/S0140-6736(96)90536-X; SCHWARTZBERG L, 1993, BONE MARROW TRANSPL, V11, P369; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SHERIDAN WP, 1994, BONE MARROW TRANSPL, V14, P105; SIENA S, 1993, STEM CELLS, V11, P72; SUTHERLAND HJ, 1994, BLOOD, V83, P3808; TAKAUE Y, 1992, BONE MARROW TRANSPL, V10, P241; TESHIMA T, 1992, BONE MARROW TRANSPL, V10, P215; THOMAS ED, 1970, BLOOD-J HEMATOL, V36, P507, DOI 10.1182/blood.V36.4.507.507; Torrance GW, 1987, METHODS EC EVALUATIO; UYLDEGROOT CA, 1994, EUR J CANCER, V30A, P1631	43	224	225	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					600	+		10.7326/0003-4819-126-8-199704150-00002	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103126				2022-12-28	WOS:A1997WT58000005
J	Huelsenbeck, JP; Rannala, B				Huelsenbeck, JP; Rannala, B			Phylogenetic methods come of age: Testing hypotheses in an evolutionary context	SCIENCE			English	Article							MAXIMUM-LIKELIHOOD; DNA-SEQUENCES; MOLECULAR EVOLUTION; SUBSTITUTION; RATES; INFERENCE; SIMULATION; PARSIMONY; PARASITES; OUTBREAK	The use of molecular phylogenies to examine evolutionary questions has become commonplace with the automation of DNA sequencing and the availability of efficient computer programs to perform phylogenetic analyses. The application of computer simulation and likelihood ratio tests to evolutionary hypotheses represents a recent methodological development in this field. Likelihood ratio tests have enabled biologists to address many questions in evolutionary biology that have been difficult td resolve in the past, such as whether host-parasite systems are cospeciating and whether models of DNA substitution adequately explain observed sequences.			Huelsenbeck, JP (corresponding author), UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA.		Rannala, Bruce/M-3188-2014; Huelsenbeck, John P/C-6398-2013; Klein, Richard G/B-5910-2009	Rannala, Bruce/0000-0002-8355-9955; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040282] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40282] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHIE JW, 1989, SYST ZOOL, V38, P239, DOI 10.2307/2992285; Barry D., 1987, STAT SCI, V2, P191, DOI DOI 10.1214/SS/1177013353; BROOKS DR, 1981, SYST ZOOL, V30, P229, DOI 10.2307/2413247; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; Chang JT, 1996, MATH BIOSCI, V134, P189, DOI 10.1016/0025-5564(95)00172-7; COX DR, 1962, J ROY STAT SOC B, V24, P406; COX DR, 1961, 4TH P BERK S MATH ST, V1, P105; DYKHUIZEN DE, 1991, J BACTERIOL, V173, P7257, DOI 10.1128/jb.173.22.7257-7268.1991; Edwards A. W. F., 1964, PHENETIC PHYLOGENETI, P67; EDWARDS AWF, 1972, LIKELIHOOD; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FELSENSTEIN J, 1983, STAT ANAL DNA SEQUEN; GAUT BS, 1995, MOL BIOL EVOL, V12, P152, DOI 10.1093/oxfordjournals.molbev.a040183; GOLDMAN N, 1993, J MOL EVOL, V36, P182, DOI 10.1007/BF00166252; HAFNER MS, 1995, PHILOS T R SOC B, V349, P77, DOI 10.1098/rstb.1995.0093; HAFNER MS, 1988, NATURE, V332, P258, DOI 10.1038/332258a0; HAFNER MS, 1994, SCIENCE, V265, P1087, DOI 10.1126/science.8066445; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Henderson WW, 1995, VIROLOGY, V214, P602, DOI 10.1006/viro.1995.0071; Hibbett DS, 1996, MOL BIOL EVOL, V13, P903, DOI 10.1093/oxfordjournals.molbev.a025658; Hillis David M., 1996, P515; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; Huelsenbeck JP, 1996, SYST BIOL, V45, P92, DOI 10.2307/2413514; Huelsenbeck JP, 1996, SYST BIOL, V45, P546, DOI 10.2307/2413530; HUELSENBECK JP, 1995, MOL BIOL EVOL, V12, P843; Huelsenbeck JP, 1997, EVOLUTION, V51, P410, DOI [10.1111/j.1558-5646.1997.tb02428.x, 10.2307/2411113]; HUELSENBECK JP, 1995, SYST BIOL, V44, P17, DOI 10.2307/2413481; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; KUHNER MK, 1994, MOL BIOL EVOL, V11, P459; MADDISON WP, 1990, EVOLUTION, V44, P539, DOI 10.2307/2409434; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; Page RDM, 1996, SYST BIOL, V45, P151, DOI 10.2307/2413612; PALUMBI SR, 1989, J MOL EVOL, V29, P180, DOI 10.1007/BF02100116; Rice J., 1995, MATH STAT DATA ANAL; RZHETSKY A, 1995, MOL BIOL EVOL, V12, P131, DOI 10.1093/oxfordjournals.molbev.a040182; SCHONIGER M, 1994, MOL PHYLOGENET EVOL, V3, P240, DOI 10.1006/mpev.1994.1026; SIMBERLOFF D, 1987, SYST ZOOL, V36, P175, DOI 10.2307/2413267; Swofford DL, 1996, SYST BIOL, V45, P575, DOI 10.2307/2413533; Swofford DL, 1996, PAUP PHYLOGENETIC AN; TATENO Y, 1994, MOL BIOL EVOL, V11, P261; Wald A., 1947, SEQUENTIAL ANAL; YANG ZB, 1994, J MOL EVOL, V39, P105; YANG ZH, 1994, MOL BIOL EVOL, V11, P316; YANG ZH, 1993, MOL BIOL EVOL, V10, P1396; YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154; Yang ZH, 1996, J MOL EVOL, V42, P587, DOI 10.1007/BF02352289; YANG ZH, 1995, MOL BIOL EVOL, V12, P451	53	649	669	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					227	232		10.1126/science.276.5310.227	http://dx.doi.org/10.1126/science.276.5310.227			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092465	Green Submitted			2022-12-28	WOS:A1997WT92500036
J	Thompson, GR; Scott, J; Walport, MJ; Oakley, CM; Hughes, JMB; Bulpitt, CJ; TaylorRobinson, SD				Thompson, GR; Scott, J; Walport, MJ; Oakley, CM; Hughes, JMB; Bulpitt, CJ; TaylorRobinson, SD			Grand rounds - Hammersmith Hospital - Hazards of running a marathon - Creatine kinase MB can be raised without myocardial infarction	BRITISH MEDICAL JOURNAL			English	Editorial Material							ISOENZYME LEVELS; RUNNERS; EXERCISE; PLAYERS; SQUASH; HEART; DEATH				Thompson, GR (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,CTR CLIN SCI,LONDON W12 0NN,ENGLAND.			Walport, Mark/0000-0001-7220-5273				APPLE FS, 1987, EUR J APPL PHYSIOL O, V56, P49, DOI 10.1007/BF00696375; BRADY HR, 1989, EUR HEART J, V10, P1029, DOI 10.1093/oxfordjournals.eurheartj.a059415; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; CURFMAN GD, 1993, NEW ENGL J MED, V329, P1730, DOI 10.1056/NEJM199312023292310; Davies MJ, 1995, EUR HEART J, V16, P3, DOI 10.1093/eurheartj/16.suppl_L.3; Hambrecht R, 1993, J AM COLL CARDIOL, V22, P468, DOI 10.1016/0735-1097(93)90051-2; Martin DE, 1977, ANN NY ACAD SCI, V301, P850; Noakes T, 1977, Ann N Y Acad Sci, V301, P593, DOI 10.1111/j.1749-6632.1977.tb38232.x; NOAKES TD, 1979, BRIT HEART J, V41, P624; NOAKES TD, 1979, NEW ENGL J MED, V301, P86, DOI 10.1056/NEJM197907123010205; NORTHCOTE RJ, 1985, INT J CARDIOL, V8, P3, DOI 10.1016/0167-5273(85)90258-X; NORTHCOTE RJ, 1984, LANCET, V1, P148; *OFF POP CENS SURV, 1993, OPCS MORT STAT CAUS; OHMAN EM, 1982, BRIT MED J, V285, P1523, DOI 10.1136/bmj.285.6354.1523; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; SIEGEL AJ, 1983, JAMA-J AM MED ASSOC, V250, P2835, DOI 10.1001/jama.250.20.2835; SIEGEL AJ, 1985, AM J MED, V79, P431, DOI 10.1016/0002-9343(85)90029-4; SIEGEL AJ, 1981, JAMA-J AM MED ASSOC, V246, P2049, DOI 10.1001/jama.246.18.2049; 1994, NY TIMES        1107, P6	19	10	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1023	1025		10.1136/bmj.314.7086.1023	http://dx.doi.org/10.1136/bmj.314.7086.1023			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112849	Green Published			2022-12-28	WOS:A1997WT15200028
J	Brockes, JP				Brockes, JP			Amphibian limb regeneration: Rebuilding a complex structure	SCIENCE			English	Article							PIGMENTED EPITHELIAL-CELLS; THYROID-HORMONE RECEPTORS; RETINOIC ACID RECEPTOR; NEWT LIMB; AXOLOTL LIMBS; NOTOPHTHALMUS-VIRIDESCENS; MUSCLE DIFFERENTIATION; BLASTEMA FORMATION; PATTERN-FORMATION; SKELETAL-MUSCLE	The ability to regenerate complex structures is widespread in metazoan phylogeny, but among vertebrates the urodele amphibians are exceptional. Adult urodeles can regenerate their limbs by local formation of a mesenchymal growth zone or blastema. The generation of blastemal cells depends not only on the local extracellular environment after amputation or wounding but also on the ability to reenter the cell cycle from the differentiated state. The blastema replaces structures appropriate to its proximodistal position. Axial identity is probably encoded as a graded property that controls cellular growth and movement through local cell interactions. The molecular basis is not understood, but proximodistal identity in newt blastemal cells may be respecified by signaling through a retinoic acid receptor isoform. The possibility of inducing a blastema on a mammalian limb cannot be discounted, although the molecular constraints are becoming clearer as we understand more about the mechanisms of urodele regeneration.	UCL, DEPT BIOCHEM & MOL BIOL, LONDON W1P 8BT, ENGLAND	University of London; University College London	Brockes, JP (corresponding author), UCL, LUDWIG INST CANC RES, 91 RIDING HOUSE ST, LONDON W1P 8BT, ENGLAND.			Brockes, Jeremy/0000-0002-3395-5159				AGATA K, 1993, DEVELOPMENT, V118, P1025; BOILLY B, 1991, DEV BIOL, V145, P302, DOI 10.1016/0012-1606(91)90128-P; BREEDIS C, 1952, CANCER RES, V12, P861; BROCKES JP, 1994, TRENDS GENET, V10, P169, DOI 10.1016/0168-9525(94)90094-9; BRYANT SV, 1992, DEV BIOL, V152, P1, DOI 10.1016/0012-1606(92)90152-7; BRYANT SV, 1993, NATO ADV SCI INST SE, V259, P37; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CHALKLEY DT, 1954, J MORPHOL, V94, P21, DOI 10.1002/jmor.1050940103; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CRAWFORD K, 1988, DEVELOPMENT, V102, P687; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; Dinsmore CE., 1991, HIST REGENERATION RE; EGAR MW, 1988, ANAT REC, V221, P550, DOI 10.1002/ar.1092210111; EGUCHI G, 1974, P NATL ACAD SCI USA, V71, P5052, DOI 10.1073/pnas.71.12.5052; EGUCHI G, 1988, REGULATORY MECHANISM, P147; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FEKETE DM, 1987, DEVELOPMENT, V99, P589; FERRETTI P, 1991, GLIA, V4, P214, DOI 10.1002/glia.440040213; FERRETTI P, 1988, J EXP ZOOL, V247, P77, DOI 10.1002/jez.1402470111; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Gann AAF, 1996, P ROY SOC B-BIOL SCI, V263, P729, DOI 10.1098/rspb.1996.0109; GARDINER DM, 1986, DEV BIOL, V118, P488, DOI 10.1016/0012-1606(86)90020-5; GARDINER DM, 1995, DEVELOPMENT, V121, P1731; GORDON H, 1988, J EXP ZOOL, V247, P232, DOI 10.1002/jez.1402470306; GOSS RJ, 1992, J THEOR BIOL, V159, P241, DOI 10.1016/S0022-5193(05)80704-0; Goss RJ., 1969, PRINCIPLES REGNERATI; GRILLO HC, 1968, DEV BIOL, V17, P571, DOI 10.1016/0012-1606(68)90006-7; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAY ED, 1959, DEV BIOL, V1, P555, DOI 10.1016/0012-1606(59)90018-1; HILL DS, 1993, DEVELOPMENT, V117, P937; ITOH Y, 1986, DEV BIOL, V115, P353, DOI 10.1016/0012-1606(86)90255-1; KIM WS, 1986, ROUX ARCH DEV BIOL, V195, P455, DOI 10.1007/BF00375749; KINTNER CR, 1985, J EMBRYOL EXP MORPH, V89, P37; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LO DC, 1993, P NATL ACAD SCI USA, V90, P7230, DOI 10.1073/pnas.90.15.7230; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; LUJVIDIN S, 1990, DIFFERENTIATION, V43, P192; MADEN M, 1993, DEV BIOL, V159, P379, DOI 10.1006/dbio.1993.1249; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; MATZ DG, 1995, FASEB J, V9, pA828; MCDONNELL TJ, 1983, TISSUE CELL, V15, P351, DOI 10.1016/0040-8166(83)90068-X; MESCHER AL, 1986, ANAT REC, V214, P495; Miyazaki K, 1996, P NATL ACAD SCI USA, V93, P6819, DOI 10.1073/pnas.93.13.6819; MOHANTYHEJMADI P, 1992, NATURE, V355, P352, DOI 10.1038/355352a0; Morgan T.H., 1901, REGENERATION; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNEOKA K, 1984, DEV BIOL, V105, P179, DOI 10.1016/0012-1606(84)90273-2; MUNEOKA K, 1982, NATURE, V298, P369, DOI 10.1038/298369a0; NACE JD, 1995, DEV DYNAM, V202, P153, DOI 10.1002/aja.1002020207; NARDI JB, 1983, DIFFERENTIATION, V25, P27; Neff AW, 1996, INT J DEV BIOL, V40, P719; NIAZI I A, 1978, Folia Biologica (Cracow), V26, P3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OBERPRILLER JO, 1974, J EXP ZOOL, V187, P249, DOI 10.1002/jez.1401870208; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Pecorino LT, 1996, CURR BIOL, V6, P563, DOI 10.1016/S0960-9822(02)00542-0; PECORINO LT, 1994, DEVELOPMENT, V120, P325; Pecorino LT, 1996, J HISTOCHEM CYTOCHEM, V44, P559, DOI 10.1177/44.6.8666741; PESCITELLI MJ, 1980, DEV BIOL, V79, P255, DOI 10.1016/0012-1606(80)90115-3; PREHN RT, 1971, PROG EXP TUMOR RES, V14, P1; RAGSDALE CW, 1989, NATURE, V341, P654, DOI 10.1038/341654a0; RAGSDALE CW, 1992, MECH DEVELOP, V40, P99; REIDER CL, 1990, INT REV CYTOL, V122, P153; REYER RW, 1973, DEV BIOL, V32, P258, DOI 10.1016/0012-1606(73)90240-6; REYER RW, 1954, Q REV BIOL, V29, P1, DOI 10.1086/399936; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SCHILTHUIS JG, 1993, EMBO J, V12, P3459, DOI 10.1002/j.1460-2075.1993.tb06020.x; SCHMID V, 1993, DEV BIOL, V155, P483, DOI 10.1006/dbio.1993.1046; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMON HG, 1995, DEV DYNAM, V202, P1, DOI 10.1002/aja.1002020102; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLACK JMW, 1980, J THEOR BIOL, V82, P105, DOI 10.1016/0022-5193(80)90092-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SOONPAA MH, 1994, CELL TISSUE RES, V275, P377, DOI 10.1007/BF00319437; STARK D, UNPUB; STEEN TP, 1968, J EXP ZOOL, V167, P49, DOI 10.1002/jez.1401670105; STOCUM DL, 1984, DIFFERENTIATION, V27, P13, DOI 10.1111/j.1432-0436.1984.tb01403.x; Tanaka EM, 1997, J CELL BIOL, V136, P155, DOI 10.1083/jcb.136.1.155; Thornton CS, 1938, J MORPHOL, V62, P17, DOI 10.1002/jmor.1050620104; TOOLE BP, 1971, DEV BIOL, V25, P57, DOI 10.1016/0012-1606(71)90019-4; TSONIS PA, 1983, DEV GROWTH DIFFER, V25, P201; Tsonis PA., 1996, LIMB REGENERATION; VIVIANO CM, 1995, DEVELOPMENT, V121, P3753; WAGNER GP, 1992, J EXP ZOOL, V261, P62, DOI 10.1002/jez.1402610108; WALLACE H, 1981, REGENERATION; Yamada T, 1977, Monogr Dev Biol, V13, P1; YANG EV, 1994, DEV BIOL, V166, P696, DOI 10.1006/dbio.1994.1348; YANG EV, 1992, J EXP ZOOL, V264, P337, DOI 10.1002/jez.1402640312; ZILAKOS NP, 1992, CANCER RES, V52, P4858	94	384	399	4	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					81	87		10.1126/science.276.5309.81	http://dx.doi.org/10.1126/science.276.5309.81			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082990				2022-12-28	WOS:A1997WR38600049
J	OByrne, PM				OByrne, PM			Treatment of mild asthma	LANCET			English	Editorial Material									MCMASTER UNIV,DEPT MED,HAMILTON,ON L8N 3ZS,CANADA	McMaster University	OByrne, PM (corresponding author), MCMASTER UNIV,ASTHMA RES GRP,HAMILTON,ON L8N 3ZS,CANADA.			O'Byrne, Paul/0000-0003-0979-281X				Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; *NAT HEART LUNG BL, 1995, PUBL US DEP HLTH HUM; O'Byrne P, 1996, CAN RESPIR J, V3, P169; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Sheffer AL, 1992, PUBLICATION US DEP H; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					818	818		10.1016/S0140-6736(05)61745-X	http://dx.doi.org/10.1016/S0140-6736(05)61745-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121251				2022-12-28	WOS:A1997WP40300004
J	Brophy, JM; Joseph, L				Brophy, JM; Joseph, L			Bayesian interim statistical analysis of randomised trials	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; MYOCARDIAL-INFARCTION; MORTALITY; TRANDOLAPRIL; MORBIDITY		MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL, PQ, CANADA	McGill University	Brophy, JM (corresponding author), CTR HOSP VERDUN, DEPT MED, 4000 BOUL LASALLE, VERDUN, PQ H3Z 2N9, CANADA.		brophy, james/H-6673-2019	brophy, james/0000-0001-8049-6875				AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; BALL SG, 1993, LANCET, V342, P821; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOBER L, 1995, AM J CARDIOL, V76, P1, DOI 10.1016/S0002-9149(99)80791-7; LIU LS, 1995, LANCET, V345, P686; Logan RL, 1996, LANCET, V347, P595, DOI 10.1016/S0140-6736(96)91284-2; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	12	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	1997	349	9059					1166	1168		10.1016/S0140-6736(96)06377-5	http://dx.doi.org/10.1016/S0140-6736(96)06377-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113025				2022-12-28	WOS:A1997WU54400042
J	Wingen, AM; FabianBach, C; Schaefer, F; Mehls, O				Wingen, AM; FabianBach, C; Schaefer, F; Mehls, O			Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children	LANCET			English	Article							BLOOD-PRESSURE; RESTRICTION; INSUFFICIENCY; DISEASE; TRIAL	Background Some studies have suggested that a low-protein diet slows the deterioration of renal function in patients with chronic renal failure (CRF). The effects of a low-protein diet on renal function and growth, have not been assessed in a large, prospective randomised trial in children with CRF. Methods A 2-year prospective, stratified, and randomised multicentre study recruited 191 patients aged 2-18 years. After a run-in period of at least 6 months, patients were stratified into either a progressive or non-progressive category based on the change in creatinine clearance in this period. The patients were also stratified into three renal-disease categories and then randomly assigned to a control or diet group. In the diet group, the protein intake was the lowest, safe WHO recommendation-ie, 0.8-1.1 g/kg daily adjusted for age. All patients were advised to have a calorie intake of at least 70% of the WHO recommendations. Glomerular filtration rate (GFR) was measured every 2 months by creatinine clearance; dietary compliance was checked by urinary urea-nitrogen excretion and dietary diaries (weighing method). 112 patients completed an optional third year of the study. Findings The low-protein diet did not affect growth. However, there was no effect of diet on the mean decline in creatinine clearance over 2 years (diet vs control: progressive group -9.7 [SD 8.0] vs -10.7 [11.8] mL/min per 1.73m(2); non-progressive group -2.5 [7.5] vs -4.3 [10.0] mL/min per 1.73 m(2)). Patients classified as having progressive disease were older and had a lower creatinine clearance and a higher blood pressure at randomisation, and had a greater decrease in creatinine clearance than non-progressive patients. On multivariate regression analysis proteinuria (partial R-2=0.259) and systolic blood pressure (partial R-2=0.087) were independent predictors of the change in GFR. Similar results were found after the study was extended for a third year. Interpretation A low-protein diet for 3 years did not affect the decrease in renal function in children with CRF. Proteinuria and blood pressure explain a large part of the variability of, and may be causally related to the decline in the GFR.			Wingen, AM (corresponding author), UNIV ESSEN GESAMTHSCH,CHILDRENS HOSP,HUFELANDSTR 55,D-45122 ESSEN,GERMANY.		Schaefer, Franz/G-4365-2010					BAUDOIN P, 1993, PEDIATR NEPHROL, V7, P536, DOI 10.1007/BF00852539; *COMM DIET ALL, 1989, REC DIET ALL; DAMICO G, 1994, NEPHROL DIAL TRANSPL, V9, P1590; DEMAN SA, 1991, J HYPERTENS, V9, P109, DOI 10.1097/00004872-199102000-00002; ECHTEN JEKT, 1993, ARCH DIS CHILD, V68, P371, DOI 10.1136/adc.68.3.371; *FAO WHO, 1973, WHO TECHNICAL REPORT, V522; FAO/WHO, 1985, TECHNICAL REPORT SER, V724; FOUQUE D, 1992, BMJ-BRIT MED J, V304, P216, DOI 10.1136/bmj.304.6821.216; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; JUREIDINI KF, 1990, PEDIATR NEPHROL, V4, P1; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levey AS, 1996, AM J KIDNEY DIS, V27, P652, DOI 10.1016/S0272-6386(96)90099-2; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; LOCATELLI F, 1992, MINER ELECTROL METAB, V18, P295; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MEHLS O, 1989, NUTR TREATMENT CHRON, P299; MOTOMURA K, 1988, NEPHRON, V49, P144, DOI 10.1159/000185041; Parving HH, 1996, KIDNEY INT, V49, P1778, DOI 10.1038/ki.1996.266; PELAYO JC, 1991, J CLIN INVEST, V88, P101, DOI 10.1172/JCI115264; Perna A, 1996, AM J KIDNEY DIS, V27, P34, DOI 10.1016/S0272-6386(96)90028-1; Prader A, 1989, Helv Paediatr Acta Suppl, V52, P1; ROSMAN JB, 1989, KIDNEY INT, V36, pS96; SALUSKY I, 1981, J LAB CLIN MED, V97, P21; SCHWARTZ GJ, 1992, PEDIATR NEPHROL, V6, P512, DOI 10.1007/BF00866487; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571; SIMONS JL, 1994, KIDNEY INT, V46, P396, DOI 10.1038/ki.1994.287; WALKER JD, 1989, LANCET, V2, P1411; WINGEN AM, 1993, CLIN NEPHROL, V40, P208	29	168	176	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1117	1123		10.1016/S0140-6736(96)09260-4	http://dx.doi.org/10.1016/S0140-6736(96)09260-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113009				2022-12-28	WOS:A1997WU54400007
J	Ota, Y; Samelson, LE				Ota, Y; Samelson, LE			The product of the proto-oncogene c-cbl: A negative regulator of the Syk tyrosine kinase	SCIENCE			English	Article							FC-EPSILON-RI; SH3 DOMAIN; T-CELL; PROTOONCOGENE PRODUCT; EGF STIMULATION; JURKAT CELLS; V-CBL; RECEPTOR; PHOSPHORYLATION; ACTIVATION	Engagement of antigen and immunoglobulin receptors on hematopoietic cells is directly coupled to activation of nonreceptor protein tyrosine kinases (PTKs) that then phosphorylate critical intracellular substrates. In mast cells stimulated through the Fc epsilon RI receptor, activation of several PTKs including Syk leads to degranulation and release of such mediators of the allergic response as histamine and serotonin. Regulation of Syk function occurred through interaction with the Cbl protein, itself a PTK substrate in this system. Overexpression of Cbl led to inhibition of Syk and suppression of serotonin release from mast cells, demonstrating its ability to inhibit a nonreceptor tyrosine kinase. Complex adaptor proteins such as Cbl can directly regulate the functions of the proteins they bind.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y., UNPUB; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SCHARENBERG AM, 1995, CHEM IMMUNOL, V61, P72; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	24	226	228	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					418	420		10.1126/science.276.5311.418	http://dx.doi.org/10.1126/science.276.5311.418			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103201				2022-12-28	WOS:A1997WU47700041
J	Becerra, JX				Becerra, JX			Insects on plants: Macroevolutionary chemical trends in host use	SCIENCE			English	Article							CHRYSOMELIDAE; COLEOPTERA; BEETLES	Determining the macroevolutionary importance of plant chemistry on herbivore host shifts is critical to understanding the evolution of insect-plant interactions. Molecular phylogenies of the ancient and speciose Blepharida (Coleoptera)-Bursera (Burseraceae) system were reconstructed and terpenoid chemical profiles for the plant species obtained. Statistical analyses show that the historical patterns of host shifts strongly correspond to the patterns of host chemical similarity, indicating that plant chemistry has played a significant role in the evolution of host shifts by phytophagous insects.	UNIV NACL AUTONOMA MEXICO,INST ECOL,MEXICO CITY 04510,DF,MEXICO	Universidad Nacional Autonoma de Mexico	Becerra, JX (corresponding author), UNIV ARIZONA,DEPT ECOL & EVOLUT BIOL,TUCSON,AZ 85721, USA.			Becerra, Judith/0000-0002-3749-9058				Baldwin BG, 1992, MOL PHYLOGENET EVOL, V1, P3, DOI 10.1016/1055-7903(92)90030-K; BECERRA JX, 1990, BIOTROPICA, V22, P320, DOI 10.2307/2388545; BECERRA JX, 1994, NOVEL ASPECTS BIOL C, P327; BECERRA JX, 1994, ECOLOGY, V7, P1991; BERENBAUM M, 1983, EVOLUTION, V37, P163, DOI 10.1111/j.1558-5646.1983.tb05524.x; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.2307/2406212; FARRELL B, 1990, EVOLUTION, V44, P1389, DOI 10.1111/j.1558-5646.1990.tb03834.x; FARRIS JS, 1973, SYST ZOOL, V22, P50, DOI 10.2307/2412378; FURTH DG, 1988, OECOLOGIA, V74, P496, DOI 10.1007/BF00380045; FURTH DG, 1992, J NEW YORK ENTOMOL S, V100, P399; FURTH DG, 1982, SPIXIANA, V7, P43; FUTUYMA DG, 1991, HERBIVORES THEIR INT, V2, P439; FUTUYMA DJ, 1990, EVOLUTION, V44, P1885, DOI 10.1111/j.1558-5646.1990.tb04298.x; *GEN COD CORP INC, 1995, SEQ 3 0 US MAN; LANGENHEIM JH, 1994, J CHEM ECOL, V20, P1223, DOI 10.1007/BF02059809; MADDISON D, 1992, MACCLADE VERSION 3, P237; McVaugh R., 1965, Kew Bulletin, V18, P317, DOI 10.2307/4109252; MITTER C, 1991, TRENDS ECOL EVOL, V6, P290, DOI 10.1016/0169-5347(91)90007-K; MOONEY HA, 1968, BRITTONIA, V20, P44, DOI 10.2307/2805460; PAGE R, 1992, COMPONENT USERS MANU; RZEDOWSKI J, 1979, TAXON, V28, P103, DOI 10.2307/1219565; *SAS INST INC, 1989, SAS STAT US GUID VER, V4; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; Swofford D.L., 1993, PHYLOGENETIC ANAL US	24	351	365	1	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					253	256		10.1126/science.276.5310.253	http://dx.doi.org/10.1126/science.276.5310.253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092474				2022-12-28	WOS:A1997WT92500045
J	Banerjee, AK				Banerjee, AK			DCC expression and prognosis in colorectal cancer	LANCET			English	Editorial Material							GENE; IDENTIFICATION				Banerjee, AK (corresponding author), ROYAL HALIFAX INFIRM,COLORECTAL UNIT,HALIFAX,NS HX1 2YP,CANADA.		Banerjee, Anjan Kumar/AAL-6375-2020	Banerjee, Anjan Kumar/0000-0002-5935-3404				BANERJEE AK, 1995, BRIT J SURG, V82, P1096; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JONES DJ, 1988, BRIT J SURG, V75, P28, DOI 10.1002/bjs.1800750111; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KOKAL WA, 1989, ANN SURG, V209, P188, DOI 10.1097/00000658-198902000-00009; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; NARAYANAN R, 1992, ONCOGENE, V7, P553; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	12	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					968	968		10.1016/S0140-6736(05)62888-7	http://dx.doi.org/10.1016/S0140-6736(05)62888-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100619				2022-12-28	WOS:A1997WR62100004
J	Wyncoll, DLA; Roberts, PC; Beale, RJ; McLuckie, A				Wyncoll, DLA; Roberts, PC; Beale, RJ; McLuckie, A			H-2 blockers in the intensive care unit: Ignoring the evidence? Telephone survey	BRITISH MEDICAL JOURNAL			English	Article							STRESS-ULCER; PROPHYLAXIS; PNEUMONIA				Wyncoll, DLA (corresponding author), GUYS HOSP,DEPT INTENS CARE,LONDON SE1 9RT,ENGLAND.							COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; NAVAB F, 1995, AM J GASTROENTEROL, V90, P708; TRYBA M, 1991, CRIT CARE MED, V19, P942, DOI 10.1097/00003246-199107000-00020	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1013	1013		10.1136/bmj.314.7086.1013	http://dx.doi.org/10.1136/bmj.314.7086.1013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112846	Green Published			2022-12-28	WOS:A1997WT15200025
J	Farrell, HE; Vally, H; Lynch, DM; Fleming, P; Shellam, GR; Scalzo, AA; DavisPoynter, NJ				Farrell, HE; Vally, H; Lynch, DM; Fleming, P; Shellam, GR; Scalzo, AA; DavisPoynter, NJ			Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo	NATURE			English	Article							NK CELLS; GENE-COMPLEX; ANTIGEN; INFECTION; VIRUS; RESISTANCE; RECEPTORS; MOLECULES; TRANSPORT; MOUSE	Herpesviruses, such as murine and human cytomegalovirus (MCMV and HCMV), can establish a persistent infection within the host and have diverse mechanisms as protection from host immune defences'. Several herpesvirus genes that are homologous to host immune modulators have been identified, and are implicated in viral evasion of the host immune response(2,3). The discovery of a viral major histocompatibility complex (MHC) class I homologue, encoded by HCMV(4), led to speculation that it might function as an immune modulator and disrupt presentation of peptides by MHC class I to cytotoxic T cells(5). However, there is no evidence concerning the biological significance of this gene during viral infection. Recent analysis of the MCMV genome has also demonstrated the presence of a MHC class I homologue(6). Here we show that a recombinant MCMV,in which. the gene encoding the class I homologue has been disrupted, has severely restricted replication during the acute stage of infection compared with wild-type MCMV, We demonstrate by in vivo depletion studies that natural killer (NK) cells are responsible for the attenuated phenotype of the mutant. Thus the viral MHC dass I homologue contributes to immune evasion through interference with NK cell-mediated clearance.			Farrell, HE (corresponding author), UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT MICROBIOL,NEDLANDS,WA 6907,AUSTRALIA.		Vally, Hassan/AFK-2936-2022; Vally, Hassan/AAG-1307-2022; Davis-Poynter, Nicholas/B-3811-2010; Farrell, Helen/F-8583-2011	Vally, Hassan/0000-0001-5281-7459; Vally, Hassan/0000-0001-5281-7459; Davis-Poynter, Nicholas/0000-0001-7368-1925; Farrell, Helen/0000-0002-7214-2767				BANCROFT GJ, 1981, J IMMUNOL, V126, P988; BANKS TA, 1992, CLIN INFECT DIS, V14, P933, DOI 10.1093/clinids/14.4.933; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWNE H, 1992, J VIROL, V66, P6784, DOI 10.1128/JVI.66.11.6784-6787.1992; BROWNE H, 1990, NATURE, V347, P770, DOI 10.1038/347770a0; BUKOWSKI JF, 1984, J VIROL, V52, P119, DOI 10.1128/JVI.52.1.119-128.1984; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; DAVISPOYNTER NJ, 1996, IMMUNOL CELL BIOL, V74, P512; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; FAHNESTOCK ML, 1995, IMMUNITY, V3, P538; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; KARLHOFER FM, 1991, J IMMUNOL, V146, P3662; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Raulet DH, 1996, CURR OPIN IMMUNOL, V8, P372, DOI 10.1016/S0952-7915(96)80127-0; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1995, IMMUNOGENETICS, V41, P148, DOI 10.1007/BF00182328; SHELLAM GR, 1985, SCAND J IMMUNOL, V22, P147, DOI 10.1111/j.1365-3083.1985.tb01867.x; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; THALE R, 1995, J VIROL, V69, P6098; VIEIRA J, 1994, J VIROL, V68, P4837, DOI 10.1128/JVI.68.8.4837-4846.1994; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILEY D, 1988, NATURE, V331, P209, DOI 10.1038/331209a0; YOKOYAMA WM, 1995, CURR OPIN IMMUNOL, V7, P110, DOI 10.1016/0952-7915(95)80036-0	30	239	244	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					510	514		10.1038/386510a0	http://dx.doi.org/10.1038/386510a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087412				2022-12-28	WOS:A1997WR25600056
J	Lenaghan, J				Lenaghan, J			The rationing debate - Central government should have a greater role in rationing decisions - The case for	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE				Lenaghan, J (corresponding author), INST PUBL POLICY RES,LONDON WC2E 7RA,ENGLAND.							BUSSE R, 1996, HARD CHOICES HLTH CA; COOPER L, 1995, VOICES; COOTE A, CITIZENS JURIES THEO; DICKSON N, 1996, GUARDIAN        0916; HAM C, 1995, BRIT MED J, V310, P1483, DOI 10.1136/bmj.310.6993.1483; HARRISON S, 1991, HLTH HLTH CARE; *HOUS COMM HLTH CO, 1995, PRIOR SETT NHS PURCH, V1; HUNTER DJ, 1995, BRIT MED BULL, V51, P876, DOI 10.1093/oxfordjournals.bmb.a073002; Kennedy Ian, 1988, TREAT ME RIGHT ESSAY; KLEIN R, 1995, NEW POLITICS NHS, P23; Lenaghan J, 1996, BRIT MED J, V312, P1591, DOI 10.1136/bmj.312.7046.1591; Lenaghan J, 1996, RATIONING RIGHTS HLT; MARWICK S, 1996, ELIGIBILITY CRITERIA; McKee M, 1996, BRIT MED J, V312, P691; MCLEAN SMA, 1996, SOC SCI MED, V39, P1221; *NAT I ASS CONC, 1995, REP 4 NAT SURV NHS F; New B, 1996, BRIT MED J, V312, P1593, DOI 10.1136/bmj.312.7046.1593; NEW B, 1996, RATIONING NHS PRINCI; REDMAYNE S, 1995, RESHAPING NHS STRATE, P51; *ROYAL COLL PHYS, 1995, SETT PRIOR NHS FRAM	20	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					967	970		10.1136/bmj.314.7085.967	http://dx.doi.org/10.1136/bmj.314.7085.967			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099126	Green Published			2022-12-28	WOS:A1997WQ16900036
J	Hakama, M; Pukkala, E; Heikkila, M; Kallio, M				Hakama, M; Pukkala, E; Heikkila, M; Kallio, M			Effectiveness of the public health policy for breast cancer screening in Finland: Population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							MAMMOGRAPHY; MORTALITY; REDUCTION; PROJECT	Objective: To evaluate the effectiveness of screening for breast cancer as a public health policy. Design: Follow up in 1987-92 of Finnish women invited to join the screening programme in 1987-9 and of the control women (balanced by age and matched by municipality of residence), who were not invited to the service screening. Setting: Finland. Subjects: Of the Finnish women born in 1927-39, 89 893 women invited for screening and 68 862 controls were followed; 1584 breast cancers were diagnosed. Main outcome measures: Rate ratio of deaths from breast cancer among the women invited for screening to deaths among those not invited. Results: There were 385 deaths from breast cancer, of which 127 were among the 1584 incident cases in 1987-92. The rate ratio of death was 0.76 (95% confidence interval 0.53 to 1.09). The effect was larger and significant (0.56; 0.33 to 0.95) among women aged under 56 years at entry. 20 cancers were prevented (one death prevented per 10 000 screens). Conclusions: A breast screening programme can achieve a similar effect on mortality as achieved by the trials for breast cancer screening. However, it may be difficult to justify a screening programme as a public health policy on the basis of the mortality reduction only. Whether to run a screening programme as a public health policy also depends on its effects on the quality of life of the target population and what the resources would be used for if screening was not done. Given all the different dimensions in the effect, mammography based breast screening is probably justifiable as a public health policy.	FINNISH CANC REGISTRY,FIN-00170 HELSINKI,FINLAND	Finnish Cancer Registry	Hakama, M (corresponding author), UNIV TAMPERE,SCH PUBL HLTH,BOX 607,FIN-33101 TAMPERE,FINLAND.							CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; COLLETTE HJA, 1984, LANCET, V1, P1224; DAY NE, 1988, SCREENING BREAST CAN; DEKONING HJ, 1995, INT J CANCER, V60, P777, DOI 10.1002/ijc.2910600608; DEKONING HJ, 1995, LANCET, V346, P438; HAKAMA M, 1991, BRIT J CANCER, V64, P962, DOI 10.1038/bjc.1991.436; Hristova L, 1997, ACTA ONCOL, V36, P1; Kallio M, 1994, Duodecim, V110, P1061; KAUPPINEN A, 1970, ACTA OBSTET GYNECOL, V7, P1; KIERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149; MILLER AB, 1991, CANC SCREENING UICC; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; Shapiro S., 1988, SCREEN BREAST CANC, P3; SKRABANEK P, 1985, LANCET, V2, P316; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; Tornberg S, 1994, J Med Screen, V1, P184; VERBEEK ALM, 1984, LANCET, V1, P1222; Wald NJ, 1993, BREAST, V2, P209; WRIGHT CJ, 1995, LANCET, V346, P29, DOI 10.1016/S0140-6736(95)92655-0	20	128	129	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					864	867						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093096				2022-12-28	WOS:A1997WQ02800025
J	GonzalezGaitan, M; Jackle, H				GonzalezGaitan, M; Jackle, H			Role of Drosophila alpha-adaptin in presynaptic vesicle recycling	CELL			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; FROG NEUROMUSCULAR JUNCTION; CLATHRIN-COATED PITS; SYNAPTIC VESICLES; MEMBRANE RETRIEVAL; PLASMA-MEMBRANE; HIGH-AFFINITY; TRANSMITTER RELEASE; REVERSIBLE BLOCKAGE; NERVE-TERMINALS	Rapid flow of information in the nervous system involves presynaptic vesicle recycling by clathrin-mediated endocytosis, an event triggered by the alpha-adaptin-containing AP2 complex. We identified a Drosophila alpha-adaptin expressed in the garland cells, imaginal discs, and the CNS. Here we show its role in presynaptic vesicle recycling. In presynaptic terminals, alpha-adaptin defines a network-like membrane structure to which the GTPase dynamin is recruited. alpha-adaptin is necessary for the formation of clathrin-coated pits and participates in the dynamin-dependent release of coated vesicles from the membrane surface. Our results suggest an alpha-adaptin-dependent control of the vesicle cycle that maintains the balance between the amount of vesicle- and surface-associated membranes.			GonzalezGaitan, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM,ABT MOL ENTWICKLUNGSBIOL,FASSBERG,D-37077 GOTTINGEN,GERMANY.			Gonzalez-Gaitan, Marcos/0000-0002-6295-7321				ALMERS W, 1994, NATURE, V367, P682; ATWOOD HL, 1993, J NEUROBIOL, V24, P1008, DOI 10.1002/neu.480240803; BALL CL, 1995, J CELL SCI, V108, P2865; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CAMPOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP, P986; CECCARELLI B, 1979, J CELL BIOL, V81, P163, DOI 10.1083/jcb.81.1.163; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN MS, 1992, J CELL SCI, V103, P619; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Estes PS, 1996, J NEUROSCI, V16, P5443; Frommer G, 1996, EMBO J, V15, P1642, DOI 10.1002/j.1460-2075.1996.tb00509.x; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GONZALEZGAITAN MA, 1996, MOL BIOL INSECT DIS, P283; Goodman Corey S., 1993, P1131; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; HALTER DA, 1995, DEVELOPMENT, V121, P317; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KARPEN GH, 1992, GENETICS, V132, P737; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; NESTEROV A, 1995, J BIOL CHEM, V270, P8320; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; RAMASWAMI M, 1993, J NEUROGENET, V9, P73, DOI 10.3109/01677069309083451; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUN BH, 1995, P NATL ACAD SCI USA, V92, P5396, DOI 10.1073/pnas.92.12.5396; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TARELLI FT, 1990, J CELL BIOL, V110, P449; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONWEDEL RJ, 1981, P NATL ACAD SCI-BIOL, V78, P1014; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	66	212	217	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					767	776		10.1016/S0092-8674(00)81923-6	http://dx.doi.org/10.1016/S0092-8674(00)81923-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118220	Bronze			2022-12-28	WOS:A1997WQ10000009
J	Rambukkana, A; Salzer, JL; Yurchenco, PD; Tuomanen, EI				Rambukkana, A; Salzer, JL; Yurchenco, PD; Tuomanen, EI			Neural targeting of Mycobacterium leprae mediated by the G domain of the laminin-alpha 2 chain	CELL			English	Article							SCHWANN-CELLS; BASEMENT-MEMBRANES; HEPARIN-BINDING; PERINEURIAL CELLS; LAMININ VARIANTS; GLOBULAR DOMAIN; A-CHAIN; EXPRESSION; MEROSIN; PROTEIN	We report that the molecular basis of the neural tropism of Mycobacterium leprae is attributable to the specific binding of M. leprae to the laminin-alpha 2 (LN-alpha 2) chain on Schwann cell-axon units. Using recombinant fragments of LN-alpha 2 (rLN-alpha 2), the M. leprae-binding site was localized to the G domain. rLN-alpha PG mediated M. leprae binding to cell lines and to sciatic nerves of dystrophic dy/dy mice lacking LN-alpha 2, but expressing laminin receptors. Anti-beta(4) integrin antibody attenuated rLN-alpha 2G-mediated M. leprae adherence, suggesting that M. leprae interacts with cells by binding to beta(4) integrin via an LN-alpha 2G bridge. Our results indicate a novel role for the G domain of LN-2 in infection and reveal a model in which a host-derived bridging molecule determines nerve tropism of a pathogen.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT NEUROL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854	New York University; New York University; New York University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rambukkana, A (corresponding author), ROCKEFELLER UNIV,LAB MOL INFECT DIS,1230 YORK AVE,NEW YORK,NY 10021, USA.		Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716; Salzer, James/0000-0001-9126-7197; rambukkana, anura/0000-0002-6286-9145; Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048045, R01DK036425, R37DK036425] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27913] Funding Source: Medline; NIDDK NIH HHS [DK36425, DK48045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; BRADLEY WG, 1975, J NEUROL SCI, V25, P249, DOI 10.1016/0022-510X(75)90144-6; BUNGE MB, 1990, ANN NY ACAD SCI, V580, P281, DOI 10.1111/j.1749-6632.1990.tb17937.x; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; CORNBROOKS CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3850, DOI 10.1073/pnas.80.12.3850; Danielssen D.C., 1848, TRAITE SPEDALSKHED E; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DUNCAN ME, 1984, PLACENTA, V5, P189, DOI 10.1016/S0143-4004(84)80028-4; DUNCAN ME, 1983, INT J LEPROSY, V51, P7; EINHEBER S, 1995, J CELL BIOL, V129, P443, DOI 10.1083/jcb.129.2.443; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Engvall E, 1996, J CELL BIOCHEM, V61, P493; ESIRI MM, 1972, J PATHOL, V106, P73, DOI 10.1002/path.1711060203; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; GAMBLE HJ, 1964, J ANAT, V98, P655; HOEPELMAN AIM, 1992, INFECT IMMUN, V60, P1729, DOI 10.1128/IAI.60.5.1729-1733.1992; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JAAKKOLA S, 1989, J CLIN INVEST, V84, P253, DOI 10.1172/JCI114148; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; JOB CK, 1989, INT J LEPROSY, V57, P532; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LUMSDEN CE, 1959, LEPROSY THEORY PRACT, P221; MAEDA M, 1987, LEPROSY REV, V58, P39; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; MOYA F, 1980, P NATL ACAD SCI-BIOL, V77, P6902, DOI 10.1073/pnas.77.11.6902; MUKHERJEE R, 1986, INT J LEPROSY, V54, P632; NIESSEN CM, 1994, J CELL SCI, V107, P543; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; Pearson J M, 1970, Lepr Rev, V41, P155; RAMBUKKANA A, 1993, INFECT IMMUN, V61, P1835, DOI 10.1128/IAI.61.5.1835-1845.1993; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHOREY JS, 1995, INFECT IMMUN, V63, P2652, DOI 10.1128/IAI.63.7.2652-2657.1995; SONNENBERG A, 1990, J CELL SCI, V96, P207; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; VANDERFLIER M, 1995, INFECT IMMUN, V63, P4317, DOI 10.1128/IAI.63.11.4317-4322.1995; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1992, J CELL BIOL, V118, P493	57	134	138	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					811	821		10.1016/S0092-8674(00)81927-3	http://dx.doi.org/10.1016/S0092-8674(00)81927-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118224	hybrid			2022-12-28	WOS:A1997WQ10000013
J	Pearson, P; Jones, K				Pearson, P; Jones, K			Primary care - Opportunities and threats - Developing professional knowledge: Making primary care education and research more relevant	BRITISH MEDICAL JOURNAL			English	Article								The trio of recent government white papers heralds a new world for primary care. Many changes in the education of future primary health care professionals and in the research ethos of the discipline will be needed to realise this vision. New skills and attitudes, not least in multidisciplinary working; lifelong learning; and greater understanding of and participation in primary care research will have to emerge from educational efforts in the next few years.	UNIV NEWCASTLE,SCH MED,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK								ALDERWICK J, 1996, EXTENDING PRIMARY CA, P37; *DEP HLTH, 1996, CM3425; *DEP HLTH, 1996, CM3512; *DEP HLTH, 1996, CM3390; General Medical Council, 1993, TOM DOCT; KINMOUTH AL, 1996, BRIT MED J, V310, P343; MANT D, 1996, NATL WORKING GROUP R; *NHS EX, 1997, R D SUPP FUND NHS PR; PEARSON P, 1994, BRIT MED J, V309, P1387, DOI 10.1136/bmj.309.6966.1387; Pearson P, 1995, Health Visit, V68, P157; ROBINSON LA, 1994, BRIT J GEN PRACT, V44, P489; *UK CETR COUNC NUR, 1988, PROJ 2000 NEW PREP P; 1988, WORLD HLTH       AUG	13	10	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					817	820		10.1136/bmj.314.7083.817	http://dx.doi.org/10.1136/bmj.314.7083.817			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081008	Green Published			2022-12-28	WOS:A1997WN64600039
J	Sattin, RW				Sattin, RW			Preventing injurious falls	LANCET			English	Editorial Material							RISK; PERSPECTIVE; COMMUNITY				Sattin, RW (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30333, USA.							PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; SATTIN RW, 1992, ANNU REV PUBL HEALTH, V13, P489, DOI 10.1146/annurev.pu.13.050192.002421; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VANWEEL C, 1995, LANCET, V345, P1549, DOI 10.1016/S0140-6736(95)91091-3; VTTERSTAD B, 1996, J EPIDEMIOL COMMUNIT, V50, P551	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					150	150		10.1016/S0140-6736(05)60975-0	http://dx.doi.org/10.1016/S0140-6736(05)60975-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111536				2022-12-28	WOS:A1997WC86100006
J	Royden, LH; Burchfiel, BC; King, RW; Wang, E; Chen, ZL; Shen, F; Liu, YP				Royden, LH; Burchfiel, BC; King, RW; Wang, E; Chen, ZL; Shen, F; Liu, YP			Surface deformation and lower crustal flow in eastern Tibet	SCIENCE			English	Article							INDIA-EURASIA COLLISION; CONTINENTAL COLLISION; TECTONIC IMPLICATIONS; ASIA; PLATEAU; UPLIFT; MODEL; EXTENSION	Field observations and satellite geodesy indicate that little crustal shortening has occurred along the central to southern margin of the eastern Tibetan plateau since about 4 million years ago. Instead, central eastern Tibet has been nearly stationary relative to southeastern China, southeastern Tibet has rotated clockwise without major crustal shortening, and the crust along portions of the eastern plateau margin has been extended. Modeling suggests that these phenomena are the result of continental convergence where the lower crust is so weak that upper crustal deformation is decoupled from the motion of the underlying mantle. This model also predicts east-west extension on the high plateau without convective removal of Tibetan lithosphere and without eastward movement of the crust east of the plateau.	CHENGDU INST GEOL & MINERAL RESOURCES,CHENGDU,PEOPLES R CHINA		Royden, LH (corresponding author), MIT,DEPT EARTH ATMOSPHER & PLANETARY SCI,CAMBRIDGE,MA 02139, USA.							ARGAND E, 1924, 13 INT GEOL C COLL R, V1, P171; ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; BEAUMONT C, 1992, ALBERTA BASEMENT TRA, V228, P22; Burchfiel B.C., 1992, 269 GEOL SOC AM; Burchfiel B.C., 1995, INT GEOL REV, V37, P661, DOI [10.1080/00206819509465424, DOI 10.1080/00206819509465424]; BURCHFIEL BC, 1991, ECLOGAE GEOL HELV, V84, P599; COLEMAN M, 1995, NATURE, V374, P49, DOI 10.1038/374049a0; COWARD MP, 1988, PHILOS T R SOC A, V327, P307, DOI 10.1098/rsta.1988.0131; DEWEY JF, 1973, J GEOL, V81, P683, DOI 10.1086/627920; ENGLAND P, 1986, J GEOPHYS RES-SOLID, V91, P3664, DOI 10.1029/JB091iB03p03664; ENGLAND P, 1982, GEOPHYS J ROY ASTR S, V70, P295, DOI 10.1111/j.1365-246X.1982.tb04969.x; ENGLAND PC, 1988, PHILOS T R SOC A, V326, P301, DOI 10.1098/rsta.1988.0089; HARRISON TM, 1992, SCIENCE, V255, P1663, DOI 10.1126/science.255.5052.1663; HOLT WE, 1991, J GEOPHYS RES-SOLID, V96, P14595, DOI 10.1029/91JB01021; HOUSEMAN G, 1993, J GEOPHYS RES-SOL EA, V98, P12233, DOI 10.1029/93JB00443; JIN Y, 1994, NATURE, V371, P669, DOI 10.1038/371669a0; JOLIVET L, 1990, TECTONICS, V9, P1409, DOI 10.1029/TC009i006p01409; King RW, 1997, GEOLOGY, V25, P179, DOI 10.1130/0091-7613(1997)025<0179:GMOCMI>2.3.CO;2; MASEK JG, 1994, TECTONICS, V13, P659, DOI 10.1029/94TC00452; MOLNAR P, 1977, GEOLOGY, V5, P212, DOI 10.1130/0091-7613(1977)5<212:ROTTOE>2.0.CO;2; MOLNAR P, 1988, PHILOS T R SOC A, V326, P33, DOI 10.1098/rsta.1988.0080; MOLNAR P, 1975, SCIENCE, V189, P419, DOI 10.1126/science.189.4201.419; Royden L, 1996, J GEOPHYS RES-SOL EA, V101, P17679, DOI 10.1029/96JB00951; SHEN F, 1995, P INT UN GEOD GEOPH, P29; TAPPONNIER P, 1982, GEOLOGY, V10, P611, DOI 10.1130/0091-7613(1982)10<611:PETIAN>2.0.CO;2; TURNER S, 1993, NATURE, V364, P50, DOI 10.1038/364050a0; WANG EG, UNPUB; WILLETT S, 1993, GEOLOGY, V21, P371, DOI 10.1130/0091-7613(1993)021<0371:MMFTTO>2.3.CO;2; Xu R., 1981, GEOLOGICAL ECOLOGICA, P139; ZHAO WL, 1985, TECTONICS, V4, P359, DOI 10.1029/TC004i004p00359	31	1267	1575	20	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					788	790		10.1126/science.276.5313.788	http://dx.doi.org/10.1126/science.276.5313.788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115202				2022-12-28	WOS:A1997WW90000056
J	Dent, AL; Shaffer, AL; Yu, X; Allman, D; Staudt, LM				Dent, AL; Shaffer, AL; Yu, X; Allman, D; Staudt, LM			Control of inflammation, cytokine expression, and germinal center formation by BCL-6	SCIENCE			English	Article							CENTER B-CELLS; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; TRANSCRIPTION FACTOR; PROTEIN; BINDING; SEQUENCE; LAZ3; IL-4; TRANSLOCATIONS	The gene encoding the BCL-6 transcriptional repressor is frequently translocated and mutated in diffuse large cell lymphoma. Mice with a disrupted BCL-6 gene developed myocarditis and pulmonary vasculitis, had no germinal centers, and had increased expression of T helper cell type 2 cytokines. The BCL-6 DNA recognition motif resembled sites bound by the STAT (signal transducers and activators of transcription) transcription factors, which mediate cytokine signaling. BCL-6 could repress interleukin-4 (IL-4)-induced transcription when bound to a site recognized by the IL-4-responsive transcription factor Stat6. Thus, dysregulation of STAT-responsive genes may underlie the inflammatory disease in BCL-6-deficient mice and participate in lymphoid malignancies.	NCI,METAB BRANCH,NATL INST HLTH,BETHESDA,MD 20892; NCI,EXPT IMMUNOL BRANCH,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Staudt, Louis/AAC-5324-2019					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DENT AJ, UNPUB; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FLENGHI L, 1995, AM J PATHOL, V147, P405; HOU J, 1994, SCIENCE, V265; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Seyfert VL, 1996, ONCOGENE, V12, P2331; SHIMODA K, 1996, IMMUNITY, V4, P313; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	38	735	753	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					589	592		10.1126/science.276.5312.589	http://dx.doi.org/10.1126/science.276.5312.589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110977				2022-12-28	WOS:A1997WV72100044
J	Sano, M; Ernesto, C; Thomas, RG; Klauber, MR; Schafer, K; Grundman, M; Woodbury, P; Growdon, J; Cotman, DW; Pfeiffer, E; Schneider, LS; Thal, LJ				Sano, M; Ernesto, C; Thomas, RG; Klauber, MR; Schafer, K; Grundman, M; Woodbury, P; Growdon, J; Cotman, DW; Pfeiffer, E; Schneider, LS; Thal, LJ			A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RATING-SCALE; L-DEPRENYL; VITAMIN-E; DEMENTIA; TACRINE; CANCER	Background There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. Methods We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). Results Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental Stale Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001), or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). Conclusions In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease. (C) 1997, Massachusetts Medical Society.	COLUMBIA UNIV, COLL PHYS & SURG, GERTRUDE H SERGIEVSKY CTR, DEPT NEUROL, NEW YORK, NY USA; UNIV CALIF SAN DIEGO, ALZHEIMERS DIS COOPERAT STUDY, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV S FLORIDA, TAMPA, FL USA; UNIV SO CALIF, LOS ANGELES, CA USA	Columbia University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Harvard Medical School; University of California System; University of California Irvine; State University System of Florida; University of South Florida; University of Southern California					NATIONAL INSTITUTE ON AGING [U01AG010483, U19AG010483] Funding Source: NIH RePORTER; NIA NIH HHS [U19 AG010483, U01-AG10483] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson DK, 1988, J NEUROTRAUM, V5, P61, DOI 10.1089/neu.1988.5.61; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BRAAK H, 1994, NEURODEGENER DIS, P585; BURKE WJ, 1993, J AM GERIATR SOC, V41, P1219, DOI 10.1111/j.1532-5415.1993.tb07306.x; DAVIES P, 1983, DEMENTIAS, V38, P75; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FLAGG EW, 1995, J AM COLL NUTR, V14, P419; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HARA H, 1990, BRAIN RES, V510, P335, DOI 10.1016/0006-8993(90)91386-U; HARMAN D, 1982, FREE RADICAL BIO MED, V5, P255; HOLM S, 1979, SCAND J STAT, V6, P65; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KNOLL J, 1983, ACTA NEUROL SCAND, V68, P57, DOI 10.1111/j.1600-0404.1983.tb01517.x; MACHLIN LJ, 1995, CRIT REV FOOD SCI, V35, P41, DOI 10.1080/10408399509527684; MANGONI, 1991, EUR NEUROL, V31, P434; MANGONI A, 1991, EUR NEUROL, V31, P100, DOI 10.1159/000116655; MEYDANI SN, 1995, AM J CLIN NUTR, V62, P1462; MILLER RG, 1983, BIOMETRICS, V39, P1077, DOI 10.2307/2531341; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; PEYSER CE, 1995, AM J PSYCHIAT, V152, P1771; PICCININ GL, 1990, CLIN NEUROPHARMACOL, V13, P147, DOI 10.1097/00002826-199004000-00004; PORTA EA, 1988, CELLULAR ANTIOXIDANT, V3, P1; RICHARDS M, 1991, ARCH NEUROL-CHICAGO, V48, P1147, DOI 10.1001/archneur.1991.00530230055021; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Sano M, 1996, ALZ DIS ASSOC DIS, V10, P132, DOI 10.1097/00002093-199601030-00004; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; STERN Y, 1994, J GERONTOL, V49, pM216, DOI 10.1093/geronj/49.5.M216; TARIOT PN, 1995, AM J PSYCHIAT, V152, P1349; Thal LJ, 1996, NEUROLOGY, V47, P705, DOI 10.1212/WNL.47.3.705; YOSHIDA S, 1985, J NEUROCHEM, V44, P1593, DOI 10.1111/j.1471-4159.1985.tb08800.x	35	1890	1994	0	160	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1216	1222		10.1056/NEJM199704243361704	http://dx.doi.org/10.1056/NEJM199704243361704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110909				2022-12-28	WOS:A1997WV33200004
J	Ooi, WL; Barrett, S; Hossain, M; KelleyGagnon, M; Lipsitz, LA				Ooi, WL; Barrett, S; Hossain, M; KelleyGagnon, M; Lipsitz, LA			Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTURAL HYPOTENSION; RESIDENT ASSESSMENT; RANDOM-ZERO; HYPERTENSION; PREVALENCE; HEALTH; RISK; ASSOCIATION; FALLS; MDS	Objectives.-To determine patterns of within-day orthostatic blood pressure (BP) changes and clinical factors correlated with them in frail, elderly nursing home residents. Design.-Prevalence study of orthostatic BP change. Setting.-Sample of 45 nursing homes. Participants.-A total of 911 long-stay residents, aged 60 years or older, able to stand for at least 1 minute. Main Outcome Measures.-Supine and 1-minute and 3-minute standing BP measurements and heart rates, taken by a random-zero sphygmomanometer before and after breakfast and before and after lunch, symptoms upon standing, medication use, and clinical and functional assessments. Results.-Four orthostatic hypotension (OH) groups were defined based on the frequency of a 20 mm Hg or greater orthostatic BP decline during any of 8 postural change measures: no OH group (48.5%); isolated OH group (only once, 18.3%); variable OH group (2-3 times, 19.9%); and persistent OH group (greater than or equal to 4 times, 13.3%), Orthostatic hypotension was most prevalent before breakfast, especially 1 minute after standing (21.3%), and least prevalent after lunch after 3 minutes of standing (4.9%) (P=.001). A regression approach to repeated measures analysis (method of general estimating equations) showed the following to be significantly associated with OH (P less than or equal to.05): elevated supine systolic BP before breakfast, dizziness/light-headedness on standing, male sex, medication for Parkinson disease, time of day (particularly before breakfast), greater independence in activities of daily living, and low body mass index. Conclusions.-Orthostatic hypotension occurs in more than half of frail, elderly nursing home residents, but is highly variable over time. It is most prevalent in the morning when subjects first arise and when supine BP is highest. The relationship of OH with elevated BP, but not antihypertensive medication use, suggests that the treatment of hypertension may improve postural BP regulation.	BETH ISRAEL MED CTR,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Ooi, WL (corresponding author), HEBREW REHABIL CTR AGED,RES & TRAINING INST,1200 CTR ST,BOSTON,MA 02131, USA.				NATIONAL INSTITUTE ON AGING [R01AG009538, P01AG004390, R01AG011023] Funding Source: NIH RePORTER; NIA NIH HHS [AG09538, AG11023, AG04390] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLEGATE WB, 1991, J AM GERIATR SOC, V39, P1057, DOI 10.1111/j.1532-5415.1991.tb02869.x; ARONOW WS, 1988, AM J CARDIOL, V62, P336, DOI 10.1016/0002-9149(88)90243-3; CAIRD FI, 1973, BRIT HEART J, V35, P527; DAVIS BR, 1987, CIRCULATION, V75, P340, DOI 10.1161/01.CIR.75.2.340; HARRIS T, 1991, J GERONTOL, V46, pM159, DOI 10.1093/geronj/46.5.M159; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; Jansen RWMM, 1996, J AM GERIATR SOC, V44, P383, DOI 10.1111/j.1532-5415.1996.tb06406.x; JANSEN RWMM, 1995, ANN INTERN MED, V122, P286, DOI 10.7326/0003-4819-122-4-199502150-00009; JOHNSON RH, 1965, LANCET, V1, P731; JONSSON PV, 1990, ARCH INTERN MED, V150, P1518; KARIM MR, 1988, 674 J HOPK U DEP BIO; KOBRIN I, 1984, J AM GERIATR SOC, V32, P896, DOI 10.1111/j.1532-5415.1984.tb00890.x; KUWAJIMA I, 1992, AM HEART J, V67, P1307; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIPSITZ LA, 1985, CLIN SCI, V69, P337, DOI 10.1042/cs0690337; LIPSITZ LA, 1986, J CHRON DIS, V39, P619, DOI 10.1016/0021-9681(86)90187-6; LIPSITZ LA, 1989, NEW ENGL J MED, V321, P952; MACLENAN WJ, 1993, CARDIOL ELDER, V1, P33; MADER SL, 1987, JAMA-J AM MED ASSOC, V258, P1511, DOI 10.1001/jama.258.11.1511; MESSERLI FH, 1985, NEW ENGL J MED, V312, P1548, DOI 10.1056/NEJM198506133122405; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS JN, 1991, RESIDENT ASSESSMENT; MYERS MG, 1978, CAN MED ASSOC J, V119, P581; PALMER KT, 1983, NEW ZEAL MED J, V96, P43; PARKER D, 1988, HYPERTENSION, V11, P269, DOI 10.1161/01.HYP.11.3.269; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RODSTEIN M, 1957, J Chronic Dis, V6, P581, DOI 10.1016/0021-9681(57)90012-7; RUTAN GH, 1992, HYPERTENSION, V19, P508, DOI 10.1161/01.HYP.19.6.508; SHIMADA K, 1992, J HYPERTENS, V10, P875; TILVIS RS, 1996, J AM GERIATR SOC, V4, P809; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TOHGI H, 1991, STROKE, V22, P603, DOI 10.1161/01.STR.22.5.603; TONKIN A, 1992, CLIN PHARMACOL THER, V52, P277, DOI 10.1038/clpt.1992.142; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; WRIGHT BM, 1970, LANCET, V1, P337; YIP YB, 1994, MED J AUSTRALIA, V160, P14, DOI 10.5694/j.1326-5377.1994.tb138194.x; 1996, CLIN AUTON RES, V6, P125	38	164	170	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1299	1304		10.1001/jama.277.16.1299	http://dx.doi.org/10.1001/jama.277.16.1299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109468				2022-12-28	WOS:A1997WU13500030
J	Chandrasekharappa, SC; Guru, SC; Manickam, P; Olufemi, SE; Collins, FS; EmmertBuck, MR; Debelenko, LV; Zhuang, ZP; Lubensky, IA; Liotta, LA; Crabtree, JS; Wang, YP; Roe, BA; Weisemann, J; Boguski, MS; Agarwal, SK; Kester, MB; Kim, YS; Heppner, C; Dong, QH; Spiegel, AM; Burns, AL; Marx, SJ				Chandrasekharappa, SC; Guru, SC; Manickam, P; Olufemi, SE; Collins, FS; EmmertBuck, MR; Debelenko, LV; Zhuang, ZP; Lubensky, IA; Liotta, LA; Crabtree, JS; Wang, YP; Roe, BA; Weisemann, J; Boguski, MS; Agarwal, SK; Kester, MB; Kim, YS; Heppner, C; Dong, QH; Spiegel, AM; Burns, AL; Marx, SJ			Positional cloning of the gene for multiple endocrine neoplasia-type 1	SCIENCE			English	Article							PROTEIN SEQUENCES; TUMORS; MUTATIONS; 11Q13	Multiple endocrine neoplasia-type 1 (MEN1) is an autosomal dominant familial cancer syndrome characterized by tumors in parathyroids, enteropancreatic endocrine tissues, and the anterior pituitary. DNA sequencing from a previously identified minimal interval on chromosome 11q13 identified several candidate genes, one of which contained 12 different frameshift, nonsense, missense, and in-frame deletion mutations in 14 probands from 15 families. The MEN1 gene contains 10 exons and encodes a ubiquitously expressed 2.8-kilobase transcript. The predicted 610-amino acid protein product, termed menin, exhibits no apparent similarities to any previously known proteins. The identification of MEN? will enable improved understanding of the mechanism of endocrine tumorigenesis and should facilitate early diagnosis.	NATL HUMAN GENOME RES INST,LAB GENE TRANSFER,NIH,BETHESDA,MD 20892; NCI,PATHOL LAB,NIH,BETHESDA,MD 20892; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,NIH,BETHESDA,MD 20894; NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oklahoma System; University of Oklahoma - Norman; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Agarwal, Sunita K/D-1428-2016; Lima, Thaísa/AAG-6483-2021	Agarwal, Sunita K/0000-0002-7557-3191; 				Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALLARD HS, 1964, MEDICINE, V43, P481, DOI 10.1097/00005792-196407000-00003; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; Debelenko LV, 1997, CANCER RES, V57, P1039; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; EMMERTBUCK MR, UNPUB; EMMERTBUCK MR, IN PRESS CANC RES; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; GURU SC, UNPUB; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lubensky IA, 1996, CANCER RES, V56, P5272; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MANICKAM P, UNPUB; Metz David C., 1994, P591; MOLDAWER MP, 1954, AM J MED SCI, V228, P190, DOI 10.1097/00000441-195408000-00008; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; PETTY EM, 1994, AM J HUM GENET, V54, P1060; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SMITH CM, 1995, HUM GENET, V96, P377; Trump D, 1996, QJM-INT J MED, V89, P653; WERMER P, 1954, AM J MED, V16, P363, DOI 10.1016/0002-9343(54)90353-8; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; [No title captured]	31	1510	1544	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					404	407		10.1126/science.276.5311.404	http://dx.doi.org/10.1126/science.276.5311.404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103196	Green Submitted			2022-12-28	WOS:A1997WU47700036
J	Crabb, BS; Cooke, BM; Reeder, JC; Waller, RF; Caruana, SR; Davern, KM; Wickham, ME; Brown, GV; Coppel, RL; Cowman, AF				Crabb, BS; Cooke, BM; Reeder, JC; Waller, RF; Caruana, SR; Davern, KM; Wickham, ME; Brown, GV; Coppel, RL; Cowman, AF			Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress	CELL			English	Article							HISTIDINE-RICH PROTEIN; HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; ADHESION MOLECULE-1; KNOBLESS CLONE; ANTIGEN CD36; BLOOD-CELLS; CDNA CLONE; ERYTHROCYTES; MEMBRANE	Knobs at the surface of erythrocytes infected with Plasmodium falciparum have been proposed to be important in adherence of these cells to the vascular endothelium. This structure contains the knob-associated histidine-rich protein (KAHRP) and the adhesion receptor P. falciparum erythrocyte membrane protein 1. We have disrupted the gene encoding KAHRP and show that it is essential for knob formation. Knob transfectants adhere to CD36 in static assays; when tested under flow conditions that mimic those of postcapillary venules, however, the binding to CD36 was dramatically reduced. These data suggest that knobs on P. falciparum-infected erythrocytes exert an important influence on adherence of parasitized-erythrocytes to microvascular endothelium, an important process in the pathogenesis of P. falciparum infections.	MONASH UNIV,DEPT MICROBIOL,CLAYTON,VIC 3168,AUSTRALIA; UNIV MELBOURNE,DEPT BOT,PLANT CELL BIOL RES CTR,PARKVILLE,VIC 3052,AUSTRALIA	Monash University; University of Melbourne	Crabb, BS (corresponding author), WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA.		Wickham, Mark/A-1396-2009; Crabb, Brendan/F-5287-2013; Wickham, Mark E/HCI-4959-2022; Coppel, Ross L/A-6626-2008; Waller, Ross F/D-5761-2016; Cowman, Alan F/C-7642-2013	Wickham, Mark/0000-0002-3473-7196; Wickham, Mark E/0000-0002-3473-7196; Coppel, Ross L/0000-0002-4476-9124; Waller, Ross F/0000-0001-6961-9344; Cowman, Alan F/0000-0001-5145-9004; Reeder, John/0000-0003-1395-1289	NIDDK NIH HHS [DK32094-10] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA M, 1988, AM J TROP MED HYG, V39, P3, DOI 10.4269/ajtmh.1988.39.3; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIANCO AE, 1986, P NATL ACAD SCI USA, V83, P8713, DOI 10.1073/pnas.83.22.8713; BIGGS BA, 1990, J EXP MED, V171, P1883, DOI 10.1084/jem.171.6.1883; BIGGS BA, 1989, EXP PARASITOL, V69, P189, DOI 10.1016/0014-4894(89)90187-2; Chien S., 1972, HEMODILUTION THEORET, P1; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; COOKE BM, 1995, EXP PARASITOL, V80, P116, DOI 10.1006/expr.1995.1013; COOKE BM, 1994, BRIT J HAEMATOL, V87, P162, DOI 10.1111/j.1365-2141.1994.tb04887.x; COPPEL RL, 1987, MOL BIOCHEM PARASIT, V25, P73, DOI 10.1016/0166-6851(87)90020-X; CORCORAN LM, 1986, CELL, V44, P87, DOI 10.1016/0092-8674(86)90487-3; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; CRANDALL I, 1993, P NATL ACAD SCI USA, V90, P4703, DOI 10.1073/pnas.90.10.4703; CULVENOR JG, 1987, EXP PARASITOL, V63, P58, DOI 10.1016/0014-4894(87)90078-6; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; KILEJIAN A, 1991, MOL BIOCHEM PARASIT, V44, P175, DOI 10.1016/0166-6851(91)90003-O; KILEJIAN A, 1977, B WORLD HEALTH ORGAN, V55, P191; KILEJIAN A, 1979, P NATL ACAD SCI USA, V76, P4650, DOI 10.1073/pnas.76.9.4650; LANGRETH SG, 1985, INFECT IMMUN, V47, P760, DOI 10.1128/IAI.47.3.760-766.1985; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; OCKENHOUSE CF, 1988, J INFECT DIS, V157, P584, DOI 10.1093/infdis/157.3.584; OCKENHOUSE CF, 1991, P NATL ACAD SCI USA, V88, P3175, DOI 10.1073/pnas.88.8.3175; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; PASLOSKE BL, 1993, MOL BIOCHEM PARASIT, V59, P59, DOI 10.1016/0166-6851(93)90007-K; POLOGE LG, 1986, NATURE, V322, P474, DOI 10.1038/322474a0; POLOGE LG, 1987, P NATL ACAD SCI USA, V84, P7139, DOI 10.1073/pnas.84.20.7139; RAVENTOSSUAREZ C, 1985, P NATL ACAD SCI USA, V82, P3829, DOI 10.1073/pnas.82.11.3829; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; TURITTO VT, 1982, PROG HEMOST THROMB, V6, P139; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; UDOMSANGPETCH R, 1989, NATURE, V338, P763, DOI 10.1038/338763a0; WAHLGREN M, 1994, PARASITOL TODAY, V10, P73, DOI 10.1016/0169-4758(94)90400-6; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	45	352	356	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					287	296		10.1016/S0092-8674(00)80207-X	http://dx.doi.org/10.1016/S0092-8674(00)80207-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108483	Bronze			2022-12-28	WOS:A1997WU88800015
J	Drewes, G; Ebneth, A; Preuss, U; Mandelkow, EM; Mandelkow, E				Drewes, G; Ebneth, A; Preuss, U; Mandelkow, EM; Mandelkow, E			MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption	CELL			English	Article							HAMSTER OVARY CELLS; DYNAMIC INSTABILITY; TAU-PROTEIN; MAMMALIAN-CELLS; POLARITY; SEQUENCE; BRAIN; ORGANIZATION; EXPRESSION; INHIBITION	MARK phosphorylates the microtubule-associated proteins tau, MAP2, and MAP4 on their microtubule-binding domain, causing their dissociation from microtubules and increased microtubule dynamics. We describe the molecular cloning, distribution, activation mechanism, and overexpression of two MARK proteins from rat that arise from distinct genes. They encode Ser/Thr kinases of 88 and 81 kDa, respectively, and show similarity to the yeast kin1(+) and C. elegans par-1 genes that are involved in the establishment of cell polarity. Expression of both isoforms is ubiquitous, and homologous genes are present in humans. Catalytic activity depends on phosphorylation of two residues in subdomain VIII. Overexpression of MARK in cells leads to hyperphosphorylation of MAPs on KXGS motifs and to disruption of the microtubule array, resulting in morphological changes and cell death.			Drewes, G (corresponding author), DESY,MAX PLANCK UNIT STRUCT MOL BIOL,NOTKESTR 85,GEBAUDE 25B,D-22603 HAMBURG,GERMANY.			Drewes, Gerard/0000-0003-0575-6766				BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Chang F, 1996, CELL, V84, P191, DOI 10.1016/S0092-8674(00)80973-3; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DONOVAN M, 1994, YEAST, V10, P113, DOI 10.1002/yea.320100111; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; INGLIS JD, 1993, MAMM GENOME, V4, P401, DOI 10.1007/BF00360595; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; LOPEZ LA, 1995, J BIOL CHEM, V270, P12511, DOI 10.1074/jbc.270.21.12511; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Mangan ME, 1996, DEVELOPMENT, V122, P771; McDermott JB, 1996, BIOCHEMISTRY-US, V35, P9415, DOI 10.1021/bi952646n; Mercken M, 1995, J NEUROSCI, V15, P8259; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; PARSA I, 1988, CANCER RES, V48, P2265; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; PRYER NK, 1992, J CELL SCI, V103, P965; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIBBETTS M, 1994, EXP CELL RES, V213, P93, DOI 10.1006/excr.1994.1177; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VANDRE DD, 1991, J CELL SCI, V98, P577; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Wang XM, 1996, J CELL BIOL, V132, P345, DOI 10.1083/jcb.132.3.345; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WATANABE A, 1993, J BIOL CHEM, V268, P25712; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q	54	668	706	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					297	308		10.1016/S0092-8674(00)80208-1	http://dx.doi.org/10.1016/S0092-8674(00)80208-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108484	Bronze			2022-12-28	WOS:A1997WU88800016
J	Hickman, AB; Waninger, S; Scocca, JJ; Dyda, F				Hickman, AB; Waninger, S; Scocca, JJ; Dyda, F			Molecular organization in site-specific recombination: The catalytic domain of bacteriophage HP1 integrase at 2.7 angstrom resolution	CELL			English	Article							4-WAY DNA JUNCTION; CRYSTAL-STRUCTURE; ACTIVE-SITE; HEMOPHILUS-INFLUENZAE; FLP RECOMBINATION; PROTEIN; IDENTIFICATION; BINDING; CHROMOSOME; CLEAVAGE	HP1 integrase promotes site-specific recombination of the HP1 genome into that of Haemophilus influenzae. The isolated C-terminal domain (residues 165-337) of the protein interacts with the recombination site and contains the four catalytic residues conserved in the integrase family. This domain represents a novel fold consisting principally of well-packed cu helices, a surface beta sheet, and an ordered 17-residue C-terminal tail. The conserved triad of basic residues and the active-site tyrosine are contributed by a single monomer and occupy fixed positions in a defined active-site cleft. Dimers are formed by mutual interactions of the tail of one monomer with an adjacent monomer; this orients active-site clefts antiparallel to each other.	NIDDK, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Johns Hopkins University			Waninger, Shani/AAX-7617-2020		NCI NIH HHS [CA09110] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Craigie R., 1995, HIV, V2, P53; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ESPOSITO D, 1994, MOL MICROBIOL, V13, P685, DOI 10.1111/j.1365-2958.1994.tb00462.x; Esposito D, 1996, NUCLEIC ACIDS RES, V24, P2360, DOI 10.1093/nar/24.12.2360; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FUREY W, 1997, IN PRESS METH ENZYMO; GOODMAN SD, 1989, J BACTERIOL, V171, P4232, DOI 10.1128/JB.171.8.4232-4240.1989; Hakimi JM, 1996, MOL MICROBIOL, V21, P147, DOI 10.1046/j.1365-2958.1996.6311351.x; HAKIMI JM, 1994, J BIOL CHEM, V269, P21340; HAKIMIASTUMIAN J, 1989, J BACTERIOL, V171, P1747; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; HATFULL GF, 1989, GENETIC RECOMBINATIO, P357; HAUSER MA, 1992, J BIOL CHEM, V267, P6859; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; JOHNSON RC, 1995, DNA PROTEIN STRUCTUR, P141; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NICHOLIS A, 1991, GRASP MANUAL; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAN H, 1991, J BIOL CHEM, V266, P11347; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; STARK WM, 1995, TRENDS GENET, V11, P121; Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; WALDMAN AS, 1987, J BACTERIOL, V169, P238, DOI 10.1128/jb.169.1.238-246.1987; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0	53	121	130	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					227	237		10.1016/S0092-8674(00)80202-0	http://dx.doi.org/10.1016/S0092-8674(00)80202-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108478	hybrid			2022-12-28	WOS:A1997WU88800010
J	Akimaru, H; Chen, Y; Dai, P; Hou, DX; Nonaka, M; Smolik, SM; Armstrong, S; Goodman, RH; Ishii, S				Akimaru, H; Chen, Y; Dai, P; Hou, DX; Nonaka, M; Smolik, SM; Armstrong, S; Goodman, RH; Ishii, S			Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signalling	NATURE			English	Article							NUCLEAR-PROTEIN CBP; GENE; EXPRESSION; MUTATIONS; EMBRYOS; CREB	The transcription factor CBP, originally identified as a coactivator for CREB(1,2), enhances transcription mediated by many other transcription factors(3-7). Mutations in the human CBP gene are associated with Rubinstein-Taybi syndrome, a haploinsufficiency disorder characterized by abnormal pattern formations, but the mechanism by which decreased CBP levels affect pattern formation is unclear. The hedgehog (hh) signalling pathway is an important determinant of pattern formation. cubitus interruptus (ci), a component in hh signalling; encodes a transcription factor homologous to the Gli family of proteins(9) and is required for induction of the hh-dependent expression of patched (ptc), decapentaplegic (dpp) and wingless (wg)(10). Haploinsufficiency for the ci-related transcription factor Gli3 causes phenotypic changes in mice (known as 'extra-toes)(11) and humans (Greig's cephalopolysyndactyly syndrome)(12) that have similarities to Rubinstein-Taybi syndrome. Here we show that Drosophila CBP (dCBP) functions as a coactivator of Ci, suggesting that the dCBF-Ci interaction may shed light on the contribution of CBP to pattern formation in mammals.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL & MED GENET,PORTLAND,OR 97201	RIKEN; Oregon Health & Science University; Oregon Health & Science University			Ishii, Shunsuke/A-5271-2016; Hou, De-Xing/C-9296-2011	Ishii, Shunsuke/0000-0002-6530-2478; 				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLAIR SS, 1995, NATURE, V373, P656, DOI 10.1038/373656a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Johnson RL, 1995, DEVELOPMENT, V121, P4161; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PETRIJ F, 1996, NATURE, V376, P344; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; SLUSARSKI DC, 1995, GENETICS, V139, P229; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; XU T, 1993, DEVELOPMENT, V117, P1223	25	238	247	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					735	738		10.1038/386735a0	http://dx.doi.org/10.1038/386735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109493				2022-12-28	WOS:A1997WU38700061
J	Risau, W				Risau, W			Mechanisms of angiogenesis	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; TUMOR-GROWTH; VASCULOGENESIS; HYPOXIA; CELLS; HEMATOPOIESIS; EXPRESSION; SURVIVAL; DISEASE	After the developing embryo has formed a primary vascular plexus by a process termed vasculogenesis, further blood vessels are generated by both sprouting and non-sprouting angiogenesis, which are progressively pruned and remodelled into a functional adult circulatory system. Recent results, particularly from the study of mice lacking some of the signalling systems involved, have greatly improved our understanding of the molecular basis underlying these events, and may suggest new approaches for treating conditions such as cancer that depend on angiogenesis.			Risau, W (corresponding author), MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, PK STR 1, D-61231 BAD NAUHEIM, GERMANY.							ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; ASHTON N, 1966, AM J OPHTHALMOL, V62, P412, DOI 10.1016/0002-9394(66)91322-5; AUGUSTIN HG, 1995, AM J PATHOL, V147, P339; BRIER G, 1996, TRENDS CELL BIOL, V6, P454; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Guillemin K, 1996, DEVELOPMENT, V122, P1353; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HENKEMEYER M, 1984, NATURE, V307, P648; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MARKWALD RR, 1990, ANN NY ACAD SCI, V588, P13, DOI 10.1111/j.1749-6632.1990.tb13193.x; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052; Pardanaud L, 1996, DEVELOPMENT, V122, P1363; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; Patan S, 1996, MICROVASC RES, V51, P80, DOI 10.1006/mvre.1996.0009; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Risau W, 1996, CANCER METAST REV, V15, P149, DOI 10.1007/BF00437466; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHORT RHD, 1950, PHILOS T ROY SOC B, V235, P35, DOI 10.1098/rstb.1950.0014; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; [No title captured]	52	4396	4715	15	558	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	1997	386	6626					671	674		10.1038/386671a0	http://dx.doi.org/10.1038/386671a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109485				2022-12-28	WOS:A1997WU38700044
J	Toscani, A; Mettus, RV; Coupland, R; Simpkins, H; Litvin, J; Orth, J; Hatton, KS; Reddy, EP				Toscani, A; Mettus, RV; Coupland, R; Simpkins, H; Litvin, J; Orth, J; Hatton, KS; Reddy, EP			Arrest of spermatogenesis and defective breast development in mice lacking A-myb	NATURE			English	Article							CULTURED-CELLS; MOUSE GENES; EXPRESSION; TESTIS; TISSUE; PROTEIN	The Myb gene family currently consists of three members, named A-, B- and c-myb(1,2). These genes encode nuclear proteins that bind DNA in a sequence-specific manner and function as regulators of transcription. In adult male mice, A-myb is expressed predominantly in male germ cells(2,3). In female mice, A-myb is expressed in breast ductal epithelium, mainly during pregnancy-induced ductal branching and alveolar development. We report here that mice homozygous for a germline mutation in A-myb develop to term but show defects in growth after birth and male infertility due to a block in spermatogenesis. Morphological examination of the testes of A-myb(-/-) males revealed that the germ cells enter meiotic prophase and arrest at pachytene. In adult homozygous null A-myb female mice, the breast epithelial compartment showed underdevelopment of breast tissue following pregnancy and the female mice were unable to nurse their newborn pups, These results demonstrate that A-myb plays a critical role in spermatogenesis and mammary gland development.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011					AMANN RP, 1976, BIOL REPROD, V15, P586, DOI 10.1095/biolreprod15.5.586; BABA T, 1994, J BIOL CHEM, V269, P10133; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; COHEN DR, 1993, ONCOGENE, V8, P443; Dix DJ, 1996, DEV BIOL, V174, P310, DOI 10.1006/dbio.1996.0076; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KANEKO Y, 1995, ONCOGENE, V10, P945; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; METTUS RV, 1994, ONCOGENE, V9, P3077; MORI C, 1995, ANAT REC, V242, P103, DOI 10.1002/ar.1092420114; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PROPST F, 1988, ONCOGENE, V2, P227; ROSAI J, 1989, ACKERMANS SURG PATHO, P949; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SORRENTINO V, 1991, ONCOGENE, V6, P149; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; WONG TW, 1973, ARCH PATHOL, V95, P151	28	185	191	3	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					713	717		10.1038/386713a0	http://dx.doi.org/10.1038/386713a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109487				2022-12-28	WOS:A1997WU38700055
J	Boriani, G; Biffi, M; Capucci, A; Botto, GL; Broffoni, T; Rubino, I; DellaCasa, S; Sanguinetti, M; Magnani, B				Boriani, G; Biffi, M; Capucci, A; Botto, GL; Broffoni, T; Rubino, I; DellaCasa, S; Sanguinetti, M; Magnani, B			Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SINUS RHYTHM; ANTIARRHYTHMIC DRUGS; FLUTTER; FLECAINIDE; AMIODARONE; QUINIDINE; BEHAVIOR; VALUES	Background: The effectiveness of oral propafenone in converting recent-onset atrial fibrillation to sinus rhythm has been established by controlled trials. However, it is not clear whether the effectiveness of propafenone is affected by the presence or absence of underlying heart disease. Objectives: To investigate the safety and effectiveness of oral propafenone and the role of underlying heart disease. Design: Randomized, single-blind, controlled study. Setting: 3 teaching hospitals. Patients: 240 hospitalized patients with recent-onset atrial fibrillation. Intervention: Propafenone (one 600-mg oral dose) or placebo. Measurements: Conversion rates at 3 and 8 hours. Results: Propafenone was more effective than placebo for converting atrial fibrillation to sinus rhythm at 3 hours: Fifty-four of 119 patients (45%) receiving propafenone and 22 of 121 patients (18%) receiving placebo had conversion (P < 0.001). It was also more effective at 8 hours: Ninety-one of 119 patients (76%) receiving propafenone and 45 of 121 patients (37%) receiving placebo had con version (P < 0.001). Subgroup analysis showed that among patients without heart disease, 78% of those receiving propafenone and 56% of those receiving placebo converted to sinus rhythm within 8 hours (P = 0.02). In those with hypertension, the rate was 70% for those receiving propafenone and 27% for those receiving placebo (P < 0.001); in patients with structural heart disease, the rate was 81% for those receiving propafenone and 17% for those receiving placebo (P < 0.001). Conclusions: Oral loading of propafenone was more effective than placebo for conversion to sinus rhythm with in 8 hours and had a favorable safety profile. The rate of spontaneous conversion to sinus rhythm was higher in patients without structural heart disease; this finding has important implications for the assessment of drug effectiveness in recent-onset atrial fibrillation.	OSPED CIVILE PIACENZA, PIACCENZA, ITALY; OSPED S ANNA COMO, COMO, ITALY; PRESIDIO OSPED LUGO, LUGO, ITALY	Ospedale Sant'Anna di Como	Boriani, G (corresponding author), UNIV BOLOGNA, IST CARDIOL, VIA MASSARENTI 9, I-40138 BOLOGNA, ITALY.		Boriani, Giuseppe/AAC-3406-2022; Boriani, Giuseppe/A-4852-2015	Boriani, Giuseppe/0000-0002-9820-4815; Boriani, Giuseppe/0000-0002-9820-4815				BIANCONI L, 1989, AM J CARDIOL, V64, P335, DOI 10.1016/0002-9149(89)90530-4; BORIANI G, 1995, CHEST, V108, P355, DOI 10.1378/chest.108.2.355; BORIANI G, 1993, DRUG INVEST, V6, P25, DOI 10.1007/BF03259424; CAPUCCI A, 1994, INT J CARDIOL, V43, P305, DOI 10.1016/0167-5273(94)90211-9; CAPUCCI A, 1992, AM J CARDIOL, V70, P69, DOI 10.1016/0002-9149(92)91392-H; CAPUCCI A, 1995, CIRCULATION, V92, P1193, DOI 10.1161/01.CIR.92.5.1193; CAPUCCI A, 1994, AM J CARDIOL, V74, P503, DOI 10.1016/0002-9149(94)90915-6; CAPUCCI A, 1990, CARDIOVASC DRUG THER, V4, P281, DOI 10.1007/BF01857646; FELD GK, 1990, AM J CARDIOL, V66, P378, DOI 10.1016/0002-9149(90)90856-V; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; LOMBARDI F, 1992, EUR HEART J, V13, P38, DOI 10.1093/eurheartj/13.suppl_F.38; MARCUS FI, 1990, AM J CARDIOL, V66, P366, DOI 10.1016/0002-9149(90)90851-Q; MURDOCK CJ, 1990, AM J CARDIOL, V66, P755, DOI 10.1016/0002-9149(90)91144-U; NEGRINI M, 1994, CURR THER RES CLIN E, V55, P1345, DOI 10.1016/S0011-393X(05)80319-4; PILATI G, 1991, CURR THER RES CLIN E, V49, P140; SUTTORP MJ, 1990, J AM COLL CARDIOL, V16, P1722, DOI 10.1016/0735-1097(90)90326-K; VONPHILIPSBORN G, 1984, ARZNEIMITTEL-FORSCH, V34-2, P1489; WEINER HL, 1991, J AM COLL CARDIOL, V17, P1283, DOI 10.1016/S0735-1097(10)80136-6; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954	19	118	125	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					621	625		10.7326/0003-4819-126-8-199704150-00006	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103129				2022-12-28	WOS:A1997WT58000008
J	Gurwitz, JH; McLaughlin, TJ; Willison, DJ; Guadagnoli, E; Hauptman, PJ; Gao, XM; Soumerai, SB				Gurwitz, JH; McLaughlin, TJ; Willison, DJ; Guadagnoli, E; Hauptman, PJ; Gao, XM; Soumerai, SB			Delayed hospital presentation in patients who have had acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; patient education; age factors; sex factors; emergency medical services	WORCESTER-HEART-ATTACK; THROMBOLYTIC THERAPY; TIME DELAYS; MORTALITY; ARRIVAL; DISEASE; TRENDS; AGE; POPULATION; OUTCOMES	Background: In patients who have had acute myocardial infarction, the delay between the onset of symptoms and hospital presentation is a critical factor in determining the initial management strategy and outcomes of treatment. Objective: To examine the determinants of delayed hospital presentation in patients who have had acute myocardial infarction. Design: Retrospective chart review. Setting: 37 hospitals in Minnesota. Patients: 2409 persons hospitalized with acute myocardial infarction between October 1992 and July 1993. Main Outcome Measure: Hospital presentation delayed more than 6 hours after the onset of symptoms of acute myocardial infarction. Results: Information on length of delay was available for 2404 patients. Of these patients, 969 (40%) delayed presentation to the hospital for more than 6 hours after the onset of symptoms. Factors associated with prolonged delay included advanced age and female sex. The presence of chest discomfort and a history of mechanical revascularization significantly reduced the risk for prolonged delay. Risk for delay was greatest during the evening and early morning hours (6:00 p.m. to 6:00 a.m.) Patients with a history of hypertension were more likely to delay presentation. Only 42% of all patients hospitalized with acute myocardial infarction had used emergency medical transport services. Conclusions: Patients who have had acute myocardial infarction often delay hospital presentation. Educational interventions that encourage the prompt use of emergency medical transport services and target specific patient populations, such as elderly persons, women, and persons with ca rd iac risk factors, may be most successful in reducing the length of delay and improving the outcomes of patients with acute myocardial infarction.	HARVARD UNIV, SCH MED, HARVARD PILGRIM HLTH CARE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; MCMASTER UNIV, HLTH SCI CTR, HAMILTON, ON L8N 3Z5, CANADA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Gurwitz, JH (corresponding author), UNIV MASSACHUSETTS, MED CTR & FALLON HEALTHCARE SYST, MEYERS PRIMARY CARE INST, 100 CENT ST, WORCESTER, MA 01608 USA.				AHRQ HHS [HSO 7357-03] Funding Source: Medline; NIA NIH HHS [KO8 AG00510] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS007357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BLEEKER JK, 1995, BRIT J GEN PRACT, V45, P181; DRACUP K, 1995, SOC SCI MED, V40, P379, DOI 10.1016/0277-9536(94)00278-2; FRANZOSI MG, 1995, ARCH INTERN MED, V155, P1481, DOI 10.1001/archinte.1995.00430140035003; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; GREENFIELD S, 1994, AM J KIDNEY DIS, V24, P298, DOI 10.1016/S0272-6386(12)80195-8; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; HACKETT TP, 1969, AM J CARDIOL, V24, P651, DOI 10.1016/0002-9149(69)90452-4; HUNGERBUHLER P, 1992, SCHWEIZ MED WSCHR, V122, P1919; Johnson J A, 1995, Am J Crit Care, V4, P29; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KATHLEEN E, 1994, AM J PUBLIC HEALTH, V84, P965, DOI 10.2105/AJPH.84.6.965; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MAYNARD C, 1989, AM J CARDIOL, V63, P1296, DOI 10.1016/0002-9149(89)91038-2; MAYNARD C, 1995, AM J CARDIOL, V76, P548, DOI 10.1016/S0002-9149(99)80152-0; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MEISCHKE H, 1995, ANN EMERG MED, V25, P193, DOI 10.1016/S0196-0644(95)70323-3; MEISCHKE H, 1993, ANN EMERG MED, V22, P1597, DOI 10.1016/S0196-0644(05)81267-3; *NAT HEART ATT COO, 1993, NIH PUBL; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; OLIN HS, 1964, JAMA-J AM MED ASSOC, V190, P977; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; ROWLEY JM, 1992, BRIT HEART J, V67, P255; *SAS I, 1989, SAS STAT US GUID VER; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SIGURDSSON E, 1995, ANN INTERN MED, V122, P96, DOI 10.7326/0003-4819-122-2-199501150-00003; TURI ZG, 1986, AM J CARDIOL, V58, P203, DOI 10.1016/0002-9149(86)90047-0; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEAVER WD, 1995, J AM COLL CARDIOL, V25, pS3; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4	38	134	136	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					593	+		10.7326/0003-4819-126-8-199704150-00001	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103125				2022-12-28	WOS:A1997WT58000004
J	Kingsley, G				Kingsley, G			Microbial DNA in the synovium - A role in aetiology or a mere bystander?	LANCET			English	Editorial Material							PARVOVIRUS B19; ARTHRITIS; FLUID				Kingsley, G (corresponding author), UNITED MED & DENT SCH,RHEUMATOL UNIT,LONDON SE1 9RT,ENGLAND.							KERR JR, 1995, BRIT J RHEUMATOL, V34, P809; Krause Andreas, 1996, Current Opinion in Rheumatology, V8, P203, DOI 10.1097/00002281-199605000-00007; NIKKARI S, 1995, ANN RHEUM DIS, V54, P597, DOI 10.1136/ard.54.7.597; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; SAAL JG, 1992, RHEUMATOL INT, V12, P147, DOI 10.1007/BF00274934; Sieper J, 1996, IMMUNOL TODAY, V17, P160, DOI 10.1016/0167-5699(96)80612-8; WOOLF AD, 1995, ANN RHEUM DIS, V54, P535, DOI 10.1136/ard.54.7.535	7	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1038	1039		10.1016/S0140-6736(97)22015-5	http://dx.doi.org/10.1016/S0140-6736(97)22015-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107236				2022-12-28	WOS:A1997WU00200002
J	Stern, RS; Nichols, KT; Vakeva, LH				Stern, RS; Nichols, KT; Vakeva, LH			Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							8-YEAR FOLLOW-UP; PLUS ULTRAVIOLET; ORAL METHOXSALEN; A RADIATION; PHOTOCHEMOTHERAPY; PATHOLOGISTS; TUMORS	Background Photochemotherapy with oral methoxsalen (psoralen) and ultraviolet A radiation (PUVA) is an effective treatment for psoriasis. However, PUVA is mutagenic, increases the risk of squamous-cell skin cancer, and can cause irregular, pigmented skin lesions. We studied the occurrence of melanoma among patients treated with PUVA. Methods We prospectively identified cases of melanoma and documented the extent of exposure to PUVA among 1380 patients with psoriasis who were first treated with PUVA in 1975 or 1976. Using incidence data, we calculated the expected incidence of melanoma in this cohort and compared it with the observed incidence. Using regression models, we assessed the risks of melanoma associated with a long time (greater than or equal to 15 years) since the first treatment and with a large number of PUVA treatments (greater than or equal to 250). Results From 1975 through 1990, we detected four malignant melanomas, about the number expected in the overall population (relative risk, 1.1). From 1991 through 1996, we detected seven malignant melanomas (relative risk, 5.4; 95 percent confidence interval, 2.2 to 11.1). The risk of melanoma was higher in the later period than in the earlier one (incidence-rate ratio, 3.8) and higher among patients who received at least 250 PUVA treatments than among those who received fewer treatments (incidence-rate ratio, 3.1). Conclusions About 15 years after the first treatment with PUVA, the risk of malignant melanoma increases, especially among patients who receive 250 treatments or more. (C) 1997, Massachusetts Medical Society.	BETH ISRAEL DEACONESS MED CTR,DEPT DERMATOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NIAMS NIH HHS [N01-AR-2214] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEL EA, 1985, J AM ACAD DERMATOL, V13, P761, DOI 10.1016/S0190-9622(85)70219-8; ALCALAY J, 1990, PHOTODERMATOL PHOTO, V7, P28; AUBIN F, 1991, CANCER RES, V51, P5893; BERGNER T, 1992, DERMATOLOGY, V184, P59, DOI 10.1159/000247501; BINET O, 1985, PRESSE MED, V14, P1842; *CANC STAT BRANCH, 1995, SURV EP END RES SEER; Corona R, 1996, J CLIN ONCOL, V14, P1218, DOI 10.1200/JCO.1996.14.4.1218; COX NH, 1987, BRIT J DERMATOL, V116, P145, DOI 10.1111/j.1365-2133.1987.tb05805.x; ELWOOD JM, 1987, J NATL CANCER I, V78, P37, DOI 10.1093/jnci/78.1.37; FRENK E, 1983, DERMATOLOGICA, V167, P152, DOI 10.1159/000249771; Gahlinger PM, 1993, COMPUTER PROGRAMS EP; GRAHAM S, 1985, AM J EPIDEMIOL, V122, P606, DOI 10.1093/oxfordjournals.aje.a114140; GUPTA AK, 1988, J AM ACAD DERMATOL, V19, P67, DOI 10.1016/S0190-9622(88)70153-X; HEENAN PJ, 1984, HISTOPATHOLOGY, V8, P717, DOI 10.1111/j.1365-2559.1984.tb02388.x; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; KEMMETT D, 1984, BRIT MED J, V289, P1498, DOI 10.1136/bmj.289.6457.1498; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KRIEGER N, 1994, J CLIN EPIDEMIOL, V47, P897, DOI 10.1016/0895-4356(94)90193-7; LINDELOF B, 1991, LANCET, V338, P91, DOI 10.1016/0140-6736(91)90083-2; MACDONALD KJS, 1986, BRIT J DERMATOL, V114, P395, DOI 10.1111/j.1365-2133.1986.tb02838.x; MOSELEY HS, 1979, CANCER, V43, P939, DOI 10.1002/1097-0142(197903)43:3<939::AID-CNCR2820430323>3.0.CO;2-N; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; RHODES AR, 1983, J AM ACAD DERMATOL, V9, P47, DOI 10.1016/S0190-9622(83)70106-4; RHODES AR, 1983, J INVEST DERMATOL, V81, P459, DOI 10.1111/1523-1747.ep12522663; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1994, CANCER-AM CANCER SOC, V73, P2759, DOI 10.1002/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C; WHITE E, 1994, AM J EPIDEMIOL, V139, P857, DOI 10.1093/oxfordjournals.aje.a117092; 1997, STATA REFERENCE MANU	30	486	497	3	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1041	1045		10.1056/NEJM199704103361501	http://dx.doi.org/10.1056/NEJM199704103361501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091799				2022-12-28	WOS:A1997WT16100001
J	Adams, SL; Gore, M				Adams, SL; Gore, M			Diagnostician's digit - A repercussion of percussion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NORTHWESTERN UNIV,SCH MED,NORTHWESTERN MEM HOSP,CHICAGO,IL 60611	Northwestern Memorial Hospital; Northwestern University								BLEEHEN SS, 1992, TXB DERMATOLOGY, P1561; DEGOWIN RL, 1987, DEGOWIN DEGOWINS BED, V40, P300; NORDLUND JJ, 1992, DERMATOLOGY, P1421; SAPIRA JD, 1990, ART SCI BEDSIDE DIAG, P245	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1168	1168						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087476				2022-12-28	WOS:A1997WR34200040
J	Green, J; Wintfeld, N; Krasner, M; Wells, C				Green, J; Wintfeld, N; Krasner, M; Wells, C			In search of America's best hospitals - The promise and reality of quality assessment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; STATES; CARE; MEDICARE; MIX	''America's Best Hospitals,'' by US News & World Report, is a sophisticated and influential appraisal of hospital care. Using measures of health care structure, process, and outcome, the report identifies outstanding hospitals in 16 medical specialties through an overall ''index of hospital quality.'' This strong conceptual design, however, has not been adequately implemented because national data sources for all 3 components are severely limited. Most importantly, since there are no national data on process of care, a reputation survey has been used to measure this component of quality. One consequence of reliance on reputation is that a small group of prominent hospitals in each specialty receives such high scores that they automatically rise to the top of the rankings, regardless of structure or outcome score. ''America's Best Hospitals'' identifies America's best regarded hospitals, but provides limited additional insight into quality. Adequate surveillance and protection of quality in an era of managed care requires measurement systems beyond the scope of existing data and methods.			Green, J (corresponding author), NYU MED CTR, DEPT CLIN EVALUAT & OUTCOMES RES, 6600 1ST AVE, 7TH FLOOR, NEW YORK, NY 10016 USA.							*AM HOSP ASS, 1994, ANN SURV HOSP DAT BA; [Anonymous], 1996, US NEWS WORLD REPORT; BLENDON RJ, 1993, NEW ENGL J MED, V328, P1011, DOI 10.1056/NEJM199304083281407; Deming EW., 1986, OUT CRISIS; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DONABEDIAN A, 1985, INQUIRY-J HEALTH CAR, V22, P282; Donabedian A., 1980, EXPLORATIONS QUALITY, V1, P77; DUFFY SQ, 1993, HEALTH AFFAIR, V12, P151, DOI 10.1377/hlthaff.12.2.151; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; *GEN ACC OFF, 1994, HLTH CAR REF REP CAR; GIEGERICH A, 1995, ACCOUNTABILITY NEWS; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Green J, 1992, BROOKLYN LAW R, V58, P55; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; HILL CA, 1995, 1995 INDEX HOSP QUAL; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KELLY JV, 1986, MED CARE, V24, P785, DOI 10.1097/00005650-198609000-00001; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; KUHN EM, 1991, MED CARE, V29, P1028, DOI 10.1097/00005650-199110000-00008; LAFFEL GL, 1992, NEW ENGL J MED, V327, P1220, DOI 10.1056/NEJM199210223271707; LUFT HS, 1985, VOLUME OUTCOME RELAT; MANHEIM LM, 1992, INQUIRY-J HEALTH CAR, V29, P55; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; *OFF TECHN ASS, 1994, OTAH608; PEAR R, 1996, NY TIMES        1013, P13; *US DEP HHS, 1988, INT CLASS DIS 9 REV; WINSLOW R, 1995, WALL STREET J   0412, pA1; WINSLOW R, 1995, WALL STREET J   0718, pB2; 1990, US NEWS WORLD R 0430, P51; 1995, MOD HEALTHCARE, V25, P92; 1993, NY TIMES        0623, P19	35	59	60	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1152	1155		10.1001/jama.277.14.1152	http://dx.doi.org/10.1001/jama.277.14.1152			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WR342	9087471				2022-12-28	WOS:A1997WR34200035
J	Doebley, J; Stec, A; Hubbard, L				Doebley, J; Stec, A; Hubbard, L			The evolution of apical dominance in maize	NATURE			English	Article							TEOSINTE	The domestication of crop plants has often involved an increase in apical dominance (the concentration of resources in the main stem of the plant and a corresponding suppression of axillary branches)(1). A striking example of this phenomenon is seen in maize (Zea mays spp. mays), which exhibits a profound increase in apical dominance compared with its probable wild ancestor, teosinte (Zea mays ssp. parviglumis)(2). Previous research has identified the teosinte branched1 (tb1) gene as a major contributor to this evolutionary change in maize(3). We have cloned tb1 by transposon tagging and show here that it encodes a protein with homology to the cycloidea gene of snapdragon(4). The pattern of tb1 expression and the morphology of tb1 mutant plants suggest that tb1 acts both to repress the growth of axillary organs and to enable the formation of female inflorescences. The maize allele of tb1 is expressed at twice the level of the teosinte allele, suggesting that gene regulatory changes underlie the evolutionary divergence of maize from teosinte.	UNIV CALIF BERKELEY,USDA,CTR PLANT GENE EXPRESS,ALBANY,CA 94710; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	United States Department of Agriculture (USDA); University of California System; University of California Berkeley; University of California System; University of California Berkeley	Doebley, J (corresponding author), UNIV MINNESOTA,DEPT PLANT BIOL,ST PAUL,MN 55108, USA.							BRIGGS S, 1993, MAIZE HDB, P653; Burnham C., 1959, MAIZE GENET COOP NEW, V33, P74; CHANDLER VL, 1992, ADV GENET, V30, P77, DOI 10.1016/S0065-2660(08)60319-3; CHRISTENSEN AH, 1989, PLANT MOL BIOL, V12, P619, DOI 10.1007/BF00044153; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DOEBLEY J, 1993, GENETICS, V134, P559; DOEBLEY J, 1995, GENETICS, V141, P333; Harlan JR, 1992, CROPS MAN, V2nd; ILTIS HH, 1983, SCIENCE, V222, P886, DOI 10.1126/science.222.4626.886; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; PATERSON AH, 1995, SCIENCE, V269, P1714, DOI 10.1126/science.269.5231.1714; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNABLE P, 1992, MAIZE GENET COOP NEW, V66, P5; WOODMAN JC, 1985, PLANT GENETICS, P834	14	1007	1133	9	268	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					485	488		10.1038/386485a0	http://dx.doi.org/10.1038/386485a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087405				2022-12-28	WOS:A1997WR25600049
J	Colloms, SD; Bath, J; Sherratt, DJ				Colloms, SD; Bath, J; Sherratt, DJ			Topological selectivity in Xer site-specific recombination	CELL			English	Article							TN3 RESOLVASE; BACTERIOPHAGE-LAMBDA; STRAND EXCHANGE; MECHANISM; PLASMID; CATENATION; PROTEIN; FLP; CER; RESOLUTION	The product topology of Xer-mediated site-specific recombination at plasmid sites has been determined. The product of deletion at pSC101 psi is a right-handed antiparallel 4-noded catenane. The ColE1 cer deletion product has an identical topology, except that only one pair of strands is exchanged. These specific product topologies imply that the productive synaptic complex and the strand exchange mechanism have fixed topologies. Further analysis suggests that synapsis traps exactly three negative supercoils between recombining sites, and that strand exchange introduces a further negative topological node in the deletion reaction. We present a model in which the requirement for a specific synaptic stucture, with two recombination sites interwrapped around the accessory proteins ArgR and PepA, ensures that recombination only occurs efficiently between directly repeated sites on the same DNA molecule.			Colloms, SD (corresponding author), UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,S PK RD,OXFORD OX1 3QU,ENGLAND.		Bath, Jonathan/E-9569-2011	Bath, Jonathan/0000-0002-7144-662X; Colloms, Sean/0000-0003-2369-8168	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1986, J MOL BIOL, V192, P17, DOI 10.1016/0022-2836(86)90460-2; ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; BEATTY LG, 1986, J MOL BIOL, V188, P529, DOI 10.1016/S0022-2836(86)80003-1; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; CHARLIER D, 1995, J MOL BIOL, V250, P392, DOI 10.1006/jmbi.1995.0385; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DROGE P, 1989, P NATL ACAD SCI USA, V86, P6062, DOI 10.1073/pnas.86.16.6062; DROGE P, 1992, METHOD ENZYMOL, V212, P120; GIANSDORFF N, 1987, SALMONELLA TYPHIMURI, P321; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2328; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KANAAR R, 1988, P NATL ACAD SCI USA, V85, P752, DOI 10.1073/pnas.85.3.752; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; PENG H, 1993, J BIOL CHEM, V268, P24481; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STARK WM, 1995, MOBILE GENETIC ELEME, P101; Stasiak A, 1996, NATURE, V384, P122, DOI 10.1038/384122a0; STIRLING CJ, 1989, EMBO J, V8, P1623, DOI 10.1002/j.1460-2075.1989.tb03547.x; STIRLING CJ, 1988, EMBO J, V7, P4389, DOI 10.1002/j.1460-2075.1988.tb03338.x; SUMMERS DK, 1988, EMBO J, V7, P851, DOI 10.1002/j.1460-2075.1988.tb02884.x; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; THOMPSON JF, 1989, MOBILE DNA, P1; VOLOGODSKII AV, 1993, J MOL BIOL, V232, P1130, DOI 10.1006/jmbi.1993.1465; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6	42	86	87	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					855	864		10.1016/S0092-8674(00)81931-5	http://dx.doi.org/10.1016/S0092-8674(00)81931-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118228	Bronze			2022-12-28	WOS:A1997WQ10000017
J	Paice, E; West, G; Cooper, R; Orton, V; Scotland, A				Paice, E; West, G; Cooper, R; Orton, V; Scotland, A			Senior house officer training: Is it getting better? A questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								A survey of senior house officer posts in North East Thames region uncovered problems with workload, supervision, and education(1 2) similar to those described by others.(3) During the following years two important stages in the implementation of the ''New Deal'' on junior doctors' hours(4) were achieved. After two years we revisited the hospitals surveyed to discover what progress had been made and whether shorter working hours had affected training.	N THAMES REG NEW DEAL TASK FORCE,LONDON W2 3QR,ENGLAND		Paice, E (corresponding author), N THAMES POSTGRAD MED & DENT EDUC,LONDON WC1N 3EJ,ENGLAND.							*DEP HLTH, 1991, HOURS WORK DOCT TRAI; DILLNER L, 1993, BRIT MED J, V306, P1549; GRANT J, 1989, BRIT MED J, V299, P1263, DOI 10.1136/bmj.299.6710.1263; PAICE E, 1994, BRIT J HOSP MED, V51, P123; PAICE E, 1995, BRIT J HOSP MED, V53, P203	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					719	720		10.1136/bmj.314.7082.719	http://dx.doi.org/10.1136/bmj.314.7082.719			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116548	Green Published			2022-12-28	WOS:A1997WM77600023
J	Schimmel, MS; Eidelman, AI; Zadka, P; Kornbluth, E; Hammerman, C				Schimmel, MS; Eidelman, AI; Zadka, P; Kornbluth, E; Hammerman, C			Increased parity and risk of trisomy 21: Review of 37110 live births	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	63rd Annual Meeting of the Society-for-Pediatric-Research	MAY 02-05, 1994	SEATTLE, WA	Soc Pediat Res			AGE	Routine amniocentesis for all women over the age of 35 for detecting trisomy 21 has been the world standard for nearly two decades. It is based on a calculated tradeoff: the documented increased risk of trisomy 21 with advancing age versus the risk of fetal loss secondary to the amniocentesis procedure. Recent data suggest that more specific individual estimates of risk can be made with a combination of maternal age and serum markers.(1) We have reported a trend towards an increased risk of trisomy 21 with increased parity.(2) Given the uniqueness of our population-ultra-Orthodox Jewish mothers who have a high rate of delivery over the age of 35, high parity, and who abstain from prenatal screening and abortion-we had an opportunity to study the interrelation of age and parity.	SHAARE ZEDEK MED CTR,DEPT NEONATOL,IL-91031 JERUSALEM,ISRAEL; ISRAEL CENT BUR STAT,HLTH DIV,JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Shaare Zedek Medical Center								EIDELMAN AI, 1988, AM J OBSTET GYNECOL, V158, P389, DOI 10.1016/0002-9378(88)90161-5; Fleiss JL, 1981, STATISTICAL METHODS, P75; HADDOW JE, 1994, NEW ENGL J MED, V330, P1114, DOI 10.1056/NEJM199404213301603; HADDOW JE, 1994, LANCET, V344, P956, DOI 10.1016/S0140-6736(94)92308-6; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353	5	23	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					720	721		10.1136/bmj.314.7082.720	http://dx.doi.org/10.1136/bmj.314.7082.720			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116549	Green Published			2022-12-28	WOS:A1997WM77600024
J	Lau, YL; Chan, LC; Chan, YYA; Ha, SY; Yeung, CY; Waye, JS; Chui, DHK				Lau, YL; Chan, LC; Chan, YYA; Ha, SY; Yeung, CY; Waye, JS; Chui, DHK			Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong - Implications for population screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOBIN GENE-CLUSTER; SOUTH CHINA; HEMOGLOBINOPATHIES	Background The thalassemias are common in southern China. We determined the prevalence of heterozygous carriers of these genetic disorders in Hang Kong and assessed the feasibility of a community-based screening program. Methods An educational and screening program far the thalassemias was carried out in three high schools with a total of 2420 students. Seventy-five percent of the students agreed to undergo screening, which consisted of blood counts, hemoglobin electrophoresis, serum ferri tin measurements, and DNA analyses. Results Of the 1800 blood samples tested, 150 (8.3 percent) had microcytosis (mean corpuscular volume, <80 mu m(3)). Ninety students (5.0 percent) were carriers of alpha-thalassemia, of whom 81 (4.5 percent) were carriers of the Southeast Asian type of deletion, in which both alpha-globin genes on the same chromosome 16 are deleted. Sixty-one students (3.4 percent) were carriers of either beta-thalassemia or the mutation coding for hemoglobin E. Six students were carriers of both alpha- and beta-thalassemias. On the basis of these figures, the estimated numbers of pregnancies in Hang Kong in which the fetus is at risk for homozygous alpha-thalassemia and beta-thalassemia major or intermedia are 145 and 80 per year, respectively. In Hang Kong the actual numbers of women referred for prenatal diagnoses of these disorders are approximately 95 and 40 per year, respectively. Conclusions Despite the availability of hospital-based screening and prenatal diagnosis for many years in Hong Kong, many women carrying fetuses at risk for thalassemia are not referred for genetic counseling. A community-based program of education, screening, and counseling is needed in Hong Kong and southern China. (C) 1997, Massachusetts Medical Society.	MCMASTER UNIV,SCH MED,PROV HEMOGLOBINOPATHY DNA DIAGNOST LAB,HAMILTON,ON L8S 4L8,CANADA; MCMASTER UNIV,SCH MED,DEPT PATHOL,HAMILTON,ON L8S 4L8,CANADA; UNIV HONG KONG,DEPT PEDIAT,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT PATHOL,HONG KONG,HONG KONG; QUEEN MARY HOSP,HONG KONG,HONG KONG	McMaster University; McMaster University; University of Hong Kong; University of Hong Kong; University of Hong Kong			Lau, Yu Lung/C-4322-2009	Chui, David/0000-0002-1475-7309; HA, Shau Yin/0000-0002-9191-8743				BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; CAO A, 1994, AM J HUM GENET, V54, P397; Chan AYY, 1996, J CLIN PATHOL, V49, P411, DOI 10.1136/jcp.49.5.411; CHAN LC, 1995, J CLIN PATHOL, V48, P861, DOI 10.1136/jcp.48.9.861; CHAN V, 1987, AM J HUM GENET, V41, P678; CHAN V, 1986, BRIT J HAEMATOL, V64, P97, DOI 10.1111/j.1365-2141.1986.tb07577.x; DOVER GJ, 1994, NEW ENGL J MED, V331, P609, DOI 10.1056/NEJM199409013310911; FUCHAROEN S, 1987, HEMOGLOBIN, V11, P65, DOI 10.3109/03630268709036587; FUCHAROEN S, 1988, HEMOGLOBIN, V12, P99; GARDNER MJ, 1991, BRIT MED J; GHOSH A, 1985, PRENATAL DIAG, V5, P59, DOI 10.1002/pd.1970050111; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; HIGGS DR, 1989, BLOOD, V73, P1081; KWAN EYW, 1995, J PAEDIATR CHILD H, V31, P83, DOI 10.1111/j.1440-1754.1995.tb00752.x; LEE ACW, 1993, BONE MARROW TRANSPL, V12, P49; LI AMC, 1982, HUM HERED, V32, P62, DOI 10.1159/000153260; LIANG R, 1994, BRIT J HAEMATOL, V86, P351, DOI 10.1111/j.1365-2141.1994.tb04738.x; MAGER DL, 1985, NUCLEIC ACIDS RES, V13, P6559, DOI 10.1093/nar/13.18.6559; Mitchell JJ, 1996, AM J HUM GENET, V59, P793; MODELL B, 1993, TRENDS GENET, V9, P46, DOI 10.1016/0168-9525(93)90186-L; Nathan DG, 1995, GENE BLOOD COURAGE, P193; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; TANG WZ, 1993, LANCET, V342, P1145, DOI 10.1016/0140-6736(93)92125-D; TODD D, 1969, BRIT J HAEMATOL, V16, P551, DOI 10.1111/j.1365-2141.1969.tb00436.x; WAYE JS, 1993, CLIN INVEST MED, V16, P358; Weatheral DJ., 1995, WILLIAMS HEMATOLOGY, P581; YUEN HL, 1996, COOLEYS ANAEMIA PRES, P31; ZHANG JZ, 1988, HUM GENET, V78, P37, DOI 10.1007/BF00291231; 1989, J R COLL PHYSICIANS, V23, P215	29	178	190	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1298	1301		10.1056/NEJM199705013361805	http://dx.doi.org/10.1056/NEJM199705013361805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113933	Green Published, Bronze			2022-12-28	WOS:A1997WW26000005
J	Lin, Y; Wong, KK; Calame, K				Lin, Y; Wong, KK; Calame, K			Repression of c-myc transcription by blimp-1, an inducer of terminal B cell differentiation	SCIENCE			English	Article							MYELOID-LEUKEMIA CELLS; HEAVY-CHAIN ENHANCER; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; GROWTH ARREST; MESSENGER-RNA; MODEL SYSTEM; PROTEIN; BINDS; INTERFERON	Transcription of c-myc in plasma cells, which are terminally differentiated B cells, is repressed by plasmacytoma repressor factor. This factor was identified as Blimp-1, known for its ability to induce B cell differentiation. Blimp-1 repressed c-myc promoter activity in a binding site-dependent manner. Treatment of BCL1 lymphoma cells with interleukin-2 (IL-2) plus IL-5 induced Blimp-1 and caused a subsequent decline in c-Myc protein. Ectopic expression of Blimp-1 in Abelson-transformed precursor B cells repressed endogenous c-Myc and caused apoptosis; Blimp-1-induced death was partially overcome by ectopic expression of c-Myc. Thus, repression of c-myc is a component of the Blimp-1 program of terminal B cell differentiation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INTEGRATED PROGRAM CELLULAR MOL & BIOPHYS STUDIES,NEW YORK,NY 10032	Columbia University; Columbia University								ADAMS JM, 1982, P NATL ACAD SCI-BIOL, V79, P6966, DOI 10.1073/pnas.79.22.6966; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHISHOLM O, 1992, INT J CANCER, V51, P149, DOI 10.1002/ijc.2910510126; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DAVIS M, COMMUNICATION; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dimitrovsky E., 1986, NATURE, V322, P748; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GERAUDIE J, 1990, P NATL ACAD SCI USA, V87, P3797, DOI 10.1073/pnas.87.10.3797; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HENDERSON AJ, 1994, MOL CELL BIOL, V14, P4286, DOI 10.1128/MCB.14.6.4286; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KAPTEIN JS, 1996, J BIOL CHEM, V271, P1875; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; Lin Y. P., UNPUB; Littlewood T D, 1990, Adv Dent Res, V4, P69; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUI K, 1989, J IMMUNOL, V142, P2918; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Nguyen HQ, 1995, ONCOGENE, V11, P2439; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PETERSON CL, 1986, MOL CELL BIOL, V6, P4168, DOI 10.1128/MCB.6.12.4168; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; PROWCHOWNIK EV, 1986, NATURE, V322, P848; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5152; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; Wu M, 1996, MOL CELL BIOL, V16, P5015; WU M, 1996, EMBO J, V15, P4662; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7367; Yu J., UNPUB; ZHAO XH, 1995, SCI CHINA SER B, V38, P580	59	347	362	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					596	599		10.1126/science.276.5312.596	http://dx.doi.org/10.1126/science.276.5312.596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110979				2022-12-28	WOS:A1997WV72100046
J	Kober, L; TorpPedersen, C; Cole, D; Hampton, JR; Camm, AJ				Kober, L; TorpPedersen, C; Cole, D; Hampton, JR; Camm, AJ			Bayesian interim statistical analysis of randomised trials: The case against	LANCET			English	Editorial Material							VENTRICULAR ENLARGEMENT TRIAL; MYOCARDIAL-INFARCTION; DYSFUNCTION; SURVIVAL		KNEBWORTH CONSULTANCY,KNEBWORTH,HERTS,ENGLAND; UNIV LONDON ST GEORGES HOSP,SCH MED,LONDON SW17 0RE,ENGLAND; QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND	St Georges University London; University of Nottingham	Kober, L (corresponding author), GENTOFTE UNIV HOSP,DEPT CARDIOL,NIELS ANDERSENS VEJ 65,DK-2900 HELLERUP,DENMARK.		Torp-Pedersen, Christian/E-5931-2013	Kober, Lars/0000-0002-6635-1466				*AC INF RAM EFF ST, 1993, LANCET, V342, P821; *CONSENSUS TRIAL S, 1987, NEW ENGL J MED, V316, P1429; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; MOYE LA, 1991, AM J CARDIOL, V68, pD70; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; *SOLVD INV, 1991, NEW ENGL J MED, V325, P293; *SOLVD INV, 1992, NEW ENGL J MED, V327, P685	7	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1168	1169		10.1016/S0140-6736(96)11416-1	http://dx.doi.org/10.1016/S0140-6736(96)11416-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113026				2022-12-28	WOS:A1997WU54400043
J	Sakai, J; Kleckner, N				Sakai, J; Kleckner, N			The Tn10 synaptic complex can capture a target DNA only after transposon excision	CELL			English	Article							STRAND TRANSFER; MU-DNA; INSERTION SPECIFICITY; CONSENSUS SEQUENCE; SITE; PROTEIN; MECHANISM; CLEAVAGE; RECOMBINATION; INTERMEDIATE	Tn10 transposes nonreplicatively. Staged in vitro reactions demonstrate that a Tn10 synaptic complex can become committed to a particular target DNA molecule via a noncovalent interaction in the absence of strand transfer. Commitment occurs only after double-strand cleavage at both transposon ends (in ''double-end break'' [DEB] complexes). Stable noncovalent DEB-target DNA cocomplexes can be detected, but no cocomplexes occur with synaptic complexes containing uncleaved ends. Preincubation of DEB complexes with target DNA accelerates the rate of strand transfer. Postcleavage target capture is remarkable for Tn10; Mu and Tn7 select a target site prior to cleavage. Promiscuous target selection may favor evolution of IS-based composite elements while being suicidal for other types of transposons.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326, R01GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENDER J, 1992, P NATL ACAD SCI USA, V89, P7996, DOI 10.1073/pnas.89.17.7996; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7814, DOI 10.1073/pnas.92.17.7814; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Chalmers RM, 1996, EMBO J, V15, P5112, DOI 10.1002/j.1460-2075.1996.tb00892.x; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; CRAIG NL, 1996, ESCHERICHIA COLI SAL, P2339; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DeBoy RT, 1996, J BACTERIOL, V178, P6184, DOI 10.1128/jb.178.21.6184-6191.1996; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Gary PA, 1996, J MOL BIOL, V257, P301; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HALLET B, 1994, MOL MICROBIOL, V14, P131, DOI 10.1111/j.1365-2958.1994.tb01273.x; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HANIFORD DB, 1994, EMBO J, V13, P5847; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JUNOP MS, 1997, IN PRESS EMBO J, V16; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KLECKNER N, 1989, MOBILE DNA, P335; Lavoie BD, 1996, CURR TOP MICROBIOL, V204, P83; May EW, 1996, SCIENCE, V272, P401, DOI 10.1126/science.272.5260.401; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MORISATO D, 1984, CELL, V39, P181, DOI 10.1016/0092-8674(84)90204-6; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; SAKAI J, 1996, THESIS HARVARD U CAM; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TERRY BJ, 1985, J BIOL CHEM, V260, P3130	36	42	42	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					205	214		10.1016/S0092-8674(00)80200-7	http://dx.doi.org/10.1016/S0092-8674(00)80200-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108476	Bronze			2022-12-28	WOS:A1997WU88800008
J	Liu, HT; Mantyh, PW; Basbaum, AI				Liu, HT; Mantyh, PW; Basbaum, AI			NMDA-receptor regulation of substance P release from primary afferent nociceptors	NATURE			English	Article							D-ASPARTIC ACID; RAT SPINAL-CORD; DORSAL HORN; DIVALENT-CATIONS; CENTRAL NEURONS; GLUTAMATE; RESPONSES; MOUSE; AUTORECEPTORS; ENDOCYTOSIS	Severe or prolonged tissue or nerve injury can induce hyperexcitability of dorsal horn neurons of the spinal cord, resulting in persistent pain, an exacerbated response to noxious stimuli (hyperalgesia), and a lowered pain threshold (allodynia). These changes are mediated by NMDA (N-methyl-D-aspartate)-type glutamate receptors in the spinal cord(1). Here we report that activation of the NMDA receptor causes release of substance P, a peptide neurotransmitter made by small-diameter, primary, sensory 'pain' fibres. Injection of NMDA in the cerebrospinal fluid of the rat spinal cord mimicked the changes that occur with persistent injury(2), and produced not only pain, but also a large-scale internalization of the substance P receptor into dorsal horn neurons, as well as structural changes in their dendrites. Both the pain and the morphological changes produced by NMDA were significantly reduced by substance P-receptor antagonists or by elimination of substance P-containing primary afferent fibres with the neurotoxin capsaicin. We suggest that prespnaptic NMDA receptors located on the terminals of small-diameter pain fibres facilitate and prolong the transmission of nociceptive messages, through the release of substance P and glutamate. Therapies directed at the presynaptic NMDA receptor could therefore ameliorate injury-evoked persistent pain states.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV MINNESOTA, MOL NEUROBIOL LAB, VET ADM MED CTR, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55417 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities								AANONSEN LM, 1987, J PHARMACOL EXP THER, V243, P9; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIES SN, 1987, BRAIN RES, V424, P402, DOI 10.1016/0006-8993(87)91487-9; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; Dubner R, 1994, TXB PAIN, P225; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; LEBARS D, 1987, BRAIN RES, V402, P188, DOI 10.1016/0006-8993(87)91066-3; LIU H, 1994, P NATL ACAD SCI USA, V91, P8383, DOI 10.1073/pnas.91.18.8383; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; OGAWA T, 1985, BRAIN RES, V359, P152, DOI 10.1016/0006-8993(85)91423-4; PETRALIA RS, 1994, J NEUROSCI, V14, P667; RUSIN KI, 1993, J NEUROCHEM, V60, P952, DOI 10.1111/j.1471-4159.1993.tb03242.x; SHIGEMOTO R, 1992, NEUROSCI LETT, V144, P229, DOI 10.1016/0304-3940(92)90756-W; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; UEDA M, 1995, NEUROPHARMACOLOGY, V34, P303, DOI 10.1016/0028-3908(94)00160-T; WILKIE GI, 1993, BIOCHEM SOC T, V21, P429, DOI 10.1042/bst0210429; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; YAKSH TL, 1981, J NEUROPHYSIOL, V46, P1056, DOI 10.1152/jn.1981.46.5.1056	28	336	350	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	1997	386	6626					721	724		10.1038/386721a0	http://dx.doi.org/10.1038/386721a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109489				2022-12-28	WOS:A1997WU38700057
J	Guyatt, GH; Naylor, CD; Juniper, E; Heyland, DK; Jaeschke, R; Cook, DJ				Guyatt, GH; Naylor, CD; Juniper, E; Heyland, DK; Jaeschke, R; Cook, DJ			Users' guides to the medical literature .12. How to use articles about health-related quality of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIAL; INFLAMMATORY BOWEL-DISEASE; OF-LIFE; RHEUMATOID-ARTHRITIS; HEART-FAILURE; CLINICAL-TRIALS; CROHNS-DISEASE; LUNG-DISEASE; THERAPY; OUTCOMES		MCMASTER UNIV, HLTH SCI CTR, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, TORONTO, ON, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, INST CLIN EVALUAT SCI, TORONTO, ON, CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Guyatt, GH (corresponding author), MCMASTER UNIV, HLTH SCI CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, 1200 MAIN ST W, ROOM 2C12, HAMILTON, ON L8N 3Z5, CANADA.							[Anonymous], 1980, Ann Intern Med, V93, P391; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; CHANG SW, 1991, ARCH INTERN MED, V151, P2402, DOI 10.1001/archinte.151.12.2402; COOK DJ, 1993, ARTHRITIS RHEUM, V36, P750, DOI 10.1002/art.1780360603; DEWEERDT I, 1991, DIABETIC MED, V8, P338; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; Guyatt, 1993, ANN INTERN MED, V70, P225; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V272, P630, DOI 10.1001/jama.272.8.630; HEATON RK, 1983, ARCH INTERN MED, V143, P1941, DOI 10.1001/archinte.143.10.1941; Hornberger J C, 1993, Int J Technol Assess Health Care, V9, P85; HORNBERGER JC, 1993, J AM SOC NEPHROL, V4, P1021; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Juniper E, 1993, AM REV RESPIR DIS, V147, P468; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; LAUPACIS A, 1991, CONTROL CLIN TRIALS, V12, pS168, DOI 10.1016/S0197-2456(05)80021-2; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MATHEW NT, 1995, ARCH NEUROL-CHICAGO, V52, P281, DOI 10.1001/archneur.1995.00540270077022; MITCHELL A, 1988, J CLIN GASTROENTEROL, V10, P306, DOI 10.1097/00004836-198806000-00014; MULROW CD, 1988, JAMA-J AM MED ASSOC, V259, P3422, DOI 10.1001/jama.259.23.3422; NAYLOR CD, 1996, ACP J CLUB, V124, pA12; *OST QUAL LIF RES, IN PRESS J BONE MINE; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; Rector TS, 1987, HEART FAIL, V3, P198; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; SALONEN R, 1994, J NEUROL, V241, P463, DOI 10.1007/BF00919706; SMITH D, 1993, EPILEPSIA, V34, P312, DOI 10.1111/j.1528-1157.1993.tb02417.x; TANDON PK, 1989, J CLIN EPIDEMIOL, V42, P955, DOI 10.1016/0895-4356(89)90160-1; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TESTA MA, 1993, NEW ENGL J MED, V328, P907, DOI 10.1056/NEJM199304013281302; TUGWELL P, 1990, ARCH INTERN MED, V150, P59, DOI 10.1001/archinte.150.1.59; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202; WIKLUND I, 1991, CLIN CARDIOL, V14, P204, DOI 10.1002/clc.4960140306; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59	50	210	219	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1232	1237		10.1001/jama.277.15.1232	http://dx.doi.org/10.1001/jama.277.15.1232			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103349				2022-12-28	WOS:A1997WT40300036
J	Blohm, F; Hahlin, M; Nielsen, S; Milsom, I				Blohm, F; Hahlin, M; Nielsen, S; Milsom, I			Fertility after a randomised trial of spontaneous abortion managed by surgical evacuation or expectant treatment	LANCET			English	Article											Blohm, F (corresponding author), SAHLGRENS UNIV HOSP,DEPT OBSTET & GYNAECOL,S-41685 GOTHENBURG,SWEDEN.							CRAMER DW, 1979, FERTIL STERIL, V32, P80; NIELSEN S, 1995, LANCET, V345, P84, DOI 10.1016/S0140-6736(95)90060-8	2	27	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					995	995		10.1016/S0140-6736(97)24014-6	http://dx.doi.org/10.1016/S0140-6736(97)24014-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100628				2022-12-28	WOS:A1997WR62100014
J	Kwon, HJ; Tirumalai, R; Landy, A; Ellenberger, T				Kwon, HJ; Tirumalai, R; Landy, A; Ellenberger, T			Flexibility in DNA recombination: Structure of the lambda integrase catalytic core	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; GAMMA-DELTA-RESOLVASE; FLP RECOMBINASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; IDENTIFYING DETERMINANTS; BACTERIOPHAGE INTEGRASES; GENETIC-RECOMBINATION; PROTEIN; MECHANISM	Lambda integrase is archetypic of site-specific recombinases that catalyze intermolecular DNA rearrangements without energetic input. DNA cleavage, strand exchange, and religation steps are linked by a covalent phosphotyrosine intermediate in which Tyr(342) is attached to the 3'-phosphate of the DNA cut site. The 1.9 angstrom crystal structure of the integrase catalytic domain reveals a protein fold that is conserved in organisms ranging from archaebacteria to yeast and that suggests a model for interaction with target DNA. The attacking Tyr(342) nucleophile is located on a flexible loop about 20 angstroms from a basic groove that contains all the other catalytically essential residues. This bipartite active site can account for several apparently paradoxical features of integrase family recombinases, including the capacity for both cis and trans cleavage of DNA.	BROWN UNIV, DIV BIOL & MED, PROVIDENCE, RI 02912 USA; HARVARD UNIV, GRAD PROGRAM BIOPHYS, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Brown University; Harvard University; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013544, R01AI013544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062723, R01GM033928] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13544] Funding Source: Medline; NIGMS NIH HHS [GM33928, R01 GM033928, R01 GM062723] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; Blakely GW, 1996, MOL MICROBIOL, V20, P234, DOI 10.1111/j.1365-2958.1996.tb02505.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; CAPARON MG, 1989, CELL, V59, P1027, DOI 10.1016/0092-8674(89)90759-9; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DORGAI L, 1995, J MOL BIOL, V252, P178, DOI 10.1006/jmbi.1995.0486; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EVANS BR, 1990, J BIOL CHEM, V265, P18504; EVANS R, 1990, VIA, V11, P134; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; JONES TA, 1992, O THE MANUAL; JONES TA, 1992, MOL REPLACEMENT, P91; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEONG JM, 1984, COLD SPRING HARB SYM, V49, P707, DOI 10.1101/SQB.1984.049.01.080; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; NUNESDUBY S, UNPUB; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PANIGRAHI GB, 1994, J BIOL CHEM, V269, P10940; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7668; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TIRUMALAI RS, UNPUB; TRIEUCUOT P, 1993, MOL MICROBIOL, V8, P179, DOI 10.1111/j.1365-2958.1993.tb01214.x; WEISBERG RA, 1983, J MOL BIOL, V170, P319, DOI 10.1016/S0022-2836(83)80151-X; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YAGIL E, 1995, J MOL BIOL, V252, P163, DOI 10.1006/jmbi.1995.0485; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; [No title captured]	60	176	179	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					126	131		10.1126/science.276.5309.126	http://dx.doi.org/10.1126/science.276.5309.126			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082984	Green Accepted			2022-12-28	WOS:A1997WR38600062
J	MacKenzie, KR; Prestegard, JH; Engelman, DM				MacKenzie, KR; Prestegard, JH; Engelman, DM			A transmembrane helix dimer: Structure and implications	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; ALPHA-HELICES; GLYCOPHORIN-A; NMR-SPECTROSCOPY; C-13; DIMERIZATION; SENSITIVITY; ASSIGNMENT; SEQUENCE	The three-dimensional structure of the dimeric transmembrane domain of glycophorin A (GpA) was determined by solution nuclear magnetic resonance spectroscopy of a 40-residue peptide solubilized in aqueous detergent micelles. The GpA membrane-spanning alpha helices cross at an angle of -40 degrees and form a small but well-packed interface that lacks intermonomer hydrogen bonds. The structure provides an explanation for the previously characterized sequence dependence of GpA dimerization and demonstrates that van der Waals interactions alone can mediate stable and specific associations between transmembrane helices.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520	Yale University; Yale University			Bremner, James D/B-1632-2013		NIGMS NIH HHS [P01 GM54160] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM054160] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, PROTEINS, V26, P257, DOI 10.1002/(SICI)1097-0134(199611)26:3<257::AID-PROT2>3.0.CO;2-B; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BURNGER AT, 1992, X PLOR VERSION 3 1 U; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI SC, 1993, J BIOL CHEM, V208, P22975; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PONDER JW, 1987, J MOL BIOL, V193, P75; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; ROSS AH, 1982, J BIOL CHEM, V257, P4152; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P6150	28	861	870	2	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					131	133		10.1126/science.276.5309.131	http://dx.doi.org/10.1126/science.276.5309.131			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082985				2022-12-28	WOS:A1997WR38600063
J	McKay, R				McKay, R			Stem cells in the central nervous system	SCIENCE			English	Review							INTERMEDIATE FILAMENT NESTIN; REGION-SPECIFIC DIFFERENTIATION; ADULT MAMMALIAN FOREBRAIN; FIBROBLAST GROWTH-FACTOR; CHICK-EMBRYO HINDBRAIN; GLIAL PROGENITOR-CELL; NEURAL CREST CELLS; RAT OPTIC-NERVE; CAENORHABDITIS-ELEGANS; HIPPOCAMPAL-NEURONS	In the vertebrate central nervous system, multipotential cells have been identified in vitro and in vivo. Defined mitogens cause the proliferation of multipotential cells in vitro, the magnitude of which is sufficient to account for the number of cells in the brain. Factors that control the differentiation of fetal stem cells to neurons and glia have been defined in vitro, and multipotential cells with similar signaling logic can be cultured from the adult central nervous system. Transplanting cells to new sites emphasizes that neuroepithelial cells have the potential to integrate into many brain regions. These results focus attention on how information in external stimuli is translated into the number and types of differentiated cells in the brain. The development of therapies for the reconstruction of the diseased or injured brain will be guided by our understanding of the origin and stability of cell type in the central nervous system.			McKay, R (corresponding author), NINCDS,MOL BIOL LAB,BLDG 36,RM 4D04,BETHESDA,MD 20892, USA.							ALAMZAN G, 1992, BRAIN RES, V579, P234; Alder J, 1996, NEURON, V17, P389, DOI 10.1016/S0896-6273(00)80172-5; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ArnoldAldea SA, 1996, DEV BIOL, V173, P148, DOI 10.1006/dbio.1996.0013; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BARRES BA, 1993, DEVELOPMENT, V118, P283; BARRES BA, 1994, DEVELOPMENT, V120, P1097; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; BRENNER S, 1974, GENETICS, V77, P71; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; BRUSTLE O, 1995, J NEURO-ONCOL, V24, P57, DOI 10.1007/BF01052659; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; Craig CG, 1996, J NEUROSCI, V16, P2649; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DONIACH T, 1995, CELL, V83, P1967; FISHELL G, 1995, DEVELOPMENT, V121, P803; FLORENES VA, 1994, CANCER RES, V54, P354; Frade JM, 1996, NATURE, V383, P166; Frantz GD, 1996, NEURON, V17, P55, DOI 10.1016/S0896-6273(00)80280-9; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GENSBURGER C, 1987, FEBS LETT, V8, P1; Golden JA, 1996, DEVELOPMENT, V122, P65; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; GRAPINBOTTON A, 1995, DEVELOPMENT, V121, P2707; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; Gritti A, 1996, J NEUROSCI, V16, P1091; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HALDANE JBS, 1920, T OXFORD U JUNIOR SC, V1, P3; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HernitGrant CS, 1996, EXP NEUROL, V139, P131, DOI 10.1006/exnr.1996.0088; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KAPLAN MS, 1985, J COMP NEUROL, V239, P117, DOI 10.1002/cne.902390110; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; LINDVALL O, 1993, FUNCTIONAL NEURAL TR; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MACKLIS JD, 1993, J NEUROSCI, V13, P3848; MartinezSerrano A, 1996, P NATL ACAD SCI USA, V93, P6355, DOI 10.1073/pnas.93.13.6355; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Miller TM, 1996, J NEUROSCI, V16, P7487; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; OGAWA M, 1993, BLOOD, V81, P2844; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAY J, 1994, J NEUROSCI, V14, P3548; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; RAY J, 1996, ISOLATION CHARACTERI, P129; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8581; RUBENSTEIN JLR, 1994, CURR TOP DEV BIOL, V29, P1, DOI 10.1016/S0070-2153(08)60546-3; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; Rudge JS, 1996, MOL CELL NEUROSCI, V7, P204, DOI 10.1006/mcne.1996.0016; RYDER EF, 1994, NEURON, V12, P1011, DOI 10.1016/0896-6273(94)90310-7; Seki T, 1995, NEUROREPORT, V6, P2479, DOI 10.1097/00001756-199512150-00010; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stemple DL, 1997, NEURON, V18, P1, DOI 10.1016/S0896-6273(01)80018-0; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TONSCH U, 1994, P NATL ACAD SCI USA, V91, P11616; TROTTER J, 1993, GLIA, V9, P25, DOI 10.1002/glia.440090105; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; UNSICKER K, 1987, P NATL ACAD SCI USA, V84, P5459, DOI 10.1073/pnas.84.15.5459; VALTZ T, 1901, NEW BIOL, V3, P364; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; VICARIOABEJON C, 1995, J NEUROSCI, V15, P6351; WEISSMAN IL, 1996, ISOLATION CHARACTERI, P1; Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WHITE LA, 1994, J NEUROSCI, V14, P6744; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; Wolfe J. H., 1994, Gene Therapy, V1, pS55; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yaginuma H, 1996, J NEUROSCI, V16, P3685; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	139	1184	1446	6	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					66	71		10.1126/science.276.5309.66	http://dx.doi.org/10.1126/science.276.5309.66			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082987				2022-12-28	WOS:A1997WR38600046
J	Virchis, AE; Patel, RK; Contreras, M; Navarrete, C; Kaczmarksi, RS; JanMohamed, R				Virchis, AE; Patel, RK; Contreras, M; Navarrete, C; Kaczmarksi, RS; JanMohamed, R			Lesson of the week - Acute non-cardiogenic lung oedema after platelet transfusion	BRITISH MEDICAL JOURNAL			English	Article							PULMONARY; ANTIBODY; INJURY		HILLINGDON HOSP,NHS TRUST,DEPT HAEMATOL MED,UXBRIDGE UB8 3NN,MIDDX,ENGLAND									ANDREWS AT, 1976, AM J CLIN PATHOL, V66, P483; BARNARD RD, 1951, NEW YORK STATE J MED, V51, P2399; Bux J, 1996, BRIT J HAEMATOL, V93, P707, DOI 10.1046/j.1365-2141.1996.d01-1703.x; LEVY GJ, 1986, TRANSFUSION, V26, P278, DOI 10.1046/j.1537-2995.1986.26386209388.x; NORDHAGEN R, 1986, VOX SANG, V51, P102, DOI 10.1111/j.1423-0410.1986.tb00223.x; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; VANBUREN NL, 1990, TRANSFUSION, V30, P42; WARD HN, 1970, ANN INTERN MED, V73, P689, DOI 10.7326/0003-4819-73-5-689; YOMTOVIAN R, 1984, LANCET, V1, P244	10	22	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					880	882						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093102				2022-12-28	WOS:A1997WQ02800033
J	Paredi, P; Pierluigi, O				Paredi, P; Pierluigi, O			Cutaneous lesions in diffuse large-B-cell lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NIGUARDA HOSP,I-22100 MILAN,ITALY		Paredi, P (corresponding author), UNIV MILAN,I-20122 MILAN,ITALY.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1302	1302		10.1056/NEJM199705013361806	http://dx.doi.org/10.1056/NEJM199705013361806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113934				2022-12-28	WOS:A1997WW26000006
J	Langermann, S; Palaszynski, S; Barnhart, M; Auguste, G; Pinkner, JS; Burlein, J; Barren, P; Koenig, S; Leath, S; Jones, CH; Hultgren, SJ				Langermann, S; Palaszynski, S; Barnhart, M; Auguste, G; Pinkner, JS; Burlein, J; Barren, P; Koenig, S; Leath, S; Jones, CH; Hultgren, SJ			Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination	SCIENCE			English	Article							URINARY-TRACT INFECTIONS; INDUCED DIARRHEAL DISEASE; HUMAN EPITHELIAL-CELLS; TYPE-1 PILI; RECEPTOR-BINDING; PAPD CHAPERONE; SUCKLING PIGS; HAEMOPHILUS-INFLUENZAE; PSEUDOMONAS-AERUGINOSA; KLEBSIELLA-PNEUMONIAE	Virtually all uropathogenic strains of Escherichia coli, the primary cause of cystitis, assemble adhesive surface organelles called type 1 pili that contain the FimH adhesin. Sera from animals vaccinated with candidate FimH vaccines inhibited uropathogenic E. coli from binding to human bladder cells in vitro. Immunization with FimH reduced in vivo colonization of the bladder mucosa by more than 99 percent in a murine cystitis model, and immunoglobulin G to FimH was detected in urinary samples from protected mice. Furthermore, passive systemic administration of immune sera to FimH also resulted in reduced bladder colonization by uropathogenic E. coli. This approach may represent a means of preventing recurrent and acute infections of the urogenital mucosa.	WASHINGTON UNIV, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Langermann, S (corresponding author), MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK51406] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1987, J BACTERIOL, V169, P5530, DOI 10.1128/jb.169.12.5530-5536.1987; ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; ACRES SD, 1979, INFECT IMMUN, V25, P121, DOI 10.1128/IAI.25.1.121-126.1979; AGACE W, 1993, INFECT IMMUN, V61, P602, DOI 10.1128/IAI.61.2.602-609.1993; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; Brinton C., 1978, IMMUNOBIOLOGY NEISER, P155; BRINTON C, 1980, CURRENT CHEMOTHERAPY, P1242; COLLINS HH, 1989, J INFECT DIS, V159, P1073, DOI 10.1093/infdis/159.6.1073; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DODD DC, 1982, INFECT IMMUN, V38, P764, DOI 10.1128/IAI.38.2.764-773.1982; DUGUID JP, 1979, J MED MICROBIOL, V12, P213, DOI 10.1099/00222615-12-2-213; DUGUID JP, 1977, BACTERIAL ADHERENCE, P184; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FIRON N, 1983, CARBOHYD RES, V120, P235, DOI 10.1016/0008-6215(83)88019-7; GERLACH GF, 1989, J BACTERIOL, V171, P1262, DOI 10.1128/jb.171.3.1262-1270.1989; GIAMPAPA CS, 1988, J BIOL CHEM, V263, P5362; HAGBERG L, 1983, INFECT IMMUN, V40, P273, DOI 10.1128/IAI.40.1.273-283.1983; HANSON MS, 1988, J BACTERIOL, V170, P3350, DOI 10.1128/jb.170.8.3350-3358.1988; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1985, INFECT IMMUN, V50, P370, DOI 10.1128/IAI.50.2.370-377.1985; HULTGREN SJ, 1986, INFECT IMMUN, V54, P613, DOI 10.1128/IAI.54.3.613-620.1986; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1995, ASM NEWS, V61, P457; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; ISAACSON RE, 1980, INFECT IMMUN, V29, P824; Jacob-Dubuisson Francoise, 1993, Trends in Microbiology, V1, P50, DOI 10.1016/0966-842X(93)90032-M; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; KUNIN CM, 1994, CLIN INFECT DIS, V18, P1, DOI 10.1093/clinids/18.1.1; LEVINE MM, 1982, SCAND J INFECT DIS, P83; LI H, 1992, INFECT IMMUN, V60, P2030, DOI 10.1128/IAI.60.5.2030-2035.1992; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDSTEDT R, 1989, INFECT IMMUN, V57, P3389, DOI 10.1128/IAI.57.11.3389-3394.1989; LOMBARDO M, 1991, INFECT IMMUN, V59, P4310; LOMBERG H, 1988, MONOGR ALLERGY, V24, P35; LUND B, 1985, J BACTERIOL, V162, P1293, DOI 10.1128/JB.162.3.1293-1301.1985; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MCCREA KW, 1994, INFECT IMMUN, V62, P4922, DOI 10.1128/IAI.62.11.4922-4928.1994; MINION FC, 1986, J BACTERIOL, V165, P1033, DOI 10.1128/jb.165.3.1033-1036.1986; MOBLEY HLT, 1990, INFECT IMMUN, V58, P1281, DOI 10.1128/IAI.58.5.1281-1289.1990; MOBLEY HLT, 1993, MOL MICROBIOL, V10, P143, DOI 10.1111/j.1365-2958.1993.tb00911.x; MORGAN RL, 1978, INFECT IMMUN, V22, P771, DOI 10.1128/IAI.22.3.771-777.1978; NAGY B, 1978, INFECT IMMUN, V21, P269, DOI 10.1128/IAI.21.1.269-274.1978; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; OFEK I, 1981, INFECT IMMUN, V34, P708, DOI 10.1128/IAI.34.3.708-711.1981; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; RUTTER JM, 1973, NATURE, V242, P531, DOI 10.1038/242531a0; SALIT IE, 1977, J EXP MED, V146, P1182, DOI 10.1084/jem.146.5.1182; SCHAEFFER AJ, 1979, INFECT IMMUN, V24, P753, DOI 10.1128/IAI.24.3.753-759.1979; SILVERBLATT FJ, 1979, J CLIN INVEST, V64, P333, DOI 10.1172/JCI109458; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; SOBEL JD, 1991, MED CLIN N AM, V75, P253, DOI 10.1016/S0025-7125(16)30452-7; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; STGEME JW, 1994, INFECT IMMUN, V62, P3881, DOI 10.1128/IAI.62.9.3881-3889.1994; STRIKER R, 1995, MOL MICROBIOL, V16, P1021, DOI 10.1111/j.1365-2958.1995.tb02327.x; TRAMONT E, 1980, CURRENT CHEMOTHERAPY, P1240; VANHAM SM, 1995, INFECT IMMUN, V63, P4883, DOI 10.1128/IAI.63.12.4883-4889.1995; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630	72	447	478	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	1997	276	5312					607	611		10.1126/science.276.5312.607	http://dx.doi.org/10.1126/science.276.5312.607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110982				2022-12-28	WOS:A1997WV72100049
J	Bergman, JJGHM; Rauws, EAJ; Fockens, P; vanBerkel, AM; Bossuyt, PMM; Tijssen, JGP; Tytgat, GNJ; Huibregtse, K				Bergman, JJGHM; Rauws, EAJ; Fockens, P; vanBerkel, AM; Bossuyt, PMM; Tijssen, JGP; Tytgat, GNJ; Huibregtse, K			Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bileduct stones	LANCET			English	Article							DUCT STONES; EXTRACTION; MANAGEMENT; VATER; ODDI; CHOLANGIOGRAPHY; AMPULLA; CALCULI; SIZE	Background Endoscopic sphincterotomy (EST) for the removal of bileduct stones is associated with acute complications and a permanent loss of biliary-sphincter function. Endoscopic balloon dilation (EBD) causes less trauma to the biliary sphincter, but may be less effective in allowing stone removal. Methods 218 consecutive patients with bileduct stones on endoscopic retrograde cholangiopancreatography (ERCP) were enrolled. 202 who met all eligibility criteria were randomly assigned EST or EBD. The patients were observed in hospital for at least 24 h and followed up at 1 month and 6 months. Complications were classified by an expert panel unaware of treatment allocation and outcome. Analysis was done by intention to treat. Findings After a single ERCP, all stones were removed from 92 (91%) of 101 patients assigned EST and 90 (89%) of 101 assigned EBD (p=0.81); in nine of the latter, successful removal required additional EST. Mechanical lithotripsy was used to fragment stones in 31 EBD procedures and 13 EST procedures (p<0.005). Early complications (before 15 days) occurred in 24 EST patients and 17 EBD patients (p=0.29). One patient died of retroperitoneal perforation after EBD. Four patients had bleeding after EST. Seven patients in each group had pancreatitis. Complications during follow-up occurred in 23 EST patients and 18 EBD patients (p=0.48). Acute cholecystitis was observed in seven EST patients and one EBD patient (p<0.05). Interpretation The success rate of EBD was similar to that of EST. We found there is no evidence of the previously suggested higher risk of pancreatitis with EBD and suggest that EBD is preferred in patients at risk of bleeding after EST. Preservation of biliary-sphincter function after EBD may prevent long-term complications and reduce the risk of acute cholecystitis during followup. This procedure is a valuable alternative to EST in patients with bileduct stones.	UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,NL-1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	Bergman, JJGHM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,MEIBERGDREEF 9,NL-1105 AZ AMSTERDAM,NETHERLANDS.		Bossuyt, Patrick M./B-4557-2016; Bergman, Jacques/AAS-2500-2021; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128				Bergman, 1995, Semin Laparosc Surg, V2, P140; BERGMAN JJGHM, 1995, GASTROINTEST ENDOSC, V42, P195, DOI 10.1016/S0016-5107(95)70091-9; Bergman JJGHM, 1996, GASTROINTEST ENDOSC, V44, P643, DOI 10.1016/S0016-5107(96)70045-7; BERKMAN WA, 1988, RADIOLOGY, V167, P453, DOI 10.1148/radiology.167.2.3357955; BOENDER J, 1994, ENDOSCOPY, V26, P209, DOI 10.1055/s-2007-1008945; CARROLL BJ, 1993, SURG ENDOSC-ULTRAS, V7, P514, DOI 10.1007/BF00316692; CLASSEN M, 1974, DEUT MED WOCHENSCHR, V99, P496, DOI 10.1055/s-0028-1107790; COTTON PB, 1984, GUT, V25, P587, DOI 10.1136/gut.25.6.587; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; GEENEN JE, 1984, GASTROENTEROLOGY, V87, P754; GOLDMAN LD, 1983, AM J SURG, V145, P450, DOI 10.1016/0002-9610(83)90038-7; GREENFIELD C, 1985, POSTGRAD MED J, V61, P213, DOI 10.1136/pgmj.61.713.213; GREGG JA, 1985, AM J SURG, V149, P668, DOI 10.1016/S0002-9610(85)80152-5; KAWAI K, 1974, GASTROINTEST ENDOSC, V20, P148, DOI 10.1016/S0016-5107(74)73914-1; KOZAREK RA, 1988, ENDOSCOPY, V20, P207, DOI 10.1055/s-2007-1018177; KURUMADO K, 1994, DIGEST DIS SCI, V39, P809, DOI 10.1007/BF02087428; LAURI A, 1993, GUT, V34, P1718, DOI 10.1136/gut.34.12.1718; MacMathuna P, 1996, GASTROINTEST ENDOSC, V44, P650; MACMATHUNA P, 1995, GASTROINTEST ENDOSC, V42, P468, DOI 10.1016/S0016-5107(95)70052-8; MAKI T, 1966, ANN SURG, V164, P90, DOI 10.1097/00000658-196607000-00010; Minami A, 1995, DIGEST DIS SCI, V40, P2550, DOI 10.1007/BF02220440; NELSON DB, 1994, J CLIN GASTROENTEROL, V19, P283, DOI 10.1097/00004836-199412000-00004; PERISSAT J, 1994, BRIT J SURG, V81, P799, DOI 10.1002/bjs.1800810606; PERSSON B, 1991, GASTROINTEST RADIOL, V16, P212, DOI 10.1007/BF01887348; SAND J, 1992, AM SURGEON, V58, P324; STARITZ M, 1984, Z GASTROENTEROL, V22, P697; STEIDLE B, 1991, ROFO FORTSCHR RONTG, V155, P128, DOI 10.1055/s-2008-1033233	28	295	307	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1124	1129		10.1016/S0140-6736(96)11026-6	http://dx.doi.org/10.1016/S0140-6736(96)11026-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113010				2022-12-28	WOS:A1997WU54400008
J	Bjorkman, PJ				Bjorkman, PJ			MHC restriction in three dimensions: A view of T cell receptor/ligand interactions	CELL			English	Review							CRYSTAL-STRUCTURE; ANTIGEN RECEPTOR; RECOGNITION				Bjorkman, PJ (corresponding author), CALTECH,HOWARD HUGHES MED INST,DIV BIOL,PASADENA,CA 91125, USA.							BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Fields BA, 1996, IMMUNOL TODAY, V17, P330, DOI 10.1016/0167-5699(96)10020-7; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; SUN R, 1995, IMMUNITY, V3, P573, DOI 10.1016/1074-7613(95)90128-0; Zerrahn J, 1997, CELL, V88, P627, DOI 10.1016/S0092-8674(00)81905-4; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	14	69	77	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					167	170		10.1016/S0092-8674(00)80195-6	http://dx.doi.org/10.1016/S0092-8674(00)80195-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108471	Bronze			2022-12-28	WOS:A1997WU88800003
J	Thomas, DP; Roberts, HR				Thomas, DP; Roberts, HR			Hypercoagulability in venous and arterial thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; FACTOR-V LEIDEN; ISCHEMIC-HEART-DISEASE; ADDITIONAL RISK FACTOR; DEEP-VEIN THROMBOSIS; FACTOR-VII ACTIVITY; MYOCARDIAL-INFARCTION; ANTIPHOSPHOLIPID ANTIBODIES; ORAL-CONTRACEPTIVES; DEFICIENT FAMILIES	The term ''hypercoagulability'' is used to describe patients who are at increased risk far thrombosis because of inherited defects in their anticoagulant pathways or because of various predisposing causes. About one in five patients of European descent who present with venous thromboembolism have a specific genetic defect in their anticoagulant pathway. In these patients, anticoagulant prophylaxis is indicated at rimes of high risk, such as after surgery. Prolonged anticoagulant therapy may be required in patients with recurrent or life-threatening thromboemboli, but decisions about this are best made on an individual basis. Patients who present with arterial thrombosis usually develop their disease as a complication of atherosclerosis. However, these patients also have a form of hypercoagulability, manifested primarily by high fibrinogen levels and elevated factor VII activity. Evidence increasingly indicates that these and other hemostatic markers may help in the assessment of patients at risk for coronary heart disease.	UNIV N CAROLINA, DEPT MED, DIV HEMATOL ONCOL, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26309] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAART CF, 1995, BRIT MED J, V311, P910; ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BALLEISEN L, 1987, LANCET, V2, P461; BAUER KA, 1995, THROMB HAEMOSTASIS, V74, P94; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; DAHLBACK B, 1995, THROMB HAEMOSTASIS, V74, P139; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Dahlback B., 1994, HAEMOSTASIS THROMBOS, P671; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DERKSEN RHWM, 1993, ANN RHEUM DIS, V52, P689, DOI 10.1136/ard.52.9.689; FEINSTEIN DI, 1995, HEMATOLOGY BASIC PRI, P1746; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HOFFMAN C, 1988, J LAB CLIN MED, V111, P475; Hultin M B, 1991, Prog Hemost Thromb, V10, P215; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; Lane DA, 1994, HEMOSTASIS THROMBOSI, V3rd, P655; Mandel H, 1996, NEW ENGL J MED, V334, P763, DOI 10.1056/NEJM199603213341204; Mannucci PM, 1996, THROMB HAEMOSTASIS, V75, P694; MEADE TW, 1995, AM J CARDIOL, V75, pB23, DOI 10.1016/0002-9149(95)80006-E; MEADE TW, 1995, EUR HEART J, V16, P31, DOI 10.1093/eurheartj/16.suppl_A.31; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILETICH J, 1987, NEW ENGL J MED, V317, P991, DOI 10.1056/NEJM198710153171604; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; Miller GJ, 1996, THROMB HAEMOSTASIS, V75, P767; MORRISSEY JH, 1993, BLOOD, V81, P734; Morrissey JH, 1996, HAEMOSTASIS, V26, P66; PICARD V, 1995, THROMB HAEMOSTASIS, V73, P1252; Pottinger P, 1996, BLOOD, V87, P2091; PRINS MH, 1991, ARCH INTERN MED, V151, P1721, DOI 10.1001/archinte.151.9.1721; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; RUDDOCK V, 1994, Q J MED, V87, P403; SAMAMA MM, 1995, BLOOD, V86, P4700, DOI 10.1182/blood.V86.12.4700.bloodjournal86124700; SANTORO SA, 1994, BLOOD, V83, P2389; SCHAFER AI, 1994, LANCET, V344, P1739, DOI 10.1016/S0140-6736(94)92888-6; Schroder W, 1996, LANCET, V347, P58; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TOSETTO A, 1995, THROMB HAEMOSTASIS, V73, P1124; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WIMAN B, 1995, THROMB HAEMOSTASIS, V74, P71; 1995, TREATMENT VENOUS THR	51	95	96	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					638	644		10.7326/0003-4819-126-8-199704150-00009	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103132				2022-12-28	WOS:A1997WT58000011
J	Mathews, S; Ramesh, R; Venkatesan, T; Benedetto, J				Mathews, S; Ramesh, R; Venkatesan, T; Benedetto, J			Ferroelectric field effect transistor based on epitaxial perovskite heterostructures	SCIENCE			English	Article								Ferroelectric field effect devices offer the possibility of nonvolatile active memory elements. Doped rare-earth manganates, which are usually associated with colossal magnetoresistive properties, have been used as the semiconductor channel material of a prototypical epitaxial field effect device. The carrier concentration of the semiconductor channel can be ''tuned'' by varying the manganate stochiometry, A device with La0.7Ca0.3MnO3 as the semiconductor and PbZr0.2Ti0.8O3 as the ferroelectric gate exhibited a modulation in channel conductance of at least a factor of 3 and a retention loss of 3 percent after 45 minutes without power.	UNIV MARYLAND,CTR SUPERCONDUCT RES,COLLEGE PK,MD 20742; USA,RES LAB,ADELPHI,MD 20783	University System of Maryland; University of Maryland College Park; United States Department of Defense; US Army Research, Development & Engineering Command (RDECOM); US Army Research Laboratory (ARL)	Mathews, S (corresponding author), UNIV MARYLAND,DEPT MAT & NUCL ENGN,COLLEGE PK,MD 20742, USA.		Venkatesan, Thirumalai V/E-1667-2013	Venkatesan, Thirumalai/0000-0001-9683-4584				AHN CH, 1995, SCIENCE, V269, P373, DOI 10.1126/science.269.5222.373; [Anonymous], 1957, US Patent, Patent No. 2791760; HEYMAN PM, 1966, PR INST ELECTR ELECT, V54, P842, DOI 10.1109/PROC.1966.4889; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; LOONEY DH, 1957, Patent No. 2791758; Ogale SB, 1996, PHYS REV LETT, V77, P1159, DOI 10.1103/PhysRevLett.77.1159; RAMESH R, 1991, SCIENCE, V252, P944, DOI 10.1126/science.252.5008.944; RAMESH R, 1994, APPL PHYS LETT, V64, P1588, DOI 10.1063/1.111848; WATANABE Y, 1995, APPL PHYS LETT, V66, P1770, DOI 10.1063/1.113362; [No title captured]; [No title captured]	11	534	566	7	247	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					238	240		10.1126/science.276.5310.238	http://dx.doi.org/10.1126/science.276.5310.238			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092468				2022-12-28	WOS:A1997WT92500039
J	Flegel, KM				Flegel, KM			My winter world: The illness of Gerard Manley Hopkins	LANCET			English	Article											Flegel, KM (corresponding author), ROYAL VICTORIA HOSP,DIV GEN INTERNAL MED,687 PINE AVE W,MONTREAL,PQ H3A 1A1,CANADA.							ABBOT CC, 1956, FURTHER LETT GM HOPK, P185; ABBOT CC, 1956, FURTHER LETT HM HOPK, P178; ABBOT CC, 1955, CORRES GM HOPKINS RW, P157; Abbott Claude Colleer, 1955, LETT GM HOPKINS R BR; Abbott Claude Colleer, 1956, FURTHER LETT GM HOPK, P132; BRIDGES R, 1948, POEMS GM HOPKINS, P106; BRIDGES R, 1948, POEMS GM HOPKINS, P113; BRIDGES R, 1948, POEMS GM HOPKINS, P173; BRIDGES R, 1948, POEMS GM HOPKINS, P72; LICHTMAN SN, 1994, INFLAMM BOWEL DIS, P326; MARTIN RB, 1991, HM HOPKINS VERY PRIV; OSLER W, 1978, CLASSICS MED LIB; RICHARDS RD, 1975, SYSTEMIC MANIFESTATI, P221; SIDOROV JJ, 1989, INFLAMM BOWEL DIS, V2, P59; WHITE N, 1992, HOPKINS LIT BIOGRAPH, P365; WHITE N, 1992, HOPKINS LIT BIOGRAPH, P455; 1889, ENGLISH PROVINCE SOC, V20, P178	17	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					1017	1019		10.1016/S0140-6736(96)08009-9	http://dx.doi.org/10.1016/S0140-6736(96)08009-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100640				2022-12-28	WOS:A1997WR62100043
J	Pan, GH; ORourke, K; Chinnaiyan, AM; Gentz, R; Ebner, R; Ni, J; Dixit, VM				Pan, GH; ORourke, K; Chinnaiyan, AM; Gentz, R; Ebner, R; Ni, J; Dixit, VM			The receptor for the cytotoxic ligand TRAIL	SCIENCE			English	Article							DEATH DOMAIN; CELL-DEATH; PROTEIN; FAS; APOPTOSIS; INTERACTS	TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. The human receptor for TRAIL was found to be an undescribed member of the TNF-receptor family (designated death receptor-4, DR4) that contains a cytoplasmic ''death domain'' capable of engaging the cell suicide apparatus but not the nuclear factor kappa B pathway in the system studied. Unlike Fas, TNFR-1, and DR3, DR4 could not use FADD to transmit the death signal, suggesting the use of distinct proximal signaling machinery. Thus, the DR4-TRAIL axis defines another receptor-ligand pair involved in regulating cell suicide and tissue homeostasis.	UNIV MICHIGAN,DEPT PATHOL,SCH MED,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL INSTITUTE ON DRUG ABUSE [R41DA016085, R42DA016085] Funding Source: NIH RePORTER; NIDA NIH HHS [DAMD17-96-1-6085] Funding Source: Medline; NIEHS NIH HHS [ES08111] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Baker SJ, 1996, ONCOGENE, V12, P1; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROJATSH J, 1996, CELL, V87, P1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PAN GZ, UNPUB; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	1494	1709	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					111	113		10.1126/science.276.5309.111	http://dx.doi.org/10.1126/science.276.5309.111			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082980				2022-12-28	WOS:A1997WR38600058
J	West, GB; Brown, JH; Enquist, BJ				West, GB; Brown, JH; Enquist, BJ			A general model for the origin of allometric scaling laws in biology	SCIENCE			English	Article							MASS; METABOLISM; SIZE	Allometric scaling relations, including the 3/4 power law for metabolic rates, are characteristic of all organisms and are here derived from a general model that describes how essential materials are transported through space-filling fractal networks of branching tubes. The model assumes that the energy dissipated is minimized and that the terminal tubes do not vary with body size. It provides a complete analysis of scaling relations for mammalian circulatory systems that are in agreement with data. More generally, the model predicts structural and functional properties of vertebrate cardiovascular and respiratory systems, plant vascular systems, insect tracheal tubes, and other distribution networks.	UNIV NEW MEXICO, DEPT BIOL, ALBUQUERQUE, NM 87131 USA; SANTA FE INST, SANTA FE, NM 87501 USA; LOS ALAMOS NATL LAB, DIV THEORET, LOS ALAMOS, NM 87545 USA	University of New Mexico; The Santa Fe Institute; United States Department of Energy (DOE); Los Alamos National Laboratory			Enquist, Brian J/B-6436-2008; Kristoffersson, Anders/I-6497-2015	Enquist, Brian J/0000-0002-6124-7096; Kristoffersson, Anders/0000-0003-3166-9981				BENNETT AF, 1988, AM ZOOL, V28, P699; BENNETT PM, 1987, J ZOOL, V213, P327, DOI 10.1111/j.1469-7998.1987.tb03708.x; BONNER JT, 1983, EVOLUTION COMPLEXITY; Brown J.H., 1995, MACROECOLOGY; CANNY MJ, 1993, PHILOS T R SOC B, V341, P87, DOI 10.1098/rstb.1993.0094; CARO CG, 1978, MECHANICS CIRCULATIO; ELLSWORTH ML, 1987, MICROVASC RES, V34, P168, DOI 10.1016/0026-2862(87)90051-3; FELDMAN HA, 1983, RESP PHYSIOL, V52, P149, DOI 10.1016/0034-5687(83)90002-6; FUNG YC, 1984, BIODYNAMICS; GEHR P, 1981, RESP PHYSIOL, V44, P61, DOI 10.1016/0034-5687(81)90077-3; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hemmingsen A. M., 1950, REP STENO MEM HOSP, V4, P1; Hemmingsen AM., 1960, REPORTS STENO MEM HO, V9, P1; IBERALL A. S., 1967, MATH BIOSCI, V1, P375, DOI 10.1016/0025-5564(67)90009-0; Krogh A, 1920, PFLUG ARCH GES PHYS, V179, P95, DOI 10.1007/BF01722125; Li J K-J, 1996, COMP CARDIOVASCULAR; Mandelbrot B. B., 1977, FRACTAL GEOMETRY NAT; MCMAHON T, 1973, SCIENCE, V179, P1201, DOI 10.1126/science.179.4079.1201; McMahon T.A., 1983, SIZE LIFE; Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207; Niklas K.J., 1994, PLANT ALLOMETRY SCAL; NIKLAS KJ, 1994, AM J BOT, V81, P134, DOI 10.2307/2445626; PATTERSON MR, 1992, SCIENCE, V255, P1421, DOI 10.1126/science.255.5050.1421; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SHERMAN TF, 1981, J GEN PHYSIOL, V78, P431, DOI 10.1085/jgp.78.4.431; SHIN YM, 1994, CELL MOL NEUROBIOL, V14, P133, DOI 10.1007/BF02090781; Shinozaki K, 1964, JPN J ECOL, V14, P97, DOI DOI 10.18960/SEITAI.14.3_97; Strahler A.N., 1953, EOS T AM GEOPHYS UN, V34, P345; Thompson D. W., 1917, GROWTH FORM; TYREE MT, 1991, NEW PHYTOL, V119, P345, DOI 10.1111/j.1469-8137.1991.tb00035.x; WOMERSLEY JR, 1955, PHILOS MAG, V46, P199; WORMERSLEY JR, 1955, J PHYSL, V127, P553; ZAMIR M, 1992, J BIOMECH, V25, P1303, DOI 10.1016/0021-9290(92)90285-9; Zimmermann M.H., 1984, XYLEM STRUCTURE ASCE, V26, P165	34	3309	3460	21	839	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					122	126		10.1126/science.276.5309.122	http://dx.doi.org/10.1126/science.276.5309.122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082983				2022-12-28	WOS:A1997WR38600061
J	Carleton, RA				Carleton, RA			Dichotomous disservice?	ANNALS OF INTERNAL MEDICINE			English	Article											Carleton, RA (corresponding author), MEM HOSP RHODE ISL, PAWTUCKET, RI 02860 USA.							LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507; LIGHT RW, 1995, PLEURAL DISEASES; Paddock FK, 1940, NEW ENGL J MED, V223, P1010, DOI 10.1056/NEJM194012192232503; ROBERTS R, 1994, HEART, P1112; RUNYON BA, 1992, ANN INTERN MED, V117, P215, DOI 10.7326/0003-4819-117-3-215; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SPODICK DH, 1983, AM J CARDIOL, V51, P913, DOI 10.1016/S0002-9149(83)80160-X	7	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					589	591		10.7326/0003-4819-126-7-199704010-00031	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00031			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092338				2022-12-28	WOS:A1997WQ19500039
J	Hunt, DL; McKibbon, KA				Hunt, DL; McKibbon, KA			Locating and appraising systematic reviews	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL LITERATURE; USERS GUIDES; ARTICLE; PREVENTION; AGREEMENT; THERAPY	In this article, we describe the strengths and weaknesses of several methods of locating systematic reviews, including electronic databases such as MEDLINE, Best Evidence (the electronic version of ACP Journal Club and Evidence-Based Medicine), and the Cochrane Library (a regularly updated source of reviews and controlled trials produced by the Cochrane Collaboration). We also present steps that can be used to critically appraise review articles; as an example, we use a systematic review that evaluates the gastrointestinal toxicity of various nonsteroidal anti-inflammatory drugs in the context of a clinical scenario.			Hunt, DL (corresponding author), MCMASTER UNIV, FAC HLTH SCI, CTR HLTH SCI, 1200 MAIN ST W, ROOM 3H7, HAMILTON, ON L8N 3Z5, CANADA.							BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; Carson J L, 1993, Drugs, V46 Suppl 1, P243; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; HAYNES RB, 1992, ACP J CLUB, V117, pA18; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Huston P, 1996, CAN MED ASSOC J, V154, P1389; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367	14	98	103	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					532	538		10.7326/0003-4819-126-7-199704010-00006	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092319				2022-12-28	WOS:A1997WQ19500015
J	Poole, CJM				Poole, CJM			Retirement on grounds of ill health: Cross sectional survey in six organisations in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess the process and outcome of retirement due to ill health in six large organisations. Design: Cross sectional study of the rate of retirement due to ill health by age, sex, and length of service. Principal diagnoses by age and length of service were also compared. Setting: Four public and two private large employers in the United Kingdom. Main outcome measures: Rates of retirement on the grounds of ill health by age, sex, and length of service of employees contributing to pension schemes. Results: Rates of ill health retirement varied from 20 to 250 per 10 000 contributing members, and in two organisations the rate varied geographically within the same organisation. In the two organisations that provided data by sex, women retired at a greater rate than men under age 40 and over age 50. In four organisations the modal age or length of service coincided with enhancements in benefits. In the four that provided information on diagnoses, musculoskeletal and minor psychiatric illnesses were the most common reasons for retirement Conclusion: The granting of ill health retirement benefits may not be determined by illness. There is a need for some employers and pension schemes to improve their processes for granting benefits. Doctors should be wary of conflicts of interest and work to guidelines when they advise pension schemes about the merits of an application for benefits.			Poole, CJM (corresponding author), DUDLEY PRIOR HLTH NHS TRUST,CENT CLIN,DUDLEY DY2 7BX,W MIDLANDS,ENGLAND.							COX RAF, 1995, FITNESS WORK; Elder A. G., 1994, Occupational Medicine (Oxford), V44, P231, DOI 10.1093/occmed/44.5.231; *I PUBL HLTH, 1995, AV AG SPEC DEATH RAT; LUNDBOM J, 1994, SCAND J SOC MED, V22, P303, DOI 10.1177/140349489402200410; MONPERE C, 1988, European Heart Journal, V9, P48; *OFF POP CENS SURV, 1992, GEN HOUS SURV 1990 1; Poole CJM, 1996, OCCUP MED-OXFORD, V46, P402, DOI 10.1093/occmed/46.6.402	7	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					929	932		10.1136/bmj.314.7085.929	http://dx.doi.org/10.1136/bmj.314.7085.929			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099115	Green Published			2022-12-28	WOS:A1997WQ16900023
J	EssexLopresti, M				EssexLopresti, M			Centenary of the medical film	LANCET			English	Editorial Material																		Longland CJ, 1944, LANCET, V2, P585; MICHAELIS AR, 1995, RES FILMS BIOL ANTHR, P133; NICHTENHAUSER A, 1952, SCI FILM, V2, P8; 1944, LANCET, V2, P601; 1897, LANCET, V1, P920; 1960, SCI FILM REV, V6, P24; 1897, LANCET, V1, P1706	7	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					819	820		10.1016/S0140-6736(05)61747-3	http://dx.doi.org/10.1016/S0140-6736(05)61747-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121253				2022-12-28	WOS:A1997WP40300006
J	Marinker, M				Marinker, M			Personal paper: Writing prescriptions is easy	BRITISH MEDICAL JOURNAL			English	Article											Marinker, M (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,LONDON SE1 7EH,ENGLAND.							HAYNES RB, 1976, LANCET, V1, P1265; HORNE R, 1997, PERCEPTIONS HLTH ILL, P115; MCGAVOCK HA, 1996, REV LIT DRUG ADHEREN; ROVELLI M, 1989, TRANSPLANT P, V21, P833; *ROYAL PHARM SOC G, 1997, COMPL CONC SHAR GOAL; Sackett DL, 1979, COMPLIANCE HLTH CARE	6	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					747	748		10.1136/bmj.314.7082.747	http://dx.doi.org/10.1136/bmj.314.7082.747			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116558	Green Published			2022-12-28	WOS:A1997WM77600036
J	Gomez, AM; Valdivia, HH; Cheng, H; Lederer, MR; Santana, LF; Cannell, MB; McCune, SA; Altschuld, RA; Lederer, WJ				Gomez, AM; Valdivia, HH; Cheng, H; Lederer, MR; Santana, LF; Cannell, MB; McCune, SA; Altschuld, RA; Lederer, WJ			Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure	SCIENCE			English	Article							RAT VENTRICULAR MYOCYTES; BETA-ADRENERGIC STIMULATION; SALT-RESISTANT RATS; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; GUINEA-PIG; RYANODINE RECEPTORS; PURKINJE-CELL; MUSCLE CELLS; PHOSPHOLAMBAN PHOSPHORYLATION	Cardiac hypertrophy and heart failure caused by high blood pressure were studied in single myocytes taken from hypertensive rats (Dahl SS/Jr) and SH-HF rats in heart failure. Confocal microscopy and patch-clamp methods were used to examine excitation-contraction (EC) coupling, and the relation between the plasma membrane calcium current (I-Ca) and evoked calcium release from the sarcoplasmic reticulum (SR), which was visualized as ''calcium sparks.'' The ability of I-Ca to trigger calcium release from the SR in both hypertrophied and failing hearts was reduced. Because I-Ca density and SR calcium-release channels were normal, the defect appears to reside in a change in the relation between SR calcium-release channels and sarcolemmal calcium channels. beta-Adrenergic stimulation largely overcame the defect in hypertrophic but not failing heart cells. Thus, the same defect in EC coupling that develops during hypertrophy may contribute to heart failure when compensatory mechanisms fail.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA; UNIV WISCONSIN, SCH MED, DEPT PHYSIOL, MADISON, WI 53706 USA; NIA, SECT CARDIOVASC RES, BALTIMORE, MD 21224 USA; UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PHARMACOL & CLIN PHARMACOL, LONDON SW17 0RE, ENGLAND; OHIO STATE UNIV, DEPT FOOD SCI & TECHNOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); St Georges University London; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Santana, Luis/AAF-9298-2019; Heping, Cheng/AAE-2680-2019; Lederer, William/B-1285-2010; Gomez, Ana M./B-5376-2013	Santana, Luis/0000-0002-4297-8029; Heping, Cheng/0000-0002-9604-6702; Gomez, Ana M./0000-0003-0009-2884	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAHANE SA, 1996, J GEN PHYSIOL, V108, P1; ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; BASSANI RA, 1995, BIOPHYS J, V68, P2015, DOI 10.1016/S0006-3495(95)80378-4; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BERS DM, 1991, EXCITATION CONTRACTI; BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; BEUCKELMANN DJ, 1992, BASIC RES CARDIOL, V87, P235; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P426; Braunwald E, 1979, HDB PHYSL 2, P533; BRISTOW MR, 1990, CIRCULATION, V82, P12; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHEVALIER B, 1992, BASIC RES CARDIOL, V87, P187; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; DAHL LK, 1962, NATURE, V194, P480, DOI 10.1038/194480b0; DUBELL WH, 1987, CELL CALCIUM, V8, P259, DOI 10.1016/0143-4160(87)90002-9; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; DUBUS I, 1993, EUR HEART J, V14, P76; Esler Murray, 1995, P755; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRANTE F, 1992, J HYPERTENS, V10, P507, DOI 10.1097/00004872-199206000-00002; GOMEZ AM, IN PRESS AM J PHYSL; Grantham CJ, 1996, CIRC RES, V79, P194, DOI 10.1161/01.RES.79.2.194; HART G, 1994, CARDIOVASC RES, V28, P933, DOI 10.1093/cvr/28.7.933; HASS GJ, 1995, AM HEART J, V130, P806, DOI 10.1016/0002-8703(95)90081-0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; INOKO M, 1994, AM J PHYSIOL-HEART C, V267, pH2471, DOI 10.1152/ajpheart.1994.267.6.H2471; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JANUARY CT, 1988, PHARMACOL REV, V40, P219; KAPLAN N, 1990, CLIN HYPERTENSION, P95; KAWAMURA K, 1976, JPN CIRC J, V40, P1119, DOI 10.1253/jcj.40.1119; KLEIMAN RB, 1988, AM J PHYSIOL, V255, pH1434, DOI 10.1152/ajpheart.1988.255.6.H1434; LI Q, 1994, AM J PHYSIOL, V266, pH1738; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; LOMPRE AM, 1979, NATURE, V282, P105, DOI 10.1038/282105a0; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; McCune SA, 1990, ILAR J, V32, P23; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MING Z, 1994, J MOL CELL CARDIOL, V26, P1133, DOI 10.1006/jmcc.1994.1132; MOALIC JM, 1993, CIRCULATION S4, V87; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NARAYAN P, 1995, J MOL CELL CARDIOL, V27, P523, DOI 10.1016/S0022-2828(08)80047-8; NEGRETTI N, 1995, J PHYSIOL-LONDON, V486, P581, DOI 10.1113/jphysiol.1995.sp020836; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; PAGE E, 1973, AM J CARDIOL, V31, P172, DOI 10.1016/0002-9149(73)91030-8; PHILLIPS RA, UNPUB; PRIMOT I, 1991, CARDIOVASC RES, V25, P875, DOI 10.1093/cvr/25.10.875; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; RAPP JP, 1985, HYPERTENSION, V7, P340, DOI 10.1161/01.HYP.7.3_Pt_1.340; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; SANTOS PED, 1995, J CARDIOVASC ELECTR, V6, P1004; SCAMPS F, 1990, CIRC RES, V67, P199, DOI 10.1161/01.RES.67.1.199; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; SHACKLOCK PS, 1995, J PHYSIOL-LONDON, V487, P601, DOI 10.1113/jphysiol.1995.sp020903; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Soeller C, 1996, BIOPHYS J, V70, pTUAM8; SOELLER C, COMMUNICATION; SPENCER CI, 1995, J PHYSIOL-LONDON, V488, P267, DOI 10.1113/jphysiol.1995.sp020965; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TATE CA, 1985, J BIOL CHEM, V260, P9618; THANDROYEN FT, 1991, CIRC RES, V69, P810, DOI 10.1161/01.RES.69.3.810; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	75	627	650	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					800	806		10.1126/science.276.5313.800	http://dx.doi.org/10.1126/science.276.5313.800			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115206				2022-12-28	WOS:A1997WW90000060
J	Cohen, JJ; Dickler, RM				Cohen, JJ; Dickler, RM			Auditing the Medicare-billing practices of teaching physicians - Welcome accountability, unfair approach	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Cohen, JJ (corresponding author), ASSOC AMER MED COLL,2450 N ST NW,WASHINGTON,DC 20037, USA.							*US DEP HHS, 1995, FED REGISTER, V60, P63138; 1996, WASHINGTON HIGH 0627, P3; 1996, WASHINGTON HIGH 0606, P1; 1995, CPT ASSISTANT    SUM, V5	4	19	19	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1317	1320		10.1056/NEJM199705013361811	http://dx.doi.org/10.1056/NEJM199705013361811			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113939				2022-12-28	WOS:A1997WW26000011
J	Burnard, P; Graham, D; Turner, G				Burnard, P; Graham, D; Turner, G			Vesicle-specific noble gas analyses of ''popping rock'': Implications for primordial noble gases in earth	SCIENCE			English	Article							MID-ATLANTIC RIDGE; STATE UPPER-MANTLE; BASALT GLASSES; LOIHI SEAMOUNT; MASS-TRANSFER; HELIUM; XENON; ARGON; 14-DEGREES-N; CRESTS	Gases trapped in individual vesicles in the volatile-rich basaltic glass ''popping rock'' were found to have the same carbon dioxide, helium-4, and argon-40 composition, but a variable Ar-40/Ar-36 ratio (similar to 4000 to greater than or equal to 40,000). The argon-36 is probably surface-adsorbed atmospheric argon; any mantle argon-36 trapped in the vesicles cannot be distinguished from an atmospheric contaminant. Consequently the Ar-40/Ar-36 ratios and He-3/Ar-36 ratios (1.45) determined are minimum estimates of the upper mantle composition. Heavy noble gas relative abundances in the mantle resemble solar noble gas abundance patterns, and a solar origin may be common to all primordial mantle noble gases.	OREGON STATE UNIV,COLL OCEAN & ATMOSPHER SCI,CORVALLIS,OR 97331	Oregon State University	Burnard, P (corresponding author), UNIV MANCHESTER,DEPT EARTH SCI,MANCHESTER M13 9PL,LANCS,ENGLAND.		Graham, David/C-3612-2014	Graham, David/0000-0002-7411-1905				Allegre C.J., 1986, EARTH PLANET SC LETT, V81, P127; BECKER RH, 1991, EARTH PLANET SC LETT, V103, P55, DOI 10.1016/0012-821X(91)90149-C; BENKERT JP, 1993, J GEOPHYS RES, V98, P13; BURNARD PG, 1994, EARTH PLANET SC LETT, V128, P243, DOI 10.1016/0012-821X(94)90148-1; CARROLL MR, 1993, GEOCHIM COSMOCHIM AC, V57, P5039, DOI 10.1016/0016-7037(93)90606-W; CLARKE WB, 1969, EARTH PLANET SC LETT, V6, P213, DOI 10.1016/0012-821X(69)90093-4; FARLEY KA, 1994, GEOCHIM COSMOCHIM AC, V58, P2509; FISHER DE, 1994, EARTH PLANET SC LETT, V123, P199, DOI 10.1016/0012-821X(94)90267-4; GRAHAM D, 1991, EARTH PLANET SC LETT, V105, P568, DOI 10.1016/0012-821X(91)90194-M; Harper CL, 1996, SCIENCE, V273, P1814, DOI 10.1126/science.273.5283.1814; HONDA M, 1991, NATURE, V349, P149, DOI 10.1038/349149a0; HUNTEN DM, 1987, ICARUS, V69, P532, DOI 10.1016/0019-1035(87)90022-4; JAVOY M, 1991, EARTH PLANET SC LETT, V107, P598, DOI 10.1016/0012-821X(91)90104-P; JOCHUM KP, 1983, NATURE, V306, P431, DOI 10.1038/306431a0; KELLOGG LH, 1990, EARTH PLANET SC LETT, V99, P276, DOI 10.1016/0012-821X(90)90116-F; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P388, DOI 10.1016/0012-821X(83)90154-1; LUPTON JE, 1975, EARTH PLANET SC LETT, V26, P133, DOI 10.1016/0012-821X(75)90080-1; MAMYRIN BA, 1969, DOKL AKAD NAUK SSSR+, V184, P1197; MARTY B, 1989, EARTH PLANET SC LETT, V94, P45, DOI 10.1016/0012-821X(89)90082-4; Marty B., 1994, NOBLE GAS GEOCHEMIST, P191; Melosh H. J, 1989, OXFORD MONOGRAPHS GE, V11; ONIONS RK, 1994, EARTH PLANET SC LETT, V124, P131, DOI 10.1016/0012-821X(94)00070-0; ONions RK, 1996, EARTH PLANET SC LETT, V139, P213, DOI 10.1016/0012-821X(96)00004-0; ONIONS RKK, 1995, PHILOS T R SOC LON A, V342, P65; OWEN T, 1992, NATURE, V358, P43, DOI 10.1038/358043a0; PATTERSON DB, 1990, GEOPHYS RES LETT, V17, P705, DOI 10.1029/GL017i006p00705; PEDRONI A, 1994, METEORITICS, V29, P632, DOI 10.1111/j.1945-5100.1994.tb00776.x; PHINNEY D, 1978, J GEOPHYS RES, V83, P2313, DOI 10.1029/JB083iB05p02313; PINEAU F, 1994, EARTH PLANET SC LETT, V123, P179, DOI 10.1016/0012-821X(94)90266-6; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P1991, DOI 10.1016/0016-7037(95)00122-0; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; POREDA RJ, 1992, EARTH PLANET SC LETT, V113, P129, DOI 10.1016/0012-821X(92)90215-H; SARDA P, 1990, EARTH PLANET SC LETT, V97, P268, DOI 10.1016/0012-821X(90)90047-2; SARDA P, 1988, EARTH PLANET SC LETT, V91, P73, DOI 10.1016/0012-821X(88)90152-5; SPASENNYKH MY, 1993, GEOCHEM J, V27, P213, DOI 10.2343/geochemj.27.213; STAUDACHER T, 1989, EARTH PLANET SC LETT, V96, P119, DOI 10.1016/0012-821X(89)90127-1; SWINDLE TD, 1988, METEORITES EARLY SOL, P535; WETHERILL GW, 1954, PHYS REV, V96, P679, DOI 10.1103/PhysRev.96.679; WETHERILL GW, 1985, SCIENCE, V228, P877, DOI 10.1126/science.228.4701.877; WIELER R, 1994, METEORITICS, V29, P570, DOI 10.1111/j.1945-5100.1994.tb00770.x; WIELER R, 1986, GEOCHIM COSMOCHIM AC, V50, P1997, DOI 10.1016/0016-7037(86)90255-3	41	198	212	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					568	571		10.1126/science.276.5312.568	http://dx.doi.org/10.1126/science.276.5312.568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110971				2022-12-28	WOS:A1997WV72100038
J	Klag, MJ; Whelton, PK; Randall, BL; Neaton, JD; Brancati, FL; Stamler, J				Klag, MJ; Whelton, PK; Randall, BL; Neaton, JD; Brancati, FL; Stamler, J			End-stage renal disease in African-American and white men - 16-year MRFIT findings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACTOR INTERVENTION TRIAL; SOCIOECONOMIC-STATUS; BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; DIABETES-MELLITUS; FAMILIAL RISK; RACE; FAILURE; BLACKS; LIFE	Objective.-To determine reasons for the 4-fold higher incidence of treated end-stage renal disease (ESRD) in African-American men compared with white men. Design.-Prospective study. Setting.-Men screened in 1973 through 1975 for entry into the Multiple Risk Factor Intervention Trial (MRFIT). Participants.-A total of 332 544 men (300 645 white, 20 222 African American, and 11 677 other ethnic groups) aged 35 to 57 years. Main Outcome Measures.-Incidence of ESRD assessed through 1990 using the Health Care Financing Administration national ESRD treatment registry and by surveillance for death from renal disease from data of the National Death Index and the Social Security Administration. Results.-Over a mean follow-up of 16 years, age-adjusted ESRD incidence was 13.90 per 100 000 person-years in white men and 44.22 per 100 000 person-years in African-American men, Higher blood pressure and lower socioeconomic status were associated with higher incidence of ESRD in both ethnic groups, With adjustment for baseline age, systolic blood pressure, number of cigarettes smoked, previous myocardial infarction, diabetes, income, and serum cholesterol level, relative risk of ESRD in African-American men compared with white men was reduced from 3.20 to 1.87 (95% confidence interval, 1.47-2.39). Both higher systolic blood pressure and lower income in African-American men as compared with white men were particularly related to this reduced relative risk. Results were similar when hypertensive ESRD was used as the outcome. Conclusion.-Both higher blood pressure and lower income are associated with a higher incidence of ESRD in both white and African-American men. Disparities in blood pressure and socioeconomic status relate importantly to the excess risk of ESRD in African-American men compared with white men.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA; NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041837] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL28715] Funding Source: Medline; NIDDK NIH HHS [R01 DK41837] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1977, Journal of Chronic Diseases, V30, P261; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BIANCHI S, 1994, AM J HYPERTENS, V7, P23, DOI 10.1093/ajh/7.1.23; BRANCATI FL, 1992, JAMA-J AM MED ASSOC, V268, P3079, DOI 10.1001/jama.268.21.3079; BRAZY PC, 1990, KIDNEY INT, V37, P1113, DOI 10.1038/ki.1990.93; BYRNE C, 1994, AM J KIDNEY DIS, V23, P16, DOI 10.1016/S0272-6386(12)80806-7; COX DR, 1972, J R STAT SOC B, V34, P187; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; FERGUSON R, 1988, J CLIN EPIDEMIOL, V41, P1189, DOI 10.1016/0895-4356(88)90023-6; FREEDMAN BI, 1993, AM J KIDNEY DIS, V21, P387, DOI 10.1016/S0272-6386(12)80266-6; FREEDMAN BI, 1995, AM J KIDNEY DIS, V25, P207, DOI 10.1016/0272-6386(95)90001-2; FREEDMAN BI, 1991, AM J HYPERTENS, V4, P393, DOI 10.1093/ajh/4.5.393; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GLASS GE, 1993, J INFECT DIS, V167, P614, DOI 10.1093/infdis/167.3.614; GREENWALD HP, 1994, J CLIN EPIDEMIOL, V47, P903, DOI 10.1016/0895-4356(94)90194-5; GRETLER DD, 1994, AM J HYPERTENS, V7, P7, DOI 10.1093/ajh/7.1.7; *HLTH CAR FIN ADM, 1987, HCFA PUBLICATION; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; NEATON JD, 1988, CONTROL CLIN TRIALS, V8, P415; *NIH, 1974, US DHEW NIH PUBLICAT, P1; PERNEGER TV, 1995, AM J KIDNEY DIS, V25, P722, DOI 10.1016/0272-6386(95)90548-0; PERNEGER TV, 1995, AM J EPIDEMIOL, V141, P10, DOI 10.1093/oxfordjournals.aje.a117338; PERNEGER TV, 1994, ANN INTERN MED, V121, P912, DOI 10.7326/0003-4819-121-12-199412150-00002; PERNEGER TV, 1995, ARCH INTERN MED, V155, P1201, DOI 10.1001/archinte.155.11.1201; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; PERRY HM, 1995, HYPERTENSION, V25, P587, DOI 10.1161/01.HYP.25.4.587; *PHS, 1988, INT CLASS DIS; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; SCHLESSINGER SD, 1994, AM J KIDNEY DIS, V23, P655, DOI 10.1016/S0272-6386(12)70275-5; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P497, DOI 10.2105/AJPH.86.4.497; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; STATIUS LW, 1988, DISEASES KIDNEY, P2561; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; TIERNEY WM, 1989, AM J KIDNEY DIS, V13, P485, DOI 10.1016/S0272-6386(89)80006-X; United States Renal Data System, 1994, USRDS 1994 ANN DAT R; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; YOUNG EW, 1994, KIDNEY INT, V45, P907, DOI 10.1038/ki.1994.120	47	468	487	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1293	1298		10.1001/jama.277.16.1293	http://dx.doi.org/10.1001/jama.277.16.1293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109467				2022-12-28	WOS:A1997WU13500029
J	Westaby, D				Westaby, D			Endoscopic balloon dilatation of biliary sphincter for removing bileduct stones	LANCET			English	Editorial Material							DUCT STONES				Westaby, D (corresponding author), CHELSEA & WESTMINSTER HOSP,DEPT GASTROENTEROL,LONDON SW10 9NH,ENGLAND.							CLASSEN M, 1974, DEUT MED WOCHENSCHR, V99, P496, DOI 10.1055/s-0028-1107790; COTTON PB, 1984, GUT, V25, P587, DOI 10.1136/gut.25.6.587; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; HUNTER JG, 1992, AM J SURG, V163, P53, DOI 10.1016/0002-9610(92)90252-M; LAM SK, 1984, BRIT J SURG, V71, P262, DOI 10.1002/bjs.1800710404; MACMATHUNA P, 1995, GASTROINTEST ENDOSC, V42, P468, DOI 10.1016/S0016-5107(95)70052-8; Minami A, 1995, DIGEST DIS SCI, V40, P2550, DOI 10.1007/BF02220440; SAND J, 1992, AM SURGEON, V58, P324	8	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1114	1115		10.1016/S0140-6736(05)63016-4	http://dx.doi.org/10.1016/S0140-6736(05)63016-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113006				2022-12-28	WOS:A1997WU54400004
J	Carroll, RG; Riley, JL; Levine, BL; Feng, Y; Kaushal, S; Ritchey, DW; Bernstein, W; Weislow, OS; Brown, CR; Berger, EA; June, CH; StLouis, DC				Carroll, RG; Riley, JL; Levine, BL; Feng, Y; Kaushal, S; Ritchey, DW; Bernstein, W; Weislow, OS; Brown, CR; Berger, EA; June, CH; StLouis, DC			Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4(+) T cells	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-CLONING; MONOCLONAL-ANTIBODIES; CROSS-LINKING; HUMAN HOMOLOG; NPY BINDING; ACTIVATION; RECEPTOR; GENE; RESPONSES	Activation of CD4(+) T lymphocytes from human immunodeficiency virus-type 1 (HIV-1)-infected donors with immobilized antibodies to CD3 and CD28 induces a virus-resistant state. This effect is specific for macrophage-tropic HIV-I, Transcripts encoding CXCR4/Fusin, the fusion cofactor used by T cell line-tropic isolates, were abundant in CD3/CD28-stimulated cells, but transcripts encoding CCR5, the fusion cofactor used by macrophage-tropic viruses, were not detectable. Thus, CD3/CD28 costimulation induces an HIV-1-resistant phenotype similar to that seen in some highly exposed and HIV-uninfected individuals.	HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD 20850; USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20889; WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD 20850; NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20889; SRA TECHNOL,ROCKVILLE,MD 20850; NIAID,INFECT DIS LAB,NIH,ROCKVILLE,MD 20852	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Riley, James L/D-1255-2009; Levine, Bruce L/D-1688-2009	June, Carl/0000-0003-0241-3557; Riley, James/0000-0002-1057-576X				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BREITMEYER JB, 1987, J IMMUNOL, V139, P2899; BRETSCHER P, 1992, IMMUNOL TODAY, V13, P74, DOI 10.1016/0167-5699(92)90138-W; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CARROLL RI, UNPUB; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GEPPERT TD, 1988, J IMMUNOL, V140, P2155; GEPPERT TD, 1988, J CLIN INVEST, V81, P1497, DOI 10.1172/JCI113481; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P1601, DOI 10.1002/eji.1830181020; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LEVINE BL, 1995, INT IMMUNOL, V7, P891, DOI 10.1093/intimm/7.6.891; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RILEY J, IN PRESS J IMMUNOL; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P398; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; Vahey Maryanne T., 1995, P17; Vahey Maryanne T., 1995, P313; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	51	172	184	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					273	276		10.1126/science.276.5310.273	http://dx.doi.org/10.1126/science.276.5310.273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092480				2022-12-28	WOS:A1997WT92500051
J	Morris, M				Morris, M			Invasive potential of carcinoma in situ of the cervix	LANCET			English	Editorial Material											Morris, M (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT GYNECOL ONCOL,HOUSTON,TX 77030, USA.							MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					967	967		10.1016/S0140-6736(05)62887-5	http://dx.doi.org/10.1016/S0140-6736(05)62887-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100618				2022-12-28	WOS:A1997WR62100003
J	Pellegrini, G; Traverso, CE; Franzi, AT; Zingirian, M; Cancedda, R; DeLuca, M				Pellegrini, G; Traverso, CE; Franzi, AT; Zingirian, M; Cancedda, R; DeLuca, M			Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium	LANCET			English	Article							AUTOGRAFT TRANSPLANTATION; STEM-CELLS; LIMBAL; RECONSTRUCTION; INVITRO	Background Complete loss of the corneal-limbal epithelium leads to re-epithelialisation by bulbar conjunctival cells. Since conjunctival and corneal-limbal epithelial cells represent two different cell lines, this conjunctival healing of the cornea is followed by stromal scarring, decreased visual acuity, and severe discomfort. Unilateral corneal-limbal epithelial defects can be resolved by the transplantation of limbal grafts taken from the uninjured eye. However, this procedure requires a large limbal graft to be taken from the healthy eye, and is not possible for bilateral lesions. We investigated the possibility of restoring the human corneal surface with autologous corneal epithelial sheets generated by serial cultivation of limbal cells. Methods Cells were cultivated from a 1 mm(2) biopsy sample taken from the limbus of the healthy eye of two patients with severe alkali burns, and thus complete loss of the corneal-limbal surface, of one eye. Normal corneal differentiation was tested with a specific biochemical marker. Autologous cultured corneal sheets were then grafted onto the damaged eyes of the two patients. The patients were followed up at more than 2 years after grafting. Findings We have shown that corneal progenitor cells are localised in the limbus, that cultured limbal cells generate cohesive sheets of authentic corneal epithelium, and that autologous cultured corneal epithelium restored the corneal surface of two patients with complete loss of the corneal-limbus epithelium. Long-term follow-up showed the stability of regenerated corneal epithelium and the striking improvement in patients' comfort and visual acuity. Interpretation The cultivation of corneal epithelium might offer an alternative to patients with unilateral lesions and a therapeutic chance to patients with severe bilateral corneal-limbal epithelial defects. Our findings give a new perspective on the treatment of ocular disorders characterised by stem-cell deficiency.	IST DERMOPAT IMMACOLATA,LAB TISSUE ENGN,I-00040 ROME,ITALY; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,CLIN OCULLIST,GENOA,ITALY; UNIV GENOA,IST ANAT UMANA NORMALE,GENOA,ITALY	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Genoa			De Luca, Michele/N-5883-2014; Pellegrini, Graziella/E-1189-2015	De Luca, Michele/0000-0002-0850-8445; Pellegrini, Graziella/0000-0001-9861-0736	Telethon [A.041] Funding Source: Medline	Telethon(Fondazione Telethon)		BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; CHEN WYW, 1994, CURR EYE RES, V13, P765, DOI 10.3109/02713689409047012; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DELUCA M, 1989, BURNS, V15, P303, DOI 10.1016/0305-4179(89)90007-7; DELUCA M, 1990, TRANSPLANTATION, V50, P454, DOI 10.1097/00007890-199009000-00019; DUA HS, 1990, AM J OPHTHALMOL, V110, P646, DOI 10.1016/S0002-9394(14)77062-X; FRIEND J, 1987, CORNEA, P16; KENYON KR, 1989, OPHTHALMOLOGY, V96, P709; KRUSE F E, 1989, Investigative Ophthalmology and Visual Science, V30, P520; LINDBERG K, 1993, INVEST OPHTH VIS SCI, V34, P2672; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROMAGNOLI G, 1990, NEW ENGL J MED, V323, P527, DOI 10.1056/NEJM199008233230806; SHAPIRO MS, 1981, INVEST OPHTH VIS SCI, V21, P135; SHERMER A, 1986, J CELL BIOL, V103, P49; THOFT RA, 1977, ARCH OPHTHALMOL-CHIC, V95, P1425; THOFT RA, 1977, INVEST OPHTH VIS SCI, V16, P14; TSAI RJF, 1990, OPHTHALMOLOGY, V97, P446, DOI 10.1016/S0161-6420(90)32575-7; TSAI RJF, 1994, CORNEA, V13, P389, DOI 10.1097/00003226-199409000-00003; Wei ZG, 1996, INVEST OPHTH VIS SCI, V37, P523; WEI ZG, 1993, INVEST OPHTH VIS SCI, V34, P1814; WEI ZG, 1995, INVEST OPHTH VIS SCI, V36, P236	22	1013	1081	3	75	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					990	993		10.1016/S0140-6736(96)11188-0	http://dx.doi.org/10.1016/S0140-6736(96)11188-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100626				2022-12-28	WOS:A1997WR62100012
J	Chervonsky, AV; Wang, Y; Wong, FS; Visintin, I; Flavell, RA; Janeway, CA; Matis, LA				Chervonsky, AV; Wang, Y; Wong, FS; Visintin, I; Flavell, RA; Janeway, CA; Matis, LA			The role of Fas in autoimmune diabetes	CELL			English	Article							ACTIVATION-INDUCED CELL; PANCREATIC BETA-CELLS; TUMOR-NECROSIS-FACTOR; T-CELLS; TRANSGENIC MICE; LYMPHOPROLIFERATIVE SYNDROME; MEDIATED CYTOTOXICITY; MONOCLONAL-ANTIBODY; ANTIGEN; LIGAND	Immunologically privileged sites express Fas ligand (FasL), which protects them from attack by activated T cells that express Fas and die upon contact with FasL. In an attempt to protect nonobese diabetic mice (NOD) from autoimmune diabetes, we made FasL transgenic NOD mice using the beta cell-specific rat insulin-1 promoter. Surprisingly, these transgenic mice showed heightened sensitivity to diabetogenic T cells, which was due to self-destruction of beta cells upon T cell-mediated induction of Fas. Fas-negative NODlpr/lpr animals were resistant to diabetogenic T cells and to spontaneous diabetes. Thus, induction of Fas expression on beta cells and their subsequent destruction constitutes the main pathogenic mechanism in autoimmune diabetes.	HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; ALEXION PHARMACEUT,NEW HAVEN,CT 06511	Howard Hughes Medical Institute	Chervonsky, AV (corresponding author), YALE UNIV,SCH MED,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06510, USA.			Chervonsky, Alexander/0000-0001-7547-871X; Wong, F. Susan/0000-0002-2812-8845	NIAID NIH HHS [AI-26810] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026810, R13AI126810] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ALLISON J, 1991, P NATL ACAD SCI USA, V88, P2070, DOI 10.1073/pnas.88.6.2070; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DHEIN J, 1995, NATURE, V375, P78; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GUERDER S, 1994, P NATL ACAD SCI USA, V91, P5138, DOI 10.1073/pnas.91.11.5138; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; Han HS, 1996, J AUTOIMMUN, V9, P331, DOI 10.1006/jaut.1996.0045; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HUGHES DPM, 1995, J EXP MED, V182, P1395, DOI 10.1084/jem.182.5.1395; JANEWAY CA, 1987, J MOL CELL IMMUNOL, V3, P121; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Lenschow DJ, 1996, IMMUNITY, V5, P285, DOI 10.1016/S1074-7613(00)80323-4; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; NAGATA M, 1994, J IMMUNOL, V152, P2042; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; STASSI G, 1996, AUTOIMMUNITY S1, V24, P6; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; Yamada K, 1996, DIABETOLOGIA, V39, P1306, DOI 10.1007/s001250050574; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	47	448	464	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					17	24		10.1016/S0092-8674(00)80178-6	http://dx.doi.org/10.1016/S0092-8674(00)80178-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094710	hybrid			2022-12-28	WOS:A1997WR68500005
J	Hammond, KA; Diamond, J				Hammond, KA; Diamond, J			Maximal sustained energy budgets in humans and animals	NATURE			English	Review							METABOLIC-RATE; LACTATING MICE; EXPENDITURE; ENERGETICS; MAMMALS; CONSTRAINTS; ADAPTATION; LIMITS; BASAL; BIRDS	Why are sustained energy budgets of humans and other vertebrates limited to not more than about seven times resting metabolic: rate? The answer to this question has potential applications to growth rates, foraging ecology, blogeography, plant metabolism, burn patients and sports medicine.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hammond, KA (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA.							ADAMS NJ, 1991, MAR ECOL PROG SER, V70, P1, DOI 10.3354/meps070001; Amthor J.S., 1989, RESP CROP PRODUCTIVI, DOI [10.1007/978-1-4615-9667-7, DOI 10.1007/978-1-4615-9667-7]; BALLANCE LT, 1995, PHYSIOL ZOOL, V68, P887, DOI 10.1086/physzool.68.5.30163937; BIRTFRIESEN VL, 1989, ECOLOGY, V70, P357, DOI 10.2307/1937540; BRYANT DM, 1984, AUK, V101, P25, DOI 10.1093/auk/101.1.25; DAAN S, 1990, AM J PHYSIOL, V259, pR333, DOI 10.1152/ajpregu.1990.259.2.R333; DRENT RH, 1980, ARDEA, V68, P225; ELSE PL, 1981, AM J PHYSIOL, V240, pR3, DOI 10.1152/ajpregu.1981.240.1.R3; HAMMOND K, 1994, PHYSIOL ZOOL, V67, P282, DOI 10.1086/physzool.67.1.30163847; HAMMOND KA, 1992, PHYSIOL ZOOL, V65, P952, DOI 10.1086/physzool.65.5.30158552; HAMMOND KA, 1994, PHYSIOL ZOOL, V67, P1479, DOI 10.1086/physzool.67.6.30163908; HANSEN LD, 1989, CAN J FOREST RES, V19, P606, DOI 10.1139/x89-095; HAYES JP, 1989, J COMP PHYSIOL B, V159, P453, DOI 10.1007/BF00692417; JOHNSON DE, 1990, J NUTR, V120, P649, DOI 10.1093/jn/120.6.649; KARASOV WH, 1985, AM J PHYSIOL, V249, pG271, DOI 10.1152/ajpgi.1985.249.2.G271; KENAGY GJ, 1990, J ANIM ECOL, V59, P73, DOI 10.2307/5159; KONARZEWSKI M, 1994, PHYSIOL ZOOL, V67, P1186, DOI 10.1086/physzool.67.5.30163889; Konarzewski M, 1995, EVOLUTION, V49, P1239, DOI 10.2307/2410448; KOTEJA P, 1991, FUNCT ECOL, V5, P56, DOI 10.2307/2389555; Koteja P, 1995, COMP BIOCHEM PHYS A, V112, P479, DOI 10.1016/0300-9629(95)02016-0; Koteja P, 1996, PHYSIOL ZOOL, V69, P994, DOI 10.1086/physzool.69.5.30164243; Koteja P, 1996, PHYSIOL ZOOL, V69, P981, DOI 10.1086/physzool.69.5.30164242; Koteja Pawel, 1994, Polish Ecological Studies, V20, P369; MARTIN ARTHUR W., 1955, PHYSIOL ZOOL, V28, P18; MCDEVITT RM, 1994, PHYSIOL ZOOL, V67, P1117, DOI 10.1086/physzool.67.5.30163885; NAGY KA, 1987, ECOL MONOGR, V57, P111, DOI 10.2307/1942620; OBST BS, 1987, PHYSIOL ZOOL, V60, P200, DOI 10.1086/physzool.60.2.30158644; PANTERBRICK C, 1993, AM J CLIN NUTR, V57, P620, DOI 10.1093/ajcn/57.5.620; PETERSON CC, 1990, P NATL ACAD SCI USA, V87, P2324, DOI 10.1073/pnas.87.6.2324; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; POPPITT SD, 1994, PHYSIOL ZOOL, V67, P976, DOI 10.1086/physzool.67.4.30163874; Rensch I., 1956, Zoologischer Anzeiger, V156, P106; Ricklefs RE, 1996, AM NAT, V147, P1047, DOI 10.1086/285892; RICKLEFS RE, 1979, BIOL REV, V54, P269, DOI 10.1111/j.1469-185X.1979.tb01013.x; ROBY DD, 1986, PHYSIOL ZOOL, V59, P661, DOI 10.1086/physzool.59.6.30158613; ROOT T, 1988, ECOLOGY, V69, P330, DOI 10.2307/1940431; ROYALL D, 1994, CRIT CARE MED, V22, P399, DOI 10.1097/00003246-199403000-00008; SECOR SM, 1994, AM J PHYSIOL, V266, pG695, DOI 10.1152/ajpgi.1994.266.4.G695; SECOR SM, 1995, J EXP BIOL, V198, P1313; TAYLOR CR, 1981, RESP PHYSIOL, V44, P1, DOI 10.1016/0034-5687(81)90073-6; TOLOZA EM, 1991, AM J PHYSIOL, V261, pG608, DOI 10.1152/ajpgi.1991.261.4.G608; WEIBEL ER, 1997, DIVERSITY BIOL DESIG; WEINER J, 1989, ACTA THERIOL, V34, P3, DOI 10.4098/AT.arch.89-1; WESTERTERP KR, 1986, J APPL PHYSIOL, V61, P2162, DOI 10.1152/jappl.1986.61.6.2162	44	407	432	1	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	1997	386	6624					457	462		10.1038/386457a0	http://dx.doi.org/10.1038/386457a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087402				2022-12-28	WOS:A1997WR25600042
J	Campbell, MJ				Campbell, MJ			Circaseptennial rhythm is an artefact	BRITISH MEDICAL JOURNAL			English	Letter											Campbell, MJ (corresponding author), SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							Slutzky E, 1937, ECONOMETRICA, V5, P105, DOI 10.2307/1907241; Verhulst J, 1996, BRIT MED J, V313, P1597, DOI 10.1136/bmj.313.7072.1597	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					978	978		10.1136/bmj.314.7085.978	http://dx.doi.org/10.1136/bmj.314.7085.978			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099140	Green Published			2022-12-28	WOS:A1997WQ16900052
J	Gallichan, M				Gallichan, M			Self monitoring of glucose by people with diabetes: Evidence based practice	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-GLUCOSE; MELLITUS; IMPACT; TRIAL	The inappropriate use of self monitoring of glucose is wasteful of NHS resources and can cause psychological harm. Although a few patients find that self monitoring enables them to understand and take control of their diabetes, many people with diabetes are performing inaccurate or unnecessary tests. There is no convincing evidence that self monitoring improves glycaemic control, nor that blood testing is necessarily better than urine testing. It may be appropriate for some patients not to monitor their own glucose but to rely instead on regular laboratory estimations of glycaemic control. Glucose self monitoring should be performed only when it serves an identified purpose.			Gallichan, M (corresponding author), E CORNWALL HOSP,BODMIN PL31 2EN,CORNWALL,ENGLAND.							ALLEN BT, 1990, DIABETES CARE, V13, P1044, DOI 10.2337/diacare.13.10.1044; *BRIT DIAB ASS, 1995, DIAB UK 1996; *BRIT DIAB ASS, 1995, BALANCE          DEC, P21; CAMPBELL LV, 1992, BRIT MED J, V305, P1194, DOI 10.1136/bmj.305.6863.1194; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; Dunn SM, 1987, PRACTICAL DIABETES, V4, P108; FONTBONNE A, 1989, DIABETES METAB, V15, P255; FOX C, 1995, DIABETES REAL WORLD; FOX C, 1994, PRACT DIABETES, V11, P244; GALLICHAN MJ, 1994, PRACTICAL DIABETES, V11, P28; HOWEDAVIES S, 1980, DIABETES CARE, V3, P607, DOI 10.2337/diacare.3.5.607; LEESE GP, 1994, PRACTICAL DIABETES, V11, P32; MARTEAU T, 1991, TECHNOLOGY DIABETES; MAZZE RS, 1984, AM J MED, V77, P211, DOI 10.1016/0002-9343(84)90693-4; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; PATRICK AW, 1994, DIABETIC MED, V11, P62, DOI 10.1111/j.1464-5491.1994.tb00231.x; POTTER R, 1996, PRACTICAL DIABETES I, V13, P63; SONKSEN PH, 1978, LANCET, V1, P729; TATTERSALL RB, 1990, DIABETES CLIN MANAGE, P69; WALFORD S, 1978, LANCET, V1, P732; WILLEY KA, 1993, PRACTICAL DIABETES, V10, P22	21	52	52	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					964	967		10.1136/bmj.314.7085.964	http://dx.doi.org/10.1136/bmj.314.7085.964			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099125	Green Published			2022-12-28	WOS:A1997WQ16900035
J	Leyns, L; Bouwmeester, T; Kim, SH; Piccolo, S; DeRobertis, EM				Leyns, L; Bouwmeester, T; Kim, SH; Piccolo, S; DeRobertis, EM			Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer	CELL			English	Article							CELL LUNG-CARCINOMA; XENOPUS EMBRYOS; DROSOPHILA; GENE; POLARITY; MESODERM; PROTEIN; XWNT-8; AXIS; PATTERN	Frzb-1 is a secreted protein containing a domain similar to the putative Wnt-binding region of the frizzled family of transmembrane receptors. Frzb-1 is widely expressed in adult mammalian tissues. In the Xenopus gastrula, it is expressed and regulated as a typical Spemann organizer component. Injection of frzb-1 mRNA blocks expression of XMyoD mRNA and leads to embryos with enlarged heads and shortened trunks. Frzb-1 antagonizes the effects of Xwnt-8 ectopic expression in a non-cell-autonomous manner. Cultured cells transfected with a membrane-tethered form of Wnt-1 bind epitope-tagged Frzb-1 in the 10(-10) M range. The results strengthen the view that the Spemann organizer is a source of secreted inhibitory factors.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Leyns, L (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095, USA.			PICCOLO, STEFANO/0000-0002-2037-0004; Leyns, Luc/0000-0001-7124-3155; De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502-13, R01 HD021502, R37 HD021502, HD21502-11] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FRANK D, 1991, DEVELOPMENT, V113, P1387; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; JONES CM, 1995, DEVELOPMENT, V121, P3651; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KOHNO T, 1994, ONCOGENE, V9, P103; KU M, 1993, DEVELOPMENT, V119, P1161; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang YS, 1996, J BIOL CHEM, V271, P4468; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHENG L, 1995, DEVELOPMENT, V121, P3045; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	46	597	686	3	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					747	756		10.1016/S0092-8674(00)81921-2	http://dx.doi.org/10.1016/S0092-8674(00)81921-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118218	Green Accepted, Bronze			2022-12-28	WOS:A1997WQ10000007
